Introducing Te Pātaka Whaioranga

We’re proud to announce that PHARMAC has adopted Te Pātaka Whaioranga into our identity as an expression of who we are and the role we play in New Zealand.

Te Pātaka Whaioranga, ‘the storehouse of wellbeing’, sums up the part we play in managing and safeguarding something that is valuable to our whole community.

Incorporating Te Reo Māori with our name signals our commitment to Te Tīriti o Waitangi, and the work we’re doing with Māori communities, our Whānau Ora partners and Māori health professionals to help them achieve the best possible health outcomes for Māori from funded medicines.
Introducing PHARMAC

The Pharmaceutical Management Agency (PHARMAC) makes decisions that help control Government spending on pharmaceuticals. This includes community pharmaceuticals, hospital pharmaceuticals, vaccines and increasingly, hospital medical devices. PHARMAC negotiates prices, sets subsidy levels and conditions, and makes decisions on changes to the subsidised list. The funding for pharmaceuticals comes from District Health Boards.

**PHARMAC’s role:**

*“Secure for eligible people in need of pharmaceuticals, the best health outcomes that can reasonably be achieved, and from within the amount of funding provided.”*

New Zealand Public Health and Disability Act 2000

To ensure our decisions are as fair and robust as possible we use a decision-making process that incorporates clinical, economic and commercial issues. We also seek the views of users and the wider community through consultation. The processes we generally use are outlined in our Operating Policies and Procedures.

Further information about PHARMAC and the way we make funding decisions can be found on the PHARMAC website at http://www.pharmac.govt.nz/about.

**Purpose of the Pharmaceutical Schedule**

The purpose of the Schedule is to list:

- the Community Pharmaceuticals that are subsidised by the Government and to show the amount of the subsidy paid to contractors, as well as the manufacturer's price and any access conditions that may apply;
- the Hospital Pharmaceuticals that may be used in DHB Hospitals, as well as any access conditions that may apply; and
- the Pharmaceuticals, including Medical Devices, used in DHB Hospitals for which national prices have been negotiated by PHARMAC.

The Schedule does not show the final cost to Government of subsidising each Community Pharmaceutical or to DHB Hospitals in purchasing each Pharmaceutical, since that will depend on any rebate and other arrangements PHARMAC has with the supplier and, for Pharmaceuticals used in DHB Hospitals, on any logistics arrangements put in place.

This book contains sections A to D and Section I of the Pharmaceutical Schedule and lists the Pharmaceuticals funded for use in the community, including vaccines, as well as haemophilia and cancer treatments given in DHB hospitals. Section H lists the Pharmaceuticals that that can be used in DHB hospitals and is a separate publication.

The Pharmaceuticals in this book are listed by therapeutic group, which is based on the WHO Anatomical Therapeutic Chemical (ATC) system. The listings are displayed alphabetically under each heading.

The index lists both chemical entities and product brand names.
Explaining pharmaceutical entries
The Pharmaceutical Schedule lists pharmaceuticals subsidised by the Government, the subsidy, the supplier's price and the access conditions that may apply.

Example

<table>
<thead>
<tr>
<th>ANATOMICAL HEADING</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>THERAPEUTIC HEADING</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>CHEMICAL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Presentation, form and strength</td>
</tr>
<tr>
<td>Presentation - Available on a PSO</td>
</tr>
<tr>
<td>Presentation - Retail pharmacy-specialist</td>
</tr>
</tbody>
</table>

a) Prescriptions must be written by a paediatrician or paediatric cardiologist; or
b) on the recommendation of a paediatrician or a paediatric cardiologist

<table>
<thead>
<tr>
<th>CHEMICAL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Presentation, form and strength</td>
</tr>
<tr>
<td>(35.27)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Sole Supply</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fully Subsidised</td>
</tr>
<tr>
<td>Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber or pharmacist.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Brand or manufacturer's name</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sole subsidised supply product</td>
</tr>
<tr>
<td>Fully subsidised product</td>
</tr>
<tr>
<td>Original Pack - Subsidy is rounded up to a multiple of whole packs</td>
</tr>
<tr>
<td>Quantity the Subsidy applies to</td>
</tr>
<tr>
<td>Subsidy paid on a product before mark-ups and GST</td>
</tr>
<tr>
<td>Manufacturer's Price if different from Subsidy</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Practitioner's Supply Order</th>
</tr>
</thead>
<tbody>
<tr>
<td>Conditions of and restrictions on prescribing (including Special Authority where it applies)</td>
</tr>
</tbody>
</table>

| Three months or six months, as applicable, dispensed all-at-once |

| Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber or pharmacist. |
Glossary

Units of Measure

<table>
<thead>
<tr>
<th>Unit</th>
<th>Abbreviation</th>
</tr>
</thead>
<tbody>
<tr>
<td>gram</td>
<td>g</td>
</tr>
<tr>
<td>kilogram</td>
<td>kg</td>
</tr>
<tr>
<td>international unit</td>
<td>iu</td>
</tr>
<tr>
<td>microgram</td>
<td>mcg</td>
</tr>
<tr>
<td>milligram</td>
<td>mg</td>
</tr>
<tr>
<td>millilitre</td>
<td>ml</td>
</tr>
<tr>
<td>millimole</td>
<td>mmol</td>
</tr>
<tr>
<td>unit</td>
<td>u</td>
</tr>
</tbody>
</table>

Abbreviations

<table>
<thead>
<tr>
<th>Type</th>
<th>Abbreviation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ampoule</td>
<td>Amp</td>
</tr>
<tr>
<td>Capsule</td>
<td>Cap</td>
</tr>
<tr>
<td>Cream</td>
<td>Crm</td>
</tr>
<tr>
<td>Device</td>
<td>Dev</td>
</tr>
<tr>
<td>Dispersible</td>
<td>Disp</td>
</tr>
<tr>
<td>Effervescent</td>
<td>Eff</td>
</tr>
<tr>
<td>Emulsion</td>
<td>Emul</td>
</tr>
<tr>
<td>Enteric Coated</td>
<td>EC</td>
</tr>
<tr>
<td>Gelatinous</td>
<td>Gel</td>
</tr>
<tr>
<td>Granules</td>
<td>Gran</td>
</tr>
<tr>
<td>Infusion</td>
<td>Inf</td>
</tr>
<tr>
<td>Injection</td>
<td>Inj</td>
</tr>
<tr>
<td>Liquid</td>
<td>Liq</td>
</tr>
<tr>
<td>Long Acting</td>
<td>LA</td>
</tr>
<tr>
<td>Ointment</td>
<td>Oint</td>
</tr>
<tr>
<td>Sachet</td>
<td>Sach</td>
</tr>
<tr>
<td>Solution</td>
<td>Soln</td>
</tr>
<tr>
<td>Suppository</td>
<td>Supp</td>
</tr>
<tr>
<td>Tablet</td>
<td>Tab</td>
</tr>
<tr>
<td>Tincture</td>
<td>Tinc</td>
</tr>
<tr>
<td>Trans Dermal Delivery</td>
<td>TDDS</td>
</tr>
</tbody>
</table>
General Rules for the Pharmaceutical Schedule are located on the PHARMAC website.
### Antacids and Antiflatulents

#### Antacids and Reflux Barrier Agents

**ALGINIC ACID**
- Sodium alginate 225 mg and magnesium alginate 87.5 mg per sachet .......................................................... 5.31 30 ✔ Gaviscon Infant

**SODIUM ALGINATE**
- Tab 500 mg with sodium bicarbonate 267 mg and calcium carbonate 160 mg - peppermint flavour .................................................. 1.80 60 Gaviscon Double Strength
- Oral liq 500 mg with sodium bicarbonate 267 mg and calcium carbonate 160 mg per 10 ml .................................................. 1.50 500 ml Acidex

#### Phosphate Binding Agents

**ALUMINIUM HYDROXIDE**
- Tab 600 mg ............................................................................ 12.56 100 ✔ Alu-Tab

**CALCIUM CARBONATE**
- Oral liq 1,250 mg per 5 ml (500 mg elemental per 5 ml) – Subsidy by endorsement .......................................................... 39.00 500 ml ✔ Roxane
  - Only when prescribed for children under 12 years of age for use as a phosphate binding agent and the prescription is endorsed accordingly.

#### Antidiarrhoeals

#### Agents Which Reduce Motility

**LOPERAMIDE HYDROCHLORIDE** – Up to 30 cap available on a PSO
- Tab 2 mg ............................................................................. 10.75 400 ✔ Nodia
- Cap 2 mg ............................................................................. 7.05 400 ✔ Diamide Relief

#### Rectal and Colonic Anti-inflammatories

**BUDESONIDE**
- Cap 3 mg – Special Authority see SA1155 below – Retail pharmacy .......................................................... 166.50 90 ✔ Entocort CIR

**SA1155**

**Special Authority for Subsidy**

**Initial application — (Crohn’s disease)** from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

1. Mild to moderate ileal, ileocaecal or proximal Crohn’s disease; and
2. Any of the following:
   - 2.1 Diabetes; or
   - 2.2 Cushingoid habitus; or
   - 2.3 Osteoporosis where there is significant risk of fracture; or

continued…
continued...

2.4 Severe acne following treatment with conventional corticosteroid therapy; or
2.5 History of severe psychiatric problems associated with corticosteroid treatment; or
2.6 History of major mental illness (such as bipolar affective disorder) where the risk of conventional corticosteroid treatment causing relapse is considered to be high; or
2.7 Relapse during pregnancy (where conventional corticosteroids are considered to be contraindicated).

Initial application — (collagenous and lymphocytic colitis (microscopic colitis)) from any relevant practitioner. Approvals valid for 6 months where patient has a diagnosis of microscopic colitis (collagenous or lymphocytic colitis) by colonoscopy with biopsies.

Initial application — (gut Graft versus Host disease) from any relevant practitioner. Approvals valid for 6 months where patient has a gut Graft versus Host disease following allogenic bone marrow transplantation*.

Note: Indication marked with * is an unapproved indication.

Renewal from any relevant practitioner. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment.

Note: Clinical trials for Entocort CIR use beyond three months demonstrated no improvement in relapse rate.

HYDROCORTISONE ACETATE
Rectal foam 10%, CFC-Free (14 applications).................................26.55 21.1 g OP ✔ Colifoam

MESALAZINE
Tab 400 mg .................................................................................49.50 100 ✔ Asacol
Tab EC 500 mg .................................................................49.50 100 ✔ Asamax
Tab long-acting 500 mg .......................................................59.05 100 ✔ Pentasa
Tab 800 mg ........................................................................85.50 90 ✔ Asacol
Modified release granules, 1 g ........................................141.72 120 OP ✔ Pentasa
Enema 1 g per 100 ml ......................................................41.30 7 ✔ Pentasa
Suppos 500 mg .................................................................22.80 20 ✔ Asacol
Suppos 1 g .................................................................54.60 30 ✔ Pentasa

OLSALAZINE
Tab 500 mg .................................................................93.37 100 ✔ Dipentum
Cap 250 mg .................................................................53.00 100 ✔ Dipentum

SODIUM CROMOGLICATE
Cap 100 mg .................................................................92.91 100 ✔ Nalcrom

SULFASALAZINE
* Tab 500 mg .................................................................14.00 100 ✔ Salazopyrin
* Tab EC 500 mg .................................................................13.50 100 ✔ Salazopyrin EN

Local preparations for Anal and Rectal Disorders

Antihaemorrhoidal Preparations

FLUCORTOLONE CAPROATE WITH FLUCORTOLONE PIVALATE AND CINCHOCAINE
Oint 950 mcg, with fluocortolone pivalate 920 mcg, and cinchoacaine hydrochloride 5 mg per g........................................6.35 30 g OP ✔ Ultraproct
Suppos 630 mcg, with fluocortolone pivalate 610 mcg, and cinchoacaine hydrochloride 1 mg........................................2.66 12 ✔ Ultraproct

HYDROCORTISONE WITH CINCHOCAINE
Oint 5 mg with cinchoacaine hydrochloride 5 mg per g .....................15.00 30 g OP ✔ Proctosedyl
Suppos 5 mg with cinchoacaine hydrochloride 5 mg per g .................9.90 12 ✔ Proctosedyl

▲Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber or pharmacist.
*Three months or six months, as applicable, dispensed all-at-once
### Management of Anal Fissures

**GLYCERYL TRINITRATE** – Special Authority see SA1329 below – Retail pharmacy

<table>
<thead>
<tr>
<th>Manufacturer’s Price</th>
<th>Fully Subsidised</th>
</tr>
</thead>
<tbody>
<tr>
<td>$22.00 30 g OP</td>
<td>✓ Rectogesic</td>
</tr>
</tbody>
</table>

**SA1329** Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified where the patient has a chronic anal fissure that has persisted for longer than three weeks.

### Antispasmodics and Other Agents Altering Gut Motility

**GLYCOPYRRONIUM BROMIDE**

- Inj 200 mcg per ml, 1 ml ampoule – Up to 10 inj available on a PSO
  - Initial application from any relevant practitioner. Approvals valid without further renewal unless notified where the patient has a chronic anal fissure that has persisted for longer than three weeks.

<table>
<thead>
<tr>
<th>Manufacturer’s Price</th>
<th>Fully Subsidised</th>
</tr>
</thead>
<tbody>
<tr>
<td>$17.14 10 inj</td>
<td>✓ Max Health</td>
</tr>
</tbody>
</table>

**HYOSCINE BUTYLBRONIDE**

<table>
<thead>
<tr>
<th>Manufacturer’s Price</th>
<th>Fully Subsidised</th>
</tr>
</thead>
<tbody>
<tr>
<td>$8.75 100 inj</td>
<td>✓ Buscopan</td>
</tr>
</tbody>
</table>

**MEBEVERINE HYDROCHLORIDE**

<table>
<thead>
<tr>
<th>Manufacturer’s Price</th>
<th>Fully Subsidised</th>
</tr>
</thead>
<tbody>
<tr>
<td>$18.00 90 inj</td>
<td>✓ Colofac</td>
</tr>
</tbody>
</table>

### Anticelebrants

#### Antisecretory and Cytoprotective

**MISOPROSTOL**

<table>
<thead>
<tr>
<th>Manufacturer’s Price</th>
<th>Fully Subsidised</th>
</tr>
</thead>
<tbody>
<tr>
<td>$41.50 120 inj</td>
<td>✓ Cytotec</td>
</tr>
</tbody>
</table>

### Helicobacter Pylori Eradication

**CLARITHROMYCIN**

<table>
<thead>
<tr>
<th>Manufacturer’s Price</th>
<th>Fully Subsidised</th>
</tr>
</thead>
<tbody>
<tr>
<td>$10.40 14 tab</td>
<td>✓ Apo-Clarithromycin</td>
</tr>
</tbody>
</table>

  a) Maximum of 14 tab per prescription

  b) Subsidised only if prescribed for helicobacter pylori eradication and prescription is endorsed accordingly.

  Note: the prescription is considered endorsed if clarithromycin is prescribed in conjunction with a proton pump inhibitor and either amoxicillin or metronidazole.

#### H2 Antagonists

**RANITIDINE** – Only on a prescription

<table>
<thead>
<tr>
<th>Manufacturer’s Price</th>
<th>Fully Subsidised</th>
</tr>
</thead>
<tbody>
<tr>
<td>$12.91 500 inj</td>
<td>✓ Ranitidine Relief</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Manufacturer’s Price</th>
<th>Fully Subsidised</th>
</tr>
</thead>
<tbody>
<tr>
<td>$18.21 500 inj</td>
<td>✓ Ranitidine Relief</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Manufacturer’s Price</th>
<th>Fully Subsidised</th>
</tr>
</thead>
<tbody>
<tr>
<td>$5.14 300 ml</td>
<td>✓ Peptisoothe</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Manufacturer’s Price</th>
<th>Fully Subsidised</th>
</tr>
</thead>
<tbody>
<tr>
<td>$8.75 5 inj</td>
<td>✓ Zantac</td>
</tr>
</tbody>
</table>

#### Proton Pump Inhibitors

**LANSOPRAZOLE**

<table>
<thead>
<tr>
<th>Manufacturer’s Price</th>
<th>Fully Subsidised</th>
</tr>
</thead>
<tbody>
<tr>
<td>$4.58 100 inj</td>
<td>✓ Lanzol Relief</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Manufacturer’s Price</th>
<th>Fully Subsidised</th>
</tr>
</thead>
<tbody>
<tr>
<td>$5.41 100 inj</td>
<td>✓ Lanzol Relief</td>
</tr>
</tbody>
</table>
**ALIMENTARY TRACT AND METABOLISM**

**Subsidy**
(Manufacturer’s Price)

<table>
<thead>
<tr>
<th>Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Fully Subsidised ✔**

### OMEPRAZOLE

- For omeprazole suspension refer Standard Formulae, page 215
- Cap 10 mg...........................................................1.98 90 ✔ Omeprazole actavis 10
- Cap 20 mg...........................................................1.96 90 ✔ Omeprazole actavis 20
- Cap 40 mg...........................................................3.12 90 ✔ Omeprazole actavis 40
- Powder – Only in combination.....................................42.50 5g ✔ Midwest
- Inj 40 mg ampoule with diluent...................................33.98 5 ✔ Dr Reddy’s Omeprazole

### PANTOPRAZOLE

- Tab EC 20 mg ......................................................2.41 100 ✔ Panzop Relief
- Tab EC 40 mg ......................................................3.35 100 ✔ Panzop Relief

### Site Protective Agents

#### COLLOIDAL BISMUTH SUBCITRATE
- Tab 120 mg .......................................................14.51 50 ✔ Gastrodenol S29

#### SUCRALFATE
- Tab 1 g .............................................................35.50 120 (48.28) Carafate

### Bile and Liver Therapy

#### RIFAXIMIN – Special Authority see SA1461 below – Retail pharmacy
- Tab 550 mg .......................................................625.00 56 ✔ Xifaxan

[SA1461] Special Authority for Subsidy

- Initial application only from a gastroenterologist, hepatologist or Practitioner on the recommendation of a gastroenterologist or hepatologist. Approvals valid for 6 months where the patient has hepatic encephalopathy despite an adequate trial of maximum tolerated doses of lactulose.
- Renewal only from a gastroenterologist, hepatologist or Practitioner on the recommendation of a gastroenterologist or hepatologist. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment.

### Diabetes

#### Hyperglycaemic Agents

#### DIAZOXIDE – Special Authority see SA1320 below – Retail pharmacy
- Cap 25 mg..........................................................110.00 100 ✔ Proglicem S29
- Cap 100 mg..........................................................280.00 100 ✔ Proglicem S29
- Oral liq 50 mg per ml ..........................................620.00 30 ml OP ✔ Proglycem S29

[SA1320] Special Authority for Subsidy

- Initial application from any relevant practitioner. Approvals valid for 12 months where used for the treatment of confirmed hypoglycaemia caused by hyperinsulinism.
- Renewal from any relevant practitioner. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment.

#### GLUCAGON HYDROCHLORIDE
- Inj 1 mg syringe kit – Up to 5 kit available on a PSO..............32.00 1 ✔ Glucagen Hypokit

▲Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber or pharmacist.

※Three months or six months, as applicable, dispensed all-at-once
<table>
<thead>
<tr>
<th>Insulin - Short-acting Preparations</th>
<th>Subsidy (Manufacturer's Price)</th>
<th>Fully Subsidised</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>INSULIN NEUTRAL</td>
<td>$25.26 10 ml OP</td>
<td>✔ Actrapid</td>
<td></td>
</tr>
<tr>
<td>▲ Inj human 100 u per ml...</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>▲ Inj human 100 u per ml, 3 ml</td>
<td>$42.66 5</td>
<td>✔ Actrapid Penfill</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>✔ Humulin R</td>
<td></td>
</tr>
<tr>
<td>Insulin - Intermediate-acting Preparations</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>INSULIN ASPART WITH INSULIN ASPART PROTAMINE</td>
<td>$52.15 5</td>
<td>✔ NovoMix 30 FlexPen</td>
<td></td>
</tr>
<tr>
<td>▲ Inj 100 iu per ml, 3 ml prefilled pen...</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>INSULIN ISOPHANE</td>
<td>$17.68 10 ml OP</td>
<td>✔ Humulin NPH</td>
<td></td>
</tr>
<tr>
<td>▲ Inj human 100 u per ml...</td>
<td></td>
<td>✔ Protaphane</td>
<td></td>
</tr>
<tr>
<td>▲ Inj human 100 u per ml, 3 ml</td>
<td>$29.86 5</td>
<td>✔ Humulin NPH</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>✔ Protaphane Penfill</td>
<td></td>
</tr>
<tr>
<td>INSULIN ISOPHANE WITH INSULIN NEUTRAL</td>
<td>$25.26 10 ml OP</td>
<td>✔ Humulin 30/70</td>
<td></td>
</tr>
<tr>
<td>▲ Inj human with neutral insulin 100 u per ml...</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>▲ Inj human with neutral insulin 100 u per ml, 3 ml...</td>
<td>$42.66 5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>INSULIN LISPRO WITH INSULIN LISPRO PROTAMINE</td>
<td>$42.66 5</td>
<td>✔ Humalog Mix 25</td>
<td></td>
</tr>
<tr>
<td>▲ Inj lispro 25% with insulin lispro protamine 75% 100 u per ml, 3 ml...</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>▲ Inj lispro 50% with insulin lispro protamine 50% 100 u per ml, 3 ml...</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Insulin - Long-acting Preparations</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>INSULIN GLARGINE</td>
<td>$63.00 1</td>
<td>✔ Lantus</td>
<td></td>
</tr>
<tr>
<td>▲ Inj 100 u per ml, 10 ml...</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>▲ Inj 100 u per ml, 3 ml...</td>
<td>$94.50 5</td>
<td>✔ Lantus</td>
<td></td>
</tr>
<tr>
<td>▲ Inj 100 u per ml, 3 ml disposable pen...</td>
<td></td>
<td>✔ Lantus SoloStar</td>
<td></td>
</tr>
<tr>
<td>Insulin - Rapid Acting Preparations</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>INSULIN ASPART</td>
<td>$30.03 1</td>
<td>✔ NovoRapid</td>
<td></td>
</tr>
<tr>
<td>▲ Inj 100 u per ml, 10 ml...</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>▲ Inj 100 u per ml, 3 ml...</td>
<td>$51.19 5</td>
<td>✔ NovoRapid Penfill</td>
<td></td>
</tr>
<tr>
<td>▲ Inj 100 u per ml, 3 ml syringe</td>
<td>$51.19 5</td>
<td>✔ NovoRapid FlexPen</td>
<td></td>
</tr>
<tr>
<td>INSULIN GLULISINE</td>
<td>$27.03 1</td>
<td>✔ Apidra</td>
<td></td>
</tr>
<tr>
<td>▲ Inj 100 u per ml, 10 ml...</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>▲ Inj 100 u per ml, 3 ml...</td>
<td>$46.07 5</td>
<td>✔ Apidra</td>
<td></td>
</tr>
<tr>
<td>▲ Inj 100 u per ml, 3 ml disposable pen...</td>
<td></td>
<td>✔ Apidra SoloStar</td>
<td></td>
</tr>
<tr>
<td>INSULIN LISPRO</td>
<td>$34.92 10 ml OP</td>
<td>✔ Humalog</td>
<td></td>
</tr>
<tr>
<td>▲ Inj 100 u per ml, 10 ml...</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>▲ Inj 100 u per ml, 3 ml...</td>
<td>$59.52 5</td>
<td>✔ Humalog</td>
<td></td>
</tr>
</tbody>
</table>
# ALIMENTARY TRACT AND METABOLISM

### Subsidy

<table>
<thead>
<tr>
<th>Manufacturer's Price</th>
<th>Fully Subsidised</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per</td>
<td>✔ Brand or Generic Manufacturer</td>
</tr>
</tbody>
</table>

### Alpha Glucosidase Inhibitors

**ACARBOSE**

- Tab 50 mg .................................................. 3.50 90 ✔ **Glucobay**
- Tab 100 mg ................................................ 6.40 90 ✔ **Glucobay**

### Oral Hypoglycaemic Agents

**GLIBENCLAMIDE**

- Tab 5 mg .................................................. 6.00 100 ✔ **Daonil**

**GLICLAZIDE**

- Tab 80 mg .................................................. 10.29 500 ✔ **Glizide**

**GLIPIZIDE**

- Tab 5 mg .................................................. 3.27 100 ✔ **Minidiab**
  
  Minidiab to be Sole Supply on 1 January 2019

**METFORMIN HYDROCHLORIDE**

- Tab immediate-release 500 mg ........................................... 8.63 1,000 ✔ **Apotex**
- Tab immediate-release 850 mg ........................................... 7.04 500 ✔ **Apotex**
  
  **Metformin Mylan**

**PIOGLITAZONE**

- Tab 15 mg .................................................. 3.47 90 ✔ **Vexazone**
- Tab 30 mg .................................................. 5.06 90 ✔ **Vexazone**
- Tab 45 mg .................................................. 7.10 90 ✔ **Vexazone**

**VILDAGLIPTIN**

  - Tab 50 mg .................................................. 40.00 60 ✔ **Galvus**

**VILDAGLIPTIN WITH METFORMIN HYDROCHLORIDE**

  - Tab 50 mg with 1,000 mg metformin hydrochloride .................................. 40.00 60 ✔ **Galvumet**
  - Tab 50 mg with 850 mg metformin hydrochloride .................................. 40.00 60 ✔ **Galvumet**

### Diabetes Management

#### Ketone Testing

**BLOOD KETONE DIAGNOSTIC TEST STRIP** – Subsidy by endorsement

a) Not on a BSO
b) Maximum of 20 strip per prescription
c) Up to 10 strip available on a PSO
d) Patient has any of the following:
   1) type 1 diabetes; or
   2) permanent neonatal diabetes; or
   3) undergone a pancreatectomy; or
   4) cystic fibrosis-related diabetes; or
   5) metabolic disease or epilepsy under the care of a paediatrician, neurologist or metabolic specialist.

The prescription must be endorsed accordingly.

- Test strips .................................................. 15.50 10 strip OP ✔ **KetoSens**

**SODIUM NITROPRUSSIDE** – Maximum of 50 strip per prescription

- Test strip – Not on a BSO .................................. 22.00 50 strip OP ✔ **Ketostix**

(Ketostix Test strip to be delisted 1 February 2019)

▲ Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber or pharmacist.

☆ Three months or six months, as applicable, dispensed all-at-once
Dual Blood Glucose and Blood Ketone Testing

DUAL BLOOD GLUCOSE AND BLOOD KETONE DIAGNOSTIC TEST METER – Subsidy by endorsement

a) Maximum of 1 pack per prescription
b) Up to 1 pack available on a PSO
c) A dual blood glucose and blood ketone diagnostic test meter is subsidised for a patient who has:
   1) type 1 diabetes; or
   2) permanent neonatal diabetes; or
   3) undergone a pancreatectomy; or
   4) cystic fibrosis-related diabetes; or
   5) metabolic disease or epilepsy under the care of a paediatrician, neurologist or metabolic specialist.

The prescription must be endorsed accordingly. Only 1 meter per patient will be subsidised (no repeat prescriptions). For the avoidance of doubt patients who have previously received a funded meter, other than CareSens, are eligible for a funded CareSens meter.

Meter with 50 lancets, a lancing device and 10 blood glucose diagnostic test strips .......................................................... 20.00 1 OP ✓ CareSens Dual

Blood Glucose Testing

BLOOD GLUCOSE DIAGNOSTIC TEST METER – Subsidy by endorsement

a) Maximum of 1 pack per prescription
b) Up to 1 pack available on a PSO
c) A diagnostic blood glucose test meter is subsidised for a patient who:
   1) is receiving insulin or sulphonylurea therapy; or
   2) is pregnant with diabetes; or
   3) is on home TPN at risk of hypoglycaemia or hyperglycaemia; or
   4) has a genetic or an acquired disorder of glucose homeostasis, excluding type 1 or type 2 diabetes and metabolic syndrome.

The prescription must be endorsed accordingly. Only one CareSens meter per patient will be subsidised (no repeat prescriptions). Patients already using the CareSens N POP meter and CareSens N meter are not eligible for a new meter, unless they have:
   1) type 1 diabetes; or
   2) permanent neonatal diabetes; or
   3) undergone a pancreatectomy; or
   4) cystic fibrosis-related diabetes.

For the avoidance of doubt patients who have previously received a funded meter, other than CareSens, are eligible for a funded CareSens meter.

Meter with 50 lancets, a lancing device and 10 diagnostic test strips .......................................................... 10.00 1 OP ✓ CareSens N ✓ CareSens N POP ✓ CareSens N Premier

Note: Only 1 meter available per PSO
BLOOD GLUCOSE DIAGNOSTIC TEST STRIP – Up to 50 test available on a PSO

The number of test strips available on a prescription is restricted to 50 unless:

1) Prescribed for a patient on insulin or a sulphonylurea and endorsed accordingly. Pharmacists may annotate the prescription as endorsed where there exists a record of prior dispensing of insulin or sulphonylurea; or
2) Prescribed on the same prescription as insulin or a sulphonylurea in which case the prescription is deemed to be endorsed; or
3) Prescribed for a pregnant woman with diabetes and endorsed accordingly; or
4) Prescribed for a patient on home TPN at risk of hypoglycaemia or hyperglycaemia and endorsed accordingly; or
5) Prescribed for a patient with a genetic or an acquired disorder of glucose homeostasis excluding type 1 or type 2 diabetes and metabolic syndrome and endorsed accordingly.

Test strips........................................................................................................ 10.56  50 test OP ✔ CareSens N ✔ CareSens PRO

BLOOD GLUCOSE TEST STRIPS (VISUALLY IMPAIRED)

The number of test strips available on a prescription is restricted to 50 unless:

1) Prescribed for a patient on insulin or a sulphonylurea and endorsed accordingly. Pharmacists may annotate the prescription as endorsed where there exists a record of prior dispensing of insulin or sulphonylurea; or
2) Prescribed on the same prescription as insulin or a sulphonylurea in which case the prescription is deemed to be endorsed; or
3) Prescribed for a pregnant woman with diabetes and endorsed accordingly; or
4) Prescribed for a patient on home TPN at risk of hypoglycaemia or hyperglycaemia and endorsed accordingly; or
5) Prescribed for a patient with a genetic or an acquired disorder of glucose homeostasis excluding type 1 or type 2 diabetes and metabolic syndrome and endorsed accordingly.

Blood glucose test strips............................................................................... 26.20  50 test OP ✔ SensoCard

Insulin Syringes and Needles

Subsidy is available for disposable insulin syringes, needles, and pen needles if prescribed on the same form as the one used for the supply of insulin or when prescribed for an insulin patient and the prescription is endorsed accordingly. Pharmacists may annotate the prescription as endorsed where there exists a record of prior dispensing of insulin.

INSULIN PEN NEEDLES – Maximum of 100 dev per prescription

* 29 g × 12.7 mm ................................................................. 10.50  100 ✔ B-D Micro-Fine
* 31 g × 5 mm ................................................................. 11.75  100 ✔ B-D Micro-Fine
* 31 g × 6 mm ................................................................. 10.50  100 ✔ ABM
* 31 g × 8 mm ................................................................. 10.50  100 ✔ B-D Micro-Fine
* 32 g × 4 mm ................................................................. 10.50  100 ✔ B-D Micro-Fine

▲ Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber or pharmacist.
※ Three months or six months, as applicable, dispensed all-at-once
INSULIN SYRINGES, DISPOSABLE WITH ATTACHED NEEDLE – Maximum of 100 dev per prescription

<table>
<thead>
<tr>
<th>Syringe Description</th>
<th>Subsidy (Manufacturer’s Price)</th>
<th>Fully Subsidised</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Syringe 0.3 ml with 29 g x 12.7 mm needle</td>
<td>13.00</td>
<td>✔</td>
<td>B-D Ultra Fine</td>
</tr>
<tr>
<td>Syringe 0.3 ml with 31 g x 8 mm needle</td>
<td>13.00</td>
<td>✔</td>
<td>B-D Ultra Fine II</td>
</tr>
<tr>
<td>Syringe 0.5 ml with 29 g x 12.7 mm needle</td>
<td>13.00</td>
<td>✔</td>
<td>B-D Ultra Fine</td>
</tr>
<tr>
<td>Syringe 0.5 ml with 31 g x 8 mm needle</td>
<td>13.00</td>
<td>✔</td>
<td>B-D Ultra Fine II</td>
</tr>
<tr>
<td>Syringe 1 ml with 29 g x 12.7 mm needle</td>
<td>13.00</td>
<td>✔</td>
<td>B-D Ultra Fine</td>
</tr>
<tr>
<td>Syringe 1 ml with 31 g x 8 mm needle</td>
<td>13.00</td>
<td>✔</td>
<td>B-D Ultra Fine II</td>
</tr>
</tbody>
</table>

Insulin Pumps

INSULIN PUMP – Special Authority see SA1603 below – Retail pharmacy

a) Maximum of 1 dev per prescription
b) Only on a prescription
c) Maximum of 1 insulin pump per patient each four year period.

Min basal rate 0.001 U/h .............................................................. 4,500.00 1 ✔ Tandem t:slim X2
Min basal rate 0.025 U/h .............................................................. 8,800.00 1 ✔ MiniMed 640G

SA1603 Special Authority for Subsidy

Initial application — (permanent neonatal diabetes) only from a relevant specialist or nurse practitioner. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:
1. Patient has permanent neonatal diabetes; and
2. A MDI regimen trial is inappropriate; and
3. Has been evaluated by the multidisciplinary team for their suitability for insulin pump therapy; and
4. Patient/Parent/Guardian has undertaken carbohydrate counting education (either a carbohydrate counting course or direct education from an appropriate health professional); and
5. Applicant is part of a multidisciplinary team experienced in the management of type 1 diabetes care; and
6. Either:
   6.1 Applicant is a relevant specialist; or
   6.2 Applicant is a nurse practitioner working within their vocational scope.

Renewal — (permanent neonatal diabetes) only from a relevant specialist or nurse practitioner. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:
1. Patient is continuing to derive benefit according to the treatment plan agreed at induction; and
2. Patient remains fully compliant and transition to MDI is considered inappropriate by the treating physician; and
3. It has been at least 4 years since the last insulin pump received by the patient or, in the case of patients qualifying under previous pump therapy for the initial application; the pump is due for replacement; and
4. Either:
   continued…
continued...

4.1 Applicant is a relevant specialist; or
4.2 Applicant is a nurse practitioner working within their vocational scope.

Initial application — (severe unexplained hypoglycaemia) only from a relevant specialist or nurse practitioner. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

1. Patient has type 1 diabetes or has undergone a pancreatectomy or has cystic fibrosis-related diabetes; and
2. Has undertaken carbohydrate counting education (either a carbohydrate counting course or direct education from an appropriate health professional); and
3. Applicant is part of a multidisciplinary team experienced in the management of type 1 diabetes care; and
4. Has adhered to an intensive MDI regimen using analogue insulins for at least six months; and
5. Has had four severe unexplained hypoglycaemic episodes over a six month period (severe as defined as requiring the assistance of another person); and
6. Has an average HbA1c between the following range: equal to or greater than 53 mmol/mol and equal to or less than 90 mmol/mol; and
7. Has been evaluated by the multidisciplinary team for their suitability for insulin pump therapy; and
8. Either:
   8.1 Applicant is a relevant specialist; or
   8.2 Applicant is a nurse practitioner working within their vocational scope.

Renewal — (severe unexplained hypoglycaemia) only from a relevant specialist or nurse practitioner. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

1. Patient is continuing to derive benefit according to the treatment plan agreed at induction of at least a 50% reduction from baseline in hypoglycaemic events; and
2. HbA1c has not increased by more than 5 mmol/mol from baseline; and
3. Either:
   3.1 It has been at least 4 years since the last insulin pump was received by the patient; or
   3.2 The pump is due for replacement; and
4. Either:
   4.1 Applicant is a relevant specialist; or
   4.2 Applicant is a nurse practitioner working within their vocational scope.

Initial application — (HbA1c) only from a relevant specialist or nurse practitioner. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

1. Patient has type 1 diabetes or has undergone a pancreatectomy or has cystic fibrosis-related diabetes; and
2. Has undertaken carbohydrate counting education (either a carbohydrate counting course or direct education from an appropriate health professional); and
3. Applicant is part of a multidisciplinary team experienced in the management of type 1 diabetes care; and
4. Has adhered to an intensive MDI regimen using analogue insulins for at least six months; and
5. Has unpredictable and significant variability in blood glucose including significant hypoglycaemia affecting the ability to reduce HbA1; and
6. In the opinion of the treating clinician, HbA1c could be reduced by at least 10 mmol/mol using insulin pump treatment; and
7. Has typical HbA1c results between the following range: equal to or greater than 65 mmol/mol and equal to or less than 90 mmol/mol; and
8. Has been evaluated by the multidisciplinary team for their suitability for insulin pump therapy; and
9. Either:
   9.1 Applicant is a relevant specialist; or
   9.2 Applicant is a nurse practitioner working within their vocational scope.

continued…
Renewal — (HbA1c) only from a relevant specialist or nurse practitioner. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

1. Patient is continuing to derive benefit according to the treatment plan agreed at induction of achieving and maintaining a reduction in HbA1c from baseline of 10 mmol/mol; and
2. The number of severe unexplained recurrent hypoglycaemic episodes has not increased from baseline; and
3. Either:
   - 3.1 It has been at least 4 years since the last insulin pump was received by the patient; or
   - 3.2 The pump is due for replacement; and
4. Either:
   - 4.1 Applicant is a relevant specialist; or
   - 4.2 Applicant is a nurse practitioner working within their vocational scope.

Initial application — (Previous use before 1 September 2012) only from a relevant specialist or nurse practitioner. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

1. Patient has type 1 diabetes or has undergone a pancreatectomy or has cystic fibrosis-related diabetes; and
2. Was already on pump treatment prior to 1 September 2012 and had been evaluated by the multidisciplinary team for their suitability for insulin pump therapy at the time of initiating that pump treatment and continues to benefit from pump treatment; and
3. The patient has adhered to an intensive MDI regimen using analogue insulins for at least six months prior to initiating pump therapy; and
4. The patient is continuing to derive benefit from pump therapy; and
5. The patient had achieved and is maintaining a HbA1c of equal to or less than 80 mmol/mol on pump therapy; and
6. The patient has had no increase in severe unexplained hypoglycaemic episodes from baseline; and
7. The patient's HbA1c has not deteriorated more than 5 mmol/mol from baseline; and
8. Either:
   - 8.1 It has been at least 4 years since the last insulin pump was received by the patient; or
   - 8.2 The pump is due for replacement; and
9. Either:
   - 9.1 Applicant is a relevant specialist; or
   - 9.2 Applicant is a nurse practitioner working within their vocational scope.

Renewal — (Previous use before 1 September 2012) only from a relevant specialist or nurse practitioner. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

1. The patient is continuing to derive benefit according to the treatment plan and has maintained a HbA1c of equal to or less than 80 mmol/mol; and
2. The patient’s HbA1c has not deteriorated more than 5 mmol/mol from the time of commencing pump treatment; and
3. The patient has not had an increase in severe unexplained hypoglycaemic episodes from baseline; and
4. Either:
   - 4.1 It has been at least 4 years since the last insulin pump was received by the patient; or
   - 4.2 The pump is due for replacement; and
5. Either:
   - 5.1 Applicant is a relevant specialist; or
   - 5.2 Applicant is a nurse practitioner working within their vocational scope.
Insulin Pump Consumables

SA1604 Special Authority for Subsidy

**Initial application — (permanent neonatal diabetes)** only from a relevant specialist or nurse practitioner. Approvals valid for 9 months for applications meeting the following criteria:

All of the following:

1. Patient has permanent neonatal diabetes; and
2. A MDI regimen trial is inappropriate; and
3. Has been evaluated by the multidisciplinary team for their suitability for insulin pump therapy; and
4. Patient/Parent/Guardian has undertaken carbohydrate counting education (either a carbohydrate counting course or direct education from an appropriate health professional); and
5. Applicant is part of a multidisciplinary team experienced in the management of type 1 diabetes care; and
6. Either:
   - 6.1 Applicant is a relevant specialist; or
   - 6.2 Applicant is a nurse practitioner working within their vocational scope.

**Renewal — (permanent neonatal diabetes)** only from a relevant specialist or nurse practitioner. Approvals valid for 2 years for applications meeting the following criteria:

All of the following:

1. Patient is continuing to derive benefit according to the treatment plan agreed at induction; and
2. Patient remains fully compliant and transition to MDI is considered inappropriate by the treating physician; and
3. Either:
   - 3.1 Applicant is a relevant specialist; or
   - 3.2 Applicant is a nurse practitioner working within their vocational scope.

**Initial application — (severe unexplained hypoglycaemia)** only from a relevant specialist or nurse practitioner. Approvals valid for 9 months for applications meeting the following criteria:

All of the following:

1. Patient has type 1 diabetes or has undergone a pancreatectomy or has cystic fibrosis-related diabetes; and
2. Has undertaken carbohydrate counting education (either a carbohydrate counting course or direct education from an appropriate health professional); and
3. Applicant is part of a multidisciplinary team experienced in the management of type 1 diabetes care; and
4. Has adhered to an intensive MDI regimen using analogue insulins for at least six months; and
5. Has had four severe unexplained hypoglycaemic episodes over a six month period (severe as defined as requiring the assistance of another person); and
6. Has an average HbA1c between the following range: equal to or greater than 53 mmol/mol and equal to or less than 90 mmol/mol; and
7. Has been evaluated by the multidisciplinary team for their suitability for insulin pump therapy; and
8. Either:
   - 8.1 Applicant is a relevant specialist; or
   - 8.2 Applicant is a nurse practitioner working within their vocational scope.

**Renewal — (severe unexplained hypoglycaemia)** only from a relevant specialist or nurse practitioner. Approvals valid for 2 years for applications meeting the following criteria:

All of the following:

1. Patient is continuing to derive benefit according to the treatment plan agreed at induction of at least a 50% reduction from baseline in hypoglycaemic events; and
2. HbA1c has not increased by more than 5 mmol/mol from baseline; and
3. Either:
   - 3.1 Applicant is a relevant specialist; or

continued…

▲ Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber or pharmacist.

★ Three months or six months, as applicable, dispensed all-at-once
3.2 Applicant is a nurse practitioner working within their vocational scope.

**Initial application — (HbA1c)** only from a relevant specialist or nurse practitioner. Approvals valid for 9 months for applications meeting the following criteria:
All of the following:
1. Patient has type 1 diabetes or has undergone a pancreatectomy or has cystic fibrosis-related diabetes; and
2. Has undertaken carbohydrate counting education (either a carbohydrate counting course or direct education from an appropriate health professional); and
3. Applicant is part of a multidisciplinary team experienced in the management of type 1 diabetes care; and
4. Has adhered to an intensive MDI regimen using analogue insulins for at least six months; and
5. Has unpredictable and significant variability in blood glucose including significant hypoglycaemia affecting the ability to reduce HbA1c; and
6. In the opinion of the treating clinician, HbA1c could be reduced by at least 10 mmol/mol using insulin pump treatment; and
7. Has typical HbA1c results between the following range: equal to or greater than 65 mmol/mol and equal to or less than 90 mmol/mol; and
8. Has been evaluated by the multidisciplinary team for their suitability for insulin pump therapy; and
9. Either:
   9.1 Applicant is a relevant specialist; or
   9.2 Applicant is a nurse practitioner working within their vocational scope.

**Renewal — (HbA1c)** only from a relevant specialist or nurse practitioner. Approvals valid for 2 years for applications meeting the following criteria:
All of the following:
1. Patient is continuing to derive benefit according to the treatment plan agreed at induction of achieving and maintaining a reduction in HbA1c from baseline of 10 mmol/mol; and
2. The number of severe unexplained recurrent hypoglycaemic episodes has not increased from baseline; and
3. Either:
   3.1 Applicant is a relevant specialist; or
   3.2 Applicant is a nurse practitioner working within their vocational scope.

**Initial application — (Previous use before 1 September 2012)** only from a relevant specialist or nurse practitioner. Approvals valid for 2 years for applications meeting the following criteria:
All of the following:
1. Patient has type 1 diabetes or has undergone a pancreatectomy or has cystic fibrosis-related diabetes; and
2. Was already on pump treatment prior to 1 September 2012 and had been evaluated by the multidisciplinary team for their suitability for insulin pump therapy at the time of initiating that pump treatment and continues to benefit from pump treatment; and
3. The patient has adhered to an intensive MDI regimen using analogue insulins for at least six months prior to initiating pump treatment; and
4. The patient is continuing to derive benefit from pump therapy; and
5. The patient had achieved and is maintaining a HbA1c of equal to or less than 80 mmol/mol on pump therapy; and
6. The patient has had no increase in severe unexplained hypoglycaemic episodes from baseline; and
7. The patient’s HbA1c has not deteriorated more than 5 mmol/mol from baseline; and
8. Either:
   8.1 Applicant is a relevant specialist; or
   8.2 Applicant is a nurse practitioner working within their vocational scope.

**Renewal — (Previous use before 1 September 2012)** only from a relevant specialist or nurse practitioner. Approvals valid for 2 years for applications meeting the following criteria:
All of the following:
1. The patient is continuing to derive benefit according to the treatment plan and has maintained a HbA1c of equal to or less...
continued...

than 80 mmol/mol; and
2 The patient’s HbA1c has not deteriorated more than 5 mmol/mol from initial application; and
3 The patient has not had an increase in severe unexplained hypoglycaemic episodes from baseline; and
4 Either:
   4.1 Applicant is a relevant specialist; or
   4.2 Applicant is a nurse practitioner working within their vocational scope.

INSULIN PUMP ACCESSORIES – Special Authority see SA1604 on page 17 – Retail pharmacy

a) Maximum of 1 cap per prescription
b) Only on a prescription
c) Maximum of 1 prescription per 180 days.

Battery cap .................................................................................................................. 32.00 1 ✔ Animas Battery Cap
(Animas Battery Cap Battery cap to be delisted 1 October 2019)

INSULIN PUMP CARTRIDGE – Special Authority see SA1604 on page 17 – Retail pharmacy

a) Maximum of 3 sets per prescription
b) Only on a prescription
c) Maximum of 13 packs of cartridge sets will be funded per year.

Cartridge 300 U, t:lock x 10................................................................. 50.00 1 OP ✔ Tandem Cartridge
**ALIMENTARY TRACT AND METABOLISM**

<table>
<thead>
<tr>
<th>Subsidy (Manufacturer's Price)</th>
<th>Fully Subsidised</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>INSULIN PUMP INFUSION SET (STEEL CANNULA)</strong> – Special Authority see SA1604 on page 17 – Retail pharmacy</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

a) Maximum of 3 sets per prescription  

b) Only on a prescription  
c) Maximum of 13 infusion sets will be funded per year.  

10 mm steel needle; 29 G; manual insertion; 60 cm tubing ×  

10 with 10 needles .......................................................... 130.00 1 OP  

Paradigm Sure-T MMT-884  

10 mm steel needle; 29 G; manual insertion; 60 cm tubing ×  

10 with 10 needles; luer lock ............................................. 130.00 1 OP  

Sure-T MMT-883  

10 mm steel needle; 29 G; manual insertion; 80 cm tubing ×  

10 with 10 needles .......................................................... 130.00 1 OP  

Paradigm Sure-T MMT-886  

10 mm steel needle; 29 G; manual insertion; 80 cm tubing ×  

10 with 10 needles; luer lock ............................................. 130.00 1 OP  

Sure-T MMT-885  

6 mm steel cannula; straight insertion; 60 cm grey line ×  

10 with 10 needles .......................................................... 130.00 1 OP  

Contact-D  

6 mm steel needle; 29 G; manual insertion; 60 cm tubing ×  

10 with 10 needles .......................................................... 130.00 1 OP  

Paradigm Sure-T MMT-864  

6 mm steel needle; 29 G; manual insertion; 60 cm tubing ×  

10 with 10 needles; luer lock ............................................. 130.00 1 OP  

Sure-T MMT-863  

Paradigm Sure-T MMT-866  

6 mm steel needle; 29 G; manual insertion; 80 cm tubing ×  

10 with 10 needles .......................................................... 130.00 1 OP  

Sure-T MMT-865  

8 mm steel cannula; straight insertion; 110 cm grey line ×  

10 with 10 needles .......................................................... 130.00 1 OP  

Contact-D  

8 mm steel cannula; straight insertion; 60 cm grey line ×  

10 with 10 needles .......................................................... 130.00 1 OP  

Contact-D  

8 mm steel needle; 29 G; manual insertion; 60 cm tubing ×  

10 with 10 needles .......................................................... 130.00 1 OP  

Paradigm Sure-T MMT-874  

8 mm steel needle; 29 G; manual insertion; 60 cm tubing ×  

10 with 10 needles; luer lock ............................................. 130.00 1 OP  

Sure-T MMT-873  

8 mm steel needle; 29 G; manual insertion; 80 cm tubing ×  

10 with 10 needles .......................................................... 130.00 1 OP  

Paradigm Sure-T MMT-876  

8 mm steel needle; 29 G; manual insertion; 80 cm tubing ×  

10 with 10 needles; luer lock ............................................. 130.00 1 OP  

Sure-T MMT-875  

(Contact-D 6 mm steel cannula; straight insertion; 60 cm grey line × 10 with 10 needles to be delisted 1 October 2019)  

(Contact-D 8 mm steel cannula; straight insertion; 110 cm grey line × 10 with 10 needles to be delisted 1 October 2019)  

(Contact-D 8 mm steel cannula; straight insertion; 60 cm grey line × 10 with 10 needles to be delisted 1 October 2019)
<table>
<thead>
<tr>
<th>Insulin Pump Infusion Set (Steel Cannula, Straight Insertion)</th>
<th>Special Authority see SA1604 on page 17 – Retail pharmacy</th>
</tr>
</thead>
<tbody>
<tr>
<td>a) Maximum of 3 sets per prescription</td>
<td>b) Only on a prescription</td>
</tr>
<tr>
<td>c) Maximum of 13 infusion sets will be funded per year.</td>
<td></td>
</tr>
<tr>
<td>6 mm steel cannula; straight insertion; 60 cm line x 10 with</td>
<td></td>
</tr>
<tr>
<td>10 needles .................................................................... 130.00 1 OP ✔ TruSteel</td>
<td></td>
</tr>
<tr>
<td>6 mm steel cannula; straight insertion; 81 cm line x 10 with</td>
<td></td>
</tr>
<tr>
<td>10 needles .................................................................... 130.00 1 OP ✔ TruSteel</td>
<td></td>
</tr>
<tr>
<td>8 mm steel cannula; straight insertion; 60 cm line x 10 with</td>
<td></td>
</tr>
<tr>
<td>10 needles .................................................................... 130.00 1 OP ✔ TruSteel</td>
<td></td>
</tr>
<tr>
<td>8 mm steel cannula; straight insertion; 81 cm line x 10 with</td>
<td></td>
</tr>
<tr>
<td>10 needles .................................................................... 130.00 1 OP ✔ TruSteel</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Insulin Pump Infusion Set (Teflon Cannula, Angle Insertion with Insertion Device)</th>
<th>Special Authority see SA1604 on page 17 – Retail pharmacy</th>
</tr>
</thead>
<tbody>
<tr>
<td>a) Maximum of 3 sets per prescription</td>
<td>b) Only on a prescription</td>
</tr>
<tr>
<td>c) Maximum of 13 infusion sets will be funded per year.</td>
<td></td>
</tr>
<tr>
<td>13 mm teflon cannula; angle insertion; insertion device; 110 cm grey line x 10</td>
<td></td>
</tr>
<tr>
<td>10 needles .................................................................... 140.00 1 OP ✔ Inset 30</td>
<td></td>
</tr>
<tr>
<td>13 mm teflon cannula; angle insertion; insertion device; 60 cm grey line x 10</td>
<td></td>
</tr>
<tr>
<td>10 needles .................................................................... 140.00 1 OP ✔ Inset 30</td>
<td></td>
</tr>
<tr>
<td>13 mm teflon cannula; angle insertion; insertion device; 110 cm line x 10 with</td>
<td></td>
</tr>
<tr>
<td>10 needles .................................................................... 140.00 1 OP ✔ AutoSoft 30</td>
<td></td>
</tr>
<tr>
<td>13 mm teflon cannula; angle insertion; insertion device; 60 cm line x 10 with</td>
<td></td>
</tr>
<tr>
<td>10 needles .................................................................... 140.00 1 OP ✔ AutoSoft 30</td>
<td></td>
</tr>
</tbody>
</table>

(Inset 30 13 mm teflon cannula; angle insertion; insertion device; 110 cm grey line x 10 with 10 needles to be delisted 1 October 2019)
(Inset 30 13 mm teflon cannula; angle insertion; insertion device; 60 cm grey line x 10 with 10 needles to be delisted 1 October 2019)
<table>
<thead>
<tr>
<th>Subsidy (Manufacturer's Price) $</th>
<th>Fully Subsidised</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subsidy</td>
<td>✓</td>
<td></td>
</tr>
</tbody>
</table>

**INSULIN PUMP INFUSION SET (TEFLON CANNULA, ANGLE INSERTION)** – Special Authority see **SA1604 on page 17** –

Retail pharmacy

- Maximum of 3 sets per prescription
- Only on a prescription
- Maximum of 13 infusion sets will be funded per year.

13 mm teflon cannula; angle insertion; 120 cm line × 10 with 10 needles ................................................................. 130.00 1 OP ✓ Paradigm Silhouette MMT-382

13 mm teflon cannula; angle insertion; 45 cm line × 10 with 10 needles ................................................................. 130.00 1 OP ✓ Paradigm Silhouette MMT-368

13 mm teflon cannula; angle insertion; 60 cm line × 10 with 10 needles ................................................................. 130.00 1 OP ✓ Paradigm Silhouette MMT-381

13 mm teflon cannula; angle insertion; 80 cm line × 10 with 10 needles ................................................................. 130.00 1 OP ✓ Paradigm Silhouette MMT-383

17 mm teflon cannula; angle insertion; 110 cm line × 10 with 10 needles ................................................................. 130.00 1 OP ✓ Paradigm Silhouette MMT-377

17 mm teflon cannula; angle insertion; 110 cm line × 10 with 10 needles; luer lock ..................................................... 130.00 1 OP ✓ Silhouette MMT-371

17 mm teflon cannula; angle insertion; 60 cm line × 10 with 10 needles ................................................................. 130.00 1 OP ✓ Paradigm Silhouette MMT-384

17 mm teflon cannula; angle insertion; 60 cm line × 10 with 10 needles; luer lock ..................................................... 130.00 1 OP ✓ Silhouette MMT-373

17 mm teflon cannula; angle insertion; 80 cm line × 10 with 10 needles ................................................................. 130.00 1 OP ✓ Paradigm Silhouette MMT-383
### INSULIN PUMP INFUSION SET (TEFLON CANNULA, STRAIGHT INSERTION WITH INSERTION DEVICE) – Special Authority

- Maximum of 3 sets per prescription
- Only on a prescription
- Maximum of 13 infusion sets will be funded per year.

<table>
<thead>
<tr>
<th>Cannula Size</th>
<th>Tubing Type</th>
<th>Length</th>
<th>needles</th>
<th>Manufacturer</th>
<th>Code</th>
<th>Price</th>
<th>Subsidised</th>
</tr>
</thead>
<tbody>
<tr>
<td>6 mm teflon</td>
<td>grey line</td>
<td>110 cm</td>
<td>10</td>
<td>Inset II</td>
<td></td>
<td>140.00</td>
<td>✔</td>
</tr>
<tr>
<td></td>
<td>blue tubing</td>
<td>45 cm</td>
<td>10</td>
<td>Paradigm Mio</td>
<td>MMT-941</td>
<td>130.00</td>
<td>✔</td>
</tr>
<tr>
<td></td>
<td>pink tubing</td>
<td>45 cm</td>
<td>10</td>
<td>Paradigm Mio</td>
<td>MMT-921</td>
<td>130.00</td>
<td>✔</td>
</tr>
<tr>
<td></td>
<td>grey line</td>
<td>60 cm</td>
<td>10</td>
<td>Paradigm Mio</td>
<td>MMT-943</td>
<td>130.00</td>
<td>✔</td>
</tr>
<tr>
<td></td>
<td>blue tubing</td>
<td>60 cm</td>
<td>10</td>
<td>Paradigm Mio</td>
<td>MMT-923</td>
<td>130.00</td>
<td>✔</td>
</tr>
<tr>
<td></td>
<td>pink tubing</td>
<td>60 cm</td>
<td>10</td>
<td>Paradigm Mio</td>
<td>MMT-925</td>
<td>130.00</td>
<td>✔</td>
</tr>
<tr>
<td></td>
<td>clear tubing</td>
<td>80 cm</td>
<td>10</td>
<td>Paradigm Mio</td>
<td>MMT-945</td>
<td>130.00</td>
<td>✔</td>
</tr>
<tr>
<td></td>
<td>grey line</td>
<td>80 cm</td>
<td>10</td>
<td>Paradigm Mio</td>
<td>MMT-965</td>
<td>130.00</td>
<td>✔</td>
</tr>
<tr>
<td>9 mm teflon</td>
<td>grey line</td>
<td>110 cm</td>
<td>10</td>
<td>Inset II</td>
<td></td>
<td>140.00</td>
<td>✔</td>
</tr>
<tr>
<td></td>
<td>grey line</td>
<td>60 cm</td>
<td>10</td>
<td>Inset II</td>
<td></td>
<td>140.00</td>
<td>✔</td>
</tr>
<tr>
<td></td>
<td>clear tubing</td>
<td>80 cm</td>
<td>10</td>
<td>Paradigm Mio</td>
<td>MMT-975</td>
<td>130.00</td>
<td>✔</td>
</tr>
<tr>
<td></td>
<td>clear tubing</td>
<td>110 cm</td>
<td>10</td>
<td>AutoSoft 90</td>
<td></td>
<td>140.00</td>
<td>✔</td>
</tr>
<tr>
<td></td>
<td>line</td>
<td>60 cm</td>
<td>10</td>
<td>AutoSoft 90</td>
<td></td>
<td>140.00</td>
<td>✔</td>
</tr>
<tr>
<td></td>
<td>line</td>
<td>110 cm</td>
<td>10</td>
<td>AutoSoft 90</td>
<td></td>
<td>140.00</td>
<td>✔</td>
</tr>
</tbody>
</table>

▲Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber or pharmacist.

※Three months or six months, as applicable, dispensed all-at-once
### ALIMENTARY TRACT AND METABOLISM

<table>
<thead>
<tr>
<th>Subsidy (Manufacturer's Price) $</th>
<th>Fully Subsidised</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$140.00</td>
<td>1 OP</td>
<td>✔</td>
</tr>
</tbody>
</table>

(Inset II 6 mm teflon cannula; straight insertion; insertion device; 110 cm grey line x 10 with 10 needles to be delisted 1 October 2019)

(Inset II 6 mm teflon cannula; straight insertion; insertion device; 60 cm grey line x 10 with 10 needles to be delisted 1 October 2019)

(Inset II 9 mm teflon cannula; straight insertion; insertion device; 110 cm grey line x 10 with 10 needles to be delisted 1 October 2019)

(Inset II 9 mm teflon cannula; straight insertion; insertion device; 60 cm grey line x 10 with 10 needles to be delisted 1 October 2019)

INSULIN PUMP INFUSION SET (TEFLON CANNULA, STRAIGHT INSERTION) – Special Authority see SA1604 on page 17 – Retail pharmacy

- Maximum of 3 sets per prescription
- Only on a prescription
- Maximum of 13 infusion sets will be funded per year.

<table>
<thead>
<tr>
<th>6 mm teflon cannula; straight insertion; 110 cm tubing x 10 with 10 needles</th>
<th>130.00 1 OP</th>
<th>✔</th>
<th>Paradigm Quick-Set MMT-398</th>
</tr>
</thead>
<tbody>
<tr>
<td>6 mm teflon cannula; straight insertion; 110 cm tubing x 10 with 10 needles; luer lock</td>
<td>130.00 1 OP</td>
<td>✔</td>
<td>Quick-Set MMT-391</td>
</tr>
<tr>
<td>6 mm teflon cannula; straight insertion; 60 cm tubing x 10 with 10 needles</td>
<td>130.00 1 OP</td>
<td>✔</td>
<td>Paradigm Quick-Set MMT-399</td>
</tr>
<tr>
<td>6 mm teflon cannula; straight insertion; 60 cm tubing x 10 with 10 needles; luer lock</td>
<td>130.00 1 OP</td>
<td>✔</td>
<td>Quick-Set MMT-393</td>
</tr>
<tr>
<td>6 mm teflon cannula; straight insertion; 80 cm tubing x 10 with 10 needles</td>
<td>130.00 1 OP</td>
<td>✔</td>
<td>Paradigm Quick-Set MMT-387</td>
</tr>
<tr>
<td>9 mm teflon cannula; straight insertion; 106 cm tubing x 10 with 10 needles</td>
<td>130.00 1 OP</td>
<td>✔</td>
<td>Paradigm Quick-Set MMT-396</td>
</tr>
<tr>
<td>9 mm teflon cannula; straight insertion; 110 cm tubing x 10 with 10 needles; luer lock</td>
<td>130.00 1 OP</td>
<td>✔</td>
<td>Quick-Set MMT-390</td>
</tr>
<tr>
<td>9 mm teflon cannula; straight insertion; 60 cm tubing x 10 with 10 needles</td>
<td>130.00 1 OP</td>
<td>✔</td>
<td>Paradigm Quick-Set MMT-397</td>
</tr>
<tr>
<td>9 mm teflon cannula; straight insertion; 60 cm tubing x 10 with 10 needles; luer lock</td>
<td>130.00 1 OP</td>
<td>✔</td>
<td>Quick-Set MMT-392</td>
</tr>
<tr>
<td>9 mm teflon cannula; straight insertion; 80 cm tubing x 10 with 10 needles</td>
<td>130.00 1 OP</td>
<td>✔</td>
<td>Paradigm Quick-Set MMT-386</td>
</tr>
</tbody>
</table>
INSULIN PUMP RESERVOIR – Special Authority see SA1604 on page 17 – Retail pharmacy

- Maximum of 3 sets per prescription
- Only on a prescription
- Maximum of 13 packs of reservoir sets will be funded per year.

10 x luer lock conversion cartridges 1.8 ml for Paradigm pumps...50.00 1 OP ✔ ADR Cartridge 1.8
Cartridge 200 U, luer lock × 10..................................................50.00 1 OP ✔ Animas Cartridge
Cartridge for 5 and 7 series pump; 1.8 ml × 10..............................50.00 1 OP ✔ Paradigm 1.8 Reservoir

Cartridge for 7 series pump; 3.0 ml × 10..........................50.00 1 OP ✔ Paradigm 3.0 Reservoir
Syringe and cartridge for 50X pump, 3.0 ml × 10...........50.00 1 OP ✔ 50X 3.0 Reservoir

Digestives Including Enzymes

PANCREATIC ENZYME

Cap pancreatin 150 mg (amylase 8,000 Ph Eur U, lipase 10,000 Ph Eur U, total protease 600 Ph Eur U)..................34.93 100 ✔ Creon 10000
Cap pancreatin (175 mg (25,000 U lipase, 22,500 U amylase, 1,250 U protease)).................................................94.40 100 ✔ Panzytrat
Cap pancreatin 300 mg (amylase 18,000 Ph Eur U, lipase 25,000 Ph Eur U, total protease 1,000 Ph Eur U)........94.38 100 ✔ Creon 25000

URSODEOXYCHOLIC ACID – Special Authority see SA1739 below – Retail pharmacy

Cap 250 mg..........................................................37.95 100 ✔ Ursosan

SA1739 Special Authority for Subsidy

Initial application — (Alagille syndrome or progressive familial intrahepatic cholestasis) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Either:
1. Patient has been diagnosed with Alagille syndrome; or
2. Patient has progressive familial intrahepatic cholestasis.

Initial application — (Chronic severe drug induced cholestatic liver injury) from any relevant practitioner. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:
1. Patient has chronic severe drug induced cholestatic liver injury; and
2. Cholestatic liver injury not due to Total Parenteral Nutrition (TPN) use in adults; and
3. Treatment with ursodeoxycholic acid may prevent hospital admission or reduce duration of stay.

Initial application — (Primary biliary cholangitis) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:
1. Primary biliary cholangitis confirmed by antimitochondrial antibody titre (AMA) > 1:80, and raised cholestatic liver enzymes with or without raised serum IgM or, if AMA is negative, by liver biopsy; and
2. Patient not requiring a liver transplant (bilirubin > 100 umol/l; decompensated cirrhosis).

Initial application — (Pregnancy) from any relevant practitioner. Approvals valid for 6 months where the patient diagnosed with cholestasis of pregnancy.

Initial application — (Haematological Transplant) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

continued…
continued...

1 Patient at risk of veno-occlusive disease or has hepatic impairment and is undergoing conditioning treatment prior to allogenic stem cell or bone marrow transplantation; and
2 Treatment for up to 13 weeks.

Initial application — (Total parenteral nutrition induced cholestasis) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:
1 Paediatric patient has developed abnormal liver function as indicated on testing which is likely to be induced by Total Parenteral Nutrition (TPN); and
2 Liver function has not improved with modifying the TPN composition.

Renewal — (Chronic severe drug induced cholestatic liver injury) from any relevant practitioner. Approvals valid for 6 months where the patient continues to benefit from treatment.
Renewal — (Pregnancy/Primary biliary cholangitis) from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Renewal — (Total parenteral nutrition induced cholestasis) from any relevant practitioner. Approvals valid for 6 months where the paediatric patient continues to require TPN and who is benefiting from treatment, defined as a sustained improvement in bilirubin levels.

Note: Ursodeoxycholic acid is not an appropriate therapy for patients requiring a liver transplant (bilirubin > 100 micromol/l; decompensated cirrhosis). These patients should be referred to an appropriate transplant centre. Treatment failure -- doubling of serum bilirubin levels, absence of a significant decrease in ALP or ALT and AST, development of varices, ascites or encephalopathy, marked worsening of pruritus or fatigue, histological progression by two stages, or to cirrhosis, need for transplantation.

Laxatives

Bulk-forming Agents

ISPAGHULA (PSYLLIUM) HUSK – Only on a prescription

* Powder for oral soln.................................................................6.05 500 g OP  ✔ Bonvit
* Powder for oral soln.................................................................6.05 500 g OP  ✔ Konsyl-D

MUCILAGINOUS LAXATIVES WITH STIMULANTS

* Dry.........................................................................................6.02 500 g OP  (17.32)
   2.41 200 g OP
   (8.72) Normacol Plus

Faecal Softeners

DOCUSATE SODIUM – Only on a prescription

* Tab 50 mg ...............................................................................2.31 100  ✔ Coloxyl
* Tab 120 mg ...........................................................................3.13 100  ✔ Coloxyl
* Enema conc 18% .................................................................5.40 100 ml OP  ✔ Coloxyl
(Coloxyl Enema conc 18% to be delisted 1 April 2019)

DOCUSATE SODIUM WITH SENNOSIDES

* Tab 50 mg with sennosides 8 mg........................................3.10 200  ✔ Laxsol

POLOXAMER – Only on a prescription

Not funded for use in the ear.

* Oral drops 10%.................................................................3.78 30 ml OP  ✔ Coloxyl

Unapproved medicine supplied under Section 29
### Opioid Receptor Antagonists - Peripheral

**METHYLNALTREXONE BROMIDE** – Special Authority see SA1691 below – Retail pharmacy

<table>
<thead>
<tr>
<th>Subsidy (Manufacturer’s Price) $</th>
<th>Fully Subsidised Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>36.00</td>
<td>1</td>
<td>✔ Relistor</td>
</tr>
<tr>
<td>246.00</td>
<td>7</td>
<td>✔ Relistor</td>
</tr>
</tbody>
</table>

**SA1691** Special Authority for Subsidy

**Initial application** — (Opioid induced constipation) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

1. The patient is receiving palliative care; and
2. Either:
   2.1 Oral and rectal treatments for opioid induced constipation are ineffective; or
   2.2 Oral and rectal treatments for opioid induced constipation are unable to be tolerated.

### Osmotic Laxatives

**GLYCEROL**

* Suppos 3.6 g – Only on a prescription ................................................. 9.25 20 ✔ PSM

**LACTULOSE** – Only on a prescription

* Oral liq 10 g per 15 ml ...................................................................... 3.18 500 ml ✔ Laevolac

**MACROGOL 3350 WITH POTASSIUM CHLORIDE, SODIUM BICARBONATE AND SODIUM CHLORIDE**

Powder for oral soln 13.125 g with potassium chloride 46.6 mg, sodium bicarbonate 178.5 mg and sodium chloride 350.7 mg .... 6.78 30 ✔ Molaxole

**SODIUM ACID PHOSPHATE – Only on a prescription**

Enema 16% with sodium phosphate 8% ..................................................... 2.50 1 ✔ Fleet Phosphate Enema

**SODIUM CITRATE WITH SODIUM LAURYL SULPHOACETATE** – Only on a prescription

Enema 90 mg with sodium lauryl sulphoacetate 9 mg per ml, 5 ml .................................................................................. 26.72 50 ✔ Micolette

### Stimulant Laxatives

**BISACODYL** – Only on a prescription

* Tab 5 mg ....................................................................................... 5.99 200 ✔ Lax-Tab
* Suppos 10 mg ................................................................................. 3.74 10 ✔ Lax-Suppositories

**SENNA** – Only on a prescription

* Tab, standardised ........................................................................ 2.17 100

(6.84) Senokot

0.43 20 ✔ Senokot

(1.72)

### Metabolic Disorder Agents

**ALGLUCOSIDASE ALFA** – Special Authority see SA1622 on the next page – Retail pharmacy

Inj 50 mg vial .................................................................................. 1,142.60 1 ✔ Myozyme

▲ Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber or pharmacist.

* Three months or six months, as applicable, dispensed all-at-once
Initial application only from a metabolic physician. Approvals valid for 12 months for applications meeting the following criteria:

1. The patient is aged up to 24 months at the time of initial application and has been diagnosed with infantile Pompe disease;
2. Any of the following:
   2.1 Diagnosis confirmed by documented deficiency of acid alpha-glucosidase by prenatal diagnosis using chorionic villus biopsies and/or cultured amniotic cells; or
   2.2 Documented deficiency of acid alpha-glucosidase, and urinary tetrasaccharide testing indicating a diagnostic elevation of glucose tetrasaccharides; or
   2.3 Documented deficiency of acid alpha-glucosidase, and documented molecular genetic testing indicating a disease-causing mutation in the acid alpha-glucosidase gene (GAA gene); or
   2.4 Documented urinary tetrasaccharide testing indicating a diagnostic elevation of glucose tetrasaccharides, and molecular genetic testing indicating a disease-causing mutation in the GAA gene; and
3. Patient has not required long-term invasive ventilation for respiratory failure prior to starting enzyme replacement therapy (ERT); and
4. Patient does not have another life-threatening or severe disease where the prognosis is unlikely to be influenced by ERT or might be reasonably expected to compromise a response to ERT; and
5. Alglucosidase alfa to be administered at doses no greater than 20 mg/kg every 2 weeks.

Renewal only from a metabolic physician. Approvals valid for 12 months for applications meeting the following criteria:

1. The treatment remains appropriate for the patient and the patient is benefiting from treatment; and
2. Alglucosidase alfa to be administered at doses no greater than 20 mg/kg every 2 weeks; and
3. Patient has not had severe infusion-related adverse reactions which were not preventable by appropriate pre-medication and/or adjustment of infusion rates; and
4. Patient has not developed another life threatening or severe disease where the long term prognosis is unlikely to be influenced by ERT; and
5. Patient has not developed another medical condition that might reasonably be expected to compromise a response to ERT; and
6. There is no evidence of life threatening progression of respiratory disease as evidenced by the needed for > 14 days of invasive ventilation; and
7. There is no evidence of new or progressive cardiomyopathy.
Special Authority for Subsidy

Initial application only from a metabolic physician. Approvals valid for 12 months for applications meeting the following criteria:

Both:
1. The patient has been diagnosed with mucopolysaccharidosis VI; and
2. Either:
   2.1 Diagnosis confirmed by demonstration of N-acetyl-galactosamine-4-sulfatase (arylsulfatase B) deficiency by either enzyme activity assay in leukocytes or skin fibroblasts; or
   2.2 Detection of two disease causing mutations and patient has a sibling who is known to have mucopolysaccharidosis VI.

Renewal only from a metabolic physician. Approvals valid for 12 months for applications meeting the following criteria:
All of the following:
1. The treatment remains appropriate for the patient and the patient is benefiting from treatment; and
2. Patient has not had severe infusion-related adverse reactions which were not preventable by appropriate pre-medication and/or adjustment of infusion rates; and
3. Patient has not developed another life threatening or severe disease where the long term prognosis is unlikely to be influenced by Enzyme Replacement Therapy (ERT); and
4. Patient has not developed another medical condition that might reasonably be expected to compromise a response to ERT.

IDURSULFASE – Special Authority see SA1623 below – Retail pharmacy

Inj 2 mg per ml, 3 ml vial...............................................................4,608.30 1 ✔ Elaprase

Special Authority for Subsidy

Initial application only from a metabolic physician. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:
1. The patient has been diagnosed with mucopolysaccharidosis VI; and
2. Either:
   2.1 Diagnosis confirmed by demonstration of N-acetyl-galactosamine-4-sulfatase (arylsulfatase B) deficiency by either enzyme activity assay in leukocytes or skin fibroblasts; or
   2.2 Detection of two disease causing mutations and patient has a sibling who is known to have mucopolysaccharidosis VI.

Renewal only from a metabolic physician. Approvals valid for 12 months for applications meeting the following criteria:
All of the following:
1. The treatment remains appropriate for the patient and the patient is benefiting from treatment; and
2. Patient has not had severe infusion-related adverse reactions which were not preventable by appropriate pre-medication and/or adjustment of infusion rates; and
3. Patient has not developed another life threatening or severe disease where the long term prognosis is unlikely to be influenced by Enzyme Replacement Therapy (ERT); and
4. Patient has not developed another medical condition that might reasonably be expected to compromise a response to ERT.

LARONIDASE – Special Authority see SA1695 below – Retail pharmacy

Inj 100 U per ml, 5 ml vial.............................................................1,335.16 1 ✔ Aldurazyme

Special Authority for Subsidy

Initial application only from a metabolic physician. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:
1. The patient has been diagnosed with Hunter Syndrome (mucopolysaccharidosis II); and
2. Either:
   2.1 Diagnosis confirmed by demonstration of iduronate 2-sulfatase deficiency in white blood cells by either enzyme assay in cultured skin fibroblasts; or
   2.2 Detection of a disease causing mutation in the iduronate 2-sulfatase gene; and
3. Patient is going to proceed with a haematopoietic stem cell transplant (HSCT) within the next 3 months and treatment with idursulfase would be bridging treatment to transplant; and
4. Patient has not required long-term invasive ventilation for respiratory failure prior to starting Enzyme Replacement Therapy (ERT); and
5. Idursulfase to be administered for a total of 24 weeks (equivalent to 12 weeks pre- and 12 weeks post-HSCT) at doses no greater than 0.5 mg/kg every week.

LARONIDASE – Special Authority see SA1695 below – Retail pharmacy

Inj 100 U per ml, 5 ml vial.............................................................1,335.16 1 ✔ Aldurazyme

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber or pharmacist.

Three months or six months, as applicable, dispensed all-at-once
continued…

laronidase would be bridging treatment to transplant; and

4 Patient has not required long-term invasive ventilation for respiratory failure prior to starting Enzyme Replacement Therapy (ERT); and

5 Laronidase to be administered for a total of 24 weeks (equivalent to 12 weeks pre- and 12 post-HSCT) at doses no greater than 100 units/kg every week.

SAPROPTERIN DIHYDROCHLORIDE – Special Authority see SA1757 below – Retail pharmacy
Tab soluble 100 mg .............................................................. 1,452.70 30 OP ✔ Kuvan

**SA1757 Special Authority for Subsidy**

*Initial application* only from a metabolic physician. Approvals valid for 1 month for applications meeting the following criteria:

All of the following:

1 Patient has phenylketonuria (PKU) and is pregnant or actively planning to become pregnant; and

2 Treatment with sapropterin is required to support management of PKU during pregnancy; and

3 Sapropterin to be administered at doses no greater than a total daily dose of 20 mg/kg; and

4 Sapropterin to be used alone or in combination with PKU dietary management; and

5 Total treatment duration with sapropterin will not exceed 22 months for each pregnancy (includes time for planning and becoming pregnant) and treatment will be stopped after delivery.

*Renewal* only from a metabolic physician or any relevant practitioner on the recommendation of a metabolic physician. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

1 Either:
   1.1 Following the initial one-month approval, the patient has demonstrated an adequate response to a 2 to 4 week trial of sapropterin with a clinically appropriate reduction in phenylalanine levels to support management of PKU during pregnancy; or
   1.2 On subsequent renewal applications, the patient has previously demonstrated response to treatment with sapropterin and maintained adequate phenylalanine levels to support management of PKU during pregnancy; and

2 Any of the following:
   2.1 Patient continues to be pregnant and treatment with sapropterin will not continue after delivery; or
   2.2 Patient is actively planning a pregnancy and this is the first renewal for treatment with sapropterin; or
   2.3 Treatment with sapropterin is required for a second or subsequent pregnancy to support management of their PKU during pregnancy; and

3 Sapropterin to be administered at doses no greater than a total daily dose of 20 mg/kg; and

4 Sapropterin to be used alone or in combination with PKU dietary management; and

5 Total treatment duration with sapropterin will not exceed 22 months for each pregnancy (includes time for planning and becoming pregnant) and treatment will be stopped after delivery.

SODIUM BENZOATE – Special Authority see SA1599 below – Retail pharmacy
Soln 100 mg per ml .............................................................. CBS 100 ml ✔ Amzoate

**SA1599 Special Authority for Subsidy**

*Initial application* only from a metabolic physician. Approvals valid for 12 months where the patient has a diagnosis of a urea cycle disorder.

*Renewal* only from a metabolic physician. Approvals valid for 12 months where the treatment remains appropriate and the patient is benefiting from treatment.

SODIUM PHENYLIBUTYRATE – Special Authority see SA1598 on the next page – Retail pharmacy
Grans 483 mg per g .............................................................. 1,920.00 174 g OP ✔ Pheburane

---

**Fully subsidised**

*Sole Subsidised Supply*

---

Unapproved medicine supplied under Section 29
ALIMENTARY TRACT AND METABOLISM

Subsidy
(Manufacturer’s Price)
$ Per
Fully Subsidised
Brand or Generic Manufacturer

SA1598 [Special Authority for Subsidy]

Initial application only from a metabolic physician. Approvals valid for 12 months where the patient has a diagnosis of a urea cycle disorder involving a deficiency of carbamylphosphate synthetase, ornithine transcarbamylase or argininosuccinate synthetase.

Renewal only from a metabolic physician. Approvals valid for 12 months where the treatment remains appropriate and the patient is benefitting from treatment.

Gaucher’s Disease

IMIGLUCERASE – Special Authority see SA0473 below – Retail pharmacy

Inj 40 iu per ml, 200 iu vial…………………………………………………………1,072.00 1 ✔ Cerezyme

Inj 40 iu per ml, 400 iu vial…………………………………………………………2,144.00 1 ✔ Cerezyme

(Cerezyme Inj 40 iu per ml, 200 iu vial to be delisted 1 March 2019)
(Cerezyme Inj 40 iu per ml, 400 iu vial to be delisted 1 March 2019)

SA0473 [Special Authority for Subsidy]

Special Authority approved by the Gaucher’s Treatment Panel

Notes: Subject to a budgetary cap. Applications will be considered and approved subject to funding availability.

Application details may be obtained from PHARMAC’s website http://www.pharmac.govt.nz or:

The Co-ordinator, Gaucher’s Treatment Panel Phone: (04) 460 4990

PHARMAC, PO Box 10 254 Facsimile: (04) 916 7571

Wellington Email: gaucherpanel@pharmac.govt.nz

TALIGLUCERASE ALFA – Special Authority see SA1734 below – Retail pharmacy

Inj 200 unit vial…………………………………………………………1,072.00 1 ✔ Elelyso

SA1734 [Special Authority for Subsidy]

Special Authority approved by the Gaucher’s Treatment Panel

Notes: Application details may be obtained from PHARMAC’s website http://www.pharmac.govt.nz or:

The Co-ordinator, Gaucher’s Treatment Panel Phone: 04 460 4990

PHARMAC PO Box 10 254 Facsimile: 04 916 7571

Wellington Email: gaucherpanel@pharmac.govt.nz

Completed application forms must be sent to the coordinator for Gaucher’s Treatment Panel and will be considered by Gaucher’s Treatment Panel at the next practicable opportunity.

Notification of Gaucher’s Treatment Panel’s decision will be sent to the patient, the applying clinician and the patient's GP (if specified).

Access Criteria

Initial application from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

1) The patient has a diagnosis of symptomatic type 1 or type 3* Gaucher disease confirmed by the demonstration of specific deficiency of glucocerebrosidase in leukocytes or cultured skin fibroblasts, and genotypic analysis; and

2) Patient does not have another life-threatening or severe disease where the prognosis is unlikely to be influenced by taliglucerase alfa or might be reasonably expected to compromise a response to therapy with taliglucerase alfa; and

3) Taliglucerase alfa is to be administered at a dose no greater than 30 unit/kg every other week rounded to the nearest whole vial (200 units), unless otherwise agreed by PHARMAC; and

4) Supporting clinical information including test reports, MRI whole body STIR, serum glucosylsphingosine, haematological data, and other relevant investigations, are submitted to the Gaucher Panel for assessment; and

5) Any of the following:

continued…
continued…

6) 1) Patient has haematological complications such as haemoglobin less than 95 g/l, symptomatic anaemia, thrombocytopenia; at least two episodes of severely symptomatic splenic infarcts confirmed with imagery; or massive symptomatic splenomegaly; or
2) Patient has skeletal complications such as acute bone crisis requiring hospitalisation or major pain management strategies; radiological MRI Evidence of incipient destruction of any major joint (e.g. hips or shoulder); spontaneous fractures or vertebral collapse; chronic bone pain not controlled by other pharmaceuticals; or
3) Patient has significant liver dysfunction or hepatomegaly attributable to Gaucher disease; or
4) Patient has reduced vital capacity from clinically significant or progressive pulmonary disease due to Gaucher disease; or
5) Patient is a child and has experienced growth failure with significant decrease in percentile linear growth over a 6-12 month period.

*Unapproved indication

Renewal from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:
All of the following:

1) Patient has demonstrated a symptomatic improvement or no deterioration in the main symptom for which therapy was initiated; and
2) Patient has demonstrated a clinically objective improvement or no deterioration in haemoglobin levels, platelet counts and liver and spleen size; and
3) Radiological (MRI) signs of bone activity performed at one year and two years since initiation of treatment begins, and two to three yearly thereafter, demonstrate no deterioration shown by the MRI, compared with MRI taken immediately prior to commencement of therapy or adjusted dose; and
4) Serum glucosylsphingosine levels taken at least 6 to 12 monthly show a decrease compared with baseline; and
5) Patient has not had severe infusion-related adverse reactions which were not preventable by appropriate pre-medication and/or adjustment of infusion rates; and
6) Patient has not developed another medical condition that might reasonably be expected to compromise a response to ERT; and
7) Patient is compliant with regular treatment and taliglucerase alfa is to be administered at a dose no greater than 30 unit/kg every other week rounded to the nearest whole vial (200 units), unless otherwise agreed by PHARMAC; and
8) Supporting clinical information including test reports, MRI whole body STIR, serum glucosylsphingosine, haematological data, and other relevant investigations are submitted to the Gaucher Panel for assessment as required.

Mouth and Throat

Agents Used in Mouth Ulceration

BENZYMATINE HYDROCHLORIDE
Soln 0.15% — Higher subsidy of up to $17.01 per 500 ml with
Endorsement .................................................................9.00 500 ml
(17.01) Difflam
3.60 200 ml
(8.50) Difflam

Additional subsidy by endorsement for a patient who has oral mucositis as a result of treatment for cancer, and the prescription is endorsed accordingly.

CARMELLOSE SODIUM WITH GELATIN AND PECTIN
Paste .................................................................17.20 56 g OP ✔ Stomahesive
4.55 15 g OP
(7.90) Orabase
1.52 5 g OP
(3.60) Orabase
Powder .................................................................8.48 28 g OP ✔ Stomahesive
(10.95) Stomahesive

Unapproved medicine supplied under Section 29
### Oropharyngeal Anti-infectives

<table>
<thead>
<tr>
<th>Product Name</th>
<th>Description</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>CHLORHEXIDINE GLUCONATE</td>
<td>Mouthwash 0.2%</td>
<td>$2.57</td>
</tr>
<tr>
<td>CHOLINE SALICYLATE WITH CETALKONIUM CHLORIDE</td>
<td>Adhesive gel 8.7% with cetalkonium chloride 0.01%</td>
<td>$2.06</td>
</tr>
<tr>
<td>TRIAMCINOLONE ACETONIDE</td>
<td>Paste 0.1%</td>
<td>$5.33</td>
</tr>
</tbody>
</table>

### Other Oral Agents

For folinic mouthwash, pilocarpine oral liquid or saliva substitute formula refer Standard Formulae, page 215

<table>
<thead>
<tr>
<th>Product Name</th>
<th>Description</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>HYDROGEN PEROXIDE</td>
<td>Soln 3% (10 vol) – Maximum of 200 ml per prescription</td>
<td>$1.40</td>
</tr>
<tr>
<td>THYMOL GLYCERIN</td>
<td>Compound, BPC</td>
<td>$9.15</td>
</tr>
</tbody>
</table>

### Vitamins

#### Vitamin A

<table>
<thead>
<tr>
<th>Product Name</th>
<th>Description</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>VITAMIN A WITH VITAMINS D AND C</td>
<td>Soln 1000 u with Vitamin D 400 u and ascorbic acid 30 mg per 10 drops</td>
<td>$4.50</td>
</tr>
</tbody>
</table>

**Vitadol C Soln 1000 u with Vitamin D 400 u and ascorbic acid 30 mg per 10 drops to be delisted 1 August 2019**

#### Vitamin B

<table>
<thead>
<tr>
<th>Product Name</th>
<th>Description</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>HYDROXOCOBALAMIN</td>
<td>Inj 1 mg per ml, 1 ml ampoule – Up to 6 inj available on a PSO</td>
<td>$1.89</td>
</tr>
<tr>
<td>PYRIDOXINE HYDROCHLORIDE</td>
<td>a) No more than 100 mg per dose</td>
<td></td>
</tr>
<tr>
<td></td>
<td>b) Only on a prescription</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Tab 25 mg – No patient co-payment payable</td>
<td>$2.70</td>
</tr>
<tr>
<td></td>
<td>Tab 50 mg</td>
<td>$13.63</td>
</tr>
<tr>
<td>THIAMINE HYDROCHLORIDE</td>
<td>– Only on a prescription</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Tab 50 mg</td>
<td>$4.89</td>
</tr>
</tbody>
</table>

**Max Health to be Sole Supply on 1 February 2019 (Apo-Thiamine Tab 50 mg to be delisted 1 February 2019)**

<table>
<thead>
<tr>
<th>Product Name</th>
<th>Description</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>VITAMIN B COMPLEX</td>
<td>Tab, strong, BPC</td>
<td>$7.15</td>
</tr>
</tbody>
</table>

▲Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once
### Vitamin C

**ASCORBIC ACID**
- a) No more than 100 mg per dose
- b) Only on a prescription

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Manufacturer’s Price</th>
<th>Subsidy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 100 mg</td>
<td>§8.10 Per 500</td>
<td>✔️ Cvite</td>
</tr>
</tbody>
</table>

### Vitamin D

**ALFACALCIDOL**
- Cap 0.25 mcg
- Cap 1 mcg
- Oral drops 2 mcg per ml

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Manufacturer’s Price</th>
<th>Subsidy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cap 0.25 mcg</td>
<td>§26.32 Per 100</td>
<td>✔️ One-Alpha</td>
</tr>
<tr>
<td>Cap 1 mcg</td>
<td>§87.98 Per 100</td>
<td>✔️ One-Alpha</td>
</tr>
<tr>
<td>Oral drops 2 mcg per ml</td>
<td>§60.68 Per 20 ml OP</td>
<td>✔️ One-Alpha</td>
</tr>
</tbody>
</table>

**CALCITRIOL**
- Cap 0.25 mcg
- Cap 0.5 mcg
- Oral drops 2 mcg per ml

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Manufacturer’s Price</th>
<th>Subsidy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cap 0.25 mcg</td>
<td>§9.95 Per 100</td>
<td>✔️ Calcitriol-AFT</td>
</tr>
<tr>
<td>Cap 0.5 mcg</td>
<td>§18.39 Per 100</td>
<td>✔️ Calcitriol-AFT</td>
</tr>
</tbody>
</table>

**COLECALCIFEROL**
- Cap 1.25 mg (50,000 iu) – Maximum of 12 cap per prescription

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Manufacturer’s Price</th>
<th>Subsidy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cap 1.25 mg (50,000 iu)</td>
<td>§2.50 Per 12</td>
<td>✔️ Vit.D3</td>
</tr>
</tbody>
</table>

### Multivitamin Preparations

**MULTIVITAMIN RENAL** – Special Authority see **SA1546 below** – Retail pharmacy
- Cap

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Manufacturer’s Price</th>
<th>Subsidy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cap</td>
<td>§6.49 Per 30</td>
<td>✔️ Clinicians Renal Vit</td>
</tr>
</tbody>
</table>

#### Special Authority for Subsidy
**Initial application** from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Either:
1. The patient has chronic kidney disease and is receiving either peritoneal dialysis or haemodialysis; or
2. The patient has chronic kidney disease grade 5, defined as patient with an estimated glomerular filtration rate of <15 ml/min/1.73 m² body surface area (BSA).

**MULTIVITAMINS** – Special Authority see **SA1036 below** – Retail pharmacy
- Powder

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Manufacturer’s Price</th>
<th>Subsidy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Powder</td>
<td>§72.00 Per 200 g OP</td>
<td>✔️ Paediatric Seravit</td>
</tr>
</tbody>
</table>

#### Special Authority for Subsidy
**Initial application** from any relevant practitioner. Approvals valid without further renewal unless notified where the patient has inborn errors of metabolism. **Renewal** from any relevant practitioner. Approvals valid without further renewal unless notified where patient has had a previous approval for multivitamins.

**VITAMINS**
- Tab (BPC cap strength)
- Cap (fat soluble vitamins A, D, E, K) – Special Authority see **SA1720 below** – Retail pharmacy

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Manufacturer’s Price</th>
<th>Subsidy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab (BPC cap strength)</td>
<td>§10.50 Per 1,000</td>
<td>✔️ Mvite</td>
</tr>
<tr>
<td>Cap (fat soluble vitamins A, D, E, K)</td>
<td>§23.40 Per 60</td>
<td>✔️ Vitabdeck</td>
</tr>
</tbody>
</table>

#### Special Authority for Subsidy
**Initial application** from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Any of the following:
1. Patient has cystic fibrosis with pancreatic insufficiency; or
2. Patient is an infant or child with liver disease or short gut syndrome; or
3. Patient has severe malabsorption syndrome.
Minerals

Calcium

CALCIUM CARBONATE

* Tab eff 1.75 g (1 g elemental) ......................................................2.07 10 ✔ Calsource
* Tab 1.25 g (500 mg elemental) ......................................................7.52 250 ✔ Arrow-Calcium

(Calsource Tab eff 1.75 g (1 g elemental) to be delisted 1 July 2019)

CALCIUM GLUCONATE

* Inj 10%, 10 ml ampoule .................................................................34.24 10 ✔ Hospira

Fluoride

SODIUM FLUORIDE

* Tab 1.1 mg (0.5 mg elemental) ......................................................5.75 100 ✔ PSM

Iodine

POTASSIUM IODATE

* Tab 253 mcg (150 mcg elemental iodine) ...........................................4.69 90 ✔ NeuroTabs

Iron

FERRIC CARBOXYMALTOSE – Special Authority see SA1675 below – Retail pharmacy

Inj 50 mg per ml, 10 ml .................................................................150.00 1 ✔ Ferinject

►SA1675 Special Authority for Subsidy

Initial application — (serum ferritin less than or equal to 20 mcg/L) from any medical practitioner. Approvals valid for 3 months for applications meeting the following criteria:

Both:
1. Patient has been diagnosed with iron-deficiency anaemia with a serum ferritin level of less than or equal to 20 mcg/L; and
2. Any of the following:
   2.1 Patient has been compliant with oral iron treatment and treatment has proven ineffective; or
   2.2 Treatment with oral iron has resulted in dose-limiting intolerance; or
   2.3 Rapid correction of anaemia is required.

Renewal — (serum ferritin less than or equal to 20 mcg/L) from any medical practitioner. Approvals valid for 3 months for applications meeting the following criteria:

Both:
1. Patient continues to have iron-deficiency anaemia with a serum ferritin level of less than or equal to 20 mcg/L; and
2. A re-trial with oral iron is clinically inappropriate.

Initial application — (iron deficiency anaemia) only from an internal medicine physician, obstetrician, gynaecologist, anaesthetist or medical practitioner on the recommendation of an internal medicine physician, obstetrician, gynaecologist or anaesthetist. Approvals valid for 3 months for applications meeting the following criteria:

Both:
1. Patient has been diagnosed with iron-deficiency anaemia; and
2. Any of the following:
   2.1 Patient has been compliant with oral iron treatment and treatment has proven ineffective; or
   2.2 Treatment with oral iron has resulted in dose-limiting intolerance; or
   2.3 Patient has symptomatic heart failure, chronic kidney disease stage 3 or more or active inflammatory bowel disease and a trial of oral iron is unlikely to be effective; or

continued...
2.4 Rapid correction of anaemia is required.

**Renewal — (iron deficiency anaemia)** only from an internal medicine physician, obstetrician, gynaecologist, anaesthetist or medical practitioner on the recommendation of a internal medicine physician, obstetrician, gynaecologist or anaesthetist.

Approvals valid for 3 months for applications meeting the following criteria:

Both:
1. Patient continues to have iron-deficiency anaemia; and
2. A re-trial with oral iron is clinically inappropriate.

**FERROUS FUMARATE**

- Tab 200 mg (65 mg elemental) ...........................................3.09
  - ✔ Ferro-tab to be Sole Supply on 1 February 2019

**FERROUS FUMARATE WITH FOLIC ACID**

- Tab 310 mg (100 mg elemental) with folic acid 350 mcg ..............4.68
  - ✔ Ferro-F-Tabs

**FERROUS SULPHATE**

- Oral liq 30 mg (6 mg elemental) per 1 ml ..............................10.80
  - ✔ Ferodan

**IRON POLYMALTOSE**

- Inj 50 mg per ml, 2 ml ampoule .............................................15.22
  - ✔ Ferrum H

(Ferrum H Inj 50 mg per ml, 2 ml ampoule to be delisted 1 April 2019)

**Magnesium**

For magnesium hydroxide mixture refer Standard Formulae, page 215

**MAGNESIUM SULPHATE**

- Inj 2 mmol per ml, 5 ml ampoule .........................................10.21
  - ✔ DBL

**Zinc**

**ZINC SULPHATE**

- Cap 137.4 mg (50 mg elemental) ............................................11.00
  - ✔ Zincaps

Unapproved medicine supplied under Section 29
**Antianaemics**

**Hypoplastic and Haemolytic**

**SA1469 Special Authority for Subsidy**

Initial application — (chronic renal failure) from any specialist. Approvals valid for 2 years for applications meeting the following criteria:

All of the following:

1. Patient in chronic renal failure; and
2. Haemoglobin is less than or equal to 100g/L; and
3. Any of the following:
   3.1 Both:
      3.1.1 Patient does not have diabetes mellitus; and
      3.1.2 Glomerular filtration rate is less than or equal to 30ml/min; or
   3.2 Both:
      3.2.1 Patient has diabetes mellitus; and
      3.2.2 Glomerular filtration rate is less than or equal to 45ml/min; or
   3.3 Patient is on haemodialysis or peritoneal dialysis.

Note: Erythropoietin alfa is indicated in the treatment of anaemia associated with chronic renal failure (CRF) where no cause for anaemia other than CRF is detected and there is adequate monitoring of iron stores and iron replacement therapy.

Initial application — (myelodysplasia) from any specialist. Approvals valid for 2 months for applications meeting the following criteria:

All of the following:

1. Patient has a confirmed diagnosis of myelodysplasia (MDS)*; and
2. Has had symptomatic anaemia with haemoglobin < 100g/L and is red cell transfusion-dependent; and
3. Patient has very low, low or intermediate risk MDS based on the WHO classification based prognostic scoring system for myelodysplastic syndrome (WPSS); and
4. Other causes of anaemia such as B12 and folate deficiency have been excluded; and
5. Patient has a serum erythropoietin level of < 500 IU/L; and
6. The minimum necessary dose of erythropoietin would be used and will not exceed 80,000 iu per week.

Note: Indication marked with * is an unapproved indication

Renewal — (chronic renal failure) from any specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

Note: Erythropoietin alfa is indicated in the treatment of anaemia associated with chronic renal failure (CRF) where no cause for anaemia other than CRF is detected and there is adequate monitoring of iron stores and iron replacement therapy.

Renewal — (myelodysplasia) from any specialist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

1. The patient's transfusion requirement continues to be reduced with erythropoietin treatment; and
2. Transformation to acute myeloid leukaemia has not occurred; and
3. The minimum necessary dose of erythropoietin would be used and will not exceed 80,000 iu per week.

Note: Indication marked with * is an unapproved indication
EPOETIN ALFA [ERYTHROPOIETIN ALFA] – Special Authority see SA1469 on the previous page – Retail pharmacy

Wastage claimable

<table>
<thead>
<tr>
<th>Inj Strength</th>
<th>Quantity</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>1,000 iu</td>
<td>6</td>
<td>Eprex</td>
</tr>
<tr>
<td>2,000 iu</td>
<td>6</td>
<td>Eprex</td>
</tr>
<tr>
<td>3,000 iu</td>
<td>6</td>
<td>Eprex</td>
</tr>
<tr>
<td>4,000 iu</td>
<td>6</td>
<td>Eprex</td>
</tr>
<tr>
<td>5,000 iu</td>
<td>6</td>
<td>Eprex</td>
</tr>
<tr>
<td>6,000 iu</td>
<td>6</td>
<td>Eprex</td>
</tr>
<tr>
<td>8,000 iu</td>
<td>6</td>
<td>Eprex</td>
</tr>
<tr>
<td>10,000 iu</td>
<td>6</td>
<td>Eprex</td>
</tr>
<tr>
<td>40,000 iu</td>
<td>1</td>
<td>Eprex</td>
</tr>
</tbody>
</table>

Megaloblastic

FOLIC ACID

- ✽ Tab 0.8 mg ............................................ 21.84 1,000 ✽ Apo-Folic Acid
- ✽ Tab 5 mg ............................................. 12.12 500 ✽ Apo-Folic Acid
- Oral liq 50 mcg per ml .................................. 24.00 25 ml OP ✽ Biomed

Antifibrinolytics, Haemostatics and Local Sclerosants

ELTROMBOPAG – Special Authority see SA1743 below – Retail pharmacy

Wastage claimable

Tab 25 mg ......................................................... 1,550.00 28 ✔ Revolade
Tab 50 mg ......................................................... 3,100.00 28 ✔ Revolade

SA1743 Special Authority for Subsidy

Initial application — (idiopathic thrombocytopenic purpura - post-splenectomy) only from a haematologist. Approvals valid for 6 weeks for applications meeting the following criteria:
All of the following:
1. Patient has had a splenectomy; and
2. Two immunosuppressive therapies have been trialled and failed after therapy of 3 months each (or 1 month for rituximab); and
3. Any of the following:
   3.1 Patient has a platelet count of 20,000 to 30,000 platelets per microlitre and has evidence of significant mucocutaneous bleeding; or
   3.2 Patient has a platelet count of less than or equal to 20,000 platelets per microlitre and has evidence of active bleeding; or
   3.3 Patient has a platelet count of less than or equal to 10,000 platelets per microlitre.

Initial application — (idiopathic thrombocytopenic purpura - preparation for splenectomy) only from a haematologist. Approvals valid for 6 weeks where the patient requires eltrombopag treatment as preparation for splenectomy.

Initial application — (idiopathic thrombocytopenic purpura contraindicated to splenectomy) only from a haematologist. Approvals valid for 3 months for applications meeting the following criteria:
All of the following:
1. Patient has a significant and well-documented contraindication to splenectomy for clinical reasons; and
2. Two immunosuppressive therapies have been trialled and failed after therapy of 3 months each (or 1 month for rituximab); and
3. Either:
   3.1 Patient has immune thrombocytopenic purpura* with a platelet count of less than or equal to 20,000 platelets per microliter; or
continued...

3.2 Patient has immune thrombocytopenic purpura* with a platelet count of 20,000 to 30,000 platelets per microlitre and significant mucocutaneous bleeding.

**Initial application — (severe aplastic anaemia)** only from a haematologist. Approvals valid for 3 months for applications meeting the following criteria:

Both:

1. Two immunosuppressive therapies have been trialled and failed after therapy of at least 3 months duration; and
2. Either:
   1. Patient has severe aplastic anaemia with a platelet count of less than or equal to 20,000 platelets per microlitre; or
   2. Patient has severe aplastic anaemia with a platelet count of 20,000 to 30,000 platelets per microlitre and significant mucocutaneous bleeding.

**Renewal — (idiopathic thrombocytopenic purpura - post-splenectomy)** only from a haematologist. Approvals valid for 12 months where the patient has obtained a response (see Note) from treatment during the initial approval or subsequent renewal periods and further treatment is required.

Note: Response to treatment is defined as a platelet count of > 30,000 platelets per microlitre.

**Renewal — (idiopathic thrombocytopenic purpura contraindicated to splenectomy)** only from a haematologist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

1. The patient's significant contraindication to splenectomy remains; and
2. The patient has obtained a response from treatment during the initial approval period; and
3. Patient has maintained a platelet count of at least 50,000 platelets per microlitre on treatment; and
4. Further treatment with eltrombopag is required to maintain response.

**Renewal — (severe aplastic anaemia)** only from a haematologist. Approvals valid for 12 months for applications meeting the following criteria:

Both:

1. The patient has obtained a response from treatment of at least 20,000 platelets per microlitre above baseline during the initial approval period; and
2. Platelet transfusion independence for a minimum of 8 weeks during the initial approval period.

**EPTACOG ALFA [RECOMBINANT FACTOR VIIA] — Xpharm**

For patients with haemophilia, whose funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.

- Inj 1 mg syringe ................................................................. 1,178.30 1 ✔ NovoSeven RT
- Inj 2 mg syringe ................................................................. 2,356.60 1 ✔ NovoSeven RT
- Inj 5 mg syringe ................................................................. 5,891.50 1 ✔ NovoSeven RT
- Inj 8 mg syringe ................................................................. 9,426.40 1 ✔ NovoSeven RT

**FACTOR EIGHT INHIBITOR BYPASSING FRACTION — Xpharm**

For patients with haemophilia, whose funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.

- Inj 500 U ................................................................. 1,450.00 1 ✔ FEIBA NF
- Inj 1,000 U ................................................................. 2,900.00 1 ✔ FEIBA NF
- Inj 2,500 U ................................................................. 7,250.00 1 ✔ FEIBA NF

**MOROCTOCOG ALFA [RECOMBINANT FACTOR VIII] — Xpharm**

Preferred Brand of recombinant factor VIII for patients with haemophilia from 1 March 2016 until 28 February 2019. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.

- Inj 250 iu prefilled syringe ................................................................. 210.00 1 ✔ Xyntha
- Inj 500 iu prefilled syringe ................................................................. 420.00 1 ✔ Xyntha
- Inj 1,000 iu prefilled syringe ................................................................. 840.00 1 ✔ Xyntha
- Inj 2,000 iu prefilled syringe ................................................................. 1,680.00 1 ✔ Xyntha
- Inj 3,000 iu prefilled syringe ................................................................. 2,520.00 1 ✔ Xyntha

▲Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once
## BLOOD AND BLOOD FORMING ORGANS

<table>
<thead>
<tr>
<th>Subsidy (Manufacturer’s Price)</th>
<th>Fully Subsidised</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per</td>
<td>✔</td>
<td></td>
</tr>
</tbody>
</table>

### NONACOG ALFA [RECOMBINANT FACTOR IX] – [Xpharm]
For patients with haemophilia, whose funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.

<table>
<thead>
<tr>
<th>Item Description</th>
<th>Subsidy</th>
<th>Quantity</th>
<th>Subsidised</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 250 iu vial</td>
<td>310.00</td>
<td>1</td>
<td>✔ BeneFIX</td>
</tr>
<tr>
<td>Inj 500 iu vial</td>
<td>620.00</td>
<td>1</td>
<td>✔ BeneFIX</td>
</tr>
<tr>
<td>Inj 1,000 iu vial</td>
<td>1,240.00</td>
<td>1</td>
<td>✔ BeneFIX</td>
</tr>
<tr>
<td>Inj 2,000 iu vial</td>
<td>2,480.00</td>
<td>1</td>
<td>✔ BeneFIX</td>
</tr>
<tr>
<td>Inj 3,000 iu vial</td>
<td>3,720.00</td>
<td>1</td>
<td>✔ BeneFIX</td>
</tr>
</tbody>
</table>

### NONACOG GAMMA, [RECOMBINANT FACTOR IX] – [Xpharm]
For patients with haemophilia, whose funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.

<table>
<thead>
<tr>
<th>Item Description</th>
<th>Subsidy</th>
<th>Quantity</th>
<th>Subsidised</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 250 iu vial</td>
<td>287.50</td>
<td>1</td>
<td>✔ RIXUBIS</td>
</tr>
<tr>
<td>Inj 500 iu vial</td>
<td>575.00</td>
<td>1</td>
<td>✔ RIXUBIS</td>
</tr>
<tr>
<td>Inj 1,000 iu vial</td>
<td>1,150.00</td>
<td>1</td>
<td>✔ RIXUBIS</td>
</tr>
<tr>
<td>Inj 2,000 iu vial</td>
<td>2,300.00</td>
<td>1</td>
<td>✔ RIXUBIS</td>
</tr>
<tr>
<td>Inj 3,000 iu vial</td>
<td>3,450.00</td>
<td>1</td>
<td>✔ RIXUBIS</td>
</tr>
</tbody>
</table>

### OCTOCOG ALFA [RECOMBINANT FACTOR VIII] (ADVATE) – [Xpharm]
Rare Clinical Circumstances Brand of recombinant factor VIII for patients with haemophilia from 1 March 2016 until 28 February 2019. Access to funded treatment by application to the Haemophilia Treatments Panel. Application details may be obtained from PHARMAC’s website [http://www.pharmac.govt.nz](http://www.pharmac.govt.nz) or:

The Co-ordinator, Haemophilia Treatments Panel
PHARMAC PO Box 10 254
Wellington

<table>
<thead>
<tr>
<th>Item Description</th>
<th>Subsidy</th>
<th>Quantity</th>
<th>Subsidised</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 250 iu vial</td>
<td>287.50</td>
<td>1</td>
<td>✔ Advate</td>
</tr>
<tr>
<td>Inj 500 iu vial</td>
<td>575.00</td>
<td>1</td>
<td>✔ Advate</td>
</tr>
<tr>
<td>Inj 1,000 iu vial</td>
<td>1,150.00</td>
<td>1</td>
<td>✔ Advate</td>
</tr>
<tr>
<td>Inj 1,500 iu vial</td>
<td>1,725.00</td>
<td>1</td>
<td>✔ Advate</td>
</tr>
<tr>
<td>Inj 2,000 iu vial</td>
<td>2,300.00</td>
<td>1</td>
<td>✔ Advate</td>
</tr>
<tr>
<td>Inj 3,000 iu vial</td>
<td>3,450.00</td>
<td>1</td>
<td>✔ Advate</td>
</tr>
</tbody>
</table>

### OCTOCOG ALFA [RECOMBINANT FACTOR VIII] (KOGENATE FS) – [Xpharm]
Second Brand of recombinant factor VIII for patients with haemophilia from 1 March 2016 until 28 February 2019. Access to funded treatment by application to the Haemophilia Treatments Panel. Application details may be obtained from PHARMAC’s website [http://www.pharmac.govt.nz](http://www.pharmac.govt.nz) or:

The Co-ordinator, Haemophilia Treatments Panel
PHARMAC PO Box 10 254
Wellington

<table>
<thead>
<tr>
<th>Item Description</th>
<th>Subsidy</th>
<th>Quantity</th>
<th>Subsidised</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 250 iu vial</td>
<td>237.50</td>
<td>1</td>
<td>✔ Kogenate FS</td>
</tr>
<tr>
<td>Inj 500 iu vial</td>
<td>475.00</td>
<td>1</td>
<td>✔ Kogenate FS</td>
</tr>
<tr>
<td>Inj 1,000 iu vial</td>
<td>950.00</td>
<td>1</td>
<td>✔ Kogenate FS</td>
</tr>
<tr>
<td>Inj 2,000 iu vial</td>
<td>1,900.00</td>
<td>1</td>
<td>✔ Kogenate FS</td>
</tr>
<tr>
<td>Inj 3,000 iu vial</td>
<td>2,850.00</td>
<td>1</td>
<td>✔ Kogenate FS</td>
</tr>
</tbody>
</table>

### SODIUM TETRADECYL SULPHATE

<table>
<thead>
<tr>
<th>Item Description</th>
<th>Subsidy</th>
<th>Quantity</th>
<th>Subsidised</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 3% 2 ml</td>
<td>28.50</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td>(73.00) Fibro-vein</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### TRANEXAMIC ACID

<table>
<thead>
<tr>
<th>Item Description</th>
<th>Subsidy</th>
<th>Quantity</th>
<th>Subsidised</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 500 mg</td>
<td>20.67</td>
<td>100</td>
<td>✔ Cyklokapron</td>
</tr>
</tbody>
</table>
## Vitamin K

<table>
<thead>
<tr>
<th>Substance</th>
<th>Dose</th>
<th>Manufacturer/Price</th>
<th>Subsidy Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>PHYTOMENADIONE</td>
<td>Inj 2 mg per 0.2 ml – Up to 5 inj available on a PSO</td>
<td>$8.00 5</td>
<td>✔ Konakion MM</td>
</tr>
<tr>
<td></td>
<td>Inj 10 mg per ml, 1 ml – Up to 5 inj available on a PSO</td>
<td>$9.21 5</td>
<td>✔ Konakion MM</td>
</tr>
</tbody>
</table>

## Antithrombotic Agents

### Antiplatelet Agents

<table>
<thead>
<tr>
<th>Substance</th>
<th>Dose</th>
<th>Manufacturer/Price</th>
<th>Subsidy Status</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ASPIRIN</strong></td>
<td>🍁 Tab 100 mg</td>
<td>$12.50 990</td>
<td>✔ Ethics Aspirin EC</td>
</tr>
<tr>
<td><strong>CLOPIDOGREL</strong></td>
<td>🍁 Tab 75 mg</td>
<td>$5.44 84</td>
<td>✔ Arrow - Clopid</td>
</tr>
<tr>
<td><strong>DIPYRIDAMOLE</strong></td>
<td>🍁 Tab long-acting 150 mg</td>
<td>$11.52 60</td>
<td>✔ Pytazen SR</td>
</tr>
<tr>
<td><strong>PRASUGREL</strong></td>
<td>– Special Authority see <strong>SA1201</strong> below – Retail pharmacy</td>
<td>Tab 5 mg $108.00 28</td>
<td>✔ Effient</td>
</tr>
<tr>
<td></td>
<td>Tab 10 mg</td>
<td>$120.00 28</td>
<td>✔ Effient</td>
</tr>
</tbody>
</table>

**SA1201** Special Authority for Subsidy

- Initial application — (coronary angioplasty and bare metal stent) from any relevant practitioner. Approvals valid for 6 months where the patient has undergone coronary angioplasty in the previous 4 weeks and is clopidogrel-allergic*.
- Initial application — (drug eluting stent) from any relevant practitioner. Approvals valid for 12 months where the patient has had a drug-eluting cardiac stent inserted in the previous 4 weeks and is clopidogrel-allergic*.
- Initial application — (stent thrombosis) from any relevant practitioner. Approvals valid without further renewal unless notified where patient has experienced cardiac stent thrombosis whilst on clopidogrel.
- Renewal — (coronary angioplasty and bare metal stent) from any relevant practitioner. Approvals valid for 6 months where the patient has undergone coronary angioplasty or had a bare metal cardiac stent inserted in the previous 4 weeks and is clopidogrel-allergic*.
- Renewal — (drug eluting stent) from any relevant practitioner. Approvals valid for 12 months where had a drug-eluting cardiac stent inserted in the previous 4 weeks and is clopidogrel-allergic*.

Note: * Clopidogrel allergy is defined as a history of anaphylaxis, urticaria, generalised rash or asthma (in non-asthmatic patients) developing soon after clopidogrel is started and is considered unlikely to be caused by any other treatment.

| **TICAGRELOR**            | – Special Authority see **SA1382** below – Retail pharmacy | Tab 90 mg $90.00 56 | ✔ Brilinta |

**SA1382** Special Authority for Subsidy

- Initial application — (acute coronary syndrome) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:
  Both:
  1. Patient has recently (within the last 60 days) been diagnosed with an ST-elevation or a non-ST-elevation acute coronary syndrome; and
  2. Fibrinolytic therapy has not been given in the last 24 hours and is not planned.
- Renewal — (subsequent acute coronary syndrome) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:
  Both:
  1. Patient has recently (within the last 60 days) been diagnosed with an ST-elevation or a non-ST-elevation acute coronary syndrome; and
  2. Fibrinolytic therapy has not been given in the last 24 hours and is not planned.

▲Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber or pharmacist.

★Three months or six months, as applicable, dispensed all-at-once

41
Heparin and Antagonist Preparations

DALTEPARIN SODIUM – Special Authority see SA1270 below – Retail pharmacy

<table>
<thead>
<tr>
<th>Brand or Manufacturer</th>
<th>Fully Subsidised</th>
<th>Subsidy (Manufacturer’s Price)</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>✔ Fragmin</td>
<td>$19.97 Per 10</td>
<td>Inj 2,500 iu per 0.2 ml prefilled syringe</td>
<td></td>
<td></td>
</tr>
<tr>
<td>✔ Fragmin</td>
<td>$39.94 Per 10</td>
<td>Inj 5,000 iu per 0.2 ml prefilled syringe</td>
<td></td>
<td></td>
</tr>
<tr>
<td>✔ Fragmin</td>
<td>$60.03 Per 10</td>
<td>Inj 7,500 iu per 0.75 ml graduated syringe</td>
<td></td>
<td></td>
</tr>
<tr>
<td>✔ Fragmin</td>
<td>$77.55 Per 10</td>
<td>Inj 10,000 iu per 1 ml graduated syringe</td>
<td></td>
<td></td>
</tr>
<tr>
<td>✔ Fragmin</td>
<td>$99.96 Per 10</td>
<td>Inj 12,500 iu per 0.5 ml prefilled syringe</td>
<td></td>
<td></td>
</tr>
<tr>
<td>✔ Fragmin</td>
<td>$120.05 Per 10</td>
<td>Inj 15,000 iu per 0.6 ml prefilled syringe</td>
<td></td>
<td></td>
</tr>
<tr>
<td>✔ Fragmin</td>
<td>$158.47 Per 10</td>
<td>Inj 18,000 iu per 0.72 ml prefilled syringe</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

➽ SA1270 Special Authority for Subsidy

Initial application — (Pregnancy or Malignancy) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Either:
1. Low molecular weight heparin treatment is required during a patient's pregnancy; or
2. For the treatment of venous thromboembolism where the patient has a malignancy.

Initial application — (Venous thromboembolism other than in pregnancy or malignancy) from any relevant practitioner. Approvals valid for 1 month for applications meeting the following criteria:

Any of the following:
1. For the short-term treatment of venous thromboembolism prior to establishing a therapeutic level of oral anti-coagulant treatment; or
2. For the prophylaxis and treatment of venous thromboembolism in high risk surgery; or
3. To enable cessation/re-establishment of existing oral anticoagulant treatment pre/post surgery; or
4. For the prophylaxis and treatment of venous thromboembolism in Acute Coronary Syndrome surgical intervention; or
5. To be used in association with cardioversion of atrial fibrillation.

Renewal — (Pregnancy or Malignancy) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Either:
1. Low molecular weight heparin treatment is required during a patient's pregnancy; or
2. For the treatment of venous thromboembolism where the patient has a malignancy.

Renewal — (Venous thromboembolism other than in pregnancy or malignancy) from any relevant practitioner. Approvals valid for 1 month where low molecular weight heparin treatment or prophylaxis is required for a second or subsequent event (surgery, Acute Coronary Syndrome, cardioversion, or prior to oral anti-coagulation).

ENOXAPARIN SODIUM – Special Authority see SA1646 below – Retail pharmacy

<table>
<thead>
<tr>
<th>Brand or Manufacturer</th>
<th>Fully Subsidised</th>
<th>Subsidy (Manufacturer’s Price)</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>✔ Clexane</td>
<td>$27.93 Per 10</td>
<td>Inj 20 mg in 0.2 ml syringe</td>
<td></td>
<td></td>
</tr>
<tr>
<td>✔ Clexane</td>
<td>$37.27 Per 10</td>
<td>Inj 40 mg in 0.4 ml syringe</td>
<td></td>
<td></td>
</tr>
<tr>
<td>✔ Clexane</td>
<td>$56.18 Per 10</td>
<td>Inj 60 mg in 0.6 ml syringe</td>
<td></td>
<td></td>
</tr>
<tr>
<td>✔ Clexane</td>
<td>$74.90 Per 10</td>
<td>Inj 80 mg in 0.8 ml syringe</td>
<td></td>
<td></td>
</tr>
<tr>
<td>✔ Clexane</td>
<td>$93.80 Per 10</td>
<td>Inj 100 mg in 1 ml syringe</td>
<td></td>
<td></td>
</tr>
<tr>
<td>✔ Clexane</td>
<td>$116.55 Per 10</td>
<td>Inj 120 mg in 0.8 ml syringe</td>
<td></td>
<td></td>
</tr>
<tr>
<td>✔ Clexane</td>
<td>$133.20 Per 10</td>
<td>Inj 150 mg in 1 ml syringe</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

➽ SA1646 Special Authority for Subsidy

Initial application — (Pregnancy, Malignancy or Haemodialysis) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Any of the following:
1. Low molecular weight heparin treatment is required during a patient's pregnancy; or
2. For the treatment of venous thromboembolism where the patient has a malignancy; or

continued…
continued...

3 For the prevention of thrombus formation in the extra-corporeal circulation during haemodialysis.

Initial application — (Venous thromboembolism other than in pregnancy or malignancy) from any relevant practitioner. Approvals valid for 1 month for applications meeting the following criteria:

Any of the following:

1. For the short-term treatment of venous thromboembolism prior to establishing a therapeutic level of oral anti-coagulant treatment; or
2. For the prophylaxis and treatment of venous thromboembolism in high risk surgery; or
3. To enable cessation/re-establishment of existing oral anticoagulant treatment pre/post surgery; or
4. For the prophylaxis and treatment of venous thromboembolism in Acute Coronary Syndrome surgical intervention; or
5. To be used in association with cardioversion of atrial fibrillation.

Renewal — (Pregnancy, Malignancy or Haemodialysis) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Any of the following:

1. Low molecular weight heparin treatment is required during a patient’s pregnancy; or
2. For the treatment of venous thromboembolism where the patient has a malignancy; or
3. For the prevention of thrombus formation in the extra-corporeal circulation during haemodialysis.

Renewal — (Venous thromboembolism other than in pregnancy or malignancy) from any relevant practitioner. Approvals valid for 1 month where low molecular weight heparin treatment or prophylaxis is required for a second or subsequent event (surgery, ACS, cardioversion, or prior to oral anti-coagulation).

HEPARIN SODIUM

<table>
<thead>
<tr>
<th>Description</th>
<th>Subsidy (Manufacturer’s Price)</th>
<th>Fully Subsidised</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 1,000 iu per ml, 35 ml vial</td>
<td>$14.53</td>
<td>✔ Hospira</td>
</tr>
<tr>
<td>Pfizer to be Sole Supply on 1 February 2019</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 1,000 iu per ml, 5 ml ampoule</td>
<td>$58.57</td>
<td>✔ Pfizer</td>
</tr>
<tr>
<td>Inj 5,000 iu per ml, 1 ml</td>
<td>$28.40</td>
<td>✔ Hospira</td>
</tr>
<tr>
<td>Inj 5,000 iu per ml, 5 ml ampoule</td>
<td>$203.68</td>
<td>✔ Pfizer</td>
</tr>
<tr>
<td>Inj 25,000 iu per ml, 0.2 ml</td>
<td>$19.00</td>
<td>✔ Hospira</td>
</tr>
</tbody>
</table>

(Hospira Inj 1,000 iu per ml, 35 ml vial to be delisted 1 February 2019)
(Hospira Inj 1,000 iu per ml, 5 ml ampoule to be delisted 1 February 2019)

HEPARINISED SALINE

<table>
<thead>
<tr>
<th>Description</th>
<th>Subsidy (Manufacturer’s Price)</th>
<th>Fully Subsidised</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 10 iu per ml, 5 ml</td>
<td>$53.40</td>
<td>✔ BD PosiFlush</td>
</tr>
<tr>
<td>Inj 25,000 iu per ml, 0.2 ml</td>
<td>$56.94</td>
<td>✔ Pfizer</td>
</tr>
</tbody>
</table>

(BD PosiFlush Inj 10 iu per ml, 5 ml to be delisted 1 March 2019)

Oral Anticoagulants

DABIGATRAN

<table>
<thead>
<tr>
<th>Description</th>
<th>Subsidy (Manufacturer’s Price)</th>
<th>Fully Subsidised</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cap 75 mg – No more than 2 cap per day</td>
<td>$76.36</td>
<td>✔ Pradaxa</td>
</tr>
<tr>
<td>Cap 110 mg</td>
<td>$76.36</td>
<td>✔ Pradaxa</td>
</tr>
<tr>
<td>Cap 150 mg</td>
<td>$76.36</td>
<td>✔ Pradaxa</td>
</tr>
</tbody>
</table>

RIVAROXABAN

<table>
<thead>
<tr>
<th>Description</th>
<th>Subsidy (Manufacturer’s Price)</th>
<th>Fully Subsidised</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 10 mg – No more than 1 tab per day</td>
<td>$83.10</td>
<td>✔ Xarelto</td>
</tr>
<tr>
<td>Tab 15 mg</td>
<td>$77.56</td>
<td>✔ Xarelto</td>
</tr>
<tr>
<td>Tab 20 mg</td>
<td>$77.56</td>
<td>✔ Xarelto</td>
</tr>
</tbody>
</table>
### Blood and Blood Forming Organs

<table>
<thead>
<tr>
<th>Subsidy (Manufacturer’s Price)</th>
<th>Fully Subsidised</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per</td>
<td>✔</td>
<td></td>
</tr>
</tbody>
</table>

#### Warfarin Sodium

Note: Marevan and Coumadin are not interchangeable.

- **Tab 1 mg**
  - $3.46 50 ✔ **Coumadin**
  - $6.86 100 ✔ **Marevan**
- **Tab 2 mg**
  - $4.31 50 ✔ **Coumadin**
- **Tab 3 mg**
  - $9.70 100 ✔ **Marevan**
- **Tab 5 mg**
  - $5.93 50 ✔ **Coumadin**
  - $11.75 100 ✔ **Marevan**

#### Blood Colony-stimulating Factors

- **FILGRASTIM** – Special Authority see SA1259 below – Retail pharmacy
  - Inj 300 mcg per 0.5 ml prefilled syringe...$270.00 5 ✔ **Zarzio**
  - Inj 480 mcg per 0.5 ml prefilled syringe...$432.00 5 ✔ **Zarzio**

- **PEGFILGRASTIM** – Special Authority see SA1384 below – Retail pharmacy
  - Inj 6 mg per 0.6 ml syringe...$1,080.00 1 ✔ **Neulastim**

#### Fluids and Electrolytes

### Intravenous Administration

#### Glucose [Dextrose]

- **Inj 50%, 10 ml ampoule** – Up to 5 inj available on a PSO...$29.50 5 ✔ **Biomed**
- **Inj 50%, 90 ml bottle** – Up to 5 inj available on a PSO...$14.50 1 ✔ **Biomed**

#### Potassium Chloride

- **Inj 75 mg per ml, 10 ml**...$55.00 50 ✔ **AstraZeneca**
## BLOOD AND BLOOD FORMING ORGANS

### SODIUM BICARBONATE

<table>
<thead>
<tr>
<th></th>
<th>Subsidy (Manufacturer’s Price) $</th>
<th>Fully Subsidised</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Inj 8.4%, 50 ml</strong></td>
<td>19.95</td>
<td>✔</td>
<td>Biomed</td>
</tr>
<tr>
<td><strong>Inj 8.4%, 100 ml</strong></td>
<td>20.50</td>
<td>✔</td>
<td>Biomed</td>
</tr>
</tbody>
</table>

- a) Up to 5 inj available on a PSO
- b) Not in combination

### SODIUM CHLORIDE

Not funded for use as a nasal drop. Only funded for nebuliser use when in conjunction with an antibiotic intended for nebuliser use.

<table>
<thead>
<tr>
<th></th>
<th>Subsidy (Manufacturer’s Price) $</th>
<th>Fully Subsidised</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Inj 0.9%, bag – Up to 2000 ml available on a PSO</strong></td>
<td>1.23 500 ml 1.26 1,000 ml</td>
<td>✔ Baxter ✔ Baxter</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| Only if prescribed on a prescription for renal dialysis, maternity or post-natal care in the home of the patient, or on a PSO for emergency use. (500 ml and 1,000 ml packs)
| **Inj 23.4% (4 mmol/ml), 20 ml ampoule** | 33.00 5 | ✔ Biomed |                                |
| For Sodium chloride oral liquid formulation refer Standard Formulae, page 215
| **Inj 0.9%, 5 ml ampoule – Up to 5 inj available on a PSO** | 7.00 50 | ✔ InterPharma ✔ Multichem ✔ Pfizer |                                |
| **Inj 0.9%, 10 ml ampoule – Up to 5 inj available on a PSO** | 6.63 50 | ✔ Pfizer ✔ Multichem ✔ InterPharma |                                |
| **Inj 0.9%, 20 ml ampoule** | 5.00 20 7.50 30 | ✔ Pfizer ✔ Multichem ✔ InterPharma |                                |

### TOTAL PARENTERAL NUTRITION (TPN) – Retail pharmacy-Specialist

Infusion..............................................................CBS 1 OP ✔ TPN

### WATER

1) On a prescription or Practitioner’s Supply Order only when on the same form as an injection listed in the Pharmaceutical Schedule requiring a solvent or diluent; or
2) On a bulk supply order; or
3) When used in the extemporaneous compounding of eye drops; or
4) When used for the dilution of sodium chloride soln 7% for cystic fibrosis patients only.

<table>
<thead>
<tr>
<th></th>
<th>Subsidy (Manufacturer’s Price) $</th>
<th>Fully Subsidised</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Inj 5 ml ampoule – Up to 5 inj available on a PSO</strong></td>
<td>7.00 50</td>
<td>✔ InterPharma</td>
<td></td>
</tr>
<tr>
<td><strong>Inj 10 ml ampoule – Up to 5 inj available on a PSO</strong></td>
<td>6.63 50</td>
<td>✔ Pfizer</td>
<td></td>
</tr>
<tr>
<td><strong>Inj 20 ml ampoule – Up to 5 inj available on a PSO</strong></td>
<td>5.00 20 7.50 30</td>
<td>✔ Pfizer ✔ Multichem ✔ InterPharma</td>
<td></td>
</tr>
</tbody>
</table>

### Oral Administration

#### CALCIUM POLYSTYRENE SULPHONATE

<table>
<thead>
<tr>
<th></th>
<th>Subsidy (Manufacturer’s Price) $</th>
<th>Fully Subsidised</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Powder</td>
<td>169.85</td>
<td>✔</td>
<td>Calcium Resonium</td>
</tr>
</tbody>
</table>

#### COMPOUND ELECTROLYTES

| Powder for oral soln – Up to 10 sach available on a PSO | 2.30 10 | ✔ Enerlyte |

#### COMPOUND ELECTROLYTES WITH GLUCOSE [DEXTROSE]

| Soln with electrolytes (2 x 500 ml) | 6.55 1,000 ml OP | ✔ Pedialyte - Bubblegum |

#### PHOSPHORUS

| Tab eff 500 mg (16 mmol) | 82.50 100 | ✔ Phosphate Phebra ✔ Phosphate-Sandoz |

*(Phosphate-Sandoz Tab eff 500 mg (16 mmol) to be delisted 1 May 2019)*

▲Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once
### BLOOD AND BLOOD FORMING ORGANS

<table>
<thead>
<tr>
<th>Subsidy (Manufacturer's Price)</th>
<th>Fully Subsidised</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per</td>
<td>$</td>
<td>$</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>POTASSIUM CHLORIDE</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>✴ Tab eff 548 mg (14 m eq) with chloride 285 mg (8 m eq)....................5.26 60</td>
<td>Chlorvescent</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(11.85)</td>
<td></td>
</tr>
<tr>
<td>✴ Tab long-acting 600 mg (8 mmol)........................................................8.90 200</td>
<td>Span-K</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SODIUM BICARBONATE</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Cap 840 mg.................................................................8.52 100</td>
<td>Sodibic</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sodibic</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SODIUM POLYSTYRENE SULPHONATE</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Powder .................................................................84.65 454 g OP</td>
<td>Resonium-A</td>
<td></td>
</tr>
</tbody>
</table>
## CARDIOVASCULAR SYSTEM

### Alpha-Adrenoceptor Blockers

<table>
<thead>
<tr>
<th>Drug</th>
<th>Strength</th>
<th>Subsidy (Manufacturer’s Price)</th>
<th>Fully Subsidised</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>DOXAZOSIN</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>✴ Tab 2 mg</td>
<td></td>
<td>6.75</td>
<td>500</td>
<td>✓ Apo-Doxazosin</td>
</tr>
<tr>
<td>✴ Tab 4 mg</td>
<td></td>
<td>9.09</td>
<td>500</td>
<td>✓ Apo-Doxazosin</td>
</tr>
<tr>
<td>PHENOXYBENZAMINE HYDROCHLORIDE</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>✴ Cap 10 mg</td>
<td></td>
<td>65.00</td>
<td>30</td>
<td>✓ BNM</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>✓ Dibenzyline</td>
</tr>
<tr>
<td>PRAZOSIN</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>✴ Tab 1 mg</td>
<td></td>
<td>5.53</td>
<td>100</td>
<td>✓ Apo-Prazosin</td>
</tr>
<tr>
<td>✴ Tab 2 mg</td>
<td></td>
<td>7.00</td>
<td>100</td>
<td>✓ Apo-Prazosin</td>
</tr>
<tr>
<td>✴ Tab 5 mg</td>
<td></td>
<td>11.70</td>
<td>100</td>
<td>✓ Apo-Prazosin</td>
</tr>
<tr>
<td>TERAZOSIN</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>✴ Tab 1 mg</td>
<td></td>
<td>0.59</td>
<td>28</td>
<td>✓ Actavis</td>
</tr>
<tr>
<td>✴ Tab 2 mg</td>
<td></td>
<td>7.50</td>
<td>500</td>
<td>✓ Apo-Terazosin</td>
</tr>
<tr>
<td>✴ Tab 5 mg</td>
<td></td>
<td>10.90</td>
<td>500</td>
<td>✓ Apo-Terazosin</td>
</tr>
</tbody>
</table>

### Agents Affecting the Renin-Angiotensin System

#### ACE Inhibitors

<table>
<thead>
<tr>
<th>Drug</th>
<th>Strength</th>
<th>Subsidy (Manufacturer’s Price)</th>
<th>Fully Subsidised</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>CAPTOPRIL</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>✴ Oral liq 5 mg per ml</td>
<td></td>
<td>94.99</td>
<td>95 ml OP</td>
<td>✓ Capoten</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Oral liquid restricted to children under 12 years of age.</td>
</tr>
<tr>
<td>CILAZAPRIL</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>✴ Tab 0.5 mg</td>
<td></td>
<td>2.00</td>
<td>90</td>
<td>✓ Zapril</td>
</tr>
<tr>
<td>✴ Tab 2.5 mg</td>
<td></td>
<td>7.20</td>
<td>200</td>
<td>✓ Apo-Cilazapril</td>
</tr>
<tr>
<td>✴ Tab 5 mg</td>
<td></td>
<td>12.00</td>
<td>200</td>
<td>✓ Apo-Cilazapril</td>
</tr>
<tr>
<td>ENALAPRIL MALEATE</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>✴ Tab 5 mg</td>
<td></td>
<td>0.96</td>
<td>100</td>
<td>✓ Ethics Enalapril</td>
</tr>
<tr>
<td>✴ Tab 10 mg</td>
<td></td>
<td>1.24</td>
<td>100</td>
<td>✓ Ethics Enalapril</td>
</tr>
<tr>
<td>✴ Tab 20 mg</td>
<td></td>
<td>1.78</td>
<td>100</td>
<td>✓ Ethics Enalapril</td>
</tr>
<tr>
<td>LISINOPRIL</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>✴ Tab 5 mg</td>
<td></td>
<td>2.07</td>
<td>90</td>
<td>✓ Ethics Lisinopril</td>
</tr>
<tr>
<td>Ethics Lisinopril to be Sole Supply on 1 January 2019</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>✴ Tab 10 mg</td>
<td></td>
<td>2.36</td>
<td>90</td>
<td>✓ Ethics Lisinopril</td>
</tr>
<tr>
<td>Ethics Lisinopril to be Sole Supply on 1 January 2019</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>✴ Tab 20 mg</td>
<td></td>
<td>3.17</td>
<td>90</td>
<td>✓ Ethics Lisinopril</td>
</tr>
<tr>
<td>Ethics Lisinopril to be Sole Supply on 1 January 2019</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PERINDOPRIL</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>✴ Tab 2 mg</td>
<td></td>
<td>3.75</td>
<td>30</td>
<td>✓ Apo-Perindopril</td>
</tr>
<tr>
<td>✴ Tab 4 mg</td>
<td></td>
<td>4.80</td>
<td>30</td>
<td>✓ Apo-Perindopril</td>
</tr>
<tr>
<td>QUINAPRIL</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>✴ Tab 5 mg</td>
<td></td>
<td>6.01</td>
<td>90</td>
<td>✓ Arrow-Quinapril 5</td>
</tr>
<tr>
<td>✴ Tab 10 mg</td>
<td></td>
<td>3.16</td>
<td>90</td>
<td>✓ Arrow-Quinapril 10</td>
</tr>
<tr>
<td>✴ Tab 20 mg</td>
<td></td>
<td>4.89</td>
<td>90</td>
<td>✓ Arrow-Quinapril 20</td>
</tr>
</tbody>
</table>

▲ Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber or pharmacist.

※ Three months or six months, as applicable, dispensed all-at-once
ACE Inhibitors with Diuretics

CILAZAPRIL WITH HYDROCHLOROTHIAZIDE

* Tab 5 mg with hydrochlorothiazide 12.5 mg................................. 10.18 100 ✔ Apo-Cilazapril/ Hydrochlorothiazide

QUINAPRIL WITH HYDROCHLOROTHIAZIDE

* Tab 10 mg with hydrochlorothiazide 12.5 mg............................... 3.83 30 ✔ Accuretic 10
  Accuretic 10 to be Sole Supply on 1 January 2019
* Tab 20 mg with hydrochlorothiazide 12.5 mg............................... 4.92 30 ✔ Accuretic 20
  Accuretic 20 to be Sole Supply on 1 January 2019

Angiotensin II Antagonists

CANDESARTAN CILEXETIL

* Tab 4 mg................................................................. 1.90 90 ✔ Candestar
* Tab 8 mg................................................................. 2.28 90 ✔ Candestar
* Tab 16 mg............................................................... 3.67 90 ✔ Candestar
* Tab 32 mg............................................................... 6.39 90 ✔ Candestar

LOSARTAN POTASSIUM

* Tab 12.5 mg.............................................................. 1.39 84 ✔ Losartan Actavis
* Tab 25 mg............................................................... 1.63 84 ✔ Losartan Actavis
* Tab 50 mg............................................................... 2.00 84 ✔ Losartan Actavis
* Tab 100 mg............................................................. 2.31 84 ✔ Losartan Actavis

Angiotensin II Antagonists with Diuretics

LOSARTAN POTASSIUM WITH HYDROCHLOROTHIAZIDE

Tab 50 mg with hydrochlorothiazide 12.5 mg................................. 1.88 30 ✔ Arrow-Losartan & Hydrochlorothiazide

Arrow-Losartan & Hydrochlorothiazide to be Sole Supply on 1 February 2019

Angiotensin II Antagonists with Neprilysin Inhibitors

SACUBITRIL WITH VALSARTAN – Special Authority see SA1751 below – Retail pharmacy

Note: Due to the angiotensin II receptor blocking activity of sacubitril with valsartan it should not be co-administered with an ACE inhibitor or another ARB.

Tab 24.3 mg with valsartan 25.7 mg................................. 190.00 56 ✔ Entresto 24/26
Tab 48.6 mg with valsartan 51.4 mg................................. 190.00 56 ✔ Entresto 49/51
Tab 97.2 mg with valsartan 102.8 mg................................. 190.00 56 ✔ Entresto 97/103

SA1751 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

1. Patient has heart failure; and
2. Any of the following:
   2.1 Patient is in NYHA/WHO functional class II; or
   2.2 Patient is in NYHA/WHO functional class III; or
   2.3 Patient is in NYHA/WHO functional class IV; and

continued…
continued...

3 Patient has a documented left ventricular ejection fraction (LVEF) of less than or equal to 35%; and
4 Patient is receiving concomitant optimal standard chronic heart failure treatments.

Renewal from any relevant practitioner. Approvals valid for 12 months where the treatment remains appropriate and the patient is benefitting from treatment.

Antiarrhythmics

For lignocaine hydrochloride refer to NERVOUS SYSTEM, Anaesthetics, Local, page 122

AMIODARONE HYDROCHLORIDE
▲ Tab 100 mg – Retail pharmacy-Specialist.................................................4.66 30 ✔ Cordarone-X
▲ Tab 200 mg – Retail pharmacy-Specialist.................................................7.63 30 ✔ Cordarone-X
Inj 50 mg per ml, 3 ml ampoule – Up to 5 inj available on a PSO......9.98 5 ✔ Lodi

ATROPINE SULPHATE
* Inj 600 mcg per ml, 1 ml ampoule – Up to 5 inj available on a
PSO.................................................................12.07 10 ✔ Martindale
.................................................................................60.35 50
..................................................................................(71.00)
AstraZeneca

Martindale to be Sole Supply on 1 January 2019
(AstraZeneca Inj 600 mcg per ml, 1 ml ampoule to be delisted 1 January 2019)

DIGOXIN
* Tab 62.5 mcg – Up to 30 tab available on a PSO.........................6.67 240 ✔ Lanoxin PG
* Tab 250 mcg – Up to 30 tab available on a PSO.........................14.52 240 ✔ Lanoxin
* Oral liq 50 mcg per ml ............................................................16.60 60 ml ✔ Lanoxin
.......................................................................................S29

DISOPYRAMIDE PHOSPHATE
▲ Cap 100 mg.............................................................23.87 100 ✔ Rythmodan

FLECAINIDE ACETATE – Retail pharmacy-Specialist
▲ Tab 50 mg .............................................................38.95 60 ✔ Tambocor
▲ Cap long-acting 100 mg ......................................................38.95 30 ✔ Tambocor CR
▲ Cap long-acting 200 mg ......................................................68.78 30 ✔ Tambocor CR
Inj 10 mg per ml, 15 ml ampoule ...........................................52.45 5 ✔ Tambocor

MEXILETINE HYDROCHLORIDE
▲ Cap 150 mg..............................................................162.00 100 ✔ Mexiletine
..........................................................................................S29

▲ Cap 250 mg..............................................................202.00 100 ✔ Mexiletine
..........................................................................................S29

PROPAFENONE HYDROCHLORIDE – Retail pharmacy-Specialist
▲ Tab 150 mg..............................................................40.90 50 ✔ Rytmonorm

Antihypotensives

MIDODRINE – Special Authority see SA1474 on the next page – Retail pharmacy
Tab 2.5 mg..............................................................53.00 100 ✔ Gutron
Tab 5 mg..............................................................79.00 100 ✔ Gutron

▲ Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber or pharmacist.
* Three months or six months, as applicable, dispensed all-at-once.
**SA1474** Special Authority for Subsidy

**Initial application** from any relevant practitioner. Approvals valid for 2 years where patient has disabling orthostatic hypotension not due to drugs.

Note: Treatment should be started with small doses and titrated upwards as necessary. Hypertension should be avoided, and the usual target is a standing systolic blood pressure of 90 mm Hg.

**Renewal** from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

---

**Beta-Adrenoceptor Blockers**

**Beta Adrenoceptor Blockers**

| ATENOLOL | Tab 50 mg | 4.26 | 500 | ✔ Mylan Atenolol |
| Tab 100 mg | 7.30 | 500 | ✔ Mylan Atenolol |
| Oral liq 25 mg per 5 ml | 21.25 | 300 ml OP | ✔ Atenolol AFT |

Restricted to children under 12 years of age.

| BISOPROLOL FUMARATE | Tab 2.5 mg | 3.53 | 90 | ✔ Bosvate |
| Tab 5 mg | 5.15 | 90 | ✔ Bosvate |
| Tab 10 mg | 9.40 | 90 | ✔ Bosvate |

| CARVEDILOL | Tab 6.25 mg | 2.24 | 60 | ✔ Carvedilol Sandoz |
| Tab 12.5 mg | 2.30 | 60 | ✔ Carvedilol Sandoz |
| Tab 25 mg | 2.95 | 60 | ✔ Carvedilol Sandoz |

| CELI PROLOL | Tab 200 mg | 21.40 | 180 | ✔ Celol |

| LABETALOL | Tab 50 mg | 8.99 | 100 | ✔ Hybloc |
| Tab 100 mg | 11.36 | 100 | ✔ Hybloc |
| Tab 200 mg | 29.74 | 100 | ✔ Hybloc |
| Inj 5 mg per ml, 20 ml ampoule | 59.06 | 5 | Trandate |

(M) METOPROLOL SUCCINATE | Tab long-acting 23.75 mg | 1.03 | 30 | ✔ Betaloc CR |
| Tab long-acting 47.5 mg | 1.25 | 30 | ✔ Betaloc CR |
| Tab long-acting 95 mg | 1.99 | 30 | ✔ Betaloc CR |
| Tab long-acting 190 mg | 3.00 | 30 | ✔ Betaloc CR |

| METOPROLOL TARTRATE | Tab 50 mg | 5.66 | 100 | ✔ Apo-Metoprolol |
| Tab 100 mg | 7.55 | 60 | ✔ Apo-Metoprolol |
| Tab long-acting 200 mg | 23.40 | 28 | ✔ Slow-Lopresor |
| Inj 1 mg per ml, 5 ml vial | 24.00 | 5 | ✔ Lopresor |
| | 29.50 | ✔ Metroprolol IV Mylan |

Metroprolol IV Mylan to be Sole Supply on 1 February 2019

(Lopresor Inj 1 mg per ml, 5 ml vial to be delisted 1 February 2019)

NADOLOL

| Tab 40 mg | 16.69 | 100 | ✔ Apo-Nadolol |
| Tab 80 mg | 26.43 | 100 | ✔ Apo-Nadolol |
CARDIOVASCULAR SYSTEM

Subsidy
(Manufacturer’s Price)

<table>
<thead>
<tr>
<th>Drug</th>
<th>Formulation</th>
<th>Price</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PINDOLOL</strong></td>
<td>Tab 5 mg</td>
<td>13.22</td>
<td>Apo-Pindolol</td>
</tr>
<tr>
<td></td>
<td>Tab 10 mg</td>
<td>23.12</td>
<td>Apo-Pindolol</td>
</tr>
<tr>
<td></td>
<td>Tab 15 mg</td>
<td>33.31</td>
<td>Apo-Pindolol</td>
</tr>
<tr>
<td><strong>PROPRANOLOL</strong></td>
<td>Tab 10 mg</td>
<td>4.64</td>
<td>Apo-Propranolol</td>
</tr>
<tr>
<td></td>
<td>Cap long-acting 160 mg</td>
<td>18.17</td>
<td>Cardio LA</td>
</tr>
<tr>
<td></td>
<td>Oral liq 4 mg per ml</td>
<td>CBS 500</td>
<td>Roxane</td>
</tr>
</tbody>
</table>

**Special Authority for Subsidy**

Initial application from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Either:

1. For the treatment of a child under 12 years with an hemangioma causing functional impairment (not for cosmetic reasons only); or
2. For the treatment of a child under 12 years with cardiac arrhythmias or congenital cardiac abnormalities.

Renewal from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Either:

1. For the treatment of a child under 12 years with an hemangioma causing functional impairment (not for cosmetic reasons only); or
2. For the treatment of a child under 12 years with cardiac arrhythmias or congenital cardiac abnormalities.

**SOTALOL**

Tab 80 mg...............................................................39.53 500  Mylan
Tab 160 mg............................................................12.48 100  Mylan

**TIMOLOL**

Tab 10 mg.............................................................10.55 100  Apo-Timol

Calcium Channel Blockers

**Dihydropyridine Calcium Channel Blockers**

**AMLODIPINE**

Tab 2.5 mg..............................................................1.72 100  Apo-Amlodipine
Tab 5 mg...............................................................3.33 250  Apo-Amlodipine
Tab 10 mg.............................................................4.40 250  Apo-Amlodipine

**FELODIPINE**

Tab long-acting 2.5 mg...........................................1.45 30  Plendil ER
Tab long-acting 5 mg...............................................3.93 90  Felo 5 ER
                  (1.31) 30  Plendil ER
                  (1.55) 30  Plendil ER

Felo 5 ER to be Sole Supply on 1 March 2019

Tab long-acting 10 mg............................................4.32 90  Felo 10 ER
                  (1.44) 30  Plendil ER
                  (2.30) 30  Plendil ER

Felo 10 ER to be Sole Supply on 1 March 2019

(Plendil ER Tab long-acting 5 mg to be delisted 1 March 2019)
(Plendil ER Tab long-acting 10 mg to be delisted 1 March 2019)
<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Subsidy (Manufacturer's Price) Per</th>
<th>Fully Subsidised</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dynacirc-SRO</td>
<td>$7.50 30</td>
<td>✓ Dynacirc-SRO</td>
</tr>
<tr>
<td>Dynacirc-SRO</td>
<td>$7.85 30</td>
<td>✓ Dynacirc-SRO</td>
</tr>
<tr>
<td>Adalat 10</td>
<td>$10.63 60</td>
<td>✓ Adalat 10</td>
</tr>
<tr>
<td>Adefin</td>
<td>$9.59 100</td>
<td>✓ Adalat 10</td>
</tr>
<tr>
<td>Adefin XL</td>
<td>$5.67 30</td>
<td>✓ Adefin XL</td>
</tr>
<tr>
<td>Diltiazem CD</td>
<td>$4.60 100</td>
<td>✓ Diltiazem CD</td>
</tr>
<tr>
<td>Diltiazem</td>
<td>$8.50 100</td>
<td>✓ Diltiazem</td>
</tr>
<tr>
<td>Adefin</td>
<td>$6.20 100</td>
<td>✓ Adefin</td>
</tr>
<tr>
<td>Perhexiline Maleate</td>
<td>$62.90 100</td>
<td>✓ Perhexiline Maleate</td>
</tr>
<tr>
<td>Verapamil SR</td>
<td>$7.01 100</td>
<td>✓ Verapamil SR</td>
</tr>
<tr>
<td>Verapamil SR</td>
<td>$11.74 100</td>
<td>✓ Verapamil SR</td>
</tr>
<tr>
<td>Verapamil SR</td>
<td>$15.20 250</td>
<td>✓ Verapamil SR</td>
</tr>
<tr>
<td>Verapamil SR</td>
<td>$25.00 250</td>
<td>✓ Verapamil SR</td>
</tr>
<tr>
<td>Catapres</td>
<td>$25.96 10</td>
<td>✓ Catapres</td>
</tr>
<tr>
<td>Clonidine BNM</td>
<td>$8.75 112</td>
<td>✓ Clonidine BNM</td>
</tr>
<tr>
<td>Catapres</td>
<td>$34.32 100</td>
<td>✓ Catapres</td>
</tr>
<tr>
<td>Methyldopa Mylan</td>
<td>$15.10 100</td>
<td>✓ Methyldopa Mylan</td>
</tr>
</tbody>
</table>

**Other Calcium Channel Blockers**

**Diltiazem Hydrochloride**

- Tab 30 mg ......................................................... $4.60 100   ✓ Diltiazem
- Tab 60 mg ......................................................... $8.50 100   ✓ Diltiazem
- Cap long-acting 120 mg ........................................ $33.42 500   ✓ Apo-Diltiazem CD
- Cap long-acting 180 mg ........................................ $50.05 500   ✓ Apo-Diltiazem CD
- Cap long-acting 240 mg ........................................ $66.76 500   ✓ Apo-Diltiazem CD

**Perhexiline Maleate**

- Tab 100 mg ......................................................... $62.90 100   ✓ Pexsig

**Verapamil Hydrochloride**

- Tab 40 mg ......................................................... $7.01 100   ✓ Isoptin
- Tab 80 mg ......................................................... $11.74 100   ✓ Isoptin
- Tab long-acting 120 mg ........................................ $15.20 250   ✓ Verapamil SR
- Tab long-acting 240 mg ........................................ $25.00 250   ✓ Verapamil SR
- Inj 2.5 mg per ml, 2 ml ampoule – Up to 5 inj available on a PSO ............................................... $25.00 5   ✓ Isoptin

**Centrally-Acting Agents**

**Clonidine**

- Patch 2.5 mg, 100 mcg per day – Only on a prescription ........................................ $7.40 4   ✓ Mylan
- Patch 5 mg, 200 mcg per day – Only on a prescription ........................................ $10.04 4   ✓ Mylan
- Patch 7.5 mg, 300 mcg per day – Only on a prescription ........................................ $12.34 4   ✓ Mylan

**Clonidine Hydrochloride**

- Tab 25 mcg ......................................................... $8.75 112   ✓ Clonidine BNM
- Tab 150 mcg ......................................................... $34.32 100   ✓ Catapres
- Inj 150 mcg per ml, 1 ml ampoule ........................................ $25.96 10   ✓ Medsurge
- (16.07) Catapres

Medsurge to be Sole Supply on 1 January 2019

(Catapres Inj 150 mcg per ml, 1 ml ampoule to be delisted 1 January 2019)

**Methyldopa**

- Tab 250 mg ......................................................... $15.10 100   ✓ Methyldopa Mylan
# Diuretics

## Loop Diuretics

### BUMETANIDE
- Tab 1 mg ................................................................. 16.36
- Inj 500 mcg per ml, 4 ml vial................................. 7.95

### FUROSEMIDE [FRUSEMIDE]
- Tab 40 mg – Up to 30 tab available on a PSO .......... 8.00
- Tab 500 mg ................................................................. 25.00
- Oral liq 10 mg per ml .................................................. 10.66
- Inj 10 mg per ml, 25 ml ampoule ......................... 57.77
- Inj 10 mg per ml, 2 ml ampoule – Up to 5 inj available on a PSO ...... 1.20

## Potassium Sparing Diuretics

### AMILORIDE HYDROCHLORIDE
- Tab 5 mg ................................................................. 15.00
- Oral liq 1 mg per ml .................................................. 30.00

(Apo-Amiloride Tab 5 mg to be delisted 1 January 2019)

### EPLERENONE – Special Authority see SA1728 below – Retail pharmacy
- Tab 50 mg ................................................................. 17.00
- Tab 25 mg ................................................................. 11.87

**SA1728** Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:
1. Patient has heart failure with ejection fraction less than 40%; and
2. Either:
   2.1 Patient is intolerant to optimal dosing of spironolactone; or
   2.2 Patient has experienced a clinically significant adverse effect while on optimal dosing of spironolactone.

### METOLAZONE – Special Authority see SA1678 below – Retail pharmacy
- Tab 5 mg ................................................................. CBS 1
- Tab 100 mg ................................................................. 11.80

**SA1678** Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Either:
1. Patient has refractory heart failure and is intolerant or has not responded to loop diuretics and/or loop-thiazide combination therapy; or
2. Paediatric patient has oedema secondary to nephrotic syndrome that has not responded to loop diuretics.

### SPIRONOLACTONE
- Tab 25 mg ................................................................. 4.38
- Tab 100 mg ................................................................. 11.80
- Oral liq 5 mg per ml .................................................. 30.00

---

▲Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once
### Potassium Sparing Combination Diuretics

<table>
<thead>
<tr>
<th>Medicine</th>
<th>Subsidy (Manufacturer's Price) Per</th>
<th>Fully Subsidised</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>AMILORIDE HYDROCHLORIDE WITH FUROSEMIDE</td>
<td>8.63 28</td>
<td>✓</td>
<td>Frumil</td>
</tr>
<tr>
<td>AMILORIDE HYDROCHLORIDE WITH HYDROCHLOROTHIAZIDE</td>
<td>5.00 50</td>
<td>✓</td>
<td>Moduretic</td>
</tr>
</tbody>
</table>

### Thiazide and Related Diuretics

<table>
<thead>
<tr>
<th>Medicine</th>
<th>Subsidy (Manufacturer's Price) Per</th>
<th>Fully Subsidised</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>BENDROFLUMETHIAZIDE [BENDROFLUAZIDE]</td>
<td>12.50 500</td>
<td>✓</td>
<td>Arrow-Bendrofluazide</td>
</tr>
<tr>
<td>Tab 2.5 mg – Up to 150 tab available on a PSO</td>
<td>20.42 500</td>
<td>✓</td>
<td>Arrow-Bendrofluazide</td>
</tr>
<tr>
<td>CHLOROTHIAZIDE</td>
<td>26.00 25 ml OP</td>
<td>✓</td>
<td>Biomed</td>
</tr>
<tr>
<td>Oral liq 50 mg per ml</td>
<td>20 90</td>
<td>✓</td>
<td>Hygroton</td>
</tr>
<tr>
<td>CHLORTALIDONE [CHLORTHALIDONE]</td>
<td>8.00 50</td>
<td>✓</td>
<td>Hygroton</td>
</tr>
<tr>
<td>INDAPAMIDE</td>
<td>2.60 90</td>
<td>✓</td>
<td>Dapa-Tabs</td>
</tr>
</tbody>
</table>

### Lipid-Modifying Agents

#### Fibrates

<table>
<thead>
<tr>
<th>Medicine</th>
<th>Subsidy (Manufacturer's Price) Per</th>
<th>Fully Subsidised</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>BEZAFIBRATE</td>
<td>19.01 90</td>
<td>✓</td>
<td>Bezalip</td>
</tr>
<tr>
<td>Tab 200 mg</td>
<td>12.89 30</td>
<td>✓</td>
<td>Bezalip Retard</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Bezalip to be Sole Supply on 1 January 2019</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Bezalip Retard to be Sole Supply on 1 January 2019</td>
</tr>
<tr>
<td>GEMFIBROZIL</td>
<td>19.56 60</td>
<td>✓</td>
<td>Lipazil</td>
</tr>
<tr>
<td>Tab 600 mg</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Other Lipid-Modifying Agents

<table>
<thead>
<tr>
<th>Medicine</th>
<th>Subsidy (Manufacturer's Price) Per</th>
<th>Fully Subsidised</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACIPIMOX</td>
<td>18.75 30</td>
<td>✓</td>
<td>Olbetam</td>
</tr>
<tr>
<td>Cap 250 mg</td>
<td>4.12 100</td>
<td>✓</td>
<td>Apo-Nicotinic Acid</td>
</tr>
<tr>
<td>NICOTINIC ACID</td>
<td>17.89 100</td>
<td>✓</td>
<td>Apo-Nicotinic Acid</td>
</tr>
<tr>
<td>Tab 50 mg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 500 mg</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
## Resins

**CHOLESTYRAMINE**
- Powder for oral liq 4 g.......................... 19.25 50
  - (52.68) Questran-Lite
  - (52.68) Questran-Lite

*(Questran-Lite Powder for oral liq 4 g to be delisted 1 June 2019)*
*(Questran-Lite S29 Powder for oral liq 4 g to be delisted 1 June 2019)*

**COLESTIPOL HYDROCHLORIDE**
- Grans for oral liq 5 g.......................... 28.60 30 ✔ Colestid

### HMG CoA Reductase Inhibitors (Statins)

#### Prescribing Guidelines

Treatment with HMG CoA Reductase Inhibitors (statins) is recommended for patients with dyslipidaemia and an absolute 5 year cardiovascular risk of 15% or greater.

**ATORVASTATIN** – See prescribing guideline above
- Tab 10 mg.............................................. 6.96 500 ✔ Lorstat
- Tab 20 mg.............................................. 9.99 500 ✔ Lorstat
- Tab 40 mg.............................................. 15.93 500 ✔ Lorstat
- Tab 80 mg.............................................. 27.19 500 ✔ Lorstat

**PRAVASTATIN** – See prescribing guideline above
- Tab 20 mg.............................................. 4.72 100 ✔ Apo-Pravastatin
- Tab 40 mg.............................................. 8.06 100 ✔ Apo-Pravastatin

**SIMVASTATIN** – See prescribing guideline above
- Tab 10 mg.............................................. 0.95 90 ✔ Simvastatin Mylan
- Tab 20 mg.............................................. 1.52 90 ✔ Simvastatin Mylan
- Tab 40 mg.............................................. 2.63 90 ✔ Simvastatin Mylan
- Tab 80 mg.............................................. 6.00 90 ✔ Simvastatin Mylan

### Selective Cholesterol Absorption Inhibitors

**EZETIMIBE** – Special Authority see **SA1045** below – Retail pharmacy
- Tab 10 mg.............................................. 2.00 30 ✔ Ezetimibe Sandoz

*[SA1045] Special Authority for Subsidy*

**Initial application** from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

- All of the following:
  1. Patient has a calculated absolute risk of cardiovascular disease of at least 15% over 5 years; and
  2. Patient's LDL cholesterol is 2.0 mmol/litre or greater; and
  3. Any of the following:
     - 3.1 The patient has rhabdomyolysis (defined as muscle aches and creatine kinase more than 10 × normal) when treated with one statin; or
     - 3.2 The patient is intolerant to both simvastatin and atorvastatin; or
     - 3.3 The patient has not reduced their LDL cholesterol to less than 2.0 mmol/litre with the use of the maximal tolerated dose of atorvastatin.

Notes: A patient who has failed to reduce their LDL cholesterol to < 2.0 mmol/litre with the use of a less potent statin should use a more potent statin prior to consideration being given to the use of non-statin therapies.

continued…
Other treatment options including fibrates, resins and nicotinic acid should be considered after failure of statin therapy. If a patient's LDL cholesterol cannot be calculated because the triglyceride level is too high then a repeat test should be performed and if the LDL cholesterol again cannot be calculated then it can be considered that the LDL cholesterol is greater than 2.0 mmol/litre.

Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

EZETIMIBE WITH SIMVASTATIN – Special Authority see SA1046 below – Retail pharmacy

| Tab 10 mg with simvastatin 10 mg | $5.15 | 30 | Zimybe |
| Tab 10 mg with simvastatin 20 mg | $6.15 | 30 | Zimybe |
| Tab 10 mg with simvastatin 40 mg | $7.15 | 30 | Zimybe |
| Tab 10 mg with simvastatin 80 mg | $8.15 | 30 | Zimybe |

➽ SA1046 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

All of the following:
1. Patient has a calculated absolute risk of cardiovascular disease of at least 15% over 5 year; and
2. Patient's LDL cholesterol is 2.0 mmol/litre or greater; and
3. The patient has not reduced their LDL cholesterol to less than 2.0 mmol/litre with the use of the maximal tolerated dose of atorvastatin.

Notes: A patient who has failed to reduce their LDL cholesterol to less than or equal to 2.0 mmol/litre with the use of a less potent statin should use a more potent statin prior to consideration being given to the use of non-statin therapies. Other treatment options including fibrates, resins and nicotinic acid should be considered after failure of statin therapy. If a patient's LDL cholesterol cannot be calculated because the triglyceride level is too high then a repeat test should be performed and if the LDL cholesterol again cannot be calculated then it can be considered that the LDL cholesterol is greater than 2.0 mmol/litre.

Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

### Nitrates

**GLYCERYL TRINITRATE**

- Tab 600 mcg – Up to 100 tab available on a PSO ............................................. $8.00 100 OP ✔️ Lycinate
- Oral pump spray, 400 mcg per dose – Up to 250 dose available on a PSO ............................................. $4.45 250 dose OP ✔️ Nitrolingual Pump Spray
- Oral spray, 400 mcg per dose – Up to 200 dose available on a PSO ............................................. $4.45 200 dose OP ✔️ Glytrin
- Patch 25 mg, 5 mg per day .............................................................. $15.73 30 ✔️ Nitroderm TTS
- Patch 50 mg, 10 mg per day ............................................................. $18.62 30 ✔️ Nitroderm TTS

**ISOSORBIDE MONONITRATE**

- Tab 20 mg ......................................................................................... $18.80 100 ✔️ Ismo 20
- Tab long-acting 40 mg ........................................................................ $7.50 30 ✔️ Ismo 40 Retard
- Tab long-acting 60 mg ......................................................................... $8.29 90 ✔️ Duride

### Sympathomimetics

**ADRENALINE**

- Inj 1 in 1,000, 1 ml ampoule – Up to 5 inj available on a PSO .......... $4.98 5 ✔️ Aspen Adrenaline
- Inj 1 in 10,000, 10 ml ampoule – Up to 5 inj available on a PSO .... $27.00 5 ✔️ Hospira
- Inj 1 in 10,000, 10 ml ampoule – Up to 10 inj available on a PSO ... $49.00 10 ✔️ Aspen Adrenaline
ISOPRENALINE [ISOPROTERENOL]

<table>
<thead>
<tr>
<th>Subsidy (Manufacturer's Price) $</th>
<th>Fully Subsidised ✔</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 200 mcg per ml, 1 ml ampoule .............................................................................</td>
<td>36.80</td>
<td>25 (164.20) Isuprel</td>
</tr>
</tbody>
</table>

Vasodilators

HYDRAZINE HYDROCHLORIDE

<table>
<thead>
<tr>
<th>Tab 25 mg – Special Authority see SA1321 below – Retail pharmacy ................................................CBS</th>
<th>1 ✔ Hydralazine</th>
</tr>
</thead>
<tbody>
<tr>
<td>56 ✔ Onelink (S29)</td>
<td></td>
</tr>
<tr>
<td>84 ✔ AMDIPHARM (S29)</td>
<td></td>
</tr>
<tr>
<td>100 ✔ Onelink (S29)</td>
<td></td>
</tr>
</tbody>
</table>

| Inj 20 mg ampoule .................................................................................................................. | 25.90               | 5 ✔ Apresoline |

[SA1321] Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Either:

1. For the treatment of refractory hypertension; or
2. For the treatment of heart failure in combination with a nitrate, in patients who are intolerant or have not responded to ACE inhibitors and/or angiotensin receptor blockers.

MINOXIDIL

| Tab 10 mg ................................................................................................................ | 70.00               | 100 ✔ Loniten |

NICORANDIL

| Tab 10 mg ................................................................................................................ | 27.95               | 60 ✔ Ikorel |
| Tab 20 mg ................................................................................................................ | 33.28               | 60 ✔ Ikorel |

PAPaverine Hydrochloride

| Inj 12 mg per ml, 10 ml ampoule ...................................................................................... | 217.90             | 5 ✔ Hospira |

PENTOXIFYLLINE [OXpentifylline]

| Tab 400 mg .................................................................................................................. | 42.26               | 50 ✔ Trental 400 |

Endothelin Receptor Antagonists

AMBRIsentan – Special Authority see SA1702 below – Retail pharmacy

| Tab 5 mg .................................................................................................................. | 4,585.00             | 30 ✔ Volbris |
| Tab 10 mg .............................................................................................................. | 4,585.00             | 30 ✔ Volbris |

[SA1702] Special Authority for Subsidy

Special Authority approved by the Pulmonary Arterial Hypertension Panel

Notes: Application details may be obtained from PHARMAC’s website [http://www.pharmac.govt.nz](http://www.pharmac.govt.nz) or:

The Coordinator, PAH Panel

PHARMAC, PO Box 10-254, WELLINGTON

Tel: (04) 916 7561, Fax: (04) 974 4858, Email: PAH@pharmac.govt.nz
BOSENTAN – Special Authority see SA1712 below – Retail pharmacy

Tab 62.5 mg .............................................................. 141.00 60 ✔  Bosentan Dr Reddy’s
Bosentan Dr Reddy’s to be Sole Supply on 1 March 2019
Tab 125 mg .............................................................. 141.00 60 ✔  Bosentan Dr Reddy’s

(Bosentan-Mylan Tab 62.5 mg to be delisted 1 March 2019)
(Bosentan-Mylan Tab 125 mg to be delisted 1 March 2019)

➽ SA1712 Special Authority for Subsidy

Initial application only from a respiratory specialist, cardiologist or medical practitioner on the recommendation of a respiratory physician or cardiologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:
1 Patient has pulmonary arterial hypertension (PAH)*; and
2 PAH is in Group 1, 4 or 5 of the WHO (Venice) clinical classifications; and
3 PAH is at NYHA/WHO functional class II, III, or IV; and
4 Any of the following:
   4.1 Both:
      4.1.1 Bosentan is to be used as PAH monotherapy; and
      4.1.2 Either:
         4.1.2.1 Patient is intolerant or contraindicated to sildenafil; or
         4.1.2.2 Patient is a child with idiopathic PAH or PAH secondary to congenital heart disease; or
   4.2 Both:
      4.2.1 Bosentan is to be used as PAH dual therapy; and
      4.2.2 Either:
         4.2.2.1 Patient has tried a PAH monotherapy for at least three months and failed to respond; or
         4.2.2.2 Patient deteriorated while on a PAH monotherapy; or
   4.3 Both:
      4.3.1 Bosentan is to be used as PAH triple therapy; and
      4.3.2 Any of the following:
         4.3.2.1 Patient is on the lung transplant list; or
         4.3.2.2 Patient is presenting acutely with idiopathic pulmonary arterial hypertension (IPAH) in New York Heart Association/World Health Organization (NYHA/WHO) Functional Class IV; or
         4.3.2.3 Patient is deteriorating rapidly to NYHA/WHO Functional Class IV who may be lung transplant recipients in the future, if their disease is stabilised; or
         4.3.2.4 Patient has PAH associated with the scleroderma spectrum of diseases (APAHSSD) who have no major morbidities and are deteriorating despite combination therapy.

Renewal only from a respiratory specialist, cardiologist or medical practitioner on the recommendation of a respiratory physician or cardiologist. Approvals valid for 2 years for applications meeting the following criteria:

Any of the following:
1 Both:
   1.1 Bosentan is to be used as PAH monotherapy; and
   1.2 Patient is stable or has improved while on bosentan; or
2 Both:
   2.1 Bosentan is to be used as PAH dual therapy; and
   2.2 Patient has tried a PAH monotherapy for at least three months and either failed to respond or later deteriorated; or

continued…
continued...

3 Both:

3.1 Bosentan is to be used as PAH triple therapy; and
3.2 Any of the following:

3.2.1 Patient is on the lung transplant list; or
3.2.2 Patient is presenting acutely with idiopathic pulmonary arterial hypertension (IPAH) in New York Heart Association/World Health Organization (NYHA/WHO) Functional Class IV; or
3.2.3 Patient is deteriorating rapidly to NYHA/WHO Functional Class IV who may be lung transplant recipients in the future, if their disease is stabilised; or
3.2.4 Patient has PAH associated with the scleroderma spectrum of diseases (APAHSDD) who have no major morbidities and are deteriorating despite combination therapy.

### Phosphodiesterase Type 5 Inhibitors

**SILDENAFIL** – Special Authority see SA1738 below – Retail pharmacy

- Tab 25 mg ............................................................... 0.64 4 ✔ Vedafil
- Tab 50 mg ............................................................... 0.64 4 ✔ Vedafil
- Tab 100 mg ............................................................ 6.60 12 ✔ Vedafil

**SA1738** Special Authority for Subsidy

**Initial application — (Raynaud’s Phenomenon*)** from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

All of the following:

1. Patient has Raynaud’s Phenomenon*; and
2. Patient has severe digital ischaemia (defined as severe pain requiring hospital admission or with a high likelihood of digital ulceration; digital ulcers; or gangrene); and
3. Patient is following lifestyle management (avoidance of cold exposure, sufficient protection, smoking cessation support, avoidance of sympathomimetic drugs); and
4. Patient is being treated with calcium channel blockers and nitrates (or these are contraindicated/not tolerated).

**Initial application — (Pulmonary arterial hypertension*)** only from a respiratory specialist, cardiologist or medical practitioner on the recommendation of a respiratory specialist or cardiologist. Approvals valid without further renewal unless notified for applications meeting the following criteria:

All of the following:

1. Patient has pulmonary arterial hypertension (PAH)*; and
2. Any of the following:
   2.1 PAH is in Group 1 of the WHO (Venice) clinical classifications; or
   2.2 PAH is in Group 4 of the WHO (Venice) clinical classifications; or
   2.3 PAH is in Group 5 of the WHO (Venice) clinical classifications; and
3. Any of the following:
   3.1 PAH is in NYHA/WHO functional class II; or
   3.2 PAH is in NYHA/WHO functional class III; or
   3.3 PAH is in NYHA/WHO functional class IV; and
4. Either:
   4.1 All of the following:
      4.1.1 Patient has a pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg; and
      4.1.2 Either:
         4.1.2.1 Patient has a mean pulmonary artery pressure (PAPm) > 25 mmHg; or
         4.1.2.2 Patient is peri Fontan repair; and
      4.1.3 Patient has a pulmonary vascular resistance (PVR) of at least 3 Wood Units or at least 240 International

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber or pharmacist.

Three months or six months, as applicable, dispensed all-at-once
continued…

Units (dyn s cm<sup>-5</sup>); or

4.2 Testing for PCWP, PAPm, or PVR cannot be performed due to the patient’s young age.

Note: Indications marked with * are unapproved indications.

**Prostacyclin Analogues**

EPOPROSTENOL – Special Authority see SA1696 below – Retail pharmacy

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Subsidy (Manufacturer’s Price) $</th>
<th>Fully Subsidised</th>
</tr>
</thead>
</table>

- Inj 500 mcg vial
  - $36.61
- Inj 1.5 mg vial
  - $73.21

[SA1696] Special Authority for Subsidy

Special Authority approved by the Pulmonary Arterial Hypertension Panel

Notes: Application details may be obtained from PHARMAC’s website [http://www.pharmac.govt.nz](http://www.pharmac.govt.nz) or:

The Coordinator, PAH Panel

PHARMAC, PO Box 10-254, WELLINGTON

Tel: (04) 916 7561, Fax: (04) 974 4858, Email: [PAH@pharmac.govt.nz](mailto:PAH@pharmac.govt.nz)

ILOPROST – Special Authority see SA1705 below – Retail pharmacy

- Nebuliser soln 10 mcg per ml, 2 ml
  - $1,185.00

[SA1705] Special Authority for Subsidy

Special Authority approved by the Pulmonary Arterial Hypertension Panel

Notes: Application details may be obtained from PHARMAC’s website [http://www.pharmac.govt.nz](http://www.pharmac.govt.nz) or:

The Coordinator, PAH Panel

PHARMAC, PO Box 10-254, WELLINGTON

Tel: (04) 916 7561, Fax: (04) 974 4858, Email: [PAH@pharmac.govt.nz](mailto:PAH@pharmac.govt.nz)
**Antiacne Preparations**

For systemic antibacterials, refer to INFECTIONS, Antibacterials, page 90

### ADAPALENE

- **a)** Maximum of 30 g per prescription
- **b)** Only on a prescription

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Manufacturer's Price</th>
<th>Subsidy (Manufacturer’s Price) $</th>
<th>Fully Subsidised</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Crm 0.1%</td>
<td>22.89</td>
<td>$ Per 30 g OP</td>
<td>✔</td>
<td></td>
</tr>
<tr>
<td>Gel 0.1%</td>
<td>22.89</td>
<td>$ Per 30 g OP</td>
<td>✔</td>
<td></td>
</tr>
</tbody>
</table>

### ISOTRETINOIN – Special Authority see SA1475 below – Retail pharmacy

- **Cap 5 mg**
- **Cap 10 mg**
- **Cap 20 mg**

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Manufacturer's Price</th>
<th>Subsidy (Manufacturer’s Price) $</th>
<th>Fully Subsidised</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cap 5 mg</td>
<td>8.14</td>
<td>$ Per 60 g OP</td>
<td>✔</td>
<td></td>
</tr>
<tr>
<td>Cap 10 mg</td>
<td>13.34</td>
<td>$ Per 120 g OP</td>
<td>✔</td>
<td></td>
</tr>
<tr>
<td>Cap 20 mg</td>
<td>17.08</td>
<td>$ Per 100 g OP</td>
<td>✔</td>
<td></td>
</tr>
</tbody>
</table>

Oratane to be Sole Supply on 1 January 2019

(Isotane 10 Cap 10 mg to be delisted 1 January 2019)

(Isotane 20 Cap 20 mg to be delisted 1 January 2019)

**SA1475** Special Authority for Subsidy

**Initial application** from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

All of the following:

1. Applicant is a vocationally registered dermatologist, vocationally registered general practitioner, or nurse practitioner working in a relevant scope of practice; and
2. Applicant has an up to date knowledge of the safety issues around isotretinoin and is competent to prescribe isotretinoin; and
3. Either:
   3.1 Patient is female and has been counselled and understands the risk of teratogenicity if isotretinoin is used during pregnancy and the applicant has ensured that the possibility of pregnancy has been excluded prior to the commencement of the treatment and that the patient is informed that she must not become pregnant during treatment and for a period of one month after the completion of the treatment; or
   3.2 Patient is male.

Note: Applicants are recommended to either have used or be familiar with using a decision support tool accredited by their professional body.

**Renewal** from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Either:

1. Patient is female and has been counselled and understands the risk of teratogenicity if isotretinoin is used during pregnancy and the applicant has ensured that the possibility of pregnancy has been excluded prior to the commencement of the treatment and that the patient is informed that she must not become pregnant during treatment and for a period of one month after the completion of the treatment; or
2. Patient is male.

Note: Applicants are recommended to either have used or be familiar with using a decision support tool accredited by their professional body.

### TRETINOIN

- **Crm 0.5 mg per g**

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Manufacturer's Price</th>
<th>Subsidy (Manufacturer’s Price) $</th>
<th>Fully Subsidised</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Crm 0.5 mg</td>
<td>13.90</td>
<td>$ Per 50 g OP</td>
<td>✔</td>
<td>ReTrieve</td>
</tr>
</tbody>
</table>
## Antibacterials Topical

For systemic antibacterials, refer to INFECTIONS, Antibacterials, page 90

<table>
<thead>
<tr>
<th>Drug</th>
<th>Formulation</th>
<th>Subsidy (Manufacturer’s Price)</th>
<th>Fully Subsidised</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Crm 1%</strong></td>
<td></td>
<td>8.56</td>
<td>15 g OP</td>
<td>☑ Crystaderm</td>
</tr>
<tr>
<td><strong>Mupirocin</strong></td>
<td></td>
<td>6.60</td>
<td>15 g OP</td>
<td><strong>Bactroban</strong></td>
</tr>
<tr>
<td></td>
<td>Oint 2%</td>
<td>(9.26)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>a) Only on a prescription</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>b) Not in combination</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Sodium Fusidate [Fusidic Acid]</strong></td>
<td>Crm 2%</td>
<td>2.52</td>
<td>15 g OP</td>
<td>☑ DP Fusidic Acid Cream</td>
</tr>
<tr>
<td></td>
<td>Oint 2%</td>
<td>3.45</td>
<td>15 g OP</td>
<td>☑ Foban</td>
</tr>
<tr>
<td></td>
<td>a) Maximum of 15 g per prescription</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>b) Only on a prescription</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>c) Not in combination</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Sulfadiazine Silver</strong></td>
<td>Crm 1%</td>
<td>10.80</td>
<td>50 g OP</td>
<td>☑ Flamazine</td>
</tr>
<tr>
<td></td>
<td>a) Up to 250 g available on a PSO</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>b) Not in combination</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

## Antifungals Topical

For systemic antifungals, refer to INFECTIONS, Antifungals, page 97

<table>
<thead>
<tr>
<th>Drug</th>
<th>Formulation</th>
<th>Subsidy (Manufacturer’s Price)</th>
<th>Fully Subsidised</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Amorolfine</strong></td>
<td>Nail soln 5%</td>
<td>15.95</td>
<td>5 ml OP</td>
<td>☑ MycoNail</td>
</tr>
<tr>
<td></td>
<td>a) Only on a prescription</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>b) Not in combination</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Ciclopirox Olamine</strong></td>
<td>Nail-soln 8%</td>
<td>5.72</td>
<td>7 ml OP</td>
<td>☑ Apo-Ciclopirox</td>
</tr>
<tr>
<td></td>
<td>a) Only on a prescription</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>b) Not in combination</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Clotrimazole</strong></td>
<td>Crm 1%</td>
<td>0.70</td>
<td>20 g OP</td>
<td>☑ Clomazol</td>
</tr>
<tr>
<td></td>
<td>a) Only on a prescription</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>b) Not in combination</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Soln 1%</td>
<td>(7.55)</td>
<td>20 ml OP</td>
<td>Canesten</td>
</tr>
<tr>
<td></td>
<td>a) Only on a prescription</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>b) Not in combination</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>DERMATOLOGICALS</strong></td>
<td><strong>Subsidy (Manufacturer’s Price)</strong></td>
<td><strong>Fully Subsidised</strong></td>
<td><strong>Brand or Generic Manufacturer</strong></td>
<td></td>
</tr>
<tr>
<td>---------------------</td>
<td>-----------------------------</td>
<td>----------------------</td>
<td>----------------------------------</td>
<td></td>
</tr>
<tr>
<td><strong>ECONAZOLE NITRATE</strong></td>
<td>Crm 1%...............................................................1.00 20 g OP</td>
<td>✔</td>
<td>Pevaryl</td>
<td></td>
</tr>
<tr>
<td></td>
<td>a) Only on a prescription</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>b) Not in combination</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Foaming soln 1%, 10 ml sachets........................................9.89 3</td>
<td></td>
<td>Pevaryl</td>
<td></td>
</tr>
<tr>
<td></td>
<td>a) Only on a prescription</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>b) Not in combination</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>MICONAZOLE NITRATE</strong></td>
<td>✭ Crm 2%..........................................................0.74 15 g OP</td>
<td>✔</td>
<td>Multichem</td>
<td></td>
</tr>
<tr>
<td></td>
<td>a) Only on a prescription</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>b) Not in combination</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Lotn 2% ............................................................4.36 30 ml OP</td>
<td></td>
<td>Daktarin</td>
<td></td>
</tr>
<tr>
<td></td>
<td>a) Only on a prescription</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>b) Not in combination</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Tinct 2%...........................................................4.36 30 ml OP</td>
<td></td>
<td>Daktarin</td>
<td></td>
</tr>
<tr>
<td></td>
<td>a) Only on a prescription</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>b) Not in combination</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>NYSTATIN</strong></td>
<td>Crm 100,000 u per g........................................1.00 15 g OP</td>
<td></td>
<td>Mycostatin</td>
<td></td>
</tr>
<tr>
<td></td>
<td>a) Only on a prescription</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>b) Not in combination</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Antipruritic Preparations

**CALAMINE**
- a) Only on a prescription
- b) Not in combination
- Crm, aqueous, BP ............................................................1.26 100 g | ✔ | healthE Calamine Aqueous Cream BP |

*Pharmacy Health Crm, aqueous, BP to be delisted 1 February 2019*

**CROTAMITON**
- a) Only on a prescription
- b) Not in combination
- Crm 10%..............................................................3.29 20 g OP | ✔ | Itch-Soothe |

**MENTHOL – Only in combination**
1) Only in combination with a dermatological base or proprietary Topical Corticosteroid – Plain
2) With or without other dermatological galenicals.

- Crystals............................................................6.92 25 g | ✔ | MidWest |
- 29.60 100 g | ✔ | MidWest |

▲Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once
## DERMATOLOGICALS

### Corticosteroids Topical

For systemic corticosteroids, refer to CORTICOSTEROIDS AND RELATED AGENTS, page 79

### Corticosteroids - Plain

<table>
<thead>
<tr>
<th>Substance</th>
<th>Formulation</th>
<th>Manufacturer</th>
<th>Per 15 g</th>
<th>Code</th>
<th>Manufacturer</th>
<th>Per 30 g</th>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>BETAMETHASONE DIPROPIONATE</td>
<td>Crm 0.05%</td>
<td>Diprosone</td>
<td>8.97</td>
<td>50 g</td>
<td>✔</td>
<td>2.96</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Crm 0.05% in propylene glycol base</td>
<td>Diprosone OV</td>
<td>4.33</td>
<td>30 g</td>
<td>✔</td>
<td>3.00</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Oint 0.05%</td>
<td>Diprosone</td>
<td>8.97</td>
<td>50 g</td>
<td>✔</td>
<td>2.96</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Oint 0.05% in propylene glycol base</td>
<td>Diprosone OV</td>
<td>4.33</td>
<td>30 g</td>
<td>✔</td>
<td>3.00</td>
<td></td>
</tr>
</tbody>
</table>

**BETAMETHASONE VALERATE**

<table>
<thead>
<tr>
<th>Substance</th>
<th>Formulation</th>
<th>Manufacturer</th>
<th>Per 50 g</th>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grey Betamethasone Valerate Cream 0.1%</td>
<td>✔</td>
<td>✔ Beta Cream</td>
<td>3.45</td>
<td></td>
</tr>
<tr>
<td>Grey Betamethasone Valerate Ointment 0.1%</td>
<td>✔</td>
<td>✔ Beta Ointment</td>
<td>3.45</td>
<td></td>
</tr>
<tr>
<td>Betnovate</td>
<td>to be Sole Supply on 1 January 2019</td>
<td>✔</td>
<td>18.00</td>
<td></td>
</tr>
</tbody>
</table>

**CLOBETASOL PROPIONATE**

<table>
<thead>
<tr>
<th>Substance</th>
<th>Formulation</th>
<th>Manufacturer</th>
<th>Per 30 g</th>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clobetasol Propionate Cream 0.05%</td>
<td>✔</td>
<td>✔ Dermol</td>
<td>2.20</td>
<td></td>
</tr>
<tr>
<td>Clobetasol Propionate Ointment 0.05%</td>
<td>✔</td>
<td>✔ Dermol</td>
<td>2.20</td>
<td></td>
</tr>
</tbody>
</table>

**CLOBETASONE BUTYRATE**

<table>
<thead>
<tr>
<th>Substance</th>
<th>Formulation</th>
<th>Manufacturer</th>
<th>Per 30 g</th>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clobetasone Butyrate Lipocream 0.1%</td>
<td>✔</td>
<td>✔ Locoid Lipocream</td>
<td>2.30</td>
<td></td>
</tr>
<tr>
<td>Clobetasone Butyrate Milky emulation 0.1%</td>
<td>✔</td>
<td>Locoid</td>
<td>6.85</td>
<td></td>
</tr>
<tr>
<td>Clobetasone Butyrate Ointment 0.1%</td>
<td>✔</td>
<td>Locoid Crelo</td>
<td>6.85</td>
<td></td>
</tr>
</tbody>
</table>

**HYDROCORTISONE**

<table>
<thead>
<tr>
<th>Substance</th>
<th>Formulation</th>
<th>Manufacturer</th>
<th>Per 30 g</th>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hydrocortisone Lipocream 0.1%</td>
<td>✔</td>
<td>Locoid Lipocream</td>
<td>2.30</td>
<td></td>
</tr>
<tr>
<td>Hydrocortisone Milky Ointment 0.1%</td>
<td>✔</td>
<td>Locoid</td>
<td>6.85</td>
<td></td>
</tr>
<tr>
<td>Hydrocortisone Ointment 0.1%</td>
<td>✔</td>
<td>Locoid Crelo</td>
<td>6.85</td>
<td></td>
</tr>
<tr>
<td>Hydrocortisone Ointment 0.1% in paraffin liquid 15.9% and lanolin 0.6%</td>
<td>✔</td>
<td>DP Lotn HC</td>
<td>10.57</td>
<td></td>
</tr>
</tbody>
</table>

**HYDROCORTISONE AND PARAFFIN LIQUID AND LANOLIN**

<table>
<thead>
<tr>
<th>Substance</th>
<th>Formulation</th>
<th>Manufacturer</th>
<th>Per 250 ml</th>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hydrocortisone and paraffin liquid 15.9% and lanolin 0.6%</td>
<td>✔</td>
<td>ABM</td>
<td>49.95</td>
<td></td>
</tr>
</tbody>
</table>

**METHYLPREDNISOLONE ACEPONATE**

<table>
<thead>
<tr>
<th>Substance</th>
<th>Formulation</th>
<th>Manufacturer</th>
<th>Per 15 g</th>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methyprednisolone Aceponate Cream 0.1%</td>
<td>✔</td>
<td>Advantan</td>
<td>4.95</td>
<td></td>
</tr>
<tr>
<td>Methyprednisolone Aceponate Ointment 0.1%</td>
<td>✔</td>
<td>Advantan</td>
<td>4.95</td>
<td></td>
</tr>
</tbody>
</table>
## Dermatologicals

<table>
<thead>
<tr>
<th>Subsidy (Manufacturer’s Price)</th>
<th>Fully Subsidised</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per</td>
<td>✔</td>
<td></td>
</tr>
</tbody>
</table>

### Mometasone Furoate

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Price</th>
<th>Quantity</th>
<th>Product Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>Crm 0.1%</td>
<td>1.51</td>
<td>15 g OP</td>
<td>Elocon Alcohol Free</td>
</tr>
<tr>
<td>Oint 0.1%</td>
<td>2.50</td>
<td>50 g OP</td>
<td>Elocon Alcohol Free</td>
</tr>
<tr>
<td>Lotn 0.1%</td>
<td>1.51</td>
<td>15 g OP</td>
<td>Elocon</td>
</tr>
<tr>
<td></td>
<td>2.90</td>
<td>50 g OP</td>
<td>Elocon</td>
</tr>
</tbody>
</table>

### Triamcinolone Acetonide

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Price</th>
<th>Quantity</th>
<th>Product Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>Crm 0.02%</td>
<td>6.30</td>
<td>100 g OP</td>
<td>Aristocort</td>
</tr>
<tr>
<td>Oint 0.02%</td>
<td>6.35</td>
<td>100 g OP</td>
<td>Aristocort</td>
</tr>
</tbody>
</table>

### Corticosteroids - Combination

**BETAMETHASONE VALERATE WITH CLIOQUINOL** – Only on a prescription

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Price</th>
<th>Quantity</th>
<th>Product Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>Crm 0.1% with clioquinol 3%</td>
<td>3.49</td>
<td>15 g OP</td>
<td>Betnovate-C</td>
</tr>
<tr>
<td></td>
<td>(4.90)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**BETAMETHASONE VALERATE WITH SODIUM FUSIDATE [FUSIDIC ACID]**

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Price</th>
<th>Quantity</th>
<th>Product Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>Crm 0.1% with sodium fusidate (fusidic acid) 2%</td>
<td>3.49</td>
<td>15 g OP</td>
<td>Fucicort</td>
</tr>
<tr>
<td></td>
<td>(10.45)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- a) Maximum of 15 g per prescription
- b) Only on a prescription

**HYDROCORTISONE WITH MICONAZOLE** – Only on a prescription

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Price</th>
<th>Quantity</th>
<th>Product Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>Crm 1% with miconazole nitrate 2%</td>
<td>2.00</td>
<td>15 g OP</td>
<td>Micreme H</td>
</tr>
</tbody>
</table>

**HYDROCORTISONE WITH NATAMYCIN AND NEOMYCIN** – Only on a prescription

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Price</th>
<th>Quantity</th>
<th>Product Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>Crm 1% with natamycin 1% and neomycin sulphate 0.5%</td>
<td>2.79</td>
<td>15 g OP</td>
<td>Pimafucort</td>
</tr>
<tr>
<td>Oint 1% with natamycin 1% and neomycin sulphate 0.5%</td>
<td>2.79</td>
<td>15 g OP</td>
<td>Pimafucort</td>
</tr>
</tbody>
</table>

**TRIAMCINOLONE ACETONIDE WITH GRAMICIDIN, NEOMYCIN AND NYSTATIN**

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Price</th>
<th>Quantity</th>
<th>Product Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>Crm 1 mg with nystatin 100,000 u, neomycin sulphate 2.5 mg and gramicidin 250 mcg per g</td>
<td>3.49</td>
<td>15 g OP</td>
<td>Viaderm KC</td>
</tr>
<tr>
<td></td>
<td>(6.60)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Disinfecting and Cleansing Agents

**CHLORHEXIDINE GLUCONATE** – Subsidy by endorsement

- a) No more than 500 ml per month
- b) Only if prescribed for a dialysis patient and the prescription is endorsed accordingly.

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Price</th>
<th>Quantity</th>
<th>Product Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>Handrub 1% with ethanol 70%</td>
<td>4.29</td>
<td>500 ml</td>
<td>healthE</td>
</tr>
<tr>
<td>Soln 1%</td>
<td>3.98</td>
<td>500 ml</td>
<td>healthE</td>
</tr>
</tbody>
</table>

**TRICLOSAN** – Subsidy by endorsement

- a) Maximum of 500 ml per prescription
- b)
  - a) Only if prescribed for a patient identified with Methicillin-resistant Staphylococcus aureus (MRSA) prior to elective surgery in hospital and the prescription is endorsed accordingly; or
  - b) Only if prescribed for a patient with recurrent Staphylococcus aureus infection and the prescription is endorsed accordingly.

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Price</th>
<th>Quantity</th>
<th>Product Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>Soln 1%</td>
<td>5.90</td>
<td>500 ml OP</td>
<td>healthE</td>
</tr>
</tbody>
</table>
## Barrier Creams and Emollients

### Barrier Creams

**DIMETHICONE**
- Crm 5% pump bottle ................................................................. $4.59 500 ml OP ✔️ healthE Dimethicone 5%
- Crm 10% pump bottle .............................................................. $4.52 500 ml OP ✔️ healthE Dimethicone 10%

**ZINC AND CASTOR OIL**
- Oint ......................................................................................... $4.25 500 g ✔️ Boucher

### Emollients

**AQUEOUS CREAM**
- Crm ......................................................................................... $1.92 500 g ✔️ Boucher
  - (1.99) AFT SLS-free Boucher to be Sole Supply on 1 March 2019
  - (AFT SLS-free Crm to be delisted 1 March 2019)

**CETOMACROGOL**
- Crm BP .................................................................................. $2.48 500 g ✔️ healthE

**CETOMACROGOL WITH GLYCEROL**
- Crm 90% with glycerol 10% ...................................................... $2.82 500 ml OP ✔️ Pharmacy Health Sorbolene with Glycerin
  - 3.87 1,000 ml OP ✔️ Pharmacy Health Sorbolene with Glycerin

**EMULSIFYING OINTMENT**
- Oint BP .................................................................................. $3.59 500 g ✔️ AFT

**OIL IN WATER EMULSION**
- Crm ......................................................................................... $2.19 500 g ✔️ O/W Fatty Emulsion Cream
  - O/W Fatty Emulsion Cream to be Sole Supply on 1 February 2019

**PARAFFIN**
- Oint liquid paraffin 50% with white soft paraffin 50% .................. $5.35 500 ml OP ✔️ healthE
  - healthE to be Sole Supply on 1 February 2019

**UREA**
- Crm 10% .................................................................................. $1.37 100 g OP ✔️ healthE Urea Cream

**WOOL FAT WITH MINERAL OIL – Only on a prescription**
- Lotn hydrous 3% with mineral oil .............................................. $5.60 1,000 ml
  - (11.95) 1.40 250 ml OP DP Lotion
  - (4.53) 5.60 1,000 ml Alpha-Keri Lotion
  - (20.53) 1.40 250 ml OP BK Lotion
  - (23.91) (7.73)
### Other Dermatological Bases

<table>
<thead>
<tr>
<th>Manufacturer's Price</th>
<th>Fully Subsidised</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per</td>
<td>Brand or Generic</td>
</tr>
<tr>
<td></td>
<td>Manufacturer</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PARAFFIN</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>White soft</td>
<td>Only in combination</td>
</tr>
<tr>
<td></td>
<td>$20.20</td>
</tr>
<tr>
<td>2,500 g</td>
<td></td>
</tr>
<tr>
<td></td>
<td>✔ IPW</td>
</tr>
<tr>
<td>3.58</td>
<td></td>
</tr>
<tr>
<td>500 g</td>
<td></td>
</tr>
<tr>
<td></td>
<td>IPW</td>
</tr>
<tr>
<td>(7.78)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>PSM</td>
</tr>
<tr>
<td>(8.69)</td>
<td></td>
</tr>
</tbody>
</table>

Only in combination with a dermatological galenical or as a diluent for a proprietary Topical Corticosteroid – Plain.

### Minor Skin Infections

**POVIDONE IODINE**

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Oint 10%</td>
<td>$3.27</td>
</tr>
<tr>
<td></td>
<td>25 g OP</td>
</tr>
<tr>
<td>[Betadine]</td>
<td></td>
</tr>
</tbody>
</table>

a) Maximum of 100 g per prescription

b) Only on a prescription

| Antiseptic soln 10%    | $6.20                    |
|                        | 500 ml                   |
| [Betadine]             |                          |
| [Riodine]              |                          |

1.28 100 ml

(4.20) Riodine

(13.27) Betadine

0.19 15 ml

(7.41) Betadine

Skin preparation, povidone iodine 10% with 30% alcohol

<table>
<thead>
<tr>
<th></th>
<th>$10.00</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>500 ml</td>
</tr>
<tr>
<td>[Betadine Skin Prep]</td>
<td></td>
</tr>
</tbody>
</table>

1.63 100 ml

(3.48) Betadine Skin Prep

Skin preparation, povidone iodine 10% with 70% alcohol

<table>
<thead>
<tr>
<th></th>
<th>$1.63</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>100 ml</td>
</tr>
<tr>
<td>[Orion]</td>
<td></td>
</tr>
<tr>
<td>[Pfizer]</td>
<td></td>
</tr>
</tbody>
</table>

(Orion Skin preparation, povidone iodine 10% with 70% alcohol to be delisted 1 June 2019)

### Parasiticidal Preparations

**DIMETHICONE**

<table>
<thead>
<tr>
<th></th>
<th>$4.98</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lotn 4%</td>
<td>200 ml OP</td>
</tr>
<tr>
<td>healthE Dimethicone 4%</td>
<td></td>
</tr>
</tbody>
</table>

**IVERMECTIN** – Special Authority see **SA1225 below** – Retail pharmacy

|                        | $17.20                   |
| Tab 3 mg               | Up to 100 tab available on a PSO |
| [Stromectol]           |                          |

1) PSO for institutional use only. Must be endorsed with the name of the institution for which the PSO is required and a valid Special Authority for patient of that institution.

2) Ivermectin available on BSO provided the BSO includes a valid Special Authority for a patient of the institution.

3) For the purposes of subsidy of ivermectin, institution means age related residential care facilities, disability care facilities or penal institutions.

**SA1225** Special Authority for Subsidy

Initial application — (Scabies) from any relevant practitioner. Approvals valid for 1 month for applications meeting the following criteria:

Both:

▲Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber or pharmacist.

★Three months or six months, as applicable, dispensed all-at-once
continued…

1 Applying clinician has discussed the diagnosis of scabies with a dermatologist, infectious disease physician or clinical microbiologist; and

2 Either:
   2.1 Both:
      2.1.1 The patient is in the community; and
      2.1.2 Any of the following:
         2.1.2.1 Patient has a severe scabies hyperinfestation (Crusted/ Norwegian scabies); or
         2.1.2.2 The community patient is physically or mentally unable to comply with the application instructions of topical therapy; or
         2.1.2.3 The patient has previously tried and failed to clear infestation using topical therapy; or

2.2 All of the following:
   2.2.1 The Patient is a resident in an institution; and
   2.2.2 All residents of the institution with scabies or at risk of carriage are to be treated for scabies concurrently; and
   2.2.3 Any of the following:
      2.2.3.1 Patient has a severe scabies hyperinfestation (Crusted/ Norwegian scabies); or
      2.2.3.2 The patient is physically or mentally unable to comply with the application instructions of topical therapy; or
      2.2.3.3 Previous topical therapy has been tried and failed to clear the infestation.

Note: Ivermectin is no more effective than topical therapy for treatment of standard scabies infestation.

**Initial application — (Other parasitic infections)** only from an infectious disease specialist, clinical microbiologist or dermatologist. Approvals valid for 1 month for applications meeting the following criteria:

Any of the following:
1 Filaricides; or
2 Cutaneous larva migrans (creeping eruption); or
3 Strongyloidiasis.

**Renewal — (Scabies)** from any relevant practitioner. Approvals valid for 1 month for applications meeting the following criteria:

Both:
1 Applying clinician has discussed the diagnosis of scabies with a dermatologist, infectious disease physician or clinical microbiologist; and

2 Either:
   2.1 Both:
      2.1.1 The patient is in the community; and
      2.1.2 Any of the following:
         2.1.2.1 Patient has a severe scabies hyperinfestation (Crusted/ Norwegian scabies); or
         2.1.2.2 The community patient is physically or mentally unable to comply with the application instructions of topical therapy; or
         2.1.2.3 The patient has previously tried and failed to clear infestation using topical therapy; or

2.2 All of the following:
   2.2.1 The Patient is a resident in an institution; and
   2.2.2 All residents of the institution with scabies or at risk of carriage are to be treated for scabies concurrently; and
   2.2.3 Any of the following:
      2.2.3.1 Patient has a severe scabies hyperinfestation (Crusted/ Norwegian scabies); or
      2.2.3.2 The patient is physically or mentally unable to comply with the application instructions of topical therapy; or
      2.2.3.3 Previous topical therapy has been tried and failed to clear the infestation.
Note: Ivermectin is no more effective than topical therapy for treatment of standard scabies infestation.

**Renewal — (Other parasitic infections)** only from an infectious disease specialist, clinical microbiologist or dermatologist.

Approvals valid for 1 month for applications meeting the following criteria:

Any of the following:
1. Filaricides; or
2. Cutaneous larva migrans (creeping eruption); or

**PERMETHRIN**

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Manufacturer</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Crm 5%</td>
<td>Lyderm</td>
<td>$4.95</td>
</tr>
<tr>
<td>Lotn 5%</td>
<td>A-Scabies</td>
<td>$3.69</td>
</tr>
</tbody>
</table>

**PHENOTHRIN**

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Manufacturer</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shampoo 0.5%</td>
<td>Parasidose</td>
<td>$11.36</td>
</tr>
</tbody>
</table>

---

**Psoriasis and Eczema Preparations**

**ACITRETIN** – Special Authority see **SA1476 below** – Retail pharmacy

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Manufacturer</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cap 10 mg</td>
<td>Novatretin</td>
<td>$17.86</td>
</tr>
<tr>
<td>Cap 25 mg</td>
<td>Novatretin</td>
<td>$41.36</td>
</tr>
</tbody>
</table>

**SA1476 Special Authority for Subsidy**

**Initial application** from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

All of the following:
1. Applicant is a vocationally registered dermatologist, vocationally registered general practitioner, or nurse practitioner working in a relevant scope of practice; and
2. Applicant has an up to date knowledge of the safety issues around acitretin and is competent to prescribe acitretin; and
3. Either:
   3.1 Patient is female and has been counselled and understands the risk of teratogenicity if acitretin is used during pregnancy and the applicant has ensured that the possibility of pregnancy has been excluded prior to the commencement of the treatment and that the patient is informed that she must not become pregnant during treatment and for a period of two years after the completion of the treatment; or
   3.2 Patient is male.

**Renewal** from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Either:
1. Patient is female and has been counselled and understands the risk of teratogenicity if acitretin is used during pregnancy and the applicant has ensured that the possibility of pregnancy has been excluded prior to the commencement of the treatment and that the patient is informed that she must not become pregnant during treatment and for a period of two years after the completion of the treatment; or
2. Patient is male.

**BETAMETHASONE DIPROPIONATE WITH CALCIPOTRIOL**

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Manufacturer</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gel 500 mcg with calcipotriol 50 mcg per g</td>
<td>Daivobet</td>
<td>$52.24</td>
</tr>
<tr>
<td>Oint 500 mcg with calcipotriol 50 mcg per g</td>
<td>Daivobet</td>
<td>$19.95</td>
</tr>
</tbody>
</table>

**CALCIPOTRIOL**

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Manufacturer</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oint 50 mcg per g</td>
<td>Daivonex</td>
<td>$45.00</td>
</tr>
</tbody>
</table>

**COAL TAR**

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Manufacturer</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Soln BP – Only in combination</td>
<td>Midwest</td>
<td>$32.95</td>
</tr>
</tbody>
</table>

1. Up to 10% only in combination with a dermatological base or proprietary Topical Corticosteroid – Plain
2. With or without other dermatological galenicals.
**DERMATOLOGICALS**

<table>
<thead>
<tr>
<th>Subsidy (Manufacturer's Price)</th>
<th>Fully Subsidised</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$</td>
<td>Per</td>
<td></td>
</tr>
</tbody>
</table>

COAL TAR WITH ALLANTOIN, MENTHOL, PHENOL AND SULPHUR
Soln 5% with sulphur 0.5%, menthol 0.75%, phenol 0.5% and allantoin crm 2.5%.................................6.59 75 g OP
(8.00) Egopsoryl TA
3.43 30 g OP
(4.35) Egopsoryl TA

COAL TAR WITH SALICYLIC ACID AND SULPHUR
Soln 12% with salicylic acid 2% and sulphur 4% oint.........................7.95 40 g OP ✔ Coco-Scalp

PINE TAR WITH TROLAMINE LAURILSULFATE AND FLUORESCEIN – Only on a prescription
Soln 2.3% with trolamine laurilsulfate and fluorescein sodium........3.86 500 ml ✔ Pinetarsol

SALICYLIC ACID
Powder – Only in combination..........................................................18.88 250 g ✔ PSM
1) Only in combination with a dermatological base or proprietary Topical Corticosteroid – Plain or collodion flexible
2) With or without other dermatological galenicals.

SULPHUR
Precipitated – Only in combination.....................................................6.35 100 g ✔ Midwest
1) Only in combination with a dermatological base or proprietary Topical Corticosteroid – Plain
2) With or without other dermatological galenicals.

<table>
<thead>
<tr>
<th>Scalp Preparations</th>
</tr>
</thead>
<tbody>
<tr>
<td>BETAMETHASONE VALERATE</td>
</tr>
<tr>
<td>Scalp app 0.1%.................................7.75 100 ml OP ✔ Beta Scalp</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CLOBETASOL PROPIONATE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scalp app 0.05%.................................6.96 30 ml OP ✔ Dermol</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>HYDROCORTISONE BUTYRATE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scalp lotn 0.1%.................................3.65 100 ml OP ✔ Locoid</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>KETOCONAZOLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shampoo 2%.................................2.99 100 ml OP ✔ Sebizole</td>
</tr>
<tr>
<td>a) Maximum of 100 ml per prescription</td>
</tr>
<tr>
<td>b) Only on a prescription</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Sunscreens</th>
</tr>
</thead>
<tbody>
<tr>
<td>SUNSCREENS, PROPRIETARY – Subsidy by endorsement</td>
</tr>
<tr>
<td>Only if prescribed for a patient with severe photosensitivity secondary to a defined clinical condition and the prescription is endorsed accordingly.</td>
</tr>
<tr>
<td>Crm.................................3.30 100 g OP Hamilton Sunscreen</td>
</tr>
<tr>
<td>(5.89)</td>
</tr>
<tr>
<td>Lotn.................................3.30 100 g OP ✔ Marine Blue Lotion SPF 50+</td>
</tr>
<tr>
<td>5.10 200 g OP ✔ Marine Blue Lotion SPF 50+</td>
</tr>
</tbody>
</table>
Wart Preparations

For salicylic acid preparations refer to PSORIASIS AND ECZEMA PREPARATIONS, page 69

IMIQUIMOD
Crm 5%, 250 mg sachet ................................................................. 21.72  24  ✔ Perrigo

PODOPHYLLOTOXIN
Soln 0.5% ................................................................................. 33.60  3.5 ml OP  ✔ Condyline
  a) Maximum of 3.5 ml per prescription
  b) Only on a prescription

Other Skin Preparations

Antineoplastics

FLUOROURACIL SODIUM
Crm 5% ...................................................................................... 7.95  20 g OP  ✔ Efudix
## GENITO-URINARY SYSTEM

<table>
<thead>
<tr>
<th>Subsidy (Manufacturer’s Price)</th>
<th>Fully Subsidised</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per</td>
<td>✔</td>
<td></td>
</tr>
</tbody>
</table>

### Contraceptives - Non-hormonal

#### Condoms

**CONDOMS**

<table>
<thead>
<tr>
<th>Size</th>
<th>Price (Fully Subsidised)</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>49 mm – Up to 144 dev available on a PSO</td>
<td>13.36 $144</td>
<td>✔ Shield 49</td>
</tr>
<tr>
<td>53 mm – Up to 144 dev available on a PSO</td>
<td>1.11 $12</td>
<td>✔ Gold Knight</td>
</tr>
<tr>
<td>53 mm (chocolate) – Up to 144 dev available on a PSO</td>
<td>13.36 $144</td>
<td>✔ Shield Blue</td>
</tr>
<tr>
<td>53 mm (strawberry) – Up to 144 dev available on a PSO</td>
<td>1.11 $12</td>
<td>✔ Gold Knight</td>
</tr>
<tr>
<td>56 mm – Up to 144 dev available on a PSO</td>
<td>1.11 $12</td>
<td>✔ Gold Knight</td>
</tr>
<tr>
<td>56 mm, shaped – Up to 144 dev available on a PSO</td>
<td>1.11 $12</td>
<td>✔ Durex Confidence</td>
</tr>
<tr>
<td>60 mm – Up to 144 dev available on a PSO</td>
<td>13.36 $144</td>
<td>✔ Shield XL</td>
</tr>
</tbody>
</table>

**Notes:**

- The approval numbers of Special Authorities approved after 1 November 1999 are interchangeable between Mercilon and Marvelon.

### Contraceptive Devices

#### INTRA-UTERINE DEVICE

- **a)** Up to 40 dev available on a PSO
- **b)** Only on a PSO

<table>
<thead>
<tr>
<th>Model</th>
<th>Price (Fully Subsidised)</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>IUD 29.1 mm length x 23.2 mm width</td>
<td>31.60 $1</td>
<td>✔ Choice TT380 Short</td>
</tr>
<tr>
<td>IUD 33.6 mm length x 29.9 mm width</td>
<td>31.60 $1</td>
<td>✔ Choice TT380 Standard</td>
</tr>
<tr>
<td>IUD 35.5 mm length x 19.6 mm width</td>
<td>31.60 $1</td>
<td>✔ Choice Load 375</td>
</tr>
</tbody>
</table>

### Contraceptives - Hormonal

#### Combined Oral Contraceptives

[SA0500] Special Authority for Alternate Subsidy

**Initial application** from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria:

- Both:
  - Either:
    - 1. Patient is on a Social Welfare benefit; or
    - 1.2 Patient has an income no greater than the benefit; and
  - 2. Has tried at least one of the fully funded options and has been unable to tolerate it.

**Renewal** from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria:

- Either:
  - 1. Patient is on a Social Welfare benefit; or
  - 2. Patient has an income no greater than the benefit.

Notes: The approval numbers of Special Authorities approved after 1 November 1999 are interchangeable between Mercilon and Marvelon.

continued…
The additional subsidy will fund Mercilon and Marvelon up to the manufacturer’s price for each of these products as identified on the Schedule at 1 November 1999. Special Authorities approved before 1 November 1999 remain valid until the expiry date and can be renewed providing that women are still either:

- on a Social Welfare benefit; or
- have an income no greater than the benefit.

The approval numbers of Special Authorities approved before 1 November 1999 are interchangeable for products within the combined oral contraceptives and progestogen-only contraceptives groups, except Loette and Microgynon 20 ED

**ETHINYLLOESTRA DIOL WITH DESO GestRE L**

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Manufacturer’s Price</th>
<th>Subsidy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mercilon 28</td>
<td>Tab 20 mcg with desogestrel 150 mcg and 7 inert tab</td>
<td>$6.62 84</td>
</tr>
<tr>
<td></td>
<td>a) Higher subsidy of $13.80 per 84 tab with Special Authority see SA0500 on the previous page</td>
<td></td>
</tr>
<tr>
<td></td>
<td>b) Up to 84 tab available on a PSO</td>
<td></td>
</tr>
<tr>
<td>Marvelon 28</td>
<td>Tab 30 mcg with desogestrel 150 mcg and 7 inert tab</td>
<td>$6.62 84</td>
</tr>
<tr>
<td></td>
<td>a) Higher subsidy of $13.80 per 84 tab with Special Authority see SA0500 on the previous page</td>
<td></td>
</tr>
<tr>
<td></td>
<td>b) Up to 84 tab available on a PSO</td>
<td></td>
</tr>
</tbody>
</table>

**ETHINYLLOESTRA DIOL WITH LEVONORGESTREL**

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Manufacturer’s Price</th>
<th>Subsidy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Microgynon 20 ED</td>
<td>Tab 20 mcg with levonorgestrel 100 mcg and 7 inert tablets</td>
<td>$2.18 84</td>
</tr>
<tr>
<td></td>
<td>a) Higher subsidy of $15.00 per 63 tab with Special Authority see SA0500 on the previous page</td>
<td></td>
</tr>
<tr>
<td></td>
<td>b) Up to 63 tab available on a PSO</td>
<td></td>
</tr>
<tr>
<td>Microgynon 50 ED</td>
<td>Tab 50 mcg with levonorgestrel 125 mcg and 7 inert tab – Up to 84 tab available on a PSO</td>
<td>$9.45 84</td>
</tr>
<tr>
<td></td>
<td>Microgynon 30</td>
<td>Tab 30 mcg with levonorgestrel 150 mcg and 7 inert tablets – Up to 84 tab available on a PSO</td>
</tr>
<tr>
<td></td>
<td>a) Higher subsidy of $15.00 per 63 tab with Special Authority see SA0500 on the previous page</td>
<td></td>
</tr>
<tr>
<td></td>
<td>b) Up to 63 tab available on a PSO</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Levlen ED</td>
</tr>
</tbody>
</table>

**ETHINYLLOESTRA DIOL WITH NORETHISTE RONE**

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Manufacturer’s Price</th>
<th>Subsidy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brevinor 1/21</td>
<td>Tab 35 mcg with norethisterone 1 mg – Up to 63 tab available on a PSO</td>
<td>$6.62 63</td>
</tr>
<tr>
<td></td>
<td>Brevinor 1/28</td>
<td>Tab 35 mcg with norethisterone 1 mg and 7 inert tab – Up to 84 tab available on a PSO</td>
</tr>
<tr>
<td></td>
<td>Brevinor 21</td>
<td>Tab 35 mcg with norethisterone 500 mcg – Up to 63 tab available on a PSO</td>
</tr>
<tr>
<td></td>
<td>Norimin</td>
<td>Tab 35 mcg with norethisterone 500 mcg and 7 inert tab – Up to 84 tab available on a PSO</td>
</tr>
</tbody>
</table>

(Brevinor 21 Tab 35 mcg with norethisterone 500 mcg to be delisted 1 July 2019)

### Progestogen-only Contraceptives

**[SA0500]** Special Authority for Alternate Subsidy

*Initial application* from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Both:

1. Either:
continued…

1.1 Patient is on a Social Welfare benefit; or
1.2 Patient has an income no greater than the benefit; and
2 Has tried at least one of the fully funded options and has been unable to tolerate it.

Renewal from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria:
Either:
1 Patient is on a Social Welfare benefit; or
2 Patient has an income no greater than the benefit.

Notes: The approval numbers of Special Authorities approved after 1 November 1999 are interchangeable between Mercilon and Marvelon.

The additional subsidy will fund Mercilon and Marvelon up to the manufacturer’s price for each of these products as identified on the Schedule at 1 November 1999.

Special Authorities approved before 1 November 1999 remain valid until the expiry date and can be renewed providing that women are still either:
- on a Social Welfare benefit; or
- have an income no greater than the benefit.

The approval numbers of Special Authorities approved before 1 November 1999 are interchangeable for products within the combined oral contraceptives and progestogen-only contraceptives groups, except Loette and Microgynon 20 ED

### LEVONORGESTREL

<table>
<thead>
<tr>
<th>Item Description</th>
<th>Subsidy (Manufacturer’s Price)</th>
<th>Fully Subsidised</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 30 mcg</td>
<td>6.62</td>
<td>✔</td>
</tr>
<tr>
<td>(16.50) Microlut</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| a) Higher subsidy of $13.80 per 84 tab with Special Authority see SA0500 on the previous page
| Subdermal implant (2 x 75 mg rods) – Up to 3 pack available on a PSO | 106.92           | ✔ Jadelle        |
| Inj 150 mg per ml, 1 ml syringe – Up to 5 inj available on a PSO | 7.25              | ✔ Depo-Provera   |
| Tab 350 mcg – Up to 84 tab available on a PSO | 6.25              | ✔ Noriday 28     |

### Emergency Contraceptives

#### LEVONORGESTREL

<table>
<thead>
<tr>
<th>Item Description</th>
<th>Subsidy (Manufacturer’s Price)</th>
<th>Fully Subsidised</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 1.5 mg</td>
<td>4.95</td>
<td>✔ Postinor-1</td>
</tr>
</tbody>
</table>
| a) Maximum of 2 tab per prescription
| b) Up to 5 tab available on a PSO
| c) Note: Direct Provision by a pharmacist permitted under the provisions in Part I of Section A.

### Antiandrogen Oral Contraceptives

Prescribers may code prescriptions “contraceptive” (code “O”) when used as indicated for contraception. The period of supply and prescription charge will be as per other contraceptives, as follows:
- $5.00 prescription charge (patient co-payment) will apply.
- Prescription may be written for up to six months supply.

Prescriptions coded in any other way are subject to the non-contraceptive prescription charges, and the non-contraceptive period of supply. ie. Prescriptions may be written for up to three months supply.

#### CYPROTERONE ACETATE WITH ETHINYL Estradiol

<table>
<thead>
<tr>
<th>Item Description</th>
<th>Subsidy (Manufacturer’s Price)</th>
<th>Fully Subsidised</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 2 mg with ethinylestradiol 35 mcg and 7 inert tabs – Up to 168 tab available on a PSO</td>
<td>4.67</td>
<td>✔ Ginet</td>
</tr>
</tbody>
</table>
### Gynaecological Anti-infectives

**ACETIC ACID WITH HYDROXYQUINOLINE AND RICINOLEIC ACID**
- Jelly with glacial acetic acid 0.94%, hydroxyquinoline sulphate, glycerol 5% and ricinoleic acid 0.75% with applicator...
  - $8.43 100 g OP
  - (24.00) Aci-Jel

**CLOTRIMAZOLE**
- Vaginal crm 1% with applicators: 1.60 35 g OP ✔ Clomazol
- Vaginal crm 2% with applicators: 2.10 20 g OP ✔ Clomazol

**MICONAZOLE NITRATE**
- Vaginal crm 2% with applicator: 3.88 40 g OP ✔ Micreme

**NYSTATIN**
- Vaginal crm 100,000 u per 5 g with applicator(s): 4.45 75 g OP ✔ Nilstat

### Myometrial and Vaginal Hormone Preparations

**ERGOMETRINE MALEATE**
- Inj 250 mcg per ml, 1 ml ampoule: 454.00 5 ✔ Ergonovine
- Inj 500 mcg per ml, 1 ml ampoule: 105.00 5 ✔ DBL Ergometrine

**OESTRIOL**
- Crm 1 mg per g with applicator: 6.62 15 g OP ✔ Ovestin
- Pessaries 500 mcg: 6.86 15 ✔ Ovestin

**OXYTOCIN**
- Up to 5 inj available on a PSO
  - Inj 5 iu per ml, 1 ml ampoule: 3.98 5 ✔ Oxytocin BNM
  - Inj 10 iu per ml, 1 ml ampoule: 4.98 5 ✔ Oxytocin BNM

**OXYTOCIN WITH ERGOMETRINE MALEATE**
- Up to 5 inj available on a PSO
  - Inj 5 iu with ergometrine maleate 500 mcg per ml, 1 ml: 15.00 5 ✔ Syntometrine

### Pregnancy Tests - hCG Urine

**PREGNANCY TESTS - HCG URINE**
- a) Up to 200 test available on a PSO
- b) Only on a PSO
  - Cassette: 12.00 40 test OP ✔ Smith BioMed Rapid Pregnancy Test

### Urinary Agents

For urinary tract Infections refer to INFECTIONS, Antibacterials, page 108

#### 5-Alpha Reductase Inhibitors

**FINASTERIDE**
- Special Authority see SA0928 on the next page – Retail pharmacy
- Tab 5 mg: 4.81 100 ✔ Ricit
GENITO-URINARY SYSTEM

Subsidy
(Manufacturer's Price)

| Brand or
| Fully
| Manufacturer |
| Subsidised |
| Per |

**SA0928 Special Authority for Subsidy**
Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:
1. Patient has symptomatic benign prostatic hyperplasia; and
2. Either:
   2.1. The patient is intolerant of non-selective alpha blockers or these are contraindicated; or
   2.2. Symptoms are not adequately controlled with non-selective alpha blockers.

Note: Patients with enlarged prostates are the appropriate candidates for therapy with finasteride.

**Alpha-1A Adrenoreceptor Blockers**

TAMSULOSIN HYDROCHLORIDE – Special Authority see SA1032 below – Retail pharmacy

<table>
<thead>
<tr>
<th>Cap 400 mcg</th>
<th>$11.25</th>
<th>100</th>
</tr>
</thead>
<tbody>
<tr>
<td>✔️ Tamsulosin-Rex</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**SA1032 Special Authority for Subsidy**
Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:
1. Patient has symptomatic benign prostatic hyperplasia; and
2. The patient is intolerant of non-selective alpha blockers or these are contraindicated.

**Other Urinary Agents**

OXYBUTYNIN

<table>
<thead>
<tr>
<th>Tab 5 mg</th>
<th>$1.77</th>
<th>100</th>
</tr>
</thead>
<tbody>
<tr>
<td>✔️ Ditropan</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Oral liq 5 mg per 5 ml</th>
<th>$60.40</th>
<th>473 ml</th>
</tr>
</thead>
<tbody>
<tr>
<td>✔️ Apo-Oxybutynin</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

(Ditropan Tab 5 mg to be delisted 1 February 2019)

POTASSIUM CITRATE

<table>
<thead>
<tr>
<th>Oral liq 3 mmol per ml</th>
<th>$31.80</th>
<th>200 ml OP</th>
</tr>
</thead>
<tbody>
<tr>
<td>✔️ Biomed</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**SA1083 Special Authority for Subsidy**
Initial application from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Both:
1. The patient has recurrent calcium oxalate urolithiasis; and
2. The patient has had more than two renal calculi in the two years prior to the application.

Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from the treatment.

SODIUM CITRO-TARTRATE

<table>
<thead>
<tr>
<th>Grans eff 4 g sachets</th>
<th>$2.34</th>
<th>28</th>
</tr>
</thead>
<tbody>
<tr>
<td>✔️ Ural</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### SOLIFENACIN SUCCINATE

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Subsidy (Manufacturer’s Price) $</th>
<th>Fully Subsidised</th>
<th>Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>Solifenacin Mylan</td>
<td>$3.00</td>
<td>✔</td>
<td>30</td>
</tr>
<tr>
<td>Solifenacin Mylan to be Sole Supply on 1 March 2019</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 5 mg</td>
<td>3.00</td>
<td>✔</td>
<td>30</td>
</tr>
<tr>
<td>(37.50) Vescicare</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 10 mg</td>
<td>5.50</td>
<td>✔</td>
<td>30</td>
</tr>
<tr>
<td>Solifenacin Mylan to be Sole Supply on 1 March 2019</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 10 mg</td>
<td>5.50</td>
<td>✔</td>
<td>30</td>
</tr>
<tr>
<td>(37.50) Vescicare</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

(Vescicare Tablet 5 mg to be delisted 1 March 2019)
(Vescicare Tablet 10 mg to be delisted 1 March 2019)

**[SA0998] Special Authority for Subsidy**

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified where the patient has overactive bladder and a documented intolerance of, or is non-responsive to oxybutynin.

TOLTERODINE – Special Authority see [SA1272 below – Retail pharmacy](#)

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Subsidy (Manufacturer’s Price) $</th>
<th>Fully Subsidised</th>
<th>Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arrow-Tolterodine</td>
<td>$14.56</td>
<td>✔</td>
<td>56</td>
</tr>
<tr>
<td>Arrow-Tolterodine</td>
<td>$14.56</td>
<td>✔</td>
<td>56</td>
</tr>
</tbody>
</table>

**[SA1272] Special Authority for Subsidy**

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified where patient has overactive bladder and a documented intolerance of, or is non-responsive to oxybutynin.

### Detection of Substances in Urine

**ORTHO-TOLIDINE**

- Compound diagnostic sticks: 7.50 $ 50 test OP

  (8.25) Hemastix

**TETRABROMOPHENOL**

- Blue diagnostic strips: 7.02 $ 100 test OP

  (13.92) Albustix

▲Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once
**Calcium Homeostasis**

**CALCITONIN**

[∗ Inj 100 iu per ml, 1 ml ampoule .......................................................121.00 5 ✔ Miacalcic]

**CINACALCET** – Special Authority see SA1618 below – Retail pharmacy

Tab 30 mg – Wastage claimable .....................................................210.30 28 ✔ Sensipar

**SA1618** Special Authority for Subsidy

**Initial application** only from a nephrologist or endocrinologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

1. All of the following:
   1.1 The patient has been diagnosed with a parathyroid carcinoma (see Note); and
   1.2 The patient has persistent hypercalcaemia (serum calcium greater than or equal to 3 mmol/L) despite previous first-line treatments including sodium thiosulfate (where appropriate) and bisphosphonates; and
   1.3 The patient is symptomatic; or

2. All of the following:
   2.1 The patient has been diagnosed with calciphylaxis (calcific uraemic arteriolopathy); and
   2.2 The patient has symptomatic (e.g. painful skin ulcers) hypercalcaemia (serum calcium greater than or equal to 3 mmol/L); and
   2.3 The patient's condition has not responded to previous first-line treatments including bisphosphonates and sodium thiosulfate.

**Renewal** only from a nephrologist or endocrinologist. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

1. The patient's serum calcium level has fallen to < 3mmol/L; and
2. The patient has experienced clinically significant symptom improvement.

**ZOLEDRONIC ACID**

Inj 4 mg per 5 ml, vial – Special Authority see SA1687 below –
Retail pharmacy .................................................................84.50 1 ✔ Zoledronic acid

Mylan

550.00

**SA1687** Special Authority for Subsidy

**Initial application** — (bone metastases) only from an oncologist, haematologist or palliative care specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Any of the following:

1. Patient has hypercalcaemia of malignancy; or
2. Both:
   2.1 Patient has bone metastases or involvement; and
   2.2 Patient has severe bone pain resistant to standard first-line treatments; or
3. Both:
   3.1 Patient has bone metastases or involvement; and
   3.2 Patient is at risk of skeletal-related events pathological fracture, spinal cord compression, radiation to bone or surgery to bone.

**Initial application** — (early breast cancer) only from an oncologist or medical practitioner on the recommendation of a oncologist. Approvals valid for 2 years for applications meeting the following criteria:

continued…
continued...

All of the following:
1. Treatment to be used as adjuvant therapy for early breast cancer; and
2. Patient has been amenorrhoeic for 12 months or greater, either naturally or induced, with endocrine levels consistent with a postmenopausal state; and
3. Treatment to be administered at a minimum interval of 6-monthly for a maximum of 2 years.

Corticosteroids and Related Agents for Systemic Use

BETAMETHASONE SODIUM PHOSPHATE WITH BETAMETHASONE ACETATE

* Inj 3.9 mg with betamethasone acetate 3 mg per ml, 1 ml..................19.20 5
  (36.96) Celestone

DEXAMETHASONE

* Tab 0.5 mg – Retail pharmacy-Specialist.................................0.99 30 ✔ Dexmethsone
  Up to 60 tab available on a PSO
* Tab 4 mg – Retail pharmacy-Specialist......................................1.90 30 ✔ Dexmethsone
  Up to 30 tab available on a PSO

Oral liq 1 mg per ml – Retail pharmacy-Specialist.......................45.00 25 ml OP ✔ Biomed
  Oral liq prescriptions:
  1) Must be written by a Paediatrician or Paediatric Cardiologist; or
  2) On the recommendation of a Paediatrician or Paediatric Cardiologist.

DEXAMETHASONE PHOSPHATE

Dexamethasone phosphate injection will not be funded for oral use.

* Inj 4 mg per ml, 1 ml ampoule – Up to 5 inj available on a PSO......14.19 10 ✔ Max Health
* Inj 4 mg per ml, 2 ml ampoule – Up to 5 inj available on a PSO......25.18 10 ✔ Max Health

FLUDROCORTISONE ACETATE

* Tab 100 mcg.............................................................................14.32 100 ✔ Florinef

HYDROCORTISONE

* Tab 5 mg..................................................................................8.10 100 ✔ Douglas
* Tab 20 mg..............................................................................20.32 100 ✔ Douglas
* Inj 100 mg vial..........................................................................5.30 1 ✔ Solu-Cortef
  a) Up to 5 inj available on a PSO
  b) Only on a PSO

METHYLPREDNISOLONE – Retail pharmacy-Specialist

* Tab 4 mg..................................................................................112.00 100 ✔ Medrol
  Medrol to be Sole Supply on 1 January 2019
* Tab 100 mg...........................................................................194.00 20 ✔ Medrol
  Medrol to be Sole Supply on 1 January 2019

▲Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber or pharmacist.
*Three months or six months, as applicable, dispensed all-at-once
## HORMONE PREPARATIONS - SYSTEMIC EXCLUDING CONTRACEPTIVE HORMONES

<table>
<thead>
<tr>
<th>Subsidy (Manufacturer’s Price) $</th>
<th>Fully Subsidised</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
</table>

### METHYLPREDNISOLONE (AS SODIUM SUCCINATE) – Retail pharmacy-Specialist

- **Inj 40 mg vial** .......................................................... 18.90 1  ✔  **Solu-Medrol-Act-O-Vial**

- **Solu-Medrol-Act-O-Vial to be Sole Supply on 1 January 2019**

- **Inj 125 mg vial** .......................................................... 28.90 1  ✔  **Solu-Medrol-Act-O-Vial**

- **Solu-Medrol-Act-O-Vial to be Sole Supply on 1 January 2019**

- **Inj 500 mg vial** .......................................................... 22.78 1  ✔  **Solu-Medrol-Act-O-Vial**

- **Solu-Medrol-Act-O-Vial to be Sole Supply on 1 January 2019**

- **Inj 1 g vial** .............................................................. 27.83 1  ✔  **Solu-Medrol**

  Solu-Medrol to be Sole Supply on 1 January 2019

### METHYLPREDNISOLONE ACETATE

- **Inj 40 mg per ml, 1 ml vial** ............................................. 44.40 5  ✔  **Depo-Medrol**

  Depo-Medrol to be Sole Supply on 1 January 2019

### METHYLPREDNISOLONE ACETATE WITH LIDOCAINE [LIGNOCAINE]

- **Inj 40 mg per ml with lidocaine [lignocaine], 1 ml vial** ................. 9.25 1  ✔  **Depo-Medrol with Lidocaine**

### PREDNISOLONE

* Oral liq 5 mg per ml – Up to 30 ml available on a PSO ...................... 6.00 30 ml OP  ✔  **Redipred**

  Restricted to children under 12 years of age.

### PREDNISONE

* Tab 1 mg ................................................................. 10.68 500  ✔  **Apo-Prednisone**

* Tab 2.5 mg .............................................................. 12.09 500  ✔  **Apo-Prednisone**

* Tab 5 mg – Up to 30 tab available on a PSO ................................... 11.09 500  ✔  **Apo-Prednisone**

* Tab 20 mg ............................................................ 29.03 500  ✔  **Apo-Prednisone**

### TETRACOSACTRIN

* Inj 250 mcg per ml, 1 ml ampoule ............................................. 75.00 1  ✔  **Synacthen**

* Inj 1 mg per ml, 1 ml ampoule ............................................... 690.00 1  ✔  **Synacthen Depot**

### TRIAMCINOLONE ACETONIDE

- **Inj 10 mg per ml, 1 ml ampoule** ........................................... 20.80 5  ✔  **Kenacort-A 10**

- **Inj 40 mg per ml, 1 ml ampoule** ......................................... 51.10 5  ✔  **Kenacort-A 40**

### Sex Hormones Non Contraceptive

#### Androgen Agonists and Antagonists

### CYPROTERONE ACETATE – Retail pharmacy-Specialist

- **Tab 50 mg** .............................................................. 13.17 50  ✔  **Siterone**

  Siterone to be Sole Supply on 1 March 2019

  (15.87)

- **Tab 100 mg** ........................................................... 26.75 50  ✔  **Siterone**

  Siterone to be Sole Supply on 1 March 2019

  (30.40)

  (Procur Tab 50 mg to be delisted 1 March 2019)

  (Procur Tab 100 mg to be delisted 1 March 2019)

### TESTOSTERONE

- **Patch 5 mg per day** ..................................................... 90.00 30  ✔  **Androderm**
### Hormone Replacement Therapy - Systemic

#### Prescribing Guideline

HRT should be taken at the lowest dose for the shortest period of time necessary to control symptoms. Patients should be reviewed 6 monthly in line with the updated NZGG “Evidence-based Best Practice Guideline on Hormone Replacement Therapy March 2004”.

#### Oestrogens

**OESTRADIOL** – See prescribing guideline above

<table>
<thead>
<tr>
<th>Description</th>
<th>Subsidy (Manufacturer's Price)</th>
<th>Fully Subsidised</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 1 mg</td>
<td>4.12</td>
<td>✔</td>
</tr>
<tr>
<td>Tab 2 mg</td>
<td>4.12</td>
<td>✔</td>
</tr>
<tr>
<td>Patch 25 mcg per day</td>
<td>6.12</td>
<td>✔</td>
</tr>
<tr>
<td>a) No more than 2 patch per week</td>
<td></td>
<td></td>
</tr>
<tr>
<td>b) Only on a prescription</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patch 50 mcg per day</td>
<td>7.04</td>
<td>✔</td>
</tr>
<tr>
<td>a) No more than 2 patch per week</td>
<td></td>
<td></td>
</tr>
<tr>
<td>b) Only on a prescription</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patch 75 mcg per day</td>
<td>7.91</td>
<td>✔</td>
</tr>
<tr>
<td>a) No more than 2 patch per week</td>
<td></td>
<td></td>
</tr>
<tr>
<td>b) Only on a prescription</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patch 100 mcg per day</td>
<td>7.91</td>
<td>✔</td>
</tr>
<tr>
<td>a) No more than 2 patch per week</td>
<td></td>
<td></td>
</tr>
<tr>
<td>b) Only on a prescription</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**OESTRADIOL VALERATE** – See prescribing guideline above

<table>
<thead>
<tr>
<th>Description</th>
<th>Subsidy (Manufacturer's Price)</th>
<th>Fully Subsidised</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 1 mg</td>
<td>12.36</td>
<td>✔</td>
</tr>
<tr>
<td>Tab 2 mg</td>
<td>12.36</td>
<td>✔</td>
</tr>
</tbody>
</table>

**OESTROGENS** – See prescribing guideline above

<table>
<thead>
<tr>
<th>Description</th>
<th>Subsidy (Manufacturer's Price)</th>
<th>Fully Subsidised</th>
</tr>
</thead>
<tbody>
<tr>
<td>Conjugated, equine tab 300 mcg</td>
<td>3.01</td>
<td></td>
</tr>
<tr>
<td>Conjugated, equine tab 625 mcg</td>
<td>4.12</td>
<td></td>
</tr>
</tbody>
</table>

#### Progestogens

**MEDROXYPROGESTERONE ACETATE** – See prescribing guideline above

<table>
<thead>
<tr>
<th>Description</th>
<th>Subsidy (Manufacturer's Price)</th>
<th>Fully Subsidised</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 2.5 mg</td>
<td>3.75</td>
<td>✔</td>
</tr>
<tr>
<td>Tab 5 mg</td>
<td>14.00</td>
<td>✔</td>
</tr>
<tr>
<td>Tab 10 mg</td>
<td>7.15</td>
<td>✔</td>
</tr>
</tbody>
</table>

▲ Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber or pharmacist.

* Three months or six months, as applicable, dispensed all-at-once.
HORMONE PREPARATIONS - SYSTEMIC EXCLUDING CONTRACEPTIVE HORMONES

Subsidy
(Manufacturer’s Price)
$ Per Brand or
Fully
Generic
Manufacturer

Subsidised

Progestogen and Oestrogen Combined Preparations

OESTRADIOL WITH NORETHISTERONE – See prescribing guideline on the previous page

* Tab 1 mg with 0.5 mg norethisterone acetate ........................................ 5.40 28 OP
(18.10) Kliovance

* Tab 2 mg with 1 mg norethisterone acetate ........................................ 5.40 28 OP
(18.10) Kliogest

* Tab 2 mg with 1 mg norethisterone acetate (10), and 2 mg oestradiol tab (12) and 1 mg oestradiol tab (6) ........................................................................ 5.40 28 OP
(18.10) Trisequens

Other Oestrogen Preparations

ETHINYLESTRODIOL

* Tab 10 mcg ................................................................................... 17.60 100 ✔ NZ Medical and Scientific

OESTRIOL

* Tab 2 mg .................................................................................... 7.00 30 ✔ Ovestin

Other Progestogen Preparations

LEVONORGESTREL

* Intra-uterine system 20 mcg per day – Special Authority see SA1608 below – Retail pharmacy ........................................ 269.50 1 ✔ Mirena

➽ SA1608 Special Authority for Subsidy

Initial application — (No previous use) only from a relevant specialist or general practitioner. Approvals valid for 6 months for applications meeting the following criteria:
All of the following:
1. The patient has a clinical diagnosis of heavy menstrual bleeding; and
2. The patient has failed to respond to or is unable to tolerate other appropriate pharmaceutical therapies as per the Heavy Menstrual Bleeding Guidelines; and
3. Either:
   3.1 serum ferritin level < 16 mcg/l (within the last 12 months); or
   3.2 haemoglobin level < 120 g/l.

Note: Applications are not to be made for use in patients as contraception except where they meet the above criteria.

Renewal only from a relevant specialist or general practitioner. Approvals valid for 6 months for applications meeting the following criteria:
Both:
1. Either:
   1.1 Patient demonstrated clinical improvement of heavy menstrual bleeding; or
   1.2 Previous insertion was removed or expelled within 3 months of insertion; and
2. Applicant to state date of the previous insertion.

MEDROXYPROGESTERONE ACETATE

* Tab 100 mg – Retail pharmacy-Specialist................................. 101.00 100 ✔ Provera HD

NORETHISTERONE

* Tab 5 mg – Up to 30 tab available on a PSO ................................ 18.29 100 ✔ Primolut N

PROGESTERONE

Cap 100 mg – Special Authority see SA1609 on the next page – Retail pharmacy ........................................ 16.50 30 ✔ Utrogestan

82 ✔ fully subsidised

Sole Subsidised Supply

Unapproved medicine supplied under Section 29
**HORMONE PREPARATIONS - SYSTEMIC EXCLUDING CONTRACEPTIVE HORMONES**

<table>
<thead>
<tr>
<th>Subsidy (Manufacturer’s Price) $</th>
<th>Fully Subsidised</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Per</td>
<td>✔</td>
<td></td>
</tr>
</tbody>
</table>

**SA1609** Special Authority for Subsidy

**Initial application** only from an obstetrician or gynaecologist. Approvals valid for 12 months for applications meeting the following criteria:

**Both:**
1. For the prevention of pre-term labour*; and
2. Either:
   2.1. The patient has a short cervix on ultrasound (defined as < 25 mm at 16 to 28 weeks); or
   2.2. The patient has a history of pre-term birth at less than 28 weeks.

**Renewal** only from an obstetrician or gynaecologist. Approvals valid for 12 months for applications meeting the following criteria:

**All of the following:**
1. For the prevention of pre-term labour*; and
2. Treatment is required for second or subsequent pregnancy; and
3. Either:
   3.1. The patient has a short cervix on ultrasound (defined as < 25 mm at 16 to 28 weeks); or
   3.2. The patient has a history of pre-term birth at less than 28 weeks.

Note: Indications marked with * are unapproved indications.

**Thyroid and Antithyroid Agents**

**CARBIMAZOLE**

* Tab 5 mg ................................................................. 10.80 100 ✔
  - AFT
  - Carbimazole 529
  - Neo-Mercazole

**LEVOTHYROXINE**

* Tab 25 mcg ............................................................... 3.89 90 ✔
* Tab 50 mcg ............................................................... 1.71 28 ✔
  - Mercury Pharma
  - Synthroid
  - Eltroxin
  - Eltroxin

Tab 100 mcg ............................................................... 1.78 28 ✔
  - Mercury Pharma
  - Synthroid
  - Eltroxin

Tab 64.28 1,000 ✔

**PROPYLTHIOURACIL** – Special Authority see SA1199 below – Retail pharmacy

Propylthiouracil is not recommended for patients under the age of 18 years unless the patient is pregnant and other treatments are contraindicated.

Tab 50 mg ................................................................. 35.00 100 ✔

**SA1199** Special Authority for Subsidy

**Initial application** from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

**Both:**
1. The patient has hyperthyroidism; and
2. The patient is intolerant of carbimazole or carbimazole is contraindicated.

**Renewal** from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefitting from the treatment.

▲ Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber or pharmacist.

* Three months or six months, as applicable, dispensed all-at-once
Trophic Hormones

Growth Hormones

SOMATROPIN (OMNITROPE) – Special Authority see SA1629 below – Retail pharmacy

- Inj 5 mg cartridge..........................................................34.88 1  ✔ Omnitrope
- Inj 10 mg cartridge..........................................................69.75 1  ✔ Omnitrope
- Inj 15 mg cartridge..........................................................104.63 1  ✔ Omnitrope

➽SA1629 Special Authority for Subsidy

Initial application — (growth hormone deficiency in children) only from a paediatric endocrinologist or endocrinologist. Approvals valid for 9 months for applications meeting the following criteria:

Either:
1 Growth hormone deficiency causing symptomatic hypoglycaemia, or with other significant growth hormone deficient sequelae (e.g. cardiomyopathy, hepatic dysfunction) and diagnosed with GH < 5 mcg/l on at least two random blood samples in the first 2 weeks of life, or from samples during established hypoglycaemia (whole blood glucose < 2 mmol/l using a laboratory device); or

2 All of the following:
   2.1 Height velocity < 25th percentile for age adjusted for bone age/pubertal status if appropriate over 6 or 12 months using the standards of Tanner and Davies (1985); and
   2.2 A current bone age is < 14 years (female patients) or < 16 years (male patients); and
   2.3 Peak growth hormone value of < 5.0 mcg per litre in response to two different growth hormone stimulation tests. In children who are 5 years or older, GH testing with sex steroid priming is required; and
   2.4 If the patient has been treated for a malignancy, they should be disease free for at least one year based upon follow-up laboratory and radiological imaging appropriate for the malignancy, unless there are strong medical reasons why this is either not necessary or appropriate; and
   2.5 Appropriate imaging of the pituitary gland has been obtained.

Renewal — (growth hormone deficiency in children) only from a paediatric endocrinologist or endocrinologist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:
1 A current bone age is 14 years or under (female patients) or 16 years or under (male patients); and
2 Height velocity is greater than or equal to 25th percentile for age (adjusted for bone age/pubertal status if appropriate) while on growth hormone treatment, as calculated over six months using the standards of Tanner and Davis (1985); and
3 Height velocity is greater than or equal to 2.0 cm per year, as calculated over 6 months; and
4 No serious adverse effect that the patients specialist considers is likely to be attributable to growth hormone treatment has occurred; and
5 No malignancy has developed since starting growth hormone.

Initial application — (Turner syndrome) only from a paediatric endocrinologist or endocrinologist. Approvals valid for 9 months for applications meeting the following criteria:

All of the following:
1 The patient has a post-natal genotype confirming Turner Syndrome; and
2 Height velocity is < 25th percentile over 6-12 months using the standards of Tanner and Davies (1985); and
3 A current bone age is < 14 years.

Renewal — (Turner syndrome) only from a paediatric endocrinologist or endocrinologist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:
1 Height velocity is greater than or equal to 50th percentile for age (while on growth hormone calculated over 6 to 12 months using the Ranke’s Turner Syndrome growth velocity charts); and
2 Height velocity is greater than or equal to 2 cm per year, calculated over six months; and

continued…
continued...

3 A current bone age is 14 years or under; and
4 No serious adverse effect that the specialist considers is likely to be attributable to growth hormone treatment has occurred; and
5 No malignancy has developed since starting growth hormone.

Initial application — (short stature without growth hormone deficiency) only from a paediatric endocrinologist or endocrinologist. Approvals valid for 9 months for applications meeting the following criteria:

All of the following:
1 The patient's height is more than 3 standard deviations below the mean for age or for bone age if there is marked growth acceleration or delay; and
2 Height velocity is < 25th percentile for age (adjusted for bone age/pubertal status if appropriate), as calculated over 6 to 12 months using the standards of Tanner and Davies (1985); and
3 A current bone age is < 14 years or under (female patients) or < 16 years (male patients); and
4 The patient does not have severe chronic disease (including malignancy or recognized severe skeletal dysplasia) and is not receiving medications known to impair height velocity.

Renewal — (short stature without growth hormone deficiency) only from a paediatric endocrinologist or endocrinologist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:
1 Height velocity is greater than or equal to 50th percentile (adjusted for bone age/pubertal status if appropriate) as calculated over 6 to 12 months using the standards of Tanner and Davies (1985); and
2 Height velocity is greater than or equal to 2 cm per year as calculated over six months; and
3 A current bone age is 14 years or under (female patients) or 16 years or under (male patients); and
4 No serious adverse effect that the patient's specialist considers is likely to be attributable to growth hormone treatment has occurred.

Initial application — (short stature due to chronic renal insufficiency) only from a paediatric endocrinologist, endocrinologist or renal physician on the recommendation of a paediatric endocrinologist or endocrinologist. Approvals valid for 9 months for applications meeting the following criteria:

All of the following:
1 The patient's height is more than 2 standard deviations below the mean; and
2 Height velocity is < 25th percentile (adjusted for bone age/pubertal status if appropriate) as calculated over 6 to 12 months using the standards of Tanner and Davies (1985); and
3 A current bone age is to 14 years or under (female patients) or to 16 years or under (male patients); and
4 The patient is metabolically stable, has no evidence of metabolic bone disease and absence of any other severe chronic disease; and
5 The patient is under the supervision of a specialist with expertise in renal medicine; and
6 Either:
   6.1 The patient has a GFR less than or equal to 30 ml/min/1.73m$^2$ as measured by the Schwartz method
   (Height(cm)/plasma creatinine (umol/l) × 40 = corrected GFR (ml/min/1.73m$^2$) in a child who may or may not be receiving dialysis; or
   6.2 The patient has received a renal transplant and has received < 5mg/m²/day of prednisone or equivalent for at least 6 months..

Renewal — (short stature due to chronic renal insufficiency) only from a paediatric endocrinologist, endocrinologist or renal physician on the recommendation of a paediatric endocrinologist or endocrinologist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:
1 Height velocity is greater than or equal to 50th percentile (adjusted for bone age/pubertal status if appropriate) as calculated over 6 to 12 months using the standards of Tanner and Davies (1985); and
2 Height velocity is greater than or equal to 2 cm per year as calculated over six months; and

continued…
3 A current bone age is 14 years or under (female patients) or 16 years or under (male patients); and
4 No serious adverse effect that the patient's specialist considers is likely to be attributable to growth hormone has occurred; and
5 No malignancy has developed after growth hormone therapy was commenced; and
6 The patient has not experienced significant biochemical or metabolic deterioration confirmed by diagnostic results; and
7 The patient has not received renal transplantation since starting growth hormone treatment; and
8 If the patient requires transplantation, growth hormone prescription should cease before transplantation and a new application should be made after transplantation based on the above criteria.

Initial application — (Prader-Willi syndrome) only from a paediatric endocrinologist or endocrinologist. Approvals valid for 9 months for applications meeting the following criteria:

All of the following:
1 The patient has a diagnosis of Prader-Willi syndrome that has been confirmed by genetic testing or clinical scoring criteria; and
2 The patient is aged six months or older; and
3 A current bone age is < 14 years (female patients) or < 16 years (male patients); and
4 Sleep studies or overnight oximetry have been performed and there is no obstructive sleep disorder requiring treatment, or if an obstructive sleep disorder is found, it has been adequately treated under the care of a paediatric respiratory physician and/or ENT surgeon; and
5 Either:
   5.1 Both:
      5.1.1 The patient is aged two years or older; and
      5.1.2 There is no evidence of type II diabetes or uncontrolled obesity defined by BMI that has increased by greater than or equal to 0.5 standard deviations in the preceding 12 months; or
   5.2 The patient is aged between six months and two years and a thorough upper airway assessment is planned to be undertaken prior to treatment commencement and at six to 12 weeks following treatment initiation.

Renewal — (Prader-Willi syndrome) only from a paediatric endocrinologist or endocrinologist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:
1 Height velocity is greater than or equal to 50th percentile (adjusted for bone age/pubertal status if appropriate) as calculated over 6 to 12 months using the standards of Tanner and Davies (1985); and
2 Height velocity is greater than or equal to 2 cm per year as calculated over six months; and
3 A current bone age is 14 years or under (female patients) or 16 years or under (male patients); and
4 No serious adverse effect that the patient's specialist considers is likely to be attributable to growth hormone treatment has occurred; and
5 No malignancy has developed after growth hormone therapy was commenced; and
6 The patient has not developed type II diabetes or uncontrolled obesity as defined by BMI that has increased by greater than or equal to 0.5 standard deviations in the preceding 12 months.

Initial application — (adults and adolescents) only from a paediatric endocrinologist or endocrinologist. Approvals valid for 9 months for applications meeting the following criteria:

All of the following:
1 The patient has a medical condition that is known to cause growth hormone deficiency (e.g. surgical removal of the pituitary for treatment of a pituitary tumour); and
2 The patient has undergone appropriate treatment of other hormonal deficiencies and psychological illnesses; and
3 The patient has severe growth hormone deficiency (see notes); and
4 The patient's serum IGF-I is more than 1 standard deviation below the mean for age and sex; and
5 The patient has poor quality of life, as defined by a score of 16 or more using the disease-specific quality of life questionnaire for adult growth hormone deficiency (QoL-AGHDA®).
Notes: For the purposes of adults and adolescents, severe growth hormone deficiency is defined as a peak serum growth hormone level of less than or equal to 3 mcg per litre during an adequately performed insulin tolerance test (ITT) or glucagon stimulation test.

Patients with one or more additional anterior pituitary hormone deficiencies and a known structural pituitary lesion only require one test. Patients with isolated growth hormone deficiency require two growth hormone stimulation tests, of which, one should be ITT unless otherwise contraindicated. Where an additional test is required, an arginine provocation test can be used with a peak serum growth hormone level of less than or equal to 0.4 mcg per litre.

The dose of somatropin should be started at 0.2 mg daily and be titrated by 0.1 mg monthly until the serum IGF-I is within 1 standard deviation of the mean normal value for age and sex; and

Dose of somatropin not to exceed 0.7 mg per day for male patients, or 1 mg per day for female patients.

At the commencement of treatment for hypopituitarism, patients must be monitored for any required adjustment in replacement doses of corticosteroid and levothyroxine.

**Renewal — (adults and adolescents)** only from a paediatric endocrinologist or endocrinologist. Approvals valid for 12 months for applications meeting the following criteria:

Either:

1. All of the following:
   1.1 The patient has been treated with somatropin for < 12 months; and
   1.2 There has been an improvement in Quality of Life defined as a reduction of at least 8 points on the Quality of Life Assessment of Growth Hormone Deficiency in Adults (QoL-AGHDA®) score from baseline; and
   1.3 Serum IGF-I levels have been increased within ±1SD of the mean of the normal range for age and sex; and
   1.4 The dose of somatropin has not exceeded 0.7 mg per day for male patients, or 1 mg per day for female patients; or

2. All of the following:
   2.1 The patient has been treated with somatropin for more than 12 months; and
   2.2 The patient has not had a deterioration in Quality of Life defined as a 6 point or greater increase from their lowest QoL-AGHDA® score on treatment (other than due to obvious external factors such as external stressors); and
   2.3 Serum IGF-I levels have continued to be maintained within ±1SD of the mean of the normal range for age and sex (other than for obvious external factors); and
   2.4 The dose of somatropin has not exceeded 0.7 mg per day for male patients or 1 mg per day for female patients.

### GnRH Analogues

**GOSERELIN**

<table>
<thead>
<tr>
<th>Implant 3.6 mg, syringe</th>
<th>66.48</th>
<th>1</th>
<th>✔ Zoladex</th>
</tr>
</thead>
<tbody>
<tr>
<td>Implant 10.8 mg, syringe</td>
<td>177.50</td>
<td>1</td>
<td>✔ Zoladex</td>
</tr>
</tbody>
</table>

**LEUPRORELIN**

Additional subsidy by endorsement where the patient is a child or adolescent and is unable to tolerate administration of goserelin and the prescription is endorsed accordingly.

<table>
<thead>
<tr>
<th>Inj 3.75 mg prefilled dual chamber syringe – Higher subsidy of $221.60 per 1 inj with Endorsement</th>
<th>66.48</th>
<th>1</th>
<th>✔ Lucrin Depot 1-month</th>
</tr>
</thead>
<tbody>
<tr>
<td>($221.60) Lucrin Depot 1-month</td>
<td>(221.60)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Inj 11.25 mg prefilled dual chamber syringe – Higher subsidy of $591.68 per 1 inj with Endorsement</th>
<th>177.50</th>
<th>1</th>
<th>✔ Lucrin Depot 3-month</th>
</tr>
</thead>
<tbody>
<tr>
<td>($591.68) Lucrin Depot 3-month</td>
<td>(591.68)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Hormone Preparations - Systemic Excluding Contraceptive Hormones

<table>
<thead>
<tr>
<th>Subsidy (Manufacturer’s Price)</th>
<th>Fully Subsidised</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per</td>
<td>✔</td>
<td></td>
</tr>
</tbody>
</table>

#### Vasopressin Agonists

**DESMOPRESSIN ACETATE**
- Tab 100 mcg – Special Authority see SA1401 below – Retail pharmacy
  - Total........................................................................25.00 30 ✔ Minirin
- Tab 200 mcg – Special Authority see SA1401 below – Retail pharmacy
  - Total........................................................................54.45 30 ✔ Minirin
- Nasal drops 100 mcg per ml – Retail pharmacy-Specialist
  - Total........................................................................39.03 2.5 ml OP ✔ Minirin
- Nasal spray 10 mcg per dose – Retail pharmacy-Specialist
  - Total........................................................................23.95 6 ml OP ✔ Desmopressin-PH&T

**SA1401** Special Authority for Subsidy

**Initial application** — (Desmopressin tablets for Nocturnal enuresis) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:
- All of the following:
  1. The patient has primary nocturnal enuresis; and
  2. The nasal forms of desmopressin are contraindicated; and
  3. An enuresis alarm is contraindicated.

**Initial application** — (Desmopressin tablets for Diabetes insipidus) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:
- Both:
  1. The patient has cranial diabetes insipidus; and
  2. The nasal forms of desmopressin are contraindicated.

**Renewal** — (Desmopressin tablets) from any relevant practitioner. Approvals valid for 12 months where the treatment remains appropriate and the patient is benefiting from the treatment.

**Renewal** — (Desmopressin injection) only from a relevant specialist. Approvals valid for 2 years where the patient cannot use desmopressin nasal spray or nasal drops.

**Renewal** — (Desmopressin injection) only from a relevant specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

#### Other Endocrine Agents

**CABERGOLINE**
- Tab 0.5 mg – Maximum of 2 tab per prescription; can be waived by Special Authority see SA1370 below
  - Total........................................................................3.75 2 ✔ Dostinex
  - Total........................................................................15.20 8 ✔ Dostinex

**SA1370** Special Authority for Waiver of Rule

**Initial application** from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:
- Either:
  1. Pathological hyperprolactinemia; or
  2. Acromegaly*.

**Renewal** — (for patients who have previously been funded under Special Authority form SA1031) from any relevant practitioner. Approvals valid without further renewal unless notified where the patient has previously held a valid Special Authority which has expired and the treatment remains appropriate and the patient is benefiting from treatment.

Note: Indication marked with * is an unapproved indication.

---

Unapproved medicine supplied under Section 29
<table>
<thead>
<tr>
<th>Subsidy (Manufacturer's Price) $</th>
<th>Fully Subsidised</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subsidy</td>
<td>Per</td>
<td></td>
</tr>
<tr>
<td>CLOMIFENE CITRATE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 50 mg</td>
<td>29.84</td>
<td>✔ Mylan</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Clomiphen $^\dagger$</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Serophene</td>
</tr>
<tr>
<td><em>(Serophene Tab 50 mg to be delisted 1 March 2019)</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DANAZOL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cap 100 mg</td>
<td>68.33</td>
<td>✔ Azol</td>
</tr>
<tr>
<td>Cap 200 mg</td>
<td>97.83</td>
<td>✔ Azol</td>
</tr>
<tr>
<td>METYRAPONE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cap 250 mg – Retail pharmacy-Specialist</td>
<td>520.00</td>
<td>✔ Metopirone</td>
</tr>
</tbody>
</table>

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

❋Three months or six months, as applicable, dispensed all-at-once
INFECTIONS - AGENTS FOR SYSTEMIC USE

<table>
<thead>
<tr>
<th>Anthelmintics</th>
<th>Subsidy (Manufacturer's Price) $</th>
<th>Fully Subsidised</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALBENDAZOLE – Special Authority see SA1318 below – Retail pharmacy</td>
<td>Tab 400 mg .............................................................................................................469.20</td>
<td>60</td>
<td>✔ Eskazole 829</td>
</tr>
<tr>
<td><strong>SA1318 Special Authority for Subsidy</strong></td>
<td><strong>Initial application</strong> only from an infectious disease specialist or clinical microbiologist. Approvals valid for 6 months where the patient has hydatids. <strong>Renewal</strong> only from an infectious disease specialist or clinical microbiologist. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefitting from the treatment.</td>
<td><strong>MEBENDAZOLE</strong> – Only on a prescription</td>
<td><strong>PRAZIQUANTEL</strong></td>
</tr>
<tr>
<td><strong>Antibacterials</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>a) For topical antibacterials, refer to DERMATOLOGICALS, page 62</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>b) For anti-infective eye preparations, refer to SENSORY ORGANS, page 208</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Cephalosporins and Cephamycins</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>CEFACLOR MONOHYDRATE</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cap 250 mg ..........................................................................................................24.70</td>
<td>100</td>
<td>✔ Ranbaxy-Cefaclor</td>
<td></td>
</tr>
<tr>
<td>Grans for oral liq 125 mg per 5 ml – Wastage claimable ........................................3.53</td>
<td>100 ml</td>
<td>✔ Ranbaxy-Cefaclor</td>
<td></td>
</tr>
<tr>
<td><strong>CEFALEXIN</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cap 250 mg ..........................................................................................................3.50</td>
<td>20</td>
<td>✔ Cephalexin ABM</td>
<td></td>
</tr>
<tr>
<td>Cap 500 mg ..........................................................................................................3.95</td>
<td>20</td>
<td>✔ Cephalexin ABM</td>
<td></td>
</tr>
<tr>
<td>Grans for oral liq 25 mg per ml – Wastage claimable ...........................................8.75</td>
<td>100 ml</td>
<td>✔ Cefalexin Sandoz</td>
<td></td>
</tr>
<tr>
<td><strong>Note:</strong> Cefalexin grans for oral liq will not be funded in amounts more than 14 days treatment per dispensing.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Grans for oral liq 50 mg per ml – Wastage claimable ...........................................11.75</td>
<td>100 ml</td>
<td>✔ Cefalexin Sandoz</td>
<td></td>
</tr>
<tr>
<td><strong>Note:</strong> Cefalexin grans for oral liq will not be funded in amounts more than 14 days treatment per dispensing.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>CEFAZOLIN</strong> – Subsidy by endorsement</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Only if prescribed for dialysis or cellulitis in accordance with a DHB approved protocol and the prescription is endorsed accordingly.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 500 mg vial ....................................................................................................3.39</td>
<td>5</td>
<td>✔ AFT</td>
<td></td>
</tr>
<tr>
<td>Inj 1 g vial ...........................................................................................................3.29</td>
<td>5</td>
<td>✔ AFT</td>
<td></td>
</tr>
<tr>
<td><strong>CEFTRIAXONE</strong> – Subsidy by endorsement</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>a) Up to 5 inj available on a PSO</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>b) Subsidised only if prescribed for a dialysis or cystic fibrosis patient, or the treatment of gonorrhoea, or the treatment of pelvic inflammatory disease, or the treatment of suspected meningitis in patients who have a known allergy to penicillin, and the prescription or PSO is endorsed accordingly.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 500 mg vial ....................................................................................................1.20</td>
<td>1</td>
<td>✔ DEVA</td>
<td></td>
</tr>
<tr>
<td>Inj 1 g vial ...........................................................................................................0.84</td>
<td>1</td>
<td>✔ DEVA</td>
<td></td>
</tr>
<tr>
<td><strong>CEFUROXIME AXETIL</strong> – Subsidy by endorsement</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Only if prescribed for prophylaxis of endocarditis and the prescription is endorsed accordingly.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 250 mg ..........................................................................................................29.40</td>
<td>50</td>
<td>✔ Zinnat</td>
<td></td>
</tr>
</tbody>
</table>
Macrolides

AZITHROMYCIN – Maximum of 5 days treatment per prescription; can be waived by Special Authority see SA1683 below

A maximum of 24 months of azithromycin treatment for non-cystic fibrosis bronchiectasis will be subsidised on Special Authority.

- Tab 250 mg ................................................................. 8.19 30 ✔ Apo-Azithromycin
- Tab 500 mg – Up to 8 tab available on a PSO ......................... 0.93 2 ✔ Apo-Azithromycin
- Grans for oral liq 200 mg per 5 ml (40 mg per ml) – Wastage claimable ......................................................... 14.38 15 ml ✔ Zithromax

Zithromax to be Sole Supply on 1 January 2019

**SA1683** Special Authority for Waiver of Rule

**Initial application — (bronchiolitis obliterans syndrome, cystic fibrosis and atypical Mycobacterium infections)** only from a relevant specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria:

- Any of the following:
  1. Patient has received a lung transplant, stem cell transplant, or bone marrow transplant and requires treatment for bronchiolitis obliterans syndrome*; or
  2. Patient has received a lung transplant and requires prophylaxis for bronchiolitis obliterans syndrome*; or
  3. Patient has cystic fibrosis and has chronic infection with Pseudomonas aeruginosa or Pseudomonas-related gram negative organisms*; or
  4. Patient has an atypical Mycobacterium infection.

Note: Indications marked with * are unapproved indications.

**Initial application — (non-cystic fibrosis bronchiectasis*)** only from a respiratory specialist or paediatrician. Approvals valid for 12 months for applications meeting the following criteria:

- All of the following:
  1. For prophylaxis of exacerbations of non-cystic fibrosis bronchiectasis*; and
  2. Patient is aged 18 and under; and
  3. Either:
     3.1 Patient has had 3 or more exacerbations of their bronchiectasis, within a 12 month period; or
     3.2 Patient has had 3 acute admissions to hospital for treatment of infective respiratory exacerbations within a 12 month period.

Note: Indications marked with * are unapproved indications.

**Renewal — (non-cystic fibrosis bronchiectasis*)** only from a respiratory specialist or paediatrician. Approvals valid for 12 months for applications meeting the following criteria:

- All of the following:
  1. The patient has completed 12 months of azithromycin treatment for non-cystic fibrosis bronchiectasis; and
  2. Following initial 12 months of treatment, the patient has not received any further azithromycin treatment for non-cystic fibrosis bronchiectasis for a further 12 months, unless considered clinically inappropriate to stop treatment; and
  3. The patient will not receive more than a total of 24 months’ azithromycin cumulative treatment (see note).

The patient must not have had more than 1 prior approval.

Note: No further renewals will be subsidised. A maximum of 24 months of azithromycin treatment for non-cystic fibrosis bronchiectasis will be subsidised. Indications marked with * are unapproved indications

CLARITHROMYCIN

- Tab 250 mg – Maximum of 28 tab per prescription; can be waived by Special Authority see SA1131 on the next page .......... 3.98 14 ✔ Apo-Clarithromycin
- Grans for oral liq 250 mg per 5 ml ................................................. 23.12 50 ml ✔ Klacid
  a) Maximum of 500 mg per prescription; can be waived by Special Authority see SA1131 on the next page
  b) Wastage claimable
**SA1131** Special Authority for Waiver of Rule

**Initial application — (Mycobacterial infections)** only from a respiratory specialist, infectious disease specialist or paediatrician. Approvals valid for 2 years for applications meeting the following criteria:

Either:
1. Atypical mycobacterial infection; or
2. Mycobacterium tuberculosis infection where there is drug-resistance or intolerance to standard pharmaceutical agents.

**Renewal — (Mycobacterial infections)** only from a respiratory specialist, infectious disease specialist or paediatrician. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

**ERYTHROMYCIN ETHYL SUCCINATE**

<table>
<thead>
<tr>
<th>Strength</th>
<th>Subsidy Price</th>
<th>Fully Subsidised</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 400 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>a) Up to 20 tab available on a PSO</td>
<td>16.95</td>
<td>✔ E-Mycin</td>
</tr>
<tr>
<td>b) Up to 2 x the maximum PSO quantity for RFPP</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Grans for oral liq 200 mg per 5 ml</td>
<td>5.00</td>
<td>✔ E-Mycin</td>
</tr>
<tr>
<td>a) Up to 300 ml available on a PSO</td>
<td></td>
<td></td>
</tr>
<tr>
<td>b) Up to 2 x the maximum PSO quantity for RFPP</td>
<td></td>
<td></td>
</tr>
<tr>
<td>c) Wastage claimable</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Grans for oral liq 400 mg per 5 ml</td>
<td>6.77</td>
<td>✔ E-Mycin</td>
</tr>
<tr>
<td>a) Up to 200 ml available on a PSO</td>
<td></td>
<td></td>
</tr>
<tr>
<td>b) Wastage claimable</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**ERYTHROMYCIN LACTOBIONATE**

<table>
<thead>
<tr>
<th>Strength</th>
<th>Subsidy Price</th>
<th>Fully Subsidised</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 1 g</td>
<td>16.00</td>
<td>✔ Erythrocin IV</td>
</tr>
</tbody>
</table>

**ERYTHROMYCIN STEARATE**

<table>
<thead>
<tr>
<th>Strength</th>
<th>Subsidy Price</th>
<th>Fully Subsidised</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 250 mg – Up to 30 tab available on a PSO</td>
<td>14.95</td>
<td>ERA</td>
</tr>
<tr>
<td>(22.29)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 500 mg</td>
<td>29.90</td>
<td>ERA</td>
</tr>
<tr>
<td>(44.58)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**ROXITHROMYCIN**

<table>
<thead>
<tr>
<th>Strength</th>
<th>Subsidy Price</th>
<th>Fully Subsidised</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab disp 50 mg</td>
<td>7.19</td>
<td>✔ Rulide D</td>
</tr>
<tr>
<td>Restricted to children under 12 years of age.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 150 mg</td>
<td>7.48</td>
<td>✔ Arrow-Roxithromycin</td>
</tr>
<tr>
<td>Tab 300 mg</td>
<td>14.40</td>
<td>✔ Arrow-Roxithromycin</td>
</tr>
</tbody>
</table>
## Penicillins

### AMOXICILLIN

Cap 250 mg ................................................................. 14.97 500  ✔ Apo-Amoxi
  a) Up to 30 cap available on a PSO
  b) Up to 10 x the maximum PSO quantity for RFPP

Cap 500 mg ................................................................. 16.75 500  ✔ Apo-Amoxi
  a) Up to 30 cap available on a PSO
  b) Up to 10 x the maximum PSO quantity for RFPP

Grans for oral liq 125 mg per 5 ml ................................. 1.20 100 ml  ✔ Alphamox 125
  a) Up to 200 ml available on a PSO
  b) Wastage claimable

Grans for oral liq 250 mg per 5 ml ................................. 1.31 100 ml  ✔ Alphamox 250
  a) Up to 300 ml available on a PSO
  b) Up to 10 x the maximum PSO quantity for RFPP
  c) Wastage claimable

Inj 250 mg vial ............................................................ 10.67 10  ✔ Ibiamox
Inj 500 mg vial ............................................................ 12.41 10  ✔ Ibiamox
Inj 1 g vial – Up to 5 inj available on a PSO ................. 17.29 10  ✔ Ibiamox

### AMOXICILLIN WITH CLAVULANIC ACID

Tab 500 mg with clavulanic acid 125 mg – Up to 30 tab
available on a PSO .................................................. 1.88 20  ✔ Augmentin

Grans for oral liq amoxicillin 25 mg with clavulanic acid 6.25 mg
per ml ................................................................. 3.83 100 ml  ✔ Augmentin
  a) Up to 200 ml available on a PSO
  b) Wastage claimable

Grans for oral liq amoxicillin 50 mg with clavulanic acid 12.5 mg
per ml – Up to 200 ml available on a PSO ....................... 2.20 100 ml OP  ✔ Curam

### BENZATHINE BENZYPENICILLIN

Inj 900 mg (1.2 million units) in 2.3 ml syringe – Up to 5 inj
available on a PSO ................................................. 344.93 10  ✔ Bicillin LA

Bicillin LA to be Sole Supply on 1 January 2019

### BENZYL-PENICILLIN SODIUM [PENICILLIN G]

Inj 600 mg (1 million units) vial – Up to 5 inj available on a PSO .... 10.35  ✔ Sandoz

### FLUCLOXACILLIN

Cap 250 mg – Up to 30 cap available on a PSO ............... 16.83 250  ✔ Staphlex
Cap 500 mg ................................................................. 56.61 500  ✔ Staphlex

Grans for oral liq 25 mg per ml .................................... 2.29 100 ml  ✔ AFT
  a) Up to 200 ml available on a PSO
  b) Wastage claimable

Grans for oral liq 50 mg per ml .................................... 3.68 100 ml  ✔ AFT
  a) Up to 200 ml available on a PSO
  b) Wastage claimable

Inj 250 mg vial ............................................................ 9.00 10  ✔ Flucloxin
Inj 500 mg vial ............................................................ 9.40 10  ✔ Flucloxin
Inj 1 g vial – Up to 5 inj available on a PSO ................... 5.22 5  ✔ Flucil

▲Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber or pharmacist.

❋Three months or six months, as applicable, dispensed all-at-once
<table>
<thead>
<tr>
<th>PHENOXYMETHYLPENICILLIN (PENICILLIN V)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cap 250 mg – Up to 30 cap available on a PSO..........................2.59 50 ✔ Cilicaine VK</td>
</tr>
<tr>
<td>Cap 500 mg.................................................................4.26 50 ✔ Cilicaine VK</td>
</tr>
<tr>
<td>a) Up to 20 cap available on a PSO</td>
</tr>
<tr>
<td>b) Up to 2 x the maximum PSO quantity for RFPP</td>
</tr>
<tr>
<td>Grans for oral liq 125 mg per 5 ml.....................................1.48 100 ml ✔ AFT</td>
</tr>
<tr>
<td>a) Up to 200 ml available on a PSO</td>
</tr>
<tr>
<td>b) Wastage claimable</td>
</tr>
<tr>
<td>Grans for oral liq 250 mg per 5 ml.....................................1.58 100 ml ✔ AFT</td>
</tr>
<tr>
<td>a) Up to 300 ml available on a PSO</td>
</tr>
<tr>
<td>b) Up to 2 x the maximum PSO quantity for RFPP</td>
</tr>
<tr>
<td>c) Wastage claimable</td>
</tr>
</tbody>
</table>

**PROCAINE PENICILLIN**

Inj 1.5 g in 3.4 ml syringe – Up to 5 inj available on a PSO........123.50 5 ✔ Cilicaine

### Tetracyclines

**DOXYCYCLINE**

* Tab 50 mg – Up to 30 tab available on a PSO..........................2.90 30 Doxy-50

* Tab 100 mg – Up to 30 tab available on a PSO..........................6.75 250 ✔ Doxine

**MINOCYCLINE HYDROCHLORIDE**

* Tab 50 mg – Additional subsidy by Special Authority see SA1355 below – Retail pharmacy..............................5.79 60 Mino-tabs

* Cap 100 mg.................................................................19.32 100 Minomycin

**SA1355** Special Authority for Manufacturers Price

**Initial application** from any relevant practitioner. Approvals valid without further renewal unless notified where the patient has rosacea.

**TETRACYCLINE** – Special Authority see SA1332 below – Retail pharmacy

Cap 500 mg.................................................................46.00 30 ✔ Tetracyclin Wolff S29

**SA1332** Special Authority for Subsidy

**Initial application** from any relevant practitioner. Approvals valid for 3 months for applications meeting the following criteria:

Both:

1. For the eradication of *Helicobacter pylori* following unsuccessful treatment with appropriate first-line therapy; and

2. For use only in combination with bismuth as part of a quadruple therapy regimen.
Other Antibiotics

For topical antibiotics, refer to DERMATOLOGICALS, page 62

CIPROFLOXACIN

Recommended for patients with any of the following:

i) microbiologically confirmed and clinically significant pseudomonas infection; or
ii) prostatitis; or
iii) pyelonephritis; or
iv) gonorrhoea.

Tab 250 mg – Up to 5 tab available on a PSO.........................1.45 28 ✔ Cipflox
Tab 500 mg – Up to 5 tab available on a PSO.........................1.99 28 ✔ Cipflox
Tab 750 mg ............................................................................3.15 28 ✔ Cipflox

CLINDAMYCIN

Cap hydrochloride 150 mg – Maximum of 4 cap per prescription; can be waived by endorsement - Retail pharmacy - Specialist .................................................4.10 16 ✔ Clindamycin ABM
Inj phosphate 150 mg per ml, 4 ml ampoule – Retail pharmacy-Specialist ...........................................................................65.00 10 ✔ Dalacin C

COLISTIN SULPHOMETHATE – Retail pharmacy-Specialist – Subsidy by endorsement

Only if prescribed for dialysis or cystic fibrosis patient and the prescription is endorsed accordingly.

Inj 150 mg...............................................................................65.00 1 ✔ Colistin-Link

GENTAMICIN SULPHATE

Inj 10 mg per ml, 1 ml ampoule – Subsidy by endorsement.........25.00 5 ✔ DBL Gentamicin
Only if prescribed for a dialysis or cystic fibrosis patient or complicated urinary tract infection and the prescription is endorsed accordingly.

Inj 10 mg per ml, 2 ml – Subsidy by endorsement ....................62.00 5 ✔ Wockhardt ✔ APP Pharmaceuticals

(Wockhardt ✔ APP Pharmaceuticals

Inj 10 mg per ml, 2 ml to be delisted 1 April 2019)

MOXIFLOXACIN – Special Authority see SA1740 below – Retail pharmacy

No patient co-payment payable

Tab 400 mg ............................................................................52.00 5 ✔ Avelox

➽ SA1740 Special Authority for Subsidy

Initial application — (Tuberculosis) only from a respiratory specialist or infectious disease specialist. Approvals valid for 1 year for applications meeting the following criteria:

Any of the following:

1 Both:

1.1 Active tuberculosis*; and

continued…

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

✽Three months or six months, as applicable, dispensed all-at-once
continued...

1.2 Any of the following:

1.2.1 Documented resistance to one or more first-line medications; or
1.2.2 Suspected resistance to one or more first-line medications (tuberculosis assumed to be contracted in an area with known resistance), as part of regimen containing other second-line agents; or
1.2.3 Impaired visual acuity (considered to preclude ethambutol use); or
1.2.4 Significant pre-existing liver disease or hepatotoxicity from tuberculosis medications; or
1.2.5 Significant documented intolerance and/or side effects following a reasonable trial of first-line medications; or
2 Mycobacterium avium-intracellulare complex not responding to other therapy or where such therapy is contraindicated.*; or
3 Patient is under five years of age and has had close contact with a confirmed multi-drug resistant tuberculosis case.

Note: Indications marked with * are unapproved indications.

Renewal only from a respiratory specialist or infectious disease specialist. Approvals valid for 1 year where the treatment remains appropriate and the patient is benefiting from treatment.

Initial application — (Mycoplasma genitalium) only from a sexual health specialist or Practitioner on the recommendation of a sexual health specialist. Approvals valid for 1 month for applications meeting the following criteria:

All of the following:

1 Has nucleic acid amplification test (NAAT) confirmed Mycoplasma genitalium* and is symptomatic; and
2 Either:
   2.1 Has tried and failed to clear infection using azithromycin; or
   2.2 Has laboratory confirmed azithromycin resistance; and
3 Treatment is only for 7 days.

Initial application — (Penetrating eye injury) only from an ophthalmologist. Approvals valid for 1 month where the patient requires prophylaxis following a penetrating eye injury and treatment is for 5 days only.

Note: Indications marked with * are unapproved indications.

PAROMOMYCIN – Special Authority see SA1689 below – Retail pharmacy

| Cap 250 mg | $126.00 | 16 | ✔ Humatin |

➤SA1689 Special Authority for Subsidy

Initial application only from an infectious disease specialist, clinical microbiologist or gastroenterologist. Approvals valid for 1 month for applications meeting the following criteria:

Either:

1 Patient has confirmed cryptosporidium infection; or
2 For the eradication of Entamoeba histolytica carriage.

Renewal only from an infectious disease specialist, clinical microbiologist or gastroenterologist. Approvals valid for 1 month for applications meeting the following criteria:

Either:

1 Patient has confirmed cryptosporidium infection; or
2 For the eradication of Entamoeba histolytica carriage.

PYRIMETHAMINE – Special Authority see SA1328 below – Retail pharmacy

| Tab 25 mg | $26.14 | 30 | ✔ Daraprim |
|          | $36.95 | 50 | ✔ Daraprim |

➤SA1328 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Any of the following:

1 For the treatment of toxoplasmosis in patients with HIV for a period of 3 months; or
2 For pregnant patients for the term of the pregnancy; or
3 For infants with congenital toxoplasmosis until 12 months of age.
### Antifungals

- **Fluconazole**
  - Cap 50 mg – Retail pharmacy-Specialist .......................... 2.09  28  ✔ Mylan
  - Cap 150 mg – Subsidy by endorsement .............................. 0.33  1  ✔ Mylan
    - a) Maximum of 1 cap per prescription; can be waived by endorsement - Retail pharmacy - Specialist
    - b) Patient has vaginal candida albicans and the practitioner considers that a topical imidazole (used intra-vaginally) is not recommended and the prescription is endorsed accordingly; can be waived by endorsement - Retail pharmacy - Specialist.
  - Cap 200 mg – Retail pharmacy-Specialist .......................... 5.08  28  ✔ Mylan
  - Powder for oral suspension 10 mg per ml – Special Authority
    - see SA1359 on the next page – Retail pharmacy .............. 34.56  28  ✔ Diflucan S29
    - Powder for oral suspension 10 mg per ml – Special Authority
    - see SA1359 on the next page – Retail pharmacy .............. 98.50  35 ml  ✔ Diflucan
  - Wastage claimable

## SODIUM FUSIDATE [FUSIDIC ACID]

**Tab 250 mg – Retail pharmacy-Specialist**.............................. 34.50  12  ✔ Fucidin

Prescriptions must be written by, or on the recommendation of, an infectious disease physician or a clinical microbiologist

## SULFADIAZINE SODIUM – Special Authority see SA1331 below – Retail pharmacy

**Tab 500 mg** ........................................................................... 543.20  56  ✔ Wockhardt S29

### SA1331 Special Authority for Subsidy

**Initial application** from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Any of the following:

1. For the treatment of toxoplasmosis in patients with HIV for a period of 3 months; or
2. For pregnant patients for the term of the pregnancy; or
3. For infants with congenital toxoplasmosis until 12 months of age.

## TOBRAMYCIN

**Inj 40 mg per ml, 2 ml vial – Subsidy by endorsement** ........... 15.00  5  ✔ Tobramycin Mylan

- Only if prescribed for dialysis or cystic fibrosis patient and the prescription is endorsed accordingly.

**Solution for inhalation 60 mg per ml, 5 ml – Subsidy by endorsement** .................................................. 2,200.00  56 dose  ✔ TOBI
  - a) Wastage claimable
  - b) Only if prescribed for a cystic fibrosis patient and the prescription is endorsed accordingly.

## TRIMETHOPRIM

**Tab 300 mg – Up to 30 tab available on a PSO** ...................... 16.50  50  ✔ TMP

## TRIMETHOPRIM WITH SULPHAMETHOXAZOLE [CO-TRIMOXAZOLE]

**Tab trimethoprim 80 mg and sulphamethoxazole 400 mg – Up to 30 tab available on a PSO** .............................. 22.90  500  ✔ Trisul

**Oral liq 8 mg sulphamethoxazole 40 mg per ml – Up to 200 ml available on a PSO** ............................................. 2.97  100 ml  ✔ Deprim

## VANCOMYCIN – Subsidy by endorsement

- Only if prescribed for a dialysis or cystic fibrosis patient or for prophylaxis of endocarditis or for treatment of Clostridium difficile following metronidazole failure and the prescription is endorsed accordingly.

**Inj 500 mg vial** ........................................................................... 2.37  1  ✔ Mylan

### Antifungals

- a) For topical antifungals refer to DERMATOLOGICALS, page 62
- b) For topical antifungals refer to GENITO URINARY, page 75

## FLUCONAZOLE

**Cap 50 mg – Retail pharmacy-Specialist** .............................. 2.09  28  ✔ Mylan

**Cap 150 mg – Subsidy by endorsement** .............................. 0.33  1  ✔ Mylan
  - a) Maximum of 1 cap per prescription; can be waived by endorsement - Retail pharmacy - Specialist
  - b) Patient has vaginal candida albicans and the practitioner considers that a topical imidazole (used intra-vaginally) is not recommended and the prescription is endorsed accordingly; can be waived by endorsement - Retail pharmacy - Specialist.

**Cap 200 mg – Retail pharmacy-Specialist** .............................. 5.08  28  ✔ Mylan

**Powder for oral suspension 10 mg per ml – Special Authority**

- see SA1359 on the next page – Retail pharmacy .............. 34.56  35 ml  ✔ Diflucan S29
- Powder for oral suspension 10 mg per ml – Special Authority
  - see SA1359 on the next page – Retail pharmacy .............. 98.50  35 ml  ✔ Diflucan

- Wastage claimable

▲Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber or pharmacist.

★Three months or six months, as applicable, dispensed all-at-once
INFECTIONS - AGENTS FOR SYSTEMIC USE

Subsidy
(Manufacturer’s Price)
Per
Fully
Brand or
Subsidised
Generic
Manufacturer

$ Per

✔

Brand or
Generic
Manufacturer

- Subsidy

SA1359 Special Authority for Subsidy

Initial application — (Systemic candidiasis) from any relevant practitioner. Approvals valid for 6 weeks for applications meeting the following criteria:

Both:

1. Patient requires prophylaxis for, or treatment of systemic candidiasis; and
2. Patient is unable to swallow capsules.

Initial application — (Immunocompromised) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

1. Patient is immunocompromised; and
2. Patient is at moderate to high risk of invasive fungal infection; and
3. Patient is unable to swallow capsules.

Renewal — (Systemic candidiasis) from any relevant practitioner. Approvals valid for 6 weeks for applications meeting the following criteria:

Both:

1. Patient requires prophylaxis for, or treatment of systemic candidiasis; and
2. Patient is unable to swallow capsules.

Renewal — (Immunocompromised) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

1. Patient remains immunocompromised; and
2. Patient remains at moderate to high risk of invasive fungal infection; and
3. Patient is unable to swallow capsules.

ITRACONAZOLE

Cap 100 mg – Subsidy by endorsement ............................................2.79 15 ✔

Itrazole

Funded for tinea vesicolor where topical treatment has not been successful and diagnosis has been confirmed by mycology, or for tinea unguium where terbinafine has not been successful in eradication or the patient is intolerant to terbinafine and diagnosis has been confirmed by mycology and the prescription is endorsed accordingly. Can be waived by endorsement - Retail pharmacy - Specialist Specialist must be an infectious disease physician, clinical microbiologist, clinical immunologist or dermatologist.

Oral liq 10 mg per ml – Special Authority see SA1322 below –

Retail pharmacy........................................................................141.80 150 ml OP ✔

SPORANOX

SA1322 Special Authority for Subsidy

Initial application only from an infectious disease specialist, clinical microbiologist, clinical immunologist or any relevant practitioner on the recommendation of an infectious disease physician, clinical microbiologist or clinical immunologist. Approvals valid for 6 months where the patient has a congenital immune deficiency.

Renewal from any relevant practitioner. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefitting from the treatment.

KETOCONAZOLE

Tab 200 mg – PCT – Retail pharmacy-Specialist – Subsidy by endorsement........................................................................CBS 30 ✔

Link Healthcare ✔

Nizoral ✔

Prescriptions must be written by, or on the recommendation of an oncologist

NYSTATIN

Tab 500,000 u .................................................................14.16 50

(Nilstat)

Cap 500,000 u.................................................................12.81 50

(Nilstat)
INFECTIONS - AGENTS FOR SYSTEMIC USE

POSACONAZOLE – Special Authority see SA1285 below – Retail pharmacy
- Tab modified-release 100 mg: $869.86 24 ✔ Noxafil
- Oral liq 40 mg per ml: $761.13 105 ml OP ✔ Noxafil

➽ SA1285 Special Authority for Subsidy
- Initial application only from a haematologist or infectious disease specialist. Approvals valid for 6 weeks for applications meeting the following criteria:
  - Either:
    1. Patient has acute myeloid leukaemia and is to be treated with high dose remission induction, re-induction or consolidation chemotherapy; or
    2. Patient has received a stem cell transplant and has graft versus host disease and is on significant immunosuppressive therapy*.

- Renewal only from a haematologist or infectious disease specialist. Approvals valid for 6 weeks for applications meeting the following criteria:
  - Either:
    1. Patient has acute myeloid leukaemia and is to be treated with high dose remission induction, re-induction or consolidation therapy; or
    2. Patient has received a stem cell transplant and has graft versus host disease and is on significant immunosuppression* and requires on going posaconazole treatment.

Note: * Graft versus host disease (GVHD) on significant immunosuppression is defined as acute GVHD, grade II to IV, or extensive chronic GVHD, or if they were being treated with intensive immunosuppressive therapy consisting of either high-dose corticosteroids (1 mg or greater per kilogram of body weight per day for patients with acute GVHD or 0.8 mg or greater per kilogram every other day for patients with chronic GVHD), antithymocyte globulin, or a combination of two or more immunosuppressive agents or types of treatment.

TERBINAFINE
- Tab 250 mg: $1.33 14 ✔ Deolate

VORICONAZOLE – Special Authority see SA1273 below – Retail pharmacy
- Tab 50 mg: $91.00 56 ✔ Vttack
- Tab 200 mg: $350.00 56 ✔ Vttack
- Powder for oral suspension 40 mg per ml – Wastage claimable: $1,437.00 70 ml ✔ Vfend

Vfend to be Sole Supply on 1 January 2019

➽ SA1273 Special Authority for Subsidy
- Initial application — (invasive fungal infection) only from a haematologist, infectious disease specialist or clinical microbiologist. Approvals valid for 3 months for applications meeting the following criteria:
  - All of the following:
    1. Patient is immunocompromised; and
    2. Applicant is part of a multidisciplinary team including an infectious disease specialist; and
    3. Any of the following:
      3.1 Patient has proven or probable invasive aspergillus infection; or
      3.2 Patient has possible invasive aspergillus infection; or
      3.3 Patient has fluconazole resistant candidiasis; or
      3.4 Patient has mould strain such as Fusarium spp. and Scedosporium spp.

- Renewal — (invasive fungal infection) only from a haematologist, infectious disease specialist or clinical microbiologist. Approvals valid for 3 months for applications meeting the following criteria:
  - All of the following:
    1. Patient is immunocompromised; and
    2. Applicant is part of a multidisciplinary team including an infectious disease specialist; and

▲ Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber or pharmacist.
★ Three months or six months, as applicable, dispensed all-at-once
continued…

3 Any of the following:
   3.1 Patient continues to require treatment for proven or probable invasive aspergillus infection; or
   3.2 Patient continues to require treatment for possible invasive aspergillus infection; or
   3.3 Patient has fluconazole resistant candidiasis; or
   3.4 Patient has mould strain such as Fusarium spp. and Scedosporium spp.

Antimalarials

PRIMAQUINE PHOSPHATE – Special Authority see SA1684 below – Retail pharmacy
Tab 7.5 mg ......................................................................................117.00  56 ✔ Primacin

SA1684 Special Authority for Subsidy
Initial application only from an infectious disease specialist or clinical microbiologist. Approvals valid for 1 month for applications meeting the following criteria:
Both:
1 The patient has vivax or ovale malaria; and
2 Primaquine is to be given for a maximum of 21 days.

Renewal only from an infectious disease specialist or clinical microbiologist. Approvals valid for 1 month for applications meeting the following criteria:
Both:
1 The patient has relapsed vivax or ovale malaria; and
2 Primaquine is to be given for a maximum of 21 days.

Antiparasitics

Antiprotozoals

QUININE SULPHATE
* Tab 300 mg ......................................................................................61.91  500 ✔ Q 300

Antitrichomonal Agents

METRONIDAZOLE
   Tab 200 mg – Up to 30 tab available on a PSO .................................10.45  100 ✔ Trichozole
   Tab 400 mg – Up to 15 tab available on a PSO .................................18.15  100 ✔ Trichozole
   Oral liq benzoate 200 mg per 5 ml ..................................................25.00  100 ml ✔ Flagyl-S
   Suppos 500 mg ................................................................................24.48  10 ✔ Flagyl

ORNIDAZOLE
   Tab 500 mg ......................................................................................23.00  10 ✔ Arrow-Ornidazole

Antituberculotics and Antileprotics

Note: There is no co-payment charge for all pharmaceuticals listed in the Antituberculotics and Antileprotics group regardless of immigration status.

CLOFAZIMINE – Retail pharmacy-Specialist
   a) No patient co-payment payable
   b) Prescriptions must be written by, or on the recommendation of, an infectious disease physician, clinical microbiologist or dermatologist.

* Cap 50 mg ......................................................................................442.00  100 ✔ Lamprene
<table>
<thead>
<tr>
<th>INFECTIONS - AGENTS FOR SYSTEMIC USE</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Subsidy (Manufacturer’s Price) $</strong></td>
</tr>
<tr>
<td><strong>Fully Subsidised</strong></td>
</tr>
<tr>
<td><strong>Brand or Generic Manufacturer</strong></td>
</tr>
</tbody>
</table>

**CYCLOSERINE – Retail pharmacy-Specialist**

a) No patient co-payment payable
b) Prescriptions must be written by, or on the recommendation of, an infectious disease physician, clinical microbiologist or respiratory physician.

Cap 250 mg.................................................................1,294.50 100 ✔ King $29

**DAPSONE – Retail pharmacy-Specialist**

a) No patient co-payment payable
b) Prescriptions must be written by, or on the recommendation of, an infectious disease physician, clinical microbiologist or dermatologist

Tab 25 mg ...............................................................268.50 100 ✔ Dapsone
Tab 100 mg .............................................................329.50 100 ✔ Dapsone

**ETHAMBUTOL HYDROCHLORIDE – Retail pharmacy-Specialist**

a) No patient co-payment payable
b) Prescriptions must be written by, or on the recommendation of, an infectious disease physician, clinical microbiologist or respiratory physician

Tab 100 mg .................................................................48.01 56 ✔ Myambutol $29
Tab 400 mg ...............................................................49.34 56 ✔ Myambutol $29

(Myambutol $29 Tab 100 mg to be delisted 1 February 2019)

**ISONIAZID – Retail pharmacy-Specialist**

a) No patient co-payment payable
b) Prescriptions must be written by, or on the recommendation of, an internal medicine physician, paediatrician, clinical microbiologist, dermatologist or public health physician

✻ Tab 100 mg ............................................................22.00 100 ✔ PSM

**ISONIAZID WITH RIFAMPICIN – Retail pharmacy-Specialist**

a) No patient co-payment payable
b) Prescriptions must be written by, or on the recommendation of, an internal medicine physician, paediatrician, clinical microbiologist, dermatologist or public health physician

✻ Tab 100 mg with rifampicin 150 mg.................................85.54 100 ✔ Rifinah
✻ Tab 150 mg with rifampicin 300 mg.............................170.60 100 ✔ Rifinah

**PARA-AMINO SALICYLIC ACID – Retail pharmacy-Specialist**

a) No patient co-payment payable
b) Specialist must be an infectious disease specialist, clinical microbiologist or respiratory specialist.

Grans for oral liq 4 g sachet ........................................280.00 30 ✔ Paser $29

**PROTIONAMIDE – Retail pharmacy-Specialist**

a) No patient co-payment payable
b) Specialist must be an infectious disease specialist, clinical microbiologist or respiratory specialist.

Tab 250 mg ...............................................................305.00 100 ✔ Peteha $29

**PYRAZINAMIDE – Retail pharmacy-Specialist**

a) No patient co-payment payable
b) Prescriptions must be written by, or on the recommendation of, an infectious disease physician, clinical microbiologist or respiratory physician

✻ Tab 500 mg ............................................................59.00 100 ✔ AFT-Pyrazinamide $29

▲ Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber or pharmacist.

✻ Three months or six months, as applicable, dispensed all-at-once
INFECTIONS - AGENTS FOR SYSTEMIC USE

<table>
<thead>
<tr>
<th>Subsidy (Manufacturer's Price)</th>
<th>Fully Subsidised</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per</td>
<td>Per</td>
<td>Manufacturer</td>
</tr>
</tbody>
</table>

RIFABUTIN – Retail pharmacy-Specialist
a) No patient co-payment payable
b) Prescriptions must be written by, or on the recommendation of, an infectious disease physician, respiratory physician or gastroenterologist

Cap 150 mg.................................................................275.00 30 ✔ Mycobutin

RIFAMPICIN – Subsidy by endorsement
a) No patient co-payment payable
b) For confirmed recurrent Staphylococcus aureus infection in combination with other effective anti-staphylococcal antimicrobial based on susceptibilities and the prescription is endorsed accordingly; can be waived by endorsement - Retail pharmacy - Specialist. Specialist must be an internal medicine physician, clinical microbiologist, dermatologist, paediatrician, or public health physician.

Cap 150 mg.................................................................55.75 100 ✔ Rifadin
Cap 300 mg.................................................................116.25 100 ✔ Rifadin
Oral liq 100 mg per 5 ml ..................................................12.00 60 ml ✔ Rifadin

Antivirals
For eye preparations refer to Eye Preparations, Anti-Infective Preparations, page 208

Hepatitis B Treatment

ADEFOVIR DIPIVOXIL – Special Authority see SA0829 below – Retail pharmacy
Tab 10 mg ...........................................................................670.00 30 ✔ Hepsera

SA0829 Special Authority for Subsidy
Initial application only from a gastroenterologist or infectious disease specialist. Approvals valid for 1 year for applications meeting the following criteria:
All of the following:
1. Patient has confirmed Hepatitis B infection (HBsAg+); and
   Documented resistance to lamivudine, defined as:
2. Patient has raised serum ALT (> 1 × ULN); and
3. Patient has HBV DNA greater than 100,000 copies per mL, or viral load 10 fold or higher over nadir; and
4. Detection of M204I or M204V mutation; and
5. Either:
   5.1 Both:
      5.1.1 Patient is cirrhotic; and
      5.1.2 adefovir dipivoxil to be used in combination with lamivudine; or
   5.2 Both:
      5.2.1 Patient is not cirrhotic; and
      5.2.2 adefovir dipivoxil to be used as monotherapy.

Renewal only from a gastroenterologist or infectious disease specialist. Approvals valid for 2 years where in the opinion of the treating physician, treatment remains appropriate and patient is benefiting from treatment.

Notes: Lamivudine should be added to adefovir dipivoxil if a patient develops documented resistance to adefovir dipivoxil, defined as:
1. raised serum ALT (> 1 × ULN); and
2. HBV DNA greater than 100,000 copies per mL, or viral load 10 fold or higher over nadir; and
3. Detection of N236T or A181T/V mutation.

Adefovir dipivoxil should be stopped 6 months following HBeAg seroconversion for patients who were HBeAg+ prior to commencing adefovir dipivoxil.

The recommended dose of adefovir dipivoxil is no more than 10mg daily.

In patients with renal insufficiency adefovir dipivoxil dose should be reduced in accordance with the datasheet guidelines. Adefovir dipivoxil should be avoided in pregnant women and children.
### INFECTIONS - AGENTS FOR SYSTEMIC USE

<table>
<thead>
<tr>
<th>Subsidy</th>
<th>Fully Subsidised</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>(Manufacturer’s Price) $</td>
<td>Per</td>
<td>✔</td>
</tr>
</tbody>
</table>

#### ENTECAVIR

* Tab 0.5 mg .......................................................... 52.00 30 ✔ Entecavir Sandoz

*(Baraclude Tab 0.5 mg to be delisted 1 January 2019)*

<table>
<thead>
<tr>
<th>LAMIVUDINE – Special Authority see SA1685 below – Retail pharmacy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 100 mg .......................................................... 4.20 28 ✔ Zetlam</td>
</tr>
<tr>
<td>Oral liq 5 mg per ml .................................................. 270.00 240 ml OP ✔ Zeffix</td>
</tr>
</tbody>
</table>

**SA1685** Special Authority for Subsidy

**Initial application** only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 1 year where used for the treatment or prevention of hepatitis B.

**Renewal** from any relevant practitioner. Approvals valid for 2 years where used for the treatment or prevention of hepatitis B.

### Herpesvirus Treatments

#### ACICLOVIR

* Tab dispersible 200 mg .................................................. 1.60 25 ✔ Lovir
* Tab dispersible 400 mg .................................................. 5.38 56 ✔ Lovir
* Tab dispersible 800 mg .................................................. 5.98 35 ✔ Lovir

#### VALACICLOVIR

| Tab 500 mg .................................................. 5.75 30 ✔ Vaclovir |
| Tab 1,000 mg .................................................. 11.35 30 ✔ Vaclovir |

#### VALGANCICLOVIR – Special Authority see SA1404 below – Retail pharmacy

| Tab 450 mg .................................................. 1,050.00 60 ✔ Valcyte |

**SA1404** Special Authority for Subsidy

**Initial application** — *(transplant cytomegalovirus prophylaxis)* only from a relevant specialist. Approvals valid for 3 months where the patient has undergone a solid organ transplant and requires valganciclovir for CMV prophylaxis.

**Renewal** — *(transplant cytomegalovirus prophylaxis)* only from a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria:

Both:

1. Patient has undergone a solid organ transplant and received anti-thymocyte globulin and requires valganciclovir therapy for CMV prophylaxis; and
2. Patient is to receive a maximum of 90 days of valganciclovir prophylaxis following anti-thymocyte globulin.

**Initial application** — *(cytomegalovirus prophylaxis following anti-thymocyte globulin)* only from a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria:

Both:

1. Patient has undergone a solid organ transplant and received valganciclovir under Special Authority more than 2 years ago (27 months); and
2. Patient has received anti-thymocyte globulin and requires valganciclovir for CMV prophylaxis.

**Renewal** — *(cytomegalovirus prophylaxis following anti-thymocyte globulin)* only from a relevant specialist. Approvals valid for 3 months where the patient has received a further course of anti-thymocyte globulin and requires valganciclovir for CMV prophylaxis.

**Initial application** — *(Lung transplant cytomegalovirus prophylaxis)* only from a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria:

---

▲Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber or pharmacist.

★Three months or six months, as applicable, dispensed all-at-once
INFECTIONS - AGENTS FOR SYSTEMIC USE

Subsidy

(Manufacturer’s Price)

$ Per

Fully Subsidised

Brand or Generic Manufacturer

continued...

Both:

1. Patient has undergone a lung transplant; and
2. Either:
   2.1 The donor was cytomegalovirus positive and the patient is cytomegalovirus negative; or
   2.2 The recipient is cytomegalovirus positive.

Initial application — (Cytomegalovirus in immunocompromised patients) only from a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria:

Both:

1. Patient is immunocompromised; and
2. Any of the following:
   2.1 Patient has cytomegalovirus syndrome or tissue invasive disease; or
   2.2 Patient has rapidly rising plasma CMV DNA in absence of disease; or
   2.3 Patient has cytomegalovirus retinitis.

Renewal — (Cytomegalovirus in immunocompromised patients) only from a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria:

Both:

1. Patient is immunocompromised; and
2. Any of the following:
   2.1 Patient has cytomegalovirus syndrome or tissue invasive disease; or
   2.2 Patient has rapidly rising plasma CMV DNA in absence of disease; or
   2.3 Patient has cytomegalovirus retinitis.

Note: for the purpose of this Special Authority "immunocompromised" includes transplant recipients, patients with immunosuppressive diseases (e.g. HIV) or those receiving immunosuppressive treatment for other conditions.

Hepatitis C Treatment

LEDIPASVIR WITH SOFOSBUVIR – Special Authority see SA1605 below – [Xpharm]

No patient co-payment payable

Tab 90 mg with sofosbuvir 400 mg.............................................24,363.46 28 ✔ Harvoni

➽ SA1605 Special Authority for Subsidy

Special Authority approved by the Hepatitis C Treatment Panel (HepCTP)

Notes: By application to the Hepatitis C Treatment Panel (HepCTP).

Applications will be considered by HepCTP and approved subject to confirmation of eligibility.

Application details may be obtained from PHARMAC’s website [http://www.pharmac.govt.nz/hepatitis-c-treatments] or:

The Coordinator, Hepatitis C Treatment Panel

PHARMAC, PO Box 10-254, WELLINGTON Tel: (04) 460 4990,

Email: hepcpanel@pharmac.govt.nz

PARITAPREVIR, RITONAVIR AND OMBITASVIR WITH DASABUVIR – [Xpharm]

a) No patient co-payment payable
b) Note – Supply of treatment is via PHARMAC’s approved direct distribution supply. Application details for accessing treatment may be obtained from PHARMAC’s website [http://www.pharmac.govt.nz/hepatitis-c-treatments] and/or

Tab 75 mg with ritonavir 50 mg, and ombitasvir 12.5 mg (56),
with dasabuvir tab 250 mg (56).............................................16,500.00 1 OP ✔ Viekira Pak

PARITAPREVIR, RITONAVIR AND OMBITASVIR WITH DASABUVIR AND RIBAVIRIN – [Xpharm]

a) No patient co-payment payable
b) Note – Supply of treatment is via PHARMAC’s approved direct distribution supply. Application details for accessing treatment may be obtained from PHARMAC’s website [http://www.pharmac.govt.nz/hepatitis-c-treatments] and/or

Tab 75 mg with ritonavir 50 mg, and ombitasvir 12.5 mg (56),
with dasabuvir tab 250 mg (56) and ribavirin tab 200 mg (168).............................................16,500.00 1 OP ✔ Viekira Pak-RBV
HIV Prophylaxis and Treatment

EMTRICITABINE WITH TENOFOVIR DISOPROXIL FUMARATE – Subsidy by endorsement; can be waived by Special Authority see SA1714 below

Endorsement for treatment of HIV: Prescription is deemed to be endorsed if emtricitabine with tenofovir disoprophyl fumarate is co-prescribed with another antiretroviral subsidised under Special Authority SA1651 and the prescription is annotated accordingly by the Pharmacist or endorsed by the prescriber.

Note: Emtricitabine with tenofovir disoprophyl fumarate prescribed under endorsement for the treatment of HIV is included in the count of up to 4 subsidised antiretrovirals, and counts as two antiretroviral medications, for the purposes of Special Authority SA1651, page 106 There is an approval process to become a named specialist to prescribe antiretroviral therapy in New Zealand. Further information is available on the PHARMAC website.

Tab 200 mg with tenofovir disoprophyl fumarate 300 mg

ซา1714 Special Authority for Waiver of Rule

Initial application only from a named specialist or medical practitioner on the recommendation of a named specialist. Approvals valid for 3 months for applications meeting the following criteria:

Both:
1. Patient has tested HIV negative; and
2. Either:
   2.1 All of the following:
      2.1.1 Patient is male or transgender; and
      2.1.2 Patient has sex with men; and
      2.1.3 Patient is likely to have multiple episodes of condomless anal intercourse in the next 3 months; and
      2.1.4 Any of the following:
         2.1.4.1 Patient has had at least one episode of condomless receptive anal intercourse with one or more casual male partners in the last 3 months; or
         2.1.4.2 A diagnosis of rectal chlamydia, rectal gonorrhoea, or infectious syphilis within the last 3 months; or
         2.1.4.3 Patient has used methamphetamine in the last three months; or
   2.2 All of the following:
      2.2.1 Patient has a regular partner who has HIV infection; and
      2.2.2 Partner is either not on treatment or has a detectable viral load; and
      2.2.3 Condoms have not been consistently used.

Renewal from any relevant practitioner. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:
1. Applicant has an up to date knowledge of the safety issues and is competent to prescribe pre-exposure prophylaxis; and
2. Patient has undergone testing for HIV, syphilis, and a full STI screen in the previous two weeks; and
3. Patient has had renal function testing (creatinine, phosphate and urine protein/creatinine ratio) within the last 12 months; and
4. Patient has received advice regarding the reduction of risk of HIV and sexually transmitted infections and how to reduce those risks; and
5. Patient has tested HIV negative; and
6. Either:
   6.1 All of the following:
      6.1.1 Patient is male or transgender; and
      6.1.2 Patient has sex with men; and
      6.1.3 Patient is likely to have multiple episodes of condomless anal intercourse in the next 3 months; and
      6.1.4 Any of the following:
         6.1.4.1 Patient has had at least one episode of condomless receptive anal intercourse with one or more casual male partners in the last 3 months; or

continued...
6.1.4.2 A diagnosis of rectal chlamydia, rectal gonorrhoea, or infectious syphilis within the last 3 months; or
6.1.4.3 Patient has used methamphetamine in the last three months; or

6.2 All of the following:
6.2.1 Patient has a regular partner who has HIV infection; and
6.2.2 Partner is either not on treatment or has a detectable viral load; and
6.2.3 Condoms have not been consistently used.

Antiretrovirals

[SA1651] Special Authority for Subsidy

Initial application — (Confirmed HIV) only from a named specialist. Approvals valid without further renewal unless notified where the patient has confirmed HIV infection.

Notes: Tenofovir disoproxil fumarate prescribed under endorsement for HIV is included in the count of up to 4 subsidised antiretrovirals.

Subsidies apply for a combination of up to four antiretroviral medications. The combination of a protease inhibitor and low-dose ritonavir given as a booster (either as part of a combination product or separately) will be counted as one protease inhibitor for the purpose of accessing funding to antiretrovirals.

Renewal — (Confirmed HIV) only from a named specialist. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment.

Initial application — (Prevention of maternal transmission) only from a named specialist. Approvals valid for 1 year for applications meeting the following criteria:

Either:
1. Prevention of maternal foetal transmission; or
2. Treatment of the newborn for up to eight weeks.

Notes: Tenofovir disoproxil fumarate prescribed under endorsement for HIV is included in the count of up to 4 subsidised antiretrovirals.

Subsidies apply for a combination of up to four antiretroviral medications. The combination of a protease inhibitor and low-dose ritonavir given as a booster (either as part of a combination product or separately) will be counted as one protease inhibitor for the purpose of accessing funding to antiretrovirals.

Some antiretrovirals are unapproved or contraindicated for this indication. Practitioners prescribing these medications should exercise their own skill, judgement, expertise and discretion, and make their own prescribing decisions with respect to the use of a Pharmaceutical for an indication for which it is not approved or contraindicated.

Initial application — (post-exposure prophylaxis following non-occupational exposure to HIV) only from a named specialist. Approvals valid for 4 weeks for applications meeting the following criteria:

Both:
1. Treatment course to be initiated within 72 hours post exposure; and
2. Any of the following:
   2.1 Patient has had unprotected receptive anal intercourse with a known HIV positive person; or
   2.2 Patient has shared intravenous injecting equipment with a known HIV positive person; or
   2.3 Patient has had non-consensual intercourse and the clinician considers that the risk assessment indicates prophylaxis is required.

Notes: Tenofovir disoproxil fumarate prescribed under endorsement for HIV is included in the count of up to 4 subsidised antiretrovirals.

Subsidies apply for a combination of up to four antiretroviral medications. The combination of a protease inhibitor and low-dose ritonavir given as a booster (either as part of a combination product or separately) will be counted as one protease inhibitor for the purpose of accessing funding to antiretrovirals.

continued…
continued...

**Renewal — (second or subsequent post-exposure prophylaxis)** only from a named specialist. Approvals valid for 4 weeks for applications meeting the following criteria:

Both:

1. Treatment course to be initiated within 72 hours post exposure; and
2. Any of the following:
   1. Patient has had unprotected receptive anal intercourse with a known HIV positive person; or
   2. Patient has shared intravenous injecting equipment with a known HIV positive person; or
   3. Patient has had non-consensual intercourse and the clinician considers that the risk assessment indicates prophylaxis is required.

**Initial application — (Percutaneous exposure)** only from a named specialist. Approvals valid for 6 weeks where the patient has percutaneous exposure to blood known to be HIV positive.

Notes: Tenofovir disoproxil fumarate prescribed under endorsement for HIV is included in the count of up to 4 subsidised antiretrovirals.

Subsidies apply for a combination of up to four antiretroviral medications. The combination of a protease inhibitor and low-dose ritonavir given as a booster (either as part of a combination product or separately) will be counted as one protease inhibitor for the purpose of accessing funding to antiretrovirals.

**Renewal — (Second or subsequent percutaneous exposure)** only from a named specialist. Approvals valid for 6 weeks where the patient has percutaneous exposure to blood known to be HIV positive.

### Non-nucleosides Reverse Transcriptase Inhibitors

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Brand or Generic Manufacturer</th>
<th>Retail pharmacy</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EFAVIRENZ</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| Tab 50 mg | ✔ | Stocrin
| Tab 200 mg | ✔ | Stocrin
| Tab 600 mg | ✔ | Stocrin
| Oral liq 30 mg per ml | ✔ | Stocrin
| **ETRAVIRINE** | | |
| Tab 200 mg | ✔ | Intence
| **NEVIRAPINE** | | |
| Tab 200 mg | ✔ | Nevirapine
| Oral suspension 10 mg per ml | ✔ | Viramune

### Nucleosides Reverse Transcriptase Inhibitors

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Brand or Generic Manufacturer</th>
<th>Retail pharmacy</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ABACAVIR SULPHATE</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| Tab 300 mg | ✔ | Ziagen
| Oral liq 20 mg per ml | ✔ | Ziagen
| **ABACAVIR SULPHATE WITH LAMIVUDINE** | | |
| Note: abacavir with lamivudine (combination tablets) counts as two anti-retroviral medications for the purposes of the anti-retroviral Special Authority. | | |
| Tab 600 mg with lamivudine 300 mg | ✔ | Kivexa
| **EFAVIRENZ WITH EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE** | | |
| Note: Efavirenz with emtricitabine and tenofovir disoproxil fumarate counts as three anti-retroviral medications for the purposes of the anti-retroviral Special Authority. | | |
| Tab 600 mg with emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg | ✔ | Atripla

▲ Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber or pharmacist.

❋ Three months or six months, as applicable, dispensed all-at-once


**INFECTIONS - AGENTS FOR SYSTEMIC USE**

<table>
<thead>
<tr>
<th>Subsidy (Manufacturer’s Price)</th>
<th>Fully Subsidised</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Subsidised**

**Fully Subsidised**

**Brand or Generic Manufacturer**

---

**EMTRICITABINE** – Special Authority see SA1651 on page 106 – Retail pharmacy

Cap 200 mg……………………………………………………………307.20 30 ✓ Emtriva

**LAMIVUDINE** – Special Authority see SA1651 on page 106 – Retail pharmacy

Tab 150 mg……………………………………………………………52.50 60 ✓ Lamivudine

Oral liq 10 mg per ml ……………………………………………102.50 240 ml OP ✓ 3TC

**ZIDOVUDINE [AZT]** – Special Authority see SA1651 on page 106 – Retail pharmacy

Cap 100 mg……………………………………………………………152.25 100 ✓ Retrovir

Oral liq 10 mg per ml ……………………………………………30.45 200 ml OP ✓ Retrovir

**ZIDOVUDINE [AZT] WITH LAMIVUDINE** – Special Authority see SA1651 on page 106 – Retail pharmacy

Note: zidovudine [AZT] with lamivudine (combination tablets) counts as two anti-retroviral medications for the purposes of the anti-retroviral Special Authority.

Tab 300 mg with lamivudine 150 mg…………………………………33.00 60 ✓ Alphapharm

---

**Protease Inhibitors**

**ATAZANAVIR SULPHATE** – Special Authority see SA1651 on page 106 – Retail pharmacy

Cap 150 mg……………………………………………………………568.34 60 ✓ Reyataz

Cap 200 mg……………………………………………………………757.79 60 ✓ Reyataz

**DARUNAVIR** – Special Authority see SA1651 on page 106 – Retail pharmacy

Tab 400 mg……………………………………………………………335.00 60 ✓ Prezista

Tab 600 mg……………………………………………………………476.00 60 ✓ Prezista

**LOPINAVIR WITH RITONAVIR** – Special Authority see SA1651 on page 106 – Retail pharmacy

Tab 100 mg with ritonavir 25 mg……………………………………183.75 60 ✓ Kaletra

Tab 200 mg with ritonavir 50 mg……………………………………463.00 120 ✓ Kaletra

Oral liq 80 mg with ritonavir 20 mg per ml…………………………735.00 300 ml OP ✓ Kaletra

**RITONAVIR** – Special Authority see SA1651 on page 106 – Retail pharmacy

Tab 100 mg…………………………………………………………….43.31 30 ✓ Norvir

---

**Strand Transfer Inhibitors**

**DOLUTEGRAVIR** – Special Authority see SA1651 on page 106 – Retail pharmacy

Tab 50 mg……………………………………………………………..1,090.00 30 ✓ Tivicay

**RALTEGRAVIR POTASSIUM** – Special Authority see SA1651 on page 106 – Retail pharmacy

Tab 400 mg……………………………………………………………..1,090.00 60 ✓ Isentress

---

**Immune Modulators**

**Guidelines for the use of interferon in the treatment of hepatitis C:**

Physicians considering treatment of patients with hepatitis C should discuss cases with a gastroenterologist or an infectious disease physician. All subjects undergoing treatment require careful monitoring for side effects. Patients should be otherwise fit. Hepatocellular carcinoma should be excluded by ultrasound examination and alpha-fetoprotein level.

**Criteria for Treatment**

1) Diagnosis

- Anti-HCV positive on at least two occasions with a positive PCR for HCV-RNA and preferably confirmed by a supplementary RIBA test; or

---

continued…

---

108 ✓ fully subsidised


Sole Subsidised Supply

Unapproved medicine supplied under Section 29
### INFECTIONS - AGENTS FOR SYSTEMIC USE

<table>
<thead>
<tr>
<th>Subsidy (Manufacturer’s Price)</th>
<th>Fully Subsidised</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per</td>
<td>✔</td>
<td></td>
</tr>
</tbody>
</table>

- **Fully Subsidised ✔**
- **Brand or Generic Manufacturer**

#### Exclusion Criteria

1. Autoimmune liver disease. (Interferon may exacerbate autoimmune liver disease as well as other autoimmune diseases such as thyroid disease).
2. Pregnancy.
3. Neutropenia (< 2.0 x 10^9) and/or thrombocytopenia.
4. Continuing alcohol abuse and/or continuing intravenous drug users.

#### Dosage

The current recommended dosage is 3 million units of interferon alfa-2a or interferon alfa-2b administered subcutaneously 3 times a week for 52 weeks (twelve months).

#### Exit Criteria

The patient’s response to interferon treatment should be reviewed at either three or four months. Interferon treatment should be discontinued in patients who do not show a substantial reduction (50%) in their mean pre-treatment ALT level at this stage.

#### INTERFERON ALFA-2A – PCT – Retail pharmacy-Specialist

- a) See prescribing guideline on the previous page
- b) Prescriptions must be written by, or on the recommendation of, an internal medicine physician or ophthalmologist

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>Price</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 3 m iu prefilled syringe</td>
<td>38.00</td>
<td>1</td>
</tr>
</tbody>
</table>

- ✔ Roferon-A

#### INTERFERON ALFA-2B – PCT – Retail pharmacy-Specialist

- a) See prescribing guideline on the previous page
- b) Prescriptions must be written by, or on the recommendation of, an internal medicine physician or ophthalmologist

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>Price</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 18 m iu, 1.2 ml multidose pen</td>
<td>206.71</td>
<td>1</td>
</tr>
<tr>
<td>Inj 30 m iu, 1.2 ml multidose pen</td>
<td>344.52</td>
<td>1</td>
</tr>
<tr>
<td>Inj 60 m iu, 1.2 ml multidose pen</td>
<td>689.04</td>
<td>1</td>
</tr>
</tbody>
</table>

- ✔ Intron-A

(Peginterferon alfa-2a 180 mcg prefilled syringe to be delisted 1 May 2019)

#### PEGYLATED INTERFERON ALFA-2A – Special Authority see SA1400 below – Retail pharmacy

- a) See prescribing guideline on the previous page
- b) Note: PHARMAC will consider funding ribavirin for the small group of patients who have a clinical need for ribavirin and meet Special Authority criteria. Please contact the Hepatitis C Coordinator at PHARMAC on 0800-023-588 option 4.

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>Price</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 180 mcg prefilled syringe</td>
<td>500.00</td>
<td>4</td>
</tr>
</tbody>
</table>

- ✔ Pegasys

#### Special Authority for Subsidy

**SA1400**

- Initial application — (chronic hepatitis C - genotype 1, 4, 5 or 6 infection or co-infection with HIV or genotype 2 or 3 post liver transplant) from any specialist. Approvals valid for 18 months for applications meeting the following criteria:

  1. Any of the following:
     1.1 Patient has chronic hepatitis C, genotype 1, 4, 5 or 6 infection; or
     1.2 Patient has chronic hepatitis C and is co-infected with HIV; or
     1.3 Patient has chronic hepatitis C genotype 2 or 3 and has received a liver transplant; and
  2. Maximum of 48 weeks therapy.

- Notes:
  - Consider stopping treatment if there is absence of a virological response (defined as at least a 2-log reduction in viral load) following 12 weeks of treatment since this is predictive of treatment failure.
  - Consider reducing treatment to 24 weeks if serum HCV RNA level at Week 4 is undetectable by sensitive PCR assay (less

---

▲ Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once
Infections - Agents for Systemic Use

Subsidy

(Manufacturer’s Price)

$ Per

Fully

Subsidised ✔

Brand or

Generic

Manufacturer

continued...

than 50IU/ml) AND Baseline serum HCV RNA is less than 400,000IU/ml

Renewal — (Chronic hepatitis C - genotype 1 infection) only from a gastroenterologist, infectious disease specialist or general physician. Approvals valid for 18 months for applications meeting the following criteria:

All of the following:

1. Patient has chronic hepatitis C, genotype 1; and
2. Patient has had previous treatment with pegylated interferon and ribavirin; and
3. Either:
   3.1 Patient has responder relapsed; or
   3.2 Patient was a partial responder; and
4. Patient is to be treated in combination with boceprevir; and
5. Maximum of 48 weeks therapy.

Initial application — (Chronic Hepatitis C - genotype 1 infection treatment more than 4 years prior) only from a gastroenterologist, infectious disease specialist or general physician. Approvals valid for 18 months for applications meeting the following criteria:

All of the following:

1. Patient has chronic hepatitis C, genotype 1; and
2. Patient has had previous treatment with pegylated interferon and ribavirin; and
3. Any of the following:
   3.1 Patient has responder relapsed; or
   3.2 Patient was a partial responder; or
   3.3 Patient received interferon treatment prior to 2004; and
4. Patient is to be treated in combination with boceprevir; and
5. Maximum of 48 weeks therapy.

Initial application — (chronic hepatitis C - genotype 2 or 3 infection without co-infection with HIV) from any specialist. Approvals valid for 12 months for applications meeting the following criteria:

Both:

1. Patient has chronic hepatitis C, genotype 2 or 3 infection; and
2. Maximum of 6 months therapy.

Initial application — (Hepatitis B) only from a gastroenterologist, infectious disease specialist or general physician. Approvals valid for 18 months for applications meeting the following criteria:

All of the following:

1. Patient has confirmed Hepatitis B infection (HBsAg positive for more than 6 months); and
2. Patient is Hepatitis B treatment-naive; and
3. ALT > 2 times Upper Limit of Normal; and
4. HBV DNA < 10 log10 IU/ml; and
5. Either:
   5.1 HBeAg positive; or
   5.2 serum HBV DNA greater than or equal to 2,000 units/ml and significant fibrosis (Metavir Stage F2 or greater or moderate fibrosis); and
6. Compensated liver disease; and
7. No continuing alcohol abuse or intravenous drug use; and
8. Not co-infected with HCV, HIV or HDV; and
9. Neither ALT nor AST > 10 times upper limit of normal; and
10. No history of hypersensitivity or contraindications to pegylated interferon; and
11. Maximum of 48 weeks therapy.

Notes:

• Approved dose is 180 mcg once weekly.

continued…
continued…

- The recommended dose of Pegylated Interferon alfa-2a is 180 mcg once weekly.
- In patients with renal insufficiency (calculated creatinine clearance less than 50ml/min), Pegylated Interferon-alfa 2a dose should be reduced to 135 mcg once weekly.
- In patients with neutropaenia and thrombocytopaenia, dose should be reduced in accordance with the datasheet guidelines.
- Pegylated Interferon-alfa 2a is not approved for use in children.

### Urinary Tract Infections

**HEXAMINE HIPPURATE**

- Tab 1 g ................................................................. 18.40 100 Hiprex

**NITROFURANTOIN**

- Tab 50 mg ............................................................. 22.20 100 ✔ Nifuran
- Tab 100 mg ............................................................ 37.50 100 ✔ Nifuran

**NORFLOXACIN**

- Tab 400 mg – Subsidy by endorsement ....................... 135.00 100 ✔ Arrow-Norfloxacin

Only if prescribed for a patient with an uncomplicated urinary tract infection that is unresponsive to a first line agent or with proven resistance to first line agents and the prescription is endorsed accordingly.
### MUSCULOSKELETAL SYSTEM

<table>
<thead>
<tr>
<th>Subsidy (Manufacturer's Price)</th>
<th>Fully Subsidised</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Per</td>
<td>✔</td>
<td></td>
</tr>
</tbody>
</table>

#### Anticholinesterases

**NEOSTIGMINE METILSULFATE**

- Inj 2.5 mg per ml, 1 ml ampoule .................................................. 98.00 50 ✔ AstraZeneca

**PYRIDOSTIGMINE BROMIDE**

- ▲ Tab 60 mg ................................................. 42.79 100 ✔ Mestinon

#### Non-Steroidal Anti-Inflammatory Drugs

**DICLOFENAC SODIUM**

- Tab EC 25 mg .......................................................... 1.23 50 ✔ Diclofenac Sandoz
- Tab 50 mg dispersible .................................................... 1.50 20 ✔ Voltaren D
- Tab EC 50 mg .......................................................... 1.23 50 ✔ Diclofenac Sandoz
- Tab long-acting 75 mg .................................................... 22.80 500 ✔ Apo-Diclo SR
- Tab long-acting 100 mg .................................................... 25.15 500 ✔ Apo-Diclo SR
- Inj 25 mg per ml, 3 ml ampoule – Up to 5 inj available on a PSO ... 13.20 5 ✔ Voltaren
- Suppos 12.5 mg ......................................................... 2.04 10 ✔ Voltaren
- Suppos 25 mg ......................................................... 2.44 10 ✔ Voltaren
- Suppos 50 mg – Up to 10 supp available on a PSO ....................... 4.22 10 ✔ Voltaren
- Suppos 100 mg ......................................................... 7.00 10 ✔ Voltaren

**IBUPROFEN**

- Tab 200 mg .......................................................... 11.71 1,000 ✔ Relieve
- Tab long-acting 800 mg .................................................... 7.99 30 ✔ Brufen SR
- Oral liq 20 mg per ml ...................................................... 2.39 200 ml ✔ Fenpaed

**KETOPROFEN**

- Cap long-acting 200 mg .................................................... 12.07 28 ✔ Oruvail SR

**MEFENAMIC ACID**

- Cap 250 mg .......................................................... 1.25 50 Ponstan
- (9.16) 0.50 20 Ponstan
- (5.60)

**NAPROXEN**

- Tab 250 mg .......................................................... 32.69 500 ✔ Noflam 250
  - Noflam 250 to be Sole Supply on 1 January 2019
- Tab 500 mg .......................................................... 22.19 250 ✔ Noflam 500
  - Noflam 500 to be Sole Supply on 1 January 2019
- Tab long-acting 750 mg .................................................... 6.16 28 ✔ Naprosyn SR 750
- Tab long-acting 1 g ...................................................... 8.21 28 ✔ Naprosyn SR 1000

**SULINDAC**

- Tab 100 mg .......................................................... 8.55 50 ✔ Acclin
- Tab 200 mg .......................................................... 15.10 50 ✔ Acclin

**TENOXYCAM**

- Tab 20 mg .......................................................... 10.95 100 ✔ Tiilcotil
- Inj 20 mg vial .......................................................... 9.95 1 ✔ AFT

#### NSAIDs Other

**CELECOXIB**

- Cap 100 mg .......................................................... 3.63 60 ✔ Celecoxib Pfizer
- Cap 200 mg .......................................................... 2.30 30 ✔ Celecoxib Pfizer

---

**Fully subsidised
Sole Subsidised Supply**

Unapproved medicine supplied under Section 29

---

112
Topical Products for Joint and Muscular Pain

CAPSAICIN
Crm 0.025% – Special Authority see SA1289 below – Retail pharmacy ................................................................. 6.95 25 g OP ✔ Zostrix
........................................................................................ 9.95 45 g OP ✔ Zostrix

☞ SA1289 Special Authority for Subsidy
Initial application from any relevant practitioner. Approvals valid without further renewal unless notified where the patient has osteoarthritis that is not responsive to paracetamol and oral non-steroidal anti-inflammatories are contraindicated.

Antirheumatoid Agents

HYDROXYCHLOROQUINE
※ Tab 200 mg ................................................................. 7.98 100 ✔ Plaquenil

LEFLUNOMIDE
Tab 10 mg ................................................................. 2.90 30 ✔ Apo-Leflunomide
Tab 20 mg ................................................................. 2.90 30 ✔ Apo-Leflunomide

PENICILLAMINE
Tab 125 mg ................................................................. 67.23 100 ✔ D-Penamine
Tab 250 mg ................................................................. 110.12 100 ✔ D-Penamine

SODIUM AUROTHIOMALATE
Inj 10 mg in 0.5 ml ampoule ........................................ 76.87 10 ✔ Myocrisin
Inj 20 mg in 0.5 ml ampoule ........................................ 113.17 10 ✔ Myocrisin
Inj 50 mg in 0.5 ml ampoule ........................................ 217.23 10 ✔ Myocrisin

Drugs Affecting Bone Metabolism

Alendronate for Osteoporosis

☞ SA1039 Special Authority for Subsidy
Initial application — (Underlying cause - Osteoporosis) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Any of the following:

1. History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) greater than or equal to 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score less than or equal to -2.5) (see Note); or
2. History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or
3. History of two significant osteoporotic fractures demonstrated radiologically; or
4. Documented T-Score less than or equal to -3.0 (see Note); or
5. A 10-year risk of hip fracture greater than or equal to 3%, calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Note); or
6. Patient has had a Special Authority approval for zoledronic acid (Underlying cause - Osteoporosis) or raloxifene.

Initial application — (Underlying cause - glucocorticosteroid therapy) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

continued
continued…

1. The patient is receiving systemic glucocorticosteriod therapy (greater than or equal to 5 mg per day prednisone equivalents) and has already received or is expected to receive therapy for at least three months; and

2. Any of the following:
   2.1. The patient has documented BMD greater than or equal to 1.5 standard deviations below the mean normal value in young adults (i.e., T-Score less than or equal to -1.5) (see Note); or
   2.2. The patient has a history of one significant osteoporotic fracture demonstrated radiologically; or
   2.3. The patient has had a Special Authority approval for zoledronic acid (Underlying cause - glucocorticosteroid therapy) or raloxifene.

Renewal — (Underlying cause was, and remains, glucocorticosteroid therapy) from any relevant practitioner. Approvals valid for 1 year where the patient is continuing systemic glucocorticosteriod therapy (greater than or equal to 5 mg per day prednisone equivalents).

Renewal — (Underlying cause was glucocorticosteroid therapy but patient now meets the `Underlying cause - osteoporosis' criteria) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Any of the following:

1. History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) greater than or equal to 2.5 standard deviations below the mean normal value in young adults (i.e., T-Score less than or equal to -2.5) (see Note); or

2. History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or

3. History of two significant osteoporotic fractures demonstrated radiologically; or

4. Documented T-Score less than or equal to -3.0 (see Note); or

5. A 10-year risk of hip fracture greater than or equal to 3%, calculated using a published risk assessment algorithm (e.g., FRAX or Garvan) which incorporates BMD measurements (see Note); or

6. Patient has had a Special Authority approval for zoledronic acid (Underlying cause was glucocorticosteroid therapy but patient now meets the `Underlying cause - Osteoporosis' criteria) or raloxifene.

Notes:

a) BMD (including BMD used to derive T-Score) must be measured using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable.

b) Evidence suggests patients aged 75 years and over who have a history of significant osteoporotic fracture demonstrated radiologically are very likely to have a T-Score less than or equal to -2.5 and, therefore, do not require BMD measurement for treatment with bisphosphonates.

c) Osteoporotic fractures are the incident events for severe (established) osteoporosis, and can be defined using the WHO definitions of osteoporosis and fragility fracture. The WHO defines severe (established) osteoporosis as a T-score below -2.5 with one or more associated fragility fractures. Fragility fractures are fractures that occur as a result of mechanical forces that would not ordinarily cause fracture (minimal trauma). The WHO has quantified this as forces equivalent to a fall from a standing height or less.

d) In line with the Australian guidelines for funding alendronate, a vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

ALENDRONATE SODIUM – Special Authority see SA1039 on the previous page – Retail pharmacy

* Tab 70 mg ........................................................................................................... 4.82 4 ✔ Fosamax

ALENDRONATE SODIUM WITH COLECALCIFEROL – Special Authority see SA1039 on the previous page – Retail pharmacy

* Tab 70 mg with colecalciferol 5,600 iu ........................................... 4.82 4 ✔ Fosamax Plus
MUSCULOSKELETAL SYSTEM

Subsidy
(Manufacturer’s Price)

Fully
Subsidised ✓

Brand or
Generic
Manufacturer

Alendronate for Paget’s Disease

**SA0949** Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

1. Paget’s disease; and
2. Any of the following:
   - 2.1 Bone or articular pain;
   - 2.2 Bone deformity; or
   - 2.3 Bone, articular or neurological complications; or
   - 2.4 Asymptomatic disease, but risk of complications due to site (base of skull, spine, long bones of lower limbs); or
   - 2.5 Preparation for orthopaedic surgery.

Renewal from any relevant practitioner. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment.

ALENDRONATE SODIUM – Special Authority see SA0949 above – Retail pharmacy

* Tab 40 mg .......................................................................................133.00 30 ✓ Fosamax

(Fosamax Tab 40 mg to be delisted 1 May 2019)

Other Treatments

DENOSUMAB – Special Authority see SA1730 below – Retail pharmacy

Inj 60 mg prefilled syringe ................................................................326.00 1 ✓ Prolia

**SA1730** Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

All of the following:

1. The patient has severe, established osteoporosis; and
2. Either:
   - 2.1 The patient is female and postmenopausal; or
   - 2.2 The patient is male or non-binary; and
3. Any of the following:
   - 3.1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) greater than or equal to 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score less than or equal to -2.5) (see Note); or
   - 3.2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons; or
   - 3.3 History of two significant osteoporotic fractures demonstrated radiologically; or
   - 3.4 Documented T-Score less than or equal to -3.0 (see Note); or
   - 3.5 A 10-year risk of hip fracture greater than or equal to 3%, calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Note); or
   - 3.6 Patient has had a Special Authority approval for alendronate (Underlying cause - Osteoporosis) or raloxifene; and
4. Zoledronic acid is contraindicated because the patient’s creatinine clearance is less than 35 mL/min; and
5. The patient has experienced at least one symptomatic new fracture after at least 12 months’ continuous therapy with a funded antiresorptive agent at adequate doses (see Notes); and
6. The patient must not receive concomitant treatment with any other funded antiresorptive agent for this condition or teriparatide.

Notes:

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once
continued…

a) BMD (including BMD used to derive T-Score) must be measured using dual-energy x-ray absorptiometry (DXA).
Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable

b) Evidence suggests that patients aged 75 years and over who have a history of significant osteoporotic fracture demonstrated radiologically are very likely to have a T-Score less than or equal to -2.5 and, therefore, do not require BMD measurement for treatment with denosumab

c) Osteoporotic fractures are the incident events for severe (established) osteoporosis and can be defined using the WHO definitions of osteoporosis and fragility fracture. The WHO defines severe (established) osteoporosis as a T-score below -2.5 with one or more associated fragility fractures. Fragility fractures are fractures that occur as a result of mechanical forces that would not ordinarily cause fracture (minimal trauma). The WHO has quantified this as forces equivalent to a fall from a standing height or less

d) A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body

e) Antiresorptive agents and their adequate doses for the purposes of this Special Authority are defined as: risedronate sodium tab 35 mg once weekly; alendronate sodium tab 70 mg or tab 70 mg with cholecalciferol 5,600 iu once weekly; raloxifene hydrochloride tab 60 mg once daily. If an intolerance of a severity necessitating permanent treatment withdrawal develops during the use of one antiresorptive agent, an alternate antiresorptive agent must be trialled so that the patient achieves the minimum requirement of 12 months' continuous therapy

ETIDRONATE DISODIUM – See prescribing guideline below

- Tab 200 mg ............................................................... 13.50 100 ✔ Arrow-Etidronate

(Arrow-Etidronate Tab 200 mg to be delisted 1 January 2019)

Prescribing Guidelines

Etidronate for osteoporosis should be prescribed for 14 days (400 mg in the morning) and repeated every three months. It should not be taken at the same time of the day as any calcium supplementation (minimum dose – 500 mg per day of elemental calcium). Etidronate should be taken at least 2 hours before or after any food or fluid, except water.

PAMIDRONATE DISODIUM

- Inj 3 mg per ml, 10 ml vial................................. 5.98 1 ✔ Pamisol
- Inj 6 mg per ml, 10 ml vial................................. 15.02 1 ✔ Pamisol
- Inj 9 mg per ml, 10 ml vial................................. 17.05 1 ✔ Pamisol

RALOXIFENE HYDROCHLORIDE – Special Authority see SA1138 below – Retail pharmacy

- Tab 60 mg ............................................................... 53.76 28 ✔ Evista

SA1138 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Any of the following:

1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) greater than or equal to 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score less than or equal to -2.5) (see Notes); or

2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or

3 History of two significant osteoporotic fractures demonstrated radiologically; or

4 Documented T-Score less than or equal to -3.0 (see Notes); or

5 A 10-year risk of hip fracture greater than or equal to 3%, calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Notes); or

6 Patient has had a prior Special Authority approval for zoledronic acid (Underlying cause - Osteoporosis) or alendronate (Underlying cause - Osteoporosis).

continued…
MUSCULOSKELETAL SYSTEM

Subsidy
(Manufacturer's Price)
$ Per

Brand or
Generic
Manufacturer

✔

Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

Three months or six months, as applicable, dispensed all-at-once

Notes:

a) BMD (including BMD used to derive T-Score) must be measured using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable.

b) Evidence suggests that patients aged 75 years and over who have a history of significant osteoporotic fracture demonstrated radiologically are very likely to have a T-Score less than or equal to -2.5 and, therefore, do not require BMD measurement for raloxifene funding.

c) Osteoporotic fractures are the incident events for severe (established) osteoporosis, and can be defined using the WHO definitions of osteoporosis and fragility fracture. The WHO defines severe (established) osteoporosis as a T-score below -2.5 with one or more associated fragility fractures. Fragility fractures are fractures that occur as a result of mechanical forces that would not ordinarily cause fracture (minimal trauma). The WHO has quantified this as forces equivalent to a fall from a standing height or less.

d) A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

RISEDRONATE SODIUM
Tab 35 mg .................................................................................. 3.80 4 ✔ Risedronate Sandoz

TERIPARATIDE – Special Authority see SA1139 below – Retail pharmacy
Inj 250 mcg per ml, 2.4 ml .................................................. 490.00 1 ✔ Forteo

➽ SA1139 Special Authority for Subsidy
Initial application from any relevant practitioner. Approvals valid for 18 months for applications meeting the following criteria:

All of the following:

1. The patient has severe, established osteoporosis; and
2. The patient has a documented T-score less than or equal to -3.0 (see Notes); and
3. The patient has had two or more fractures due to minimal trauma; and
4. The patient has experienced at least one symptomatic new fracture after at least 12 months’ continuous therapy with a funded antiresorptive agent at adequate doses (see Notes).

Notes:

a) The bone mineral density (BMD) measurement used to derive the T-score must be made using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable.

b) Antiresorptive agents and their adequate doses for the purposes of this Special Authority are defined as: alendronate sodium tab 70 mg or tab 70 mg with colecalciferol 5,600 iu once weekly; raloxifene hydrochloride tab 60 mg once daily; zoledronic acid 5 mg per year. If an intolerance of a severity necessitating permanent treatment withdrawal develops during the use of one antiresorptive agent, an alternate antiresorptive agent must be trialled so that the patient achieves the minimum requirement of 12 months’ continuous therapy.

c) A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

d) A maximum of 18 months of treatment (18 cartridges) will be subsidised.

ZOLEDRONIC ACID
Inj 0.05 mg per ml, 100 ml, vial – Special Authority see SA1187 below – Retail pharmacy ........................................ 600.00 100 ml OP ✔ Aclasta

➽ SA1187 Special Authority for Subsidy
Initial application — (Paget’s disease) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

All of the following:

1. Paget’s disease; and

continued…
2 Any of the following:
   2.1 Bone or articular pain; or
   2.2 Bone deformity; or
   2.3 Bone, articular or neurological complications; or
   2.4 Asymptomatic disease, but risk of complications; or
   2.5 Preparation for orthopaedic surgery; and

3 The patient will not be prescribed more than 5 mg of zoledronic acid in the 12-month approval period.

Initial application — (Underlying cause - Osteoporosis) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

1 Any of the following:
   1.1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) greater than or equal to 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score less than or equal to -2.5) (see Note); or
   1.2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or
   1.3 History of two significant osteoporotic fractures demonstrated radiologically; or
   1.4 Documented T-Score less than or equal to -3.0 (see Note); or
   1.5 A 10-year risk of hip fracture greater than or equal to 3%, calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Note); or
   1.6 Patient has had a Special Authority approval for alendronate (Underlying cause - Osteoporosis) or raloxifene; and

2 The patient will not be prescribed more than 5 mg of zoledronic acid in the 12-month period.

Initial application — (Underlying cause - glucocorticosteroid therapy) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

All of the following:

1 The patient is receiving systemic glucocorticosteroid therapy (greater than or equal to 5 mg per day prednisone equivalents) and has already received or is expected to receive therapy for at least three months; and

2 Any of the following:
   2.1 The patient has documented BMD greater than or equal to 1.5 standard deviations below the mean normal value in young adults (i.e. T-Score less than or equal to -1.5) (see Note); or
   2.2 The patient has a history of one significant osteoporotic fracture demonstrated radiologically; or
   2.3 The patient has had a Special Authority approval for alendronate (Underlying cause - glucocorticosteroid therapy) or raloxifene; and

3 The patient will not be prescribed more than 5 mg of zoledronic acid in the 12-month approval period.

Renewal — (Paget's disease) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

1 Any of the following:
   1.1 The patient has relapsed (based on increases in serum alkaline phosphatase); or
   1.2 The patient's serum alkaline phosphatase has not normalised following previous treatment with zoledronic acid; or
   1.3 Symptomatic disease (prescriber determined); and

2 The patient will not be prescribed more than 5 mg of zoledronic acid in the 12-month approval period.

The patient must not have had more than 1 prior approval in the last 12 months.

Renewal — (Underlying cause was, and remains, glucocorticosteroid therapy) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

continued…
continued...

1. The patient is continuing systemic glucocorticosteroid therapy (greater than or equal to 5 mg per day prednisone equivalents); and

2. The patient will not be prescribed more than 5 mg of zoledronic acid in the 12-month approval period.

The patient must not have had more than 1 prior approval in the last 12 months.

Renewal — (Underlying cause was glucocorticosteroid therapy but patient now meets the 'Underlying cause - osteoporosis' criteria) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

1. Any of the following:
   1.1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) greater than or equal to 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score less than or equal to -2.5) (see Note); or
   1.2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or
   1.3 History of two significant osteoporotic fractures demonstrated radiologically; or
   1.4 Documented T-Score less than or equal to -3.0 (see Note); or
   1.5 A 10-year risk of hip fracture greater than or equal to 3%, calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Note); or
   1.6 Patient has had a Special Authority approval for alendronate (Underlying cause was glucocorticosteroid therapy but patient now meets the 'Underlying cause - Osteoporosis' criteria) or raloxifene; and

2. The patient will not be prescribed more than 5 mg of zoledronic acid in a 12-month period.

Notes:

a) BMD (including BMD used to derive T-Score) must be measured using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable.

b) Evidence suggests that patients aged 75 years and over who have a history of significant osteoporotic fracture demonstrated radiologically are very likely to have a T-Score less than or equal to -2.5 and, therefore, do not require BMD measurement for treatment with bisphosphonates.

c) Osteoporotic fractures are the incident events for severe (established) osteoporosis and can be defined using the WHO definitions of osteoporosis and fragility fracture. The WHO defines severe (established) osteoporosis as a T-score below -2.5 with one or more associated fragility fractures. Fragility fractures are fractures that occur as a result of mechanical forces that would not ordinarily cause fracture (minimal trauma). The WHO has quantified this as forces equivalent to a fall from a standing height or less.

d) A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

Hyperuricaemia and Antigout

<table>
<thead>
<tr>
<th>Hyperuricaemia and Antigout</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALLOPURINOL</td>
</tr>
<tr>
<td>✻ Tab 100 mg</td>
</tr>
<tr>
<td>✻ Tab 300 mg</td>
</tr>
<tr>
<td>BENZBROMARONE – Special Authority see SA1537 on the next page – Retail pharmacy</td>
</tr>
<tr>
<td>Tab 100 mg</td>
</tr>
</tbody>
</table>

Notes:

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

✴ Three months or six months, as applicable, dispensed all-at-once
**SA1537 Special Authority for Subsidy**

**Initial application** from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

1. Patient has been diagnosed with gout; and
2. Any of the following:
   2.1 The patient has a serum urate level greater than 0.36 mmol/l despite treatment with allopurinol at doses of at least 600 mg/day and addition of probenecid at doses of up to 2 g per day or maximum tolerated dose; or
   2.2 The patient has experienced intolerable side effects from allopurinol such that treatment discontinuation is required and serum urate remains greater than 0.36 mmol/l despite use of probenecid at doses of up to 2 g per day or maximum tolerated dose; or
   2.3 Both:
      2.3.1 The patient has renal impairment such that probenecid is contraindicated or likely to be ineffective and serum urate remains greater than 0.36 mmol/l despite optimal treatment with allopurinol (see Notes); and
      2.3.2 The patient has a rate of creatinine clearance greater than or equal to 20 ml/min; or
2.4 All of the following:
   2.4.1 The patient is taking azathioprine and requires urate-lowering therapy; and
   2.4.2 Allopurinol is contraindicated; and
   2.4.3 Appropriate doses of probenecid are ineffective or probenecid cannot be used due to reduced renal function; and
3. The patient is receiving monthly liver function tests.

**Renewal** from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Both:

1. The treatment remains appropriate and the patient is benefitting from the treatment; and
2. There is no evidence of liver toxicity and patient is continuing to receive regular (at least every three months) liver function tests.

Notes: Benzbromarone has been associated with potentially fatal hepatotoxicity.
In chronic renal insufficiency, particularly when the glomerular filtration rate is 30 ml/minute or less, probenecid may not be effective. Optimal treatment with allopurinol in patients with renal impairment is defined as treatment to the creatinine clearance-adjusted dose of allopurinol then, if serum urate remains greater than 0.36 mmol/l, a gradual increase of the dose of allopurinol to 600 mg or the maximum tolerated dose.
The New Zealand Rheumatology Association has developed information for prescribers which can be accessed from its website at [www.rheumatology.org.nz/home/resources-2/](http://www.rheumatology.org.nz/home/resources-2/)

**COLCHICINE**

* Tab 500 mcg.................................................................9.58 100 ✔ Colgout

Colgout to be Sole Supply on 1 February 2019

**FEBXOSTAT – Special Authority see SA1538 below – Retail pharmacy**

Tab 80 mg .................................................................39.50 28 ✔ Adenuric
Tab 120 mg ...............................................................39.50 28 ✔ Adenuric

**SA1538 Special Authority for Subsidy**

**Initial application** from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

1. Patient has been diagnosed with gout; and
2. Any of the following:
   2.1 The patient has a serum urate level greater than 0.36 mmol/l despite treatment with allopurinol at doses of at least 600 mg/day and addition of probenecid at doses of up to 2 g per day or maximum tolerated dose; or
   2.2 The patient has experienced intolerable side effects from allopurinol such that treatment discontinuation is required continued…
and serum urate remains greater than 0.36 mmol/l despite use of probenecid at doses of up to 2 g per day or maximum tolerated dose; or

2.3 The patient has renal impairment such that probenecid is contraindicated or likely to be ineffective and serum urate remains greater than 0.36 mmol/l despite optimal treatment with allopurinol (see Note).

Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

Note: In chronic renal insufficiency, particularly when the glomerular filtration rate is 30 ml/minute or less, probenecid may not be effective. The efficacy and safety of febuxostat have not been fully evaluated in patients with severe renal impairment (creatinine clearance less than 30 ml/minute). No dosage adjustment of febuxostat is necessary in patients with mild or moderate renal impairment. Optimal treatment with allopurinol in patients with renal impairment is defined as treatment to the creatinine clearance-adjusted dose of allopurinol then, if serum urate remains greater than 0.36 mmol/l, a gradual increase of the dose of allopurinol to 600 mg or the maximum tolerated dose.

PROBENECID

- Tab 500 mg ................................................................................. 55.00 100 ✔ Probenecid-AFT

Muscle Relaxants

BACLOFEN

- Tab 10 mg .................................................................................. 4.20 100 ✔ Pacifen
- Inj 0.05 mg per ml, 1 ml ampoule – Subsidy by endorsement........... 11.55 1 ✔ Lioresal Intrathecal
  Subsidised only for use in a programmable pump in patients where oral antispastic agents have been ineffective or have caused intolerable side effects and the prescription is endorsed accordingly.
- Inj 2 mg per ml, 5 ml ampoule – Subsidy by endorsement........... 209.29 1 ✔ Lioresal Intrathecal
  Subsidised only for use in a programmable pump in patients where oral antispastic agents have been ineffective or have caused intolerable side effects and the prescription is endorsed accordingly.

DANTROLENE

- Cap 25 mg .................................................................................. 65.00 100 ✔ Dantrium
- Cap 50 mg .................................................................................. 77.00 100 ✔ Dantrium S29

ORPHENADRINE CITRATE

- Tab 100 mg .................................................................................. 18.54 100 ✔ Norflex
### NERVOUS SYSTEM

<table>
<thead>
<tr>
<th>Subsidy (Manufacturer's Price)</th>
<th>Fully Subsidised</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Per $</td>
<td>✓</td>
<td></td>
</tr>
</tbody>
</table>

#### Agents for Parkinsonism and Related Disorders

##### Dopamine Agonists and Related Agents

**AMANTADINE HYDROCHLORIDE**
- Cap 100 mg ................................................................. 38.24  60  ✓ Symmetrel

**APOMORPHINE HYDROCHLORIDE**
- Inj 10 mg per ml, 2 ml ampoule ...................................... 119.00  5  ✓ Movapo

**BROMOCRIPTINE MESYLATE**
- Tab 2.5 mg ................................................................. 32.08  100  ✓ Apo-Bromocriptine

**ENTACAPONE**
- Tab 200 mg ..................................................................... 22.00  100  ✓ Entapone

**LEVODOPA WITH BENSERAZIDE**
- Tab dispersible 50 mg with benzerazide 12.5 mg ............... 13.25  100  ✓ Madopar Rapid
- Cap 50 mg with benzerazide 12.5 mg ................................ 13.75  100  ✓ Madopar 62.5
- Cap 100 mg with benzerazide 25 mg .................................. 15.80  100  ✓ Madopar 125
- Cap long-acting 100 mg with benzerazide 25 mg ............... 22.85  100  ✓ Madopar HBS
- Cap 200 mg with benzerazide 50 mg .................................. 26.25  100  ✓ Madopar 250

**LEVODOPA WITH CARBIDOPA**
- Tab 100 mg with carbidopa 25 mg ............................... 17.97  100  ✓ Kinson
- Tab long-acting 200 mg with carbidopa 50 mg ............... 37.15  100  ✓ Sinemet
- Tab 250 mg with carbidopa 25 mg ............................... 32.67  100  ✓ Sinemet

*(Kinson Tab 100 mg with carbidopa 25 mg to be delisted 1 June 2019)*

**PRAMIPEXOLE HYDROCHLORIDE**
- Tab 0.25 mg ................................................................. 7.20  100  ✓ Ramipex
- Tab 1 mg ......................................................................... 24.39  100  ✓ Ramipex

**ROPINIROLE HYDROCHLORIDE**
- Tab 0.25 mg ................................................................. 2.78  100  ✓ Apo-Ropinirole
- Tab 1 mg ......................................................................... 5.00  100  ✓ Apo-Ropinirole
- Tab 2 mg ......................................................................... 7.72  100  ✓ Apo-Ropinirole
- Tab 5 mg ......................................................................... 16.51  100  ✓ Apo-Ropinirole

**SELEGILINE HYDROCHLORIDE**
- Tab 5 mg ......................................................................... 22.00  100  ✓ Apo-Selegiline

**TOLCAPONE**
- Tab 100 mg ................................................................. 132.50  100  ✓ Tasmor

##### Anticholinergics

**BENZATROPINE MESYLATE**
- Tab 2 mg ......................................................................... 7.99  60  ✓ Benztrop
- Inj 1 mg per ml, 2 ml ...................................................... 95.00  10  ✓ Cogentin

  a) Up to 10 inj available on a PSO
  b) Only on a PSO

**PROCYCLIDINE HYDROCHLORIDE**
- Tab 5 mg ......................................................................... 7.40  100  ✓ Kemadrin
Agents for Essential Tremor, Chorea and Related Disorders

RILUZOLE – Special Authority see SA1403 below – Retail pharmacy
Wastage claimable
Tab 50 mg ................................................................. 130.00 56 ✓ Rilutek

♫ SA1403 Special Authority for Subsidy
Initial application only from a neurologist or respiratory specialist. Approvals valid for 6 months for applications meeting the following criteria:
All of the following:
1. The patient has amyotrophic lateral sclerosis with disease duration of 5 years or less; and
2. The patient has at least 60 percent of predicted forced vital capacity within 2 months prior to the initial application; and
3. The patient has not undergone a tracheostomy; and
4. The patient has not experienced respiratory failure; and
5. Any of the following:
   5.1. The patient is ambulatory; or
   5.2. The patient is able to use upper limbs; or
   5.3. The patient is able to swallow.

Renewal from any relevant practitioner. Approvals valid for 18 months for applications meeting the following criteria:
All of the following:
1. The patient has not undergone a tracheostomy; and
2. The patient has not experienced respiratory failure; and
3. Any of the following:
   3.1. The patient is ambulatory; or
   3.2. The patient is able to use upper limbs; or
   3.3. The patient is able to swallow.

TETRABENAZINE
Tab 25 mg ................................................................. 91.10 112 ✓ Motetis

Anaesthetics

Local

LIDOCAINE [LIGNOCAINE]
Gel 2%, tube – Subsidy by endorsement................................. 14.50 30 ml ✓ Xylocaine 2% Jelly
   a) Up to 150 ml available on a PSO
   b) Subsidised only if prescribed for urethral or cervical administration and the prescription is endorsed accordingly.

Gel 2%, 10 ml urethral syringe – Subsidy by endorsement........... 81.50 10 ✓ Pfizer
  160.00 25 ✓ Cathejell
   a) Up to 5 each available on a PSO
   b) Subsidised only if prescribed for urethral or cervical administration and the prescription is endorsed accordingly.

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.
★ Three months or six months, as applicable, dispensed all-at-once
### Nervous System

<table>
<thead>
<tr>
<th>Subsidy (Manufacturer's Price) $</th>
<th>Fully Subsidised</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Per</td>
<td></td>
</tr>
</tbody>
</table>

#### Lidocaine [LignoCAINE] Hydrochloride

<table>
<thead>
<tr>
<th>Description</th>
<th>Price</th>
<th>Quantity</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral (gel) soln 2%</td>
<td>38.00</td>
<td>200 ml</td>
<td>✔ Mucosothe</td>
</tr>
<tr>
<td>Inj 1%, 5 ml ampoule – Up to 25 inj available on a PSO</td>
<td>8.75</td>
<td>25</td>
<td>✔ Lidocaine-Claris</td>
</tr>
<tr>
<td></td>
<td>17.50</td>
<td>50</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(35.00)</td>
<td></td>
<td>Xylocaine</td>
</tr>
<tr>
<td>Inj 2%, 5 ml ampoule – Up to 5 inj available on a PSO</td>
<td>6.75</td>
<td>25</td>
<td>✔ Lidocaine-Claris</td>
</tr>
<tr>
<td>Inj 1%, 20 ml ampoule – Up to 5 inj available on a PSO</td>
<td>2.40</td>
<td>1</td>
<td>✔ Lidocaine-Claris</td>
</tr>
<tr>
<td></td>
<td>12.00</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(20.00)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 1%, 20 ml vial – Up to 5 inj available on a PSO</td>
<td>12.00</td>
<td>5</td>
<td>✔ Lidocaine-Claris</td>
</tr>
<tr>
<td>Inj 2%, 20 ml ampoule – Up to 5 inj available on a PSO</td>
<td>2.40</td>
<td>1</td>
<td>✔ Lidocaine-Claris</td>
</tr>
<tr>
<td>Inj 2%, 20 ml vial – Up to 5 inj available on a PSO</td>
<td>12.00</td>
<td>5</td>
<td>✔ Lidocaine-Claris</td>
</tr>
</tbody>
</table>

*(Lidocaine-Claris Inj 1%, 20 ml ampoule to be delisted 1 February 2019)*

*(Lidocaine-Claris Inj 2%, 20 ml ampoule to be delisted 1 February 2019)*

#### Lidocaine [LignoCAINE] with Chlorhexidine

<table>
<thead>
<tr>
<th>Description</th>
<th>Price</th>
<th>Quantity</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gel 2% with chlorhexidine 0.05%, 10 ml urethral syringes – Subsidy by endorsement</td>
<td>81.50</td>
<td>10</td>
<td>✔ Pfizer</td>
</tr>
<tr>
<td>a) Up to 5 each available on a PSO</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>b) Subsidised only if prescribed for urethral or cervical administration and the prescription is endorsed accordingly.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Topical Local Anaesthetics

**SA0906** Special Authority for Subsidy

- Initial application from any relevant practitioner. Approvals valid for 2 years where the patient is a child with a chronic medical condition requiring frequent injections or venepuncture.
- Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

#### Lidocaine [LignoCAINE] – Special Authority see SA0906 above – Retail pharmacy

<table>
<thead>
<tr>
<th>Description</th>
<th>Price</th>
<th>Quantity</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Crm 4%</td>
<td>5.40</td>
<td>5 g OP</td>
<td>✔ LMX4</td>
</tr>
<tr>
<td></td>
<td>27.00</td>
<td>30 g OP</td>
<td>✔ LMX4</td>
</tr>
</tbody>
</table>

#### Lidocaine [LignoCAINE] with Prilocaine – Special Authority see SA0906 above – Retail pharmacy

<table>
<thead>
<tr>
<th>Description</th>
<th>Price</th>
<th>Quantity</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Crm 2.5% with prilocaine 2.5%</td>
<td>45.00</td>
<td>30 g OP</td>
<td>✔ EMLA</td>
</tr>
<tr>
<td>Crm 2.5% with prilocaine 2.5% (5 g tubes)</td>
<td>45.00</td>
<td>5</td>
<td>✔ EMLA</td>
</tr>
</tbody>
</table>

#### Analgesics

For Anti-inflammatory NSAIDS refer to MUSCULOSKELETAL, page 112

#### Non-opioid Analgesics

For aspirin & chloroform application refer Standard Formulae, page 215

**Aspirin**

- Tab dispersible 300 mg – Up to 30 tab available on a PSO.................. 3.90 100 ✔ Ethics Aspirin

**Capsaicin** – Subsidy by endorsement

Subsidised only if prescribed for post-herpetic neuralgia or diabetic peripheral neuropathy and the prescription is endorsed accordingly.

Crm 0.075%................................................................. 12.50 45 g OP ✔ Zostrix HP

**Neofopam Hydrochloride**

- Tab 30 mg .............................................................. 23.40 90 ✔ Acupan
### NERVOUS SYSTEM

**Subsidy (Manufacturer's Price)**

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Fully Subsidised</th>
<th>Subsidy Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>Priceline</td>
<td>✔</td>
<td>$7.12</td>
</tr>
<tr>
<td>Pharmacare</td>
<td>✔</td>
<td>$0.71</td>
</tr>
</tbody>
</table>

**PARACETAMOL**

- Tab 500 mg - blister pack
  - Maximum of 300 tab per prescription; can be waived by endorsement
  - Up to 30 tab available on a PSO
  - Subsidy by endorsement for higher quantities is available for patients with long term conditions who require regular daily dosing for one month or greater who do not use compliance packaging, and the prescription is annotated accordingly. Pharmacists may annotate the prescription as endorsed where dispensing history supports a long-term condition.
  - Maximum of 100 tab per dispensing for non-endorsed patients. If quantities prescribed for more than 100 tabs (for non-endorsed patients), then dispense in repeat dispensings not exceeding 100 tab per dispensing.

- Tab 500 mg - bottle pack
  - Maximum of 100 tab per dispensing
  - Not in combination

- Oral liq 120 mg per 5 ml
  - Up to 200 ml available on a PSO
  - Not in combination

- Oral liq 250 mg per 5 ml
  - Up to 100 ml available on a PSO
  - Not in combination

- Suppos 125 mg
  - Maximum of 300 tab per prescription; can be waived by endorsement

- Suppos 250 mg
  - Maximum of 300 tab per prescription; can be waived by endorsement

- Suppos 500 mg
  - Maximum of 300 tab per prescription; can be waived by endorsement

#### Opioid Analgesics

**CODEINE PHOSPHATE** – Safety medicine; prescriber may determine dispensing frequency

- Tab 15 mg
  - Maximum of 300 tab per prescription; can be waived by endorsement

- Tab 30 mg
  - Maximum of 300 tab per prescription; can be waived by endorsement

- Tab 60 mg
  - Maximum of 300 tab per prescription; can be waived by endorsement

**DIHYDROCODEINE TARTRATE**

- Tab long-acting 60 mg
  - Maximum of 300 tab per prescription; can be waived by endorsement

**FENTANYL**

- Inj 50 mcg per ml, 2 ml ampoule
  - Only on a controlled drug form

- Inj 50 mcg per ml, 10 ml ampoule
  - Only on a controlled drug form

- Patch 12.5 mcg per hour
  - Only on a controlled drug form

- Patch 25 mcg per hour
  - Only on a controlled drug form

- Patch 50 mcg per hour
  - Only on a controlled drug form

- Patch 75 mcg per hour
  - Only on a controlled drug form

- Patch 100 mcg per hour
  - Only on a controlled drug form

*Three months of six months, as applicable, dispensed all-at-once

▲ Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber or pharmacist.
NERVOUS SYSTEM

METHADONE HYDROCHLORIDE

a) Only on a controlled drug form
b) No patient co-payment payable
c) Safety medicine; prescriber may determine dispensing frequency
d) Extemporaneously compounded methadone will only be reimbursed at the rate of the cheapest form available (methadone powder, not methadone tablets).
e) For methadone hydrochloride oral liquid refer Standard Formulae, page 215

<table>
<thead>
<tr>
<th>Product</th>
<th>Manufacturer's Price $</th>
<th>Fully Subsidised Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 5 mg</td>
<td>1.85</td>
<td>✔ Methatabs</td>
</tr>
<tr>
<td>Oral liq 2 mg per ml</td>
<td>5.79</td>
<td>✔ Biodone</td>
</tr>
<tr>
<td>Oral liq 5 mg per ml</td>
<td>5.79</td>
<td>✔ Biodone Forte</td>
</tr>
<tr>
<td>Oral liq 10 mg per ml</td>
<td>6.79</td>
<td>✔ Biodone Extra Forte</td>
</tr>
<tr>
<td>Inj 10 mg per ml, 1 ml</td>
<td>61.00</td>
<td>✔ AFT</td>
</tr>
</tbody>
</table>

MORPHINE HYDROCHLORIDE

a) Only on a controlled drug form
b) No patient co-payment payable
c) Safety medicine; prescriber may determine dispensing frequency

<table>
<thead>
<tr>
<th>Product</th>
<th>Manufacturer's Price $</th>
<th>Fully Subsidised Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral liq 1 mg per ml</td>
<td>9.28</td>
<td>✔ RA-Morph</td>
</tr>
<tr>
<td>RA-Morph to be Sole Supply on 1 January 2019</td>
<td>1.62</td>
<td>✔ RA-Morph</td>
</tr>
<tr>
<td>Oral liq 5 mg per ml</td>
<td>19.44</td>
<td>✔ RA-Morph</td>
</tr>
<tr>
<td>RA-Morph to be Sole Supply on 1 January 2019</td>
<td>27.74</td>
<td>✔ RA-Morph</td>
</tr>
</tbody>
</table>

MORPHINE SULPHATE

a) Only on a controlled drug form
b) No patient co-payment payable
c) Safety medicine; prescriber may determine dispensing frequency

<table>
<thead>
<tr>
<th>Product</th>
<th>Manufacturer's Price $</th>
<th>Fully Subsidised Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab immediate-release 10 mg</td>
<td>2.80</td>
<td>✔ Sevredol</td>
</tr>
<tr>
<td>Tab long-acting 10 mg</td>
<td>1.93</td>
<td>✔ Arrow-Morphine LA</td>
</tr>
<tr>
<td>Tab immediate-release 20 mg</td>
<td>5.52</td>
<td>✔ Sevredol</td>
</tr>
<tr>
<td>Tab long-acting 30 mg</td>
<td>2.85</td>
<td>✔ Arrow-Morphine LA</td>
</tr>
<tr>
<td>Tab long-acting 60 mg</td>
<td>5.60</td>
<td>✔ Arrow-Morphine LA</td>
</tr>
<tr>
<td>Tab long-acting 100 mg</td>
<td>6.10</td>
<td>✔ Arrow-Morphine LA</td>
</tr>
<tr>
<td>Cap long-acting 10 mg</td>
<td>1.70</td>
<td>✔ m-Eslon</td>
</tr>
<tr>
<td>Cap long-acting 30 mg</td>
<td>2.50</td>
<td>✔ m-Eslon</td>
</tr>
<tr>
<td>Cap long-acting 60 mg</td>
<td>5.40</td>
<td>✔ m-Eslon</td>
</tr>
<tr>
<td>Cap long-acting 100 mg</td>
<td>6.38</td>
<td>✔ m-Eslon</td>
</tr>
<tr>
<td>Inj 5 mg per ml, 1 ml ampoule – Up to 5 inj available on a PSO</td>
<td>6.27</td>
<td>✔ DBL Morphine Sulphate</td>
</tr>
<tr>
<td>Inj 10 mg per ml, 1 ml ampoule – Up to 5 inj available on a PSO</td>
<td>4.47</td>
<td>✔ DBL Morphine Sulphate</td>
</tr>
<tr>
<td>Inj 15 mg per ml, 1 ml ampoule – Up to 5 inj available on a PSO</td>
<td>4.76</td>
<td>✔ DBL Morphine Sulphate</td>
</tr>
<tr>
<td>Inj 30 mg per ml, 1 ml ampoule – Up to 5 inj available on a PSO</td>
<td>6.19</td>
<td>✔ DBL Morphine Sulphate</td>
</tr>
</tbody>
</table>
**NERVOUS SYSTEM**

**MORPHINE TARTRATE**
- a) Only on a controlled drug form
- b) No patient co-payment payable
- c) Safety medicine; prescriber may determine dispensing frequency

<table>
<thead>
<tr>
<th>Item Description</th>
<th>Manufacturer's Price</th>
<th>Fully Subsidised</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 80 mg per ml, 1.5 ml ampoule</td>
<td>42.72</td>
<td>✔ DBL Morphine Tartrate</td>
</tr>
</tbody>
</table>

**OXYCODOONE HYDROCHLORIDE**
- a) Only on a controlled drug form
- b) No patient co-payment payable
- c) Safety medicine; prescriber may determine dispensing frequency

<table>
<thead>
<tr>
<th>Item Description</th>
<th>Manufacturer's Price</th>
<th>Fully Subsidised</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab controlled-release 5 mg</td>
<td>2.63</td>
<td>✔ BNM</td>
</tr>
<tr>
<td>Tab controlled-release 10 mg</td>
<td>2.76</td>
<td>✔ BNM</td>
</tr>
<tr>
<td>Tab controlled-release 20 mg</td>
<td>4.72</td>
<td>✔ BNM</td>
</tr>
<tr>
<td>Tab controlled-release 40 mg</td>
<td>7.69</td>
<td>✔ BNM</td>
</tr>
<tr>
<td>Tab controlled-release 80 mg</td>
<td>14.11</td>
<td>✔ BNM</td>
</tr>
<tr>
<td>Cap immediate-release 5 mg</td>
<td>1.88</td>
<td>✔ OxyNorm</td>
</tr>
<tr>
<td>Cap immediate-release 10 mg</td>
<td>3.32</td>
<td>✔ OxyNorm</td>
</tr>
<tr>
<td>Cap immediate-release 20 mg</td>
<td>5.81</td>
<td>✔ OxyNorm</td>
</tr>
<tr>
<td>Oral liq 5 mg per 5 ml</td>
<td>11.20</td>
<td>✔ OxyNorm</td>
</tr>
<tr>
<td>Inj 10 mg per ml, 1 ml ampoule</td>
<td>7.28</td>
<td>✔ OxyNorm</td>
</tr>
<tr>
<td>Inj 10 mg per ml, 2 ml ampoule</td>
<td>14.36</td>
<td>✔ OxyNorm</td>
</tr>
<tr>
<td>Inj 50 mg per ml, 1 ml ampoule</td>
<td>30.60</td>
<td>✔ OxyNorm</td>
</tr>
</tbody>
</table>

**PARACETAMOL WITH CODEINE** – Safety medicine; prescriber may determine dispensing frequency
- * Tab paracetamol 500 mg with codeine phosphate 8 mg.....18.21

**PETHIDINE HYDROCHLORIDE**
- a) Only on a controlled drug form
- b) No patient co-payment payable
- c) Safety medicine; prescriber may determine dispensing frequency

<table>
<thead>
<tr>
<th>Item Description</th>
<th>Manufacturer's Price</th>
<th>Fully Subsidised</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 50 mg</td>
<td>4.46</td>
<td>✔ PSM</td>
</tr>
<tr>
<td>Inj 50 mg per ml, 1 ml ampoule – Up to 5 inj available on a PSO</td>
<td>4.98</td>
<td>✔ DBL Pethidine Hydrochloride</td>
</tr>
<tr>
<td>Inj 50 mg per ml, 2 ml ampoule – Up to 5 inj available on a PSO</td>
<td>5.12</td>
<td>✔ DBL Pethidine Hydrochloride</td>
</tr>
</tbody>
</table>

**TRAMADOL HYDROCHLORIDE**

<table>
<thead>
<tr>
<th>Item Description</th>
<th>Manufacturer's Price</th>
<th>Fully Subsidised</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab sustained-release 100 mg</td>
<td>1.55</td>
<td>✔ Tramal SR 100</td>
</tr>
<tr>
<td>Tab sustained-release 150 mg</td>
<td>2.10</td>
<td>✔ Tramal SR 150</td>
</tr>
<tr>
<td>Tab sustained-release 200 mg</td>
<td>2.75</td>
<td>✔ Tramal SR 200</td>
</tr>
<tr>
<td>Cap 50 mg</td>
<td>2.25</td>
<td>✔ Arrow-Tramadol</td>
</tr>
</tbody>
</table>

**Antidepressants**

**Cyclic and Related Agents**

**AMITRIPTYLINE** – Safety medicine; prescriber may determine dispensing frequency

<table>
<thead>
<tr>
<th>Item Description</th>
<th>Manufacturer's Price</th>
<th>Fully Subsidised</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 10 mg</td>
<td>1.96</td>
<td>✔ Arrow-Amitriptyline</td>
</tr>
<tr>
<td>Tab 25 mg</td>
<td>1.52</td>
<td>✔ Arrow-Amitriptyline</td>
</tr>
<tr>
<td>Tab 50 mg</td>
<td>2.51</td>
<td>✔ Arrow-Amitriptyline</td>
</tr>
</tbody>
</table>

**CLOMIPRAMINE HYDROCHLORIDE** – Safety medicine; prescriber may determine dispensing frequency

<table>
<thead>
<tr>
<th>Item Description</th>
<th>Manufacturer's Price</th>
<th>Fully Subsidised</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 10 mg</td>
<td>13.99</td>
<td>✔ Apo-Clomipramine</td>
</tr>
<tr>
<td>Tab 25 mg</td>
<td>9.46</td>
<td>✔ Apo-Clomipramine</td>
</tr>
</tbody>
</table>

▲Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber or pharmacist.

※Three months or six months, as applicable, dispensed all-at-once
### NERVOUS SYSTEM

<table>
<thead>
<tr>
<th>Subsidy (Manufacturer’s Price)</th>
<th>Fully Subsidised</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>DOSULEPIN [DOTHIEPIN] HYDROCHLORIDE – Safety medicine; prescriber may determine dispensing frequency</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 75 mg</td>
<td>11.19</td>
<td>100 ✔</td>
</tr>
<tr>
<td>Cap 25 mg</td>
<td>6.45</td>
<td>100 ✔</td>
</tr>
<tr>
<td>DOXEPIN HYDROCHLORIDE – Safety medicine; prescriber may determine dispensing frequency</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cap 10 mg</td>
<td>6.30</td>
<td>100 ✔</td>
</tr>
<tr>
<td>Cap 25 mg</td>
<td>6.86</td>
<td>100 ✔</td>
</tr>
<tr>
<td>Cap 50 mg</td>
<td>8.55</td>
<td>100 ✔</td>
</tr>
<tr>
<td>IMIPRAMINE HYDROCHLORIDE – Safety medicine; prescriber may determine dispensing frequency</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 10 mg</td>
<td>5.48</td>
<td>50 ✔</td>
</tr>
<tr>
<td></td>
<td>6.58</td>
<td>60 ✔</td>
</tr>
<tr>
<td></td>
<td>10.96</td>
<td>100 ✔</td>
</tr>
<tr>
<td>Tab 25 mg</td>
<td>8.80</td>
<td>50 ✔</td>
</tr>
<tr>
<td>(Tofranil s29 Tab 10 mg to be delisted 1 February 2019)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MAPROTILINE HYDROCHLORIDE – Safety medicine; prescriber may determine dispensing frequency</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 25 mg</td>
<td>7.52</td>
<td>30 ✔</td>
</tr>
<tr>
<td></td>
<td>12.53</td>
<td>50 ✔</td>
</tr>
<tr>
<td></td>
<td>25.06</td>
<td>100 ✔</td>
</tr>
<tr>
<td>Tab 75 mg</td>
<td>14.01</td>
<td>20 ✔</td>
</tr>
<tr>
<td></td>
<td>21.01</td>
<td>30 ✔</td>
</tr>
<tr>
<td>NORTRIPTYLINE HYDROCHLORIDE – Safety medicine; prescriber may determine dispensing frequency</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 10 mg</td>
<td>3.22</td>
<td>100 ✔</td>
</tr>
<tr>
<td>Tab 25 mg</td>
<td>7.08</td>
<td>180 ✔</td>
</tr>
</tbody>
</table>

### Monoamine-Oxidase Inhibitors (MAOIs) - Non Selective

<table>
<thead>
<tr>
<th>Subsidy (Manufacturer’s Price)</th>
<th>Fully Subsidised</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>PHENELZINE SULPHATE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>★ Tab 15 mg</td>
<td>95.00</td>
<td>100 ✔</td>
</tr>
<tr>
<td>TRANYLCYPROMINE SULPHATE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>★ Tab 10 mg</td>
<td>22.94</td>
<td>50 ✔</td>
</tr>
</tbody>
</table>

### Monoamine-Oxidase Type A Inhibitors

<table>
<thead>
<tr>
<th>Subsidy (Manufacturer’s Price)</th>
<th>Fully Subsidised</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>MOCLOBEMIDE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>★ Tab 150 mg</td>
<td>85.10</td>
<td>500 ✔</td>
</tr>
<tr>
<td>★ Tab 300 mg</td>
<td>30.70</td>
<td>100 ✔</td>
</tr>
</tbody>
</table>

### Selective Serotonin Reuptake Inhibitors

<table>
<thead>
<tr>
<th>Subsidy (Manufacturer’s Price)</th>
<th>Fully Subsidised</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>CITALOPRAM HYDROBROMIDE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>★ Tab 20 mg</td>
<td>1.52</td>
<td>84 ✔</td>
</tr>
<tr>
<td>ESCITALOPRAM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>★ Tab 10 mg</td>
<td>1.11</td>
<td>28 ✔</td>
</tr>
<tr>
<td>★ Tab 20 mg</td>
<td>1.90</td>
<td>28 ✔</td>
</tr>
<tr>
<td>Subsidy (Manufacturer’s Price) $</td>
<td>Fully Subsidised Per</td>
<td>Brand or Generic Manufacturer</td>
</tr>
<tr>
<td>--------------------------------</td>
<td>----------------------</td>
<td>-----------------------------</td>
</tr>
<tr>
<td>FLUOXETINE HYDROCHLORIDE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>✴ Tab dispersible 20 mg, scored – Subsidy by endorsement................. 2.47</td>
<td>30</td>
<td>✓ Arrow-Fluoxetine</td>
</tr>
<tr>
<td></td>
<td>Subsidised by endorsement</td>
<td></td>
</tr>
<tr>
<td>1) When prescribed for a patient who cannot swallow whole tablets or capsules and the prescription is endorsed accordingly; or</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2) When prescribed in a daily dose that is not a multiple of 20 mg in which case the prescription is deemed to be endorsed. Note: Tablets should be combined with capsules to facilitate incremental 10 mg doses.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>✴ Cap 20 mg................................................................. 1.99</td>
<td>90</td>
<td>✓ Arrow-Fluoxetine</td>
</tr>
<tr>
<td>PAROXETINE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>✴ Tab 20 mg................................................................. 4.02</td>
<td>90</td>
<td>✓ Apo-Paroxetine</td>
</tr>
<tr>
<td>SERTRALINE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>✴ Tab 50 mg................................................................. 3.05</td>
<td>90</td>
<td>✓ Arrow-Sertraline</td>
</tr>
<tr>
<td>✴ Tab 100 mg............................................................... 5.25</td>
<td>90</td>
<td>✓ Arrow-Sertraline</td>
</tr>
<tr>
<td>Other Antidepressants</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MIRTAZAPINE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 30 mg................................................................. 2.63</td>
<td>30</td>
<td>✓ Apo-Mirtazapine</td>
</tr>
<tr>
<td>Tab 45 mg................................................................. 3.48</td>
<td>30</td>
<td>✓ Apo-Mirtazapine</td>
</tr>
<tr>
<td>VENLAFAXINE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>✴ Cap 37.5 mg............................................................. 6.38</td>
<td>84</td>
<td>✓ Enlafax XR</td>
</tr>
<tr>
<td>✴ Cap 75 mg................................................................. 8.11</td>
<td>84</td>
<td>✓ Enlafax XR</td>
</tr>
<tr>
<td>✴ Cap 150 mg..........................11.16</td>
<td>84</td>
<td>✓ Enlafax XR</td>
</tr>
<tr>
<td>Antiepilepsy Drugs</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Agents for Control of Status Epilepticus</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CLONAZEPAM – Safety medicine; prescriber may determine dispensing frequency</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 1 mg per ml, 1 ml..........................................................21.00</td>
<td>5</td>
<td>✓ Rivotril</td>
</tr>
<tr>
<td>DIAZEPAM – Safety medicine; prescriber may determine dispensing frequency</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 5 mg per ml, 2 ml ampoule – Subsidy by endorsement................. 11.83</td>
<td>5</td>
<td>✓ Hospira</td>
</tr>
<tr>
<td>a) Up to 5 inj available on a PSO</td>
<td></td>
<td></td>
</tr>
<tr>
<td>b) Only on a PSO</td>
<td></td>
<td></td>
</tr>
<tr>
<td>c) PSO must be endorsed “not for anaesthetic procedures”</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rectal tubes 5 mg – Up to 5 tube available on a PSO................. 40.87</td>
<td>5</td>
<td>✓ Stesolid</td>
</tr>
<tr>
<td>Rectal tubes 10 mg – Up to 5 tube available on a PSO................. 40.87</td>
<td>5</td>
<td>✓ Stesolid</td>
</tr>
<tr>
<td>PARALDEHYDE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>✴ Inj 5 ml...............................................................1,500.00</td>
<td>5</td>
<td>✓ AFT S29</td>
</tr>
<tr>
<td>PHENYTOIN SODIUM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>✴ Inj 50 mg per ml, 2 ml ampoule – Up to 5 inj available on a PSO..... 88.63</td>
<td>5</td>
<td>✓ Hospira</td>
</tr>
<tr>
<td>✴ Inj 50 mg per ml, 5 ml ampoule – Up to 5 inj available on a PSO..... 133.92</td>
<td>5</td>
<td>✓ Hospira</td>
</tr>
</tbody>
</table>

▲Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber or pharmacist.

✴Three months or six months, as applicable, dispensed all-at-once
Control of Epilepsy

<table>
<thead>
<tr>
<th>Product</th>
<th>Formulation</th>
<th>Manufacturer</th>
<th>Price Per Unit</th>
<th>Quantity</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>CARBAMAZEPINE</td>
<td>Tab 200 mg</td>
<td>Tegretol</td>
<td>14.53</td>
<td>100</td>
<td>✔</td>
</tr>
<tr>
<td></td>
<td>Tab long-acting 200 mg</td>
<td>Tegretol CR</td>
<td>16.98</td>
<td>100</td>
<td>✔</td>
</tr>
<tr>
<td></td>
<td>Tab 400 mg</td>
<td>Tegretol</td>
<td>34.58</td>
<td>100</td>
<td>✔</td>
</tr>
<tr>
<td></td>
<td>Tab long-acting 400 mg</td>
<td>Tegretol CR</td>
<td>39.17</td>
<td>100</td>
<td>✔</td>
</tr>
<tr>
<td></td>
<td>Oral liq 20 mg per ml</td>
<td>Tegretol</td>
<td>26.37</td>
<td>250 ml</td>
<td>✔</td>
</tr>
<tr>
<td>CLOBAZAM</td>
<td>Tab 10 mg</td>
<td>Frisium</td>
<td>9.12</td>
<td>50</td>
<td>✔</td>
</tr>
<tr>
<td>CLONAZEPAM</td>
<td>Oral drops 2.5 mg per ml</td>
<td>Rivotril</td>
<td>7.38</td>
<td>10 ml OP</td>
<td>✔</td>
</tr>
<tr>
<td>ETHOSUXIMIDE</td>
<td>Cap 250 mg</td>
<td>Zarontin</td>
<td>281.75</td>
<td>200</td>
<td>✔</td>
</tr>
<tr>
<td></td>
<td>Oral liq 250 mg per 5 ml</td>
<td>Zarontin</td>
<td>56.35</td>
<td>200 ml</td>
<td>✔</td>
</tr>
<tr>
<td>GABAPENTIN</td>
<td>Cap 100 mg</td>
<td>Apo-Gabapentin</td>
<td>2.65</td>
<td>100</td>
<td>✔</td>
</tr>
<tr>
<td></td>
<td>Cap 300 mg</td>
<td>Apo-Gabapentin</td>
<td>4.07</td>
<td>100</td>
<td>✔</td>
</tr>
<tr>
<td></td>
<td>Cap 400 mg</td>
<td>Apo-Gabapentin</td>
<td>5.64</td>
<td>100</td>
<td>✔</td>
</tr>
<tr>
<td>LACOSAMIDE</td>
<td>Tab 50 mg</td>
<td>Vimpat</td>
<td>25.04</td>
<td>14</td>
<td>✔</td>
</tr>
<tr>
<td></td>
<td>Tab 100 mg</td>
<td>Vimpat</td>
<td>50.06</td>
<td>14</td>
<td>✔</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>200.24</td>
<td>56</td>
<td>✔</td>
</tr>
<tr>
<td></td>
<td>Tab 150 mg</td>
<td>Vimpat</td>
<td>75.10</td>
<td>14</td>
<td>✔</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>300.40</td>
<td>56</td>
<td>✔</td>
</tr>
<tr>
<td></td>
<td>Tab 200 mg</td>
<td>Vimpat</td>
<td>400.55</td>
<td>56</td>
<td>✔</td>
</tr>
</tbody>
</table>

**SA1125 Special Authority for Subsidy**

Initial application from any relevant practitioner. Approvals valid for 15 months for applications meeting the following criteria:

Both:

1. Patient has partial-onset epilepsy; and
2. Seizures are not adequately controlled by, or patient has experienced unacceptable side effects from, optimal treatment with all of the following: sodium valproate, topiramate, levetiracetam and any two of carbamazepine, lamotrigine and phenytoin sodium (see Note).

Note: "Optimal treatment" is defined as treatment which is indicated and clinically appropriate for the patient, given in adequate doses for the patient's age, weight and other features affecting the pharmacokinetics of the drug with good evidence of compliance. Women of childbearing age are not required to have a trial of sodium valproate.

Renewal from any relevant practitioner. Approvals valid for 24 months where the patient has demonstrated a significant and sustained improvement in seizure rate or severity and/or quality of life compared with that prior to starting lacosamide treatment (see Note).

Note: As a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success with anticonvulsant therapy and have assessed quality of life from the patient's perspective.
### NERVOUS SYSTEM

#### LAMOTRIGINE

<table>
<thead>
<tr>
<th>Description</th>
<th>Subsidy (Manufacturer’s Price)</th>
<th>Fully Subsidised Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>▲ Tab dispersible 2 mg</td>
<td>6.74</td>
<td>30</td>
<td>Lamictal</td>
</tr>
<tr>
<td>▲ Tab dispersible 5 mg</td>
<td>9.64</td>
<td>30</td>
<td>Lamictal</td>
</tr>
<tr>
<td></td>
<td>15.00</td>
<td>56</td>
<td>Arrow-Lamotrigine</td>
</tr>
<tr>
<td>▲ Tab dispersible 25 mg</td>
<td>19.38</td>
<td>56</td>
<td>Logem</td>
</tr>
<tr>
<td></td>
<td>20.40</td>
<td></td>
<td>Arrow-Lamotrigine</td>
</tr>
<tr>
<td></td>
<td>29.09</td>
<td></td>
<td>Lamictal</td>
</tr>
<tr>
<td>▲ Tab dispersible 50 mg</td>
<td>32.97</td>
<td>56</td>
<td>Logem</td>
</tr>
<tr>
<td></td>
<td>34.70</td>
<td></td>
<td>Arrow-Lamotrigine</td>
</tr>
<tr>
<td></td>
<td>47.89</td>
<td></td>
<td>Lamictal</td>
</tr>
<tr>
<td>▲ Tab dispersible 100 mg</td>
<td>56.91</td>
<td>56</td>
<td>Logem</td>
</tr>
<tr>
<td></td>
<td>59.90</td>
<td></td>
<td>Arrow-Lamotrigine</td>
</tr>
<tr>
<td></td>
<td>79.16</td>
<td></td>
<td>Lamictal</td>
</tr>
</tbody>
</table>

#### LEVETIRACETAM

<table>
<thead>
<tr>
<th>Description</th>
<th>Subsidy (Manufacturer’s Price)</th>
<th>Fully Subsidised Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 250 mg</td>
<td>24.03</td>
<td>60</td>
<td>Everet</td>
</tr>
<tr>
<td>Tab 500 mg</td>
<td>28.71</td>
<td>60</td>
<td>Everet</td>
</tr>
<tr>
<td>Tab 750 mg</td>
<td>45.23</td>
<td>60</td>
<td>Everet</td>
</tr>
<tr>
<td>Tab 1,000 mg</td>
<td>59.12</td>
<td>60</td>
<td>Everet</td>
</tr>
<tr>
<td>Oral liq 100 mg per ml</td>
<td>44.78</td>
<td>300 ml OP</td>
<td>Levetiracetam-AFT</td>
</tr>
</tbody>
</table>

#### PHENOBARBITONE

For phenobarbitone oral liquid refer Standard Formulae, page 215

<table>
<thead>
<tr>
<th>Description</th>
<th>Subsidy (Manufacturer’s Price)</th>
<th>Fully Subsidised Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>★ Tab 15 mg</td>
<td>40.00</td>
<td>500</td>
<td>PSM</td>
</tr>
<tr>
<td>★ Tab 30 mg</td>
<td>40.00</td>
<td>500</td>
<td>PSM</td>
</tr>
</tbody>
</table>

#### PHENYTOIN SODIUM

<table>
<thead>
<tr>
<th>Description</th>
<th>Subsidy (Manufacturer’s Price)</th>
<th>Fully Subsidised Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>★ Tab 50 mg</td>
<td>50.51</td>
<td>200</td>
<td>Dilantin Infatab</td>
</tr>
<tr>
<td>Cap 30 mg</td>
<td>22.00</td>
<td>200</td>
<td>Dilantin</td>
</tr>
<tr>
<td>Cap 100 mg</td>
<td>19.79</td>
<td>200</td>
<td>Dilantin</td>
</tr>
<tr>
<td>Oral liq 30 mg per 5 ml</td>
<td>22.03</td>
<td>500 ml</td>
<td>Dilantin</td>
</tr>
</tbody>
</table>

#### PREGABALIN

Note: Not subsidised in combination with subsidised gabapentin

<table>
<thead>
<tr>
<th>Description</th>
<th>Subsidy (Manufacturer’s Price)</th>
<th>Fully Subsidised Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>★ Cap 25 mg</td>
<td>2.25</td>
<td>56</td>
<td>Pregabalin Pfizer</td>
</tr>
<tr>
<td>★ Cap 75 mg</td>
<td>2.65</td>
<td>56</td>
<td>Pregabalin Pfizer</td>
</tr>
<tr>
<td>★ Cap 150 mg</td>
<td>4.01</td>
<td>56</td>
<td>Pregabalin Pfizer</td>
</tr>
<tr>
<td>★ Cap 300 mg</td>
<td>7.38</td>
<td>56</td>
<td>Pregabalin Pfizer</td>
</tr>
</tbody>
</table>

#### PRIMIDONE

<table>
<thead>
<tr>
<th>Description</th>
<th>Subsidy (Manufacturer’s Price)</th>
<th>Fully Subsidised Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>★ Tab 250 mg</td>
<td>17.25</td>
<td>100</td>
<td>Apo-Primidone</td>
</tr>
<tr>
<td></td>
<td>62.00</td>
<td>200</td>
<td>Mysoline S29</td>
</tr>
</tbody>
</table>

#### SODIUM VALPROATE

<table>
<thead>
<tr>
<th>Description</th>
<th>Subsidy (Manufacturer’s Price)</th>
<th>Fully Subsidised Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 100 mg</td>
<td>13.65</td>
<td>100</td>
<td>Epilim Crushable</td>
</tr>
<tr>
<td>Tab 200 mg EC</td>
<td>27.44</td>
<td>100</td>
<td>Epilim</td>
</tr>
<tr>
<td>Tab 500 mg EC</td>
<td>52.24</td>
<td>100</td>
<td>Epilim</td>
</tr>
<tr>
<td>★ Oral liq 200 mg per 5 ml</td>
<td>20.48</td>
<td>300 ml</td>
<td>Epilim S/F Liquid</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Epilim Syrup</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Description</th>
<th>Subsidy (Manufacturer’s Price)</th>
<th>Fully Subsidised Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>★ Inj 100 mg per ml, 4 ml</td>
<td>41.50</td>
<td>1</td>
<td>Epilim IV</td>
</tr>
</tbody>
</table>

#### STIRIPENTOL – Special Authority see SA1330 on the next page – Retail pharmacy

<table>
<thead>
<tr>
<th>Description</th>
<th>Subsidy (Manufacturer’s Price)</th>
<th>Fully Subsidised Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cap 250 mg</td>
<td>509.29</td>
<td>60</td>
<td>Diacomit S29</td>
</tr>
<tr>
<td>Powder for oral liq 250 mg sachet</td>
<td>509.29</td>
<td>60</td>
<td>Diacomit S29</td>
</tr>
</tbody>
</table>

▲ Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber or pharmacist.

★ Three months or six months, as applicable, dispensed all-at-once
**SA1330** Special Authority for Subsidy

**Initial application** only from a paediatric neurologist or Practitioner on the recommendation of a paediatric neurologist.
Approved for 6 months for applications meeting the following criteria:

Both:

1. Patient has confirmed diagnosis of Dravet syndrome; and
2. Seizures have been inadequately controlled by appropriate courses of sodium valproate, clobazam and at least two of the following: topiramate, levetiracetam, ketogenic diet.

**Renewal** from any relevant practitioner. Approvals valid without further renewal unless notified where the patient continues to benefit from treatment as measured by reduced seizure frequency from baseline.

**TOPIRAMATE**

<table>
<thead>
<tr>
<th>Dose</th>
<th>Price</th>
<th>Per</th>
<th>Subsidised</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 25 mg</td>
<td>11.07</td>
<td>60</td>
<td>✔ Arrow-Topiramate, Topiramate Actavis, Topamax</td>
</tr>
<tr>
<td>Tab 50 mg</td>
<td>18.81</td>
<td>60</td>
<td>✔ Arrow-Topiramate, Topiramate Actavis, Topamax</td>
</tr>
<tr>
<td>Tab 100 mg</td>
<td>31.99</td>
<td>60</td>
<td>✔ Arrow-Topiramate, Topiramate Actavis, Topamax</td>
</tr>
<tr>
<td>Tab 200 mg</td>
<td>55.19</td>
<td>60</td>
<td>✔ Arrow-Topiramate, Topiramate Actavis, Topamax</td>
</tr>
<tr>
<td>Sprinkle cap 15 mg</td>
<td>20.84</td>
<td>60</td>
<td>✔ Topamax</td>
</tr>
<tr>
<td>Sprinkle cap 25 mg</td>
<td>26.04</td>
<td>60</td>
<td>✔ Topamax</td>
</tr>
</tbody>
</table>

**VIGABATRIN** – Special Authority see **SA1072** below – Retail pharmacy

<table>
<thead>
<tr>
<th>Dose</th>
<th>Price</th>
<th>Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 500 mg</td>
<td>119.30</td>
<td>100</td>
</tr>
</tbody>
</table>

**SA1072** Special Authority for Subsidy

**Initial application** from any relevant practitioner. Approvals valid for 15 months for applications meeting the following criteria:

Both:

1. Either:
   1.1 Patient has infantile spasms; or
   1.2 Both:
      1.2.1 Patient has epilepsy; and
      1.2.2 Either:
         1.2.2.1 Seizures are not adequately controlled with optimal treatment with other antiepilepsy agents; or
         1.2.2.2 Seizures are controlled adequately but the patient has experienced unacceptable side effects from optimal treatment with other antiepilepsy agents; and
2. Either:
   2.1 Patient is, or will be, receiving regular automated visual field testing (ideally before starting therapy and on a 6-monthly basis thereafter); or
   2.2 It is impractical or impossible (due to comorbid conditions) to monitor the patient's visual fields.

Notes: **"Optimal treatment with other antiepilepsy agents"** is defined as treatment with other antiepilepsy agents which are indicated and clinically appropriate for the patient, given in adequate doses for the patient's age, weight, and other features affecting the pharmacokinetics of the drug with good evidence of compliance.

Vigabatrin is associated with a risk of irreversible visual field defects, which may be asymptomatic in the early stages.

**Renewal** from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

continued…
NERVOUS SYSTEM

![Subsidy](Manufacturer’s Price) $ Fully Brand or Generic Subsidised Per Manufacturer

continued...

Both:

1. The patient has demonstrated a significant and sustained improvement in seizure rate or severity and or quality of life; and
2. Either:
   2.1 Patient is receiving regular automated visual field testing (ideally every 6 months) on an ongoing basis for duration of treatment with vigabatrin; or
   2.2 It is impractical or impossible (due to comorbid conditions) to monitor the patient's visual fields.

Notes: As a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success with anticonvulsant therapy and have assessed quality of life from the patient's perspective.

Vigabatrin is associated with a risk of irreversible visual field defects, which may be asymptomatic in the early stages.

### Antimigraine Preparations

For Anti-inflammatory NSAIDS refer to MUSCULOSKELETAL, page 112

#### Acute Migraine Treatment

<table>
<thead>
<tr>
<th>Product Name</th>
<th>Description</th>
<th>Price</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>ERGOTAMINE TARTRATE WITH CAFFEINE</td>
<td>Tab 1 mg with caffeine 100 mg</td>
<td>31.00</td>
<td>100</td>
</tr>
<tr>
<td>RIZATRIPTAN</td>
<td>Tab orodispersible 10 mg</td>
<td>5.26</td>
<td>30</td>
</tr>
<tr>
<td>SUMATRIPTAN</td>
<td>Tab 50 mg</td>
<td>24.44</td>
<td>100</td>
</tr>
<tr>
<td></td>
<td>Tab 100 mg</td>
<td>46.23</td>
<td>100</td>
</tr>
<tr>
<td>Inj 12 mg per ml, 0.5 ml prefilled pen</td>
<td>Maximum of 10 inj per prescription</td>
<td>42.67</td>
<td>2 OP</td>
</tr>
</tbody>
</table>

#### Prophylaxis of Migraine

For Beta Adrenoceptor Blockers refer to CARDIOVASCULAR SYSTEM, page 50

<table>
<thead>
<tr>
<th>Product Name</th>
<th>Description</th>
<th>Price</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>PIZOTIFEN</td>
<td>Tab 500 mcg</td>
<td>23.21</td>
<td>100</td>
</tr>
</tbody>
</table>

#### Antinausea and Vertigo Agents

For Antispasmodics refer to ALIMENTARY TRACT, page 8

APREPITANT – Special Authority see SA0987 below – Retail pharmacy

Cap 2 x 80 mg and 1 x 125 mg………………………………………84.00 3 OP ✔ Emend Tri-Pack

**SA0987** Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 12 months where the patient is undergoing highly emetogenic chemotherapy and/or anthracycline-based chemotherapy for the treatment of malignancy.

Renewal from any relevant practitioner. Approvals valid for 12 months where the patient is undergoing highly emetogenic chemotherapy and/or anthracycline-based chemotherapy for the treatment of malignancy.

BETAHISTINE DIHYDROCHLORIDE

* Tab 16 mg……………………………………………………2.89 84 ✔ Vergo 16
## NERVOUS SYSTEM

<table>
<thead>
<tr>
<th>Subsidy (Manufacturer's Price) $</th>
<th>Fully Subsidised</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>CYCLIZINE HYDROCHLORIDE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 50 mg</td>
<td>0.55</td>
<td>✔ Nausicalm</td>
</tr>
<tr>
<td></td>
<td>0.59</td>
<td>✔ Nauzene</td>
</tr>
<tr>
<td><em>(Nause Tab 50 mg to be delisted 1 April 2019)</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CYCLIZINE LACTATE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 50 mg per ml, 1 ml</td>
<td>14.95</td>
<td>✔ Nausicalm</td>
</tr>
<tr>
<td>DOMPERIDONE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 10 mg</td>
<td>3.20</td>
<td>✔ Prokinex</td>
</tr>
<tr>
<td>HYOSCINE HYDROBROMIDE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 400 mcg per ml, 1 ml ampoule</td>
<td>46.50</td>
<td>✔ Hospira</td>
</tr>
<tr>
<td>Patch 1.5 mg – Special Authority see SA1387 below – Retail pharmacy</td>
<td>11.95</td>
<td>✔ Scopoderm TTS</td>
</tr>
<tr>
<td></td>
<td>93.00</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>❇ SA1387 Special Authority for Subsidy</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Initial application</strong> from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria: Either:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 Control of intractable nausea, vomiting, or inability to swallow saliva in the treatment of malignancy or chronic disease where the patient cannot tolerate or does not adequately respond to oral anti-nausea agents; or</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2 Control of clozapine-induced hypersalivation where trials of at least two other alternative treatments have proven ineffective.</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Renewal</strong> from any relevant practitioner. Approvals valid for 1 year where the treatment remains appropriate and the patient is benefiting from treatment.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>METOCLOPRAMIDE HYDROCHLORIDE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 10 mg</td>
<td>1.30</td>
<td>✔ Metoclopramide</td>
</tr>
<tr>
<td>❇ Tab 5 mg per ml, 2 ml ampoule – Up to 5 inj available on a PSO</td>
<td>4.50</td>
<td>✔ Pfizer</td>
</tr>
<tr>
<td>ONDANSETRON</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 4 mg</td>
<td>3.36</td>
<td>✔ Apo-Ondansetron</td>
</tr>
<tr>
<td>Tab disp 4 mg</td>
<td>0.95</td>
<td>✔ Ondansetron</td>
</tr>
<tr>
<td>❇ Tab 8 mg</td>
<td>4.77</td>
<td>✔ Apo-Ondansetron</td>
</tr>
<tr>
<td>Tab disp 8 mg</td>
<td>1.43</td>
<td>✔ Ondansetron</td>
</tr>
<tr>
<td></td>
<td>100</td>
<td></td>
</tr>
<tr>
<td>PROCHLORPERAZINE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 3 mg buccal</td>
<td>5.97</td>
<td></td>
</tr>
<tr>
<td>❇ Tab 5 mg – Up to 30 tab available on a PSO</td>
<td>6.35</td>
<td>✔ Nausafix</td>
</tr>
<tr>
<td>❇ Inj 12.5 mg per ml, 1 ml – Up to 5 inj available on a PSO</td>
<td>25.81</td>
<td>✔ Stemetil</td>
</tr>
<tr>
<td>PROMETHAZINE THEOCLATE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 25 mg</td>
<td>1.20</td>
<td></td>
</tr>
<tr>
<td>❇ Tab 25 mg – Up to 30 tab available on a PSO</td>
<td>1.20</td>
<td></td>
</tr>
<tr>
<td><em>(Avomine Tab 25 mg to be delisted 1 March 2019)</em></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
## Antipsychotics

### General

**AMISULPRIDE** – Safety medicine; prescriber may determine dispensing frequency

<table>
<thead>
<tr>
<th>Strength</th>
<th>Subsidy (Manufacturer’s Price) $</th>
<th>Fully Subsidised</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 100 mg</td>
<td>4.56</td>
<td>✔ Sulprix</td>
<td></td>
</tr>
<tr>
<td>Tab 200 mg</td>
<td>14.75</td>
<td>✔ Sulprix</td>
<td></td>
</tr>
<tr>
<td>Tab 400 mg</td>
<td>27.70</td>
<td>✔ Sulprix</td>
<td></td>
</tr>
<tr>
<td>Oral liq 100 mg per ml</td>
<td>65.53</td>
<td>✔ Solian</td>
<td></td>
</tr>
</tbody>
</table>

**ARIPIPRAZOLE**

a) Brand switch fee payable (Pharmacode 2556634) - see page 213 for details

b) Safety medicine; prescriber may determine dispensing frequency

<table>
<thead>
<tr>
<th>Strength</th>
<th>Subsidy (Manufacturer’s Price) $</th>
<th>Fully Subsidised</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 5 mg</td>
<td>17.50</td>
<td>✔ Aripiprazole Sandoz</td>
<td></td>
</tr>
<tr>
<td>Tab 10 mg</td>
<td>17.50</td>
<td>✔ Aripiprazole Sandoz</td>
<td></td>
</tr>
<tr>
<td>Tab 15 mg</td>
<td>17.50</td>
<td>✔ Aripiprazole Sandoz</td>
<td></td>
</tr>
<tr>
<td>Tab 20 mg</td>
<td>17.50</td>
<td>✔ Aripiprazole Sandoz</td>
<td></td>
</tr>
<tr>
<td>Tab 30 mg</td>
<td>17.50</td>
<td>✔ Aripiprazole Sandoz</td>
<td></td>
</tr>
</tbody>
</table>

**CHLORPROMAZINE HYDROCHLORIDE** – Safety medicine; prescriber may determine dispensing frequency

<table>
<thead>
<tr>
<th>Strength</th>
<th>Subsidy (Manufacturer’s Price) $</th>
<th>Fully Subsidised</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 10 mg – Up to 30 tab available on a PSO</td>
<td>12.36</td>
<td>✔ Largactil</td>
<td></td>
</tr>
<tr>
<td>Tab 25 mg – Up to 30 tab available on a PSO</td>
<td>13.02</td>
<td>✔ Largactil</td>
<td></td>
</tr>
<tr>
<td>Tab 100 mg – Up to 30 tab available on a PSO</td>
<td>30.61</td>
<td>✔ Largactil</td>
<td></td>
</tr>
<tr>
<td>Inj 25 mg per ml, 2 ml – Up to 5 inj available on a PSO</td>
<td>25.66</td>
<td>✔ Largactil</td>
<td></td>
</tr>
</tbody>
</table>

**CLOZAPINE** – Hospital pharmacy [HP4]

Safety medicine; prescriber may determine dispensing frequency

<table>
<thead>
<tr>
<th>Strength</th>
<th>Subsidy (Manufacturer’s Price) $</th>
<th>Fully Subsidised</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 25 mg</td>
<td>5.69</td>
<td>✔ Clozaril</td>
<td></td>
</tr>
<tr>
<td></td>
<td>6.69</td>
<td>✔ Clopate</td>
<td></td>
</tr>
<tr>
<td></td>
<td>11.36</td>
<td>✔ Clozaril</td>
<td></td>
</tr>
<tr>
<td></td>
<td>13.37</td>
<td>✔ Clopate</td>
<td></td>
</tr>
<tr>
<td>Tab 50 mg</td>
<td>8.67</td>
<td>✔ Clopate</td>
<td></td>
</tr>
<tr>
<td></td>
<td>17.33</td>
<td>✔ Clopate</td>
<td></td>
</tr>
<tr>
<td>Tab 100 mg</td>
<td>14.73</td>
<td>✔ Clozaril</td>
<td></td>
</tr>
<tr>
<td></td>
<td>17.33</td>
<td>✔ Clopate</td>
<td></td>
</tr>
<tr>
<td></td>
<td>29.45</td>
<td>✔ Clozaril</td>
<td></td>
</tr>
<tr>
<td></td>
<td>34.65</td>
<td>✔ Clopate</td>
<td></td>
</tr>
<tr>
<td>Tab 200 mg</td>
<td>34.65</td>
<td>✔ Clopate</td>
<td></td>
</tr>
<tr>
<td></td>
<td>69.30</td>
<td>✔ Clopate</td>
<td></td>
</tr>
<tr>
<td>Suspension 50 mg per ml</td>
<td>17.33</td>
<td>✔ Clopate</td>
<td></td>
</tr>
</tbody>
</table>

**HALOPERIDOL** – Safety medicine; prescriber may determine dispensing frequency

<table>
<thead>
<tr>
<th>Strength</th>
<th>Subsidy (Manufacturer’s Price) $</th>
<th>Fully Subsidised</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 500 mcg – Up to 30 tab available on a PSO</td>
<td>6.23</td>
<td>✔ Serenate</td>
<td></td>
</tr>
<tr>
<td>Tab 1.5 mg – Up to 30 tab available on a PSO</td>
<td>9.43</td>
<td>✔ Serenate</td>
<td></td>
</tr>
<tr>
<td>Tab 5 mg – Up to 30 tab available on a PSO</td>
<td>29.72</td>
<td>✔ Serenate</td>
<td></td>
</tr>
<tr>
<td>Oral liq 2 mg per ml – Up to 200 ml available on a PSO</td>
<td>23.84</td>
<td>✔ Serenate</td>
<td></td>
</tr>
<tr>
<td>Inj 5 mg per ml, 1 ml ampoule – Up to 5 inj available on a PSO</td>
<td>21.55</td>
<td>✔ Serenate</td>
<td></td>
</tr>
</tbody>
</table>

**LEVOMEPROMAZINE HYDROCHLORIDE** – Safety medicine; prescriber may determine dispensing frequency

<table>
<thead>
<tr>
<th>Strength</th>
<th>Subsidy (Manufacturer’s Price) $</th>
<th>Fully Subsidised</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 25 mg per ml, 1 ml ampoule</td>
<td>47.89</td>
<td>✔ Wockhardt</td>
<td></td>
</tr>
</tbody>
</table>

**LEVOMEPROMAZINE MALEATE** – Safety medicine; prescriber may determine dispensing frequency

<table>
<thead>
<tr>
<th>Strength</th>
<th>Subsidy (Manufacturer’s Price) $</th>
<th>Fully Subsidised</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 25 mg</td>
<td>16.93</td>
<td>✔ Nozinan</td>
<td></td>
</tr>
<tr>
<td>Tab 100 mg</td>
<td>43.96</td>
<td>✔ Nozinan</td>
<td></td>
</tr>
</tbody>
</table>

▲Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once
### NERVOUS SYSTEM

<table>
<thead>
<tr>
<th>Subsidy (Manufacturer's Price) $</th>
<th>Fully Subsidised</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Per</td>
<td></td>
</tr>
</tbody>
</table>

#### LITHIUM CARBONATE – Safety medicine; prescriber may determine dispensing frequency

<table>
<thead>
<tr>
<th>Strength</th>
<th>Price</th>
<th>Availability</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 250 mg</td>
<td>34.30</td>
<td>✔ Lithicarb FC</td>
</tr>
<tr>
<td>Tab 400 mg</td>
<td>12.83</td>
<td>✔ Lithicarb FC</td>
</tr>
<tr>
<td>Tab long-acting 400 mg</td>
<td>19.20</td>
<td>✔ Priadel</td>
</tr>
<tr>
<td>Cap 250 mg</td>
<td>9.42</td>
<td>✔ Douglas</td>
</tr>
</tbody>
</table>

*(Lithicarb FC Tab 400 mg to be delisted 1 March 2019)*

#### OLANZAPINE – Safety medicine; prescriber may determine dispensing frequency

<table>
<thead>
<tr>
<th>Strength</th>
<th>Price</th>
<th>Availability</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 2.5 mg</td>
<td>0.64</td>
<td>✔ Zypine</td>
</tr>
<tr>
<td>Tab 5 mg</td>
<td>1.15</td>
<td>✔ Zypine</td>
</tr>
<tr>
<td>Tab orodispersible 5 mg</td>
<td>1.25</td>
<td>✔ Zypine ODT</td>
</tr>
<tr>
<td>Tab 10 mg</td>
<td>1.65</td>
<td>✔ Zypine</td>
</tr>
<tr>
<td>Tab orodispersible 10 mg</td>
<td>2.05</td>
<td>✔ Zypine ODT</td>
</tr>
</tbody>
</table>

#### PERICYAZINE – Safety medicine; prescriber may determine dispensing frequency

<table>
<thead>
<tr>
<th>Strength</th>
<th>Price</th>
<th>Availability</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 2.5 mg</td>
<td>10.49</td>
<td>✔ Neulactil</td>
</tr>
<tr>
<td>Tab 10 mg</td>
<td>12.49</td>
<td>✔ Neulactil</td>
</tr>
<tr>
<td></td>
<td>37.34</td>
<td>✔ Neulactil</td>
</tr>
<tr>
<td></td>
<td>44.45</td>
<td>✔ Neulactil</td>
</tr>
</tbody>
</table>

#### QUETIAPINE – Safety medicine; prescriber may determine dispensing frequency

<table>
<thead>
<tr>
<th>Strength</th>
<th>Price</th>
<th>Availability</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 25 mg</td>
<td>1.79</td>
<td>✔ Quetapel</td>
</tr>
<tr>
<td>Tab 100 mg</td>
<td>3.45</td>
<td>✔ Quetapel</td>
</tr>
<tr>
<td>Tab 200 mg</td>
<td>5.75</td>
<td>✔ Quetapel</td>
</tr>
<tr>
<td>Tab 300 mg</td>
<td>9.60</td>
<td>✔ Quetapel</td>
</tr>
</tbody>
</table>

#### RISPERIDONE – Safety medicine; prescriber may determine dispensing frequency

<table>
<thead>
<tr>
<th>Strength</th>
<th>Price</th>
<th>Availability</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 0.5 mg</td>
<td>1.86</td>
<td>✔ Actavis</td>
</tr>
<tr>
<td>Tab 1 mg</td>
<td>2.06</td>
<td>✔ Actavis</td>
</tr>
<tr>
<td>Tab 2 mg</td>
<td>2.29</td>
<td>✔ Actavis</td>
</tr>
<tr>
<td>Tab 3 mg</td>
<td>2.50</td>
<td>✔ Actavis</td>
</tr>
<tr>
<td>Tab 4 mg</td>
<td>3.43</td>
<td>✔ Actavis</td>
</tr>
<tr>
<td>Oral liq 1 mg per ml</td>
<td>7.66</td>
<td>✔ Risperon</td>
</tr>
</tbody>
</table>

#### ZIPRASIDONE – Safety medicine; prescriber may determine dispensing frequency

<table>
<thead>
<tr>
<th>Strength</th>
<th>Price</th>
<th>Availability</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cap 20 mg</td>
<td>14.50</td>
<td>✔ Zusdone</td>
</tr>
<tr>
<td></td>
<td>14.56</td>
<td>✔ Zeldox</td>
</tr>
</tbody>
</table>

*Zusdone to be Sole Supply on 1 March 2019*

<table>
<thead>
<tr>
<th>Strength</th>
<th>Price</th>
<th>Availability</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cap 40 mg</td>
<td>24.70</td>
<td>✔ Zusdone</td>
</tr>
<tr>
<td>Cap 60 mg</td>
<td>33.80</td>
<td>✔ Zusdone</td>
</tr>
<tr>
<td>Cap 80 mg</td>
<td>39.70</td>
<td>✔ Zusdone</td>
</tr>
</tbody>
</table>

*(Zeldox Cap 20 mg to be delisted 1 March 2019)*

#### ZUCLOPENTHIXOL HYDROCHLORIDE – Safety medicine; prescriber may determine dispensing frequency

<table>
<thead>
<tr>
<th>Strength</th>
<th>Price</th>
<th>Availability</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 10 mg</td>
<td>31.45</td>
<td>✔ Clopixol</td>
</tr>
</tbody>
</table>

#### Depot Injections

<table>
<thead>
<tr>
<th>Strength</th>
<th>Price</th>
<th>Availability</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 20 mg per ml, 1 ml – Up to 5 inj available on a PSO</td>
<td>13.14</td>
<td>✔ Fluanxol</td>
</tr>
<tr>
<td>Inj 20 mg per ml, 2 ml – Up to 5 inj available on a PSO</td>
<td>20.90</td>
<td>✔ Fluanxol</td>
</tr>
<tr>
<td>Inj 100 mg per ml, 1 ml – Up to 5 inj available on a PSO</td>
<td>40.87</td>
<td>✔ Fluanxol</td>
</tr>
</tbody>
</table>

#### HALOPERIDOL DECANOATE – Safety medicine; prescriber may determine dispensing frequency

<table>
<thead>
<tr>
<th>Strength</th>
<th>Price</th>
<th>Availability</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 50 mg per ml, 1 ml – Up to 5 inj available on a PSO</td>
<td>28.39</td>
<td>✔ Haldol</td>
</tr>
<tr>
<td>Inj 100 mg per ml, 1 ml – Up to 5 inj available on a PSO</td>
<td>55.90</td>
<td>✔ Haldol Concentrate</td>
</tr>
<tr>
<td></td>
<td></td>
<td>✔ Haldol</td>
</tr>
</tbody>
</table>

*Decanoas 529*
NERVOUS SYSTEM

OLANZAPINE – Special Authority see SA1428 below – Retail pharmacy
Safety medicine; prescriber may determine dispensing frequency

<table>
<thead>
<tr>
<th>Subsidy (Manufacturer’s Price) $</th>
<th>Fully Subsidised</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 210 mg vial ..........................................................</td>
<td>252.00</td>
<td>✔ Zyprexa Relprevv</td>
</tr>
<tr>
<td>Inj 300 mg vial ..........................................................</td>
<td>414.00</td>
<td>✔ Zyprexa Relprevv</td>
</tr>
<tr>
<td>Inj 405 mg vial ..........................................................</td>
<td>504.00</td>
<td>✔ Zyprexa Relprevv</td>
</tr>
</tbody>
</table>

**SA1428** Special Authority for Subsidy
**Initial application** from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:
Either:
1. The patient has had an initial Special Authority approval for paliperidone depot injection or risperidone depot injection; or
2. All of the following:
   2.1 The patient has schizophrenia; and
   2.2 The patient has tried but failed to comply with treatment using oral atypical antipsychotic agents; and
   2.3 The patient has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in the last 12 months.

**Renewal** from any relevant practitioner. Approvals valid for 12 months where the initiation of olanzapine depot injection has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of an atypical antipsychotic depot injection.

Note: The patient should be monitored for post-injection syndrome for at least two hours after each injection.

PALIPERIDONE – Special Authority see SA1429 below – Retail pharmacy
Safety medicine; prescriber may determine dispensing frequency

<table>
<thead>
<tr>
<th>Subsidy (Manufacturer’s Price) $</th>
<th>Fully Subsidised</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 25 mg syringe .................................</td>
<td>194.25</td>
<td>✔ Invega Sustenna</td>
</tr>
<tr>
<td>Inj 50 mg syringe .................................</td>
<td>271.95</td>
<td>✔ Invega Sustenna</td>
</tr>
<tr>
<td>Inj 75 mg syringe .................................</td>
<td>357.42</td>
<td>✔ Invega Sustenna</td>
</tr>
<tr>
<td>Inj 100 mg syringe .................................</td>
<td>435.12</td>
<td>✔ Invega Sustenna</td>
</tr>
<tr>
<td>Inj 150 mg syringe .................................</td>
<td>435.12</td>
<td>✔ Invega Sustenna</td>
</tr>
</tbody>
</table>

**SA1429** Special Authority for Subsidy
**Initial application** from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:
Either:
1. The patient has had an initial Special Authority approval for risperidone depot injection or olanzapine depot injection; or
2. All of the following:
   2.1 The patient has schizophrenia or other psychotic disorder; and
   2.2 Has tried but failed to comply with treatment using oral atypical antipsychotic agents; and
   2.3 Has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in last 12 months.

**Renewal** from any relevant practitioner. Approvals valid for 12 months where the initiation of paliperidone depot injection has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of an atypical antipsychotic depot injection.

Note: Paliperidone depot injection should ideally be used as monotherapy (i.e. without concurrent use of any other antipsychotic medication). In some cases, it may be clinically appropriate to attempt to treat a patient with typical antipsychotic agents in depot injectable form before trialling paliperidone depot injection.

PIPOTHIAZINE PALMITATE – Subsidy by endorsement
a) Safety medicine; prescriber may determine dispensing frequency
b) Subsidised for patients who were taking pipothiazine palmitate prior to 1 August 2014 and the prescription or PSO is endorsed accordingly. Pharmacists may annotate the prescription as endorsed where there exists a record of prior dispensing of pipothiazine palmitate.

<table>
<thead>
<tr>
<th>Subsidy (Manufacturer’s Price) $</th>
<th>Fully Subsidised</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 50 mg per ml, 1 ml – Up to 5 inj available on a PSO ...............</td>
<td>178.48</td>
<td>✔ Piportil</td>
</tr>
<tr>
<td>Inj 50 mg per ml, 2 ml – Up to 5 inj available on a PSO ................</td>
<td>353.32</td>
<td>✔ Piportil</td>
</tr>
</tbody>
</table>

(Piportil Inj 50 mg per ml, 1 ml to be delisted 1 June 2019)
(Piportil Inj 50 mg per ml, 2 ml to be delisted 1 June 2019)

▲Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber or pharmacist.
※Three months or six months, as applicable, dispensed all-at-once
NERVOUS SYSTEM

<table>
<thead>
<tr>
<th>Subsidy (Manufacturer's Price) $</th>
<th>Fully Subsidised</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>RISPERIDONE – Special Authority see SA1427 below – Retail pharmacy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Safety medicine; prescriber may determine dispensing frequency</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 25 mg vial .......................................................... 135.98 1 ✓ Risperdal Consta</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 37.5 mg vial .......................................................... 178.71 1 ✓ Risperdal Consta</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 50 mg vial .......................................................... 217.56 1 ✓ Risperdal Consta</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**SA1427 Special Authority for Subsidy**

*Initial application* from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Either:

1. The patient has had an initial Special Authority approval for paliperidone depot injection or olanzapine depot injection; or

2. All of the following:
   1.1 The patient has schizophrenia or other psychotic disorder; and
   1.2 Has tried but failed to comply with treatment using oral atypical antipsychotic agents; and
   1.3 Has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in last 12 months.

*Renewal* from any relevant practitioner. Approvals valid for 12 months where the initiation of risperidone depot injection has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of an atypical antipsychotic depot injection.

Note: Risperidone depot injection should ideally be used as monotherapy (i.e. without concurrent use of any other antipsychotic medication). In some cases, it may be clinically appropriate to attempt to treat a patient with typical antipsychotic agents in depot injectable form before trialing risperidone depot injection.

ZUCLOPENTHIXOL DECANOATE – Safety medicine; prescriber may determine dispensing frequency

| Inj 200 mg per ml, 1 ml – Up to 5 inj available on a PSO .................. 19.80 5 ✓ Clopixol |

**Anxiolytics**

BUSPIRONE HYDROCHLORIDE

* Tab 5 mg .......................................................... 20.23 100 ✓ Orion
* Tab 10 mg .......................................................... 13.16 100 ✓ Orion

CLONAZEPAM – Safety medicine; prescriber may determine dispensing frequency

| Tab 500 mcg .......................................................... 5.64 100 ✓ Paxam |
| Tab 2 mg .......................................................... 10.78 100 ✓ Paxam |

DIAZEPAM – Safety medicine; prescriber may determine dispensing frequency

| Tab 2 mg .......................................................... 15.05 500 ✓ Arrow-Diazepam |
| Tab 5 mg .......................................................... 16.18 500 ✓ Arrow-Diazepam |

LORAZEPAM – Safety medicine; prescriber may determine dispensing frequency

| Tab 1 mg .......................................................... 9.72 250 ✓ Ativan |
| Tab 2.5 mg .......................................................... 12.50 100 ✓ Ativan |

OXAZEPAM – Safety medicine; prescriber may determine dispensing frequency

| Tab 10 mg .......................................................... 6.17 100 ✓ Ox-Pam |
| Tab 15 mg .......................................................... 8.53 100 ✓ Ox-Pam |

**Multiple Sclerosis Treatments**

DIMETHYL FUMARATE – Special Authority see SA1559 on the next page – Retail pharmacy

<table>
<thead>
<tr>
<th>Wastage claimable</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cap 120 mg .......................................................... 520.00 14 ✓ Tecfidera</td>
</tr>
<tr>
<td>Cap 240 mg .......................................................... 2,000.00 56 ✓ Tecfidera</td>
</tr>
</tbody>
</table>
Special Authority approved by the Multiple Sclerosis Treatment Committee

Notes: Special Authority approved by the Multiple Sclerosis Treatment Assessment Committee (MSTAC). Applications will be considered by MSTAC at its regular meetings and approved subject to eligibility according to the Entry and Stopping criteria (below).

Application details may be obtained from PHARMAC’s website [http://www.pharmac.govt.nz](http://www.pharmac.govt.nz) or:

- The coordinator Phone: 04 460 4990
- Multiple Sclerosis Treatment Assessment Committee Facsimile: 04 916 7571
- PHARMAC PO Box 10 254 Email: mstaccoordinator@pharmac.govt.nz
- Wellington

Completed application forms must be sent to the coordinator for MSTAC and will be considered by MSTAC at the next practicable opportunity.

Notification of MSTAC’s decision will be sent to the patient, the applying clinician and the patient’s GP (if specified).

**Entry Criteria**

a) Diagnosis of multiple sclerosis (MS) must be confirmed by a neurologist. Diagnosis must include MRI confirmation; and

b) patients must have Clinically Definite Relapsing Remitting MS with or without underlying progression; and

c) patients must have:
   a) EDSS score 0 - 4.0 and:
      i) Experienced at least 1 significant relapse of MS in the previous 12 months or 2 significant relapses in the past 24 months; and
      ii) Evidence of new inflammatory activity on an MR scan within the past 24 months, any of the following:
         1) a gadolinium enhancing lesion; or
         2) a Diffusion Weighted Imaging positive lesion; or
         3) a T2 lesion with associated local swelling; or
         4) a prominent T2 lesion that clearly is responsible for the clinical features of a recent relapse; or
         v) new T2 lesions compared with a previous MR scan; and

   d) A significant relapse must:
      a) be confirmed by the applying neurologist or general physician (the patient may not necessarily have been seen by them during the relapse but the neurologist/physician must be satisfied that the clinical features were characteristic and met the specified criteria);
      b) be associated with characteristic new symptom(s)/sign(s) or substantial worsening of previously experienced symptom(s)/sign(s);
      c) last at least one week;
      d) start at least one month after the onset of a previous relapse;
      e) be severe enough to change either the EDSS or at least one of the Kurtzke Functional System scores by at least 1 point;
      f) be distinguishable from the effects of general fatigue; and
      g) not be associated with a fever (T> 37.5°C); and

   e) applications must be made by the patient's neurologist or general physician; and
   f) patients must have no previous history of lack of response to dimethyl fumarate; and
   g) patients must have not previously had intolerance to dimethyl fumarate; and
   h) patient must not be co-prescribed beta interferon or glatiramer acetate.

**Stopping Criteria**

Any of the following:

1) Confirmed progression of disability that is sustained for six months. Progression of disability is defined as progress by any of the following EDDSS points:

   continued…
NERVOUS SYSTEM

Subsidy (Manufacturer's Price) $ Per Fully Subsidised ✔ Brand or Generic Manufacturer

continued...

a) from starting at EDSS 0 increasing to (i.e. stopping on reaching) EDSS 3.0; or
b) 1.0 to 3.0; or
c) 1.5 to 3.5; or
d) 2.0 to 4.0; or
e) 2.5 to 4.5; or
f) 3.0 to 4.5; or
g) 3.5 to 4.5; or
h) 4.0 to 4.5.

2) increasing relapse rate over 12 months of treatment (compared with the relapse rate on starting treatment)(see note); or
3) intolerance to dimethyl fumarate; or
4) non-compliance with treatment, including refusal to undergo annual assessment.

Note: Switching between natalizumab, fingolimod, dimethyl fumarate and teriflunomide is permitted provided the EDSS stopping criteria are not met. Switching to interferon or glatiramer acetate is only permitted provided the EDSS stopping criteria are not met and both fingolimod and natalizumab are either not tolerated or treatment with both agents would be clinically inappropriate. Continued relapses on treatment would be expected to lead to a switch of treatment provided the stopping criteria are not met. If a relapse has resulted in an increased EDSS score that potentially may lead to discontinuation of treatment according to stopping criteria, a period of 6 months is allowed from the start of the relapse for recovery to occur.

FINGOLIMOD – Special Authority see SA1562 below – Retail pharmacy

Wastage claimable
Cap 0.5 mg. ................................................................................................................2,200.00 28 ✔

SA1562 Special Authority for Subsidy

Special Authority approved by the Multiple Sclerosis Treatment Committee
Notes: Special Authority approved by the Multiple Sclerosis Treatment Assessment Committee (MSTAC). Applications will be considered by MSTAC at its regular meetings and approved subject to eligibility according to the Entry and Stopping criteria (below).

Application details may be obtained from PHARMAC’s website http://www.pharmac.govt.nz or:

The coordinator Phone: 04 460 4990
Multiple Sclerosis Treatment Assessment Committee Facsimile: 04 916 7571
PHARMAC PO Box 10 254 Email: mstaccoordinator@pharmac.govt.nz
Wellington

Completed application forms must be sent to the coordinator for MSTAC and will be considered by MSTAC at the next practicable opportunity.

Notification of MSTAC’s decision will be sent to the patient, the applying clinician and the patient’s GP (if specified).

Entry Criteria

1) Diagnosis of multiple sclerosis (MS) must be confirmed by a neurologist. Diagnosis must include MRI confirmation; and
2) patients must have Clinically Definite Relapsing Remitting MS with or without underlying progression; and
3) patients must have:
   a) EDSS score 0 - 4.0 and:
      • Experienced at least 1 significant relapse of MS in the previous 12 months or 2 significant relapses in the past 24 months; and
      • Evidence of new inflammatory activity on an MR scan within the past 24 months, any of the following:
        i) a gadolinium enhancing lesion; or
        ii) a Diffusion Weighted Imaging positive lesion; or
        iii) a T2 lesion with associated local swelling; or
        iv) a prominent T2 lesion that clearly is responsible for the clinical features of a recent relapse; or
        v) new T2 lesions compared with a previous MR scan; and

continued…
continued...

4) A significant relapse must:
   a) be confirmed by the applying neurologist or general physician (the patient may not necessarily have been seen by
      them during the relapse but the neurologist/physician must be satisfied that the clinical features were characteristic
      and met the specified criteria);
   b) be associated with characteristic new symptom(s)/sign(s) or substantial worsening of previously experienced
      symptom(s)/sign(s);
   c) last at least one week;
   d) start at least one month after the onset of a previous relapse;
   e) be severe enough to change either the EDSS or at least one of the Kurtzke Functional System scores by at least
      1 point;
   f) be distinguishable from the effects of general fatigue; and
   g) not be associated with a fever (T> 37.5°C); and

5) applications must be made by the patient's neurologist or general physician; and

6) patients must have no previous history of lack of response to fingolimod; and

7) patients must have not previously had intolerance to fingolimod; and

8) patient must not be co-prescribed beta interferon or glatiramer acetate.

Stopping Criteria
Any of the following:

1) Confirmed progression of disability that is sustained for six months. Progression of disability is defined as progress by any
   of the following EDDS points:
   a) from starting at EDSS 0 increasing to (i.e. stopping on reaching) EDSS 3.0; or
   b) 1.0 to 3.0; or
   c) 1.5 to 3.5; or
   d) 2.0 to 4.0; or
   e) 2.5 to 4.5; or
   f) 3.0 to 4.5; or
   g) 3.5 to 4.5; or
   h) 4.0 to 4.5.

2) increasing relapse rate over 12 months of treatment (compared with the relapse rate on starting treatment)(see note); or

3) intolerance to fingolimod; or

4) non-compliance with treatment, including refusal to undergo annual assessment.

Note: Switching between natalizumab, fingolimod, dimethyl fumarate and teriflunomide is permitted provided the EDSS stopping
criteria are not met. Switching to interferon or glatiramer acetate is only permitted provided the EDSS stopping criteria are not
met and both fingolimod and natalizumab are either not tolerated or treatment with both agents would be clinically inappropriate.
Continued relapses on treatment would be expected to lead to a switch of treatment provided the stopping criteria are not met. If
a relapse has resulted in an increased EDSS score that potentially may lead to discontinuation of treatment according to stopping
criteria, a period of 6 months is allowed from the start of the relapse for recovery to occur.

NATALIZUMAB – Special Authority see SA1563 below – Retail pharmacy

Inj 20 mg per ml, 15 ml vial...........................................................1,750.00 1 ✔ Tysabri

[SA1563] Special Authority for Subsidy

Special Authority approved by the Multiple Sclerosis Treatment Committee

Notes: Special Authority approved by the Multiple Sclerosis Treatment Assessment Committee (MSTAC). Applications will be
considered by MSTAC at its regular meetings and approved subject to eligibility according to the Entry and Stopping criteria
(below).

Application details may be obtained from PHARMAC's website http://www.pharmac.govt.nz or:
NERVOUS SYSTEM

The coordinator Phone: 04 460 4990
Multiple Sclerosis Treatment Assessment Committee Facsimile: 04 916 7571
PHARMAC PO Box 10 254 Email: mstaccoordinator@pharmac.govt.nz
Wellington

Completed application forms must be sent to the coordinator for MSTAC and will be considered by MSTAC at the next practicable opportunity.

Notification of MSTAC’s decision will be sent to the patient, the applying clinician and the patient’s GP (if specified).

Entry Criteria
1) Diagnosis of multiple sclerosis (MS) must be confirmed by a neurologist. Diagnosis must include MRI confirmation; and
2) patients must have Clinically Definite Relapsing Remitting MS with or without underlying progression; and
3) patients must have:
   a) EDSS score 0 - 4.0 and:
      • Experienced at least 1 significant relapse of MS in the previous 12 months or 2 significant relapses in the past 24 months; and
   • Evidence of new inflammatory activity on an MR scan within the past 24 months, any of the following:
      i) a gadolinium enhancing lesion; or
      ii) a Diffusion Weighted Imaging positive lesion; or
      iii) a T2 lesion with associated local swelling; or
      iv) a prominent T2 lesion that clearly is responsible for the clinical features of a recent relapse; or
      v) new T2 lesions compared with a previous MR scan; and
4) A significant relapse must:
   a) be confirmed by the applying neurologist or general physician (the patient may not necessarily have been seen by them during the relapse but the neurologist/physician must be satisfied that the clinical features were characteristic and met the specified criteria);
   b) be associated with characteristic new symptom(s)/sign(s) or substantial worsening of previously experienced symptom(s)/sign(s);
   c) last at least one week;
   d) start at least one month after the onset of a previous relapse;
   e) be severe enough to change either the EDSS or at least one of the Kurtzke Functional System scores by at least 1 point;
   f) be distinguishable from the effects of general fatigue; and
   g) not be associated with a fever (T> 37.5°C); and
5) applications must be made by the patient’s neurologist or general physician; and
6) treatment must be initiated and supervised by a neurologist who is registered in the Tysabri Australasian Prescribing Programme operated by the supplier; and
7) patients must have no previous history of lack of response to natalizumab; and
8) patients must have not previously had intolerance to natalizumab; and
9) a) Patient is JC virus negative, or
   b) Patient is JC virus positive and has given written informed consent acknowledging an understanding of the risk of progressive multifocal leucoencephalopathy (PML) associated with natalizumab
10) patient must not be co-prescribed beta interferon or glatiramer acetate.

Stopping Criteria
Any of the following:
1) Confirmed progression of disability that is sustained for six months. Progression of disability is defined as progress by any of the following EDSS points:
   a) from starting at EDSS 0 increasing to (i.e. stopping on reaching) EDSS 3.0; or
NERVOUS SYSTEM

Subsidy
(Manufacturer’s Price)

$ Per

Fully Subsidised ✔ Brand or Generic Manufacturer

continued…

b) 1.0 to 3.0; or
c) 1.5 to 3.5; or
d) 2.0 to 4.0; or
e) 2.5 to 4.5; or
f) 3.0 to 4.5; or
g) 3.5 to 4.5; or
h) 4.0 to 4.5.

2) increasing relapse rate over 12 months of treatment (compared with the relapse rate on starting treatment)(see note); or
3) intolerance to natalizumab; or
4) non-compliance with treatment, including refusal to undergo annual assessment.

Note: Natalizumab can only be dispensed from a pharmacy registered in the Tysabri Australasian Prescribing Programme operated by the supplier.

Switching between natalizumab, fingolimod, dimethyl fumarate and teriflunomide is permitted provided the EDSS stopping criteria are not met. Switching to interferon or glatiramer acetate is only permitted provided the EDSS stopping criteria are not met and both fingolimod and natalizumab are either not tolerated or treatment with both agents would be clinically inappropriate.

Continued relapses on treatment would be expected to lead to a switch of treatment provided the stopping criteria are not met. If a relapse has resulted in an increased EDSS score that potentially may lead to discontinuation of treatment according to stopping criteria, a period of 6 months is allowed from the start of the relapse for recovery to occur.

TERIFLUNOMIDE – Special Authority see SA1560 below – Retail pharmacy

Wastage claimable

Tab 14 mg ..................................................... 1,582.62 28 ✔ Aubagio

SA1560 Special Authority for Subsidy

Special Authority approved by the Multiple Sclerosis Treatment Committee

Notes: Special Authority approved by the Multiple Sclerosis Treatment Assessment Committee (MSTAC). Applications will be considered by MSTAC at its regular meetings and approved subject to eligibility according to the Entry and Stopping criteria (below).

Application details may be obtained from PHARMAC’s website http://www.pharmac.govt.nz or:
The coordinator  Phone: 04 460 4990
Multiple Sclerosis Treatment Assessment Committee  Facsimile: 04 916 7571
PHARMAC PO Box 10 254  Email: mstaccoordinator@pharmac.govt.nz
Wellington

Completed application forms must be sent to the coordinator for MSTAC and will be considered by MSTAC at the next practicable opportunity.

Notification of MSTAC’s decision will be sent to the patient, the applying clinician and the patient’s GP (if specified).

Entry Criteria

1) Diagnosis of multiple sclerosis (MS) must be confirmed by a neurologist. Diagnosis must include MRI confirmation; and
2) patients must have Clinically Definite Relapsing Remitting MS with or without underlying progression; and
3) patients must have:
   a) EDSS score 0 - 4.0 and:
      ● Experienced at least 1 significant relapse of MS in the previous 12 months or 2 significant relapses in the past 24 months; and
      ● Evidence of new inflammatory activity on an MR scan within the past 24 months, any of the following:
         i) a gadolinium enhancing lesion; or
         ii) a Diffusion Weighted Imaging positive lesion; or
         iii) a T2 lesion with associated local swelling; or
         iv) a prominent T2 lesion that clearly is responsible for the clinical features of a recent relapse; or

continued…
continued…

v) new T2 lesions compared with a previous MR scan; and

4) A significant relapse must:
   a) be confirmed by the applying neurologist or general physician (the patient may not necessarily have been seen by
      them during the relapse but the neurologist/physician must be satisfied that the clinical features were characteristic
      and met the specified criteria);
   b) be associated with characteristic new symptom(s)/sign(s) or substantial worsening of previously experienced
      symptom(s)/sign(s);
   c) last at least one week;
   d) start at least one month after the onset of a previous relapse;
   e) be severe enough to change either the EDSS or at least one of the Kurtzke Functional System scores by at least 1
      point;
   f) be distinguishable from the effects of general fatigue; and
   g) not be associated with a fever (T> 37.5°C); and

5) applications must be made by the patient's neurologist or general physician; and

6) patients must have no previous history of lack of response to teriflunomide; and

7) patients must have not previously had intolerance to teriflunomide; and

8) patient must not be co-prescribed beta interferon or glatiramer acetate.

**Stopping Criteria**

Any of the following:

1) Confirmed progression of disability that is sustained for six months. Progression of disability is defined as progress by any
   of the following EDDS points:
   a) from starting at EDSS 0 increasing to (i.e. stopping on reaching) EDSS 3.0; or
   b) 1.0 to 3.0; or
   c) 1.5 to 3.5; or
   d) 2.0 to 4.0; or
   e) 2.5 to 4.5; or
   f) 3.0 to 4.5; or
   g) 3.5 to 4.5; or
   h) 4.0 to 4.5.

2) increasing relapse rate over 12 months of treatment (compared with the relapse rate on starting treatment)(see note); or

3) intolerance to teriflunomide; or

4) non-compliance with treatment, including refusal to undergo annual assessment.

Note: Switching between natalizumab, fingolimod, dimethyl fumarate and teriflunomide is permitted provided the EDSS stopping
   criteria are not met. Switching to interferon or glatiramer acetate is only permitted provided the EDSS stopping criteria are not
   met and both fingolimod and natalizumab are either not tolerated or treatment with both agents would be clinically inappropriate.

Continued relapses on treatment would be expected to lead to a switch of treatment provided the stopping criteria are not met. If
   a relapse has resulted in an increased EDSS score that potentially may lead to discontinuation of treatment according to stopping
   criteria, a period of 6 months is allowed from the start of the relapse for recovery to occur.

**Other Multiple Sclerosis Treatments**

**SA1564 Special Authority for Subsidy**

Special Authority approved by the Multiple Sclerosis Treatment Committee

Notes: Special Authority approved by the Multiple Sclerosis Treatment Assessment Committee (MSTAC). Applications will be
considered by MSTAC at its regular meetings and approved subject to eligibility according to the Entry and Stopping criteria
(below).
NERVOUS SYSTEM

补贴
（制造商的价格）

$ 每

完全补贴
✔

品牌或

generic

制造商

应用详情可从PHARMAC的网站http://www.pharmac.govt.nz获得，或：

协调官 电话：04 460 4990

多发性硬化症治疗评估委员会 传真：04 916 7571

PHARMAC PO Box 10 254 电子邮件：mstaccoordinator@pharmac.govt.nz

惠灵顿

完成的申请表必须寄给协调官，由MSTAC考虑。

MSTAC的决定将被通知给病人、申请的医生以及病人的全科医生（如果指定）。

这些药物不会补贴如果由社区或医院药房分发。定期供应将由协调官通过快递分发给所有批准的病人或其医生。

开票人必须每季度为批准的病人开立处方给MSTAC协调官。

只能补贴每週6百万IU的干扰素β-1-α或每週8百万IU的干扰素β-1-β，或每天20毫克的格拉替胺。

治疗的转换在12个月的批准期内被允许，无需重新审批MSTAC。MSTAC协调官应通知更改和新处方。

进入标准

1) 多发性硬化症（MS）的诊断必须由神经科医生确认。诊断必须包括MRI确认；
2) 病人必须有临床明确的复发性缓解型多发性硬化症，且
3) 病人必须有：
   a) EDSS评分为0-4.0，并：
      i) 在过去的24个月内至少经历了1次严重的复发；
      ii) 在过去的24个月内的MRI扫描中，任何一项新发的炎性活动；
      iii) 一个钆增强的病灶；
      iv) 一个扩散加权成像的阳性病灶；
      v) 一个T2病灶伴有局部肿胀；
      vi) 一个明显的T2病灶，被认为是造成最近一次复发的主要原因；
      vii) 新的T2病灶，与先前的MRI扫描比较；
4) 显著的复发必须：
   a) 由申请的神经科医生或全科医生确认（患者不一定必须在复发期间被他们见过，但神经科医生/医生必须确认临床特征符合指定的标准）；
   b) 与先前经历的症状/体征相关；
   c) 持续至少一周；
   d) 在上次复发后至少一个月开始；
   e) 严重到足以改变EDSS或至少一项的Kurtzke功能系统分数至少1分；
   f) 与一般疲劳的不同；
   g) 不与发热（T>37.5°C）相关；
5) 申请必须由病人的神经科医生提出；
6) 病人必须没有先前的历史，对β-干扰素或格拉替胺无反应；
7) 病人必须有以下之一：
   a) 对百利美和丙酸盐不耐受；
   b) 对百利美和丙酸盐的治疗被认为是临床不合适的；
8) 病人不能同时使用百利美和丙酸盐。
**NERVOUS SYSTEM**

<table>
<thead>
<tr>
<th>Subsidy (Manufacturer’s Price)</th>
<th>Fully Subsidised</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Per</td>
<td>✔</td>
<td></td>
</tr>
</tbody>
</table>

**Subsidy**

Unapproved medicine supplied under Section 29

**Sole Subsidised Supply**

**Stopping Criteria**

Any of the following:

1. Confirmed progression of disability that is sustained for six months during a minimum of one year of treatment.
   - Progression of disability is defined as progress by any of the following EDDS Points:
     a) from starting at EDSS 0 increasing to (i.e. stopping on reaching) EDSS 3.0; or
     b) 1.0 to 3.0; or
     c) 1.5 to 3.5; or
     d) 2.0 to 4.0; or
     e) 2.5 to 4.5; or
     f) 3.0 to 4.5; or
     g) 3.5 to 4.5; or
     h) 4.0 to 4.5.

2. Increasing relapse rate over 12 months of treatment (compared with the relapse rate on starting treatment) (see note); or

3. Intolerance to interferon beta-1-alpha, and/or interferon beta-1-beta and/or glatiramer acetate; or

4. Non-compliance with treatment, including refusal to undergo annual assessment.

Note: Treatment with interferon beta-1-beta, interferon beta-1-alpha and glatiramer acetate, is permitted only if treatment with both natalizumab and fingolimod is not tolerated or treatment with both would be clinically inappropriate. Beta-interferon or glatiramer acetate will not be funded as second line treatments if EDSS progression has occurred on treatment with natalizumab or fingolimod. Patients who have an increasing relapse rate over 12 months of treatment (compared with the relapse rate on starting treatment) who do not meet the EDSS Stopping Criteria at annual review may switch from either of the beta-interferon's [interferon beta-1-beta or interferon beta-1-alpha] to glatiramer acetate or vice versa. Patients may switch from either of the beta-interferon's [interferon beta-1-beta or interferon beta-1-alpha] to glatiramer acetate or vice versa for increased relapses only once, after which they will be required to stop funded treatment if they meet any of the Stopping Criteria at annual review (including the criterion relating to increasing relapse rate over 12 months of treatment). If a relapse has resulted in an increased EDSS score that potentially may lead to discontinuation of treatment according to stopping criteria, a period of 6 months is allowed from the start of the relapse for recovery to occur. In this setting anti-JCV antibody positive status may be accepted as a clinically inappropriate reason for treatment with natalizumab.

**GLATIRAMER ACETATE** – Special Authority see SA1564 on page 144 – [Xpharm]

| Inj 20 mg prefilled syringe | 2,250.00 | 28 | ✔ Copaxone |

**INTERFERON BETA-1-ALPHA** – Special Authority see SA1564 on page 144 – [Xpharm]

| Inj 6 million iu prefilled syringe | 1,170.00 | 4 | ✔ Avonex |
| Injection 6 million iu per 0.5 ml pen injector | 1,170.00 | 4 | ✔ Avonex Pen |

**INTERFERON BETA-1-BETA** – Special Authority see SA1564 on page 144 – [Xpharm]

| Inj 8 million iu per 1 ml | 1,322.89 | 15 | ✔ Betaferon |

**Sedatives and Hypnotics**

**LORMETAZEPAM** – Safety medicine; prescriber may determine dispensing frequency

| Tab 1 mg | 3.11 | 30 |
| (23.50) | Noctamid |

*(Noctamid Tab 1 mg to be delisted 1 March 2019)*

**MELATONIN** – Special Authority see SA1666 below – Retail pharmacy

| Tab modified-release 2 mg – No more than 5 tab per day | 28.22 | 30 | ✔ Circadin |

**SA1666** Special Authority for Subsidy

Initial application only from a psychiatrist, paediatrician, neurologist, respiratory specialist or medical practitioner on the recommendation of a psychiatrist, paediatrician, neurologist or respiratory specialist. Approvals valid for 12 months for applications meeting the following criteria:

continued…
continued...

All of the following:
1. Patient has been diagnosed with persistent and distressing insomnia secondary to a neurodevelopmental disorder (including, but not limited to, autism spectrum disorder or attention deficit hyperactivity disorder)*; and
2. Behavioural and environmental approaches have been tried and were unsuccessful, or are inappropriate; and
3. Funded modified-release melatonin is to be given at doses no greater than 10 mg per day; and
4. Patient is aged 18 years or under*.

Renewal only from a psychiatrist, paediatrician, neurologist, respiratory specialist or medical practitioner on the recommendation of a psychiatrist, paediatrician, neurologist or respiratory specialist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:
1. Patient is aged 18 years or under*; and
2. Patient has demonstrated clinically meaningful benefit from funded modified-release melatonin (clinician determined); and
3. Patient has had a trial of funded modified-release melatonin discontinuation within the past 12 months and has had a recurrence of persistent and distressing insomnia; and
4. Funded modified-release melatonin is to be given at doses no greater than 10 mg per day.

Note: Indications marked with * are unapproved indications.

<table>
<thead>
<tr>
<th>NERVOUS SYSTEM</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subsidy (Manufacturer’s Price)</td>
</tr>
<tr>
<td>$/Per</td>
</tr>
</tbody>
</table>

MIDAZOLAM – Safety medicine; prescriber may determine dispensing frequency
- Inj 1 mg per ml, 5 ml ampoule ..............................................4.30 10 ✔ Midazolam-Claris
- Inj 1 mg per ml, 5 ml plastic ampoule – Up to 10 inj available on a PSO .........................................................14.90 10 ✔ Pfizer
  - On a PSO for status epilepticus use only. PSO must be endorsed for status epilepticus use only.
- Inj 5 mg per ml, 3 ml ampoule ..............................................2.50 5 ✔ Midazolam-Claris
- Inj 5 mg per ml, 3 ml plastic ampoule – Up to 5 inj available on a PSO .................................................................11.90 5 ✔ Pfizer
  - On a PSO for status epilepticus use only. PSO must be endorsed for status epilepticus use only.

NITRAZEPAM – Safety medicine; prescriber may determine dispensing frequency
- Tab 5 mg ...............................................................................5.22 100 ✔ Nitrados

PHENOBARBITONE SODIUM – Special Authority see SA1386 below – Retail pharmacy
- Inj 200 mg per ml, 1 ml ampoule .............................................46.20 10 ✔ Martindale

[SA1386] Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:
1. For the treatment of terminal agitation that is unresponsive to other agents; and
2. The applicant is part of a multidisciplinary team working in palliative care.

TEMAZEPAM – Safety medicine; prescriber may determine dispensing frequency
- Tab 10 mg ..............................................................................1.27 25 ✔ Normison

TRIAZOLAM – Safety medicine; prescriber may determine dispensing frequency
- Tab 125 mcg .........................................................................5.10 100 ✔ Hypam
  - (9.85)
- Tab 250 mcg .........................................................................4.10 100 ✔ Hypam
  - (11.20)

ZOPICLONE – Safety medicine; prescriber may determine dispensing frequency
- Tab 7.5 mg .............................................................................9.56 500 ✔ Zopiclone Actavis
  - Zopiclone Actavis to be Sole Supply on 1 January 2019

▲Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber or pharmacist.
★Three months or six months, as applicable, dispensed all-at-once
NERVOUS SYSTEM

Subsidy
(Manufacturer's Price)
$ Per Fully Subsidised Brand or
Fully Subsidised
Manufacturer

Stimulants/ADHD Treatments

<table>
<thead>
<tr>
<th>Medicine</th>
<th>Dose</th>
<th>Price Per Cap</th>
<th>$ Per 28 Cap</th>
</tr>
</thead>
<tbody>
<tr>
<td>ATOMOXETINE</td>
<td>Cap 10mg</td>
<td>107.03</td>
<td>28 Strattera</td>
</tr>
<tr>
<td></td>
<td>Cap 18mg</td>
<td>107.03</td>
<td>28 Strattera</td>
</tr>
<tr>
<td></td>
<td>Cap 25mg</td>
<td>107.03</td>
<td>28 Strattera</td>
</tr>
<tr>
<td></td>
<td>Cap 40mg</td>
<td>107.03</td>
<td>28 Strattera</td>
</tr>
<tr>
<td></td>
<td>Cap 60mg</td>
<td>107.03</td>
<td>28 Strattera</td>
</tr>
<tr>
<td></td>
<td>Cap 80mg</td>
<td>139.11</td>
<td>28 Strattera</td>
</tr>
<tr>
<td></td>
<td>Cap 100mg</td>
<td>139.11</td>
<td>28 Strattera</td>
</tr>
</tbody>
</table>

**SA1416** Special Authority for Subsidy

**Initial application** from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

1. Patient has ADHD (Attention Deficit and Hyperactivity Disorder) diagnosed according to DSM-IV or ICD 10 criteria; and
2. Once-daily dosing; and
3. Any of the following:
   3.1 Treatment with a subsidised formulation of a stimulant has resulted in the development or worsening of serious adverse reactions or where the combination of subsidised stimulant treatment with another agent would pose an unacceptable medical risk; or
   3.2 Treatment with a subsidised formulation of a stimulant has resulted in worsening of co-morbid substance abuse or there is a significant risk of diversion with subsidised stimulant therapy; or
   3.3 An effective dose of a subsidised formulation of a stimulant has been trialled and has been discontinued because of inadequate clinical response; or
   3.4 Treatment with a subsidised formulation of a stimulant is considered inappropriate because the patient has a history of psychoses or has a first-degree relative with schizophrenia; and
4. The patient will not be receiving treatment with atomoxetine in combination with a subsidised formulation of a stimulant, except for the purposes of transitioning from subsidised stimulant therapy to atomoxetine.

**Renewal** from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

Note: A "subsidised formulation of a stimulant" refers to currently subsidised methylphenidate hydrochloride tablet formulations (immediate-release, sustained-release and extended-release) or dexamfetamine sulphate tablets.

DEXAMFETAMINE SULFATE – Special Authority see **SA1149** below – Retail pharmacy

a) Only on a controlled drug form
b) Safety medicine; prescriber may determine dispensing frequency

<table>
<thead>
<tr>
<th>Medicine</th>
<th>Dose</th>
<th>Price Per Tab</th>
<th>$ Per 100 Tab</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>5 mg</td>
<td>20.00</td>
<td>100 PSM</td>
</tr>
</tbody>
</table>

**SA1149** Special Authority for Subsidy

**Initial application** — (ADHD in patients 5 or over) only from a paediatrician, psychiatrist or medical practitioner on the recommendation of a paediatrician or psychiatrist (in writing). Approvals valid for 24 months for applications meeting the following criteria:

All of the following:

1. ADHD (Attention Deficit and Hyperactivity Disorder) patients aged 5 years or over; and
2. Diagnosed according to DSM-IV or ICD 10 criteria; and
3. Either:
   3.1 Applicant is a paediatrician or psychiatrist; or
   3.2 Applicant is a medical practitioner and confirms that a paediatrician or psychiatrist has been consulted within the last 2 years and has recommended treatment for the patient in writing.

**Initial application** — (ADHD in patients under 5) only from a paediatrician or psychiatrist. Approvals valid for 12 months for continued…
applications meeting the following criteria:
Both:

1. ADHD (Attention Deficit and Hyperactivity Disorder) patients under 5 years of age; and
2. Diagnosed according to DSM-IV or ICD 10 criteria.

Initial application — (Narcolepsy) only from a neurologist or respiratory specialist. Approvals valid for 24 months where the patient suffers from narcolepsy.

Renewal — (ADHD in patients 5 or over) only from a paediatrician, psychiatrist or medical practitioner on the recommendation of a paediatrician or psychiatrist (in writing). Approvals valid for 24 months for applications meeting the following criteria:
Both:

1. The treatment remains appropriate and the patient is benefiting from treatment; and
2. Either:
   2.1 Applicant is a paediatrician or psychiatrist; or
   2.2 Applicant is a medical practitioner and confirms that a paediatrician or psychiatrist has been consulted within the last 2 years and has recommended treatment for the patient in writing.

Renewal — (ADHD in patients under 5) only from a paediatrician or psychiatrist. Approvals valid for 12 months where the treatment remains appropriate and the patient is benefiting from treatment.

Renewal — (Narcolepsy) only from a neurologist or respiratory specialist. Approvals valid for 24 months where the patient suffers from narcolepsy.

METHYLPHENIDATE HYDROCHLORIDE – Special Authority see SA1150 below – Retail pharmacy

a) Only on a controlled drug form
b) Safety medicine; prescriber may determine dispensing frequency

<table>
<thead>
<tr>
<th>Strength</th>
<th>Subsidy</th>
<th>Fully Subsidised</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab immediate-release 5 mg</td>
<td>3.20</td>
<td>✔</td>
<td>Rubifen</td>
</tr>
<tr>
<td>Tab immediate-release 10 mg</td>
<td>3.00</td>
<td>✔</td>
<td>Ritalin</td>
</tr>
<tr>
<td>Tab immediate-release 20 mg</td>
<td>7.85</td>
<td>✔</td>
<td>Rubifen</td>
</tr>
<tr>
<td>Tab sustained-release 20 mg</td>
<td>10.95</td>
<td>✔</td>
<td>Rubifen SR</td>
</tr>
<tr>
<td></td>
<td>50.00</td>
<td>✔</td>
<td>Ritalin SR</td>
</tr>
</tbody>
</table>

SA1150 Special Authority for Subsidy

Initial application — (ADHD in patients 5 or over) only from a paediatrician, psychiatrist or medical practitioner on the recommendation of a paediatrician or psychiatrist (in writing). Approvals valid for 24 months for applications meeting the following criteria:

All of the following:

1. ADHD (Attention Deficit and Hyperactivity Disorder) patients aged 5 years or over; and
2. Diagnosed according to DSM-IV or ICD 10 criteria; and
3. Either:
   3.1 Applicant is a paediatrician or psychiatrist; or
   3.2 Applicant is a medical practitioner and confirms that a paediatrician or psychiatrist has been consulted within the last 2 years and has recommended treatment for the patient in writing.

Initial application — (ADHD in patients under 5) only from a paediatrician or psychiatrist. Approvals valid for 12 months for applications meeting the following criteria:
Both:

1. ADHD (Attention Deficit and Hyperactivity Disorder) patients under 5 years of age; and
2. Diagnosed according to DSM-IV or ICD 10 criteria.

Initial application — (Narcolepsy) only from a neurologist or respiratory specialist. Approvals valid for 24 months where the patient suffers from narcolepsy.

Renewal — (ADHD in patients 5 or over) only from a paediatrician, psychiatrist or medical practitioner on the recommendation of a paediatrician or psychiatrist (in writing). Approvals valid for 24 months for applications meeting the following criteria:
continued…

Both:

1. The treatment remains appropriate and the patient is benefiting from treatment; and

2. Either:

   2.1 Applicant is a paediatrician or psychiatrist; or

   2.2 Applicant is a medical practitioner and confirms that a paediatrician or psychiatrist has been consulted within the last 2 years and has recommended treatment for the patient in writing.

Renewal — (ADHD in patients under 5) only from a paediatrician or psychiatrist. Approvals valid for 12 months where the treatment remains appropriate and the patient is benefiting from treatment.

Renewal — (Narcolepsy) only from a neurologist or respiratory specialist. Approvals valid for 24 months where the treatment remains appropriate and the patient is benefiting from treatment.

METHYLPHENIDATE HYDROCHLORIDE EXTENDED-RELEASE – Special Authority see SA1151 below – Retail pharmacy

a) Only on a controlled drug form

b) Safety medicine; prescriber may determine dispensing frequency

<table>
<thead>
<tr>
<th>Strength</th>
<th>Manufacturer's Price</th>
<th>Fully Subsidised</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab extended-release 18 mg</td>
<td>$58.96</td>
<td>✔ Concerta</td>
<td></td>
</tr>
<tr>
<td>Tab extended-release 27 mg</td>
<td>$65.44</td>
<td>✔ Concerta</td>
<td></td>
</tr>
<tr>
<td>Tab extended-release 36 mg</td>
<td>$71.93</td>
<td>✔ Concerta</td>
<td></td>
</tr>
<tr>
<td>Tab extended-release 54 mg</td>
<td>$86.24</td>
<td>✔ Concerta</td>
<td></td>
</tr>
<tr>
<td>Cap modified-release 10 mg</td>
<td>$15.60</td>
<td>✔ Ritalin LA</td>
<td></td>
</tr>
<tr>
<td>Cap modified-release 20 mg</td>
<td>$20.40</td>
<td>✔ Ritalin LA</td>
<td></td>
</tr>
<tr>
<td>Cap modified-release 30 mg</td>
<td>$25.52</td>
<td>✔ Ritalin LA</td>
<td></td>
</tr>
<tr>
<td>Cap modified-release 40 mg</td>
<td>$30.60</td>
<td>✔ Ritalin LA</td>
<td></td>
</tr>
</tbody>
</table>

➽ SA1151 Special Authority for Subsidy

Initial application only from a paediatrician, psychiatrist or medical practitioner on the recommendation of a paediatrician or psychiatrist (in writing). Approvals valid for 24 months for applications meeting the following criteria:

All of the following:

1. ADHD (Attention Deficit and Hyperactivity Disorder); and

2. Diagnosed according to DSM-IV or ICD 10 criteria; and

3. Either:

   3.1 Applicant is a paediatrician or psychiatrist; or

   3.2 Applicant is a medical practitioner and confirms that a paediatrician or psychiatrist has been consulted within the last 2 years and has recommended treatment for the patient in writing; and

4. Either:

   4.1 Patient is taking a currently subsidised formulation of methylphenidate hydrochloride (immediate-release or sustained-release) which has not been effective due to significant administration and/or compliance difficulties; or

   4.2 There is significant concern regarding the risk of diversion or abuse of immediate-release methylphenidate hydrochloride.

Renewal only from a paediatrician, psychiatrist or medical practitioner on the recommendation of a paediatrician or psychiatrist (in writing). Approvals valid for 24 months for applications meeting the following criteria:

Both:

1. The treatment remains appropriate and the patient is benefiting from treatment; and

2. Either:

   2.1 Applicant is a paediatrician or psychiatrist; or

   2.2 Applicant is a medical practitioner and confirms that a paediatrician or psychiatrist has been consulted within the last 2 years and has recommended treatment for the patient in writing.

MODAFINIL – Special Authority see SA1126 on the next page – Retail pharmacy

<table>
<thead>
<tr>
<th>Strength</th>
<th>Manufacturer's Price</th>
<th>Fully Subsidised</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 100 mg</td>
<td>$72.50</td>
<td>✔ Modavigil</td>
</tr>
</tbody>
</table>

Unapproved medicine supplied under Section 29

Sole Subsidised Supply
NERVOUS SYSTEM

Subsidy

<table>
<thead>
<tr>
<th>Manufacturer’s Price</th>
<th>Fully Subsidised</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per</td>
<td>✔</td>
<td></td>
</tr>
</tbody>
</table>

SA1126 Special Authority for Subsidy

Initial application only from a neurologist or respiratory specialist. Approvals valid for 24 months for applications meeting the following criteria:

All of the following:
1. The patient has a diagnosis of narcolepsy and has excessive daytime sleepiness associated with narcolepsy occurring almost daily for three months or more; and
2. Either:
   2.1. The patient has a multiple sleep latency test with a mean sleep latency of less than or equal to 10 minutes and 2 or more sleep onset rapid eye movement periods; or
   2.2. The patient has at least one of: cataplexy, sleep paralysis or hypnagogic hallucinations; and
3. Either:
   3.1. An effective dose of a subsidised formulation of methylphenidate or dexamfetamine has been trialled and discontinued because of intolerable side effects; or
   3.2. Methylphenidate and dexamfetamine are contraindicated.

Renewal only from a neurologist or respiratory specialist. Approvals valid for 24 months where the treatment remains appropriate and the patient is benefiting from treatment.

Treatments for Dementia

DONEPEZIL HYDROCHLORIDE

* Tab 5 mg ................................................................. 4.34 90 ✔ Donepezil-Rex
* Tab 10 mg ................................................................. 6.64 90 ✔ Donepezil-Rex

RIVASTIGMINE – Special Authority see SA1488 below – Retail pharmacy

Patch 4.6 mg per 24 hour ............................................ 90.00 30 ✔ Exelon
Patch 9.5 mg per 24 hour ............................................ 90.00 30 ✔ Exelon

SA1488 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:
1. The patient has been diagnosed with dementia; and
2. The patient has experienced intolerable nausea and/or vomiting from donepezil tablets.

Renewal from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Both:
1. The treatment remains appropriate; and
2. The patient has demonstrated a significant and sustained benefit from treatment.

Treatments for Substance Dependence

BUPRENORPHINE WITH NALOXONE – Special Authority see SA1203 below – Retail pharmacy

a) No patient co-payment payable
b) Safety medicine; prescriber may determine dispensing frequency

Tab sublingual 2 mg with naloxone 0.5 mg ........................................ 57.40 28 ✔ Suboxone
Tab sublingual 8 mg with naloxone 2 mg ........................................ 166.00 28 ✔ Suboxone

SA1203 Special Authority for Subsidy

Initial application — (Detoxification) from any medical practitioner. Approvals valid for 1 month for applications meeting the following criteria:

All of the following:

continued…

▲ Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber or pharmacist.

* Three months or six months, as applicable, dispensed all-at-once

151
NERVOUS SYSTEM

BUPROPION HYDROCHLORIDE
Tab modified-release 150 mg............................................................11.00 30 ✔ Zyban

DISULFIRAM
Tab 200 mg .......................................................................................55.00 100 ✔ Antabuse

NALTREXONE HYDROCHLORIDE – Special Authority see SA1408 below – Retail pharmacy
Tab 50 mg .......................................................................................112.55 30 ✔ Naltraccord

➽ SA1408 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:
1. Patient is currently enrolled in a recognised comprehensive treatment programme for alcohol dependence; and
2. Applicant works in or with a community Alcohol and Drug Service contracted to one of the District Health Boards or accredited against the New Zealand Alcohol and Other Drug Sector Standard or the National Mental Health Sector

continued…
continued...

Standard.

**Renewal** from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

1. Compliance with the medication (prescriber determined); and
2. Any of the following:
   1. Patient is still unstable and requires further treatment; or
   2. Patient achieved significant improvement but requires further treatment; or
   3. Patient is well controlled but requires maintenance therapy.

**NICOTINE**

a) Nicotine will not be funded in amounts less than 4 weeks of treatment.
b) Note: Direct Provision by a pharmacist permitted under the provisions in Part I of Section A.

<table>
<thead>
<tr>
<th>Item Description</th>
<th>Per 28 patches/loz/strip</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patch 7 mg – Up to 28 patch available on a PSO</td>
<td>16.00</td>
<td>✔ Habitrol</td>
</tr>
<tr>
<td>Patch 7 mg for direct distribution only – [Xpharm]</td>
<td>3.94</td>
<td>✔ Habitrol</td>
</tr>
<tr>
<td>Patch 14 mg – Up to 28 patch available on a PSO</td>
<td>17.59</td>
<td>✔ Habitrol</td>
</tr>
<tr>
<td>Patch 14 mg for direct distribution only – [Xpharm]</td>
<td>4.52</td>
<td>✔ Habitrol</td>
</tr>
<tr>
<td>Patch 21 mg – Up to 28 patch available on a PSO</td>
<td>20.16</td>
<td>✔ Habitrol</td>
</tr>
<tr>
<td>Patch 21 mg for direct distribution only – [Xpharm]</td>
<td>5.18</td>
<td>✔ Habitrol</td>
</tr>
<tr>
<td>Lozenge 1 mg – Up to 216 loz available on a PSO</td>
<td>16.61</td>
<td>216 ✔ Habitrol</td>
</tr>
<tr>
<td>Lozenge 1 mg for direct distribution only – [Xpharm]</td>
<td>3.20</td>
<td>36 ✔ Habitrol</td>
</tr>
<tr>
<td>Lozenge 2 mg – Up to 216 loz available on a PSO</td>
<td>18.20</td>
<td>216 ✔ Habitrol</td>
</tr>
<tr>
<td>Lozenge 2 mg for direct distribution only – [Xpharm]</td>
<td>3.24</td>
<td>36 ✔ Habitrol</td>
</tr>
<tr>
<td>Gum 2 mg (Fruit) – Up to 384 piece available on a PSO</td>
<td>33.69</td>
<td>384 ✔ Habitrol</td>
</tr>
<tr>
<td>Gum 2 mg (Fruit) for direct distribution only – [Xpharm]</td>
<td>8.64</td>
<td>96 ✔ Habitrol</td>
</tr>
<tr>
<td>Gum 2 mg (Mint) – Up to 384 piece available on a PSO</td>
<td>33.69</td>
<td>384 ✔ Habitrol</td>
</tr>
<tr>
<td>Gum 2 mg (Mint) for direct distribution only – [Xpharm]</td>
<td>8.64</td>
<td>96 ✔ Habitrol</td>
</tr>
<tr>
<td>Gum 4 mg (Fruit) – Up to 384 piece available on a PSO</td>
<td>38.95</td>
<td>384 ✔ Habitrol</td>
</tr>
<tr>
<td>Gum 4 mg (Fruit) for direct distribution only – [Xpharm]</td>
<td>10.01</td>
<td>96 ✔ Habitrol</td>
</tr>
<tr>
<td>Gum 4 mg (Mint) – Up to 384 piece available on a PSO</td>
<td>38.95</td>
<td>384 ✔ Habitrol</td>
</tr>
<tr>
<td>Gum 4 mg (Mint) for direct distribution only – [Xpharm]</td>
<td>10.01</td>
<td>96 ✔ Habitrol</td>
</tr>
</tbody>
</table>

**VARENICLINE TARTRATE** – Special Authority see **SA1575** below – Retail pharmacy

a) Varenicline will not be funded in amounts less than 2 weeks of treatment.
b) A maximum of 12 weeks' varenicline will be subsidised on each Special Authority approval, including the starter pack

<table>
<thead>
<tr>
<th>Item Description</th>
<th>Per 28 strips</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 1 mg</td>
<td>67.74</td>
<td>✔ Champix</td>
</tr>
<tr>
<td>Tab 0.5 mg × 11 and 1 mg × 14</td>
<td>135.48</td>
<td>56 ✔ Champix</td>
</tr>
<tr>
<td>Tab 0.5 mg × 11 and 1 mg × 14</td>
<td>60.48</td>
<td>25 OP ✔ Champix</td>
</tr>
</tbody>
</table>

**SA1575** Special Authority for Subsidy

**Initial application** from any relevant practitioner. Approvals valid for 5 months for applications meeting the following criteria:

All of the following:

1. Short-term therapy as an aid to achieving abstinence in a patient who has indicated that they are ready to cease smoking; and
2. The patient is part of, or is about to enrol in, a comprehensive support and counselling smoking cessation programme, which includes prescriber or nurse monitoring; and
3. Either:
   1. The patient has tried but failed to quit smoking after at least two separate trials of nicotine replacement therapy, at least one of which included the patient receiving comprehensive advice on the optimal use of nicotine replacement therapy; or

continued...
continued...

3.2 The patient has tried but failed to quit smoking using bupropion or nortriptyline; and
4 The patient has not used funded varenicline in the last 12 months; and
5 Varenicline is not to be used in combination with other pharmacological smoking cessation treatments and the patient has agreed to this; and
6 The patient is not pregnant; and
7 The patient will not be prescribed more than 12 weeks’ funded varenicline (see note).

Renewal from any relevant practitioner. Approvals valid for 5 months for applications meeting the following criteria:

All of the following:

1 Short-term therapy as an aid to achieving abstinence in a patient who has indicated that they are ready to cease smoking; and
2 The patient is part of, or is about to enrol in, a comprehensive support and counselling smoking cessation programme, which includes prescriber or nurse monitoring; and
3 The patient has not used funded varenicline in the last 12 months; and
4 Varenicline is not to be used in combination with other pharmacological smoking cessation treatments and the patient has agreed to this; and
5 The patient is not pregnant; and
6 The patient will not be prescribed more than 12 weeks’ funded varenicline (see note).

The patient must not have had an approval in the past 12 months.

Notes: a maximum of 12 weeks’ varenicline will be subsidised on each Special Authority approval.

This includes the 2-week ‘starter’ pack.
Chemotherapeutic Agents

Alkylating Agents

BENDAMUSTINE HYDROCHLORIDE – PCT only – Specialist – Special Authority see SA1667 below

<table>
<thead>
<tr>
<th>Brand or Manufacturer</th>
<th>Subsidy (Manufacturer’s Price)</th>
<th>Fully Subsidised</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ribomustin</td>
<td>$271.35 per 1 vial</td>
<td>✔</td>
</tr>
<tr>
<td>Ribomustin</td>
<td>$1,085.38 per 1 vial</td>
<td>✔</td>
</tr>
<tr>
<td>Baxter</td>
<td>$11.40 per 1 mg</td>
<td>✔</td>
</tr>
</tbody>
</table>

Special Authority for Subsidy

Initial application — (treatment naive CLL) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

1. The patient has Binet stage B or C, or progressive stage A chronic lymphocytic leukaemia requiring treatment; and
2. The patient is chemotherapy treatment naive; and
3. The patient is unable to tolerate toxicity of full-dose FCR; and
4. Patient has ECOG performance status 0-2; and
5. Patient has a Cumulative Illness Rating Scale (CIRS) score of < 6; and
6. Bendamustine is to be administered at a maximum dose of 100 mg/m² on days 1 and 2 every 4 weeks for a maximum of 6 cycles.

Note: 'Chronic lymphocytic leukaemia (CLL)' includes small lymphocytic lymphoma (SLL). Chemotherapy treatment is considered to comprise a known standard therapeutic chemotherapy regimen and supportive treatments.

Initial application — (Indolent, Low-grade lymphomas) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 9 months for applications meeting the following criteria:

All of the following:

1. The patient has indolent low grade NHL requiring treatment; and
2. Patient has a WHO performance status of 0-2; and
3. Either:
   3.1 Both:
      3.1.1 Patient is treatment naive; and
      3.1.2 Bendamustine is to be administered for a maximum of 6 cycles (in combination with rituximab when CD20+); or
   3.2 All of the following:
      3.2.1 Patient has relapsed refractory disease following prior chemotherapy; and
      3.2.2 The patient has not received prior bendamustine therapy; and
      3.2.3 Either:
         3.2.3.1 Both:
            3.2.3.1.1 Bendamustine is to be administered for a maximum of 6 cycles in relapsed patients (in combination with rituximab when CD20+); and
            3.2.3.1.2 Patient has had a rituximab treatment-free interval of 12 months or more; or
         3.2.3.2 Bendamustine is to be administered as a monotherapy for a maximum of 6 cycles in rituximab refractory patients.

Renewal — (Indolent, Low-grade lymphomas) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 9 months for applications meeting the following criteria:

Both:

1. Patients have not received a bendamustine regimen within the last 12 months; and
2. Either:
   2.1 Both:
continued…

2.1.1 Bendamustine is to be administered for a maximum of 6 cycles in relapsed patients (in combination with rituximab when CD20+); and

2.1.2 Patient has had a rituximab treatment-free interval of 12 months or more; or

2.2 Bendamustine is to be administered as a monotherapy for a maximum of 6 cycles in rituximab refractory patients.

Note: ‘indolent, low-grade lymphomas’ includes follicular, mantle cell, marginal zone and lymphoplasmacytic/ Waldenstrom’s macroglobulinaemia.

BUSULFAN – PCT – Retail pharmacy-Specialist
Tab 2 mg……………………………………...89.25 100 ✔ Myleran

CARBOPLATIN – PCT only – Specialist
Inj 10 mg per ml, 5 ml vial…………………………..15.07 1 ✔ DBL Carboplatin
Inj 10 mg per ml, 15 ml vial…………………………..14.05 1 ✔ DBL Carboplatin
Inj 10 mg per ml, 45 ml vial…………………………..32.59 1 ✔ DBL Carboplatin

Inj 1 mg for ECP …………………………………..0.08 1 mg ✔ Baxter

(DBL Carboplatin Inj 10 mg per ml, 5 ml vial to be delisted 1 March 2019)
(DBL Carboplatin Inj 10 mg per ml, 15 ml vial to be delisted 1 March 2019)
(DBL Carboplatin Inj 10 mg per ml, 45 ml vial to be delisted 1 March 2019)

CARMUSTINE – PCT only – Specialist
Inj 100 mg vial……………………………………..532.00 1 ✔ BiCNU
Inj 100 mg for ECP …………………………………532.00 100 mg OP ✔ Baxter

CHLORAMBUCIL – PCT – Retail pharmacy-Specialist
Tab 2 mg……………………………………...29.06 25 ✔ Leukeran FC

CISPLATIN – PCT only – Specialist
Inj 1 mg per ml, 50 ml vial…………………………..12.29 1 ✔ DBL Cisplatin
Inj 1 mg per ml, 100 ml vial…………………………..19.70 1 ✔ DBL Cisplatin
Inj 1 mg for ECP …………………………………..0.25 1 mg ✔ Baxter

CYCLOPHOSPHAMIDE
Tab 50 mg – PCT – Retail pharmacy-Specialist…………………79.00 50 ✔ Endoxan
158.00 100 ✔ Procytox

Wastage claimable
Inj 1 g vial – PCT – Retail pharmacy-Specialist………………………35.65 1 ✔ Endoxan
127.80 6 ✔ Cytosan

Inj 2 g vial – PCT only – Specialist ……………………71.25 1 ✔ Endoxan
Inj 1 mg for ECP – PCT only – Specialist…………………0.04 1 mg ✔ Baxter

IFOSFAMIDE – PCT only – Specialist
Inj 1 g………………………………………96.00 1 ✔ Holoxan
Inj 2 g………………………………………180.00 1 ✔ Holoxan

Inj 1 mg for ECP …………………………………0.10 1 mg ✔ Baxter

LOMUSTINE – PCT – Retail pharmacy-Specialist
Cap 10 mg………………………………………132.59 20 ✔ CeeNU
Cap 40 mg………………………………………399.15 20 ✔ CeeNU

Unapproved medicine supplied under Section 29
ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

Subsidy
(Manufacturer’s Price)

<table>
<thead>
<tr>
<th>Product</th>
<th>Formulation</th>
<th>Per</th>
<th>Subsidised</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>MELPHALAN</td>
<td>Tab 2 mg – PCT – Retail pharmacy-Specialist</td>
<td>$40.70</td>
<td>25</td>
<td>✔️ Alkeran</td>
</tr>
<tr>
<td></td>
<td>Inj 50 mg – PCT only – Specialist</td>
<td>$67.80</td>
<td>1</td>
<td>✔️ Alkeran</td>
</tr>
<tr>
<td>OXALIPLATIN – PCT only – Specialist</td>
<td>Inj 5 mg per ml, 10 ml vial</td>
<td>$13.32</td>
<td>1</td>
<td>✔️ Oxaliccord</td>
</tr>
<tr>
<td></td>
<td>Inj 50 mg vial</td>
<td>$15.32</td>
<td>1</td>
<td>✔️ Oxaliplatin Actavis 50</td>
</tr>
<tr>
<td></td>
<td>Inj 100 mg vial</td>
<td>$25.01</td>
<td>1</td>
<td>✔️ Oxaliplatin Ebewe 100</td>
</tr>
<tr>
<td></td>
<td>Inj 5 mg per ml, 20 ml vial</td>
<td>$46.32</td>
<td>1</td>
<td>✔️ Oxaliccord</td>
</tr>
<tr>
<td></td>
<td>Inj 1 mg for ECP</td>
<td>$0.18</td>
<td>1 mg</td>
<td>✔️ Baxter</td>
</tr>
<tr>
<td></td>
<td>(Oxaliccord Inj 5 mg per ml, 10 ml vial to be delisted 1 January 2019)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>(Oxaliplatin Actavis 50 Inj 50 mg vial to be delisted 1 January 2019)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>(Oxaliplatin Ebewe Inj 50 mg vial to be delisted 1 January 2019)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>THIOTEPA – PCT only – Specialist</td>
<td>Inj 15 mg vial</td>
<td>CBS</td>
<td>1</td>
<td>✔️ Bedford</td>
</tr>
<tr>
<td></td>
<td>Inj 100 mg vial</td>
<td>CBS</td>
<td>1</td>
<td>✔️ THIO-TEPA</td>
</tr>
<tr>
<td></td>
<td>(Tepadina)</td>
<td>✔️ Tepadina</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>(Azacitidine)</td>
<td>✔️ Vidaza</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Antimetabolites</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AZACITIDINE – PCT only – Specialist – Special Authority see SA1467 below</td>
<td>Inj 100 mg vial</td>
<td>$139.00</td>
<td>1</td>
<td>✔️ Azacitidine Dr Reddy’s</td>
</tr>
<tr>
<td></td>
<td>Inj 1 mg for ECP</td>
<td>$605.00</td>
<td>1 mg</td>
<td>✔️ Baxter</td>
</tr>
<tr>
<td></td>
<td>(SA1467 Special Authority for Subsidy)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Initial application</td>
<td>only from a haematologist or medical practitioner on the recommendation of a haematologist. Approvals valid for 12 months for applications meeting the following criteria:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All of the following:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 Any of the following:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1.1 The patient has International Prognostic Scoring System (IPSS) intermediate-2 or high risk myelodysplastic syndrome; or</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1.2 The patient has chronic myelomonocytic leukaemia (10%-29% marrow blasts without myeloproliferative disorder); or</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1.3 The patient has acute myeloid leukaemia with 20-30% blasts and multi-lineage dysplasia, according to World Health Organisation Classification (WHO); and</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2 The patient has performance status (WHO/ECOG) grade 0-2; and</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3 The patient does not have secondary myelodysplastic syndrome resulting from chemical injury or prior treatment with chemotherapy and/or radiation for other diseases; and</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4 The patient has an estimated life expectancy of at least 3 months.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Renewal</td>
<td>only from a haematologist or medical practitioner on the recommendation of a haematologist. Approvals valid for 12 months for applications meeting the following criteria:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Both:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 No evidence of disease progression; and</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2 The treatment remains appropriate and patient is benefitting from treatment.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### CALCIUM FOLINATE

<table>
<thead>
<tr>
<th>Item Description</th>
<th>Manufacturer</th>
<th>Price</th>
<th>Subsidy</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 15 mg – PCT – Retail pharmacy-Specialist</td>
<td>DBL Leucovorin</td>
<td>$104.26</td>
<td>✓</td>
<td>Fully Subsidised</td>
</tr>
<tr>
<td>Inj 3 mg per ml, 1 ml – PCT – Retail pharmacy-Specialist</td>
<td>Hospira</td>
<td>$17.10</td>
<td>✓</td>
<td>Fully Subsidised</td>
</tr>
<tr>
<td>Inj 10 mg per ml, 5 ml vial – PCT – Retail pharmacy-Specialist</td>
<td>Calcium Folinate Sandoz</td>
<td>$4.55</td>
<td>✓</td>
<td>Fully Subsidised</td>
</tr>
<tr>
<td>Inj 50 mg – PCT – Retail pharmacy-Specialist</td>
<td>Calcium Folinate Ebewe</td>
<td>$18.25</td>
<td>✓</td>
<td>Fully Subsidised</td>
</tr>
<tr>
<td>Inj 10 mg per ml, 10 ml vial – PCT only – Specialist</td>
<td>Calcium Folinate Sandoz</td>
<td>$7.30</td>
<td>✓</td>
<td>Fully Subsidised</td>
</tr>
<tr>
<td>Inj 100 mg – PCT only – Specialist</td>
<td>Calcium Folinate Ebewe</td>
<td>$7.33</td>
<td>✓</td>
<td>Fully Subsidised</td>
</tr>
<tr>
<td>Inj 300 mg – PCT only – Specialist</td>
<td>Calcium Folinate Ebewe</td>
<td>$22.51</td>
<td>✓</td>
<td>Fully Subsidised</td>
</tr>
<tr>
<td>Inj 10 mg per ml, 35 ml vial – PCT only – Specialist</td>
<td>Calcium Folinate Sandoz</td>
<td>$20.95</td>
<td>✓</td>
<td>Fully Subsidised</td>
</tr>
<tr>
<td>Inj 1 g – PCT only – Specialist</td>
<td>Calcium Folinate Ebewe</td>
<td>$67.51</td>
<td>✓</td>
<td>Fully Subsidised</td>
</tr>
<tr>
<td>Inj 10 mg per ml, 100 ml vial – PCT only – Specialist</td>
<td>Calcium Folinate Sandoz</td>
<td>$60.00</td>
<td>✓</td>
<td>Fully Subsidised</td>
</tr>
<tr>
<td>Inj 1 mg for ECP – PCT only – Specialist</td>
<td>Baxter</td>
<td>$0.06</td>
<td>✓</td>
<td>Fully Subsidised</td>
</tr>
</tbody>
</table>

### CAPECITABINE

<table>
<thead>
<tr>
<th>Item Description</th>
<th>Manufacturer</th>
<th>Price</th>
<th>Subsidy</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 150 mg</td>
<td>Brinov</td>
<td>$11.15</td>
<td>60</td>
<td>✓</td>
</tr>
<tr>
<td>Tab 500 mg</td>
<td>Brinov</td>
<td>$62.28</td>
<td>120</td>
<td>✓</td>
</tr>
</tbody>
</table>

### CLADRIBINE

<table>
<thead>
<tr>
<th>Item Description</th>
<th>Manufacturer</th>
<th>Price</th>
<th>Subsidy</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 1 mg per ml, 10 ml</td>
<td>Leustatin</td>
<td>$5,249.72</td>
<td>7</td>
<td>✓</td>
</tr>
<tr>
<td>Inj 10 mg for ECP</td>
<td>Baxter</td>
<td>$749.96</td>
<td>10 mg OP</td>
<td>✓</td>
</tr>
</tbody>
</table>

### CYTARABINE

<table>
<thead>
<tr>
<th>Item Description</th>
<th>Manufacturer</th>
<th>Price</th>
<th>Subsidy</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 20 mg per ml, 5 ml vial – PCT – Retail pharmacy-Specialist</td>
<td>Pfizer</td>
<td>$400.00</td>
<td>5</td>
<td>✓</td>
</tr>
<tr>
<td>Inj 100 mg per ml, 20 ml vial – PCT – Retail pharmacy-Specialist</td>
<td>Pfizer</td>
<td>$41.36</td>
<td>1</td>
<td>✓</td>
</tr>
<tr>
<td>Inj 1 mg for ECP – PCT only – Specialist</td>
<td>Baxter</td>
<td>$0.25</td>
<td>10 mg</td>
<td>✓</td>
</tr>
<tr>
<td>Inj 100 mg intrathecal syringe for ECP – PCT only – Specialist</td>
<td>Baxter</td>
<td>$80.00</td>
<td>100 mg OP</td>
<td>✓</td>
</tr>
</tbody>
</table>

### FLUDARABINE PHOSPHATE

<table>
<thead>
<tr>
<th>Item Description</th>
<th>Manufacturer</th>
<th>Price</th>
<th>Subsidy</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 10 mg – PCT – Retail pharmacy-Specialist</td>
<td>Fludara Oral</td>
<td>$412.00</td>
<td>20</td>
<td>✓</td>
</tr>
<tr>
<td>Inj 50 mg vial – PCT only – Specialist</td>
<td>Fludarabine Ebewe</td>
<td>$525.00</td>
<td>5</td>
<td>✓</td>
</tr>
<tr>
<td>Inj 50 mg for ECP – PCT only – Specialist</td>
<td>Baxter</td>
<td>$105.00</td>
<td>50 mg OP</td>
<td>✓</td>
</tr>
</tbody>
</table>

### FLUOROURACIL

<table>
<thead>
<tr>
<th>Item Description</th>
<th>Manufacturer</th>
<th>Price</th>
<th>Subsidy</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 50 mg per ml, 20 ml vial – PCT only – Specialist</td>
<td>Fluorouracil Ebewe</td>
<td>$12.00</td>
<td>1</td>
<td>✓</td>
</tr>
<tr>
<td>Inj 50 mg per ml, 50 ml vial – PCT only – Specialist</td>
<td>Fluorouracil Ebewe</td>
<td>$17.00</td>
<td>1</td>
<td>✓</td>
</tr>
<tr>
<td>Inj 50 mg per ml, 100 ml vial – PCT only – Specialist</td>
<td>Fluorouracil Ebewe</td>
<td>$30.00</td>
<td>1</td>
<td>✓</td>
</tr>
<tr>
<td>Inj 1 mg for ECP – PCT only – Specialist</td>
<td>Baxter</td>
<td>$0.66</td>
<td>100 mg</td>
<td>✓</td>
</tr>
</tbody>
</table>

(Fluorouracil Ebewe Inj 50 mg per ml, 50 ml vial to be delisted 1 March 2019)

### GEMCITABINE HYDROCHLORIDE

<table>
<thead>
<tr>
<th>Item Description</th>
<th>Manufacturer</th>
<th>Price</th>
<th>Subsidy</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 1 g, 26.3 ml vial</td>
<td>DBL Gemcitabine</td>
<td>$62.50</td>
<td>1</td>
<td>✓</td>
</tr>
<tr>
<td>Inj 1 g</td>
<td>Gemcitabine Ebewe</td>
<td>$15.89</td>
<td>1</td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>Gemzar</td>
<td>$349.20</td>
<td>1</td>
<td>✓</td>
</tr>
<tr>
<td>Inj 200 mg</td>
<td>Gemcitabine Ebewe</td>
<td>$8.36</td>
<td>1</td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>Gemzar</td>
<td>$78.00</td>
<td>1</td>
<td>✓</td>
</tr>
<tr>
<td>Inj 1 mg for ECP</td>
<td>Baxter</td>
<td>$0.02</td>
<td>1 mg</td>
<td>✓</td>
</tr>
</tbody>
</table>
IRINOTECAN HYDROCHLORIDE – PCT only – Specialist

<table>
<thead>
<tr>
<th>Subsidy (Manufacturer’s Price) $</th>
<th>Fully Subsidised</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 20 mg per ml, 2 ml vial</td>
<td>11.50</td>
<td>✔ Irinotecan Actavis 40</td>
</tr>
<tr>
<td>Inj 20 mg per ml, 5 ml vial</td>
<td>17.80</td>
<td>✔ Camptosar</td>
</tr>
<tr>
<td>Inj 1 mg for ECP</td>
<td>0.19</td>
<td>✔ Irinotecan-Rex</td>
</tr>
</tbody>
</table>

(Camptosar Inj 20 mg per ml, 2 ml vial to be delisted 1 February 2019)
(Camptosar Inj 20 mg per ml, 5 ml vial to be delisted 1 February 2019)

MERCAPTOPURINE

<table>
<thead>
<tr>
<th>Subsidy (Manufacturer’s Price) $</th>
<th>Fully Subsidised</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 50 mg – PCT – Retail pharmacy-Specialist</td>
<td>49.41</td>
<td>✔ Puri-nethol</td>
</tr>
<tr>
<td>Oral suspension 20 mg per ml – Retail pharmacy-Specialist</td>
<td>428.00</td>
<td>✔ Allmercap</td>
</tr>
</tbody>
</table>

**SA1725** Special Authority for Subsidy

**Initial application** only from a paediatric haematologist or paediatric oncologist. Approvals valid for 12 months where the patient requires a total dose of less than one full 50 mg tablet per day.

**Renewal** only from a paediatric haematologist or paediatric oncologist. Approvals valid for 12 months where patient still requires a total dose of less than one full 50 mg tablet per day.

METHOTREXATE

<table>
<thead>
<tr>
<th>Subsidy (Manufacturer’s Price) $</th>
<th>Fully Subsidised</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 2.5 mg – PCT – Retail pharmacy-Specialist</td>
<td>3.18</td>
<td>✔ Trexate</td>
</tr>
<tr>
<td>Tab 10 mg – PCT – Retail pharmacy-Specialist</td>
<td>8.05</td>
<td>✔ Trexate</td>
</tr>
<tr>
<td>Inj 2.5 mg per ml, 2 ml – PCT – Retail pharmacy-Specialist</td>
<td>21.00</td>
<td>✔ Trexate</td>
</tr>
<tr>
<td>Inj 7.5 mg prefilled syringe</td>
<td>14.61</td>
<td>✔ Methotrexate Sandoz</td>
</tr>
<tr>
<td>Inj 10 mg prefilled syringe</td>
<td>14.66</td>
<td>✔ Methotrexate Sandoz</td>
</tr>
<tr>
<td>Inj 15 mg prefilled syringe</td>
<td>14.77</td>
<td>✔ Methotrexate Sandoz</td>
</tr>
<tr>
<td>Inj 20 mg prefilled syringe</td>
<td>14.88</td>
<td>✔ Methotrexate Sandoz</td>
</tr>
<tr>
<td>Inj 25 mg prefilled syringe</td>
<td>14.99</td>
<td>✔ Methotrexate Sandoz</td>
</tr>
<tr>
<td>Inj 30 mg prefilled syringe</td>
<td>15.09</td>
<td>✔ Methotrexate Sandoz</td>
</tr>
<tr>
<td>Inj 25 mg per ml, 2 ml vial – PCT – Retail pharmacy-Specialist</td>
<td>30.00</td>
<td>✔ DBL Methotrexate Onco-Vial</td>
</tr>
<tr>
<td>Inj 25 mg per ml, 20 ml vial – PCT – Retail pharmacy-Specialist</td>
<td>45.00</td>
<td>✔ DBL Methotrexate Onco-Vial</td>
</tr>
<tr>
<td>Inj 100 mg per ml, 10 ml – PCT – Retail pharmacy-Specialist</td>
<td>25.00</td>
<td>✔ Methotrexate Ebewe</td>
</tr>
<tr>
<td>Inj 100 mg per ml, 50 ml vial – PCT – Retail pharmacy-Specialist</td>
<td>79.99</td>
<td>✔ Methotrexate Ebewe</td>
</tr>
<tr>
<td>Inj 1 mg for ECP – PCT only – Specialist</td>
<td>0.06</td>
<td>✔ Baxter</td>
</tr>
<tr>
<td>Inj 5 mg intrathecal syringe for ECP – PCT only – Specialist</td>
<td>4.73</td>
<td>✔ Baxter</td>
</tr>
<tr>
<td><strong>ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-----------------------------------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>PEMETREXED – PCT only – Specialist – Special Authority see SA1679 below</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Inj 100 mg vial</strong> ................................................................. $60.89</td>
<td>1</td>
<td>✔</td>
</tr>
<tr>
<td><strong>Inj 500 mg vial</strong> ................................................................. 217.77</td>
<td>1</td>
<td>✔</td>
</tr>
<tr>
<td><strong>Inj 1 mg for ECP</strong> ................................................................. 0.55</td>
<td>1 mg</td>
<td>✔</td>
</tr>
</tbody>
</table>

**SA1679 Special Authority for Subsidy**

**Initial application — (mesothelioma)** only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 8 months for applications meeting the following criteria:

Both:
1. Patient has been diagnosed with mesothelioma; and
2. Pemetrexed to be administered at a dose of 500 mg/m² every 21 days in combination with cisplatin or carboplatin for a maximum of 6 cycles.

**Renewal — (mesothelioma)** only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 8 months for applications meeting the following criteria:

All of the following:
1. No evidence of disease progression; and
2. The treatment remains appropriate and the patient is benefitting from treatment; and
3. Pemetrexed to be administered at a dose of 500 mg/m² every 21 days for a maximum of 6 cycles.

**Initial application — (non-small cell lung carcinoma)** only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 8 months for applications meeting the following criteria:

Both:
1. Patient has locally advanced or metastatic non-squamous non-small cell lung carcinoma; and
2. Either:
   2.1 Both:
      2.1.1 Patient has chemotherapy-naive disease; and
      2.1.2 Pemetrexed is to be administered at a dose of 500 mg/m² every 21 days in combination with cisplatin or carboplatin for a maximum of 6 cycles; or
   2.2 All of the following:
      2.2.1 Patient has had first-line treatment with platinum based chemotherapy; and
      2.2.2 Patient has not received prior funded treatment with pemetrexed; and
      2.2.3 Pemetrexed is to be administered at a dose of 500 mg/m² every 21 days for a maximum of 6 cycles.

**Renewal — (non-small cell lung carcinoma)** only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 8 months for applications meeting the following criteria:

All of the following:
1. No evidence of disease progression; and
2. The treatment remains appropriate and the patient is benefitting from treatment; and
3. Pemetrexed is to be administered at a dose of 500 mg/m² every 21 days.

**THIOGUANINE – PCT – Retail pharmacy-Specialist**

| Tab 40 mg ............................................................................... | $126.31 | 25 | ✔ | Lanvis |

**Other Cytotoxic Agents**

**AMSACRINE – PCT only – Specialist**

| Inj 50 mg per ml, 1.5 ml ampoule ......................................... | $1,500.00 | 6 | ✔ | Amsidine ☞ |
| Inj 75 mg .................................................................................. | $1,250.00 | 5 | ✔ | AmsaLyo ☞ |

**ANAGRELIDE HYDROCHLORIDE – PCT – Retail pharmacy-Specialist**

| Cap 0.5 mg .................................................................................. | CBS | 100 | ✔ | Agrylin ☞ |
| Inj 10 mg ........................................................................................ | ✔ | 10 | ✔ | AFT ☞ |

Unapproved medicine supplied under Section 29
ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

Subsidy (Manufacturer’s Price) $ Per Fully Subsidised ✔ Brand or Generic Manufacturer

BLEOMYCIN SULPHATE – PCT only – Specialist

Inj 15,000 iu, vial……………………………………………………………161.01 1 ✔ DBL Bleomycin Sulfate

Inj 1,000 iu for ECP …………………………………………………………12.45 1,000 iu ✔ Baxter

BORTEZOMIB – PCT only – Specialist – Special Authority see SA1576 below

Inj 3.5 mg vial ………………………………………………………………1,892.50 1 ✔ Velcade

Inj 1 mg for ECP ……………………………………………………………594.77 1 mg ✔ Baxter

➽ SA1576 Special Authority for Subsidy

Initial application — (Treatment naive multiple myeloma/amyloidosis) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria:

Both:

1 Either:
   1.1 The patient has treatment-naive symptomatic multiple myeloma; or
   1.2 The patient has treatment-naive symptomatic systemic AL amyloidosis *; and

2 Maximum of 9 treatment cycles.

Note: Indications marked with * are unapproved indications.

Initial application — (Relapsed/refractory multiple myeloma/amyloidosis) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 8 months for applications meeting the following criteria:

All of the following:

1 Either:
   1.1 The patient has relapsed or refractory multiple myeloma; or
   1.2 The patient has relapsed or refractory systemic AL amyloidosis *; and

2 The patient has received only one prior front line chemotherapy for multiple myeloma or amyloidosis; and

3 The patient has not had prior publicly funded treatment with bortezomib; and

4 Maximum of 4 treatment cycles.

Note: Indications marked with * are unapproved indications.

Renewal — (Relapsed/refractory multiple myeloma/amyloidosis) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 8 months for applications meeting the following criteria:

Both:

1 The patient's disease obtained at least a partial response from treatment with bortezomib at the completion of cycle 4; and

2 Maximum of 4 further treatment cycles (making a total maximum of 8 consecutive treatment cycles).

Notes: Responding relapsed/refractory multiple myeloma patients should receive no more than 2 additional cycles of treatment beyond the cycle at which a confirmed complete response was first achieved. A line of therapy is considered to comprise either:

a) a known therapeutic chemotherapy regimen and supportive treatments; or

b) a transplant induction chemotherapy regimen, stem cell transplantation and supportive treatments.

Refer to datasheet for recommended dosage and number of doses of bortezomib per treatment cycle.

COLASPASE [L-ASPARAGINASE] – PCT only – Specialist

Inj 10,000 iu………………………………………………………………………102.32 1 ✔ Leunase

Inj 10,000 iu for ECP …………………………………………………………102.32 10,000 iu OP ✔ Baxter

DACARBAZINE – PCT only – Specialist

Inj 200 mg vial …………………………………………………………………58.06 1 ✔ DBL Dacarbazine

580.60 10 ✔ Dacarbazine APP 523

Inj 200 mg for ECP ……………………………………………………………58.06 200 mg OP ✔ Baxter

DACTINOMYCIN [ACTINOMYCIN D] – PCT only – Specialist

Inj 0.5 mg vial …………………………………………………………………166.75 1 ✔ Cosmegen

Inj 0.5 mg for ECP ……………………………………………………………166.75 0.5 mg OP ✔ Baxter

▲ Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber or pharmacist.

❋ Three months or six months, as applicable, dispensed all-at-once

161
### ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

**DAUNORUBICIN** – PCT only – Specialist
- Inj 2 mg per ml, 10 ml.......................................................... $130.00 1 ✓ Pfizer
- Inj 20 mg for ECP ............................................................. $130.00 20 mg OP ✓ Baxter

**DOCETAXEL** – PCT only – Specialist
- Inj 10 mg per ml, 2 ml vial.................................................... $12.40 1 ✓ DBL Docetaxel
- Inj 20 mg................................................................. $48.75 1 ✓ Docetaxel Sandoz
- Inj 20 mg per ml, 8 ml vial........................................... $26.95 1 ✓ DBL Docetaxel
- Inj 80 mg................................................................. $195.00 1 ✓ Docetaxel Sandoz
- Inj 1 ml for ECP ............................................................. $0.55 1 mg ✓ Baxter

**DOXORUBICIN HYDROCHLORIDE** – PCT only – Specialist
- Inj 2 mg per ml, 5 ml vial.................................................. $10.00 1 ✓ Doxorubicin Ebewe
- Inj 2 mg per ml, 25 ml vial........................................ $11.50 1 ✓ Doxorubicin Ebewe
- Inj 2 mg per ml, 50 ml vial........................................... $23.00 1 ✓ Doxorubicin Ebewe
- Inj 2 mg per ml, 100 ml vial........................................ $56.15 1 ✓ Doxorubicin Ebewe
- Inj 1 mg for ECP ............................................................. $0.25 1 mg ✓ Baxter

**EPIRUBICIN HYDROCHLORIDE** – PCT only – Specialist
- Inj 2 mg per ml, 5 ml vial.................................................. $25.00 1 ✓ Epirubicin Ebewe
- Inj 2 mg per ml, 25 ml vial........................................ $30.00 1 ✓ Epirubicin Ebewe
- Inj 2 mg per ml, 50 ml vial........................................... $32.50 1 ✓ Epirubicin Ebewe
- Inj 2 mg per ml, 100 ml vial........................................ $65.00 1 ✓ Epirubicin Ebewe
- Inj 1 mg for ECP ............................................................. $0.36 1 mg ✓ Baxter

**ETOPOSIDE**
- Cap 50 mg – PCT – Retail pharmacy-Specialist........................ $340.73 20 ✓ Vepesid
- Cap 100 mg – PCT – Retail pharmacy-Specialist.................. $340.73 10 ✓ Vepesid
- Inj 20 mg per ml, 5 ml vial – PCT – Retail pharmacy-Specialist...... $7.90 1 ✓ Rex Medical
- Inj 1 mg for ECP – PCT only – Specialist.............................. $0.09 1 mg ✓ Baxter

**ETOPOSIDE PHOSPHATE** – PCT only – Specialist
- Inj 100 mg (of etoposide base)...................................... $40.00 1 ✓ Etopophos
- Inj 1 mg (of etoposide base) for ECP................................. $0.47 1 mg ✓ Baxter

**HYDROXYUREA** – PCT – Retail pharmacy-Specialist
- Cap 500 mg..................................................................... $31.76 100 ✓ Hydrea

**IDARUBICIN HYDROCHLORIDE**
- Inj 5 mg vial – PCT only – Specialist............................... $93.00 1 ✓ Zavedos
- Inj 10 mg vial – PCT only – Specialist.............................. $198.00 1 ✓ Zavedos
- Inj 1 mg for ECP – PCT only – Specialist.......................... $21.84 1 mg ✓ Baxter

**LENALIDOMIDE** – Retail pharmacy-Specialist – Special Authority see SA1468 below
- Wastage claimable
  - Cap 10 mg.............................................................. $6,207.00 21 ✓ Revlimid
  - Cap 15 mg.............................................................. $7,239.18 21 ✓ Revlimid
  - Cap 25 mg.............................................................. $7,627.00 21 ✓ Revlimid

---

**SA1468** Special Authority for Subsidy

**Initial application — (Relapsed/refractory disease)** only from a haematologist or medical practitioner on the recommendation of a haematologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:
1. Patient has relapsed or refractory multiple myeloma with progressive disease; and

---

Unapproved medicine supplied under Section 29
2 Either:
   2.1 Lenalidomide to be used as third line* treatment for multiple myeloma; or
   2.2 Both:
      2.2.1 Lenalidomide to be used as second line treatment for multiple myeloma; and
      2.2.2 The patient has experienced severe (grade 3 or higher), dose limiting, peripheral neuropathy with either bortezomib or thalidomide that precludes further treatment with either of these treatments; and

3 Lenalidomide to be administered at a maximum dose of 25 mg/day in combination with dexamethasone.

Renewal only from a haematologist or medical practitioner on the recommendation of a haematologist. Approvals valid for 6 months for applications meeting the following criteria:

Both:
1 No evidence of disease progression; and
2 The treatment remains appropriate and patient is benefiting from treatment.

Note: Indication marked with * is an unapproved indication. A line of treatment is considered to comprise either: a) a known therapeutic chemotherapy regimen and supportive treatments or b) a transplant induction chemotherapy regimen, stem cell transplantation and supportive treatments. Prescriptions must be written by a registered prescriber in the lenalidomide risk management programme operated by the supplier.

**Mesna**

| Tab 400 mg – PCT – Retail pharmacy-Specialist | 273.00 | ✔️ Uromitexan |
| Tab 600 mg – PCT – Retail pharmacy-Specialist | 407.50 | ✔️ Uromitexan |
| Inj 100 mg per ml, 4 ml ampoule – PCT only – Specialist | 161.25 | ✔️ Uromitexan |
| Inj 100 mg per ml, 10 ml ampoule – PCT only – Specialist | 370.35 | ✔️ Uromitexan |
| Inj 1 mg for ECP – PCT only – Specialist | 2.69 | ✔️ Baxter |

**Mitomycin C** – PCT only – Specialist

| Inj 5 mg vial | 204.08 | ✔️ Arrow |
| Inj 1 mg for ECP | 42.04 | ✔️ Baxter |

**Mitozantrone** – PCT only – Specialist

| Inj 2 mg per ml, 10 ml vial | 97.50 | ✔️ Mitozantrone Ebewe |
| Inj 1 mg for ECP | 5.51 | ✔️ Baxter |

**Paclitaxel** – PCT only – Specialist

| Inj 30 mg | 47.30 | ✔️ Paclitaxel Ebewe |
| Inj 100 mg | 20.00 | ✔️ Paclitaxel Ebewe |
| Inj 150 mg | 26.69 | ✔️ Paclitaxel Ebewe |
| Inj 300 mg | 35.35 | ✔️ Paclitaxel Ebewe |
| Inj 1 mg for ECP | 275.00 | ✔️ Paclitaxel Actavis |

**Pegasparagase** – PCT only – Special Authority see SA1325 below

| Inj 3,750 IU per 5 ml | 3,005.00 | ✔️ Oncaspar |

**SA1325** Special Authority for Subsidy

Initial application only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

continued…
continued…

1. The patient has newly diagnosed acute lymphoblastic leukaemia; and
2. Pegaspargase to be used with a contemporary intensive multi-agent chemotherapy treatment protocol; and
3. Treatment is with curative intent.

Renewal only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

1. The patient has relapsed acute lymphoblastic leukaemia; and
2. Pegaspargase to be used with a contemporary intensive multi-agent chemotherapy treatment protocol; and
3. Treatment is with curative intent.

PENTOSTATIN [DEOXYCOFORMYCIN] – PCT only – Specialist

Inj 10 mg................................................................. CBS 1 ✔ Nipent $29

PROCARBAZINE HYDROCHLORIDE – PCT – Retail pharmacy-Specialist

Cap 50 mg............................................................ 498.00 50 ✔ Natulan $29

TEMOZOLOMIDE – Special Authority see SA1741 below – Retail pharmacy

Cap 5 mg............................................................. 10.20 5 ✔ Orion Temozolomide

Cap 20 mg............................................................ 18.30 5 ✔ Orion Temozolomide

Cap 100 mg........................................................... 40.20 5 ✔ Orion Temozolomide

Cap 140 mg........................................................... 56.00 5 ✔ Orion Temozolomide

Cap 250 mg........................................................... 96.80 5 ✔ Orion Temozolomide

SA1741 Special Authority for Subsidy

Initial application — (high grade gliomas) only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

1. Either:
   1.1 Patient has newly diagnosed glioblastoma multiforme; or
   1.2 Patient has newly diagnosed anaplastic astrocytoma*; and
2. Temozolomide is to be (or has been) given concomitantly with radiotherapy; and
3. Following concomitant treatment temozolomide is to be used for a maximum of 5 days treatment per cycle, at a maximum dose of 200 mg/m² per day.

Initial application — (neuroendocrine tumours) only from a relevant specialist. Approvals valid for 9 months for applications meeting the following criteria:

All of the following:

1. Patient has been diagnosed with metastatic or unresectable well-differentiated neuroendocrine tumour*; and
2. Temozolomide is to be given in combination with capecitabine; and
3. Temozolomide is to be used in 28 day treatment cycles for a maximum of 5 days treatment per cycle at a maximum dose of 200 mg/m² per day; and
4. Temozolomide to be discontinued at disease progression.

Initial application — (Ewing’s sarcoma) only from a relevant specialist. Approvals valid for 9 months where the patient has relapsed/refractory Ewing’s sarcoma.
continued…

Renewal — (high grade gliomas) only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

Either:

1. Both:
   1.1 Patient has glioblastoma multiforme; and
   1.2 The treatment remains appropriate and the patient is benefitting from treatment; or

2. All of the following:
   2.1 Patient has anaplastic astrocytoma*; and
   2.2 The treatment remains appropriate and the patient is benefitting from treatment; and
   2.3 Adjuvant temozolomide is to be used for a maximum of 24 months.

Renewal — (neuroendocrine tumours) only from a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

1. No evidence of disease progression; and
2. The treatment remains appropriate and the patient is benefitting from treatment.

Renewal — (Ewing's sarcoma) only from a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

1. No evidence of disease progression; and
2. The treatment remains appropriate and the patient is benefitting from treatment.

Note: Indication marked with * is an unapproved indication. Temozolomide is not subsidised for the treatment of relapsed high grade glioma.

THALIDOMIDE – Retail pharmacy-Specialist – Special Authority see SA1124 below

Initial application only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

Either:

1. The patient has multiple myeloma; or
2. The patient has systemic AL amyloidosis*.

Renewal only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid without further renewal unless notified where the patient has obtained a response from treatment during the initial approval period.

Notes: Prescription must be written by a registered prescriber in the thalidomide risk management programme operated by the supplier.

Maximum dose of 400 mg daily as monotherapy or in a combination therapy regimen. Indication marked with * is an unapproved indication.

TRETINOIN

Cap 10 mg – PCT – Retail pharmacy-Specialist ........................................ 479.50 100  ✔ Vesnoid

VINBLASTINE SULPHATE

Inj 1 mg per ml, 10 ml vial – PCT – Retail pharmacy-Specialist..............186.46 5  ✔ Hospira

Inj 1 mg for ECP – PCT only – Specialist.................................................. 4.14 1 mg  ✔ Baxter

VINCRISTINE SULPHATE

Inj 1 mg per ml, 1 ml vial – PCT – Retail pharmacy-Specialist..............74.52 5  ✔ DBL Vincristine Sulfate

Inj 1 mg per ml, 2 ml vial – PCT – Retail pharmacy-Specialist..............85.61 5  ✔ DBL Vincristine Sulfate

Inj 1 mg for ECP – PCT only – Specialist..................................................11.30 1 mg  ✔ Baxter

⚠️ Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber or pharmacist.

※ Three months or six months, as applicable, dispensed all-at-once
VINORELBINE – PCT only – Specialist

<table>
<thead>
<tr>
<th>Subsidy (Manufacturer’s Price) $</th>
<th>Fully Subsidised</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 10 mg per ml, 1 ml vial................................. 8.00 1 ✔</td>
<td>Navelbine</td>
<td>Navelbine</td>
</tr>
<tr>
<td></td>
<td>42.00</td>
<td>Vinorelbine Ebewe</td>
</tr>
<tr>
<td>Inj 10 mg per ml, 5 ml vial................................. 40.00 1 ✔</td>
<td>Navelbine</td>
<td>Vinorelbine Ebewe</td>
</tr>
<tr>
<td></td>
<td>210.00</td>
<td></td>
</tr>
<tr>
<td>Inj 1 mg for ECP ................................................ 0.90 1 mg ✔</td>
<td>Baxter</td>
<td></td>
</tr>
</tbody>
</table>

Protein-tyrosine Kinase Inhibitors

DASATINIB – Special Authority see SA0976 below – [Xpharm]

<table>
<thead>
<tr>
<th>Subsidy (Manufacturer’s Price) $</th>
<th>Fully Subsidised</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 20 mg.................................................. 3,774.06 60 ✔</td>
<td>Sprycel</td>
<td></td>
</tr>
<tr>
<td>Tab 50 mg................................. 6,214.20 60 ✔</td>
<td>Sprycel</td>
<td></td>
</tr>
<tr>
<td>Tab 70 mg................................. 7,692.58 60 ✔</td>
<td>Sprycel</td>
<td></td>
</tr>
<tr>
<td>Tab 100 mg................................. 6,214.20 30 ✔</td>
<td>Sprycel</td>
<td></td>
</tr>
</tbody>
</table>

Special Authority criteria for CML - access by application

- Funded for patients with diagnosis (confirmed by a haematologist) of a chronic myeloid leukaemia (CML) in blast crisis, accelerated phase, or in chronic phase.
- Maximum dose of 140 mg/day for accelerated or blast phase, and 100 mg/day for chronic phase CML.
- Subsidised for use as monotherapy only.
- Initial approvals valid seven months.
- Subsequent approval(s) are granted on application and are valid for six months. The first reapplication (after seven months) should provide details of the haematological response. The third reapplication should provide details of the cytogenetic response after 14-18 months from initiating therapy. All other reapplications should provide details of haematological response, and cytogenetic response if such data is available. Applications to be made and subsequent prescriptions can be written by a haematologist or an oncologist.

Note: Dasatinib is indicated for the treatment of adults with chronic, accelerated or blast phase CML with resistance or intolerance to prior therapy including imatinib.

Guideline on discontinuation of treatment for patients with CML

- Prescribers should consider discontinuation of treatment if, after 6 months from initiating therapy, a patient did not obtain a haematological response as defined by any of the following three levels of response:
  1. complete haematologic response (as characterised by an absolute neutrophil count (ANC) > 1.5 x 10^9/L, platelets > 100 x 10^9/L, absence of peripheral blood (PB) blasts, bone marrow (BM) blasts < 5% (or FISH Ph+ 0-35% metaphases), and absence of extramedullary disease); or
  2. no evidence of leukaemia (as characterised by an absolute neutrophil count (ANC) > 1.0 x 10^9/L, platelets > 20 x 10^9/L, absence of peripheral blood (PB) blasts, bone marrow (BM) blasts < 5% (or FISH Ph+ 0-35% metaphases), and absence of extramedullary disease); or
  3. return to chronic phase (as characterised by BM and PB blasts < 15%, BM and PB blasts and promyelocytes < 30%, PB basophils < 20% and absence of extramedullary disease other than spleen and liver).
- Prescribers should consider discontinuation of treatment if, after 18 months from initiating therapy, a patient did not obtain a major cytogenetic response defined as 0-35% Ph+ metaphases.
ERLOTINIB – Retail pharmacy-Specialist – Special Authority see **SA1653 below**

<table>
<thead>
<tr>
<th>Subsidy (Manufacturer’s Price) $</th>
<th>Fully Subsidised Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 100 mg ..........</td>
<td>764.00</td>
<td>✔ Tarceva</td>
</tr>
<tr>
<td>Tab 150 mg ..........</td>
<td>1,146.00</td>
<td>✔ Tarceva</td>
</tr>
</tbody>
</table>

**SA1653** Special Authority for Subsidy

*Initial application* only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

1. Patient has locally advanced or metastatic, unresectable, non-squamous Non Small Cell Lung Cancer (NSCLC); and
2. There is documentation confirming that the disease expresses activating mutations of EGFR tyrosine kinase; and
3. Either:
   3.1 Patient is treatment naive; or
   3.2 Both:
      3.2.1 The patient has discontinued gefitinib due to intolerance; and
      3.2.2 The cancer did not progress while on gefitinib; and
4. Erlotinib is to be given for a maximum of 3 months.

*Renewal* only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 6 months where radiological assessment (preferably including CT scan) indicates NSCLC has not progressed.

GEFITINIB – Retail pharmacy-Specialist – Special Authority see **SA1654 below**

<table>
<thead>
<tr>
<th>Subsidy (Manufacturer’s Price) $</th>
<th>Fully Subsidised Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 250 mg ..........</td>
<td>1,700.00</td>
<td>✔ Iressa</td>
</tr>
</tbody>
</table>

**SA1654** Special Authority for Subsidy

*Initial application* only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

1. Patient has locally advanced or metastatic, unresectable, non-squamous Non Small Cell Lung Cancer (NSCLC); and
2. Either:
   2.1 Patient is treatment naive; or
   2.2 Both:
      2.2.1 The patient has discontinued erlotinib due to intolerance; and
      2.2.2 The cancer did not progress whilst on erlotinib; and
3. There is documentation confirming that disease expresses activating mutations of EGFR tyrosine kinase; and
4. Gefitinib is to be given for a maximum of 3 months.

*Renewal* only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 6 months where radiological assessment (preferably including CT scan) indicates NSCLC has not progressed.

IMATINIB MESILATE

Note: Imatinib-AFT is not a registered for the treatment of Gastro Intestinal Stromal Tumours (GIST). The Glivec brand of imatinib mesilate (supplied by Novartis) remains fully subsidised under Special Authority for patients with unresectable and/or metastatic malignant GIST, see SA1460 in Section B of the Pharmaceutical Schedule.

<table>
<thead>
<tr>
<th>Subsidy (Manufacturer’s Price) $</th>
<th>Fully Subsidised Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 100 mg ..........</td>
<td>2,400.00</td>
<td>✔ Glivec</td>
</tr>
</tbody>
</table>
* Cap 100 mg ..........| 98.00               | ✔ Imatinib-AFT              |
* Cap 400 mg ..........| 197.50              | ✔ Imatinib-AFT              |

**SA1460** Special Authority for Subsidy

Special Authority approved by the CML/GIST Co-ordinator

Notes: Application details may be obtained from PHARMAC’s website [http://www.pharmac.govt.nz](http://www.pharmac.govt.nz), and prescriptions should be sent to:

continued…

▲Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber or pharmacist.

※Three months or six months, as applicable, dispensed all-at-once
### ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

<table>
<thead>
<tr>
<th>Subsidy</th>
<th>Fully Subsidised</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Manufacturer's Price</td>
<td>$</td>
<td>Per</td>
</tr>
</tbody>
</table>

**continued…**

The CML/GIST Co-ordinator
Phone: (04) 460 4990
PHARMAC
Facsimile: (04) 916 7571
PO Box 10 254
Email: cmlgistcoordinator@pharmac.govt.nz
Wellington

**Special Authority criteria for GIST – access by application**

Funded for patients:

a) With a diagnosis (confirmed by an oncologist) of unresectable and/or metastatic malignant gastrointestinal stromal tumour (GIST).

b) Maximum dose of 400 mg/day.

c) Applications to be made and subsequent prescriptions can be written by an oncologist.

d) Initial and subsequent applications are valid for one year. The re-application criterion is an adequate clinical response to the treatment with imatinib (prescriber determined).

**LAPATINIB DITOSYLATE** – Special Authority see **SA1191 below** – Retail pharmacy

<table>
<thead>
<tr>
<th>Tab 250 mg</th>
<th>$1,899.00</th>
<th>70</th>
</tr>
</thead>
</table>

**SA1191 Special Authority for Subsidy**

**Initial application** — **(metastatic breast cancer)** only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

Either:

1. All of the following:
   - 1.1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
   - 1.2 The patient has not previously received trastuzumab treatment for HER 2 positive metastatic breast cancer; and
   - 1.3 Lapatinib not to be given in combination with trastuzumab; and
   - 1.4 Lapatinib to be discontinued at disease progression; or

2. All of the following:
   - 2.1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
   - 2.2 The patient started trastuzumab for metastatic breast cancer but discontinued trastuzumab within 3 months of starting treatment due to intolerance; and
   - 2.3 The cancer did not progress whilst on trastuzumab; and
   - 2.4 Lapatinib not to be given in combination with trastuzumab; and
   - 2.5 Lapatinib to be discontinued at disease progression.

**Renewal** — **(metastatic breast cancer)** only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

1. The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and

2. The cancer has not progressed at any time point during the previous 12 months whilst on lapatinib; and

3. Lapatinib not to be given in combination with trastuzumab; and

4. Lapatinib to be discontinued at disease progression.

**NILOTINIB** – Special Authority see **SA1489 on the next page** – Retail pharmacy

Wastage claimable

<table>
<thead>
<tr>
<th>Wastage claimable</th>
<th>$</th>
<th>120</th>
<th>✔</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cap 150 mg</td>
<td>4,680.00</td>
<td>120</td>
<td>✔</td>
</tr>
<tr>
<td>Cap 200 mg</td>
<td>6,532.00</td>
<td>120</td>
<td>✔</td>
</tr>
</tbody>
</table>

---

Unapproved medicine supplied under Section 29

Sole Subsidised Supply

168

✔ fully subsidised

168

Unapproved medicine supplied under Section 29

Sole Subsidised Supply
ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

Subsidy
(Manufacturer's Price)
$ Per
Fully Subsidised ✔
Brand or Generic Manufacturer

 ➽ SA1489 Special Authority for Subsidy

Initial application only from a haematologist. Approvals valid for 6 months for applications meeting the following criteria:
All of the following:
1 Patient has a diagnosis of chronic myeloid leukaemia (CML) in blast crisis, accelerated phase, or in chronic phase; and
2 Either:
   2.1 Patient has documented CML treatment failure* with imatinib; or
   2.2 Patient has experienced treatment limiting toxicity with imatinib precluding further treatment with imatinib; and
3 Maximum nilotinib dose of 800 mg/day; and
4 Subsidised for use as monotherapy only.

Note: *treatment failure as defined by Leukaemia Net Guidelines.

Renewal only from a haematologist. Approvals valid for 6 months for applications meeting the following criteria:
All of the following:
1 Lack of treatment failure while on nilotinib as defined by Leukaemia Net Guidelines; and
2 Nilotinib treatment remains appropriate and the patient is benefiting from treatment; and
3 Maximum nilotinib dose of 800 mg/day; and
4 Subsidised for use as monotherapy only.

PAZOPANIB – Special Authority see SA1190 below – Retail pharmacy
Tab 200 mg .................................................................1,334.70 30 ✔ Votrient
Tab 400 mg .................................................................2,669.40 30 ✔ Votrient

 ➽ SA1190 Special Authority for Subsidy

Initial application only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist.
Approvals valid for 3 months for applications meeting the following criteria:
All of the following:
1 The patient has metastatic renal cell carcinoma; and
2 Any of the following:
   2.1 The patient is treatment naive; or
   2.2 The patient has only received prior cytokine treatment; or
   2.3 Both:
      2.3.1 The patient has discontinued sunitinib within 3 months of starting treatment due to intolerance; and
      2.3.2 The cancer did not progress whilst on sunitinib; and
3 The patient has good performance status (WHO/ECOG grade 0-2); and
4 The disease is of predominant clear cell histology; and
   The patient has intermediate or poor prognosis defined as:
5 Any of the following:
   5.1 Lactate dehydrogenase level > 1.5 times upper limit of normal; or
   5.2 Haemoglobin level < lower limit of normal; or
   5.3 Corrected serum calcium level > 10 mg/dL (2.5 mmol/L); or
   5.4 Interval of < 1 year from original diagnosis to the start of systemic therapy; or
   5.5 Karnofsky performance score of less than or equal to 70; or
   5.6 2 or more sites of organ metastasis; and
6 Pazopanib to be used for a maximum of 3 months.

Renewal only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria:
Both:
1 No evidence of disease progression; and
2 The treatment remains appropriate and the patient is benefiting from treatment.

Notes: Pazopanib treatment should be stopped if disease progresses.
Poor prognosis patients are defined as having at least 3 of criteria 5.1-5.6. Intermediate prognosis patients are defined as having 1 or 2 of criteria 5.1-5.6.
RUXOLITINIB – Special Authority see SA1753 below – Retail pharmacy

Wastage claimable

Tab 5 mg .................................................................2,500.00 56 ✔ Jakavi
Tab 15 mg ............................................................5,000.00 56 ✔ Jakavi
Tab 20 mg ............................................................5,000.00 56 ✔ Jakavi

SA1753 Special Authority for Subsidy

Initial application only from a haematologist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:
1. The patient has primary myelofibrosis or post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis; and
2. A classification of risk of intermediate-2 or high-risk myelofibrosis according to either the International Prognostic Scoring System (IPSS), Dynamic International Prognostic Scoring System (DIPSS), or the Age-Adjusted DIPSS; and
3. A maximum dose of 20 mg twice daily is to be given.

Renewal only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

Both:
1. The treatment remains appropriate and the patient is benefiting from treatment; and
2. A maximum dose of 20 mg twice daily is to be given.

SUNITINIB – Special Authority see SA1266 below – Retail pharmacy

Cap 12.5 mg ............................................................2,315.38 28 ✔ Sutent
Cap 25 mg ............................................................4,630.77 28 ✔ Sutent
Cap 50 mg ............................................................9,261.54 28 ✔ Sutent

SA1266 Special Authority for Subsidy

Initial application — (RCC) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:
1. The patient has metastatic renal cell carcinoma; and
2. Any of the following:
   2.1 The patient is treatment naive; or
   2.2 The patient has only received prior cytokine treatment; or
   2.3 The patient has only received prior treatment with an investigational agent within the confines of a bona fide clinical trial which has Ethics Committee approval; or
   2.4 Both:
      2.4.1 The patient has discontinued pazopanib within 3 months of starting treatment due to intolerance; and
      2.4.2 The cancer did not progress whilst on pazopanib; and
3. The patient has good performance status (WHO/ECOG grade 0-2); and
4. The disease is of predominant clear cell histology; and
   The patient has intermediate or poor prognosis defined as:
5. Any of the following:
   5.1 Lactate dehydrogenase level > 1.5 times upper limit of normal; or
   5.2 Haemoglobin level < lower limit of normal; or
   5.3 Corrected serum calcium level > 10 mg/dL (2.5 mmol/L); or
   5.4 Interval of < 1 year from original diagnosis to the start of systemic therapy; or
   5.5 Karnofsky performance score of less than or equal to 70; or
   5.6 2 or more sites of organ metastasis; and
6. Sunitinib to be used for a maximum of 2 cycles.

Initial application — (GIST) only from a relevant specialist or medical practitioner on the recommendation of a relevant

continued…
continued...

specialist. Approvals valid for 3 months for applications meeting the following criteria:

Both:

1. The patient has unresectable or metastatic malignant gastrointestinal stromal tumour (GIST); and
2. Either:
   2.1 The patient’s disease has progressed following treatment with imatinib; or
   2.2 The patient has documented treatment-limiting intolerance, or toxicity to, imatinib.

Renewal — (RCC) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist.

Approvals valid for 3 months for applications meeting the following criteria:

Both:

1. No evidence of disease progression; and
2. The treatment remains appropriate and the patient is benefiting from treatment.

Notes: Sunitinib treatment should be stopped if disease progresses.

Poor prognosis patients are defined as having at least 3 of criteria 5.1-5.6. Intermediate prognosis patients are defined as having 1 or 2 of criteria 5.1-5.6.

Renewal — (GIST) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist.

Approvals valid for 6 months for applications meeting the following criteria:

Both:

The patient has responded to treatment or has stable disease as determined by Choi’s modified CT response evaluation criteria as follows:

1. Any of the following:
   1.1 The patient has had a complete response (disappearance of all lesions and no new lesions); or
   1.2 The patient has had a partial response (a decrease in size of 10% or more or decrease in tumour density in Hounsfield Units (HU) of 15% or more on CT and no new lesions and no obvious progression of non measurable disease); or
   1.3 The patient has stable disease (does not meet criteria the two above) and does not have progressive disease and no symptomatic deterioration attributed to tumour progression; and
2. The treatment remains appropriate and the patient is benefiting from treatment.

Note: It is recommended that response to treatment be assessed using Choi’s modified CT response evaluation criteria (J Clin Oncol, 2007, 25:1753-1759). Progressive disease is defined as either: an increase in tumour size of 10% or more and not meeting criteria of partial response (PR) by tumour density (HU) on CT; or: new lesions, or new intratumoral nodules, or increase in the size of the existing intratumoral nodules.

Endocrine Therapy

For GnRH ANALOGUES – refer to HORMONE PREPARATIONS, Trophic Hormones, page 84

ABIRATERONE ACETATE – Retail pharmacy-Specialist – Special Authority see SA1767 below

Wastage claimable

Tab 250 mg ................................................................. ...................... 4,276.19 120 ✔ Zytiga

►SA1767 Special Authority for Subsidy

Initial application only from a medical oncologist, radiation oncologist, urologist or medical practitioner on the recommendation of a medical oncologist, radiation oncologist or urologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

1. Patient has prostate cancer; and
2. Patient has metastases; and
3. Patient’s disease is castration resistant; and
4. Either:

continued…
continued...

4.1 All of the following:

4.1.1 Patient is symptomatic; and
4.1.2 Patient has disease progression (rising serum PSA) after second line anti-androgen therapy; and
4.1.3 Patient has ECOG performance score of 0-1; and
4.1.4 Patient has not had prior treatment with taxane chemotherapy; or

4.2 All of the following:

4.2.1 Patient's disease has progressed following prior chemotherapy containing a taxane; and
4.2.2 Patient has ECOG performance score of 0-2; and
4.2.3 Patient has not had prior treatment with abiraterone.

Renewal — (abiraterone acetate) only from a medical oncologist, radiation oncologist, urologist or medical practitioner on the recommendation of a medical oncologist, radiation oncologist or urologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

1 Significant decrease in serum PSA from baseline; and
2 No evidence of clinical disease progression; and
3 No initiation of taxane chemotherapy with abiraterone; and
4 The treatment remains appropriate and the patient is benefiting from treatment.

BICALUTAMIDE
Tab 50 mg .................................................................3.80 28 ✔ Binarex

FLUTAMIDE – Retail pharmacy-Specialist
Tab 250 mg ...............................................................16.50 30 ✔ Flutamide

Mylan 55.00 100 ✔ Flutamin

MEGESTROL ACETATE – Retail pharmacy-Specialist
Tab 160 mg ...............................................................63.53 30 ✔ Apo-Megestrol

OCTREOTIDE
Inj 50 mcg per ml, 1 ml vial ..............................................30.64 5 ✔ DBL Octreotide
Inj 100 mcg per ml, 1 ml vial ...........................................18.69 5 ✔ DBL Octreotide
Inj 500 mcg per ml, 1 ml vial .............................................72.50 5 ✔ DBL Octreotide

OCTREOTIDE LAR (SOMATOSTATIN ANALOGUE) – Special Authority see SA1016 below – Retail pharmacy
Inj LAR 10 mg prefilled syringe .......................................1,772.50 1 ✔ Sandostatin LAR
Inj LAR 20 mg prefilled syringe .......................................2,358.75 1 ✔ Sandostatin LAR
Inj LAR 30 mg prefilled syringe .......................................2,951.25 1 ✔ Sandostatin LAR

➽ SA1016 Special Authority for Subsidy
Initial application — (Malignant Bowel Obstruction) from any relevant practitioner. Approvals valid for 2 months for applications meeting the following criteria:

All of the following:

1 The patient has nausea* and vomiting* due to malignant bowel obstruction*; and
2 Treatment with antiemetics, rehydration, antimuscarinic agents, corticosteroids and analgesics for at least 48 hours has failed; and
3 Octreotide to be given at a maximum dose 1500 mcg daily for up to 4 weeks.

Note: Indications marked with * are unapproved indications.

Renewal — (Malignant Bowel Obstruction) from any relevant practitioner. Approvals valid for 3 months where the treatment remains appropriate and the patient is benefiting from treatment.

Initial application — (Acromegaly) only from a relevant specialist or medical practitioner on the recommendation of a relevant

continued…
continued...
specialist. Approvals valid for 3 months for applications meeting the following criteria:

Both:
1. The patient has acromegaly; and
2. Any of the following:
   2.1. Treatment with surgery, radiotherapy and a dopamine agonist has failed; or
   2.2. Treatment with octreotide is for an interim period while awaiting the effects of radiotherapy and a dopamine agonist has failed; or
   2.3. The patient is unwilling, or unable, to undergo surgery and/or radiotherapy.

Renewal — (Acromegaly) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist.
Approvals valid for 2 years for applications meeting the following criteria:

Both:
1. IGF1 levels have decreased since starting octreotide; and
2. The treatment remains appropriate and the patient is benefiting from treatment.

Note: In patients with Acromegaly octreotide treatment should be discontinued if IGF1 levels have not decreased after 3 months treatment. In patients treated with radiotherapy octreotide treatment should be withdrawn every 2 years, for 1 month, for assessment of remission. Octreotide treatment should be stopped where there is biochemical evidence of remission (normal IGF1 levels) following octreotide treatment withdrawal for at least 4 weeks

Initial application — (Other Indications) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria:

Any of the following:
1. VIPomas and Glucagonomas - for patients who are seriously ill in order to improve their clinical state prior to definitive surgery; or
2. Both:
   2.1. Gastrinoma; and
   2.2. Either:
      2.2.1. Patient has failed surgery; or
      2.2.2. Patient in metastatic disease after H2 antagonists (or proton pump inhibitors) have failed; or
3. Both:
   3.1. Insulinomas; and
   3.2. Surgery is contraindicated or has failed; or
4. For pre-operative control of hypoglycaemia and for maintenance therapy; or
5. Both:
   5.1. Carcinoid syndrome (diagnosed by tissue pathology and/or urinary 5HIAA analysis); and
   5.2. Disabling symptoms not controlled by maximal medical therapy.

Note: The use of octreotide in patients with fistulae, oesophageal varices, miscellaneous diarrhoea and hypotension will not be funded as a Special Authority item

Renewal — (Other Indications) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

**TAMOXIFEN CITRATE**

<table>
<thead>
<tr>
<th>Tab 10 mg</th>
<th>Tab 20 mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>11.75</td>
<td>2.63</td>
</tr>
<tr>
<td>19.50</td>
<td>5.60</td>
</tr>
<tr>
<td>40</td>
<td>30</td>
</tr>
</tbody>
</table>

© Tamoxifen Sandoz
© Genox
© Tamoxifen Sandoz
© Genox
© Rolin

- Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber or pharmacist.
- Three months or six months, as applicable, dispensed all-at-once
### Oncology Agents and Immunosuppressants

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Manufacturer’s Price</th>
<th>Per Subsidised</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pfizer Exemestane</td>
<td>$14.50</td>
<td>30</td>
</tr>
<tr>
<td>Letrole</td>
<td>$4.68</td>
<td>30</td>
</tr>
</tbody>
</table>

#### Exemestane

- Tab 25 mg: $14.50 for 30
- Tab 2.5 mg: $4.68 for 30

**Immunosuppressants**

#### Cytotoxic Immunosuppressants

**AZATHIOPRINE – Retail pharmacy-Specialist**

- Tab 25 mg: $9.66 for 100, ✔ Imuran
- Tab 50 mg: $10.58 for 100, ✔ Imuran
- Inj 50 mg vial: $60.00 for 1, ✔ Imuran

**Mycophenolate MOFETIL**

- Tab 500 mg: $25.00 for 50, ✔ Cellcept
- Cap 250 mg: $25.00 for 100, ✔ Cellcept
- Powder for oral liq 1 g per 5 ml – Subsidy by endorsement: $187.25 for 165 ml OP, ✔ Cellcept

Mycophenolate powder for oral liquid is subsidised only for patients unable to swallow tablets and capsules, and when the prescription is endorsed accordingly.

#### Fusion Proteins

**ETANERCEPT – Special Authority see SA1620 below – Retail pharmacy**

- Inj 25 mg: $799.96 for 4, ✔ Enbrel
- Inj 50 mg autoinjector: $1,599.96 for 4, ✔ Enbrel
- Inj 50 mg prefilled syringe: $1,599.96 for 4, ✔ Enbrel

### Special Authority for Subsidy

**Initial application — (juvenile idiopathic arthritis)** only from a named specialist or rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

**Either:**

1. **Both:**
   1.1 The patient has had an initial Special Authority approval for adalimumab for juvenile idiopathic arthritis (JIA); and
   1.2 Either:
      1.2.1 The patient has experienced intolerable side effects from adalimumab; or
      1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for JIA; or

2. **All of the following:**
   2.1 To be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
   2.2 Patient diagnosed with Juvenile Idiopathic Arthritis (JIA); and
   2.3 Patient has had severe active polyarticular course JIA for 6 months duration or longer; and
   2.4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate (at a dose of 10-20 mg/m² weekly or at the maximum tolerated dose) in combination with either oral corticosteroids (prednisone 0.25 mg/kg or at the maximum tolerated dose) or a full trial of serial intra-articular corticosteroid injections; and

**SA1620**

**Special Authority**

2.5 **Both:**
   2.5.1 Either:
      2.5.1.1 Patient has persistent symptoms of poorly-controlled and active disease in at least 20 swollen, tender joints; or

continued…
2.5.1.2 Patient has persistent symptoms of poorly-controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, shoulder, cervical spine, hip; and

2.5.2 Physician’s global assessment indicating severe disease.

Initial application — (rheumatoid arthritis) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

1 Both:
   1.1 The patient has had an initial Special Authority approval for adalimumab for rheumatoid arthritis; and
   1.2 Either:
      1.2.1 The patient has experienced intolerable side effects from adalimumab; or
      1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for rheumatoid arthritis; or

2 All of the following:

2.1 Patient has had severe and active erosive rheumatoid arthritis (either confirmed by radiology imaging, or the patient is cyclic citrullinated peptide (CCP) antibody positive) for six months duration or longer; and

2.2 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and

2.3 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and

2.4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with sulfasalazine and hydroxychloroquine sulphate (at maximum tolerated doses); and

2.5 Any of the following:

2.5.1 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with the maximum tolerated dose of ciclosporin; or

2.5.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with intramuscular gold; or

2.5.3 Patient has tried and not responded to at least three months of therapy at the maximum tolerated dose of leflunomide alone or in combination with oral or parenteral methotrexate; and

2.6 Either:

2.6.1 Patient has persistent symptoms of poorly controlled and active disease in at least 20 swollen, tender joints; or

2.6.2 Patient has persistent symptoms of poorly controlled and active disease in at least 4 joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and

2.7 Either:

2.7.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or

2.7.2 C-reactive protein levels not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Initial application — (severe chronic plaque psoriasis) only from a dermatologist. Approvals valid for 4 months for applications meeting the following criteria:

Either:

1 Both:
   1.1 The patient has had an initial Special Authority approval for adalimumab for severe chronic plaque psoriasis; and
   1.2 Either:
      1.2.1 The patient has experienced intolerable side effects from adalimumab; or
      1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for severe chronic plaque psoriasis; or

continued…
continued...

2. All of the following:
   2.1 Either:
      2.1.1 Patient has "whole body" severe chronic plaque psoriasis with a Psoriasis Area and Severity Index (PASI) score of greater than 15, where lesions have been present for at least 6 months from the time of initial diagnosis; or
      2.1.2 Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and
   2.2 Patient has tried, but had an inadequate response (see Note) to, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, methotrexate, ciclosporin, or acitretin; and
   2.3 A PASI assessment has been completed for at least the most recent prior treatment course (but preferably all prior treatment courses), preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course; and
   2.4 The most recent PASI assessment is no more than 1 month old at the time of application.

Note: "Inadequate response" is defined as: for whole body severe chronic plaque psoriasis, a PASI score of greater than 15, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment; for severe chronic plaque psoriasis of the face, hand or foot, at least 2 of the 3 PASI symptom subscores for erythema, thickness and scaling are rated as severe or very severe, and the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment.

Initial application — (ankylosing spondylitis) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:
   1 Both:
      1.1 The patient has had an initial Special Authority approval for adalimumab for ankylosing spondylitis; and
      1.2 Either:
         1.2.1 The patient has experienced intolerable side effects from adalimumab; or
         1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for ankylosing spondylitis; or
   2 All of the following:
      2.1 Patient has a confirmed diagnosis of ankylosing spondylitis present for more than six months; and
      2.2 Patient has low back pain and stiffness that is relieved by exercise but not by rest; and
      2.3 Patient has bilateral sacroiliitis demonstrated by plain radiographs, CT or MRI scan; and
      2.4 Patient's ankylosing spondylitis has not responded adequately to treatment with two or more non-steroidal anti-inflammatory drugs (NSAIDs), in combination with anti-ulcer therapy if indicated, while patient was undergoing at least 3 months of a regular exercise regimen for ankylosing spondylitis; and
      2.5 Either:
         2.5.1 Patient has limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by the following Bath Ankylosing Spondylitis Metrology Index (BASMI) measures: a modified Schober's test of less than or equal to 4 cm and lumbar side flexion measurement of less than or equal to 10 cm (mean of left and right); or
         2.5.2 Patient has limitation of chest expansion by at least 2.5 cm below the average normal values corrected for age and gender (see Notes); and
      2.6 A Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 6 on a 0-10 scale.

Notes: The BASDAI must have been determined at the completion of the 3 month exercise trial, but prior to ceasing NSAID treatment. The BASDAI measure must be no more than 1 month old at the time of initial application.

Average normal chest expansion corrected for age and gender:
18-24 years - Male: 7.0 cm; Female: 5.5 cm

continued...
25-34 years - Male: 7.5 cm; Female: 5.5 cm
35-44 years - Male: 6.5 cm; Female: 4.5 cm
45-54 years - Male: 6.0 cm; Female: 5.0 cm
55-64 years - Male: 5.5 cm; Female: 4.0 cm
65-74 years - Male: 4.0 cm; Female: 4.0 cm
75+ years - Male: 3.0 cm; Female: 2.5 cm

Initial application — (psoriatic arthritis) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:
1. Both:
   1.1 The patient has had an initial Special Authority approval for adalimumab for psoriatic arthritis; and
2. Either:
   1.2.1 The patient has experienced intolerable side effects from adalimumab; or
   1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for psoriatic arthritis; or

2. All of the following:
   2.1 Patient has had severe active psoriatic arthritis for six months duration or longer; and
   2.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
   2.3 Patient has tried and not responded to at least three months of sulfasalazine at a dose of at least 2 g per day or leflunomide at a dose of up to 20 mg daily (or maximum tolerated doses); and
   2.4 Either:
      2.4.1 Patient has persistent symptoms of poorly controlled and active disease in at least 15 swollen, tender joints; or
      2.4.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and

2.5 Any of the following:
   2.5.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
   2.5.2 Patient has an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or
   2.5.3 ESR and CRP not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Initial application — (pyoderma gangrenosum) only from a dermatologist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:
1. Patient has pyoderma gangrenosum*; and
2. Patient has received three months of conventional therapy including a minimum of three pharmaceuticals (e.g. prednisone, ciclosporine, azathioprine, or methotrexate) and not received an adequate response; and
3. A maximum of 4 doses.

Note: Indications marked with * are unapproved indications.

Initial application — (adult-onset Still's disease) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:
1. Both:
   1.1 Either:
      1.1.1 The patient has had an initial Special Authority approval for adalimumab for adult-onset Still's disease (AOSD); or

continued…
continued…

1.1.2 The patient has been started on tocilizumab for AOSD in a DHB hospital in accordance with the HML rules; and

1.2 Either:

1.2.1 The patient has experienced intolerable side effects from adalimumab and/or tocilizumab; or

1.2.2 The patient has received insufficient benefit from at least a three-month trial of adalimumab and/or tocilizumab such that they do not meet the renewal criteria for AOSD; or

2 All of the following:

2.1 Patient diagnosed with AOSD according to the Yamaguchi criteria (J Rheumatol 1992;19:424-430); and

2.2 Patient has tried and not responded to at least 6 months of glucocorticosteroids at a dose of at least 0.5 mg/kg, non-steroidal anti-inflammatory drugs (NSAIDs) and methotrexate; and

2.3 Patient has persistent symptoms of disabling poorly controlled and active disease.

Renewal — (juvenile idiopathic arthritis) only from a named specialist, rheumatologist or Practitioner on the recommendation of a named specialist or rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

1 Either:

1.1 Applicant is a named specialist or rheumatologist; or

1.2 Applicant is a Practitioner and confirms that a named specialist or rheumatologist has provided a letter, email or fax recommending that the patient continues with etanercept treatment; and

2 Subsidised as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and

3 Either:

3.1 Following 3 to 4 months’ initial treatment, the patient has at least a 50% decrease in active joint count and an improvement in physician’s global assessment from baseline; or

3.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count and continued improvement in physician’s global assessment from baseline.

Renewal — (rheumatoid arthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

1 Either:

1.1 Applicant is a rheumatologist; or

1.2 Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with etanercept treatment; and

2 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and

3 Either:

3.1 Following 3 to 4 months’ initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or

3.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and

4 Etanercept to be administered at doses no greater than 50 mg every 7 days.

Renewal — (severe chronic plaque psoriasis) only from a dermatologist or Practitioner on the recommendation of a dermatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

1 Either:

1.1 Applicant is a dermatologist; or

1.2 Applicant is a Practitioner and confirms that a dermatologist has provided a letter, email or fax recommending that the patient continues with etanercept treatment; and

continued…
2 Either:

2.1 Both:
2.1.1 Patient had “whole body” severe chronic plaque psoriasis at the start of treatment; and
2.1.2 Following each prior etanercept treatment course the patient has a PASI score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-treatment baseline value; or

2.2 Both:
2.2.1 Patient had severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot at the start of treatment; and
2.2.2 Either:
2.2.2.1 Following each prior etanercept treatment course the patient has a reduction in the PASI symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the treatment course baseline values; or
2.2.2.2 Following each prior etanercept treatment course the patient has a reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre-treatment baseline value; and

3 Etanercept to be administered at doses no greater than 50 mg every 7 days.

Note: A treatment course is defined as a minimum of 12 weeks of etanercept treatment

Renewal — (ankylosing spondylitis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:
All of the following:
1 Either:
1.1 Applicant is a rheumatologist; or
1.2 Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with etanercept treatment; and

2 Following 12 weeks’ initial treatment and for subsequent renewals, treatment has resulted in an improvement in BASDAI of 4 or more points from pre-treatment baseline on a 10 point scale, or an improvement in BASDAI of 50%, whichever is less; and

3 Physician considers that the patient has benefited from treatment and that continued treatment is appropriate; and

4 Etanercept to be administered at doses no greater than 50 mg every 7 days.

Renewal — (psoriatic arthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:
All of the following:
1 Either:
1.1 Applicant is a rheumatologist; or
1.2 Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with etanercept treatment; and

2 Either:
2.1 Following 3 to 4 months’ initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or

2.2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to prior etanercept treatment in the opinion of the treating physician; and

3 Etanercept to be administered at doses no greater than 50 mg every 7 days.

Renewal — (pyoderma gangrenosum) only from a dermatologist or Practitioner on the recommendation of a dermatologist. Approvals valid for 4 months for applications meeting the following criteria:
All of the following:
1 Patient has shown clinical improvement; and
2 Patient continues to require treatment; and
3 A maximum of 4 doses.

continued
ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

### Immune Modulators

**ANTITHYMOCYTE GLOBULIN (EQUINE) – PCT only – Specialist**

- Inj 50 mg per ml, 5 ml ........................................................................... 2,351.25
  - ✔ ATGAM

**BACILLUS CALMETTE-GUERIN (BCG) VACCINE – PCT only – Specialist**

- Subsidised only for bladder cancer.
- Inj 2-8 × 100 million CFU ................................................................. 149.37
  - ✔ OncoTICE

### Monoclonal Antibodies

**ADALIMUMAB – Special Authority see SA1742 below – Retail pharmacy**

- Inj 20 mg per 0.4 ml prefilled syringe ............................................. 1,599.96
  - ✔ Humira
- Inj 40 mg per 0.8 ml prefilled pen ................................................. 1,599.96
  - ✔ HumiraPen
- Inj 40 mg per 0.8 ml prefilled syringe ............................................. 1,599.96
  - ✔ Humira

**SA1742 Special Authority for Subsidy**

**Initial application — (rheumatoid arthritis) only from a rheumatologist.** Approvals valid for 6 months for applications meeting the following criteria:

**Either:**

1. Both:
   1.1 The patient has had an initial Special Authority approval for etanercept for rheumatoid arthritis; and
   1.2 Either:
      1.2.1 The patient has experienced intolerable side effects from etanercept; or
      1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for rheumatoid arthritis; or

2. All of the following:
   2.1 Patient has had severe and active erosive rheumatoid arthritis (either confirmed by radiology imaging, or the patient is cyclic citrullinated peptide (CCP) antibody positive) for six months duration or longer; and
   2.2 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
   2.3 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
   2.4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with sulfasalazine and hydroxychloroquine sulphate (at maximum tolerated doses); and
   2.5 Any of the following:
      2.5.1 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with the maximum tolerated dose of ciclosporin; or
      2.5.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with intramuscular gold; or

continued…
2.5.3 Patient has tried and not responded to at least three months of therapy at the maximum tolerated dose of leflunomide alone or in combination with oral or parenteral methotrexate; and

2.6 Either:

2.6.1 Patient has persistent symptoms of poorly controlled and active disease in at least 20 swollen, tender joints; or

2.6.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and

2.7 Either:

2.7.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or

2.7.2 C-reactive protein levels not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Initial application — (Crohn’s disease - adults) only from a gastroenterologist. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

1 Patient has severe active Crohn’s disease; and

2 Any of the following:

2.1 Patient has a Crohn’s Disease Activity Index (CDAI) score of greater than or equal to 300; or

2.2 Patient has extensive small intestine disease affecting more than 50 cm of the small intestine; or

2.3 Patient has evidence of short gut syndrome or would be at risk of short gut syndrome with further bowel resection; or

2.4 Patient has an ileostomy or colostomy, and has intestinal inflammation; and

3 Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior systemic therapy with immunomodulators at maximum tolerated doses (unless contraindicated) and corticosteroids; and

4 Surgery (or further surgery) is considered to be clinically inappropriate.

Initial application — (Crohn’s disease - children) only from a gastroenterologist. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

1 Paediatric patient has severe active Crohn’s disease; and

2 Either:

2.1 Patient has a Paediatric Crohn’s Disease Activity Index (PCDAI) score of greater than or equal to 30; or

2.2 Patient has extensive small intestine disease; and

3 Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior systemic therapy with immunomodulators at maximum tolerated doses (unless contraindicated) and corticosteroids; and

4 Surgery (or further surgery) is considered to be clinically inappropriate.

Initial application — (severe chronic plaque psoriasis) only from a dermatologist. Approvals valid for 4 months for applications meeting the following criteria:

Either:

1 Both:

1.1 The patient has had an initial Special Authority approval for etanercept for severe chronic plaque psoriasis; and

1.2 Either:

1.2.1 The patient has experienced intolerable side effects from etanercept; or

1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for severe chronic plaque psoriasis; or

2 All of the following:

2.1 Either:

continued…
2.1.1 Patient has "whole body" severe chronic plaque psoriasis with a Psoriasis Area and Severity Index (PASI) score of greater than 15, where lesions have been present for at least 6 months from the time of initial diagnosis; or

2.1.2 Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and

2.2 Patient has tried, but had an inadequate response (see Note) to, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, methotrexate, ciclosporin, or acitretin; and

2.3 A PASI assessment has been completed for at least the most recent prior treatment course (but preferably all prior treatment courses), preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course; and

2.4 The most recent PASI assessment is no more than 1 month old at the time of application.

Note: "Inadequate response" is defined as: for whole body severe chronic plaque psoriasis, a PASI score of greater than 15, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment; for severe chronic plaque psoriasis of the face, hand or foot, at least 2 of the 3 PASI symptom subscores for erythema, thickness and scaling are rated as severe or very severe, and the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment.

Initial application — (ankylosing spondylitis) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

1 Both:
   1.1 The patient has had an initial Special Authority approval for etanercept for ankylosing spondylitis; and
   1.2 Either:
      1.2.1 The patient has experienced intolerable side effects from etanercept; or
      1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for ankylosing spondylitis; or

2 All of the following:
   2.1 Patient has a confirmed diagnosis of ankylosing spondylitis for more than six months; and
   2.2 Patient has low back pain and stiffness that is relieved by exercise but not by rest; and
   2.3 Patient has bilateral sacroiliitis demonstrated by plain radiographs, CT or MRI scan; and
   2.4 Patient's ankylosing spondylitis has not responded adequately to treatment with two or more non-steroidal anti-inflammatory drugs (NSAIDs), in combination with anti-ulcer therapy if indicated, while patient was undergoing at least 3 months of a regular exercise regimen for ankylosing spondylitis; and

2.5 Either:
   2.5.1 Patient has limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by the following Bath Ankylosing Spondylitis Metrology Index (BASMI) measures: a modified Schober's test of less than or equal to 4 cm and lumbar side flexion measurement of less than or equal to 10 cm (mean of left and right); or
   2.5.2 Patient has limitation of chest expansion by at least 2.5 cm below the following average normal values corrected for age and gender (see Notes); and

2.6 A Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 6 on a 0-10 scale.

Notes: The BASDAI must have been determined at the completion of the 3 month exercise trial, but prior to ceasing NSAID treatment. The BASDAI measure must be no more than 1 month old at the time of initial application.

Average normal chest expansion corrected for age and gender:
- 18-24 years - Male: 7.0 cm; Female: 5.5 cm
- 25-34 years - Male: 7.5 cm; Female: 5.5 cm
- 35-44 years - Male: 6.5 cm; Female: 4.5 cm

continued…
continued...

45-54 years - Male: 6.0 cm; Female: 5.0 cm
55-64 years - Male: 5.5 cm; Female: 4.0 cm
65-74 years - Male: 4.0 cm; Female: 4.0 cm
75+ years - Male: 3.0 cm; Female: 2.5 cm

**Initial application — (psoriatic arthritis)** only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

1. Both:
   1.1 The patient has had an initial Special Authority approval for etanercept for psoriatic arthritis; and
   1.2 Either:
      1.2.1 The patient has experienced intolerable side effects from etanercept; or
      1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for psoriatic arthritis; or

2. All of the following:
   2.1 Patient has had severe active psoriatic arthritis for six months duration or longer; and
   2.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
   2.3 Patient has tried and not responded to at least three months of sulfasalazine at a dose of at least 2 g per day or leflunomide at a dose of up to 20 mg daily (or maximum tolerated doses); and
   2.4 Either:
      2.4.1 Patient has persistent symptoms of poorly controlled and active disease in at least 15 swollen, tender joints; or
      2.4.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and

2.5 Any of the following:
   2.5.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
   2.5.2 Patient has an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or
   2.5.3 ESR and CRP not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

**Initial application — (juvenile idiopathic arthritis)** only from a named specialist or rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

1. Both:
   1.1 The patient has had an initial Special Authority approval for etanercept for juvenile idiopathic arthritis (JIA); and
   1.2 Either:
      1.2.1 The patient has experienced intolerable side effects from etanercept; or
      1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for juvenile idiopathic arthritis; or

2. All of the following:
   2.1 To be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
   2.2 Patient diagnosed with JIA; and
   2.3 Patient has had severe active polyarticular course JIA for 6 months duration or longer; and
   2.4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate (at a dose of 10-20 mg/m² weekly or at the maximum tolerated dose) in combination with either oral corticosteroids (prednisone 0.25 mg/kg or at the maximum tolerated dose) or a full trial of serial intra-articular corticosteroid injections; and

continued…

▲Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber or pharmacist.

 asterisk Three months or six months, as applicable, dispensed all-at-once
continued...

2.5 Both:

2.5.1 Either:

2.5.1.1 Patient has persistent symptoms of poorly-controlled and active disease in at least 20 swollen, tender joints; or

2.5.1.2 Patient has persistent symptoms of poorly-controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, shoulder, cervical spine, hip; and

2.5.2 Physician's global assessment indicating severe disease.

Initial application — (fistulising Crohn’s disease) only from a gastroenterologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

1 Patient has confirmed Crohn’s disease; and

2 Either:

2.1 Patient has one or more complex externally draining enterocutaneous fistula(e); or

2.2 Patient has one or more rectovaginal fistula(e); and

3 A Baseline Fistula Assessment has been completed and is no more than 1 month old at the time of application; and

4 The patient will be assessed for response to treatment after 4 months’ adalimumab treatment (see Note).

Note: A maximum of 4 months’ adalimumab will be subsidised on an initial Special Authority approval for fistulising Crohn’s disease.

Initial application — (pyoderma gangrenosum) only from a dermatologist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

1 Patient has pyoderma gangrenosum*; and

2 Patient has received three months of conventional therapy including a minimum of three pharmaceuticals (e.g. prednisone, ciclosporin, azathioprine, or methotrexate) and not received an adequate response; and

3 A maximum of 4 doses.

Note: Note: Indications marked with * are unapproved indications.

Initial application — (adult-onset Still’s disease) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

1 Both:

1.1 Either:

1.1.1 The patient has had an initial Special Authority approval for etanercept for adult-onset Still’s disease (AOSD); or

1.1.2 The patient has been started on tocilizumab for AOSD in a DHB hospital in accordance with the HML rules; and

1.2 Either:

1.2.1 The patient has experienced intolerable side effects from etanercept and/or tocilizumab; or

1.2.2 The patient has received insufficient benefit from at least a three-month trial of etanercept and/or tocilizumab such that they do not meet the renewal criteria for AOSD; or

2 All of the following:

2.1 Patient diagnosed with AOSD according to the Yamaguchi criteria (J Rheumatol 1992;19:424-430); and

2.2 Patient has tried and not responded to at least 6 months of glucocorticosteroids at a dose of at least 0.5 mg/kg, non-steroidal anti-inflammatory drugs (NSAIDs) and methotrexate; and

2.3 Patient has persistent symptoms of disabling poorly controlled and active disease.

Renewal — (rheumatoid arthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

continued…
1 Either:
   1.1 Applicant is a rheumatologist; or
   1.2 Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that
       the patient continues with adalimumab treatment; and
2 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by
   toxicity or intolerance; and
3 Either:
   3.1 Following 3 to 4 months’ initial treatment, the patient has at least a 50% decrease in active joint count from baseline
       and a clinically significant response to treatment in the opinion of the physician; or
   3.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint
       count from baseline and a clinically significant response to treatment in the opinion of the physician; and
4 Either:
   4.1 Adalimumab to be administered at doses no greater than 40 mg every 14 days; or
   4.2 Patient cannot take concomitant methotrexate and requires doses of adalimumab higher than 40 mg every 14 days
       to maintain an adequate response.

Renewal — (Crohn's disease - adults) only from a gastroenterologist or Practitioner on the recommendation of a
   gastroenterologist. Approvals valid for 6 months for applications meeting the following criteria:
All of the following:
1 Either:
   1.1 Applicant is a gastroenterologist; or
   1.2 Applicant is a Practitioner and confirms that a gastroenterologist has provided a letter, email or fax recommending
       that the patient continues with adalimumab treatment; and
2 Either:
   2.1 Either:
       2.1.1 CDAI score has reduced by 100 points from the CDAI score when the patient was initiated on adalimumab; or
       2.1.2 CDAI score is 150 or less; or
   2.2 Both:
       2.2.1 The patient has demonstrated an adequate response to treatment but CDAI score cannot be assessed; and
       2.2.2 Applicant to indicate the reason that CDAI score cannot be assessed; and
3 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Renewal — (Crohn's disease - children) only from a gastroenterologist or Practitioner on the recommendation of a
   gastroenterologist. Approvals valid for 6 months for applications meeting the following criteria:
All of the following:
1 Either:
   1.1 Applicant is a gastroenterologist; or
   1.2 Applicant is a Practitioner and confirms that a gastroenterologist has provided a letter, email or fax recommending
       that the patient continues with adalimumab treatment; and
2 Either:
   2.1 Either:
       2.1.1 PCDAI score has reduced by 10 points from the PCDAI score when the patient was initiated on
           adalimumab; or
       2.1.2 PCDAI score is 15 or less; or
   2.2 Both:
       2.2.1 The patient has demonstrated an adequate response to treatment but PCDAI score cannot be assessed; and
       2.2.2 Applicant to indicate the reason that PCDAI score cannot be assessed; and

continued…
2.2.2 Applicant to indicate the reason that PCDAI score cannot be assessed; and

3 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

**Renewal — (severe chronic plaque psoriasis)** only from a dermatologist or Practitioner on the recommendation of a dermatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

1 Either:
   1.1 Applicant is a dermatologist; or
   1.2 Applicant is a Practitioner and confirms that a dermatologist has provided a letter, email or fax recommending that the patient continues with adalimumab treatment; and

2 Either:
   2.1 Both:
      2.1.1 Patient had “whole body” severe chronic plaque psoriasis at the start of treatment; and
      2.1.2 Following each prior adalimumab treatment course the patient has a PASI score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-adalimumab treatment baseline value; or

   2.2 Both:
      2.2.1 Patient had severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot at the start of treatment; and
      2.2.2 Either:
         2.2.2.1 Following each prior adalimumab treatment course the patient has a reduction in the PASI symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the treatment course baseline values; or
         2.2.2.2 Following each prior adalimumab treatment course the patient has a reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre-adalimumab treatment baseline value; and

3 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Note: A treatment course is defined as a minimum of 12 weeks adalimumab treatment

**Renewal — (ankylosing spondylitis)** only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

1 Either:
   1.1 Applicant is a rheumatologist; or
   1.2 Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with adalimumab treatment; and

2 Following 12 weeks’ initial treatment and for subsequent renewals, treatment has resulted in an improvement in BASDAI of 4 or more points from pre-treatment baseline on a 10 point scale, or an improvement in BASDAI of 50%, whichever is less; and

3 Physician considers that the patient has benefited from treatment and that continued treatment is appropriate; and

4 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

**Renewal — (psoriatic arthritis)** only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

1 Either:
   1.1 Applicant is a rheumatologist; or
   1.2 Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with adalimumab treatment; and

2 Either:
   continued…
continued...

2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or

2.2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to prior adalimumab treatment in the opinion of the treating physician; and

3 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Renewal — (juvenile idiopathic arthritis) only from a named specialist, rheumatologist or Practitioner on the recommendation of a named specialist or rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

1 Either:
   1.1 Applicant is a named specialist or rheumatologist; or
   1.2 Applicant is a Practitioner and confirms that a named specialist or rheumatologist has provided a letter, email or fax recommending that the patient continues with adalimumab treatment; and

2 Subsidised as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and

3 Either:
   3.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count and an improvement in physician's global assessment from baseline; or
   3.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count and continued improvement in physician's global assessment from baseline.

Renewal — (fistulising Crohn's disease) only from a gastroenterologist or Practitioner on the recommendation of a gastroenterologist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

1 Either:
   1.1 Applicant is a gastroenterologist; or
   1.2 Applicant is a Practitioner and confirms that a gastroenterologist has provided a letter, email or fax recommending that the patient continues with adalimumab treatment; and

2 Either:
   2.1 The number of open draining fistulae have decreased from baseline by at least 50%; or
   2.2 There has been a marked reduction in drainage of all fistula(e) from baseline as demonstrated by a reduction in the Fistula Assessment score, together with less induration and patient-reported pain.

Renewal — (pyoderma gangrenosum) only from a dermatologist or Practitioner on the recommendation of a dermatologist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

1 Patient has shown clinical improvement; and
2 Patient continues to require treatment; and
3 A maximum of 4 doses.

Renewal — (adult-onset Still's disease) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

1 Either:
   1.1 Applicant is a rheumatologist; or
   1.2 Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with adalimumab treatment; and

2 The patient has a sustained improvement in inflammatory markers and functional status.
Special Authority for Subsidy

Initial application — (wet age related macular degeneration) only from an ophthalmologist. Approvals valid for 3 months for applications meeting the following criteria:

Either:

1. All of the following:
   1.1 Any of the following:
      1.1.1 Wet age-related macular degeneration (wet AMD); or
      1.1.2 Polypoidal choroidal vasculopathy; or
      1.1.3 Choroidal neovascular membrane from causes other than wet AMD; and
   1.2 Either:
      1.2.1 The patient has developed severe endophthalmitis or severe posterior uveitis following treatment with bevacizumab; or
      1.2.2 There is worsening of vision or failure of retina to dry despite three intraocular injections of bevacizumab four weeks apart; and
   1.3 There is no structural damage to the central fovea of the treated eye; and
   1.4 Patient has not previously been treated with ranibizumab for longer than 3 months; or

2. Any of the following:
   2.1 Patient has current approval to use ranibizumab for treatment of wAMD and was found to be intolerant to ranibizumab within 3 months; or
   2.2 Patient has previously* (*before June 2018) received treatment with ranibizumab for wAMD and disease was stable while on treatment; or
   2.3 Patient has current approval to use ranibizumab for treatment of wAMD; or
   2.4 Patient is currently receiving treatment with aflibercept and has documented previous poor response to bevacizumab.

Note: Criteria 2.3 and 2.4 will be removed from 1 January 2019.

Initial application — (diabetic macular oedema) only from an ophthalmologist. Approvals valid for 4 months for applications meeting the following criteria:

Either:

1. All of the following:
   1.1 Patient has centre involving diabetic macular oedema (DMO); and
   1.2 Patient’s disease is non-responsive to 4 doses of intravitreal bevacizumab when administered 4-6 weekly; and
   1.3 Patient has reduced visual acuity between 6/9 – 6/36 with functional awareness of reduction in vision; and
   1.4 Patient has DMO within central OCT (ocular coherence tomography) subfield > 350 micrometers; and
   1.5 There is no centre-involving sub-retinal fibrosis or foveal atrophy; or

2. Patient is currently receiving treatment with aflibercept and has documented previous poor response to bevacizumab.

Note: Criterion 2 will be removed from 1 January 2019.

Renewal — (wet age related macular degeneration) only from an ophthalmologist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

1. Documented benefit must be demonstrated to continue; and
2. Patient’s vision is 6/36 or better on the Snellen visual acuity score; and
3. There is no structural damage to the central fovea of the treated eye.

Renewal — (diabetic macular oedema) only from an ophthalmologist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

1. There is stability or two lines of Snellen visual acuity gain; and
continued...

2 There is structural improvement on OCT scan (with reduction in intra-retinal cysts, central retinal thickness, and sub-retinal fluid); and
3 Patient's vision is 6/36 or better on the Snellen visual acuity score; and
4 There is no centre-involving sub-retinal fibrosis or foveal atrophy; and
5 After each consecutive 12 months treatment with (2nd line anti-VEGF agent), patient has retrialled with at least one injection of bevacizumab and had no response.

CETUXIMAB – PCT only – Specialist – Special Authority see SA1697 below

<table>
<thead>
<tr>
<th>Description</th>
<th>Price</th>
<th>Subsidised</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 5 mg per ml, 20 ml vial</td>
<td>364.00</td>
<td>✔ Erbitux</td>
</tr>
<tr>
<td>Inj 5 mg per ml, 100 ml vial</td>
<td>1,820.00</td>
<td>✔ Erbitux</td>
</tr>
<tr>
<td>Inj 1 mg for ECP</td>
<td>3.82</td>
<td>✔ Baxter</td>
</tr>
</tbody>
</table>

**SA1697** Special Authority for Subsidy

Initial application only from a medical oncologist or medical practitioner on the recommendation of a medical oncologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

1. Patient has locally advanced, non-metastatic, squamous cell cancer of the head and neck; and
2. Patient is contraindicated to, or is intolerant of, cisplatin; and
3. Patient has good performance status; and
4. To be administered in combination with radiation therapy.

OBINUTUZUMAB – PCT only – Specialist – Special Authority see SA1627 below

<table>
<thead>
<tr>
<th>Description</th>
<th>Price</th>
<th>Subsidised</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 25 mg per ml, 40 ml vial</td>
<td>5,910.00</td>
<td>✔ Gazyva</td>
</tr>
<tr>
<td>Inj 1 mg for ECP</td>
<td>6.21</td>
<td>✗ Baxter</td>
</tr>
</tbody>
</table>

**SA1627** Special Authority for Subsidy

Initial application — (chronic lymphocytic leukaemia) only from a haematologist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

1. The patient has progressive Binet stage A, B or C CD20+ chronic lymphocytic leukaemia requiring treatment; and
2. The patient is obinutuzumab treatment naive; and
3. The patient is not eligible for full dose FCR due to comorbidities with a score > 6 on the Cumulative Illness Rating Scale (CIRS) or reduced renal function (creatinine clearance < 70mL/min); and
4. Patient has adequate neutrophil and platelet counts* unless the cytopenias are a consequence of marrow infiltration by CLL; and
5. Patient has good performance status; and
6. Obinutuzumab to be administered at a maximum cumulative dose of 8,000 mg and in combination with chlorambucil for a maximum of 6 cycles.

Notes: Chronic lymphocytic leukaemia includes small lymphocytic lymphoma. Comorbidity refers only to illness/impairment other than CLL induced illness/impairment in the patient. ‘Good performance status’ means ECOG score of 0-1, however, in patients temporarily debilitated by their CLL disease symptoms a higher ECOG (2 or 3) is acceptable where treatment with obinutuzumab is expected to improve symptoms and improve ECOG score to < 2.

* Neutrophil greater than or equal to 1.5 x 10^9/L and platelets greater than or equal to 75 x 10^9/L.

OMALIZUMAB – Special Authority see SA1744 below – Retail pharmacy

<table>
<thead>
<tr>
<th>Description</th>
<th>Price</th>
<th>Subsidised</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 150 mg prefilled syringe</td>
<td>450.00</td>
<td>✔ Xolair</td>
</tr>
<tr>
<td>Inj 150 mg vial</td>
<td>450.00</td>
<td>✔ Xolair</td>
</tr>
</tbody>
</table>

**SA1744** Special Authority for Subsidy

Initial application — (severe asthma) only from a respiratory specialist or clinical immunologist. Approvals valid for 6 months for applications meeting the following criteria:

continued…
ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

Subsidy
(Manufacturer's Price) $ Per
Fully Subsidised ✔
Brand or
Generic Manufacturer

continued...

All of the following:
1 Patient must be aged 6 years or older; and
2 Patient has a diagnosis of severe asthma; and
3 Past or current evidence of atopy, documented by skin prick testing or RAST; and
4 Total serum human immunoglobulin E (IgE) between 76 IU/mL and 1300 IU/ml at baseline; and
5 Proven adherence with optimal inhaled therapy including high dose inhaled corticosteroid (budesonide 1,600 mcg per day or fluticasone propionate 1,000 mcg per day or equivalent), plus long-acting beta-2 agonist therapy (at least salmeterol 50 mcg bd or eformoterol 12 mcg bd) for at least 12 months, unless contraindicated or not tolerated; and
6 Either:
   6.1 Patient has received courses of systemic corticosteroids equivalent to at least 28 days treatment in the past 12 months, unless contraindicated or not tolerated; or
   6.2 Patient has had at least 4 exacerbations needing systemic corticosteroids in the previous 12 months, where an exacerbation is defined as either documented use of oral corticosteroids for at least 3 days or parenteral steroids; and
7 Patient has an Asthma Control Test (ACT) score of 10 or less; and
8 Baseline measurements of the patient's asthma control using the ACT and oral corticosteroid dose must be made at the time of application, and again at around 26 weeks after the first dose to assess response to treatment.

Initial application — (severe chronic spontaneous urticaria) only from a clinical immunologist or dermatologist. Approvals valid for 6 months for applications meeting the following criteria:
All of the following:
1 Patient must be aged 12 years or older; and
2 Either:
   2.1 Both:
      2.1.1 Patient is symptomatic with Urticaria Activity Score 7 (UAS7) of 20 or above; and
      2.1.2 Patient has a Dermatology life quality index (DLQI) of 10 or greater; or
   2.2 Patient has a Urticaria Control Test (UCT) of 8 or less; and
3 Any of the following:
   3.1 Patient has been taking high dose antihistamines (e.g. 4 times standard dose) and ciclosporin (> 3 mg/kg day) for at least 6 weeks; or
   3.2 Patient has been taking high dose antihistamines (e.g. 4 times standard dose) and at least 3 courses of systemic corticosteroids (> 20 mg prednisone per day for at least 5 days) in the previous 6 months; or
   3.3 Patient has developed significant adverse effects whilst on corticosteroids or ciclosporin; and
4 Either:
   4.1 Treatment to be stopped if inadequate response* following 4 doses; or
   4.2 Complete response* to 6 doses of omalizumab.

Renewal — (severe asthma) only from a clinical immunologist or respiratory specialist. Approvals valid for 2 years for applications meeting the following criteria:
Both:
1 An increase in the Asthma Control Test (ACT) score of at least 5 from baseline; and
2 A reduction in the maintenance oral corticosteroid dose or number of exacerbations of at least 50% from baseline.

Renewal — (severe chronic spontaneous urticaria) only from a clinical immunologist or dermatologist. Approvals valid for 6 months for applications meeting the following criteria:
Either:
1 Patient has previously adequately responded* to 6 doses of omalizumab; or
2 Both:
   2.1 Patient has previously had a complete response* to 6 doses of omalizumab; and
   2.2 Patient has relapsed after cessation of omalizumab therapy.

continued…
Note: *Inadequate response defined as less than 50% reduction in baseline UAS7 and DLQI score, or an increase in Urticaria Control Test (UCT) score of less than 4 from baseline. Patient is to be reassessed for response after 4 doses of omalizumab. Complete response is defined as UAS7 less than or equal to 6 and DLQI less than or equal to 5; or UCT of 16. Relapse of chronic urticaria on stopping prednisone/ciclosporin does not justify the funding of omalizumab.

PERTUZUMAB – PCT only – Specialist – Special Authority see SA1606 below

Inj 30 mg per ml, 14 ml vial...........................................................3,927.00
Inj 420 mg for ECP .......................................................................3,927.00

[SA1606] Special Authority for Subsidy
Initial application — (metastatic breast cancer) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:
All of the following:
1. The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
2. Either:
   2.1. Patient is chemotherapy treatment naïve; or
   2.2. Patient has not received prior treatment for their metastatic disease and has had a treatment free interval of at least 12 months between prior (neo)adjuvant chemotherapy treatment and diagnosis of metastatic breast cancer; and
3. The patient has good performance status (ECOG grade 0-1); and
4. Pertuzumab to be administered in combination with trastuzumab; and
5. Pertuzumab maximum first dose of 840 mg, followed by maximum of 420 mg every 3 weeks; and
6. Pertuzumab to be discontinued at disease progression.

Renewal — (metastatic breast cancer) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:
Both:
1. The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
2. The cancer has not progressed at any time point during the previous 12 months whilst on pertuzumab and trastuzumab.

RITUXIMAB – PCT only – Specialist – Special Authority see SA1686 below

Inj 100 mg per 10 ml vial ..............................................................1,075.50
Inj 500 mg per 50 ml vial ..............................................................2,688.30
Inj 1 mg for ECP ..................................................................................5.64

[SA1686] Special Authority for Subsidy
Initial application — (Post-transplant) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:
Both:
1. The patient has B-cell post-transplant lymphoproliferative disorder*; and
2. To be used for a maximum of 8 treatment cycles.

Note: Indications marked with * are unapproved indications.

Initial application — (Indolent, Low-grade lymphomas or hairy cell leukaemia*) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 9 months for applications meeting the following criteria:
Either:
1. Both:
   1.1. The patient has indolent low grade NHL or hairy cell leukaemia* with relapsed disease following prior chemotherapy; and
   1.2. To be used for a maximum of 6 treatment cycles; or

continued…
continued...

2 Both:
   2.1 The patient has indolent, low grade lymphoma or hairy cell leukaemia* requiring first-line systemic chemotherapy; and
   2.2 To be used for a maximum of 6 treatment cycles.

Note: 'Indolent, low-grade lymphomas' includes follicular, mantle, marginal zone and lymphoplasmacytic/Waldenstrom macroglobulinaemia. *Hairy cell leukaemia includes hairy cell leukaemia variant.* Unapproved indication.

Initial application — (Aggressive CD20 positive NHL) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

Either:

1 All of the following:
   1.1 The patient has treatment naive aggressive CD20 positive NHL; and
   1.2 To be used with a multi-agent chemotherapy regimen given with curative intent; and
   1.3 To be used for a maximum of 8 treatment cycles; or

2 Both:
   2.1 The patient has aggressive CD20 positive NHL with relapsed disease following prior chemotherapy; and
   2.2 To be used for a maximum of 6 treatment cycles.

Note: 'Aggressive CD20 positive NHL' includes large B-cell lymphoma and Burkitt's lymphoma/leukaemia

Initial application — (Chronic Lymphocytic Leukaemia) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

1 The patient has progressive Binet stage A, B or C chronic lymphocytic leukaemia (CLL) requiring treatment; and
2 The patient is rituximab treatment naive; and
3 Either:
   3.1 The patient is chemotherapy treatment naive; or
   3.2 Both:
      3.2.1 The patient's disease has relapsed following no more than three prior lines of chemotherapy treatment; and
      3.2.2 The patient has had a treatment-free interval of 12 months or more if previously treated with fludarabine and cyclophosphamide chemotherapy; and

4 The patient has good performance status; and
5 The patient does not have chromosome 17p deletion CLL; and
6 Rituximab to be administered in combination with fludarabine and cyclophosphamide or bendamustine for a maximum of 6 treatment cycles; and
7 It is planned that the patient receives full dose fludarabine and cyclophosphamide (orally or dose equivalent intravenous administration) or bendamustine.

Note: 'Chronic lymphocytic leukaemia (CLL)' includes small lymphocytic lymphoma. A line of chemotherapy treatment is considered to comprise a known standard therapeutic chemotherapy regimen and supportive treatments. 'Good performance status' means ECOG score of 0-1, however, in patients temporarily debilitated by their CLL disease symptoms a higher ECOG (2 or 3) is acceptable where treatment with rituximab is expected to improve symptoms and improve ECOG score to < 2.

Renewal — (Post-transplant) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 9 months for applications meeting the following criteria:

All of the following:

1 The patient has had a rituximab treatment-free interval of 12 months or more; and
2 The patient has B-cell post-transplant lymphoproliferative disorder*; and
3 To be used for no more than 6 treatment cycles.

Note: Indications marked with * are unapproved indications.

Renewal — (Indolent, Low-grade lymphomas or hairy cell leukaemia*) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 9 months for applications meeting the following criteria:

continued…
continued...

All of the following:
1. The patient has had a rituximab treatment-free interval of 12 months or more; and
2. The patient has indolent, low-grade NHL or hairy cell leukaemia* with relapsed disease following prior chemotherapy; and
3. To be used for no more than 6 treatment cycles.

Note: 'Indolent, low-grade lymphomas' includes follicular, mantle, marginal zone and lymphoplasmacytic/Waldenstrom macroglobulinaemia. “Hairy cell leukaemia includes hairy cell leukaemia variant *Unapproved indication.

Renewal — (Aggressive CD20 positive NHL) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:
1. The patient has had a rituximab treatment-free interval of 12 months or more; and
2. The patient has relapsed refractory/aggressive CD20 positive NHL; and
3. To be used with a multi-agent chemotherapy regimen given with curative intent; and
4. To be used for a maximum of 4 treatment cycles.

Note: 'Aggressive CD20 positive NHL' includes large B-cell lymphoma and Burkitt's lymphoma/leukaemia

Renewal — (Chronic Lymphocytic Leukaemia) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:
1. The patient's disease has relapsed following no more than one prior line of treatment with rituximab for CLL; and
2. The patient has had an interval of 36 months or more since commencement of initial rituximab treatment; and
3. The patient does not have chromosome 17p deletion CLL; and
4. It is planned that the patient receives full dose fludarabine and cyclophosphamide (orally or dose equivalent intravenous administration) or bendamustine; and
5. Rituximab to be administered in combination with fludarabine and cyclophosphamide or bendamustine for a maximum of 6 treatment cycles.

Note: 'Chronic lymphocytic leukaemia (CLL)' includes small lymphocytic lymphoma. A line of chemotherapy treatment is considered to comprise a known standard therapeutic chemotherapy regimen and supportive treatments.

SECUKINUMAB – Special Authority see SA1754 below – Retail pharmacy

Inj 150 mg per ml, 1 ml prefilled syringe.......................................1,599.00 2 ✔

Cosentyx

☛ SA1754 Special Authority for Subsidy

Initial application — (severe chronic plaque psoriasis – second-line biologic) only from a dermatologist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:
1. The patient has had an initial Special Authority approval for adalimumab or etanercept, or has trialled infliximab in a DHB hospital in accordance with the General Rules of the Pharmaceutical Schedule, for severe chronic plaque psoriasis; and
2. Either:
   2.1 The patient has experienced intolerable side effects from adalimumab, etanercept or infliximab; or
   2.2 The patient has received insufficient benefit from adalimumab, etanercept or infliximab; and
3. A Psoriasis Area and Severity Index (PASI) assessment or Dermatology Quality of Life Index (DLQI) assessment has been completed for at least the most recent prior treatment course, preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course; and
4. The most recent PASI or DQLI assessment is no more than 1 month old at the time of application.

Initial application — (severe chronic plaque psoriasis – first-line biologic) only from a dermatologist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:
1. Either:
   1.1 Patient has "whole body" severe chronic plaque psoriasis with a Psoriasis Area and Severity Index (PASI) score of
ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

Subsidy (Manufacturer's Price) $ Per Fully Subsidised Brand or Generic Manufacturer

continued...

greater than 10, where lesions have been present for at least 6 months from the time of initial diagnosis; or

1.2 Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and

2 Patient has tried, but had an inadequate response (see Note) to, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, methotrexate, ciclosporin, or acitretin; and

3 A PASI assessment or Dermatology Quality of Life Index (DLQI) assessment has been completed for at least the most recent prior treatment course, preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course; and

4 The most recent PASI or DLQI assessment is no more than 1 month old at the time of application.

Note: A treatment course is defined as a minimum of 12 weeks of treatment. "Inadequate response" is defined as: for whole body severe chronic plaque psoriasis, a PASI score of greater than 10, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment; for severe chronic plaque psoriasis of the face, hand or foot, at least 2 of the 3 PASI symptom sub scores for erythema, thickness and scaling are rated as severe or very severe, and the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment.

Renewal — (severe chronic plaque psoriasis – first and second-line biologic) only from a dermatologist or medical practitioner on the recommendation of a dermatologist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

1 Either:
   1.1 Patient's PASI score has reduced by 75% or more (PASI 75) as compared to baseline PASI prior to commencing secukinumab; or
   1.2 Patient has a Dermatology Quality of Life Index (DLQI) improvement of 5 or more, as compared to baseline DLQI prior to commencing secukinumab; and

2 Secukinumab to be administered at a maximum dose of 300 mg monthly.

SILTUXIMAB – Special Authority see SA1596 below – Retail pharmacy

Note: Siltuximab is to be administered at doses no greater than 11 mg/kg every 3 weeks.

Inj 100 mg vial .................................................................770.57 1 ✔ Sylvant
Inj 400 mg vial ...............................................................3,082.33 1 ✔ Sylvant

➽ SA1596 Special Authority for Subsidy

Initial application only from a haematologist or rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

1 Patient has severe HHV-8 negative idiopathic multicentric Castleman's Disease; and

2 Treatment with an adequate trial of corticosteroids has proven ineffective; and

3 Siltuximab is to be administered at doses no greater than 11 mg/kg every 3 weeks.

Renewal only from a haematologist or rheumatologist. Approvals valid for 12 months where the treatment remains appropriate and the patient has sustained improvement in inflammatory markers and functional status.

TRASTUZUMAB – PCT only – Specialist – Special Authority see SA1632 below

Inj 150 mg vial .................................................................1,350.00 1 ✔ Herceptin
Inj 440 mg vial ...............................................................3,875.00 1 ✔ Herceptin
Inj 1 mg for ECP ...........................................................9.36 1 mg ✔ Baxter

➽ SA1632 Special Authority for Subsidy

Initial application — (metastatic breast cancer) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

continued…
continued...

All of the following:

1. The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
2. Either:
   2.1. The patient has not previously received lapatinib treatment for HER-2 positive metastatic breast cancer; or
   2.2. Both:
      2.2.1. The patient started lapatinib treatment for metastatic breast cancer but discontinued lapatinib within 3 months of starting treatment due to intolerance; and
      2.2.2. The cancer did not progress whilst on lapatinib; and
3. Either:
   3.1. Trastuzumab will not be given in combination with pertuzumab; or
   3.2. All of the following:
      3.2.1. Trastuzumab to be administered in combination with pertuzumab; and
      3.2.2. Patient has not received prior treatment for their metastatic disease and has had a treatment-free interval of at least 12 months between prior (neo)adjuvant chemotherapy treatment and diagnosis of metastatic breast cancer; and
      3.2.3. The patient has good performance status (ECOG grade 0-1); and
4. Trastuzumab not to be given in combination with lapatinib; and
5. Trastuzumab to be discontinued at disease progression.

Renewal — (metastatic breast cancer) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

1. The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
2. The cancer has not progressed at any time point during the previous 12 months whilst on trastuzumab; and
3. Trastuzumab not to be given in combination with lapatinib; and
4. Trastuzumab to be discontinued at disease progression.

Initial application — (early breast cancer) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 15 months for applications meeting the following criteria:

All of the following:

1. The patient has early breast cancer expressing HER 2 IHC 3+ or ISH+ (including FISH or other current technology); and
2. Maximum cumulative dose of 106 mg/kg (12 months' treatment); and
3. Any of the following:
   3.1. 9 weeks' concurrent treatment with adjuvant chemotherapy is planned; or
   3.2. 12 months' concurrent treatment with adjuvant chemotherapy is planned; or
   3.3. 12 months' sequential treatment following adjuvant chemotherapy is planned; or
   3.4. 12 months' treatment with neoadjuvant and adjuvant chemotherapy is planned; or
   3.5. Other treatment regimen, in association with adjuvant chemotherapy, is planned.

Renewal — (early breast cancer*) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

1. The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
2. The patient received prior adjuvant trastuzumab treatment for early breast cancer; and
3. Any of the following:
   3.1. The patient has not previously received lapatinib treatment for HER-2 positive metastatic breast cancer; or
   3.2. Both:
3.2.1 The patient started lapatinib treatment for metastatic breast cancer but discontinued lapatinib within 3 months of starting treatment due to intolerance; and

3.2.2 The cancer did not progress whilst on lapatinib; or

3.3 The cancer has not progressed at any time point during the previous 12 months whilst on trastuzumab; and

4 Either:

4.1 Trastuzumab will not be given in combination with pertuzumab; or

4.2 All of the following:

4.2.1 Trastuzumab to be administered in combination with pertuzumab; and

4.2.2 Patient has not received prior treatment for their metastatic disease and has had a treatment-free interval of at least 12 months between prior (neo)adjuvant chemotherapy treatment and diagnosis of metastatic breast cancer; and

4.2.3 The patient has good performance status (ECOG grade 0-1); and

5 Trastuzumab not to be given in combination with lapatinib; and

6 Trastuzumab to be discontinued at disease progression.

Note: * For patients with relapsed HER-2 positive disease who have previously received adjuvant trastuzumab for early breast cancer.

### Programmed Cell Death-1 (PD-1) Inhibitors

**NIVOLUMAB** – PCT only – Specialist – Special Authority see [SA1656 below](#)

<table>
<thead>
<tr>
<th>Dose</th>
<th>Price</th>
<th>Subsidy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 10 mg per ml, 4 ml vial</td>
<td>$1,051.98</td>
<td>✓</td>
</tr>
<tr>
<td>Inj 10 mg per ml, 10 ml vial</td>
<td>$2,629.96</td>
<td>✓</td>
</tr>
<tr>
<td>Inj 1 mg for ECP</td>
<td>$27.62</td>
<td>✓</td>
</tr>
</tbody>
</table>

**SA1656** Special Authority for Subsidy

**Initial application — (unresectable or metastatic melanoma)** only from a medical oncologist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

1 Patient has metastatic or unresectable melanoma stage III or IV; and

2 Patient has measurable disease as defined by the presence of at least one CT or MRI measurable lesion; and

3 The patient has ECOG performance score of 0-2; and

4 Either:

4.1 Patient has not received funded pembrolizumab; or

4.2 Both:

4.2.1 Patient has received an initial Special Authority approval for pembrolizumab and has discontinued pembrolizumab within 12 weeks of starting treatment due to intolerance; and

4.2.2 The cancer did not progress while the patient was on pembrolizumab; and

5 Nivolumab is to be used at a maximum dose of 3 mg/kg every 2 weeks for a maximum of 12 weeks (6 cycles); and

6 Baseline measurement of overall tumour burden is documented (see Note); and

7 Documentation confirming that the patient has been informed and acknowledges that the initial funded treatment period of nivolumab will not be continued beyond 12 weeks (6 cycles) if their disease progresses during this time.

**Renewal — (unresectable or metastatic melanoma)** only from a medical oncologist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

1 Any of the following:

1.1 Patient’s disease has had a complete response to treatment according to RECIST criteria (see Note; or

1.2 Patient’s disease has had a partial response to treatment according to RECIST criteria (see Note; or

1.3 Patient has stable disease according to RECIST criteria (see Note; and

continued…
continued...

2 Response to treatment in target lesions has been determined by radiologic assessment (CT or MRI scan) following the most recent treatment period; and
3 No evidence of progressive disease according to RECIST criteria (see Note); and
4 The treatment remains clinically appropriate and the patient is benefitting from the treatment; and
5 Nivolumab will be used at a maximum dose of 3 mg/kg every 2 weeks for a maximum of 12 weeks (6 cycles).

Notes: Disease responses to be assessed according to the Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1 (Eisenhauer EA, et al. Eur J Cancer 2009;45:228-47). Assessments of overall tumour burden and measurable disease to be undertaken on a minimum of one lesion and maximum of 5 target lesions (maximum two lesions per organ). Target lesions should be selected on the basis of their size (lesions with the longest diameter), be representative of all involved organs, and suitable for reproducible repeated measurements. Target lesion measurements should be assessed using CT or MRI imaging with the same method of assessment and the same technique used to characterise each identified and reported lesion at baseline and every 12 weeks. Response definitions as follows:

- Complete Response: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to < 10 mm.
- Partial Response: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
- Progressive Disease: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression).
- Stable Disease: Neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease.

PEMBROLIZUMAB – PCT only – Specialist – Special Authority see SA1657 below

| Inj 50 mg vial | 2,340.00 | ✔ Keytruda |
| Inj 1 mg for ECP | 49.14 | ✔ Baxter |

**SA1657** Special Authority for Subsidy

**Initial application — (unresectable or metastatic melanoma)** only from a medical oncologist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

1 Patient has metastatic or unresectable melanoma stage III or IV; and
2 Patient has measurable disease as defined by the presence of at least one CT or MRI measurable lesion; and
3 The patient has ECOG performance score of 0-2; and
4 Either:
   4.1 Patient has not received funded nivolumab; or
   4.2 Both:
      4.2.1 Patient has received an initial Special Authority approval for nivolumab and has discontinued nivolumab within 12 weeks of starting treatment due to intolerance; and
      4.2.2 The cancer did not progress while the patient was on nivolumab; and
5 Pembrolizumab is to be used at a maximum dose of 2 mg/kg every 3 weeks for a maximum of 12 weeks (4 cycles); and
6 Baseline measurement of overall tumour burden is documented (see Note); and
7 Documentation confirming that the patient has been informed and acknowledges that the initial funded treatment period of pembrolizumab will not be continued beyond 12 weeks (4 cycles) if their disease progresses during this time.

**Renewal — (unresectable or metastatic melanoma)** only from a medical oncologist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

1 Any of the following:
   1.1 Patient’s disease has had a complete response to treatment according to RECIST criteria (see Note); or

continued…
continued…

1.2 Patient’s disease has had a partial response to treatment according to RECIST criteria (see Note); or
1.3 Patient has stable disease according to RECIST criteria (see Note); and
2 Response to treatment in target lesions has been determined by radiologic assessment (CT or MRI scan) following the most recent treatment period; and
3 No evidence of progressive disease according to RECIST criteria (see Note); and
4 The treatment remains clinically appropriate and the patient is benefitting from the treatment; and
5 Pembrolizumab will be used at a maximum dose of 2 mg/kg every 3 weeks for a maximum of 12 weeks (4 cycles).

Notes: Disease responses to be assessed according to the Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1 (Eisenhauer EA, et al. Eur J Cancer 2009;45:228-47). Assessments of overall tumour burden and measurable disease to be undertaken on a minimum of one lesion and maximum of 5 target lesions (maximum two lesions per organ). Target lesions should be selected on the basis of their size (lesions with the longest diameter), be representative of all involved organs, and suitable for reproducible repeated measurements. Target lesion measurements should be assessed using CT or MRI imaging with the same method of assessment and the same technique used to characterise each identified and reported lesion at baseline and every 12 weeks. Response definitions as follows:

- Complete Response: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to < 10 mm.
- Partial Response: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
- Progressive Disease: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression).
- Stable Disease: Neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease.

Other Immunosuppressants

CICLOSPORIN

- Cap 25 mg.................................................................44.63 50 ✔ Neoral
- Cap 50 mg...............................................................88.91 50 ✔ Neoral
- Cap 100 mg............................................................177.81 50 ✔ Neoral
- Oral liq 100 mg per ml.........................................198.13 50 ml OP ✔ Neoral

EVEROLIMUS – Special Authority see SA1491 below – Retail pharmacy

Wastage claimable

- Tab 10 mg ...........................................................6,512.29 30 ✔ Afinitor
- Tab 5 mg ...........................................................4,555.76 30 ✔ Afinitor

➽ SA1491 Special Authority for Subsidy

Initial application only from a neurologist or oncologist. Approvals valid for 3 months for applications meeting the following criteria:

Both:
1 Patient has tuberous sclerosis; and
2 Patient has progressively enlarging subependymal giant cell astrocytomas (SEGAs) that require treatment.

Renewal only from a neurologist or oncologist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:
1 Documented evidence of SEGA reduction or stabilisation by MRI within the last 3 months; and
2 The treatment remains appropriate and the patient is benefiting from treatment; and
3 Everolimus to be discontinued at progression of SEGAs.

Note: MRI should be performed at minimum once every 12 months, more frequent scanning should be performed with new onset of symptoms such as headaches, visual complaints, nausea or vomiting, or increase in seizure activity.
ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

<table>
<thead>
<tr>
<th>Subsidy (Manufacturer’s Price) $</th>
<th>Fully Subsidised</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>SIROLIMUS – Special Authority see SA0866 below – Retail pharmacy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 1 mg .......................................................... 749.99 100 ✔ Rapamune</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 2 mg .......................................................... 1,499.99 100 ✔ Rapamune</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oral liq 1 mg per ml ......................... 449.99 60 ml OP ✔ Rapamune</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**SA0866** Special Authority for Subsidy

Initial application from any medical practitioner. Approvals valid without further renewal unless notified where the drug is to be used for rescue therapy for an organ transplant recipient.

Notes: Rescue therapy defined as unresponsive to calcineurin inhibitor treatment as defined by refractory rejection; or intolerant to calcineurin inhibitor treatment due to any of the following:

- GFR < 30 ml/min; or
- Rapidly progressive transplant vasculopathy; or
- Rapidly progressive obstructive bronchiolitis; or
- HUS or TTP; or
- Leukoencephalopathy; or
- Significant malignant disease

TACROLIMUS – Special Authority see SA1745 below – Retail pharmacy

<table>
<thead>
<tr>
<th>Subsidy (Manufacturer’s Price) $</th>
<th>Fully Subsidised</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cap 0.5 mg .......................................................... 55.64 100 ✔ Tacrolimus Sandoz</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cap 1 mg .......................................................... 111.28 100 ✔ Tacrolimus Sandoz</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cap 5 mg .......................................................... 278.20 50 ✔ Tacrolimus Sandoz</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**SA1745** Special Authority for Subsidy

Initial application — (organ transplant) only from a relevant specialist. Approvals valid without further renewal unless notified where the patient is an organ transplant recipient.

Note: Subsidy applies for either primary or rescue therapy.

Initial application — (non-transplant indications*) only from a relevant specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

1. Patient requires long-term systemic immunosuppression; and
2. Ciclosporin has been trialled and discontinued treatment because of unacceptable side effects or inadequate clinical response.

Note: Indications marked with * are unapproved indications

▲ Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber or pharmacist.

* Three months or six months, as applicable, dispensed all-at-once
# RESPIRATORY SYSTEM AND ALLERGIES

<table>
<thead>
<tr>
<th>Subsidy (Manufacturer's Price)</th>
<th>Fully Subsidised</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per</td>
<td>✅</td>
<td></td>
</tr>
</tbody>
</table>

## Antiallergy Preparations

### Allergic Emergencies

**ICATIBANT** – Special Authority see **SA1558 below** – Retail pharmacy

Inj 10 mg per ml, 3 ml prefilled syringe........................................2,668.00 1  ✔  *Firazyr*

**SA1558** – *Special Authority for Subsidy*

**Initial application** only from a clinical immunologist or relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

Both:

1. Supply for anticipated emergency treatment of laryngeal/oro-pharyngeal or severe abdominal attacks of acute hereditary angioedema (HAE) for patients with confirmed diagnosis of C1-esterase inhibitor deficiency; and
2. The patient has undergone product training and has agreed upon an action plan for self-administration.

**Renewal** from any relevant practitioner. Approvals valid for 12 months where the treatment remains appropriate and the patient is benefiting from treatment.

### Allergy Desensitisation

**SA1367** – *Special Authority for Subsidy*

**Initial application** only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria:

Both:

1. RAST or skin test positive; and
2. Patient has had severe generalised reaction to the sensitising agent.

**Renewal** only from a relevant specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

**BEE VENOM ALLERGY TREATMENT** – Special Authority see **SA1367 above** – Retail pharmacy

- **Maintenance kit** - 6 vials 120 mcg freeze dried venom, with diluent..........................................................285.00 1 OP  ✔  *Venomil*
- **Treatment kit** - 1 vial 550 mcg freeze dried venom, 1 diluent 9 ml, 3 diluent 1.8 ml.................................305.00 1 OP  ✔  *Venomil*
- **Treatment kit** - 1 vial 550 mcg freeze dried venom, with diluent..........................................................305.00 1 OP  ✔  *Hymenoptera*

**WASP VENOM ALLERGY TREATMENT** – Special Authority see **SA1367 above** – Retail pharmacy

- **Treatment kit (Paper wasp venom)** - 1 vial 550 mcg freeze dried polister venom, 1 diluent 9 ml, 1 diluent 1.8 ml........305.00 1 OP  ✔  *Albey*
- **Treatment kit (Paper wasp venom)** - 6 vials 120 mcg freeze dried venom, with diluent........................................305.00 1 OP  ✔  *Venomil*
- **Treatment kit (Yellow Jacket venom)** - 1 vial 550 mcg freeze dried vespula venom, 1 diluent 9 ml, 1 diluent 1.8 ml........305.00 1 OP  ✔  *Venomil*
- **Treatment kit (Yellow jacket venom)** - 6 vials 120 mcg freeze dried venom, with diluent........................................305.00 1 OP  ✔  *Venomil*
### Antihistamines

**CETIRIZINE HYDROCHLORIDE**

* Tab 10 mg ................................................................. $1.01 100 ✔ Zista

* Oral liq 1 mg per ml ....................................................... $2.99 200 ml ✔ Histaclear

**CHLORPHENIRAMINE MALEATE**

* Oral liq 2 mg per 5 ml ..................................................... $8.06 500 ml ✔ Histafen

**DEXTROCHLORPHENIRAMINE MALEATE**

* Tab 2 mg ............................................................................ $2.02 40

* Oral liq 2 mg per 5 ml ....................................................... $1.77 100 ml

(8.40) Polaramine

(5.99) Polaramine

**FEXOFENADINE HYDROCHLORIDE**

* Tab 60 mg .......................................................................... $4.34 20

* Tab 120 mg ....................................................................... $4.74 10

* Oral liq 2 mg per 5 ml ....................................................... $1.77 100 ml

(8.23) Telfast

(8.23) Telfast

(10.29) Telfast

**LORATADINE**

* Tab 10 mg .......................................................................... $1.28 100 ✔ Lorafix

* Oral liq 1 mg per ml ........................................................... $2.15 120 ml ✔ Lorfast

**PROMETHAZINE HYDROCHLORIDE**

* Tab 10 mg .......................................................................... $1.68 50 ✔ Allersoothe

* Tab 25 mg .......................................................................... $1.89 50 ✔ Allersoothe

* Oral liq 1 mg per 1 ml ....................................................... $2.69 100 ml ✔ Allersoothe

* Inj 25 mg per ml, 2 ml ampoule – Up to 5 inj available on a PSO .... $15.54 5 ✔ Hospira

**TRIMEPRAZINE TARTRATE**

Oral liq 30 mg per 5 ml ....................................................... $2.79 100 ml OP

(8.06) Vallergan Forte

(4.34) Polaramine

(2.69) Polaramine

### Inhaled Corticosteroids

**BECLOMETHASONE DIPROPIONATE**

Aerosol inhaler, 50 mcg per dose ........................................ $9.30 200 dose OP ✔ Qvar

Aerosol inhaler, 50 mcg per dose CFC-free ......................... $8.54 200 dose OP ✔ Beclazone 50

Aerosol inhaler, 100 mcg per dose ...................................... $15.50 200 dose OP ✔ Qvar

Aerosol inhaler, 100 mcg per dose CFC-free ....................... $12.50 200 dose OP ✔ Beclazone 100

Aerosol inhaler, 250 mcg per dose CFC-free ....................... $22.67 200 dose OP ✔ Beclazone 250

**BUDENOSIDE**

Powder for inhalation, 100 mcg per dose ............................ $17.00 200 dose OP ✔ Pulmicort Turbuhaler

Powder for inhalation, 200 mcg per dose ............................ $19.00 200 dose OP ✔ Pulmicort Turbuhaler

Powder for inhalation, 400 mcg per dose ............................ $32.00 200 dose OP ✔ Pulmicort Turbuhaler

▲ Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber or pharmacist.

* Three months or six months, as applicable, dispensed all-at-once.
RESPIRATORY SYSTEM AND ALLERGIES

<table>
<thead>
<tr>
<th>Subsidy (Manufacturer’s Price) $</th>
<th>Fully Subsidised</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
</table>

**FLUTICASONE**
- Aerosol inhaler, 50 mcg per dose ........................................... 4.68 120 dose OP ✓ Floair
- Aerosol inhaler, 50 mcg per dose CFC-free .................................... 7.50 120 dose OP ✓ Flixotide
- Powder for inhalation, 50 mcg per dose ...................................... 7.50 60 dose OP ✓ Flixotide Accuhaler
- Powder for inhalation, 100 mcg per dose .................................... 7.50 60 dose OP ✓ Flixotide Accuhaler
- Aerosol inhaler, 125 mcg per dose ............................................. 7.22 120 dose OP ✓ Floair
- Aerosol inhaler, 125 mcg per dose CFC-free ................................ 13.60 120 dose OP ✓ Flixotide
- Aerosol inhaler, 250 mcg per dose ............................................. 10.18 120 dose OP ✓ Floair
- Aerosol inhaler, 250 mcg per dose CFC-free ................................ 27.20 120 dose OP ✓ Flixotide
- Powder for inhalation, 250 mcg per dose .................................... 13.60 60 dose OP ✓ Flixotide Accuhaler

**Inhaled Long-acting Beta-adrenoceptor Agonists**

**EFORMOTEROL FUMARATE**
- Powder for inhalation, 6 mcg per dose, breath activated .............. 10.32 60 dose OP Oxis Turbuhaler
- Powder for inhalation, 12 mcg per dose, and monodose device ...... 20.64 60 dose Oxis Turbuhaler
- Powder for inhalation 4.5 mcg per dose, breath activated (equivalent to eformoterol fumarate 6 mcg metered dose) ...... 10.32 60 dose Oxis Turbuhaler

(Oxis Turbuhaler Powder for inhalation, 6 mcg per dose, breath activated to be delisted 1 April 2019)

**EFORMOTEROL FUMARATE DIHYDRATE**
- Powder for inhalation 4.5 mcg per dose, breath activated (equivalent to eformoterol fumarate 6 mcg metered dose) ...... 10.32 60 dose Oxis Turbuhaler

**INDACATEROL**
- Powder for inhalation 150 mcg .................................................... 61.00 30 dose OP ✓ Onbrez Breezhaler
- Powder for inhalation 300 mcg .................................................... 61.00 30 dose OP ✓ Onbrez Breezhaler

**SALMETEROL**
- Aerosol inhaler CFC-free, 25 mcg per dose ................................ 25.00 120 dose OP ✓ Serevent
- Aerosol inhaler 25 mcg per dose .................................................. 9.90 120 dose OP ✓ Meterol
- Powder for inhalation, 50 mcg per dose, breath activated ............. 25.00 60 dose OP ✓ Serevent Accuhaler

**Inhaled Corticosteroids with Long-Acting Beta-Adrenoceptor Agonists**

**BUDESONIDE WITH EFORMOTEROL**
- Aerosol inhaler 100 mcg with eformoterol fumarate 6 mcg ........... 18.23 120 dose OP ✓ Vannair
- Powder for inhalation 100 mcg with eformoterol fumarate 6 mcg .... 33.74 120 dose OP ✓ Symbicort Turbuhaler 100/6
- Aerosol inhaler 200 mcg with eformoterol fumarate 6 mcg ............ 21.40 120 dose OP ✓ Vannair
- Powder for inhalation 200 mcg with eformoterol fumarate 6 mcg .... 44.08 120 dose OP ✓ Symbicort Turbuhaler 200/6
- Powder for inhalation 400 mcg with eformoterol fumarate 12 mcg – No more than 2 dose per day ............................................. 44.08 60 dose OP ✓ Symbicort Turbuhaler 400/12

**FLUTICASONE FURATE WITH VILANTEROL**
- Powder for inhalation 100 mcg with vilanterol 25 mcg .................. 44.08 30 dose OP ✓ Breo Ellipta
## Respiratory System and Allergies

<table>
<thead>
<tr>
<th>Subsidy (Manufacturer’s Price)</th>
<th>Fully Subsidised</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per</td>
<td>✔ Full Subsidised</td>
<td></td>
</tr>
</tbody>
</table>

### Fluticasone with Salmeterol

<table>
<thead>
<tr>
<th>Description</th>
<th>Cost</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aerosol inhaler 50 mcg with salmeterol 25 mcg</td>
<td>14.58</td>
<td>120 dose OP</td>
</tr>
<tr>
<td>Aerosol inhaler 125 mcg with salmeterol 25 mcg</td>
<td>33.74</td>
<td></td>
</tr>
<tr>
<td>Powder for inhalation 100 mcg with salmeterol 50 mcg – No more than 2 dose per day</td>
<td>33.74</td>
<td>60 dose OP</td>
</tr>
<tr>
<td>Powder for inhalation 250 mcg with salmeterol 50 mcg – No more than 2 dose per day</td>
<td>44.08</td>
<td>60 dose OP</td>
</tr>
</tbody>
</table>

### Beta-Adrenoceptor Agonists

#### Salbutamol

<table>
<thead>
<tr>
<th>Description</th>
<th>Cost</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral liq 400 mcg per ml</td>
<td>20.00</td>
<td>150 ml</td>
</tr>
<tr>
<td>Infusion 1 mg per ml, 5 ml</td>
<td>118.38</td>
<td>10</td>
</tr>
<tr>
<td>Nebuliser soln, 1 mg per ml, 2.5 ml ampoule – Up to 30 neb available on a PSO</td>
<td>3.93</td>
<td>20</td>
</tr>
<tr>
<td>Nebuliser soln, 2 mg per ml, 2.5 ml ampoule – Up to 30 neb available on a PSO</td>
<td>4.03</td>
<td>20</td>
</tr>
</tbody>
</table>

#### Inhaled Beta-Adrenoceptor Agonists

<table>
<thead>
<tr>
<th>Description</th>
<th>Cost</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aerosol inhaler, 100 mcg per dose CFC free – Up to 1000 dose available on a PSO</td>
<td>3.80</td>
<td>200 dose OP</td>
</tr>
<tr>
<td>Nebuliser soln, 1 mg per ml, 2.5 ml ampoule – Up to 30 neb available on a PSO</td>
<td>3.93</td>
<td>20</td>
</tr>
<tr>
<td>Nebuliser soln, 2 mg per ml, 2.5 ml ampoule – Up to 30 neb available on a PSO</td>
<td>4.03</td>
<td>20</td>
</tr>
</tbody>
</table>

#### Terbutaline Sulphate

<table>
<thead>
<tr>
<th>Description</th>
<th>Cost</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Powder for inhalation, 250 mcg per dose, breath activated</td>
<td>27.30</td>
<td>200 dose OP</td>
</tr>
</tbody>
</table>

### Anticholinergic Agents

#### Ipratropium Bromide

<table>
<thead>
<tr>
<th>Description</th>
<th>Cost</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aerosol inhaler, 20 mcg per dose CFC-free – Up to 400 dose available on a PSO</td>
<td>16.20</td>
<td>200 dose OP</td>
</tr>
<tr>
<td>Nebuliser soln, 250 mcg per ml, 1 ml ampoule – Up to 40 neb available on a PSO</td>
<td>3.35</td>
<td>20</td>
</tr>
<tr>
<td>Nebuliser soln, 250 mcg per ml, 2 ml ampoule – Up to 40 neb available on a PSO</td>
<td>3.52</td>
<td>20</td>
</tr>
</tbody>
</table>

### Inhaled Beta-Adrenoceptor Agonists with Anticholinergic Agents

#### Salbutamol with Ipratropium Bromide

<table>
<thead>
<tr>
<th>Description</th>
<th>Cost</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aerosol inhaler, 100 mcg with ipratropium bromide, 20 mcg per dose CFC-free</td>
<td>12.19</td>
<td>200 dose OP</td>
</tr>
<tr>
<td>Nebuliser soln, 2.5 mg with ipratropium bromide 0.5 mg per vial, 2.5 ml ampoule</td>
<td>5.20</td>
<td>20</td>
</tr>
</tbody>
</table>

▲Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once.
## RESPIRATORY SYSTEM AND ALLERGIES

<table>
<thead>
<tr>
<th>Subsidy (Manufacturer’s Price)</th>
<th>Fully Subsidised</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Per</td>
<td>✔</td>
<td></td>
</tr>
</tbody>
</table>

### Long-Acting Muscarinic Antagonists

**GLYCOPYRRONIUM** – Subsidy by endorsement

a) Inhaled glycopyrronium treatment will not be subsidised if patient is also receiving treatment with subsidised tiotropium or umeclidinium.

b) Glycopyrronium powder for inhalation 50 mcg per dose is subsidised only for patients who have been diagnosed as having COPD using spirometry, and the prescription is endorsed accordingly.

<table>
<thead>
<tr>
<th>Powder for inhalation 50 mcg per dose</th>
<th>61.00</th>
<th>30 dose OP</th>
<th>✔ Seebri Breezhaler</th>
</tr>
</thead>
</table>

**TIOTROPIUM BROMIDE** – Subsidy by endorsement

a) Tiotropium treatment will not be subsidised if patient is also receiving treatment with subsidised inhaled glycopyrronium or umeclidinium.

b) Tiotropium bromide is subsidised only for patients who have been diagnosed as having COPD using spirometry, and the prescription is endorsed accordingly. Patients who had tiotropium dispensed before 1 October 2018 with a valid Special Authority are deemed endorsed.

<table>
<thead>
<tr>
<th>Powder for inhalation, 18 mcg per dose</th>
<th>50.37</th>
<th>30 dose</th>
<th>✔ Spiriva</th>
</tr>
</thead>
<tbody>
<tr>
<td>Soln for inhalation 2.5 mcg per dose</td>
<td>50.37</td>
<td>60 dose OP</td>
<td>✔ Spiriva Respimat</td>
</tr>
</tbody>
</table>

**UMECLIDINIUM** – Subsidy by endorsement

a) Umeclidinium will not be subsidised if patient is also receiving treatment with subsidised inhaled glycopyrronium or tiotropium bromide.

b) Umeclidinium powder for inhalation 62.5 mcg per dose is subsidised only for patients who have been diagnosed as having COPD using spirometry, and the prescription is endorsed accordingly.

<table>
<thead>
<tr>
<th>Powder for inhalation 62.5 mcg per dose</th>
<th>61.50</th>
<th>30 dose OP</th>
<th>✔ Incruse Ellipta</th>
</tr>
</thead>
</table>

### Long-Acting Muscarinic Antagonists with Long-Acting Beta-Adrenoceptor Agonists

Combination long acting muscarinic antagonist and long acting beta-2 agonist will not be subsidised if patient is also receiving treatment with a combination inhaled corticosteroid and long acting beta-2 agonist.

#### Special Authority for Subsidy

**SA1584**

- **Initial application** from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:
  
  Both:
  1. Patient has been stabilised on a long acting muscarinic antagonist; and
  2. The prescriber considers that the patient would receive additional benefit from switching to a combination product.

- **Renewal** from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:
  
  Both:
  1. Patient is compliant with the medication; and
  2. Patient has experienced improved COPD symptom control (prescriber determined).

**GLYCOPYRRONIUM WITH INDACATEROL** – Special Authority see **SA1584 above** – Retail pharmacy

<table>
<thead>
<tr>
<th>Powder for Inhalation 50 mcg with indacaterol 110 mcg</th>
<th>81.00</th>
<th>30 dose OP</th>
<th>✔ Ultibro Breezhaler</th>
</tr>
</thead>
</table>

**TIOTROPIUM BROMIDE WITH OLODATEROL** – Special Authority see **SA1584 above** – Retail pharmacy

<table>
<thead>
<tr>
<th>Soln for inhalation 2.5 mcg with olodaterol 2.5 mcg</th>
<th>81.00</th>
<th>60 dose OP</th>
<th>✔ Spiolto Respimat</th>
</tr>
</thead>
</table>

**UMECLIDINIUM WITH VILANTEROL** – Special Authority see **SA1584 above** – Retail pharmacy

<table>
<thead>
<tr>
<th>Powder for inhalation 62.5 mcg with vilanterol 25 mcg</th>
<th>77.00</th>
<th>30 dose OP</th>
<th>✔ Anoro Ellipta</th>
</tr>
</thead>
</table>

### Antifibrotics

**NINTEDANIB** – Special Authority see **SA1755 on the next page** – Retail pharmacy

Note: Nintedanib not subsidised in combination with subsidised pirfenidone.

<table>
<thead>
<tr>
<th>Cap 100 mg</th>
<th>2,554.00</th>
<th>60 OP</th>
<th>✔ Ofev</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cap 150 mg</td>
<td>3,870.00</td>
<td>60 OP</td>
<td>✔ Ofev</td>
</tr>
</tbody>
</table>

**Unapproved medicine supplied under Section 29**

**Sole Subsidised Supply**
SA1755 Special Authority for Subsidy

Initial application — (idiopathic pulmonary fibrosis) only from a respiratory specialist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

1. Patient has been diagnosed with idiopathic pulmonary fibrosis by a multidisciplinary team including a radiologist; and
2. Forced vital capacity is between 50% and 90% predicted; and
3. Nintedanib is to be discontinued at disease progression (see Note); and
4. Nintedanib is not to be used in combination with subsidised pirfenidone; and
5. Any of the following:
   5.1 The patient has not previously received treatment with pirfenidone; or
   5.2 Patient has previously received pirfenidone, but discontinued pirfenidone within 12 weeks due to intolerance; or
   5.3 Patient has previously received pirfenidone, but the patient’s disease has not progressed (disease progression defined as 10% or more decline in predicted FVC within any 12 month period since starting treatment with pirfenidone).

Renewal — (idiopathic pulmonary fibrosis) only from a respiratory specialist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

1. Treatment remains clinically appropriate and patient is benefitting from and tolerating treatment; and
2. Nintedanib is not to be used in combination with subsidised pirfenidone; and
3. Nintedanib is to be discontinued at disease progression (see Note).

Note: disease progression is defined as a decline in percent predicted FVC of 10% or more within any 12 month period.

PIRFENIDONE – Retail pharmacy-Specialist – Special Authority see SA1748 below

Note: Pirfenidone is not subsidised in combination with subsidised nintedanib.

Cap 267 mg – Wastage claimable…………………………………………………………3,645.00 270 ✔

Esbriet

SA1748 Special Authority for Subsidy

Initial application — (idiopathic pulmonary fibrosis) only from a respiratory specialist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

1. Patient has been diagnosed with idiopathic pulmonary fibrosis by a multidisciplinary team including a radiologist; and
2. Forced vital capacity is between 50% and 80% predicted; and
3. Pirfenidone is to be discontinued at disease progression (see Note); and
4. Pirfenidone is not to be used in combination with subsidised nintedanib; and
5. Any of the following:
   5.1 The patient has not previously received treatment with nintedanib; or
   5.2 Patient has previously received nintedanib, but discontinued nintedanib within 12 weeks due to intolerance; or
   5.3 Patient has previously received nintedanib, but the patient’s disease has not progressed (disease progression defined as 10% or more decline in predicted FVC within any 12 month period since starting treatment with nintedanib).

Renewal — (idiopathic pulmonary fibrosis) only from a respiratory specialist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

1. Treatment remains clinically appropriate and patient is benefitting from and tolerating treatment; and
2. Pirfenidone is not to be used in combination with subsidised nintedanib; and
3. Pirfenidone is to be discontinued at disease progression (see Note).

Note: disease progression is defined as a decline in percent predicted FVC of 10% or more within any 12 month period.
# RESPIRATORY SYSTEM AND ALLERGIES

<table>
<thead>
<tr>
<th>Subsidy (Manufacturer's Price)</th>
<th>Fully Subsidised</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

## Leukotriene Receptor Antagonists

<table>
<thead>
<tr>
<th>Drug</th>
<th>Strength</th>
<th>Price</th>
<th>Fully Subsidised</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>MONTELUKAST</td>
<td>Tab 4 mg</td>
<td>5.25</td>
<td>28</td>
<td>Apo-Montelukast</td>
</tr>
<tr>
<td></td>
<td>Tab 5 mg</td>
<td>5.50</td>
<td>28</td>
<td>Apo-Montelukast</td>
</tr>
<tr>
<td></td>
<td>Tab 10 mg</td>
<td>5.65</td>
<td>28</td>
<td>Accord</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Apo-Montelukast</td>
</tr>
</tbody>
</table>

## Mast Cell Stabilisers

<table>
<thead>
<tr>
<th>Drug</th>
<th>Strength</th>
<th>Price</th>
<th>Fully Subsidised</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>NEDOCROMIL</td>
<td>Aerosol inhaler, 2 mg per dose CFC-free</td>
<td>28.07</td>
<td>112 dose OP</td>
<td>Tilade</td>
</tr>
<tr>
<td>SODIUM CROMOGLICATE</td>
<td>Aerosol inhaler, 5 mg per dose CFC-free</td>
<td>28.07</td>
<td>112 dose OP</td>
<td>Intal Forte CFC Free</td>
</tr>
</tbody>
</table>

## Methylxanthines

<table>
<thead>
<tr>
<th>Drug</th>
<th>Strength</th>
<th>Price</th>
<th>Fully Subsidised</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>AMINOPHYLLINE</td>
<td>Inj 25 mg per ml, 10 ml ampoule – Up to 5 inj available on a PSO</td>
<td>124.37</td>
<td>5</td>
<td>DBL Aminophylline</td>
</tr>
<tr>
<td>THEOPHYLLINE</td>
<td>Tab long-acting 250 mg</td>
<td>21.51</td>
<td>100</td>
<td>Nuelin-SR</td>
</tr>
<tr>
<td></td>
<td>Oral liq 80 mg per 15 ml</td>
<td>15.50</td>
<td>500 ml</td>
<td>Nuelin</td>
</tr>
</tbody>
</table>

## Mucolytics

<table>
<thead>
<tr>
<th>Drug</th>
<th>Strength</th>
<th>Price</th>
<th>Fully Subsidised</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>DORNASE ALFA – Special Authority see SA0611 below – Retail pharmacy</td>
<td>Nebuliser soln, 2.5 mg per 2.5 ml ampoule</td>
<td>250.00</td>
<td>6</td>
<td>Pulmozyme</td>
</tr>
</tbody>
</table>

### SA0611 Special Authority for Subsidy

Special Authority approved by the Cystic Fibrosis Advisory Panel

Notes: Application details may be obtained from PHARMAC's website [http://www.pharmac.govt.nz](http://www.pharmac.govt.nz) or:

- The Co-ordinator, Cystic Fibrosis Advisory Panel
  - Phone: (04) 460 4990
  - Facsimile: (04) 916 7571
  - Wellington
  - Email: CFPanell@pharmac.govt.nz

Prescriptions for patients approved for treatment must be written by respiratory physicians or paediatricians who have experience and expertise in treating cystic fibrosis.

### SODIUM CHLORIDE

Soln 7% | 23.50 | 90 ml OP | Biomed |

## Nasal Preparations

### Allergy Prophylactics

<table>
<thead>
<tr>
<th>Drug</th>
<th>Strength</th>
<th>Price</th>
<th>Fully Subsidised</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>BECLOMETHASONE DIPROPIONATE</td>
<td>Metered aqueous nasal spray, 50 mcg per dose</td>
<td>2.35</td>
<td>200 dose OP</td>
<td>Alanase</td>
</tr>
<tr>
<td></td>
<td>Metered aqueous nasal spray, 100 mcg per dose</td>
<td>2.46</td>
<td>200 dose OP</td>
<td>Alanase</td>
</tr>
</tbody>
</table>

\[529\] Unapproved medicine supplied under Section 29
## RESPIRATORY SYSTEM AND ALLERGIES

### BUDESONIDE

<table>
<thead>
<tr>
<th>Substance</th>
<th>Manufacturer</th>
<th>Price</th>
<th>Dose</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Metered aqueous nasal spray, 50 mcg per dose</td>
<td></td>
<td>2.59</td>
<td>200 dose</td>
<td>SteroClear</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2.35</td>
<td>200 dose</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>(5.26)</td>
<td>200 dose</td>
<td></td>
</tr>
</tbody>
</table>

SteroClear to be Sole Supply on 1 January 2019

<table>
<thead>
<tr>
<th>Substance</th>
<th>Manufacturer</th>
<th>Price</th>
<th>Dose</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Metered aqueous nasal spray, 100 mcg per dose</td>
<td></td>
<td>2.87</td>
<td>200 dose</td>
<td>SteroClear</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2.61</td>
<td>200 dose</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>(6.00)</td>
<td>200 dose</td>
<td></td>
</tr>
</tbody>
</table>

SteroClear to be Sole Supply on 1 January 2019

(Butacort Aqueous Metered aqueous nasal spray, 50 mcg per dose to be delisted 1 January 2019)

(Butacort Aqueous Metered aqueous nasal spray, 100 mcg per dose to be delisted 1 January 2019)

### FLUTICASONE PROPIONATE

<table>
<thead>
<tr>
<th>Substance</th>
<th>Manufacturer</th>
<th>Price</th>
<th>Dose</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Metered aqueous nasal spray, 50 mcg per dose</td>
<td></td>
<td>1.98</td>
<td>120 dose</td>
<td>Flixonase Hayfever &amp; Allergy</td>
</tr>
</tbody>
</table>

### IPRATROPIUM BROMIDE

<table>
<thead>
<tr>
<th>Substance</th>
<th>Manufacturer</th>
<th>Price</th>
<th>Dose</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aqueous nasal spray, 0.03%</td>
<td></td>
<td>4.61</td>
<td>15 ml</td>
<td>Univent</td>
</tr>
</tbody>
</table>

### Respiratory Devices

#### MASK FOR SPACER DEVICE

- a) Up to 50 dev available on a PSO
- b) Only on a PSO
- c) Only for children aged six years and under

<table>
<thead>
<tr>
<th>Model</th>
<th>Price</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Small</td>
<td>2.20</td>
<td>e-chamber Mask</td>
</tr>
</tbody>
</table>

#### PEAK FLOW METER

- a) Up to 25 dev available on a PSO
- b) Only on a PSO

<table>
<thead>
<tr>
<th>Model</th>
<th>Price</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low range</td>
<td>9.54</td>
<td>Mini-Wright AFS Low Range</td>
</tr>
<tr>
<td>Normal range</td>
<td>9.54</td>
<td>Mini-Wright Standard</td>
</tr>
</tbody>
</table>

#### SPACER DEVICE

- a) Up to 50 dev available on a PSO
- b) Only on a PSO

<table>
<thead>
<tr>
<th>Model</th>
<th>Price</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>220 ml (single patient)</td>
<td>2.95</td>
<td>e-chamber Turbo</td>
</tr>
<tr>
<td>510 ml (single patient)</td>
<td>5.12</td>
<td>e-chamber La Grande</td>
</tr>
<tr>
<td>800 ml</td>
<td>6.50</td>
<td>Volumatic</td>
</tr>
</tbody>
</table>

### Respiratory Stimulants

#### CAFFEINE CITRATE

<table>
<thead>
<tr>
<th>Substance</th>
<th>Price</th>
<th>Dose</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral liq 20 mg per ml (10 mg base per ml)</td>
<td>14.85</td>
<td>25 ml</td>
<td>Biomed</td>
</tr>
</tbody>
</table>

▲Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once
**Ear Preparations**

**ACETIC ACID WITH 1, 2-PROPANEDIOL DIACETATE AND BENZETHONIUM**

For Vosol ear drops with hydrocortisone powder refer Standard Formulae, page 215

Ear drops 2% with 1, 2-Propanediol diacetate 3% and benzethonium chloride 0.02% .................................6.97 35 ml OP ✔ Vosol

**FLUMETASONE PIVALATE**

Ear drops 0.02% with clioquinol 1% ......................................................4.46 7.5 ml OP ✔ Locacorten-Viaform ED’s ✔ Locacorten-Vioform

**TRIAMCINOLONE ACETONIDE WITH GRAMICIDIN, NEOMYCIN AND NYSTATIN**

Ear drops 1 mg with nystatin 100,000 u, neomycin sulphate

2.5 mg and gramicidin 250 mcg per g .............................................5.16 7.5 ml OP ✔ Kenacomb

**Eye Preparations**

Eye preparations are only funded for use in the eye, unless explicitly stated otherwise.

**Anti-Infective Preparations**

**ACICLOVIR**

❋ Eye oint 3% .......................................................................................14.92 4.5 g OP ✔ ViruPOS

**CHLORAMPHENICOL**

Eye oint 1% .........................................................................................2.48 4 g OP ✔ Chlorsig

Eye drops 0.5% .....................................................................................0.98 10 ml OP ✔ Chlorafast

Funded for use in the ear*. Indications marked with * are unapproved indications.

**CIPROFLOXACIN**

Eye drops 0.3% – Subsidy by endorsement..............................................9.99 5 ml OP ✔ Ciprofloxacin Teva

When prescribed for the treatment of bacterial keratitis or severe bacterial conjunctivitis resistant to chloramphenicol; or for the second line treatment of chronic suppurative otitis media (CSOM)*; and the prescription is endorsed accordingly.

Note: Indication marked with a * is an unapproved indication.

**GENTAMICIN SULPHATE**

Eye drops 0.3% .....................................................................................11.40 5 ml OP ✔ Genoptic

**PROPAMIDINE ISETHIONATE**

❋ Eye drops 0.1% .....................................................................................2.97 10 ml OP (14.55) Brolene

**SODIUM FUSIDATE [FUSICID ACID]**

Eye drops 1% .........................................................................................5.29 5 g OP ✔ Fucithalmic

---

*Fully subsidised* Sole Subsidised Supply

Unapproved medicine supplied under Section 29
TOBRAMYCIN

<table>
<thead>
<tr>
<th>Type</th>
<th>Description</th>
<th>Manufacturer</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eye oint 0.3%</td>
<td>..................................................</td>
<td></td>
<td>10.45</td>
</tr>
<tr>
<td>Eye drops 0.3%</td>
<td>..................................................</td>
<td></td>
<td>11.48</td>
</tr>
</tbody>
</table>

Corticosteroids and Other Anti-Inflammatory Preparations

DEXAMETHASONE

<table>
<thead>
<tr>
<th>Type</th>
<th>Description</th>
<th>Manufacturer</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eye oint 0.1%</td>
<td>..................................................</td>
<td></td>
<td>5.86</td>
</tr>
<tr>
<td>Eye drops 0.1%</td>
<td>..................................................</td>
<td></td>
<td>4.50</td>
</tr>
</tbody>
</table>

Ocular implant 700 mcg – Special Authority see SA1680 below

<table>
<thead>
<tr>
<th>Description</th>
<th>Manufacturer</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eye oint 0.1% with neomycin sulphate 0.35% and polymyxin b sulphate 6,000 u per g</td>
<td>Maxitrol</td>
<td>5.39</td>
</tr>
<tr>
<td>Eye drops 0.1% with neomycin sulphate 0.35% and polymyxin b sulphate 6,000 u per ml</td>
<td>Maxitrol</td>
<td>4.50</td>
</tr>
</tbody>
</table>

DICLOFENAC SODIUM

<table>
<thead>
<tr>
<th>Type</th>
<th>Description</th>
<th>Manufacturer</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eye drops 0.1%</td>
<td>..................................................</td>
<td></td>
<td>13.80</td>
</tr>
</tbody>
</table>

Special Authority for Subsidy

Initial application — (Diabetic macular oedema) only from an ophthalmologist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:
1. Patient has diabetic macular oedema with pseudophakic lens; and
2. Patient has reduced visual acuity of between 6/9 - 6/48 with functional awareness of reduction in vision; and
3. Either:
   3.1 Patient’s disease has progressed despite 3 injections with bevacizumab; or
   3.2 Patient is unsuitable or contraindicated to treatment with anti-VEGF agents; and
4. Dexamethasone implants are to be administered not more frequently than once every 4 months into each eye, and up to a maximum of 3 implants per eye per year.

Renewal — (Diabetic macular oedema) only from an ophthalmologist. Approvals valid for 12 months for applications meeting the following criteria:

Both:
1. Patient’s vision is stable or has improved (prescriber determined); and
2. Dexamethasone implants are to be administered not more frequently than once every 4 months into each eye, and up to a maximum of 3 implants per eye per year.

Initial application — (Women of child bearing age with diabetic macular oedema) only from an ophthalmologist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:
1. Patient has diabetic macular oedema; and
2. Patient has reduced visual acuity of between 6/9 - 6/48 with functional awareness of reduction in vision; and
3. Patient is of child bearing potential and has not yet completed a family; and
4. Dexamethasone implants are to be administered not more frequently than once every 4 months into each eye, and up to a maximum of 3 implants per eye per year.

Renewal — (Women of child bearing age with diabetic macular oedema) only from an ophthalmologist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:
1. Patient’s vision is stable or has improved (prescriber determined); and
2. Patient is of child bearing potential and has not yet completed a family; and
3. Dexamethasone implants are to be administered not more frequently than once every 4 months into each eye, and up to a maximum of 3 implants per eye per year.

Dexamethasone with Neomycin Sulphate and Polymyxin B Sulphate

<table>
<thead>
<tr>
<th>Type</th>
<th>Description</th>
<th>Manufacturer</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eye oint 0.1% with neomycin sulphate 0.35% and polymyxin b sulphate 6,000 u per g</td>
<td>Maxitrol</td>
<td>5.39</td>
<td></td>
</tr>
<tr>
<td>Eye drops 0.1% with neomycin sulphate 0.35% and polymyxin b sulphate 6,000 u per ml</td>
<td>Maxitrol</td>
<td>4.50</td>
<td></td>
</tr>
</tbody>
</table>

DICLOFENAC SODIUM

<table>
<thead>
<tr>
<th>Type</th>
<th>Description</th>
<th>Manufacturer</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eye drops 0.1%</td>
<td>..................................................</td>
<td></td>
<td>13.80</td>
</tr>
</tbody>
</table>

Notes:

▲ Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber or pharmacist.

★ Three months or six months, as applicable, dispensed all-at-once
<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Subsidy (Manufacturer's Price) $</th>
<th>Fully Subsidised Per</th>
<th>Subsidy</th>
</tr>
</thead>
</table>

**SENSORY ORGANS**

<table>
<thead>
<tr>
<th><strong>FLUOROMETHOLONE</strong></th>
<th>✔ Eye drops 0.1% .......................... 3.09 5 ml OP</th>
<th>✓ FML</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>LEVOCABASTINE</strong></td>
<td>✔ Eye drops 0.5 mg per ml .......................... 8.71 4 ml OP</td>
<td>Livostin</td>
</tr>
<tr>
<td></td>
<td>(10.34)</td>
<td></td>
</tr>
<tr>
<td><strong>LODOXAMIDE</strong></td>
<td>✔ Eye drops 0.1% .......................... 8.71 10 ml OP</td>
<td>✓ Lomide</td>
</tr>
<tr>
<td><strong>PREDNISOLONE ACETATE</strong></td>
<td>Eye drops 1% ......................................... 3.93 10 ml OP</td>
<td>✓ Prednisolone-AFT</td>
</tr>
<tr>
<td></td>
<td></td>
<td>✔ Pred Forte</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>PREDNISOLONE SODIUM PHOSPHATE</strong> – Special Authority see <strong>SA1715 below</strong> – Retail pharmacy</td>
<td>Eye drops 0.5%, single dose (preservative free) .......................... 38.50 20 dose</td>
<td>✓ Minims Prednisolone</td>
</tr>
</tbody>
</table>

**SA1715** Special Authority for Subsidy

Initial application only from an ophthalmologist or optometrist. Approvals valid for 6 months for applications meeting the following criteria:

- Both:
  1. Patient has severe inflammation; and
  2. Patient has a confirmed allergic reaction to preservative in eye drops.

Renewal from any relevant practitioner. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment.

| **SODIUM CROMOGLICATE** | Eye drops 2% ......................................... 0.85 5 ml OP | ✓ Rexacrom |

### Glaucoma Preparations - Beta Blockers

| **BETAXOLOL** | ✔ Eye drops 0.25% ......................................... 11.80 5 ml OP | ✓ Betoptic S |
|               | ✔ Eye drops 0.5% ......................................... 7.50 5 ml OP | ✓ Betoptic |
| **LEVOBUNOLOL** | ✔ Eye drops 0.5% ......................................... 7.00 5 ml OP | ✓ Betagan |
| **TIMOLOL** | ✔ Eye drops 0.25% ......................................... 1.43 5 ml OP | ✓ Arrow-Timolol |
|               | ✔ Eye drops 0.25%, gel forming ......................... 3.30 2.5 ml OP | ✓ Timoptol XE |
|               | ✔ Eye drops 0.5% ......................................... 1.43 5 ml OP | ✓ Arrow-Timolol |
|               | ✔ Eye drops 0.5%, gel forming ......................... 3.78 2.5 ml OP | ✓ Timoptol XE |

### Glaucoma Preparations - Carbonic Anhydrase Inhibitors

| **ACETAZOLAMIDE** | ✔ Tab 250 mg ......................................... 17.03 100 | ✓ Diamox |
| **BRINZOLAMIDE** | ✔ Eye drops 1% ......................................... 9.77 5 ml OP | ✓ Azopt |
| **DORZOLAMIDE HYDROCHLORIDE** | ✔ Eye drops 2% ......................................... 9.77 5 ml OP | Trusopt |
| **DORZOLAMIDE WITH TIMOLOL** | ✔ Eye drops 2% with timolol 0.5% .......................... 2.87 5 ml OP | ✓ Dortimopt |
|                     |                                                   | ✓ Arrow-Dortim |

210 ✓ fully subsidised

Sole Subsidised Supply

529 Unapproved medicine supplied under Section 29
SENSORY ORGANS

### Glaucoma Preparations - Prostaglandin Analogues

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Subsidy (Manufacturer’s Price) $</th>
<th>Fully Subsidised ✔</th>
<th>Per</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>BIMATOPROST</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>* Eye drops 0.03%</td>
<td>3.30</td>
<td></td>
<td>3 ml OP</td>
</tr>
<tr>
<td>* Bimatoprost Multichem</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>* Bimatoprost Actavis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>LATANOPROST</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>* Eye drops 0.005%</td>
<td>1.50</td>
<td></td>
<td>2.5 ml OP</td>
</tr>
<tr>
<td>* Hysite</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>TRAVOPROST</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>* Eye drops 0.004%</td>
<td>7.30</td>
<td></td>
<td>5 ml OP</td>
</tr>
<tr>
<td>* Travopt</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>* Travatan</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Glaucoma Preparations - Other

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Subsidy (Manufacturer’s Price) $</th>
<th>Fully Subsidised ✔</th>
<th>Per</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>BRIMONIDINE TARTRATE</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>* Eye drops 0.2%</td>
<td>4.29</td>
<td></td>
<td>5 ml OP</td>
</tr>
<tr>
<td>* Arrow-Brimonidine</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>BRIMONIDINE TARTRATE WITH TIMOLOL MALEATE</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>* Eye drops 0.2% with timolol maleate 0.5%</td>
<td>18.50</td>
<td></td>
<td>5 ml OP</td>
</tr>
<tr>
<td>* Combigan</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>PILOCARPINE HYDROCHLORIDE</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>* Eye drops 1%</td>
<td>4.26</td>
<td></td>
<td>15 ml OP</td>
</tr>
<tr>
<td>* Isopto Carpine</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>* Eye drops 2%</td>
<td>5.35</td>
<td></td>
<td>15 ml OP</td>
</tr>
<tr>
<td>* Isopto Carpine</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>* Eye drops 4%</td>
<td>7.99</td>
<td></td>
<td>15 ml OP</td>
</tr>
<tr>
<td>* Isopto Carpine</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Subsidised for oral use pursuant to the Standard Formulae.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>* Eye drops 2% single dose – Special Authority see SA0895 below – Retail pharmacy</td>
<td>31.95</td>
<td></td>
<td>20 dose</td>
</tr>
<tr>
<td>* Minims Pilocarpine</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**SA0895** Special Authority for Subsidy

**Initial application** from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria: Either:
1. Patient has to use an unpreserved solution due to an allergy to the preservative; or
2. Patient wears soft contact lenses.

Note: Minims for a general practice are considered to be “tools of trade” and are not approved as special authority items.

**Renewal** from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

### Mydriatics and Cycloplegics

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Subsidy (Manufacturer’s Price) $</th>
<th>Fully Subsidised ✔</th>
<th>Per</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ATROPINE SULPHATE</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>* Eye drops 1%</td>
<td>17.36</td>
<td></td>
<td>15 ml OP</td>
</tr>
<tr>
<td>* Atrop</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>CYCLOPENTOLATE HYDROCHLORIDE</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>* Eye drops 1%</td>
<td>8.76</td>
<td></td>
<td>15 ml OP</td>
</tr>
<tr>
<td>* Cyclogyl</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>TROPICAMIDE</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>* Eye drops 0.5%</td>
<td>7.15</td>
<td></td>
<td>15 ml OP</td>
</tr>
<tr>
<td>* Mydriacyl</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>* Eye drops 1%</td>
<td>8.66</td>
<td></td>
<td>15 ml OP</td>
</tr>
<tr>
<td>* Mydriacyl</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Preparations for Tear Deficiency

For acetylcysteine eye drops refer Standard Formulae, page 215

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Subsidy (Manufacturer’s Price) $</th>
<th>Fully Subsidised ✔</th>
<th>Per</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>HYPROMELLOSE</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>* Eye drops 0.5%</td>
<td>2.00</td>
<td></td>
<td>15 ml OP</td>
</tr>
<tr>
<td>Methopt</td>
<td>(3.92)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

▲ Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber or pharmacist.

★ Three months or six months, as applicable, dispensed all-at-once
## Sensory Organs

<table>
<thead>
<tr>
<th>Subsidy (Manufacturer's Price)</th>
<th>Fully Subsidised</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>$</td>
<td>Per</td>
</tr>
<tr>
<td>HYDROMELLOSE WITH DEXTRAN</td>
<td></td>
<td></td>
</tr>
<tr>
<td>* Eye drops 0.3% with dextran 0.1%</td>
<td>2.30</td>
<td>15 ml OP</td>
</tr>
<tr>
<td>POLYVINYL ALCOHOL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>* Eye drops 1.4%</td>
<td>2.62</td>
<td>15 ml OP</td>
</tr>
<tr>
<td>* Eye drops 3%</td>
<td>3.68</td>
<td>15 ml OP</td>
</tr>
</tbody>
</table>

### Preservative Free Ocular Lubricants

**SA1388** Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Both:
1. Confirmed diagnosis by slit lamp of severe secretory dry eye; and
2. Either:
   2.1 Patient is using eye drops more than four times daily on a regular basis; or
   2.2 Patient has had a confirmed allergic reaction to preservative in eye drop.

Renewal from any relevant practitioner. Approvals valid for 24 months where the patient continues to require lubricating eye drops and has benefited from treatment.

**CARBOMER** – Special Authority see SA1388 above – Retail pharmacy

* Ophthalmic gel 0.3%, 0.5 g: 8.25 30 ✔ Poly-Gel

**MACROGOL 400 AND PROPYLENE GLYCOL** – Special Authority see SA1388 above – Retail pharmacy

* Eye drops 0.4% and propylene glycol 0.3%, 0.4 ml: 4.30 24 ✔ Systane Unit Dose

**SODIUM HYALURONATE [HYALURONIC ACID]** – Special Authority see SA1388 above – Retail pharmacy

* Eye drops 1 mg per ml: 22.00 10 ml OP ✔ Hylo-Fresh

Hylo-Fresh has a 6 month expiry after opening. The Pharmacy Procedures Manual restriction allowing one bottle per month is not relevant and therefore only the prescribed dosage to the nearest OP may be claimed.

### Other Eye Preparations

**NAPHAZOLINE HYDROCHLORIDE**

* Eye drops 0.1%: 4.15 15 ml OP ✔ Naphcon Forte

**OLOPATADINE**

* Eye drops 0.1%: 10.00 5 ml OP ✔ Patanol

**PARAFFIN LIQUID WITH SOFT WHITE PARAFFIN**

* Eye oint with soft white paraffin: 3.63 3.5 g OP ✔ Refresh Night Time

**PARAFFIN LIQUID WITH WOOL FAT**

* Eye oint 3% with wool fat 3%: 3.63 3.5 g OP ✔ Poly-Visc

**RETINOL PALMITATE**

* Eye oint 138 mcg per g: 3.80 5 g OP ✔ VitA-POS

---

✓ fully subsidised

Sole Subsidised Supply

Unapproved medicine supplied under Section 29
VARIOUS

PHARMACY SERVICES
May only be claimed once per patient.

* Brand switch fee ................................................................. 4.50 1 fee
  ✔ BSF Apo-Gabapentin
  ✔ BSF Aripiprazole Sandoz
  ✔ BSF Tenofovir Disproxil Teva

a) The Pharmacode for BSF Aripiprazole Sandoz is 2556634 - see also page 135
b) The Pharmacode for BSF Tenofovir Disproxil Teva is 2556642 - see also page 103
c) The Pharmacode for BSF Apo-Gabapentin is 2556626 - see also page 130

(BSF Apo-Gabapentin Brand switch fee to be delisted 1 February 2019)
(BSF Aripiprazole Sandoz Brand switch fee to be delisted 1 February 2019)
(BSF Tenofovir Disproxil Teva Brand switch fee to be delisted 1 February 2019)

Agents Used in the Treatment of Poisonings

Antidotes

ACETYLCYSTEINE – Retail pharmacy-Specialist
  Inj 200 mg per ml, 10 ml ampoule .............................................. 58.76 10
  ✔ DBL Acetylcysteine

NALOXONE HYDROCHLORIDE
  a) Up to 5 inj available on a PSO
  b) Only on a PSO
  * Inj 400 mcg per ml, 1 ml ampoule ........................................... 22.60 5
  ✔ DBL Naloxone Hydrochloride

Removal and Elimination

CHARCOAL
  * Oral liq 50 g per 250 ml ..................................................... 43.50 250 ml OP
    a) Up to 250 ml available on a PSO
    b) Only on a PSO

DEFERASIROX – Special Authority see SA1492 below – Retail pharmacy
  Wastage claimable
    Tab 125 mg dispersible ......................................................... 276.00 28  ✔ Exjade
    Tab 250 mg dispersible ......................................................... 552.00 28  ✔ Exjade
    Tab 500 mg dispersible ......................................................... 1,105.00 28  ✔ Exjade

*SA1492 Special Authority for Subsidy

Initial application only from a haematologist. Approvals valid for 2 years for applications meeting the following criteria:
All of the following:
  1 The patient has been diagnosed with chronic iron overload due to congenital inherited anaemia; and
  2 Deferasirox is to be given at a daily dose not exceeding 40 mg/kg/day; and
  3 Any of the following:
    3.1 Treatment with maximum tolerated doses of deferiprone monotherapy or deferiprone and desferrioxamine combination therapy have proven ineffective as measured by serum ferritin levels, liver or cardiac MRI T2*; or

continued…

▲Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber or pharmacist.
*Three months or six months, as applicable, dispensed all-at-once
continued...

3.2 Treatment with deferiprone has resulted in severe persistent vomiting or diarrhoea; or
3.3 Treatment with deferiprone has resulted in arthritis; or
3.4 Treatment with deferiprone is contraindicated due to a history of agranulocytosis (defined as an absolute neutrophil count (ANC) of < 0.5 cells per µL) or recurrent episodes (greater than 2 episodes) of moderate neutropenia (ANC 0.5 - 1.0 cells per µL).

Renewal only from a haematologist. Approvals valid for 2 years for applications meeting the following criteria:

Either:
1. For the first renewal following 2 years of therapy, the treatment has been tolerated and has resulted in clinical improvement in all three parameters namely serum ferritin, cardiac MRI T2* and liver MRI T2* levels; or
2. For subsequent renewals, the treatment has been tolerated and has resulted in clinical stability or continued improvement in all three parameters namely serum ferritin, cardiac MRI T2* and liver MRI T2* levels.

DEFERIPRONE – Special Authority see SA1480 below – Retail pharmacy

<table>
<thead>
<tr>
<th>Description</th>
<th>Price</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 500 mg</td>
<td>533.17</td>
<td>100</td>
</tr>
<tr>
<td>Oral liq 100 mg per 1 ml</td>
<td>266.59</td>
<td>250 ml OP</td>
</tr>
</tbody>
</table>

SA1480 Special Authority for Subsidy

Initial application only from a haematologist. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Either:
1. The patient has been diagnosed with chronic iron overload due to congenital inherited anaemia; or
2. The patient has been diagnosed with chronic iron overload due to acquired red cell aplasia.

DESFERRIOXAMINE MESILATE

<table>
<thead>
<tr>
<th>Description</th>
<th>Price</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 500 mg vial</td>
<td>51.52</td>
<td>10</td>
</tr>
</tbody>
</table>

SODIUM CALCIUM EDETATE

<table>
<thead>
<tr>
<th>Description</th>
<th>Price</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 200 mg per ml, 5 ml</td>
<td>53.31</td>
<td>6</td>
</tr>
</tbody>
</table>

Calcium Disodium Versenate
Standard Formulae

ACETYLICYSTEINE EYE DROPS
Acetylcysteine inj 200 mg per ml, 10 ml
Suitable eye drop base

ASPIRIN AND CHLOROFORM APPLICATION
Aspirin Soluble tabs 300 mg
Chloroform

CODEINE LINCTUS PAEDIATRIC (3 mg per 5 ml)
Codeine phosphate
Glycerol
Preservative
Water

CODEINE LINCTUS DIABETIC (15 mg per 5 ml)
Codeine phosphate
Glycerol
Preservative
Water

FOLINIC MOUTHWASH
Calcium folinate 15 mg tab
Preservative
Water

MAGNESIUM HYDROXIDE 8% MIXTURE
Magnesium hydroxide paste 29%
Methyl hydroxybenzoate
Water

METHADONE MIXTURE
Methodone powder
Glycerol
Water

METHYL HYDROXYBENOZATE 10% SOLUTION
Methyl hydroxybenzoate
Propylene glycol
(Use 1 ml of the 10% solution per 100 ml of oral liquid mixture)

OMEPRAZOLE SUSPENSION
Omeprazole capules or powder
Sodium bicarbonate powder BP
Water

PHENOBARBITONE ORAL LIQUID
Phenobarbitone Sodium
Glycerol BP
Water

PHENOBARBITONE SODIUM PAEDIATRIC ORAL LIQUID (10 mg per ml)
Phenobarbitone Sodium
Glycerol BP
Water

PILOCARPINE ORAL LIQUID
Pilocarpine 4% eye drops
Preservative
Water

SALIVA SUBSTITUTE FORMULA
Methylcellulose
Preservative
Water

SODIUM CHLORIDE ORAL LIQUID
Sodium chloride inj 23.4%, 20 ml
Water

VANCOMYCIN ORAL SOLUTION (50 mg per ml)
Vancomycin 500 mg injection
Glycerol BP
Water

VOSOL EAR DROPS
Hydrocortisone powder
Vosol Ear Drops
## Extemporaneously Compounded Preparations and Galenicals

### BENZOIN
- **Tincture compound BP**
  - 24.42 $ 500 ml
  - (39.90) $ 250 ml
  - (5.10) $ 50 ml

### CHLOROFORM
- **Chloroform BP**
  - 25.50 $ 500 ml
  - ✔ PSM

### CODEINE PHOSPHATE
- **Powder**
  - 63.09 $ 25 g
  - (90.09) $ 10 g

### COLLODION FLEXIBLE
- 19.30 $ 100 ml

### COMPOUND HYDROXYBENZOATE
- Only in combination
  - Only in extemporaneously compounded oral mixtures.
  - **Soln**
    - 30.00 $ 100 ml
    - 34.18 $ 100 ml

### GLYCERIN WITH SODIUM SACCHARIN
- **Suspension**
  - 32.50 $ 473 ml

### GLYCERIN WITH SUCROSE
- **Suspension**
  - 32.50 $ 473 ml

### GLYCEROL
- ❋ Liquid
  - 3.28 $ 500 ml

### MAGNESIUM HYDROXIDE
- **Paste 29%**
  - 22.61 $ 500 g

### METHADONE HYDROCHLORIDE
- **Powder**
  - 7.84 $ 1 g

### METHYL HYDROXYBENZOATE
- **Powder**
  - 8.00 $ 25 g

### METHYLCELLULOSE
- **Powder**
  - 36.95 $ 100 g
  - 32.50 $ 473 ml

### METHYLCELLULOSE WITH GLYCERIN AND SODIUM SACCHARIN
- **Suspension**
  - 32.50 $ 473 ml

---

**Fully Subsidised**: ✔

**Manufacturer**: Pharmacy Health

**Brand or Generic Manufacturer**: ✔

*Unapproved medicine supplied under Section 29*
### Extemporaneously Compounded Preparations and Galenicals

#### Subsidy (Manufacturer's Price) $ Per

<table>
<thead>
<tr>
<th>Fully Subsidised</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>✔</td>
<td></td>
</tr>
</tbody>
</table>

#### Methyccellulose with Glycerin and Sucrose – Only in combination
- Suspension: $32.50 473 ml ✔ Ora-Blend

#### Phenobarbitone Sodium
- Powder – Only in combination: $52.50 10 g ✔ MidWest
- 325.00 100 g ✔ MidWest

- Only in children up to 12 years

#### Propylene Glycol
- Only in extemporaneously compounded methyl hydroxybenzoate 10% solution.
  - Liq: $11.25 500 ml ✔ Midwest

#### Sodium Bicarbonate
- Powder BP – Only in combination: $8.95 500 g ✔ Midwest
- 9.80 (29.50) David Craig

- Only in extemporaneously compounded omeprazole and lansoprazole suspension.

#### Syrup (Pharmaceutical Grade) – Only in combination
- Only in extemporaneously compounded oral liquid preparations.
  - Liq: $21.75 2,000 ml ✔ Midwest

#### Water
- Tap – Only in combination: $0.00 1 ml ✔ Tap water

▲ Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber or pharmacist.

※ Three months or six months, as applicable, dispensed all-at-once.
### SECTION D: SPECIAL FOODS

#### Nutrient Modules

**Carbohydrate**

<table>
<thead>
<tr>
<th>Special Authority for Subsidy</th>
<th>Initial application — <em>(Cystic fibrosis or kidney disease)</em> only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria: Either: 1. cystic fibrosis; or 2. chronic kidney disease.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>**Initial application — <em>(Indications other than cystic fibrosis or renal failure)</em> only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: Any of the following: 1. cancer in children; or 2. cancers affecting alimentary tract where there are malabsorption problems in patients over the age of 20 years; or 3. faltering growth in an infant/child; or 4. bronchopulmonary dysplasia; or 5. premature and post premature infant; or 6. inborn errors of metabolism; or 7. for use as a component in a modular formula made from at least one nutrient module and at least one further product listed in Section D of the Pharmaceutical Schedule or breast milk. Note: Patients are required to meet any Special Authority criteria associated with all of the products used in the modular formula.</td>
</tr>
<tr>
<td></td>
<td>**Renewal — <em>(Cystic fibrosis or renal failure)</em> only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria: Both: 1. The treatment remains appropriate and the patient is benefiting from treatment; and 2. General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.</td>
</tr>
<tr>
<td></td>
<td>**Renewal — <em>(Indications other than cystic fibrosis or renal failure)</em> only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: Both: 1. The treatment remains appropriate and the patient is benefiting from treatment; and 2. General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.</td>
</tr>
<tr>
<td></td>
<td>CARBOHYDRATE SUPPLEMENT – Special Authority see <strong>SA1522 above</strong> – Hospital pharmacy [HP3] Powder ..........................5.29 400 g OP ✔ Polycal</td>
</tr>
</tbody>
</table>

**Carbohydrate And Fat**

<table>
<thead>
<tr>
<th>Special Authority for Subsidy</th>
<th>Initial application — <em>(Cystic fibrosis)</em> only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria: Both:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>continued…</td>
</tr>
</tbody>
</table>
continued...

1. Infant or child aged four years or under; and
2. cystic fibrosis.

Initial application — (Indications other than cystic fibrosis) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

1. infant or child aged four years or under; and
2. Any of the following:
   2.1 cancer in children; or
   2.2 faltering growth; or
   2.3 bronchopulmonary dysplasia; or
   2.4 premature and post premature infants.

Renewal — (Cystic fibrosis) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria:

Both:

1. The treatment remains appropriate and the patient is benefiting from treatment; and
2. General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

Renewal — (Indications other than cystic fibrosis) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

1. The treatment remains appropriate and the patient is benefiting from treatment; and
2. General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

CARBOHYDRATE AND FAT SUPPLEMENT – Special Authority see SA1376 on the previous page – Hospital pharmacy [HP3]

Powder (neutral) .................................................................60.31 400 g OP ✔ Duocal Super Soluble Powder

Fat

**SA1523** Special Authority for Subsidy

Initial application — (Inborn errors of metabolism) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years where the patient has inborn errors of metabolism.

Initial application — (Indications other than inborn errors of metabolism) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Any of the following:

1. faltering growth in an infant/child; or
2. bronchopulmonary dysplasia; or
3. fat malabsorption; or
4. lymphangiectasia; or
5. short bowel syndrome; or
6. infants with necrotising enterocolitis; or
7. biliary atresia; or
8. for use in a ketogenic diet; or
9. chyle leak; or

continued…

✔ fully subsidised
continued...

10 ascites; or
11 for use as a component in a modular formula made from at least one nutrient module and at least one further product listed in Section D of the Pharmaceutical Schedule or breast milk.

Note: Patients are required to meet any Special Authority criteria associated with all of the products used in the modular formula.

Renewal — (Inborn errors of metabolism) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria:

Both:

1 The treatment remains appropriate and the patient is benefiting from treatment; and
2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

Renewal — (Indications other than inborn errors of metabolism) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

1 The treatment remains appropriate and the patient is benefiting from treatment; and
2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

FAT SUPPLEMENT – Special Authority see SA1523 on the previous page – Hospital pharmacy [HP3]

<table>
<thead>
<tr>
<th>Description</th>
<th>Price</th>
<th>Quantity</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Emulsion (neutral)</td>
<td>12.30</td>
<td>200 ml</td>
<td>Calogen</td>
</tr>
<tr>
<td>Emulsion (strawberry)</td>
<td>30.75</td>
<td>500 ml</td>
<td>Calogen</td>
</tr>
<tr>
<td>Oil</td>
<td>12.30</td>
<td>200 ml</td>
<td>Calogen</td>
</tr>
<tr>
<td>Oil, 250 ml</td>
<td>30.00</td>
<td>500 ml</td>
<td>MCT oil (Nutricia)</td>
</tr>
<tr>
<td></td>
<td>114.92</td>
<td>4 OP</td>
<td>Liquigen</td>
</tr>
</tbody>
</table>

Protein

Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Any of the following:

1 protein losing enteropathy; or
2 high protein needs; or
3 for use as a component in a modular formula made from at least one nutrient module and at least one further product listed in Section D of the Pharmaceutical Schedule or breast milk.

Note: Patients are required to meet any Special Authority criteria associated with all of the products used in the modular formula.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

1 The treatment remains appropriate and the patient is benefiting from treatment; and
2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

PROTEIN SUPPLEMENT – Special Authority see SA1524 above – Hospital pharmacy [HP3]

<table>
<thead>
<tr>
<th>Description</th>
<th>Price</th>
<th>Quantity</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Powder</td>
<td>7.90</td>
<td>225 g</td>
<td>Protifar</td>
</tr>
<tr>
<td></td>
<td>8.95</td>
<td>227 g</td>
<td>Resource</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Beneprotein</td>
</tr>
</tbody>
</table>
Oral Supplements/Complete Diet (Nasogastric/Gastrostomy Tube Feed)

Respiratory Products

[SA1094] Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year where the patient has CORD and hypercapnia, defined as a CO2 value exceeding 55 mmHg.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:
1. The treatment remains appropriate and the patient is benefiting from treatment; and
2. General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

CORD ORAL FEED 1.5KCAL/ML – Special Authority see SA1094 above – Hospital pharmacy [HP3]

- Liquid ................................................................. 1.66 237 ml OP ✔ Pulmocare

Diabetic Products

[SA1095] Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year where the patient is a type I or type II diabetic who is suffering weight loss and malnutrition that requires nutritional support.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:
1. The treatment remains appropriate and the patient is benefiting from treatment; and
2. General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

DIABETIC ENTERAL FEED 1KCAL/ML – Special Authority see SA1095 above – Hospital pharmacy [HP3]

- Liquid ........................................................................................................ 7.50 1,000 ml OP ✔ Dison RTH ✔ Glucerna Select RTH

DIABETIC ORAL FEED 1KCAL/ML – Special Authority see SA1095 above – Hospital pharmacy [HP3]

- Liquid (strawberry) ................................................................. 1.50 200 ml OP ✔ Diasip
- Liquid (vanilla) ................................................................. 1.88 250 ml OP ✔ Diasip
- Liquid ...................................................................................... 1.78 237 ml OP ✔ Glucerna Select
  (2.10) Resource Diabetic
  (2.10) Sustagen Diabetic

✓ fully subsidised
Fat Modified Products

**SA1525** Special Authority for Subsidy

*Initial application* only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Any of the following:

1. Patient has metabolic disorders of fat metabolism; or
2. Patient has a chyle leak; or
3. Modified as a modular feed, made from at least one nutrient module and at least one further product listed in Section D of the Pharmaceutical Schedule, for adults.

Note: Patients are required to meet any Special Authority criteria associated with all of the products used in the modular formula.

**Renewal** only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

1. The treatment remains appropriate and the patient is benefiting from treatment; and
2. General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

FAT MODIFIED FEED – Special Authority see SA1525 above – Hospital pharmacy [HP3]

| Powder | $60.48 | 400 g | ✔ Monogen |

Paediatric Products For Children Awaiting Liver Transplant

**SA1098** Special Authority for Subsidy

*Initial application* only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years where the patient is a child (up to 18 years) who requires a liver transplant.

**Renewal** only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria:

Both:

1. The treatment remains appropriate and the patient is benefiting from treatment; and
2. General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

ENTERAL/ORAL FEED 1KCAL/ML – Special Authority see SA1098 above – Hospital pharmacy [HP3]

| Powder (unflavoured) | $78.97 | 400 g | ✔ Heparon Junior |

Paediatric Products For Children With Chronic Renal Failure

**SA1099** Special Authority for Subsidy

*Initial application* only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years where the patient is a child (up to 18 years) with acute or chronic kidney disease.

**Renewal** only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria:

Both:

1. The treatment remains appropriate and the patient is benefiting from treatment; and
2. General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.
Paediatric Products

**Special Authority for Subsidy**

**Initial application** only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

1. Child is aged one to ten years; and
2. Any of the following:
   2.1 the child is being fed via a tube or a tube is to be inserted for the purposes of feeding; or
   2.2 any condition causing malabsorption; or
   2.3 faltering growth in an infant/child; or
   2.4 increased nutritional requirements; or
   2.5 the child is being transitioned from TPN or tube feeding to oral feeding.

**Renewal** only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

1. The treatment remains appropriate and the patient is benefiting from treatment; and
2. General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

<table>
<thead>
<tr>
<th>Paediatric Enteral Feed 1.5KCAL/ML – Special Authority see SA1379 above – Hospital pharmacy [HP3]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Liquid ..........................................................</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Paediatric Enteral Feed 1KCAL/ML – Special Authority see SA1379 above – Hospital pharmacy [HP3]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Liquid ..........................................................</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Paediatric Enteral Feed with Fibre 1.5KCAL/ML – Special Authority see SA1379 above – Hospital pharmacy [HP3]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Liquid ..........................................................</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Paediatric Oral Feed 1.5KCAL/ML – Special Authority see SA1379 above – Hospital pharmacy [HP3]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Liquid (strawberry)..................</td>
</tr>
<tr>
<td>Liquid (vanilla) ....................</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Paediatric Oral Feed 1KCAL/ML – Special Authority see SA1379 above – Hospital pharmacy [HP3]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Liquid (chocolate) ..................</td>
</tr>
<tr>
<td>Liquid (strawberry) ...............</td>
</tr>
<tr>
<td>Liquid (vanilla) ....................</td>
</tr>
<tr>
<td>Liquid ................................................</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Paediatric Oral Feed with Fibre 1.5KCAL/ML – Special Authority see SA1379 above – Hospital pharmacy [HP3]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Liquid (chocolate) ..................</td>
</tr>
<tr>
<td>Liquid (strawberry) ...............</td>
</tr>
<tr>
<td>Liquid (vanilla) ....................</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Peptide-Based Oral Feed – Special Authority see SA1379 above – Hospital pharmacy [HP3]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Powder ..................................................</td>
</tr>
</tbody>
</table>
Renal Products

**SA1101** Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years where the patient has acute or chronic kidney disease.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria:

Both:

1. The treatment remains appropriate and the patient is benefiting from treatment; and
2. General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

RENAL ENTERAL FEED 1.8 KCAL/ML – Special Authority see SA1101 above – Hospital pharmacy [HP3]

- Liquid...................................................................................................6.08 500 ml OP ✔ Nepro HP RTH

RENAL ORAL FEED 1.8 KCAL/ML – Special Authority see SA1101 above – Hospital pharmacy [HP3]

- Liquid...................................................................................................2.67 220 ml OP ✔ Nepro HP (strawberry)
- Liquid...................................................................................................2.67 220 ml OP ✔ Nepro HP (vanilla)

RENAL ORAL FEED 2 KCAL/ML – Special Authority see SA1101 above – Hospital pharmacy [HP3]

- Liquid...................................................................................................2.88 237 ml OP (3.31) NovaSource Renal
  - Liquid (apricot) 125 ml.................................................................11.52 4 OP ✔ Renilon 7.5
  - Liquid (caramel) 125 ml.................................................................11.52 4 OP ✔ Renilon 7.5

Specialised And Elemental Products

**SA1377** Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Any of the following:

1. malabsorption; or
2. short bowel syndrome; or
3. enterocutaneous fistulas; or
4. eosinophilic oesophagitis; or
5. inflammatory bowel disease; or
6. patients with multiple food allergies requiring enteral feeding.

Notes: Each of these products is highly specialised and would be prescribed only by an expert for a specific disorder. The alternative is hospitalisation.

Elemental 028 Extra is more expensive than other products listed in this section and should only be used where the alternatives have been tried first and/or are unsuitable.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

1. The treatment remains appropriate and the patient is benefiting from treatment; and
2. General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

ENTERAL/ORAL SEMI-ELEMENTAL FEED 1.5KCAL/ML – Special Authority see SA1377 above – Hospital pharmacy [HP3]

- Liquid..................................................................................................18.06 1,000 ml OP ✔ Vital
### Paediatric Products For Children With Low Energy Requirements

**SA1196** Special Authority for Subsidy

**Initial application** only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:
1. Child aged one to eight years; and
2. The child has a low energy requirement but normal protein and micronutrient requirements.

**Renewal** only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:
1. The treatment remains appropriate and the patient is benefiting from treatment; and
2. General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

### Standard Supplements

**SA1554** Special Authority for Subsidy

**Initial application** — (Children - indications other than exclusive enteral nutrition for Crohn's disease) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

All of the following:
1. The patient is under 18 years of age; and
2. Any of the following:
   1. The patient has a condition causing malabsorption; or
   2. The patient has failure to thrive; or
   3. The patient has increased nutritional requirements; and
3. Nutrition goal has been set (eg reach a specific weight or BMI).

**Renewal** — (Children - indications other than exclusive enteral nutrition for Crohn's disease) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

All of the following:

---

### ORAL ELEMENTAL FEED 0.8KCAL/ML

- **Brand or Generic Manufacturer**: Fully Subsidised ✔
- **Subsidy (Manufacturer’s Price) Per**: $171.00 18 OP ✔

<table>
<thead>
<tr>
<th>Subsidy (Manufacturer’s Price) Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$171.00 18 OP ✔</td>
<td>Fully Subsidised ✔</td>
</tr>
</tbody>
</table>

- **Manufacturer**: Elemental 028 Extra

**SA1377 on the previous page** – Hospital pharmacy [HP3]

**Liquid (grapefruit)**, 250 ml carton .......................................................... 171.00 18 OP ✔

**Liquid (pineapple & orange)**, 250 ml carton ........................................... 171.00 18 OP ✔

**Liquid (summer fruits)**, 250 ml carton .................................................... 171.00 18 OP ✔

### ORAL ELEMENTAL FEED 1KCAL/ML

- **Brand or Generic Manufacturer**: Fully Subsidised ✔
- **Subsidy (Manufacturer’s Price) Per**: $4.50 80 g OP ✔

<table>
<thead>
<tr>
<th>Subsidy (Manufacturer’s Price) Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$4.50 80 g OP ✔</td>
<td>Fully Subsidised ✔</td>
</tr>
</tbody>
</table>

- **Manufacturer**: Vivonex TEN

**SA1377 on the previous page** – Hospital pharmacy [HP3]

**Powder (unflavoured)** .......................................................... 4.50 80 g OP ✔

### SEMI-ELEMENTAL ENTERAL FEED 1KCAL/ML

- **Brand or Generic Manufacturer**: Fully Subsidised ✔
- **Subsidy (Manufacturer’s Price) Per**: $12.04 1,000 ml OP ✔

<table>
<thead>
<tr>
<th>Subsidy (Manufacturer’s Price) Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$12.04 1,000 ml OP ✔</td>
<td>Fully Subsidised ✔</td>
</tr>
</tbody>
</table>

- **Manufacturer**: Peptisorb

**SA1377 on the previous page** – Hospital pharmacy [HP3]

**Liquid** .......................................................... 12.04 1,000 ml OP ✔

### PAEDIATRIC ENTERAL FEED WITH FIBRE 0.76 KCAL/ML

- **Brand or Generic Manufacturer**: Fully Subsidised ✔
- **Subsidy (Manufacturer’s Price) Per**: $4.00 500 ml OP ✔

<table>
<thead>
<tr>
<th>Subsidy (Manufacturer’s Price) Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$4.00 500 ml OP ✔</td>
<td>Fully Subsidised ✔</td>
</tr>
</tbody>
</table>

- **Manufacturer**: Nutrini Low Energy Multi Fibre

**SA1196 above** – Hospital pharmacy [HP3]

**Liquid** .......................................................... 4.00 500 ml OP ✔

---

**fully subsidised**
continued…

1 The patient is under 18 years of age; and
2 The treatment remains appropriate and the patient is benefiting from treatment; and
3 A nutrition goal has been set (e.g. reach a specific weight or BMI).

**Initial application — (Children - exclusive enteral nutrition for Crohn’s disease)** only from a gastroenterologist or dietitian on the recommendation of a gastroenterologist. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

1 The patient is under 18 years of age; and
2 It is to be used as exclusive enteral nutrition for the treatment of Crohn’s disease; and
3 Dietitians must include the name of the gastroenterologist recommending treatment and the date the gastroenterologist was contacted.

**Renewal — (Children - exclusive enteral nutrition for Crohn’s disease)** only from a gastroenterologist, dietitian on the recommendation of a gastroenterologist or vocationally registered general practitioner on the recommendation of a gastroenterologist. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

1 The patient is under 18 years of age; and
2 It is to be used as exclusive enteral nutrition for the treatment of Crohn’s disease; and
3 General Practitioners and dietitians must include the name of the gastroenterologist recommending treatment and the date the gastroenterologist was contacted.

**Initial application — (Adults)** only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

1 Any of the following:
   - Patient is Malnourished
     1.1 Patient has a body mass index (BMI) of less than 18.5 kg/m$^2$; or
     1.2 Patient has unintentional weight loss greater than 10% within the last 3-6 months; or
     1.3 Patient has a BMI of less than 20 kg/m$^2$ and unintentional weight loss greater than 5% within the last 3-6 months;
     and
   2 Any of the following:
      - Patient has not responded to first-line dietary measures over a 4 week period by:
        2.1 Increasing their food intake frequency (e.g. snacks between meals); or
        2.2 Using high-energy foods (e.g. milkshakes, full fat milk, butter, cream, cheese, sugar etc); or
        2.3 Using over the counter supplements (e.g. Complan); and
   3 A nutrition goal has been set (e.g. to reach a specific weight or BMI).

**Renewal — (Adults)** only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

1 A nutrition goal has been set (e.g. reach a specific weight or BMI); and
2 Any of the following:
   - Patient is Malnourished
     2.1 Patient has a body mass index (BMI) of less than 18.5 kg/m$^2$; or
     2.2 Patient has unintentional weight loss greater than 10% within the last 3-6 months; or
     2.3 Patient has a BMI of less than 20 kg/m$^2$ and unintentional weight loss greater than 5% within the last 3-6 months.

**Initial application — (Short-term medical condition)** only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Any of the following:

1 Is being fed via a nasogastric tube or a nasogastric tube is to be inserted for feeding; or
continued...

2 Malignancy and is considered likely to develop malnutrition as a result; or
3 Is undergoing a bone marrow transplant; or
4 Tempomandibular surgery or glossectomy; or
5 Both:
   5.1 Pregnant; and
   5.2 Any of the following:
      5.2.1 Patient is in early pregnancy (< 13 weeks) and has severe clinical hyperemesis gravidarum requiring admission to hospital and is unlikely to meet her nutritional requirements due to continuing hyperemesis gravidarum; or
      5.2.2 Patient has clinical hyperemesis gravidarum continuing past 13 weeks and either there is concern that the patient is unlikely to meet the Institute of Medicine’s (1990) recommended weight gain guidelines for pregnancy or the patient’s weight has not increased past her booking/pre-pregnancy weight; or
      5.2.3 Patient is having multiple births and is under the care of an obstetric team who consider the nutritional needs of the patient are not being met.

Renewal — (Short-term medical condition) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Any of the following:
1 Is being fed via a nasogastric tube; or
2 Malignancy and is considered likely to develop malnutrition as a result; or
3 Has undergone a bone marrow transplant; or
4 Tempomandibular surgery or glossectomy; or
5 Both:
   5.1 Pregnant; and
   5.2 Any of the following:
      5.2.1 Patient is in early pregnancy (< 13 weeks) and has severe clinical hyperemesis gravidarum requiring admission to hospital and is unlikely to meet her nutritional requirements due to continuing hyperemesis gravidarum; or
      5.2.2 Patient has clinical hyperemesis gravidarum continuing past 13 weeks and either there is concern that the patient is unlikely to meet the Institute of Medicine’s (1990) recommended weight gain guidelines for pregnancy or the patient’s weight has not increased past her booking/pre-pregnancy weight; or
      5.2.3 Patient is having multiple births and is under the care of an obstetric team who consider the nutritional needs of the patient are not being met.

Initial application — (Long-term medical condition) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Any of the following:
1 Is being fed via a tube or a tube is to be inserted for the purpose of feeding (not nasogastric tube - refer to specific medical condition criteria); or
2 Cystic Fibrosis; or
3 Liver disease; or
4 Chronic Renal failure; or
5 Inflammatory bowel disease; or
6 Chronic obstructive pulmonary disease with hypercapnia; or
7 Short bowel syndrome; or
8 Bowel fistula; or
9 Severe chronic neurological conditions; or
10 Epidermolysis bullosa; or

continued…
continued…

11 AIDS (CD4 count < 200 cells/mm³); or
12 Chronic pancreatitis.

Renewal — (Chronic disease OR tube feeding for patients who have previously been funded under Special Authority forms SA0702 or SA0583) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Any of the following:

1. Is being fed via a tube or a tube is to be inserted for the purpose of feeding (not nasogastric tube - refer to specific medical condition criteria); or
2. Cystic Fibrosis; or
3. Liver disease; or
4. Chronic Renal failure; or
5. Inflammatory bowel disease; or
6. Chronic obstructive pulmonary disease with hypercapnia; or
7. Short bowel syndrome; or
8. Bowel fistula; or
9. Severe chronic neurological conditions.

ENTERAL FEED 1.5KCAL/ML – Special Authority see SA1554 on page 225 – Hospital pharmacy [HP3]

- Liquid...................................................................................................7.00 1,000 ml OP ✔ Nutrison Energy

ENTERAL FEED 1KCAL/ML – Special Authority see SA1554 on page 225 – Hospital pharmacy [HP3]

- Liquid...................................................................................................1.24 250 ml OP 5.29 1,000 ml OP ✔ Isosource Standard ✔ Nutrison Standard RTH ✔ Osmolite RTH

ENTERAL FEED WITH FIBRE 0.83 KCAL/ML – Special Authority see SA1554 on page 225 – Hospital pharmacy [HP3]

- Liquid...................................................................................................5.29 1,000 ml OP ✔ Nutrison 800 Complete Multi Fibre

ENTERAL FEED WITH FIBRE 1 KCAL/ML – Special Authority see SA1554 on page 225 – Hospital pharmacy [HP3]

- Liquid...................................................................................................5.29 1,000 ml OP ✔ Jevity RTH ✔ Nutrison Multi Fibre

ENTERAL FEED WITH FIBRE 1.5KCAL/ML – Special Authority see SA1554 on page 225 – Hospital pharmacy [HP3]

- Liquid...................................................................................................1.75 250 ml OP 7.00 1,000 ml OP ✔ Ensure Plus HN ✔ Ensure Plus RTH ✔ Jevity HiCal RTH ✔ Nutrison Energy Multi Fibre
ORAL FEED (POWDER) – Special Authority see SA1554 on page 225 – Hospital pharmacy [HP3]

Note: Higher subsidy for Sustagen Hospital Formula will only be reimbursed for patients with both a valid Special Authority number and an appropriately endorsed prescription.

Powder (chocolate) – Higher subsidy of up to $26.00 per 850 g

with Endorsement.................................................................................

26.00 850 g OP

9.54 840 g OP

(26.00) Sustagen Hospital

Formula Active

Additional subsidy by endorsement is available for patients with fat malabsorption, fat intolerance or chyle leak. The prescription must be endorsed accordingly.

Powder (vanilla) – Higher subsidy of up to $26.00 per 850 g

with Endorsement.................................................................................

26.00 850 g OP

9.54 840 g OP

(26.00) Sustagen Hospital

Formula Active

Additional subsidy by endorsement is available for patients with fat malabsorption, fat intolerance or chyle leak. The prescription must be endorsed accordingly.

ORAL FEED 1.5KCAL/ML – Special Authority see SA1554 on page 225 – Hospital pharmacy [HP3]

Additional subsidy by endorsement is available for patients being bolus fed through a feeding tube, who have severe epidermolysis bullosa, or as exclusive enteral nutrition in children under the age of 18 years for the treatment of Crohn's disease. The prescription must be endorsed accordingly.

Liquid (banana) – Higher subsidy of $1.26 per 200 ml with

Endorsement......................................................................................

0.72 200 ml OP

(1.26) Ensure Plus

(1.26) Fortisip

Liquid (chocolate) – Higher subsidy of $1.26 per 200 ml with

Endorsement......................................................................................

0.72 200 ml OP

(1.26) Ensure Plus

(1.26) Fortisip

Liquid (fruit of the forest) – Higher subsidy of $1.26 per 200 ml with

Endorsement......................................................................................

0.72 200 ml OP

(1.26) Ensure Plus

(1.26) Fortisip

Liquid (strawberry) – Higher subsidy of $1.26 per 200 ml with

Endorsement......................................................................................

0.72 200 ml OP

(1.26) Ensure Plus

(1.26) Fortisip

Liquid (vanilla) – Higher subsidy of up to $1.33 per 237 ml with

Endorsement......................................................................................

0.85 237 ml OP

(1.33)

0.72 200 ml OP

(1.26)

(1.26) Ensure Plus

(1.26) Fortisip

(1.26) Fortisip

(1.26) Fortisip
SPECIAL FOODS

<table>
<thead>
<tr>
<th>Subsidy (Manufacturer’s Price) $</th>
<th>Fully Subsidised</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>ORAL FEED WITH FIBRE 1.5 KCAL/ML – Special Authority see SA1554 on page 225 – Hospital pharmacy [HP3]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Additional subsidy by endorsement is available for patients being bolus fed through a feeding tube, or who have severe epidermolysis bullosa. The prescription must be endorsed accordingly.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liquid (chocolate) – Higher subsidy of $1.26 per 200 ml with endorsement</td>
<td>0.72</td>
<td>200 ml OP</td>
</tr>
<tr>
<td>Liquid (strawberry) – Higher subsidy of $1.26 per 200 ml with endorsement</td>
<td>0.72</td>
<td>200 ml OP</td>
</tr>
<tr>
<td>Liquid (vanilla) – Higher subsidy of $1.26 per 200 ml with endorsement</td>
<td>0.72</td>
<td>200 ml OP</td>
</tr>
</tbody>
</table>

High Calorie Products

**SA1195 Special Authority for Subsidy**

*Initial application — (Cystic fibrosis)* only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria:

All of the following:

1. Cystic fibrosis; and
2. other lower calorie products have been tried; and
3. patient has substantially increased metabolic requirements.

*Initial application — (Indications other than cystic fibrosis)* only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

All of the following:

1. Any of the following:
   1.1 any condition causing malabsorption; or
   1.2 faltering growth in an infant/child; or
   1.3 increased nutritional requirements; or
   1.4 fluid restricted; and
2. other lower calorie products have been tried; and
3. patient has substantially increased metabolic requirements or is fluid restricted.

*Renewal — (Cystic fibrosis)* only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria:

Both:

1. The treatment remains appropriate and the patient is benefiting from treatment; and
2. General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

*Renewal — (Indications other than cystic fibrosis)* only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

1. The treatment remains appropriate and the patient is benefiting from treatment; and
2. General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

**ENTERAL FEED 2 KCAL/ML – Special Authority see SA1195 above – Hospital pharmacy [HP3]**

<table>
<thead>
<tr>
<th>Liquid</th>
<th>500 ml OP</th>
<th>✔ Nutrison Concentrated Two Cal HN RTH</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>5.50</td>
<td></td>
</tr>
<tr>
<td></td>
<td>11.00</td>
<td></td>
</tr>
</tbody>
</table>

230 ✔ fully subsidised
ORAL FEED 2 KCAL/ML – Special Authority see SA1195 on the previous page – Hospital pharmacy [HP3]

Additional subsidy by endorsement is available for patients being bolus fed through a feeding tube, or who have severe epidermolysis bullosa. The prescription must be endorsed accordingly.

- Liquid (vanilla) – Higher subsidy of $1.90 per 200 ml with endorsement:
  - 0.96 per 200 ml OP (1.90) Two Cal HN

Food Thickeners

-SA1106 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year where the patient has motor neurone disease with swallowing disorder.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:
1. The treatment remains appropriate and the patient is benefiting from treatment; and
2. General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

- FOOD THICKENER – Special Authority see SA1106 above – Hospital pharmacy [HP3]
  - Powder..........................6.53 300 g OP
  - Nutilis
  - 7.25 380 g OP
  - Feed Thickener
  - Karicare Aptamil

Gluten Free Foods

The funding of gluten free foods is no longer being actively managed by PHARMAC from 1 April 2011. This means that we are no longer considering the listing of new products, or making subsidy, or other changes to the existing listings. As a result we anticipate that the range of funded items will reduce over time. Management of Coeliac disease with a gluten free diet is necessary for good outcomes. A range of gluten free options are available through retail outlets.

-SA1729 Special Authority for Subsidy

Initial application — (all patients) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Either:
1. Gluten enteropathy has been diagnosed by biopsy; or
2. Patient suffers from dermatitis herpetiformis.

Initial application — (paediatric patients diagnosed by ESPGHAN criteria) only from a paediatric gastroenterologist. Approvals valid without further renewal unless notified where the paediatric patient fulfils ESPGHAN criteria for biopsy free diagnosis of coeliac disease.

- GLUTEN FREE BAKING MIX – Special Authority see SA1729 above – Hospital pharmacy [HP3]
  - Powder..........................2.81 1,000 g OP
  - Healtheries Simple Baking Mix
  - (5.15)

- GLUTEN FREE BREAD MIX – Special Authority see SA1729 above – Hospital pharmacy [HP3]
  - Powder..........................3.93 1,000 g OP
  - NZB Low Gluten Bread Mix
  - 3.51
  - Horleys Bread Mix
  - (10.87)
GLUTEN FREE FLOUR – Special Authority see SA1729 on the previous page – Hospital pharmacy [HP3]
Powder ................................................................................................5.62 2,000 g OP
(18.10) Horleys Flour

GLUTEN FREE PASTA – Special Authority see SA1729 on the previous page – Hospital pharmacy [HP3]
Buckwheat Spirals...............................................................................2.00 250 g OP
(3.11) Orgran
Corn and Vegetable Shells...................................................................2.00 250 g OP
(2.92) Orgran
Corn and Vegetable Spirals...................................................................2.00 250 g OP
(2.92) Orgran
Rice and Corn Lasagne Sheets...............................................................1.60 200 g OP
(3.82) Orgran
Rice and Corn Macaroni.......................................................................2.00 250 g OP
(2.92) Orgran
Rice and Corn Penne...........................................................................2.00 250 g OP
(2.92) Orgran
Rice and Maize Pasta Spirals.................................................................2.00 250 g OP
(2.92) Orgran
Rice and Millet Spirals..........................................................................2.00 250 g OP
(3.11) Orgran
Rice and corn spaghetti noodles...........................................................2.00 375 g OP
(2.92) Orgran
Vegetable and Rice Spirals....................................................................2.00 250 g OP
(2.92) Orgran
Italian long style spaghetti....................................................................2.00 220 g OP
(3.11) Orgran

Foods And Supplements For Inborn Errors Of Metabolism

➽ SA1108 Special Authority for Subsidy
Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:
Any of the following:
1. Dietary management of homocystinuria; or
2. Dietary management of maple syrup urine disease; or
3. Dietary management of phenylketonuria (PKU); or
4. For use as a supplement to the Ketogenic diet in patients diagnosed with epilepsy.

Supplements For Homocystinuria
AMINOACID FORMULA WITHOUT METHIONINE – Special Authority see SA1108 above – Hospital pharmacy [HP3]
Powder .................................................................................461.94 500 g OP ✔ XMET Maxamum

Supplements For MSUD
AMINOACID FORMULA WITHOUT VALINE, LEUCINE AND ISOLEUCINE – Special Authority see SA1108 above – Hospital pharmacy [HP3]
Powder ....................................................................................437.22 500 g OP ✔ MSUD Maxamum
### Supplements For PKU

<table>
<thead>
<tr>
<th>AMINOACID FORMULA WITHOUT PHENYLALANINE – Special Authority see SA1108 on the previous page – Hospital pharmacy [HP3]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tabs</td>
</tr>
<tr>
<td>Powder (unflavoured) 27.8 g sachets</td>
</tr>
<tr>
<td>Powder (unflavoured) 36 g sachets</td>
</tr>
<tr>
<td>Infant formula</td>
</tr>
<tr>
<td>Powder (orange)</td>
</tr>
<tr>
<td>Powder (unflavoured)</td>
</tr>
<tr>
<td>Liquid (berry)</td>
</tr>
<tr>
<td>Liquid (orange)</td>
</tr>
<tr>
<td>Liquid (unflavoured)</td>
</tr>
<tr>
<td>Liquid (forest berries), 250 ml carton</td>
</tr>
<tr>
<td>Liquid (juicy tropical)</td>
</tr>
<tr>
<td>Oral semi-solid (berries)</td>
</tr>
<tr>
<td>Liquid (juicy berries) 62.5 ml</td>
</tr>
<tr>
<td>Liquid (juicy citrus) 62.5 ml</td>
</tr>
<tr>
<td>Liquid (juicy orange)</td>
</tr>
<tr>
<td>Liquid (juicy berries) 125 ml</td>
</tr>
<tr>
<td>Liquid (juicy orange) 125 ml</td>
</tr>
</tbody>
</table>

*(XP Maxamaid Powder (orange) to be delisted 1 April 2019)*

*(XP Maxamaid Powder (unflavoured) to be delisted 1 April 2019)*

### Foods

<table>
<thead>
<tr>
<th>LOW PROTEIN BAKING MIX – Special Authority see SA1108 on the previous page – Hospital pharmacy [HP3]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Powder</td>
</tr>
<tr>
<td>LOW PROTEIN PASTA – Special Authority see SA1108 on the previous page – Hospital pharmacy [HP3]</td>
</tr>
<tr>
<td>Animal shapes</td>
</tr>
<tr>
<td>Lasagne</td>
</tr>
<tr>
<td>Low protein rice pasta</td>
</tr>
<tr>
<td>Macaroni</td>
</tr>
<tr>
<td>Penne</td>
</tr>
<tr>
<td>Spaghetti</td>
</tr>
<tr>
<td>Spirals</td>
</tr>
</tbody>
</table>

✓ fully subsidised
## Infant Formulae

### For Williams Syndrome

**SA1110 Special Authority for Subsidy**

**Initial application** only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year where the patient is an infant suffering from Williams Syndrome and associated hypercalcaemia.

**Renewal** only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

- The treatment remains appropriate and the patient is benefiting from treatment; and
- General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

**LOW CALCIUM INFANT FORMULA** – Special Authority see SA1110 above – Hospital pharmacy [HP3]

<table>
<thead>
<tr>
<th>Product</th>
<th>Subsidy (Manufacturer's Price)</th>
<th>Fully Subsidised</th>
</tr>
</thead>
<tbody>
<tr>
<td>Locasol</td>
<td>44.40</td>
<td>✔</td>
</tr>
</tbody>
</table>

### Gastrointestinal and Other Malabsorptive Problems

**AMINO ACID FORMULA** – Special Authority see SA1219 below – Hospital pharmacy [HP3]

<table>
<thead>
<tr>
<th>Product</th>
<th>Subsidy (Manufacturer's Price)</th>
<th>Fully Subsidised</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alfamino Junior</td>
<td>43.60</td>
<td>✔</td>
</tr>
<tr>
<td>Neocate LCP</td>
<td>53.00</td>
<td>✔</td>
</tr>
<tr>
<td>Elecare</td>
<td>53.00</td>
<td>✔</td>
</tr>
<tr>
<td>Elecare LCP</td>
<td>53.00</td>
<td>✔</td>
</tr>
<tr>
<td>Neocate Gold</td>
<td>53.00</td>
<td>✔</td>
</tr>
<tr>
<td>Neocate Junior Unflavoured</td>
<td>53.00</td>
<td>✔</td>
</tr>
<tr>
<td>Neocate SYNEO</td>
<td>53.00</td>
<td>✔</td>
</tr>
<tr>
<td>Neocate Junior Vanilla</td>
<td>53.00</td>
<td>✔</td>
</tr>
</tbody>
</table>

*(Neocate LCP Powder to be delisted 1 May 2019)*

**SA1219 Special Authority for Subsidy**

**Initial application** only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 6 months for applications meeting the following criteria:

- Any of the following:
  1. Extensively hydrolysed formula has been reasonably trialled and is inappropriate due to documented severe intolerance or allergy or malabsorption; or
  2. History of anaphylaxis to cows milk protein formula or dairy products; or
  3. Eosinophilic oesophagitis.

**Renewal** only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 6 months for applications meeting the following criteria:

- All of the following:
  1. An assessment as to whether the infant can be transitioned to a cows milk protein, soy, or extensively hydrolysed infant formula has been undertaken; and
  2. The outcome of the assessment is that the infant continues to require an amino acid infant formula; and
  3. General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.
EXTENSIVELY HYDROLYSED FORMULA – Special Authority see SA1557 below – Hospital pharmacy [HP3]
Powder ................................................................. 15.21 450 g OP ✔ Aptamil Gold+ Pepti Junior

**SA1557** Special Authority for Subsidy

**Initial application** only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Any of the following:

1. Both:
   1.1 Cows milk formula is inappropriate due to severe intolerance or allergy to its protein content; and
   1.2 Either:
      1.2.1 Soy milk formula has been reasonably trialled without resolution of symptoms; or
      1.2.2 Soy milk formula is considered clinically inappropriate or contraindicated; or

2. Severe malabsorption; or
3. Short bowel syndrome; or
4. Intractable diarrhoea; or
5. Biliary atresia; or
6. Cholestatic liver diseases causing malabsorption; or
7. Cystic fibrosis; or
8. Proven fat malabsorption; or
9. Severe intestinal motility disorders causing significant malabsorption; or
10. Intestinal failure; or
11. All of the following:
   11.1 For step down from Amino Acid Formula; and
   11.2 The infant is currently receiving funded amino acid formula; and
   11.3 The infant is to be trialled on, or transitioned to, an extensively hydrolysed formula; and
   11.4 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and the date contacted.

Note: A reasonable trial is defined as a 2-4 week trial, or signs of an immediate IgE mediated allergic reaction.

**Renewal** only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

1. An assessment as to whether the infant can be transitioned to a cows milk protein or soy infant formula has been undertaken; and
2. The outcome of the assessment is that the infant continues to require an extensively hydrolysed infant formula; and
3. General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and the date contacted.

---

**Fluid Restricted**

PAEDIATRIC ORAL/ENTERAL FEED 1 KCAL/ML – Special Authority see SA1698 below – Hospital pharmacy [HP3]
Liquid ................................................................................................................. 2.35 125 ml OP ✔ Infatrini

**SA1698** Special Authority for Subsidy

**Initial application** only from a paediatrician, dietitian or general practitioner on the recommendation of a paediatrician or dietitian. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

1. Patient is fluid restricted or volume intolerant and has been diagnosed with faltering growth; and
2. Patient is under the care of a paediatrician or dietitian who has recommended treatment with a high energy infant formula;

---

✔ fully subsidised
continued…

and

3 Patient is under 18 months of age or weighs less than 8 kg.

Note: 'Volume intolerant' patients are those who are unable to tolerate an adequate volume of infant formula to achieve expected growth rate. These patients should have first trialled appropriate clinical alternative treatments, such as concentrating, fortifying and adjusting the frequency of feeding.

Renewal only from a paediatrician, dietitian or general practitioner on the recommendation of a paediatrician or dietitian. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

1 Patient continues to be fluid restricted or volume intolerant and has faltering growth; and
2 Patient is under the care of a hospital paediatrician or dietitian who has recommended treatment with a high energy infant formula; and
3 Patient is under 18 months of age or weighs less than 8 kg.

Note: 'Volume intolerant' patients are those who are unable to tolerate an adequate volume of infant formula to achieve expected growth rate. These patients should have first trialled appropriate clinical alternative treatments, such as concentrating, fortifying and adjusting the frequency of feeding.

Ketogenic Diet

**SA1197 Special Authority for Subsidy**

Initial application only from a metabolic physician or paediatric neurologist. Approvals valid for 3 months where the patient has intractable epilepsy, pyruvate dehydrogenase deficiency or glucose transported type-1 deficiency and other conditions requiring a ketogenic diet.

Renewal only from a metabolic physician or paediatric neurologist. Approvals valid for 2 years where the patient is on a ketogenic diet and the patient is benefiting from the diet.

HIGH FAT LOW CARBOHYDRATE FORMULA – Special Authority see SA1197 above – Retail pharmacy

- Powder (unflavoured) .......................................................... 35.50 300 g OP ✓ KetoCal 4:1
- Powder (vanilla) ................................................................. 35.50 300 g OP ✓ KetoCal 4:1
SECTION I: NATIONAL IMMUNISATION SCHEDULE

Vaccinations

ADULT DIPHTHERIA AND TETANUS VACCINE – [Xpharm]

Inj 2 IU diphtheria toxoid with 20 IU tetanus toxoid in 0.5 ml..............0.00 5 ✔ ADT Booster

Any of the following:
1) For vaccination of patients aged 45 and 65 years old; or
2) For vaccination of previously unimmunised or partially immunised patients; or
3) For revaccination following immunosuppression; or
4) For boosting of patients with tetanus-prone wounds; or
5) For use in testing for primary immunodeficiency diseases, on the recommendation of an internal medicine physician or paediatrician.

Note: Please refer to the Immunisation Handbook for appropriate schedule for catch up programmes.

BACILLUS CALMETTE-GUERIN VACCINE – [Xpharm]

For infants at increased risk of tuberculosis. Increased risk is defined as:
1) living in a house or family with a person with current or past history of TB; or
2) having one or more household members or carers who within the last 5 years lived in a country with a rate of TB > or equal to 40 per 100,000 for 6 months or longer; or
3) during their first 5 years will be living 3 months or longer in a country with a rate of TB > or equal to 40 per 100,000

Note a list of countries with high rates of TB are available at www.health.govt.nz/tuberculosis (search for downloads) or www.bcgatlas.org/index.php.

Inj Mycobacterium bovis BCG (Bacillus Calmette-Guerin),
Danish strain 1331, live attenuated, vial with diluent.................0.00 10 ✔ BCG Vaccine

DIPHTHERIA, TETANUS AND PERTUSSIS VACCINE – [Xpharm]

Funded for any of the following criteria:
1) A single vaccine for pregnant woman between gestational weeks 28 and 38; or
2) A course of up to four vaccines is funded for children from age 7 up to the age of 18 years inclusive to complete full primary immunisation; or
3) An additional four doses (as appropriate) are funded for (re-)immunisation for patients post haematopoietic stem cell transplantation or chemotherapy; pre or post splenectomy; pre- or post solid organ transplant, renal dialysis and other severely immunosuppressive regimens.

Notes: Tdap is not registered for patients aged less than 10 years. Please refer to the Immunisation Handbook for appropriate schedule for catch up programmes.

Inj 2 IU diphtheria toxoid with 20 IU tetanus toxoid, 8 mcg pertussis toxoid, 8 mcg pertussis filamentous haemagglutinin and 2.5 mcg pertactin in 0.5 ml syringe ...............0.00 10 ✔ Boostrix

DIPHTHERIA, TETANUS, PERTUSSIS AND POLIO VACCINE – [Xpharm]

Funded for any of the following:
1) A single dose for children up to the age of 7 who have completed primary immunisation; or
2) A course of four vaccines is funded for catch up programmes for children (to the age of 10 years) to complete full primary immunisation; or
3) An additional four doses (as appropriate) are funded for (re-)immunisation for patients post HSCT, or chemotherapy; pre- or post splenectomy; pre- or post solid organ transplant, renal dialysis and other severely immunosuppressive regimens; or
4) Five doses will be funded for children requiring solid organ transplantation.

Note: Please refer to the Immunisation Handbook for appropriate schedule for catch up programmes.

Inj 30 IU diphtheria toxoid with 40 IU tetanus toxoid, 25 mcg pertussis toxoid, 25 mcg pertussis filamentous haemagglutinin, 8 mcg pertactin and 80 D-antigen units poliomylitis virus in 0.5ml syringe .........................0.00 10 ✔ Infanrix IPV

▲Three months supply may be dispensed at one time if endorsed "certified exemption” by the prescriber or pharmacist.
 ❋Three months or six months, as applicable, dispensed all-at-once
**DIPHTHERIA, TETANUS, PERTUSSIS, POLIO, HEPATITIS B AND HAEMOPHILUS INFLUENZAE TYPE B VACCINE** – [Xpharm]

Funded for patients meeting any of the following criteria:

1) Up to four doses for children up to and under the age of 10 for primary immunisation; or
2) An additional four doses (as appropriate) are funded for (re-)immunisation for children up to and under the age of 10 who are patients post haematopoietic stem cell transplantation, or chemotherapy; pre or post splenectomy; pre- or post solid organ transplant, renal dialysis and other severely immunosuppressive regimens; or
3) Up to five doses for children up to and under the age of 10 receiving solid organ transplantation.

Note: A course of up-to four vaccines is funded for catch up programmes for children (up to and under the age of 10 years) to complete full primary immunisation. Please refer to the Immunisation Handbook for the appropriate schedule for catch up programmes.

Inj 30IU diphtheriatoxoid with 40IU tetanustoxoid, 25mcg pertussistoxoid, 25mcg pertussisfilamentoushaemaglutinin, 8 mcgpertactin, 80 D-AgUpoliovirus, 10mcghepatitisBsurfaceantigen in 0.5ml syringe ...............................................................................0.00 10 ✔️ **Infanrix-hexa**

**HAEMOPHILUS INFLUENZAE TYPE B VACCINE** – [Xpharm]

One dose for patients meeting any of the following:

1) For primary vaccination in children; or
2) An additional dose (as appropriate) is funded for (re-)immunisation for patients post haematopoietic stem cell transplantation, or chemotherapy; functional asplenic; pre or post splenectomy; pre- or post solid organ transplant, pre- or post cochlear implants, renal dialysis and other severely immunosuppressive regimens; or
3) For use in testing for primary immunodeficiency diseases, on the recommendation of an internal medicine physician or paediatrician.

Haemophilus Influenzae type B polysaccharide 10 mcg conjugated to tetanus toxoid as carrier protein 20-40 mcg;
prefilled syringe plus vial 0.5 ml.................................................................................0.00 1 ✔️ **Hiberix**

**HEPATITIS A VACCINE** – [Xpharm]

Funded for patients meeting any of the following criteria:

1) Two vaccinations for use in transplant patients; or
2) Two vaccinations for use in children with chronic liver disease; or
3) One dose of vaccine for close contacts of known hepatitis A cases.

Inj 1440 ELISA units in 1 ml syringe..........................................................0.00 1 ✔️ **Havrix**

Inj 720 ELISA units in 0.5 ml syringe..........................................................0.00 1 ✔️ **Havrix Junior**

---

**Notes:**
- Subsidy (Manufacturer's Price) $ Per Fully Subsidised ✔️
- Brand or Generic Manufacturer

**Sole Subsidised Supply**

---

**Unapproved medicine supplied under Section 29**
### HEPATITIS B RECOMBINANT VACCINE – [Xpharm]

<table>
<thead>
<tr>
<th>Subsidy (Manufacturer’s Price) $</th>
<th>Fully Subsidised</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 5 mcg per 0.5 ml vial</td>
<td>0.00</td>
<td>✔ HBvaxPRO</td>
</tr>
</tbody>
</table>

Funded for patients meeting any of the following criteria:
1) for household or sexual contacts of known acute hepatitis B patients or hepatitis B carriers; or
2) for children born to mothers who are hepatitis B surface antigen (HBsAg) positive; or
3) for children up to and under the age of 18 years inclusive who are considered not to have achieved a positive serology and require additional vaccination or require a primary course of vaccination; or
4) for HIV positive patients; or
5) for hepatitis C positive patients; or
6) for patients following non-consensual sexual intercourse; or
7) for patients following immunosuppression; or
8) for solid organ transplant patients; or
9) for post-haematopoietic stem cell transplant (HSCT) patients; or
10) following needle stick injury.

| Inj 10 mcg per 1 ml vial          | 0.00             | ✔ HBvaxPRO                   |

Funded for patients meeting any of the following criteria:
1) for household or sexual contacts of known acute hepatitis B patients or hepatitis B carriers; or
2) for children born to mothers who are hepatitis B surface antigen (HBsAg) positive; or
3) for children up to and under the age of 18 years inclusive who are considered not to have achieved a positive serology and require additional vaccination or require a primary course of vaccination; or
4) for HIV positive patients; or
5) for hepatitis C positive patients; or
6) for patients following non-consensual sexual intercourse; or
7) for patients following immunosuppression; or
8) for solid organ transplant patients; or
9) for post-haematopoietic stem cell transplant (HSCT) patients; or
10) following needle stick injury.

| Inj 20 mcg per 1 ml prefilled syringe | 0.00 | ✔ Engerix-B |

Funded for patients meeting any of the following criteria:
1) for household or sexual contacts of known acute hepatitis B patients or hepatitis B carriers; or
2) for children born to mothers who are hepatitis B surface antigen (HBsAg) positive; or
3) for children up to and under the age of 18 years inclusive who are considered not to have achieved a positive serology and require additional vaccination or require a primary course of vaccination; or
4) for HIV positive patients; or
5) for hepatitis C positive patients; or
6) for patients following non-consensual sexual intercourse; or
7) for patients following immunosuppression; or
8) for solid organ transplant patients; or
9) for post-haematopoietic stem cell transplant (HSCT) patients; or
10) following needle stick injury.

| Inj 40 mcg per 1 ml vial          | 0.00             | ✔ HBvaxPRO                   |

Funded for any of the following criteria:
1) for dialysis patients; or
2) for liver or kidney transplant patient.

▲ Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber or pharmacist.

★ Three months or six months, as applicable, dispensed all-at-once

239
HUMAN PAPILLOMAVIRUS (6, 11, 16, 18, 31, 33, 45, 52 AND 58) VACCINE [HPV] – [Xpharm]

Any of the following:

1) Maximum of two doses for children aged 14 years and under; or
2) Maximum of three doses for patients meeting any of the following criteria:
   1) People aged 15 to 26 years inclusive; or
   2) Either:
      People aged 9 to 26 years inclusive
      1) Confirmed HIV infection; or
      2) Transplant (including stem cell) patients; or
   3) Maximum of four doses for people aged 9 to 26 years inclusive post chemotherapy

Inj 270 mcg in 0.5 ml syringe...............................................................0.00 10 ✔ Gardasil 9
INFLUENZA VACCINE

Inj 45 mcg in 0.5 ml syringe (trivalent vaccine).................................90.00 10 ✔ Influvac

a) Only on a prescription
b) No patient co-payment payable

c) A) is available each year for patients who meet the following criteria, as set by PHARMAC, for use if a funded quadrivalent influenza vaccine is not available:
   a) all people 65 years of age and over; or
   b) people under 65 years of age who:
      i) have any of the following cardiovascular diseases:
         a) ischaemic heart disease, or
         b) congestive heart failure, or
         c) rheumatic heart disease, or
         d) congenital heart disease, or
         e) cerebro-vascular disease; or
      ii) have either of the following chronic respiratory diseases:
         a) asthma, if on a regular preventative therapy, or
         b) other chronic respiratory disease with impaired lung function; or
   iii) have diabetes; or
   iv) have chronic renal disease; or
   v) have any cancer, excluding basal and squamous skin cancers if not invasive; or
   vi) have any of the following other conditions:
      a) autoimmune disease, or
      b) immune suppression or immune deficiency, or
      c) HIV, or
      d) transplant recipients, or
      e) neuromuscular and CNS diseases/disorders, or
      f) haemoglobinopathies, or
      g) on long term aspirin, or
      h) have a cochlear implant, or
      i) errors of metabolism at risk of major metabolic decompensation, or
      j) pre and post splenectomy, or
      k) down syndrome, or
   vii) are pregnant; or
   c) children aged four years and under who have been hospitalised for respiratory illness or have a history of significant respiratory illness;
   d) people under 18 years of age living in the Seddon/Ward and rural Eastern Marlborough region (within the Nelson Marlborough District Health Board) and Kaikoura and Hurunui areas (within the Canterbury District Health Board);
   e) People under 18 years of age who have been displaced from their homes in Edgecumbe and the surrounding region;

Unless meeting the criteria set out above, the following conditions are excluded from funding:
   a) asthma not requiring regular preventative therapy,
   b) hypertension and/or dyslipidaemia without evidence of end-organ disease.

B) Contractors will be entitled to claim payment from the Funder for the supply of influenza vaccine to patients eligible under the above criteria pursuant to their contract with their DHB for subsidised immunisation, and they may only do so in respect of the influenza vaccine listed in the Pharmaceutical Schedule.

C) Contractors may only claim for patient populations within the criteria that are covered by their contract, which may be a sub-set of the population described in paragraph A above.

Inj 60 mcg in 0.5 ml syringe (paediatric quadrivalent vaccine) – [Xpharm].......................................................................................9.00 1 ✔ Fluarix Tetra

▲Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber or pharmacist.

❋Three months or six months, as applicable, dispensed all-at-once
A) **INFLUENZA VACCINE – child aged 6 months to 35 months**

is available each year for patients aged 6 months to 35 months who meet the following criteria, as set by PHARMAC:

i) have any of the following cardiovascular diseases
   a) ischaemic heart disease, or
   b) congestive heart failure, or
   c) rheumatic heart disease, or
   d) congenital heart disease, or
   e) cerebro-vascular disease; or

ii) have either of the following chronic respiratory diseases:
   a) asthma, if on a regular preventative therapy, or
   b) other chronic respiratory disease with impaired lung function; or

iii) have diabetes; or

iv) have chronic renal disease; or

v) have any cancer, excluding basal and squamous skin cancers if not invasive; or

vi) have any of the following other conditions:
   a) autoimmune disease, or
   b) immune suppression or immune deficiency, or
   c) HIV, or
   d) transplant recipients, or
   e) neuromuscular and CNS diseases/disorders, or
   f) haemoglobinopathies, or
   g) on long term aspirin, or
   h) have a cochlear implant, or
   i) errors of metabolism at risk of major metabolic decompensation, or
   j) pre and post splenectomy, or
   k) down syndrome, or

vii) have been hospitalised for respiratory illness or have a history of significant respiratory illness;

viii) are living in the Seddon/Ward and rural Eastern Marlborough region (within the Nelson Marlborough District Health Board) and Kaikoura and Hurunui areas (within the Canterbury District Health Board);

ix) have been displaced from their homes in Edgecumbe and the surrounding region;

Unless meeting the criteria set out above, the following conditions are excluded from funding:

a) asthma not requiring regular preventative therapy,
b) hypertension and/or dyslipidaemia without evidence of end-organ disease.

B) Doctors are the only Contractors entitled to claim payment from the Funder for the supply of influenza vaccine inj 60 mcg in 0.5 ml syringe (paediatric quadrivalent vaccine) to patients eligible under the above criteria for subsidised immunisation and they may only do so in respect of the influenza vaccine listed in the Pharmaceutical Schedule.

<table>
<thead>
<tr>
<th>Subsidy</th>
<th>Fully Subsidised</th>
<th>Brand or Generic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Manufacturer's Price</td>
<td>$</td>
<td>Per</td>
</tr>
<tr>
<td>242 ✔</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Inj 60 mcg in 0.5 ml syringe (quadrivalent vaccine)...........................90.00 10 ✔ Influvac Tetra
a) Only on a prescription
b) No patient co-payment payable
c) A) **INFLUENZA VACCINE – people 3 years and over**
   is available each year for patients aged 3 years and over who meet the following criteria, as set by PHARMAC:
   a) all people 65 years of age and over; or
   b) people under 65 years of age who:
      i) have any of the following cardiovascular diseases:
         a) ischaemic heart disease, or
         b) congestive heart failure, or
         c) rheumatic heart disease, or
         d) congenital heart disease, or
         e) cerebro-vascular disease; or
      ii) have either of the following chronic respiratory diseases:
         a) asthma, if on a regular preventative therapy, or
         b) other chronic respiratory disease with impaired lung function; or
      iii) have diabetes; or
      iv) have chronic renal disease; or
      v) have any cancer, excluding basal and squamous skin cancers if not invasive; or
   vi) have any of the following other conditions:
      a) autoimmune disease, or
      b) immune suppression or immune deficiency, or
      c) HIV, or
      d) transplant recipients, or
      e) neuromuscular and CNS diseases/disorders, or
      f) haemoglobinopathies, or
      g) are children on long term aspirin, or
      h) have a cochlear implant, or
      i) errors of metabolism at risk of major metabolic decompensation, or
      j) pre and post splenectomy, or
      k) down syndrome, or
   vii) are pregnant; or
   c) children aged four years or less (but over three years) who have been hospitalised for respiratory illness or have a history of significant respiratory illness;
   d) people under 18 years of age living in the Seddon/Ward and rural Eastern Marlborough region (within the Nelson Marlborough District Health Board) and Kaikoura and Hurunui areas (within the Canterbury District Health Board);
   e) People under 18 years of age who have been displaced from their homes in Edgecumbe and the surrounding region;
   Unless meeting the criteria set out above, the following conditions are excluded from funding:
   a) asthma not requiring regular preventative therapy,
   b) hypertension and/or dyslipidaemia without evidence of end-organ disease.
   B) Contractors will be entitled to claim payment from the Funder for the supply of influenza vaccine to patients eligible under the above criteria pursuant to their contract with their DHB for subsidised immunisation, and they may only do so in respect of the influenza vaccine listed in the Pharmaceutical Schedule.
   C) Contractors may only claim for patient populations within the criteria that are covered by their contract, which may be a sub-set of the population described in paragraph A above.
## NATIONAL IMMUNISATION SCHEDULE

### MEASLES, MUMPS AND RUBELLA VACCINE – [Xpharm]

<table>
<thead>
<tr>
<th>Subsidy (Manufacturer’s Price)</th>
<th>Fully Subsidised</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per</td>
<td>✔</td>
<td></td>
</tr>
</tbody>
</table>

A maximum of two doses for any patient meeting the following criteria:

1. For primary vaccination in children; or
2. For revaccination following immunosuppression; or
3. For any individual susceptible to measles, mumps or rubella; or
4. A maximum of three doses for children who have had their first dose prior to 12 months.

Note: Please refer to the Immunisation Handbook for appropriate schedule for catch up programmes.

Inj, measles virus 1,000 CCID50, mumps virus 5,012 CCID50,
Rubella virus 1,000 CCID50; prefilled syringe/ampoule of
diluent 0.5 ml ................................................................................0.00 10 ✔ Priorix

### MENINGOCOCCAL (GROUPS A, C, Y AND W-135) CONJUGATE VACCINE – [Xpharm]

Any of the following:

1. Up to three doses and a booster every five years for patients pre- and post splenectomy and for patients with functional
or anatomic asplenia, HIV, complement deficiency (acquired or inherited), or pre or post solid organ transplant; or
2. One dose for close contacts of meningococcal cases; or
3. A maximum of two doses for bone marrow transplant patients; or
4. A maximum of two doses for patients following immunosuppression*.

Note: children under seven years of age require two doses 8 weeks apart, a booster dose three years after the primary
series and then five yearly.

*Immunosuppression due to steroid or other immunosuppressive therapy must be for a period of greater than 28 days.

Inj 4 mcg of each meningococcal polysaccharide conjugated to
a total of approximately 48 mcg of diphtheria toxoid carrier
per 0.5 ml vial ................................................................................0.00 1 ✔ Menactra

### MENINGOCOCCAL C CONJUGATE VACCINE – [Xpharm]

Any of the following:

1. Up to three doses and a booster every five years for patients pre- and post splenectomy and for patients with functional
or anatomic asplenia, HIV, complement deficiency (acquired or inherited), or pre or post solid organ transplant; or
2. One dose for close contacts of meningococcal cases; or
3. A maximum of two doses for bone marrow transplant patients; or
4. A maximum of two doses for patients following immunosuppression*.

Note: children under seven years of age require two doses 8 weeks apart, a booster dose three years after the primary
series and then five yearly.

*Immunosuppression due to steroid or other immunosuppressive therapy must be for a period of greater than 28 days.

Inj 10 mcg in 0.5 ml syringe ................................................................................0.00 1 ✔ Neisvac-C

### PNEUMOCOCCAL (PCV10) CONJUGATE VACCINE – [Xpharm]

Either:

1. A primary course of four doses for previously unvaccinated individuals up to the age of 59 months inclusive; or
2. Up to three doses as appropriate to complete the primary course of immunisation for individuals under the age of
59 months who have received one to three doses of PCV13.

Note: please refer to the Immunisation Handbook for the appropriate schedule for catch up programmes

Inj 1 mcg of pneumococcal polysaccharide serotypes 1, 5, 6B,
7F, 9V, 14 and 23F; 3 mcg of pneumococcal
polysaccharide serotypes 4, 18C and 19F in 0.5 ml
prefilled syringe ................................................................................0.00 10 ✔ Synflorix
NATIONAL IMMUNISATION SCHEDULE

PNEUMOCOCCAL (PCV13) CONJUGATE VACCINE – [Xpharm]

Any of the following:

1) One dose is funded for high risk children (over the age of 17 months and under 18 years) who have previously received four doses of PCV10; or

2) Up to an additional four doses (as appropriate) are funded for high risk children aged under 5 years for (re-)immunisation of patients with any of the following:
   a) on immunosuppressive therapy or radiation therapy, vaccinate when there is expected to be a sufficient immune response; or
   b) with primary immune deficiencies; or
   c) with HIV infection; or
   d) with renal failure, or nephrotic syndrome; or
   e) who are immune-suppressed following organ transplantation (including haematopoietic stem cell transplant); or
   f) with cochlear implants or intracranial shunts; or
   g) with cerebrospinal fluid leaks; or
   h) receiving corticosteroid therapy for more than two weeks, and who are on an equivalent daily dosage of prednisone of 2 mg/kg per day or greater, or children who weigh more than 10 kg on a total daily dosage of 20 mg or greater; or
   i) with chronic pulmonary disease (including asthma treated with high-dose corticosteroid therapy); or
   j) pre term infants, born before 28 weeks gestation; or
   k) with cardiac disease, with cyanosis or failure; or
   l) with diabetes; or
   m) with Down syndrome; or
   n) who are pre-or post-splenectomy, or with functional asplenia; or

3) Up to an additional four doses (as appropriate) are funded for (re-)immunisation of patients 5 years and over with HIV, for patients pre or post haematopoietic stem cell transplantation, or chemotherapy; pre- or post splenectomy; functional asplenia, pre- or post- solid organ transplant, renal dialysis, complement deficiency (acquired or inherited), cochlear implants, or primary immunodeficiency; or

4) For use in testing for primary immunodeficiency diseases, on the recommendation of an internal medicine physician or paediatrician.

Note: please refer to the Immunisation Handbook for the appropriate schedule for catch up programmes

Inj 30.8 mcg of pneumococcal polysaccharide serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F in 0.5ml syringe ................................................................................................................. 0.00 10 ✔ Prevenar 13

1 ✔ Prevenar 13
PNEUMOCOCCAL (PPV23) POLYSACCHARIDE VACCINE – [Xpharm]

Either:

1) Up to three doses (as appropriate) for patients with HIV, for patients post haematopoietic stem cell transplant, or chemotherapy; pre- or post-splenectomy or with functional asplenia, pre- or post-solid organ transplant, renal dialysis, complement deficiency (acquired or inherited), cochlear implants, or primary immunodeficiency; or

2) All of the following:
   a) Patient is a child under 18 years for (re-)immunisation; and
   b) Treatment is for a maximum of two doses; and
   c) Any of the following:
      i) on immunsuppressive therapy or radiation therapy, vaccinate when there is expected to be a sufficient immune response; or
      ii) with primary immune deficiencies; or
      iii) with HIV infection; or
      iv) with renal failure, or nephrotic syndrome; or
      v) who are immune-suppressed following organ transplantation (including haematopoietic stem cell transplant); or
      vi) with cochlear implants or intracranial shunts; or
      vii) with cerebrospinal fluid leaks; or
      viii) receiving corticosteroid therapy for more than two weeks, and who are on an equivalent daily dosage of prednisone of 2 mg/kg per day or greater, or children who weigh more than 10 kg on a total daily dosage of 20 mg or greater; or
      ix) with chronic pulmonary disease (including asthma treated with high-dose corticosteroid therapy); or
      x) pre term infants, born before 28 weeks gestation; or
      xi) with cardiac disease, with cyanosis or failure; or
      xii) with diabetes; or
      xiii) with Down syndrome; or
      xiv) who are pre-or post-splenectomy, or with functional asplenia.

Inj 575 mcg in 0.5 ml prefilled syringe (25 mcg of each 23 pneumococcal serotype) .............................................. 0.00 1 ✔ Pneumovax 23

POLIOMYELITIS VACCINE – [Xpharm]

Up to three doses for patients meeting either of the following:

1) For partially vaccinated or previously unvaccinated individuals; or

2) For revaccination following immunosuppression.

Note: Please refer to the Immunisation Handbook for appropriate schedule for catch-up programmes.

Inj 80D antigen units in 0.5 ml syringe .............................................. 0.00 1 ✔ IPOL

ROTAVIRUS ORAL VACCINE – [Xpharm]

Maximum of two doses for patients meeting the following:

1) first dose to be administered in infants aged under 14 weeks of age; and

2) no vaccination being administered to children aged 24 weeks or over.

Oral susp live attenuated human rotavirus
1,000,000 CCID50 per dose, prefilled oral applicator .................. 0.00 10 ✔ Rotarix
VARICELLA VACCINE [CHICKENPOX VACCINE] – [Xpharm]

Either:

1) Maximum of one dose for primary vaccination for either:
   a) Any infant born on or after 1 April 2016; or
   b) For previously unvaccinated children turning 11 years old on or after 1 July 2017, who have not previously had a varicella infection (chickenpox), or

2) Maximum of two doses for any of the following:
   a) Any of the following for non-immune patients:
      i) with chronic liver disease who may in future be candidates for transplantation; or
      ii) with deteriorating renal function before transplantation; or
      iii) prior to solid organ transplant; or
      iv) prior to any elective immunosuppression*, or
      v) for post exposure prophylaxis who are immune competent inpatients.; or
   b) For patients at least 2 years after bone marrow transplantation, on advice of their specialist, or
   c) For patients at least 6 months after completion of chemotherapy, on advice of their specialist, or
   d) For HIV positive non immune to varicella with mild or moderate immunosuppression on advice of HIV specialist, or
   e) For patients with inborn errors of metabolism at risk of major metabolic decompensation, with no clinical history of varicella, or
   f) For household contacts of paediatric patients who are immunocompromised, or undergoing a procedure leading to immune compromise where the household contact has no clinical history of varicella, or
   g) For household contacts of adult patients who have no clinical history of varicella and who are severely immunocompromised, or undergoing a procedure leading to immune compromise where the household contact has no clinical history of varicella.

* immunosuppression due to steroid or other immunosuppressive therapy must be for a treatment period of greater than 28 days

Inj 2000 PFU prefilled syringe plus vial ..............................................0.00 1 ✔ Varilrix

10 ✔ Varilrix

VARICELLA ZOSTER VIRUS (OKA STRAIN) LIVE ATTENUATED VACCINE [SHINGLES VACCINE] – [Xpharm]

Funded for patients meeting either of the following criteria:

1) One dose for all people aged 65 years; or
2) One dose for all people aged between 66 and 80 years inclusive from 1 April 2018 and 31 March 2020.

Inj 19,400 PFU prefilled syringe plus vial ..............................................0.00 1 ✔ Zostavax

10 ✔ Zostavax

Diagnostic Agents

TUBERCULIN PPD [MANTOUX] TEST – [Xpharm]

Inj 5 TU per 0.1 ml, 1 ml vial.................................................................0.00 1 ✔ Tubersol

▲Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber or pharmacist.

❋Three months or six months, as applicable, dispensed all-at-once
INDEX: Generic Chemicals and Brands

- Symbols -

TC..............................................108
50X 3.0 Reservoir.........................25

- A -

A-Scabies...................................69
Abacavir sulphate.........................107
Abacavir sulphate with
lamivudine.................................107
Abariterone acetate.......................171
Acarbose....................................11
Accuretic 10...............................48
Accuretic 20...............................48
Acetazolamide............................210
Acetic acid with 1, 2-propanediol
diacetate and
benzethonium............................208
Acetic acid with hydroxyquinoline and
ricinoleic acid............................75
Acetylcysteine................................213
Aciclovir....................................75
Aciclovir
Infection................................103
Sensory....................................208
Acidex.........................................6
Acipimox...................................54
Acitretin....................................59
Aclesta.......................................117
Aclin..........................................112
Actinomycin D.............................161
Acaptopran................................10
Acraptopran Penfii................................10
Acupan......................................124
Adalat 10..................................52
Adalat Oros.................................52
Adalimumab...............................180
Adapalene..................................61
Adefin.......................................52
Adefin XL...................................52
Adefovir dipivoxil.......................102
Adenuric....................................120
ADR Cartridge 1.8.........................25
Adrenaline..................................56
ADT Booster...............................237
Adult diphtheria and tetanus
vaccine...................................237
Advantan...................................64
Advate.....................................40
Afinitor.....................................198
Afibricert.................................187
AFT Carbimazole.........................83
AFT SLS-free..............................66
AFT-Pyrazinamide.......................101
AFT-Pyrazinamide S29..................101
Agents Affecting the
Renin-Angiotensin System........47
Agents for Parkinsonism and Related
Disorders.................................122
Agents Used in the Treatment of
Poisonings...............................213
Agraflow.................................160
Alanase.................................206
Albendazole..............................90
Albentrazol...............................200
Albey.......................................77
Aldurazyme...............................29
Aldosterone sodium.............114–115
Aldosterone sodium with
colecalciferol.........................114
Alfacalcidol..............................34
Alfamino Junior.........................234
Alginic acid................................6
Alglucosidase alfa.......................27
Alkeran.....................................157
Allersothe.................................201
Allmercap...............................159
Allopurinol...............................119
Alpha-Adrenoceptor Blockers.....47
Alpha-Keri Lotion......................66
Alphamox 125.........................93
Alphamox 250.........................93
Alu-Tab......................................6
Aluminium hydroxide.................6
Amantadine hydrochloride.......122
Ambrotos.................................57
Aminolide hydrochloride...........53
Aminolide hydrochloride with
furosemide............................54
Aminolide hydrochloride with
hydrochlorothiazide...........54
Aminophylline.........................206
Amidarone hydrochloride..........49
Amisulprim..............................135
Amiridyl.................................127
Amlodipine..............................51
Amorolfine...............................62
Amoxicillin..............................93
Amoxicillin with clavulanic acid...93
Amphotericin B.........................33
Amscrine..................................160
AmsaLy..................................160
Amsidrine...............................160
Amzoate....................................30
Anaesthetics............................123
Anagrelide hydrochloride.......160
Analgesics...............................124
Anastrozole..............................173
Andiol Testocaps.......................81
Androderm..............................80
Animas Battery Cap..................19
Animas Cartridge......................25
Anoro Ellipta..........................204
Antabuse.................................152
Antacids and Antiflatulents........6
Anten........................................128
Anthelmintics.............................90
Antiacne Preparations..............61
Antiallergy Preparations..........200
Antianaemias............................37
Antiangen Oral..........................96
Contraceptives............................74
Antiarhythmics.........................49
Antibacterials............................90
Antibacterials Topical...............62
Anticholinergic Agents..............203
Anticholinesterases....................112
Antidepressants.........................127
Antidiarrhoeals...........................6
Antiepilepsy Drugs.....................129
Antifibrinolytics, Haemostatics and
Local Sclerosants....................38
Antifibrinolytics, Haemostatics and
Local Sclerosants....................38
Antifibrinolitics, Haemostatics and
Local Sclerosants....................38
Antihistamines...........................201
Antihypotensives.........................49
Antimalarias.............................100
Antimigraine Preparations.........133
Antinausea and Vertigo Agents....133
Antiparasitics.............................100
Antipruritic Preparations..........63
Antipsychotics...........................135
Antiretrovirals...........................106
Antirethematoid Agents.............113
Antispasmodics and Other Agents
Altering Gut Motility...............8
Antithrombotic Agents..............41
Antithymocyte globulin
(equine).................................180
Anticholinomimetic Agents.........100
Antituberculotics and
Antileperotics........................100
Antilucrents..............................8
Antiviral..................................102
Anxiolytics...............................138
Arzatam.................................163
Apidra......................................10
Apidra SoloStar................................10
Apo-Amilider............................53
Apo-Amlodipine.......................51
Apo-Amoxicillin.......................93
Apo-Azithromycin.....................91
Apo-Bromocriptine...........122
<table>
<thead>
<tr>
<th>Prescription Item</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bacillus Calmette-Guerin (BCG) vaccine</td>
<td>180</td>
</tr>
<tr>
<td>Bactroban</td>
<td>62</td>
</tr>
<tr>
<td>BCG Vaccine</td>
<td>237</td>
</tr>
<tr>
<td>Beclomethasone dipropionate</td>
<td>201, 206</td>
</tr>
<tr>
<td>Bendamustine hydrochloride</td>
<td>155</td>
</tr>
<tr>
<td>Bendroflumethiazide</td>
<td>54</td>
</tr>
<tr>
<td>Benzathine benzylpenicillin</td>
<td>93</td>
</tr>
<tr>
<td>Benztropine mesylate</td>
<td>122</td>
</tr>
<tr>
<td>Betamethasone acetate</td>
<td>79</td>
</tr>
<tr>
<td>Betamethasone sodium phosphate with betamethasone acetate</td>
<td>79</td>
</tr>
<tr>
<td>Betamethasone valerate</td>
<td>64, 70</td>
</tr>
<tr>
<td>Betamethasone valerate with clopiogrel</td>
<td>65</td>
</tr>
<tr>
<td>Betoptic</td>
<td>210</td>
</tr>
</tbody>
</table>
## INDEX: Generic Chemicals and Brands

<table>
<thead>
<tr>
<th>Chemical/Brand</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aripiprazole Sandoz</td>
<td>213</td>
</tr>
<tr>
<td>Apo-Gabapentin</td>
<td>211</td>
</tr>
<tr>
<td>Bicalutamide</td>
<td>172</td>
</tr>
<tr>
<td>Bicillin LA</td>
<td>93</td>
</tr>
<tr>
<td>BicNU</td>
<td>156</td>
</tr>
<tr>
<td>Bile and Liver Therapy</td>
<td>9</td>
</tr>
<tr>
<td>Biltricide</td>
<td>90</td>
</tr>
<tr>
<td>Bimatoprost</td>
<td>211</td>
</tr>
<tr>
<td>Bimatoprost Actavis</td>
<td>211</td>
</tr>
<tr>
<td>Bimatoprost Multichem</td>
<td>211</td>
</tr>
<tr>
<td>Binarex</td>
<td>172</td>
</tr>
<tr>
<td>Biodone</td>
<td>126</td>
</tr>
<tr>
<td>Biodone Extra Forte</td>
<td>126</td>
</tr>
<tr>
<td>Biodone Forte</td>
<td>126</td>
</tr>
<tr>
<td>Bisacodyl</td>
<td>27</td>
</tr>
<tr>
<td>Bisoprolol fumarate</td>
<td>50</td>
</tr>
<tr>
<td>BK Lotion</td>
<td>66</td>
</tr>
<tr>
<td>Bleomycin sulphate</td>
<td>161</td>
</tr>
<tr>
<td>Blood Colony-stimulating Factors</td>
<td>44</td>
</tr>
<tr>
<td>Blood glucose diagnostic test meter</td>
<td>12</td>
</tr>
<tr>
<td>Blood glucose diagnostic test strip</td>
<td>13</td>
</tr>
<tr>
<td>Blood glucose test strips (visually impaired)</td>
<td>13</td>
</tr>
<tr>
<td>Blood Ketone Diagnostic Test Strip</td>
<td>11</td>
</tr>
<tr>
<td>Bonjela</td>
<td>33</td>
</tr>
<tr>
<td>Bonvit</td>
<td>26</td>
</tr>
<tr>
<td>Boostrix</td>
<td>237</td>
</tr>
<tr>
<td>Bortezomib</td>
<td>161</td>
</tr>
<tr>
<td>Bosentan</td>
<td>58</td>
</tr>
<tr>
<td>Bosentan Dr Reddy's</td>
<td>58</td>
</tr>
<tr>
<td>Bosentan-Mylan</td>
<td>58</td>
</tr>
<tr>
<td>Bosvate</td>
<td>50</td>
</tr>
<tr>
<td>Bplex</td>
<td>33</td>
</tr>
<tr>
<td>Bree Elliot</td>
<td>202</td>
</tr>
<tr>
<td>Brevinor 1/21</td>
<td>73</td>
</tr>
<tr>
<td>Brevinor 1/28</td>
<td>73</td>
</tr>
<tr>
<td>Brevinor 21</td>
<td>73</td>
</tr>
<tr>
<td>Bricanyl Turbuhaler</td>
<td>203</td>
</tr>
<tr>
<td>Brilinta</td>
<td>41</td>
</tr>
<tr>
<td>Brimonidine tartrate</td>
<td>211</td>
</tr>
<tr>
<td>Brimonidine tartrate with timolol maleate</td>
<td>211</td>
</tr>
<tr>
<td>Brinov</td>
<td>158</td>
</tr>
<tr>
<td>Brinzolamide</td>
<td>210</td>
</tr>
<tr>
<td>Brolene</td>
<td>208</td>
</tr>
<tr>
<td>Bromocriptine mesylate</td>
<td>122</td>
</tr>
<tr>
<td>Brufen SR</td>
<td>112</td>
</tr>
<tr>
<td>BSF Apo-Gabapentin</td>
<td>213</td>
</tr>
<tr>
<td>BSF Aripiprazole Sandoz</td>
<td>213</td>
</tr>
<tr>
<td>BSF Tenofovir Disproxil Teva</td>
<td>213</td>
</tr>
<tr>
<td>Bucceastern</td>
<td>134</td>
</tr>
<tr>
<td>Budesonide</td>
<td>6</td>
</tr>
<tr>
<td>Budesonide Respiratory</td>
<td>201, 207</td>
</tr>
<tr>
<td>Budesonide with efomoterol</td>
<td>202</td>
</tr>
<tr>
<td>Bumetanide</td>
<td>53</td>
</tr>
<tr>
<td>Buprenorphine with naloxone</td>
<td>151</td>
</tr>
<tr>
<td>Bupropion hydrochloride</td>
<td>152</td>
</tr>
<tr>
<td>Burinex</td>
<td>53</td>
</tr>
<tr>
<td>Buscopan</td>
<td>8</td>
</tr>
<tr>
<td>Buspirone hydrochloride</td>
<td>138</td>
</tr>
<tr>
<td>Busulfan</td>
<td>156</td>
</tr>
<tr>
<td>Butacort Aqueous</td>
<td>207</td>
</tr>
<tr>
<td>Cabergoline</td>
<td>88</td>
</tr>
<tr>
<td>Cafergot</td>
<td>133</td>
</tr>
<tr>
<td>Cafergot S29</td>
<td>133</td>
</tr>
<tr>
<td>Caffeine citrate</td>
<td>207</td>
</tr>
<tr>
<td>Calamine</td>
<td>63</td>
</tr>
<tr>
<td>Calcipotriol</td>
<td>69</td>
</tr>
<tr>
<td>Calcitonin</td>
<td>78</td>
</tr>
<tr>
<td>Calcitriol</td>
<td>34</td>
</tr>
<tr>
<td>Calcitriol-AFT</td>
<td>34</td>
</tr>
<tr>
<td>Calcium carbonate</td>
<td>6, 35</td>
</tr>
<tr>
<td>Calcium Channel Blockers</td>
<td>51</td>
</tr>
<tr>
<td>Calcium Disodium Versenate</td>
<td>214</td>
</tr>
<tr>
<td>Calcium folinate</td>
<td>158</td>
</tr>
<tr>
<td>Calcium Folinate Ebeve</td>
<td>158</td>
</tr>
<tr>
<td>Calcium Folinate Sandoz</td>
<td>158</td>
</tr>
<tr>
<td>Calcium gluconate</td>
<td>35</td>
</tr>
<tr>
<td>Calcium Homeostasis</td>
<td>78</td>
</tr>
<tr>
<td>Calcium polystyrene sulphonate</td>
<td>45</td>
</tr>
<tr>
<td>Calcium Resonium</td>
<td>45</td>
</tr>
<tr>
<td>Calogen</td>
<td>220</td>
</tr>
<tr>
<td>Calsource</td>
<td>35</td>
</tr>
<tr>
<td>Camptosar</td>
<td>159</td>
</tr>
<tr>
<td>Candesartan cilexetil</td>
<td>48</td>
</tr>
<tr>
<td>Canester</td>
<td>48</td>
</tr>
<tr>
<td>Canesten</td>
<td>62</td>
</tr>
<tr>
<td>Capicitabine</td>
<td>158</td>
</tr>
<tr>
<td>Capoten</td>
<td>47</td>
</tr>
<tr>
<td>Capsaicin</td>
<td>113</td>
</tr>
<tr>
<td>Musculoskeletal</td>
<td>124</td>
</tr>
<tr>
<td>Nervous</td>
<td>47</td>
</tr>
<tr>
<td>Captopril</td>
<td>9</td>
</tr>
<tr>
<td>Carbachol</td>
<td>156</td>
</tr>
<tr>
<td>Carbamazepine</td>
<td>130</td>
</tr>
<tr>
<td>Carbimazole</td>
<td>83</td>
</tr>
<tr>
<td>Carbomer</td>
<td>212</td>
</tr>
<tr>
<td>Carboplatin</td>
<td>156</td>
</tr>
<tr>
<td>Carboplatin Ebeve</td>
<td>156</td>
</tr>
<tr>
<td>Carbosorb-X</td>
<td>213</td>
</tr>
<tr>
<td>Cardinol LA</td>
<td>51</td>
</tr>
<tr>
<td>CareSens Dual</td>
<td>12</td>
</tr>
<tr>
<td>CareSens N</td>
<td>12-13</td>
</tr>
<tr>
<td>CareSens N POP</td>
<td>12</td>
</tr>
<tr>
<td>CareSens N Premier</td>
<td>12</td>
</tr>
<tr>
<td>CareSens PRO</td>
<td>13</td>
</tr>
<tr>
<td>Carmellose sodium with gelatin and pectin</td>
<td>32</td>
</tr>
<tr>
<td>Carmustine</td>
<td>156</td>
</tr>
<tr>
<td>Carvedilol</td>
<td>50</td>
</tr>
<tr>
<td>Carvedilol Sandoz</td>
<td>50</td>
</tr>
<tr>
<td>Catapres</td>
<td>52</td>
</tr>
<tr>
<td>Cathejell</td>
<td>123</td>
</tr>
<tr>
<td>CeeNU</td>
<td>156</td>
</tr>
<tr>
<td>Cefaclor monohydrate</td>
<td>90</td>
</tr>
<tr>
<td>Cefalexin</td>
<td>90</td>
</tr>
<tr>
<td>Cefalexin Sandoz</td>
<td>90</td>
</tr>
<tr>
<td>Cefazolin</td>
<td>90</td>
</tr>
<tr>
<td>Ceftriaxone</td>
<td>90</td>
</tr>
<tr>
<td>Cefuroxime axetil</td>
<td>90</td>
</tr>
<tr>
<td>Celecoxib</td>
<td>112</td>
</tr>
<tr>
<td>Celecoxib Pfizer</td>
<td>112</td>
</tr>
<tr>
<td>Celestone Chronodose</td>
<td>79</td>
</tr>
<tr>
<td>Celifrol</td>
<td>50</td>
</tr>
<tr>
<td>Celicept</td>
<td>174</td>
</tr>
<tr>
<td>Celol</td>
<td>50</td>
</tr>
<tr>
<td>Centrally-Acting Agents</td>
<td>52</td>
</tr>
<tr>
<td>Cephalolin ABM</td>
<td>90</td>
</tr>
<tr>
<td>Cerezyme</td>
<td>31</td>
</tr>
<tr>
<td>Cetirizine hydrochloride</td>
<td>201</td>
</tr>
<tr>
<td>Cetomacrogol</td>
<td>66</td>
</tr>
<tr>
<td>Cetomacrogol with glycerol</td>
<td>66</td>
</tr>
<tr>
<td>Cetuximab</td>
<td>189</td>
</tr>
<tr>
<td>Champix</td>
<td>153</td>
</tr>
<tr>
<td>Charcoal</td>
<td>213</td>
</tr>
<tr>
<td>Chemotherapeutic Agents</td>
<td>155</td>
</tr>
<tr>
<td>Chickenpox vaccine</td>
<td>247</td>
</tr>
<tr>
<td>Chlorafast</td>
<td>208</td>
</tr>
<tr>
<td>Chlorambucil</td>
<td>156</td>
</tr>
<tr>
<td>Chloramphenicol</td>
<td>208</td>
</tr>
<tr>
<td>Chlorhexidine gluconate</td>
<td>33</td>
</tr>
<tr>
<td>Dermatological</td>
<td>65</td>
</tr>
<tr>
<td>Chlorform</td>
<td>216</td>
</tr>
<tr>
<td>Chlorothiazide</td>
<td>54</td>
</tr>
<tr>
<td>Chlorpheniramine maleate</td>
<td>201</td>
</tr>
<tr>
<td>Chlorpromazine hydrochloride</td>
<td>135</td>
</tr>
<tr>
<td>Chlorsig</td>
<td>208</td>
</tr>
<tr>
<td>Chloralhidone [Chlortalidone]</td>
<td>54</td>
</tr>
<tr>
<td>Chlortalidone</td>
<td>54</td>
</tr>
<tr>
<td>Chlorvescent</td>
<td>46</td>
</tr>
<tr>
<td>Choice Load 375</td>
<td>72</td>
</tr>
<tr>
<td>Choice TT380 Short</td>
<td>72</td>
</tr>
<tr>
<td>Choice TT380 Standard</td>
<td>72</td>
</tr>
<tr>
<td>Cholestyramine</td>
<td>55</td>
</tr>
<tr>
<td>Choline salicylate with cetalkonium chloride</td>
<td>33</td>
</tr>
<tr>
<td>Ciclopirox olamine</td>
<td>62</td>
</tr>
<tr>
<td>Ciclosporin</td>
<td>198</td>
</tr>
</tbody>
</table>
INDEX: Generic Chemicals and Brands

Cilazapril........................................47
Cilazapril with hydrochlorothiazide...48
Cilicaine.......................................94
Cilicaine VK.................................94
Cinacalcet.....................................78
Cipflox.......................................95
Ciprofloxacin Infection....................95
Ciprofloxacin Teva..........................208
Circadin......................................146
Cisplatin......................................156
Cisplatin Ebewe.............................156
Citalopram hydrobromide.............128
Cladribine.....................................158
Clarithromycin

- Nervous................................6
- Sensory................................91
- Extemporaneous.....................208
Clexane.......................................42
Clindamycin...............................95
Clindamycin ABM.........................95
Clinicians Renal Vit...................34
Clobazam....................................130
Cllobetasol propionate..................64,70
Cllobetasone butyrate....................64
Clofazimine................................100
Clomazol

- Dermatological.........................62
- Genito-Urinary...........................75
Clomifene citrate............................89
Clomipramine hydrochloride.........127
Clonazepam.................................129–130,138
Clonidine.....................................52
Clonidine BNM..............................52
Clonidine hydrochloride.................52
Clopidogrel..................................41
Clopine.......................................135
Clopixol.......................................136,138
Clotrimazole

- Dermatological.........................62
- Genito-Urinary...........................75
Clozapine....................................135
Clozaril.......................................135
Clustran.....................................133
Co-trimoxazole.............................97
Coal tar.......................................69
Coal tar with allantoin, menthol, phenol and sulphur...70
Coal tar with salicylic acid and sulphur....70
Coco-Scalp...................................70
Codeline phosphate

- Extemporaneous.......................216
- Nervous................................125
Cogentin.....................................122
Colaspase [L-asparaginase].............161
Colchicine...................................120
Colecalciferol..............................34
Colestid.......................................55
Colestipol hydrochloride..............55
Colgout.......................................120
Colifoam......................................7
Colistin sulphomethate..................95
Colistin-Link...............................95
Colloidal bismuth subcitrate.........9
Colloidion flexible......................216
Contraceptives - Hormonal..........72
Contraceptives - Non-hormonal.......72
Copaxone.....................................146
Cordarone-X................................49
Corticosteroids and Related Agents

- for Systemic Use.......................79
- Corticosteroids Topical..............64
Cosentyx.....................................193
Cosmegen....................................161
Coumadin....................................44
Creon 10000................................25
Creon 25000.................................25
Crotonit......................................63
Crystaderm...................................62
Curam.........................................93
Cvite...........................................34
Cyclizine hydrochloride..............134
Cyclizine lactate..........................134
Cyclobrig.....................................211
Cyclopentolate hydrochloride........211
Cyclophosphamide.......................156
Cycloserine.................................101
Cyklokapron................................40
Cyproterone acetate.....................80
Cyproterone acetate with

- ethinyloestradiol.................74
Cystadane...................................28
Cytarabine....................................158
Cytotec.........................................8
Cytoxan......................................156
D-Penamine..................................113
Dabigatran...................................43
Dacarbazine.................................161
Dacarbazine APP.........................161
Dactinomycin [Actinomycin D]........161
Daivobet....................................69
Daivonex.....................................69
Daktarin......................................63
Dalacin C.....................................95
Dalteparin sodium.........................42
Danazol.......................................89
Dantrium......................................121
Dantrium S29.................................121
Dantrolene..................................121
Dapavital.....................................11
Dapakazal....................................74
Dapa-Tabs....................................54
Dapsone......................................101
Dasatinib.....................................166
Daonil..........................................11
Danocrine....................................69
Danogel.......................................110
Daraprim.....................................96
Darunavir.....................................108
Daunorubicin...............................162
DBL Acetylsalicylic acid..............213
DBL Aminophylline.......................206
DBL Bleomycin Sulfate...............161
DBL Carboplatin............................156
DBL Cisplatin...............................156
DBL Dacarbazine.........................161
DBL Docetaxel...............................162
DBL Ergometrine............................75
DBL Gemcitabine...........................158
DBL Gentamicin............................95
DBL Leucovorin Calcium..............158
DBL Methotrexate Onco-Vial..........159
DBL Morphine Sulfate....................126
DBL Morphine Tartrate..................127
DBL Naloxone Hydrochloride.........213
DBL Octreotide.............................172
DBL Pethidine Hydrochloride.........127
DBL Vincristine Sulfate..............165
De-Worm .......................................90
Decozol........................................33
Deferasirox.................................213
Deferiprone..................................214
Denosumab.................................115
Deolate........................................99
Deoxycoformycin..........................164
Depo-Medrol.................................80
Depo-Medrol with Lidocaine...........80
Depo-Provera.................................74
Depo-Provera.................................81
Depo-Testosterone.........................81
Deprin.........................................97
DermAssist....................................64
Dermol.........................................64,70
Desferal.......................................214
Desferrioxamine mesilate..............214
Desmopressin acetate....................88
Desmopressin-Ph&T........................88
Detection of Substances in Urine....77
INDEX: Generic Chemicals and Brands

Dexamethasone ........................................ 79
Hormone ................................................ 79
Sensory .................................................. 209
Dexamethasone phosphate ......................... 79
Dexamethasone with framycetin and gramicidin ...... 208
Dexamethasone with neomycin sulphate and polymyxin B sulphate ........................................ 209
Dexametaminate sulphate ............................. 148
Dexamethone ............................................ 79
Dextrochlorpheniramime maleate .................... 201
Dextrose ................................................. 44-45
DHC Continus ........................................... 125
Diabetes .................................................. 9
Diabetes Management ................................. 11
Diaconit .................................................. 131
Diagnostic Agents ....................................... 247
Diamide Relief .......................................... 6
Diamox ................................................... 210
Diaip ........................................................ 221
Diason RTH .............................................. 221
Diazepam .............................................. 129, 138
Diazoxide ................................................ 9
Dibenzyline ............................................. 47
Diclofenac Sandoz ....................................... 112
Diclofenac sodium ......................................
Musculoskeletal ......................................... 112
Sensory .................................................. 209
Differin ................................................... 61
Diffiam ................................................... 32
Diffucan .................................................. 97
Diffucan S29 ............................................. 97
Diflucortolone valerate ................................ 64
Digestives Including Enzymes ...................... 25
Digoxin ................................................... 49
Dihydrcodine tartrate ................................ 125
Dilantin ................................................... 131
Dilantin Infatab ......................................... 131
Diltiazem hydrochloride .............................. 52
Dilzem .................................................... 52
Dimethicone ............................................ 66-67
Dimethyl fumarate .................................... 138
Dipentum ................................................. 7
Diphtheria, tetanus and pertussis vaccine .............. 237
Diphtheria, tetanus, pertussis and polio vaccine ...... 237
Diphtheria, tetanus, pertussis, polio, hepatitis B and haemophilus influenzae type B vaccine .... 238
Diprosone ............................................... 64
Diprosone OV .......................................... 64
Dipyridamole .......................................... 41
Disinfecting and Cleansing .........................
Agents .................................................. 65
Disopyramide phosphate ............................ 49
Disulfiram .............................................. 152
Ditropan ............................................... 76
Diuretics ................................................. 53
Diurin 40 .............................................. 53
Docetaxel ............................................... 162
Docetaxel Sandoz ..................................... 162
Docusate sodium ...................................... 26
Docusate sodium with sennosides ..................... 26
Dolutegravir ............................................ 108
Domperidone ......................................... 134
Donepezil hydrochloride ............................. 151
Donepezil-Rex ........................................ 151
Dopress ............................................... 128
Domnase alfa ......................................... 206
Dortimopt .............................................. 210
Dorzolamide hydrochloride ......................... 210
Dorzolamide with timolol ............................ 210
Dostinex ............................................... 88
Dosulepin [Dothiepin] hydrochloride ............... 128
Doxepin ................................................ 128
Doxazosin .............................................. 47
Doxepin hydrochloride ............................... 128
Doxine ................................................ 94
Doxorubicin Ebewe .................................. 162
Doxorubicin hydrochloride ......................... 162
Doxy-50 .............................................. 94
Doxycline ............................................. 94
DP Fusidic Acid Cream .............................. 62
DP Lotion .............................................. 66
DP Lotn HC ............................................ 64
DP-Allopurinol ....................................... 119
Dr Reddy's Omeprazole .............................. 9
Drugs Affecting Bone
Metabolism ............................................ 113
Dual blood glucose and blood ketone diagnostic test meter ........................................ 12
Duocal Super Soluble Powder ...................... 219
Duolin ............................................... 203
Duolin HFA ........................................... 203
Durex Confidence .................................... 72
Durex Extra Safe .................................... 72
Duride ................................................ 56
Dynacirc-SRO ......................................... 52
- E -
e-chamber La Grande ................................ 207
e-chamber Mask ....................................... 207
e-chamber Turbo ..................................... 207
E-Mycin ............................................... 92
Ear Preparations ..................................... 208
Ear/Eye Preparations ................................. 208
Easiphen Liquid ....................................... 233
Econazole nitrate .................................... 63
Efavirenz .............................................. 107
Efavirenz with emtricitabine and tenofovir disoproxil fumarate .................................... 107
Effient .................................................. 41
Efomotere fumarate ................................. 202
Efomotere fumarate dihydrate ..................... 202
Ekindix .................................................. 71
Egopsoryl TA ......................................... 70
Elaprase ............................................... 29
Elecare ............................................... 234
Elecare LCP ......................................... 234
Elelyso ............................................... 31
Elemental 028 Extra ................................ 225
Elocon ............................................... 65
Elocon Alcohol Free ................................... 65
Eltrombopag ......................................... 38
Eltroxin ............................................... 83
Emb Fatol ............................................. 101
Emend Tri-Pack ....................................... 133
Emulsioning ointment ............................... 66
Enalapril maleate ..................................... 47
Enbrel .................................................. 174
Endocrine Therapy ................................... 171
Endoxan .............................................. 156
Enerlyte ............................................. 45
Engelix-B ............................................. 239
Enlax XR ............................................. 129
Enoxaparin sodium ................................... 42
Ensure ............................................... 229
Ensure Plus .......................................... 229
Ensure Plus HN ...................................... 228
Ensure Plus RTH .................................... 228
Entacapone .......................................... 122
Entapone ............................................. 122
Entecavir ............................................. 103
Entecavir Sandoz .................................... 103
Entecavir Capsule .................................. 6
Ent covert CIR ......................................... 6
Entresto 24/26 ....................................... 48
Entresto 49/51 ....................................... 48
Entresto 97/103 ....................................... 48
Epilim ............................................... 131
Epilim Crushable ..................................... 131
Epilim IV ............................................ 131
Epilim S/F Liquid ..................................... 131
Epilim Syrup ......................................... 131
Epipubicin Ebewe .................................. 162
Epipubicin hydrochloride ......................... 162
Eplerenone .......................................... 53
Epoetin alfa [Erythropoietin alfa] .................. 38
Epoprostenol ........................................ 60
INDEX: Generic Chemicals and Brands

<table>
<thead>
<tr>
<th>Chemical Name</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ezetimibe with simvastatin</td>
<td>38</td>
</tr>
<tr>
<td>Eylea</td>
<td></td>
</tr>
<tr>
<td>Eye Preparations</td>
<td>208</td>
</tr>
<tr>
<td>Eylea</td>
<td>187</td>
</tr>
<tr>
<td>Ezetimibe</td>
<td>56</td>
</tr>
<tr>
<td>Ezetimibe Sandoz</td>
<td>55</td>
</tr>
<tr>
<td>Ezetimibe with simvastatin</td>
<td>56</td>
</tr>
<tr>
<td>- F -</td>
<td></td>
</tr>
<tr>
<td>Factor eight inhibitor bypassing fraction</td>
<td>39</td>
</tr>
<tr>
<td>Febugostat</td>
<td>120</td>
</tr>
<tr>
<td>Feed Thickener Karicare</td>
<td></td>
</tr>
<tr>
<td>FEIBA NF</td>
<td>39</td>
</tr>
<tr>
<td>Feno 10 ER</td>
<td>51</td>
</tr>
<tr>
<td>Feno 5 ER</td>
<td>51</td>
</tr>
<tr>
<td>Felodipine</td>
<td>51</td>
</tr>
<tr>
<td>Fenpaed</td>
<td>112</td>
</tr>
<tr>
<td>Ferric carboxymaltose</td>
<td>35</td>
</tr>
<tr>
<td>Ferriprox</td>
<td>214</td>
</tr>
<tr>
<td>Ferro-F-Tabs</td>
<td>36</td>
</tr>
<tr>
<td>Ferro-tab</td>
<td>36</td>
</tr>
<tr>
<td>Ferrograd</td>
<td>36</td>
</tr>
<tr>
<td>Ferrous fumarate</td>
<td>36</td>
</tr>
<tr>
<td>Ferrous fumarate with folic acid</td>
<td>36</td>
</tr>
<tr>
<td>Ferrous sulphate</td>
<td>36</td>
</tr>
<tr>
<td>Ferrum H</td>
<td>36</td>
</tr>
<tr>
<td>Fexofenadine hydrochloride</td>
<td>201</td>
</tr>
<tr>
<td>Fibro-vein</td>
<td>40</td>
</tr>
<tr>
<td>Filgrastim</td>
<td>44</td>
</tr>
<tr>
<td>Finasteride</td>
<td>75</td>
</tr>
<tr>
<td>Fingolimod</td>
<td>140</td>
</tr>
<tr>
<td>Fizazyr</td>
<td>200</td>
</tr>
<tr>
<td>Flagyl</td>
<td>100</td>
</tr>
<tr>
<td>Flagyl-S</td>
<td>100</td>
</tr>
<tr>
<td>Flamazine</td>
<td>62</td>
</tr>
<tr>
<td>Flecaidine acetate</td>
<td>49</td>
</tr>
<tr>
<td>Fleet Phosphate Enema</td>
<td>27</td>
</tr>
<tr>
<td>Flixonase Hayfery &amp; Allergy</td>
<td>207</td>
</tr>
<tr>
<td>Flixotide</td>
<td>202</td>
</tr>
<tr>
<td>Flixotide Accuhaler</td>
<td>202</td>
</tr>
<tr>
<td>Floair</td>
<td>202</td>
</tr>
<tr>
<td>Florinef</td>
<td>79</td>
</tr>
<tr>
<td>Fluoxanil</td>
<td>136</td>
</tr>
<tr>
<td>Flurix Tetra</td>
<td>241</td>
</tr>
<tr>
<td>Fluorouracil</td>
<td>158</td>
</tr>
<tr>
<td>Fluorouracil Ebewe</td>
<td>158</td>
</tr>
<tr>
<td>Fluorouracil sodium</td>
<td>71</td>
</tr>
<tr>
<td>Fluoxetine hydrochloride</td>
<td>129</td>
</tr>
<tr>
<td>Fluphenix decanoate</td>
<td>136</td>
</tr>
<tr>
<td>Flutamide</td>
<td>172</td>
</tr>
<tr>
<td>Flutamide Mylan</td>
<td>172</td>
</tr>
<tr>
<td>Flutamin</td>
<td>172</td>
</tr>
<tr>
<td>Fluticasone</td>
<td>202</td>
</tr>
<tr>
<td>Fluticasone furoate with vilenanterol</td>
<td>202</td>
</tr>
<tr>
<td>Fluticasone propionate</td>
<td>207</td>
</tr>
<tr>
<td>Fluticasone with salmeterol</td>
<td>203</td>
</tr>
<tr>
<td>FML</td>
<td>210</td>
</tr>
<tr>
<td>Fobani</td>
<td>62</td>
</tr>
<tr>
<td>Folic acid</td>
<td>38</td>
</tr>
<tr>
<td>Food Thickeners</td>
<td>231</td>
</tr>
<tr>
<td>Foods And Supplements For Inborn</td>
<td></td>
</tr>
<tr>
<td>Foradil</td>
<td>202</td>
</tr>
<tr>
<td>Forteo</td>
<td>117</td>
</tr>
<tr>
<td>Fortini</td>
<td>223</td>
</tr>
<tr>
<td>Fortini Multi Fibre</td>
<td>223</td>
</tr>
<tr>
<td>Fortisip</td>
<td>229</td>
</tr>
<tr>
<td>Fortisip Multi Fibre</td>
<td>230</td>
</tr>
<tr>
<td>Fosamax</td>
<td>114-115</td>
</tr>
<tr>
<td>Fosamx Plus</td>
<td>114</td>
</tr>
<tr>
<td>Fragmin</td>
<td>42</td>
</tr>
<tr>
<td>Framycetin sulphate</td>
<td>208</td>
</tr>
<tr>
<td>Frisium</td>
<td>130</td>
</tr>
<tr>
<td>Frumil</td>
<td>54</td>
</tr>
<tr>
<td>Frusenamide</td>
<td>53</td>
</tr>
<tr>
<td>Frusenamide-Claris</td>
<td>53</td>
</tr>
<tr>
<td>Fucicort</td>
<td>65</td>
</tr>
<tr>
<td>Fucidin</td>
<td>97</td>
</tr>
<tr>
<td>Fucithalmic</td>
<td>208</td>
</tr>
<tr>
<td>Fungulin</td>
<td>33</td>
</tr>
<tr>
<td>Furosemide [Frusenamide]</td>
<td>53</td>
</tr>
<tr>
<td>fusidic acid</td>
<td></td>
</tr>
<tr>
<td>Dermatological</td>
<td>62, 65</td>
</tr>
<tr>
<td>Infection</td>
<td>.97</td>
</tr>
<tr>
<td>Sensory</td>
<td>208</td>
</tr>
<tr>
<td>- G -</td>
<td></td>
</tr>
<tr>
<td>Gabapentin</td>
<td>130</td>
</tr>
<tr>
<td>Gacet</td>
<td>125</td>
</tr>
<tr>
<td>Galsulfate</td>
<td>28</td>
</tr>
<tr>
<td>Galvumet</td>
<td>11</td>
</tr>
<tr>
<td>Galvus</td>
<td>11</td>
</tr>
<tr>
<td>Gardasil</td>
<td>240</td>
</tr>
<tr>
<td>Gastrodenol</td>
<td>9</td>
</tr>
<tr>
<td>Gaviscon Double Strength</td>
<td>6</td>
</tr>
<tr>
<td>Gaviscon Infant</td>
<td>6</td>
</tr>
<tr>
<td>Gazayva</td>
<td>189</td>
</tr>
<tr>
<td>Gefitinib</td>
<td>167</td>
</tr>
<tr>
<td>Gemicitabine Ebewe</td>
<td>158</td>
</tr>
<tr>
<td>Gemicitabine hydrochloride</td>
<td>158</td>
</tr>
</tbody>
</table>

- F -
Factor eight inhibitor bypassing fraction
Febugostat
Feed Thickener Karicare
FEIBA NF
Feno 10 ER
Feno 5 ER
Felodipine
Fenpaed
Ferric carboxymaltose
Ferriprox
Ferro-F-Tabs
Ferro-tab
Ferrograd
Ferrous fumarate
Ferrous fumarate with folic acid
Ferrous sulphate
Ferrum H
Fexofenadine hydrochloride
Fibro-vein
Filgrastim
Finasteride
Fingolimod
Fizazyr
Flagyl
Flagyl-S
Flamazine
Flecaidine acetate
Fleet Phosphate Enema
Flixonase Hayfery & Allergy
Flixotide
Flixotide Accuhaler
Floair
Florinef
Fluoxanil
Flurix Tetra
Fluorouracil
Fluorouracil Ebewe
Fluorouracil sodium
Fluoxetine hydrochloride
Fluphenix decanoate
Flutamide
Flutamide Mylan
Flutamin
Fluticasone
Fluticasone furoate with vilenanterol
Fluticasone propionate
Fluticasone with salmeterol
FML
Fobani
Folic acid
Food Thickeners
Foods And Supplements For Inborn
Foradil
Forteo
Fortini
Fortini Multi Fibre
Fortisip
Fortisip Multi Fibre
Fosamax
Fosamx Plus
Fragmin
Framycetin sulphate
Frisium
Frumil
Frusenamide
Frusenamide-Claris
Fucicort
Fucidin
Fucithalmic
Fungulin
Furosemide [Frusenamide]
fusidic acid
Dermatological
Infection
Sensory
Gabapentin
Gacet
Galsulfate
Galvumet
Galvus
Gardasil
Gastrodenol
Gaviscon Double Strength
Gaviscon Infant
Gazayva
Gefitinib
Gemicitabine Ebewe
Gemicitabine hydrochloride
<table>
<thead>
<tr>
<th>INDEX: Generic Chemicals and Brands</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Gemfibrozil</strong>..........................54</td>
</tr>
<tr>
<td><strong>Gemzar</strong>................................158</td>
</tr>
<tr>
<td><strong>Genoptic</strong>...............................208</td>
</tr>
<tr>
<td><strong>Genox</strong>...................................173</td>
</tr>
<tr>
<td><strong>Gentamicin sulphate</strong></td>
</tr>
<tr>
<td><strong>Infection</strong>.............................95</td>
</tr>
<tr>
<td><strong>Sensory</strong>...............................208</td>
</tr>
<tr>
<td><strong>Gilena</strong>.................................140</td>
</tr>
<tr>
<td><strong>Ginet</strong>...................................74</td>
</tr>
<tr>
<td><strong>Glatiramer acetate</strong>...................146</td>
</tr>
<tr>
<td><strong>Glibenclamide</strong>........................11</td>
</tr>
<tr>
<td><strong>Gliclazide</strong>.............................11</td>
</tr>
<tr>
<td><strong>Glipizide</strong>..............................11</td>
</tr>
<tr>
<td><strong>Glivec</strong>..................................167</td>
</tr>
<tr>
<td><strong>Glimide</strong>..................................11</td>
</tr>
<tr>
<td><strong>Glucadren</strong>............................. 9</td>
</tr>
<tr>
<td><strong>Glucagon hydrochloride</strong>.............221</td>
</tr>
<tr>
<td><strong>Glucam Select</strong>.......................221</td>
</tr>
<tr>
<td><strong>Glucam Select RTH</strong>...................221</td>
</tr>
<tr>
<td><strong>Glucobay</strong>...............................11</td>
</tr>
<tr>
<td><strong>Glucose [Dextrose]</strong>..................44</td>
</tr>
<tr>
<td><strong>Gluten Free Foods</strong>...................231</td>
</tr>
<tr>
<td><strong>Glycerin with sodium saccharin</strong>....216</td>
</tr>
<tr>
<td><strong>Glycerin with sucrose</strong>..............216</td>
</tr>
<tr>
<td><strong>Glycerol</strong>................................</td>
</tr>
<tr>
<td><strong>Alimentary</strong>.........................27</td>
</tr>
<tr>
<td><strong>Extemporaneous</strong>.....................216</td>
</tr>
<tr>
<td><strong>Glycercyl trinitrate</strong>................</td>
</tr>
<tr>
<td><strong>Alimentary</strong>......................... 8</td>
</tr>
<tr>
<td><strong>Cardiovascular</strong>......................56</td>
</tr>
<tr>
<td><strong>Glycopyronium</strong>.......................204</td>
</tr>
<tr>
<td><strong>Glycopyronium bromide</strong>............. 8</td>
</tr>
<tr>
<td><strong>Glycopyronium with indacaterol</strong>....204</td>
</tr>
<tr>
<td><strong>Glyset</strong>..................................56</td>
</tr>
<tr>
<td><strong>Gold Knight</strong>..........................72</td>
</tr>
<tr>
<td><strong>Goserepin</strong>..............................87</td>
</tr>
<tr>
<td><strong>Gutone</strong>..................................49</td>
</tr>
<tr>
<td><strong>Gynaecological Anti-infectives</strong>....75</td>
</tr>
<tr>
<td><strong>- H -</strong></td>
</tr>
<tr>
<td><strong>Habitrol</strong>..............................153</td>
</tr>
<tr>
<td><strong>Haemophilus influenzae type B</strong>......</td>
</tr>
<tr>
<td><strong>vaccine</strong>................................</td>
</tr>
<tr>
<td><strong>Haldol</strong>..................................136</td>
</tr>
<tr>
<td><strong>Haldol Concentrate</strong>..................136</td>
</tr>
<tr>
<td><strong>Haldol Decanoas</strong>.....................136</td>
</tr>
<tr>
<td><strong>Haloperidol</strong>...........................135</td>
</tr>
<tr>
<td><strong>Haloperidol decanoate</strong>.............136</td>
</tr>
<tr>
<td><strong>Hamilton Sunscreen</strong>..................70</td>
</tr>
<tr>
<td><strong>Harvoni</strong>................................104</td>
</tr>
<tr>
<td><strong>Havrix</strong>..................................238</td>
</tr>
<tr>
<td><strong>Havrix Junior</strong>........................238</td>
</tr>
<tr>
<td><strong>HBvaxPRO</strong>................................239</td>
</tr>
<tr>
<td><strong>healthE Calamine Aqueous Cream BP</strong>63</td>
</tr>
<tr>
<td><strong>healthE Dimethicone 10%</strong>...........66</td>
</tr>
<tr>
<td><strong>Hydrocortisone with cinchocaine</strong>...</td>
</tr>
<tr>
<td><strong>Hydrocortisone butyrate</strong>...........</td>
</tr>
<tr>
<td><strong>Hydrocortisone and paraffin liquid</strong></td>
</tr>
<tr>
<td><strong>Hydrocortisone acetate</strong>............</td>
</tr>
<tr>
<td><strong>Hydrocortisone butyrate</strong>...........64</td>
</tr>
<tr>
<td><strong>Hydrocortisone with miconazole</strong>...65</td>
</tr>
<tr>
<td><strong>Hydrocortisone with natamycin and</strong></td>
</tr>
<tr>
<td><strong>neomycin</strong>..............................</td>
</tr>
<tr>
<td><strong>Hydrogen peroxide</strong>..................</td>
</tr>
<tr>
<td><strong>Alimentary</strong>.........................33</td>
</tr>
<tr>
<td><strong>Dermalogical</strong>.........................62</td>
</tr>
<tr>
<td><strong>Hydroxycobalamin</strong>....................33</td>
</tr>
<tr>
<td><strong>Hydroxychloroquine</strong>..................113</td>
</tr>
<tr>
<td><strong>Hydroxyurea</strong>..........................162</td>
</tr>
<tr>
<td><strong>Hygron</strong>..................................54</td>
</tr>
<tr>
<td><strong>Hylo-Fresh</strong>............................212</td>
</tr>
<tr>
<td><strong>Hymenoptera</strong>...........................</td>
</tr>
<tr>
<td><strong>Humulin NPH</strong>...........................260</td>
</tr>
<tr>
<td><strong>HumiraPen</strong>..............................</td>
</tr>
<tr>
<td><strong>Humatin</strong>...............................</td>
</tr>
<tr>
<td><strong>Human papillomavirus (6, 11, 16, 18, 31, 33, 45, 52 and 58) vaccine</strong>[HPV]**</td>
</tr>
<tr>
<td><strong>Humalog</strong>..................................</td>
</tr>
<tr>
<td><strong>Humalog Mix 25</strong>......................</td>
</tr>
<tr>
<td><strong>Humalog Mix 50</strong>......................</td>
</tr>
<tr>
<td><strong>Hydroxycobalamin</strong>....................</td>
</tr>
<tr>
<td><strong>Ibiamox</strong>..................................93</td>
</tr>
<tr>
<td><strong>Ibuprofen</strong>.............................112</td>
</tr>
<tr>
<td><strong>Icatinib</strong>...............................200</td>
</tr>
<tr>
<td><strong>Idarubicin hydrochloride</strong>...........162</td>
</tr>
<tr>
<td><strong>Idursulfase</strong>............................29</td>
</tr>
<tr>
<td><strong>Ifosfamide</strong>.............................156</td>
</tr>
<tr>
<td><strong>Ikorel</strong>...................................57</td>
</tr>
<tr>
<td><strong>Iloprost</strong>..................................60</td>
</tr>
<tr>
<td><strong>Imatinib mesilate</strong>....................167</td>
</tr>
<tr>
<td><strong>Imatinib-AFT</strong>...........................167</td>
</tr>
<tr>
<td><strong>Imiglucerase</strong>.........................31</td>
</tr>
<tr>
<td><strong>Imipramine hydrochloride</strong>..........128</td>
</tr>
<tr>
<td><strong>Imiquimod</strong>............................. 71</td>
</tr>
<tr>
<td><strong>Immune Modulators</strong>..................108</td>
</tr>
<tr>
<td><strong>Immunosuppressants</strong>................174</td>
</tr>
<tr>
<td><strong>Imuran</strong>...................................174</td>
</tr>
<tr>
<td><strong>Incruse Ellipta</strong>......................204</td>
</tr>
<tr>
<td><strong>Indacaterol</strong>...........................202</td>
</tr>
<tr>
<td><strong>Indapamide</strong>......................... 54</td>
</tr>
<tr>
<td><strong>Infantix IPV</strong>..........................237</td>
</tr>
<tr>
<td><strong>Infantix-hexa</strong>.......................238</td>
</tr>
<tr>
<td><strong>Infant Formulae</strong>.....................234</td>
</tr>
<tr>
<td><strong>Infatrini</strong>..............................235</td>
</tr>
<tr>
<td><strong>Influenza vaccine</strong>....................241</td>
</tr>
<tr>
<td><strong>Influvac</strong>...............................241</td>
</tr>
<tr>
<td><strong>Influvac Tetra</strong>.......................242</td>
</tr>
<tr>
<td><strong>Inhaled Corticosteroids</strong>.............</td>
</tr>
<tr>
<td><strong>Inhaled Long-acting</strong>................</td>
</tr>
<tr>
<td><strong>Beta-adrenoceptor Agonists</strong>........</td>
</tr>
<tr>
<td><strong>Beta-adrenoceptor Agonists</strong>........</td>
</tr>
<tr>
<td><strong>Insulin aspart</strong>.......................10</td>
</tr>
<tr>
<td><strong>Insulin aspart with insulin aspart</strong></td>
</tr>
<tr>
<td><strong>protamine</strong>......................... 10</td>
</tr>
<tr>
<td><strong>Insulin glargine</strong>....................10</td>
</tr>
<tr>
<td><strong>Insulin glulisine</strong>...................10</td>
</tr>
<tr>
<td><strong>Insulin isophane</strong>....................10</td>
</tr>
<tr>
<td><strong>Insulin isophane with insulin</strong>......</td>
</tr>
<tr>
<td><strong>neutral</strong>..............................10</td>
</tr>
<tr>
<td><strong>Insulin lispro</strong>.......................10</td>
</tr>
<tr>
<td><strong>Insulin lispro with insulin lispro</strong></td>
</tr>
</tbody>
</table>
INDEX: Generic Chemicals and Brands

- I -
Ispaghula (psyllium) husk ........................................... 20
Insulin neutral .......................................................... 10
Insulin pen needles ...................................................... 13
Insulin pump .............................................................. 14
Insulin pump accessories .............................................. 19
Insulin pump cartridge ................................................. 19
Insulin pump infusion set (steel cannula) ....................... 20
Insulin pump infusion set (steel cannula, straight insertion) 21
Insulin pump infusion set (teflon cannula, angle insertion with insertion device) 21
Insulin pump infusion set (teflon cannula, straight insertion) 22
Insulin pump infusion set (teflon cannula, straight insertion with insertion device) 23
Insulin pump infusion set (teflon cannula, angle insertion with insertion device) 24
Insulin pump reservoir .................................................. 25
Insulin syringes, disposable with attached needle ............. 14
Intal Forte CFC Free.................................................. 206
Intelex ................................................................. 107
Interferon alfa-2a ....................................................... 109
Interferon alfa-2b ....................................................... 109
Interferon beta-1-alpha ................................................ 146
Interferon beta-1-beta ................................................ 146
Intra-uterine device ..................................................... 72
Intron-A ................................................................. 109
Invega Sustenna ........................................................ 137
IPOL ................................................................... 246
Ipratropium bromide .................................................. 203, 207
Iressa ................................................................. 167
Irinotecan Actavis 100 ................................................ 159
Irinotecan Actavis 40 .................................................. 159
Irinotecan hydrochloride ............................................ 159
Irinotecan-Rex ........................................................ 159
Iron polymaltose .......................................................... 36
Isentress ................................................................. 108
Ismo 20 ................................................................. 108
Ismo 40 Retard .......................................................... 108
Isoniazid ................................................................. 101
Isoniazid with rifampicin ............................................. 101
Isoprenaline [Isoproterenol] ....................................... 57
Isoproterenol ............................................................. 57
Isoptin ................................................................. 52
Isoproterenol ............................................................. 57
Itch-Soothe ............................................................. 63
Itraconazole ............................................................ 98
Itrafol ................................................................. 98
Ivermectin ............................................................. 67
Jadelle ................................................................. 74
Jakavi ................................................................. 170
Jevisy HiCal RTH ..................................................... 228
Jevisy RTH ............................................................ 228
Juno Pemetrexed ...................................................... 160
Kaletra ................................................................. 108
Kemadrin ............................................................. 122
Kenacomb ............................................................. 208
Kenacort-A 10 ......................................................... 80
Kenacort-A 40 ......................................................... 80
Karenol in Orabase .................................................... 33
Ketocal 3:1 ............................................................. 236
KetoCal 4:1 ............................................................. 236
Ketofol ................................................................. 236
Ketoconazole .......................................................... 70
Kinesion ............................................................... 122
Kivexa ................................................................. 107
Klacid ................................................................. 91
Kligen ................................................................. 82
Kloveanza ............................................................ 82
Kogenate FS .......................................................... 40
Konakion M.M. ......................................................... 41
Konsyl-D ............................................................. 26
Kuvan ................................................................. 30
Lanvis ................................................................. 160
Lanzol Relief .......................................................... 8
Lapatinib ditosylate ................................................... 168
Largactil ............................................................... 135
Laronidase ............................................................ 29
Lasix ................................................................. 53
Latanoprost ........................................................... 211
Lax-Suppositories ..................................................... 27
Lax-Tab ............................................................... 27
Laxatives ............................................................... 26
Laxsol ................................................................. 26
Ledipasvir with sofosbuvir .......................................... 104
Leflunomide .......................................................... 113
Lenalidomide ........................................................ 162
Leukotriene Receptor .................................................. 3
Antagonists ........................................................... 206
Leunase ............................................................... 161
Leuprorelin ........................................................... 87
Leustatin .............................................................. 158
Levetiracetam ........................................................ 131
Levetiracetam-AFT .................................................. 131
Levlen ED .............................................................. 73
Levobunolol ........................................................... 210
Levocabastine ........................................................ 210
Levodopa with benserazide ........................................... 122
Levodopa with carbidopa ............................................ 122
Levomepromazine ..................................................... 135
Levomepromazine maleate ....................................... 135
Levonorgestrel ........................................................ 73
Genito-Urinary ......................................................... 74
Hormone ............................................................... 82
Levothyroxine ........................................................ 83
Lidocaine [Lignocaine] ............................................. 123–124
Lidocaine [Lignocaine] hydrochloride ......................... 124
Lidocaine [Lignocaine] with chlorhexidine ................. 124
Lidocaine [Lignocaine] with prilocaine ....................... 124
Lidocaine-Claris ..................................................... 124
Lignocaine ............................................................ 80
Lipozene ............................................................. 123–124
Lioresal Intrathecal ..................................................... 121
Lipazil ................................................................. 54
Lipid-Modifying Agents ............................................ 54
Liquigent ............................................................. 220
Lisinopril .............................................................. 47
Lithicarb FC .......................................................... 136
Lithium carbonate .................................................... 136
Livostin ............................................................... 210
LMX4 ................................................................. 124
Locacorten-Viaform ED’s .......................................... 208
INDEX: Generic Chemicals and Brands

Local preparations for Anal and Rectal Disorders .......................................................... 7

Locascol ............................................................................................................................. 234
Locoid ............................................................................................................................... 64, 70
Locoid Crelo ..................................................................................................................... 64
Locoid Lipocream ........................................................................................................... 64
Locorten-Vioform .......................................................................................................... 208
Lodi ................................................................................................................................. 49
Lodoxamide .................................................. 210
Logem .............................................................................................................................. 131
Lomide ............................................................................................................................. 210
Lomustine ......................................................................................................................... 156
Loniten ............................................................................................................................ 57
Loperamide hydrochloride .......................................................... 6
Lopinavir with ritonavir ................................................................................................. 108
Lopresor ......................................................................................................................... 50
Loprofin ........................................................ 233

Loprofin Mix ................................................................................................................. 233
Lorafin .............................................................................................................................. 201
Loratadine ......................................................................................................................... 201
Lorazepam ......................................................................................................................... 138
Lorfast .............................................................................................................................. 201

Lormetazepam ............................................................................................................. 146
Lorstat .............................................................................................................................. 55
Losartan Actavis ........................................................................................................... 48

Losartan potassium ........................................................................................................... 48

Losartan potassium with hydrochlorothiazide ........................................................ 48

Lovir ................................................................................................................................. 103

Lucrin Depot 1-month ................................................................................................... 87

Lucrin Depot 3-month ................................................................................................... 87

Ludomil ............................................................................................................................ 128
Lycinate ........................................................................................................................... 56
Lyderm .............................................................................................................................. 69

Maxidex ................................................................. 209
Maxitrol ................................................................. 209
MCT oil (Nutricia) ................................................................. 220
Measles, mumps and rubella vaccine .......................................................................... 244

Mebendazole .................................................................................................................. 90
Mebverine hydrochloride .............................................................................................. 8
Medrol ................................................................................................................... 79
Medroxypregesterone acetate .................................................................................... 74

Hormone ........................................................................................................................ 81-82
Mecaptourine ................................................................................................................. 159
Mercilon 28 ..................................................................................................................... 73
Mesalazine ....................................................................................................................... 7
Mesna ............................................................................................................................... 163
Mestinon .......................................................................................................................... 112

Metabolic Disorder Agents ........................................................................................... 27

Metchek ........................................................................................................................... 11
Meterol ............................................................................................................................. 202
Metformin hydrochloride ............................................................................................... 11

Metformin Mylan ........................................................................................................... 11

Methadone hydrochloride ............................................................................................. 216

Extemporaneous ............................................................................................................ 216

Nervous ............................................................................................................................. 126

Methabuse ...................................................................................................................... 126

Methopt ........................................................................................................................... 211

Methotrexate .................................................................................................................. 159

Methotrexate Ebewe ....................................................................................................... 159

Methotrexate Sandoz ...................................................................................................... 159

Methyl hydroxybenzoate ................................................................. 216

Methylocellulose ............................................................................................................ 216

Methylocellulose with glycerin and sodium saccharin .............................................. 216

Methylocellulose with glycerin and sucrose ................................................................ 217

Methylhydralazine ......................................................................................................... 52

Methylhydroxocarbamide ............................................................................................. 27

Methylidopa ..................................................................................................................... 52

Methylidopa Mylan .......................................................................................................... 52

Methylaltruxone bromide .............................................................................................. 27

Methylphenidate hydrochloride .................................................................................... 149

Methylphenidate hydrochloride extended-release ..................................................... 150

Methylprednisolone acetate .......................................................................................... 80

Methylprednisolone acetone ......................................................................................... 64

Methylprednisolone acetate ......................................................................................... 80

Methylprednisolone acetate with lidocaine [Lignocaine] ........................................... 80

Methylxanthines ............................................................................................................. 206

Metoclopramide Actavis 10 ......................................................................................... 134

Metoclopramide hydrochloride ..................................................................................... 134

Metolazone ...................................................................................................................... 53

Metopirone ....................................................................................................................... 89

Metoprolol succinate .................................................................................................... 50

Metoprolol tartrate ........................................................................................................ 50

Metronidazole ................................................................................................................ 100

Metroprol IV Mylan ....................................................................................................... 50

Metyrapone ..................................................................................................................... 89

Mexiletine hydrochloride ............................................................................................... 49

Mexiletine hydrochloride USP ...................................................................................... 49

Miacalics .......................................................................................................................... 78

Micolette .......................................................................................................................... 27

Miconazole nitrate ........................................................................................................... 33

Miconazole ....................................................................................................................... 33

Dermatological .............................................................................................................. 63

Genito-Urinary ................................................................................................................. 75

Micreme .......................................................................................................................... 75

Mircrome H ..................................................................................................................... 65

Microgynon 20 ED .......................................................................................................... 73

Microgynon 30 ................................................................................................................ 73

Microgynon 50 ED .......................................................................................................... 73

Microlut ........................................................................................................................... 74

Mizardol ........................................................................................................................... 147

Mizardol-Claris ............................................................................................................... 147

Middrin ............................................................................................................................. 49

Minerals ............................................................................................................................ 35

Mini-Wright AFS Low Range ....................................................................................... 207

Mini-Wright Standard ................................................................................................... 207

Minidab ............................................................................................................................ 11

Minimed 640G ............................................................................................................... 14

Minims Pilocarpine ........................................................................................................ 211

Minims Prednisolone ..................................................................................................... 210

Minin ................................................................................................................................. 88

Mirtazapine ...................................................................................................................... 129

Misoprostol ....................................................................................................................... 8

Mitozantrone .................................................................................................................. 163

Mitozantrone Ebewe ....................................................................................................... 163

Mixtard 30 ....................................................................................................................... 10

Moclobemide ............................................................................................................... 128

Modafinil ........................................................................................................................ 150

Modavigil ......................................................................................................................... 150

Moduretic ........................................................................................................................ 54

Molaxole ........................................................................................................................... 27

Mometasone furoate ....................................................................................................... 69

- M -

m-Eslon .......................................................................................................................... 126

Mabthera ........................................................................................................................ 191

Macrocol 3350 with potassium chloride, sodium bicarbonate and sodium chloride ....... 27

Macrocol 400 and propylene glycol ....................................................................... 212

Madopar 125 ................................................................................................................... 122

Madopar 250 ................................................................................................................... 122

Madopar 62.5 ............................................................................................................... 122

Madopar HBS ................................................................................................................ 122

Madopar Rapid ............................................................................................................... 122

Magnesium hydroxide ................................................................................................. 216

Magnesium sulphate ..................................................................................................... 36

Mantoux ........................................................................................................................... 247

Mapepam ........................................................................................................................ 128

Marine Blue Lotion SPF 50+ ......................................................................................... 70

Marvlon 28 ....................................................................................................................... 73

Mask for spacer device ................................................................................................. 207

Mast Cell Stabilisers ....................................................................................................... 206

Methylprednisolone acetate .......................................................................................... 80

Methylprednisolone acetate with lidocaine [Lignocaine] ........................................... 80

Methylxanthines ............................................................................................................. 206

Methoclopramide Actavis 10 ......................................................................................... 134

Metoclopramide hydrochloride ..................................................................................... 134

Metolazone ...................................................................................................................... 53

Metopirone ....................................................................................................................... 89

Metoprolol succinate .................................................................................................... 50

Metoprolol tartrate ........................................................................................................ 50

Metronidazole ................................................................................................................ 100

Metyrapone ..................................................................................................................... 89

Mexiletine hydrochloride ............................................................................................... 49

Mexiletine hydrochloride USP ...................................................................................... 49

Miacalics .......................................................................................................................... 78

Micolette .......................................................................................................................... 27

Miconazole nitrate ........................................................................................................... 33

Miconazole ....................................................................................................................... 33

Dermatological .............................................................................................................. 63

Genito-Urinary ................................................................................................................. 75

Micreme .......................................................................................................................... 75

Mircreme H ..................................................................................................................... 65

Microgynon 20 ED .......................................................................................................... 73

Microgynon 30 ................................................................................................................ 73

Microgynon 50 ED .......................................................................................................... 73

Microlut ........................................................................................................................... 74

Mizardol ........................................................................................................................... 147

Mizardol-Claris ............................................................................................................... 147

Middrin ............................................................................................................................. 49

Minerals ............................................................................................................................ 35

Mini-Wright AFS Low Range ....................................................................................... 207

Mini-Wright Standard ................................................................................................... 207

Minidab ............................................................................................................................ 11

Minimed 640G ............................................................................................................... 14

Minims Pilocarpine ........................................................................................................ 211

Minims Prednisolone ..................................................................................................... 210

Minin ................................................................................................................................. 88

Mirtazapine ...................................................................................................................... 129

Misoprostol ....................................................................................................................... 8

Mitozantrone .................................................................................................................. 163

Mitozantrone Ebewe ....................................................................................................... 163

Mixtard 30 ....................................................................................................................... 10

Moclobemide ............................................................................................................... 128

Modafinil ........................................................................................................................ 150

Modavigil ......................................................................................................................... 150

Moduretic ........................................................................................................................ 54

Molaxole ........................................................................................................................... 27

Mometasone furoate ....................................................................................................... 69
<table>
<thead>
<tr>
<th>INDEX: Generic Chemicals and Brands</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>N</strong></td>
</tr>
<tr>
<td>Nabolol .................................. 50</td>
</tr>
<tr>
<td>Naglazyme ................................ 28</td>
</tr>
<tr>
<td>Nalcrom ................................... 7</td>
</tr>
<tr>
<td>Naloxone hydrochloride .................. 213</td>
</tr>
<tr>
<td>Naltraccord .............................. 152</td>
</tr>
<tr>
<td>Naltrexone hydrochloride .............. 152</td>
</tr>
<tr>
<td>Naphazoline hydrochloride ............. 212</td>
</tr>
<tr>
<td>Naphcon Forte ................................ 212</td>
</tr>
<tr>
<td>Naprosyn SR 1000 ........................ 112</td>
</tr>
<tr>
<td>Naprosyn SR 750 .......................... 112</td>
</tr>
<tr>
<td>Naproxen .................................. 112</td>
</tr>
<tr>
<td>Nardil ..................................... 128</td>
</tr>
<tr>
<td>Nasal Preparations ....................... 206</td>
</tr>
<tr>
<td>Natalizumab ................................ 141</td>
</tr>
<tr>
<td>Natulan .................................... 164</td>
</tr>
<tr>
<td>Nausafix ................................... 134</td>
</tr>
<tr>
<td>Nausicalm .................................. 134</td>
</tr>
<tr>
<td>Nauzene .................................... 134</td>
</tr>
<tr>
<td>Navelbine .................................. 166</td>
</tr>
<tr>
<td>Nedocromil ................................ 206</td>
</tr>
<tr>
<td>Nefopam hydrochloride ................... 124</td>
</tr>
<tr>
<td>Neisvac-C .................................. 244</td>
</tr>
<tr>
<td>Neo-B12 .................................... 33</td>
</tr>
<tr>
<td>Neo-Mercazololate ....................... 83</td>
</tr>
<tr>
<td>Neocate Gold ................................ 234</td>
</tr>
<tr>
<td>Neocate Junior Unflavoured ........... 234</td>
</tr>
<tr>
<td>Neocate Junior Vanilla .................. 234</td>
</tr>
<tr>
<td>Neoral ..................................... 198</td>
</tr>
<tr>
<td>Neostrigmine metilsulfate ............. 112</td>
</tr>
<tr>
<td>Nepril (vanilla) ......................... 224</td>
</tr>
<tr>
<td>Nepril (strawberry) ..................... 224</td>
</tr>
<tr>
<td>Nepril HP RTH ............................. 224</td>
</tr>
<tr>
<td>Nepril Nepril ................................ 64</td>
</tr>
<tr>
<td>Neulactil .................................. 136</td>
</tr>
<tr>
<td>Neulastim .................................. 44</td>
</tr>
<tr>
<td>NeuroTabs ................................... 35</td>
</tr>
<tr>
<td>Nevirapine ................................. 107</td>
</tr>
<tr>
<td>Nevirapine Alphapharm .................. 107</td>
</tr>
<tr>
<td>Nicorandil .................................. 57</td>
</tr>
<tr>
<td>Nicotinic acid ............................. 54</td>
</tr>
<tr>
<td>Nifedipine .................................. 52</td>
</tr>
<tr>
<td>Nifuran ..................................... 111</td>
</tr>
<tr>
<td>Nitrostat .................................... 168</td>
</tr>
<tr>
<td>Nitrovascula Pump Spray ............... 56</td>
</tr>
<tr>
<td>Nivolumab .................................. 196</td>
</tr>
<tr>
<td>Nitrazepam .................................. 147</td>
</tr>
<tr>
<td>Nitroderm TTS .............................. 56</td>
</tr>
<tr>
<td>Nitrofurantoin ............................. 111</td>
</tr>
<tr>
<td>Nitrofurantoinalloy.......................... 56</td>
</tr>
<tr>
<td>Non-Steroidal Anti-Inflammatory Drugs .................................................. 112</td>
</tr>
<tr>
<td>Nonacog alfa [Recombinant factor IX] ........ 40</td>
</tr>
<tr>
<td>Nonacog gamma, [Recombinant Factor IX] ............................................ 40</td>
</tr>
<tr>
<td>Norethisterone ............................. 40</td>
</tr>
<tr>
<td>Genito-Urinary ............................ 74</td>
</tr>
<tr>
<td>Hormone ........................... 82</td>
</tr>
<tr>
<td>Hormone .................................... 82</td>
</tr>
<tr>
<td>Hormone .................................... 82</td>
</tr>
<tr>
<td>Hormone .................................... 82</td>
</tr>
<tr>
<td>Oestradiol .................................. 81</td>
</tr>
<tr>
<td>Oestradiol valerate ........................ 81</td>
</tr>
<tr>
<td>Oestradiol with nordihydroguaiaretic acid ........ 82</td>
</tr>
<tr>
<td>Oestriol .................................... 81</td>
</tr>
<tr>
<td>Oestrogens .................................. 81</td>
</tr>
<tr>
<td>Ofedra ...................................... 204</td>
</tr>
</tbody>
</table>
### INDEX: Generic Chemicals and Brands

<table>
<thead>
<tr>
<th>Chemical Name</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oil in water emulsion</td>
<td>66</td>
</tr>
<tr>
<td>Olanzapine</td>
<td>136-137</td>
</tr>
<tr>
<td>Olbetam</td>
<td>54</td>
</tr>
<tr>
<td>Olopatadine</td>
<td>212</td>
</tr>
<tr>
<td>Olsalazine</td>
<td>7</td>
</tr>
<tr>
<td>Omalizumab</td>
<td>189</td>
</tr>
<tr>
<td>Omeprazole</td>
<td>9</td>
</tr>
<tr>
<td>Omeprazole actavis 10</td>
<td>9</td>
</tr>
<tr>
<td>Omeprazole actavis 20</td>
<td>9</td>
</tr>
<tr>
<td>Omeprazole actavis 40</td>
<td>9</td>
</tr>
<tr>
<td>Omitrope</td>
<td>84</td>
</tr>
<tr>
<td>Onbrez Breezhaler</td>
<td>202</td>
</tr>
<tr>
<td>Oncaspar</td>
<td>163</td>
</tr>
<tr>
<td>OncoTICE</td>
<td>180</td>
</tr>
<tr>
<td>Ondansetron</td>
<td>134</td>
</tr>
<tr>
<td>Ondansetron ODT-DRLA</td>
<td>134</td>
</tr>
<tr>
<td>Ondansetron ODT-ORLA</td>
<td>134</td>
</tr>
<tr>
<td>One-Alpha</td>
<td>34</td>
</tr>
<tr>
<td>Opdivo</td>
<td>196</td>
</tr>
<tr>
<td>Ora-Blend</td>
<td>217</td>
</tr>
<tr>
<td>Ora-Blend SF</td>
<td>216</td>
</tr>
<tr>
<td>Ora-Plus</td>
<td>216</td>
</tr>
<tr>
<td>Ora-Sweet</td>
<td>216</td>
</tr>
<tr>
<td>Ora-Sweet SF</td>
<td>216</td>
</tr>
<tr>
<td>Orabase</td>
<td>32</td>
</tr>
<tr>
<td>Oral Supplements/Complete Diet</td>
<td></td>
</tr>
<tr>
<td>(Nasogastric/Gastrostomy Tube Feed)</td>
<td>221</td>
</tr>
<tr>
<td>Oratane</td>
<td>61</td>
</tr>
<tr>
<td>Orgran</td>
<td>232</td>
</tr>
<tr>
<td>Orion Temozolomide</td>
<td>164</td>
</tr>
<tr>
<td>Ornidazole</td>
<td>100</td>
</tr>
<tr>
<td>Orphenadrine citrate</td>
<td>121</td>
</tr>
<tr>
<td>Ortho-tolidine</td>
<td>77</td>
</tr>
<tr>
<td>Oruvial</td>
<td>112</td>
</tr>
<tr>
<td>Osmolite RTH</td>
<td>228</td>
</tr>
<tr>
<td>Other Endocrine Agents</td>
<td>88</td>
</tr>
<tr>
<td>Other Oestrogen Preparations</td>
<td>82</td>
</tr>
<tr>
<td>Other Progestogen Preparations</td>
<td>82</td>
</tr>
<tr>
<td>Other Skin Preparations</td>
<td>71</td>
</tr>
<tr>
<td>Ovestin</td>
<td></td>
</tr>
<tr>
<td>Genito-Urinary</td>
<td>75</td>
</tr>
<tr>
<td>Hormone</td>
<td>82</td>
</tr>
<tr>
<td>Ox-Pam</td>
<td>138</td>
</tr>
<tr>
<td>Oxaliscord</td>
<td>157</td>
</tr>
<tr>
<td>Oxaliplatin</td>
<td>157</td>
</tr>
<tr>
<td>Oxaliplatin Actavis 100</td>
<td>157</td>
</tr>
<tr>
<td>Oxaliplatin Actavis 50</td>
<td>157</td>
</tr>
<tr>
<td>Oxaliplatin Ebewe</td>
<td>157</td>
</tr>
<tr>
<td>Oxazepam</td>
<td>138</td>
</tr>
<tr>
<td>Oxis Turbuhaler</td>
<td>202</td>
</tr>
<tr>
<td>Oxpentifylline</td>
<td>57</td>
</tr>
<tr>
<td>Oxybutynin</td>
<td>76</td>
</tr>
<tr>
<td>Oxycodeone hydrochloride</td>
<td>127</td>
</tr>
<tr>
<td>OxyNorm</td>
<td>127</td>
</tr>
<tr>
<td>Oxytocin</td>
<td>75</td>
</tr>
<tr>
<td>Oxytocin BN</td>
<td>75</td>
</tr>
<tr>
<td>Oxytocin with ergometrine maleate</td>
<td>75</td>
</tr>
<tr>
<td>Ozurdex</td>
<td>209</td>
</tr>
<tr>
<td>Pacifen</td>
<td>121</td>
</tr>
<tr>
<td>Paclitaxel</td>
<td>163</td>
</tr>
<tr>
<td>Paclitaxel Actavis</td>
<td>163</td>
</tr>
<tr>
<td>Paclitaxel Ebewe</td>
<td>163</td>
</tr>
<tr>
<td>Paediatric Seravit</td>
<td>34</td>
</tr>
<tr>
<td>Paliperidone</td>
<td>137</td>
</tr>
<tr>
<td>Pamidronate disodium</td>
<td>116</td>
</tr>
<tr>
<td>Pamisol</td>
<td>116</td>
</tr>
<tr>
<td>Pancreatic enzyme</td>
<td>25</td>
</tr>
<tr>
<td>Panzopor</td>
<td>9</td>
</tr>
<tr>
<td>Panzop Relief</td>
<td>9</td>
</tr>
<tr>
<td>Panzyrat</td>
<td>25</td>
</tr>
<tr>
<td>Papaverine hydrochloride</td>
<td>57</td>
</tr>
<tr>
<td>Para-amino salicylic acid</td>
<td>101</td>
</tr>
<tr>
<td>Paracare</td>
<td>125</td>
</tr>
<tr>
<td>Paracare Double Strength</td>
<td>125</td>
</tr>
<tr>
<td>Paracetamol</td>
<td>125</td>
</tr>
<tr>
<td>Paracetamol + Codeine (Relieve)</td>
<td>127</td>
</tr>
<tr>
<td>Paracetamol with codeine</td>
<td>127</td>
</tr>
<tr>
<td>Paradigm 1.8 Reservoir</td>
<td>25</td>
</tr>
<tr>
<td>Paradigm 3.0 Reservoir</td>
<td>25</td>
</tr>
<tr>
<td>Paradigm Mio MMT-921</td>
<td>23</td>
</tr>
<tr>
<td>Paradigm Mio MMT-923</td>
<td>23</td>
</tr>
<tr>
<td>Paradigm Mio MMT-925</td>
<td>23</td>
</tr>
<tr>
<td>Paradigm Mio MMT-941</td>
<td>23</td>
</tr>
<tr>
<td>Paradigm Mio MMT-943</td>
<td>23</td>
</tr>
<tr>
<td>Paradigm Mio MMT-945</td>
<td>23</td>
</tr>
<tr>
<td>Paradigm Mio MMT-965</td>
<td>23</td>
</tr>
<tr>
<td>Paradigm Mio MMT-975</td>
<td>23</td>
</tr>
<tr>
<td>Paradigm Quick-Set MMT-386</td>
<td>24</td>
</tr>
<tr>
<td>Paradigm Quick-Set MMT-387</td>
<td>24</td>
</tr>
<tr>
<td>Paradigm Quick-Set MMT-396</td>
<td>24</td>
</tr>
<tr>
<td>Paradigm Quick-Set MMT-397</td>
<td>24</td>
</tr>
<tr>
<td>Paradigm Quick-Set MMT-398</td>
<td>24</td>
</tr>
<tr>
<td>Paradigm Quick-Set MMT-399</td>
<td>24</td>
</tr>
<tr>
<td>Paradigm Quick-Set MMT-399</td>
<td>24</td>
</tr>
<tr>
<td>Paradigm Silhouette MMT-368</td>
<td>22</td>
</tr>
<tr>
<td>Paradigm Silhouette MMT-377</td>
<td>22</td>
</tr>
<tr>
<td>Paradigm Silhouette MMT-378</td>
<td>22</td>
</tr>
<tr>
<td>Paradigm Silhouette MMT-381</td>
<td>22</td>
</tr>
<tr>
<td>Paradigm Silhouette MMT-382</td>
<td>22</td>
</tr>
<tr>
<td>Paradigm Silhouette MMT-383</td>
<td>22</td>
</tr>
<tr>
<td>Paradigm Silhouette MMT-384</td>
<td>22</td>
</tr>
<tr>
<td>Paradigm Sure-T MMT-864</td>
<td>20</td>
</tr>
<tr>
<td>Paradigm Sure-T MMT-886</td>
<td>20</td>
</tr>
<tr>
<td>Paradigm Sure-T MMT-866</td>
<td>20</td>
</tr>
<tr>
<td>Paradigm Sure-T MMT-874</td>
<td>20</td>
</tr>
<tr>
<td>Paradigm Sure-T MMT-876</td>
<td>20</td>
</tr>
<tr>
<td>Paradigm Sure-T MMT-884</td>
<td>20</td>
</tr>
<tr>
<td>Paradigm Sure-T MMT-886</td>
<td>20</td>
</tr>
<tr>
<td>Paraffin liquid with soft white</td>
<td>212</td>
</tr>
<tr>
<td>paraffin</td>
<td>212</td>
</tr>
<tr>
<td>Paraffin liquid with wool fat</td>
<td>129</td>
</tr>
<tr>
<td>Paraldehyde</td>
<td>69</td>
</tr>
<tr>
<td>Parasidose</td>
<td>69</td>
</tr>
<tr>
<td>Parasiticidal Preparations</td>
<td>67</td>
</tr>
<tr>
<td>Paritaprevir, ritonavir and ombitasvir</td>
<td>104</td>
</tr>
<tr>
<td>with dasabuvir</td>
<td>104</td>
</tr>
<tr>
<td>Paritaprevir, ritonavir and ombitasvir</td>
<td>104</td>
</tr>
<tr>
<td>with dasabuvir and ribavirin</td>
<td>104</td>
</tr>
<tr>
<td>Parnate</td>
<td>128</td>
</tr>
<tr>
<td>Paromomycin</td>
<td>96</td>
</tr>
<tr>
<td>Paroxetine</td>
<td>129</td>
</tr>
<tr>
<td>Paser</td>
<td>101</td>
</tr>
<tr>
<td>Patanol</td>
<td>212</td>
</tr>
<tr>
<td>Paxam</td>
<td>138</td>
</tr>
<tr>
<td>Pazopanib</td>
<td>169</td>
</tr>
<tr>
<td>Peak flow meter</td>
<td>207</td>
</tr>
<tr>
<td>Pedialyte - Bubblegum</td>
<td>45</td>
</tr>
<tr>
<td>Pedisasure</td>
<td>223</td>
</tr>
<tr>
<td>Pedisasure RTH</td>
<td>223</td>
</tr>
<tr>
<td>Pegaspargase</td>
<td>163</td>
</tr>
<tr>
<td>Pegsys</td>
<td>109</td>
</tr>
<tr>
<td>Pegfilgrastim</td>
<td>44</td>
</tr>
<tr>
<td>Pegylated interferon alfa-2a</td>
<td>109</td>
</tr>
<tr>
<td>Pembrolizumab</td>
<td>197</td>
</tr>
<tr>
<td>Pemetrexed</td>
<td>160</td>
</tr>
<tr>
<td>Penicillamine</td>
<td>113</td>
</tr>
<tr>
<td>Penicillin G.</td>
<td>93</td>
</tr>
<tr>
<td>PenMix 30</td>
<td>10</td>
</tr>
<tr>
<td>PenMix 40</td>
<td>10</td>
</tr>
<tr>
<td>PenMix 50</td>
<td>10</td>
</tr>
<tr>
<td>Pentasa</td>
<td>7</td>
</tr>
<tr>
<td>Pentostatin [Deoxycoformycin]</td>
<td>164</td>
</tr>
<tr>
<td>Pentoxifylline [Oxpentifylline]</td>
<td>57</td>
</tr>
<tr>
<td>Peptamen Junior</td>
<td>223</td>
</tr>
<tr>
<td>Peptisoothe</td>
<td>8</td>
</tr>
<tr>
<td>Peptisorb</td>
<td>225</td>
</tr>
<tr>
<td>Perhexilene maleate</td>
<td>52</td>
</tr>
<tr>
<td>Pericylezine</td>
<td>136</td>
</tr>
<tr>
<td>Perindopril</td>
<td>47</td>
</tr>
<tr>
<td>Perjeta</td>
<td>191</td>
</tr>
<tr>
<td>Permethrin</td>
<td>69</td>
</tr>
<tr>
<td>Perrigo</td>
<td>71</td>
</tr>
<tr>
<td>Pertuzumab</td>
<td>191</td>
</tr>
<tr>
<td>Peteha</td>
<td>101</td>
</tr>
<tr>
<td>Pethidine hydrochloride</td>
<td>127</td>
</tr>
<tr>
<td>Pevaryl</td>
<td>63</td>
</tr>
<tr>
<td>Pexsig</td>
<td>52</td>
</tr>
<tr>
<td>Pfizer Exemestane</td>
<td>174</td>
</tr>
<tr>
<td>Pharmacy Health Sorbolene with Glycerin</td>
<td>66</td>
</tr>
<tr>
<td>Pharmacy Services</td>
<td>213</td>
</tr>
<tr>
<td>Pheburane</td>
<td>30</td>
</tr>
<tr>
<td>Phenelzine sulphate</td>
<td>128</td>
</tr>
<tr>
<td>Phenobarbitone</td>
<td>131</td>
</tr>
<tr>
<td>INDEX: Generic Chemicals and Brands</td>
<td></td>
</tr>
<tr>
<td>-------------------------------------</td>
<td></td>
</tr>
<tr>
<td>Revolade..................................</td>
<td>38</td>
</tr>
<tr>
<td>Rexacrom..................................</td>
<td>210</td>
</tr>
<tr>
<td>RexAir....................................</td>
<td>203</td>
</tr>
<tr>
<td>Reyataz.................................</td>
<td>108</td>
</tr>
<tr>
<td>Ribavirin..................................</td>
<td>155</td>
</tr>
<tr>
<td>Ricit.....................................</td>
<td>75</td>
</tr>
<tr>
<td>Rifabutin..................................</td>
<td>102</td>
</tr>
<tr>
<td>Rifadin....................................</td>
<td>102</td>
</tr>
<tr>
<td>Rifampicin..................................</td>
<td>102</td>
</tr>
<tr>
<td>Rifaxim....................................</td>
<td>9</td>
</tr>
<tr>
<td>Rifinah....................................</td>
<td>101</td>
</tr>
<tr>
<td>Rilutek....................................</td>
<td>123</td>
</tr>
<tr>
<td>Rifuzole.....................................</td>
<td>123</td>
</tr>
<tr>
<td>Riodine....................................</td>
<td>67</td>
</tr>
<tr>
<td>Risedronate Sandoz........................</td>
<td>117</td>
</tr>
<tr>
<td>Risedronate sodium........................</td>
<td>117</td>
</tr>
<tr>
<td>Risperdal Consta...........................</td>
<td>138</td>
</tr>
<tr>
<td>Risperdone..................................</td>
<td>136, 138</td>
</tr>
<tr>
<td>Risperon....................................</td>
<td>136</td>
</tr>
<tr>
<td>Ritalin.....................................</td>
<td>149</td>
</tr>
<tr>
<td>Ritalin LA.................................</td>
<td>150</td>
</tr>
<tr>
<td>Ritalin SR...................................</td>
<td>149</td>
</tr>
<tr>
<td>Ritonavir....................................</td>
<td>108</td>
</tr>
<tr>
<td>Rituximab...................................</td>
<td>191</td>
</tr>
<tr>
<td>Rivaroxaban................................</td>
<td>43</td>
</tr>
<tr>
<td>Rivastigmine................................</td>
<td>151</td>
</tr>
<tr>
<td>Rivotril....................................</td>
<td>129–130</td>
</tr>
<tr>
<td>RIXUBIS....................................</td>
<td>40</td>
</tr>
<tr>
<td>Rizamelt....................................</td>
<td>133</td>
</tr>
<tr>
<td>Rizatriptan..................................</td>
<td>133</td>
</tr>
<tr>
<td>Roferon-A...................................</td>
<td>109</td>
</tr>
<tr>
<td>Rolin........................................</td>
<td>173</td>
</tr>
<tr>
<td>Ropinirole hydrochloride..................</td>
<td>122</td>
</tr>
<tr>
<td>Rotax.........................................</td>
<td>246</td>
</tr>
<tr>
<td>Rotaviruses oral vaccine..................</td>
<td>246</td>
</tr>
<tr>
<td>Roxane......................................</td>
<td>43</td>
</tr>
<tr>
<td>Roxal........................................</td>
<td>38</td>
</tr>
<tr>
<td>- S -</td>
<td></td>
</tr>
<tr>
<td>Sabril.......................................</td>
<td>132</td>
</tr>
<tr>
<td>Sacubitril with valsartan..................</td>
<td>48</td>
</tr>
<tr>
<td>SalAir.......................................</td>
<td>203</td>
</tr>
<tr>
<td>Salazopyrin..................................</td>
<td>7</td>
</tr>
<tr>
<td>Salazopyrin EN..............................</td>
<td>7</td>
</tr>
<tr>
<td>Salbutamol...................................</td>
<td>203</td>
</tr>
<tr>
<td>Salbutamol with ipratropium bromide.....</td>
<td>203</td>
</tr>
<tr>
<td>Salicylic acid..............................</td>
<td>70</td>
</tr>
<tr>
<td>Salmeterol...................................</td>
<td>202</td>
</tr>
<tr>
<td>Saldronigran..................................</td>
<td>133</td>
</tr>
<tr>
<td>Saldronigran S29............................</td>
<td>133</td>
</tr>
<tr>
<td>Sandostatin LAR............................</td>
<td>172</td>
</tr>
<tr>
<td>Sapropterin dihydrochloride..............</td>
<td>30</td>
</tr>
<tr>
<td>Scalp Preparations..........................</td>
<td>70</td>
</tr>
<tr>
<td>Scopolide TTS................................</td>
<td>134</td>
</tr>
<tr>
<td>Sebinox......................................</td>
<td>70</td>
</tr>
<tr>
<td>Secukinumab..................................</td>
<td>193</td>
</tr>
<tr>
<td>Sedatives and Hypnotics....................</td>
<td>146</td>
</tr>
<tr>
<td>Seebr Breezhaler............................</td>
<td>204</td>
</tr>
<tr>
<td>Selegiline hydrochloride...................</td>
<td>122</td>
</tr>
<tr>
<td>Sena..........................................</td>
<td>27</td>
</tr>
<tr>
<td>Senokot......................................</td>
<td>27</td>
</tr>
<tr>
<td>Sensipar.....................................</td>
<td>78</td>
</tr>
<tr>
<td>Sensocardi...................................</td>
<td>13</td>
</tr>
<tr>
<td>Sereñace....................................</td>
<td>135</td>
</tr>
<tr>
<td>Seretide.....................................</td>
<td>203</td>
</tr>
<tr>
<td>Seretide Accuhaler..........................</td>
<td>203</td>
</tr>
<tr>
<td>Serevent.....................................</td>
<td>202</td>
</tr>
<tr>
<td>Serevent Accuhaler..........................</td>
<td>202</td>
</tr>
<tr>
<td>Serophene....................................</td>
<td>89</td>
</tr>
<tr>
<td>Sertraline....................................</td>
<td>129</td>
</tr>
<tr>
<td>Sevedrol.....................................</td>
<td>126</td>
</tr>
<tr>
<td>Sex Hormones Non Contraceptive...........</td>
<td>80</td>
</tr>
<tr>
<td>Shield 49....................................</td>
<td>72</td>
</tr>
<tr>
<td>Shield Blue...................................</td>
<td>72</td>
</tr>
<tr>
<td>Shield XL.....................................</td>
<td>72</td>
</tr>
<tr>
<td>Shingles vaccine............................</td>
<td>247</td>
</tr>
<tr>
<td>Silodenai....................................</td>
<td>59</td>
</tr>
<tr>
<td>Silhouette MMT-371..........................</td>
<td>22</td>
</tr>
<tr>
<td>Silhouette MMT-373..........................</td>
<td>22</td>
</tr>
<tr>
<td>Siltuximab....................................</td>
<td>194</td>
</tr>
<tr>
<td>Simvastatin..................................</td>
<td>55</td>
</tr>
<tr>
<td>Simvastatin Mylan...........................</td>
<td>55</td>
</tr>
<tr>
<td>Sinemet......................................</td>
<td>122</td>
</tr>
<tr>
<td>Sinemet CR...................................</td>
<td>122</td>
</tr>
<tr>
<td>Sirolimus....................................</td>
<td>199</td>
</tr>
<tr>
<td>Sistine.......................................</td>
<td>80</td>
</tr>
<tr>
<td>Slow-LoPresor................................</td>
<td>50</td>
</tr>
<tr>
<td>Smith BioMed Rapid Pregnancy Test........</td>
<td>75</td>
</tr>
<tr>
<td>Sodobic......................................</td>
<td>46</td>
</tr>
<tr>
<td>Sodium acid phosphate.....................</td>
<td>27</td>
</tr>
<tr>
<td>Sodium alginate............................</td>
<td>6</td>
</tr>
<tr>
<td>Sodium aurothiomalate......................</td>
<td>113</td>
</tr>
<tr>
<td>Sodium benzoate............................</td>
<td>30</td>
</tr>
<tr>
<td>Sodium bicarbonate..........................</td>
<td>45–46</td>
</tr>
<tr>
<td>Sodium calcium edetate.....................</td>
<td>214</td>
</tr>
<tr>
<td>Sodium chloride.............................</td>
<td>45</td>
</tr>
<tr>
<td>Sodium chloride.............................</td>
<td>45</td>
</tr>
<tr>
<td>Sodium citrate with sodium lauryl sulphocetate</td>
<td>27</td>
</tr>
<tr>
<td>INDEX: Generic Chemicals and Brands</td>
<td></td>
</tr>
<tr>
<td>------------------------------------</td>
<td></td>
</tr>
</tbody>
</table>

| Sunscreens ........................................ | 70 |
| Sunscreens, proprietary .................. | 70 |
| Sure-T MMT-863 ..................................... | 20 |
| Sure-T MMT-865 ..................................... | 20 |
| Sure-T MMT-873 ..................................... | 20 |
| Sure-T MMT-875 ..................................... | 20 |
| Sure-T MMT-883 ..................................... | 20 |
| Sure-T MMT-885 ..................................... | 20 |
| Sustagen Diabetic .................................. | 221 |
| Sustagen Hospital Formula ...................... | 229 |
| Sustanon Ampoules .................................. | 81 |
| Sutent ................................................ | 194 |
| Sylvanta ............................................. | 174 |
| Symbicort Turbuhaler 100/6 .................... | 202 |
| Symbicort Turbuhaler 200/6 .................... | 202 |
| Symbicort Turbuhaler 400/12 ................. | 202 |
| Symmetrel ............................................ | 122 |
| Symptomimetics .................................... | 56 |
| Synacthen .......................................... | 80 |
| Synacthen Depot .................................... | 80 |
| Synflorix ............................................ | 244 |
| Synthroid ............................................. | 83 |
| Syntometrine ....................................... | 75 |
| Syrup (pharmaceutical grade) ............... | 217 |
| Systane Unit Dose ................................. | 212 |
| **- T -** ............................................ |  
| Tacrolimus ........................................... | 199 |
| Tacrolimus Sandoz ................................... | 199 |
| Taliglucerase alfa ............................... | 31 |
| Tambocor ........................................... | 49 |
| Tambocor CR ....................................... | 49 |
| Tamoxifen citrate .................................. | 173 |
| Tamoxifen Sandoz ................................... | 173 |
| Tamsulosin hydrochloride ..................... | 76 |
| Tamsulosin-Rex ..................................... | 76 |
| Tandem Cartridge ................................... | 19 |
| Tandem t'slim X2 ................................... | 14 |
| Tap water ............................................ | 217 |
| Tarceva ............................................. | 167 |
| Tasigna ............................................. | 168 |
| Tasmar ................................................ | 122 |
| Tecfidera .......................................... | 138 |
| Tegretol ............................................. | 130 |
| Tegretol CR ....................................... | 130 |
| Telfast .............................................. | 201 |
| Temazepam .......................................... | 147 |
| Temizole 20 ....................................... | 164 |
| Temozolomide ...................................... | 164 |
| Tenofovir disoproxil ......................... | 103 |
| Tenofovir Disoproxil Teva .................. | 103 |
| Tenoxicam .......................................... | 112 |
| Tepadin ............................................. | 157 |
| Terazosin .......................................... | 47 |
| Terbinafine ....................................... | 99 |
| Terbutaline sulphate ....................... | 203 |
| Teriflunomide ...................................... | 143 |
| Teriparatide ....................................... | 117 |
| Testosterone ....................................... | 80 |
| Testosterone cipionate ..................... | 81 |
| Testosterone esters ............................ | 81 |
| Testosterone undecanoate ................... | 81 |
| Tetrabenazine ..................................... | 123 |
| Tetrabromophenol ................................ | 77 |
| Tetracosactrin ................................... | 80 |
| Tetracyclin Wolf .................................. | 94 |
| Tetracycline ..................................... | 94 |
| Thalidomide ....................................... | 165 |
| Thalomid ........................................... | 165 |
| Theophylline ..................................... | 206 |
| Thiamine hydrochloride ..................... | 33 |
| THIO-TEPA ......................................... | 157 |
| Thiguanine ........................................ | 160 |
| Thiotepa ........................................... | 157 |
| Thyroid and Antithyroid Agents ........... | 83 |
| Ticagrelor ........................................ | 41 |
| Tilade .............................................. | 206 |
| Ticlopidine ....................................... | 112 |
| Timolol ............................................. | 177 |
| Cardiovascular .................................. | 51 |
| Sensory ............................................ | 210 |
| Timoptol XE ....................................... | 210 |
| Tiotropium bromide ............................ | 204 |
| Tiotropium bromide with olodaterol ....... | 204 |
| Tivicay ............................................. | 108 |
| TMP ................................................... | 97 |
| TOBI ................................................. | 97 |
| Tobramycin ....................................... | 97 |
| Tobramycin Mylan ................................ | 97 |
| Tobrex ............................................. | 209 |
| Tofranil ............................................ | 128 |
| Tofranil s29 ...................................... | 128 |
| Tolcapone ......................................... | 122 |
| Tolterodine ....................................... | 77 |
| Topamax ............................................ | 132 |
| Topical Products for Joint and Muscular Pain | 113 |
| Topiramate ....................................... | 132 |
| Topiramate Actavis ................................ | 132 |
| Total parenteral nutrition (TPN) .......... | 45 |
| TPN .................................................. | 45 |
| Tromadol hydrochloride .................... | 127 |
| Tramadol SR 100 .................................. | 127 |
| Tramadol SR 150 ................................ | 127 |
| Tramadol SR 200 ................................ | 127 |
| Tranilcipant ..................................... | 50 |
| Tranexamic acid .................................. | 40 |
| Tranylcypromine sulphate ................... | 128 |
| Trastuzumab ....................................... | 194 |
| Travatan .......................................... | 211 |
| Trarvoprost ...................................... | 211 |
| Travot ........................... ................. | 211 |
| Treatments for Dementia ................. | 151 |
| Treatments for Substance Dependence .... | 151 |
| Trexate ............................................ | 57 |
| Tretinoin .......................................... | 159 |
| Triamcinolone acetonide .................. | 33 |
| Alimentary ....................................... | 65 |
| Dermatological ................................ | 80 |
| Sensory ............................................ | 208 |
| TriaZolam ........................................... | 147 |
| Trichozole ....................................... | 100 |
| Triclosan ........................................... | 65 |
| Trimeprazine tartrate .................... | 201 |
| Trimeprazone with sulphamethoxazole ... | 97 |
| Trisquel .......................................... | 82 |
| Trisul ............................................. | 97 |
| Triclabendazole ............................... | 84 |
| Tropicamide ..................................... | 211 |
| Trusopt ............................................ | 210 |
| TruSteel .......................................... | 21 |
| Truvada ............................................ | 105 |
| Tuberculin PPD [Mantoux] test ............ | 247 |
| Tubersol .......................................... | 247 |
| Two Cal HN ....................................... | 231 |
| Two Cal HN RTH ................................. | 230 |
| Tykerb ............................................. | 168 |
| Tysabri ............................................ | 141 |
| **- U -** ............................................ |  
| Ulitro Breezhaler .............................. | 204 |
| Ultracop .......................................... | 7 |
| Umeclidinium ..................................... | 204 |
| Umeclidinium with vila.... | 204 |
| Unive... ......................................... | 203, 207 |
| Ural .............................................. | 76 |
| Urea .............................................. | 66 |
| Urex Forte ....................................... | 53 |
| Urinary Agents .................................. | 75 |
| Urinary Tract Infections ............... | 111 |
| Uromitexan ....................................... | 163 |
| Ursodeoxycholic acid .................... | 25 |
| Ursosan .......................................... | 25 |
| Utrogestan ....................................... | 82 |
## INDEX: Generic Chemicals and Brands

<table>
<thead>
<tr>
<th>- V -</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Vaccinations</td>
<td>237</td>
</tr>
<tr>
<td>Valclovir</td>
<td>103</td>
</tr>
<tr>
<td>Valaciclovir</td>
<td>103</td>
</tr>
<tr>
<td>Valcyte</td>
<td>103</td>
</tr>
<tr>
<td>Valganclovir</td>
<td>103</td>
</tr>
<tr>
<td>Vallergan Forte</td>
<td>201</td>
</tr>
<tr>
<td>Vancomycin</td>
<td>97</td>
</tr>
<tr>
<td>Vannair</td>
<td>202</td>
</tr>
<tr>
<td>Varenicline tartrate</td>
<td>153</td>
</tr>
<tr>
<td>Varicelle vaccine [Chickenpox vaccine]</td>
<td>247</td>
</tr>
<tr>
<td>Varicella zoster virus (Oka strain) live attenuated vaccine [shingles vaccine]</td>
<td>247</td>
</tr>
<tr>
<td>Varilrix</td>
<td>247</td>
</tr>
<tr>
<td>Various</td>
<td>213</td>
</tr>
<tr>
<td>Vasodilators</td>
<td>57</td>
</tr>
<tr>
<td>Vasopressin Agonists</td>
<td>88</td>
</tr>
<tr>
<td>Vedafi</td>
<td>59</td>
</tr>
<tr>
<td>Velcade</td>
<td>161</td>
</tr>
<tr>
<td>Veleti</td>
<td>60</td>
</tr>
<tr>
<td>Venlafaxine</td>
<td>129</td>
</tr>
<tr>
<td>Venolin</td>
<td>200</td>
</tr>
<tr>
<td>Ventavis</td>
<td>60</td>
</tr>
<tr>
<td>Ventolin</td>
<td>203</td>
</tr>
<tr>
<td>Vepesid</td>
<td>162</td>
</tr>
<tr>
<td>Verapamil hydrochloride</td>
<td>52</td>
</tr>
<tr>
<td>Vergo 16</td>
<td>133</td>
</tr>
<tr>
<td>Vermox</td>
<td>90</td>
</tr>
<tr>
<td>Verpamil SR</td>
<td>52</td>
</tr>
<tr>
<td>Vesanoloid</td>
<td>165</td>
</tr>
<tr>
<td>Vesicare</td>
<td>77</td>
</tr>
<tr>
<td>Vexazone</td>
<td>11</td>
</tr>
<tr>
<td>Vfend</td>
<td>99</td>
</tr>
<tr>
<td>Viaderm KC</td>
<td>65</td>
</tr>
<tr>
<td>Vidaza</td>
<td>157</td>
</tr>
<tr>
<td>Viekira Pak</td>
<td>104</td>
</tr>
<tr>
<td>Viekira Pak-RBV</td>
<td>104</td>
</tr>
<tr>
<td>Vigabatrin</td>
<td>132</td>
</tr>
<tr>
<td>Vildagliptin</td>
<td>11</td>
</tr>
<tr>
<td>Vildagliptin with metformin hydrochloride</td>
<td>11</td>
</tr>
<tr>
<td>Vimpat</td>
<td>130</td>
</tr>
<tr>
<td>Vinblastine sulphate</td>
<td>165</td>
</tr>
<tr>
<td>Vincristine sulphate</td>
<td>165</td>
</tr>
<tr>
<td>Vinoreline</td>
<td>166</td>
</tr>
<tr>
<td>Vinoreline Ebewe</td>
<td>166</td>
</tr>
<tr>
<td>Viramune Suspension</td>
<td>107</td>
</tr>
<tr>
<td>VirusPOS</td>
<td>208</td>
</tr>
<tr>
<td>Vistil</td>
<td>212</td>
</tr>
<tr>
<td>Vistil Forte</td>
<td>212</td>
</tr>
<tr>
<td>Vit.D3</td>
<td>34</td>
</tr>
<tr>
<td>VitA-POS</td>
<td>34</td>
</tr>
<tr>
<td>Vitabdeck</td>
<td>212</td>
</tr>
<tr>
<td>Vitadol C</td>
<td>33</td>
</tr>
<tr>
<td>Vital</td>
<td>224</td>
</tr>
<tr>
<td>Vitamin A with vitamins D and C</td>
<td>33</td>
</tr>
<tr>
<td>Vitamin B complex</td>
<td>33</td>
</tr>
<tr>
<td>Vitamin B6 25</td>
<td>33</td>
</tr>
<tr>
<td>Vitamins</td>
<td>33-34</td>
</tr>
<tr>
<td>Viconex TEN</td>
<td>225</td>
</tr>
<tr>
<td>Volibris</td>
<td>57</td>
</tr>
<tr>
<td>Voltaren</td>
<td>112</td>
</tr>
<tr>
<td>Voltaren D</td>
<td>112</td>
</tr>
<tr>
<td>Voltaren Ophtha</td>
<td>209</td>
</tr>
<tr>
<td>Volumatic</td>
<td>207</td>
</tr>
<tr>
<td>Voriconazole</td>
<td>99</td>
</tr>
<tr>
<td>Vosol</td>
<td>208</td>
</tr>
<tr>
<td>Votrient</td>
<td>169</td>
</tr>
<tr>
<td>Vttack</td>
<td>99</td>
</tr>
<tr>
<td>Water</td>
<td>45</td>
</tr>
<tr>
<td>Blood</td>
<td>217</td>
</tr>
<tr>
<td>Extemporaneous</td>
<td>200</td>
</tr>
<tr>
<td>Wool fat with mineral oil</td>
<td>66</td>
</tr>
<tr>
<td>- W -</td>
<td></td>
</tr>
<tr>
<td>Warfarin sodium</td>
<td>44</td>
</tr>
<tr>
<td>Wart Preparations</td>
<td>71</td>
</tr>
<tr>
<td>Wasp venom allergy treatment</td>
<td>200</td>
</tr>
<tr>
<td>Water Blood</td>
<td>45</td>
</tr>
<tr>
<td>Water Extemporaneous</td>
<td>217</td>
</tr>
<tr>
<td>Water Wool fat with mineral oil</td>
<td>66</td>
</tr>
<tr>
<td>- X -</td>
<td></td>
</tr>
<tr>
<td>Xarelto</td>
<td>43</td>
</tr>
<tr>
<td>Xifaxan</td>
<td>9</td>
</tr>
<tr>
<td>XMET Maxamum</td>
<td>232</td>
</tr>
<tr>
<td>Xolair</td>
<td>189</td>
</tr>
<tr>
<td>XP Maxamaid</td>
<td>233</td>
</tr>
<tr>
<td>XP Maxamum</td>
<td>233</td>
</tr>
<tr>
<td>Xylocaine</td>
<td>124</td>
</tr>
<tr>
<td>Xylocaine 2% Jelly</td>
<td>123</td>
</tr>
<tr>
<td>Xylocaine</td>
<td>39</td>
</tr>
<tr>
<td>Xyntha</td>
<td></td>
</tr>
<tr>
<td>- Z -</td>
<td></td>
</tr>
<tr>
<td>Zantac</td>
<td>8</td>
</tr>
<tr>
<td>Zapril</td>
<td>47</td>
</tr>
<tr>
<td>Zaronstin</td>
<td>130</td>
</tr>
<tr>
<td>Zaroxolyn</td>
<td>53</td>
</tr>
<tr>
<td>Zarzio</td>
<td>44</td>
</tr>
<tr>
<td>Zavedos</td>
<td>162</td>
</tr>
<tr>
<td>Zeffix</td>
<td>103</td>
</tr>
<tr>
<td>Zeldox</td>
<td>136</td>
</tr>
<tr>
<td>Zetlami</td>
<td>103</td>
</tr>
<tr>
<td>Ziagen</td>
<td>107</td>
</tr>
<tr>
<td>Zidovudine [AZT]</td>
<td>108</td>
</tr>
<tr>
<td>Zidovudine [AZT] with lamivudine</td>
<td>108</td>
</tr>
<tr>
<td>Zimybe</td>
<td>56</td>
</tr>
<tr>
<td>Zinc and castor oil</td>
<td>66</td>
</tr>
<tr>
<td>Zinc sulphate</td>
<td>36</td>
</tr>
<tr>
<td>Zincaps</td>
<td>36</td>
</tr>
<tr>
<td>Zinnat</td>
<td>90</td>
</tr>
<tr>
<td>Ziprasidone</td>
<td>136</td>
</tr>
<tr>
<td>Zista</td>
<td>201</td>
</tr>
<tr>
<td>Zithromax</td>
<td>91</td>
</tr>
<tr>
<td>Zoladex</td>
<td>87</td>
</tr>
</tbody>
</table>

Zoledronic acid
Hormone ........................................ 78
Musculoskeletal ................................ 117
Zoledronic acid Mylan ......................... 78
Zometa ........................................... 78
Zopiclone ....................................... 147
Zopiclone Actavis ............................ 147
Zostavax ........................................ 247
Zostrix .......................................... 113
Zostrix HP ..................................... 124
Zuclopenthiol decanoate .................... 138
Zuclopenthiol hydrochloride ............... 136
Zusdone ......................................... 136
Zyban ............................................ 152
Zypine .......................................... 136
Zypine ODT ..................................... 136
Zyprexa Relprev ................................ 137
Zyliga .......................................... 171
Choosing the Te Reo expression of our identity

“The term was gifted to us by our Kaumātua, Bill Kaua ONZM, and the feedback we received reassured us that it embodies what PHARMAC is about, and the ‘story’ we want to tell,” says Sarah Fitt. “We adopted Te Pātaka Whaioranga after seeking feedback from Māori communities and healthcare professionals.”

A pātaka has many literal and metaphorical associations in Te Reo Māori. It refers, literally, to the raised platform for food storage and protection of taonga, and is also a symbol of safeguarding of things that are precious to the community. Within the PHARMAC context, the concept of the pātaka symbolises a solid and reliable structure safeguarding the continuous flow of supplies, such as medicines and medical devices, and it’s our role to keep the flow constant and maintain availability for the benefit of all New Zealanders.

“Whaioranga, or the pursuit of wellbeing, is already reflected in the name of our Māori Responsiveness Strategy, Te Whaioranga, signaling the central importance of meeting the needs of Māori through our work. Altogether, the term Te Pātaka Whaioranga reflects that we are the guardians of the pātaka, with a role in replenishing and sustaining the wellbeing of whānau and all communities in Aotearoa New Zealand,” says Sarah.

Accompanying visual identity

We’ve also updated the look and feel of PHARMAC’s visual identity to reflect the concepts expressed by Te Pātaka Whaioranga.

The new design retains elements of our previous logo, to reflect continuity with our 25-year history and the confidence our communities have in it. The infinite double spiral also reinforces the theme of supplying an ongoing stream of medicines and medical devices to support health and wellbeing of New Zealanders.

“The visual pattern that is part of our new identity takes inspiration from the decorated carved slabs of many pātaka around the country. Traditionally, carvings on pātaka signal the importance of the supplies being stored. Our unique design is our way of signaling the importance of our role in supporting better health outcomes for New Zealand,” says Sarah.